# EDGAR Filing Document

**Accession Number:** 0001333141
**File Stem:** 0001104659-26-019005
**Filing Date:** 2026-2
**Character Count:** 1654389
**Document Hash:** d68ec8c166be896dac8c079f0bd84d7f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-019005.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001104659-26-019005

**CONFORMED SUBMISSION TYPE**: 20-F

**PUBLIC DOCUMENT COUNT**: 216

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260224

**DATE AS OF CHANGE**: 20260224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Fresenius Medical Care AG
- **CENTRAL INDEX KEY:** 0001333141
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 20-F
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32749
- **FILM NUMBER:** 26669819

**BUSINESS ADDRESS:**
- **STREET 1:** ELSE-KROENER STRASSE 1
- **CITY:** BAD HOMBURG
- **STATE:** 2M
- **ZIP:** 61352
- **BUSINESS PHONE:** 011-49-6172-6090

**MAIL ADDRESS:**
- **STREET 1:** ELSE-KROENER STRASSE 1
- **CITY:** BAD HOMBURG
- **STATE:** 2M
- **ZIP:** 61352

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Fresenius Medical Care AG & Co. KGaA
- **DATE OF NAME CHANGE:** 20050714

?xml version='1.0' encoding='ASCII'? FRESENIUS MEDICAL CARE AG_December 31, 2025

[**Table of Contents**](#TOC)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 20-F**

(Mark One)

☐ **REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934**

**or**

&nbsp;&nbsp;&nbsp;&nbsp;☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the fiscal year ended December 31, 2025**

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**or**

☐ **SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of event requiring this shell company report**

**Commission file number 001-32749**

**FRESENIUS MEDICAL CARE AG**

(Exact name of Registrant as specified in its charter)

**FRESENIUS MEDICAL CARE AG**

(Translation of Registrant's name into English)

**Germany**

(Jurisdiction of incorporation or organization)

**Else-Kröner-Strasse 1, 61352 Bad Homburg, Germany**

(Address of principal executive offices)

**Olga Renkewitsch, +49 151 149 65 619, olga.renkewitsch@freseniusmedicalcare.com, Else-Kröner-Strasse 1, 61352 Bad Homburg, Germany**

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

**Securities registered or to be registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **American Depositary Shares representing ordinary shares** | **FMS** | **New York Stock Exchange** |
| **Ordinary shares, no par value** | **N/A** | **New York Stock Exchange**<sup>(1)</sup> |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Not for trading, but only in connection with the registration of American Depositary Shares representing such shares.

Securities registered or to be registered pursuant to Section 12(g) of the Act: **None**

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: **None**

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report:

Ordinary Shares, no par value: 279,288,885

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

☒ Yes&nbsp;&nbsp;&nbsp;&nbsp;☐ No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

☐ Yes&nbsp;&nbsp;&nbsp;&nbsp;☒ No

[**Table of Contents**](#TOC)

Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes&nbsp;&nbsp;&nbsp;&nbsp;☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

☒ Yes&nbsp;&nbsp;&nbsp;&nbsp;☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of "large accelerated filer, "accelerated filer," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ <br> Emerging growth company ☐

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards<sup>†</sup> provided pursuant to Section 13(a) of the Exchange Act. ☐

†&nbsp;&nbsp;&nbsp;&nbsp; The term "new or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

☐&nbsp;&nbsp;&nbsp;&nbsp;U.S. GAAP

☒&nbsp;&nbsp;&nbsp;&nbsp;International Financial Reporting Standards as issued by the International Accounting Standards Board

☐&nbsp;&nbsp;&nbsp;&nbsp;Other

If "Other" has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:

☐&nbsp;&nbsp;&nbsp;&nbsp;Item 17

☐&nbsp;&nbsp;&nbsp;&nbsp;Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes&nbsp;&nbsp;&nbsp;&nbsp;☒ No

------

[**Table of Contents**](#TOC)

**Table of contents**

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **Page** |
| **Introduction** |  |  |  |
| [**Part I**](#PartI_305172) |  |  |  |
| [Item 1.](#Item1Identityofdirectors_486075) | N/A | [Identity of directors, senior management, and advisors](#Item1Identityofdirectors_486075) | 6 |
| [Item 2.](#Item2Offerstatistics_453633) | N/A | [Offer statistics and expected timetable](#Item2Offerstatistics_453633) | 6 |
| [Item 3.](#Item3Keyinformation_949764) |  | [Key information](#Item3Keyinformation_949764) | 6 |
| [Item 4.](#Item4Informationonthe_557471) |  | [Information on the Company](#Item4Informationonthe_557471) | 21 |
| [Item 4A.](#Item4AUnresolvedstaff_457219) | N/A | [Unresolved staff comments](#Item4AUnresolvedstaff_457219) | 67 |
| [Item 5.](#Item5Operatingandfinancial_588770) |  | [Operating and financial review and prospects](#Item5Operatingandfinancial_588770) | 68 |
| [Item 6.](#Item6Directorsseniormanagement_582668) |  | [Directors, senior management, and employees](#Item6Directorsseniormanagement_582668) | 103 |
| [Item 7.](#Item7Majorshareholdersand_481100) |  | [Major shareholders and related party transactions](#Item7Majorshareholdersand_481100) | 143 |
| [Item 8.](#Item8Financialinformatio_342628) |  | [Financial information](#Item8Financialinformatio_342628) | 146 |
| [Item 9.](#Item9Theofferandlisting_40424) |  | [The offer and listing](#Item9Theofferandlisting_40424) | 147 |
| [Item 10.](#Item10Additionalinformation_785752) |  | [Additional information](#Item10Additionalinformation_785752) | 148 |
| [Item 11.](#Item11Quantitativeandqualitativedisclosu) |  | [Quantitative and qualitative disclosures about market risk](#Item11Quantitativeandqualitativedisclosu) | 156 |
| [Item 12.](#Item12Descriptionofsecuritiesotherthaneq) |  | [Description of securities other than equity securities](#Item12Descriptionofsecuritiesotherthaneq) | 158 |
| [**Part II**](#PartII_486390) |  |  |  |
| [Item 13.](#Item13Defaultsdividendarrearages_576264) | N/A | [Defaults, dividend arrearages, and delinquencies](#Item13Defaultsdividendarrearages_576264) | 160 |
| [Item 14.](#Item14Materialmodificationstotherights_5) | N/A | [Material modifications to the rights of security holders and use of proceeds](#Item14Materialmodificationstotherights_5) | 160 |
| [Item 15A.](#Item15ADisclosurecontrolsand_636192) |  | [Disclosure controls and procedures](#Item15ADisclosurecontrolsand_636192) | 160 |
| [Item 15B.](#Item15BManagementsannualreportoninternal) |  | [Management's annual report on internal control over financial reporting](#Item15BManagementsannualreportoninternal) | 160 |
| [Item 15C.](#Item15CAttestationreportoftheindependent) |  | [Attestation report of the registered public accounting firm](#Item15CAttestationreportoftheindependent) | 160 |
| [Item 15D.](#Item15DChangesininternalcontrolover_3625) |  | [Changes in internal control over financial reporting](#Item15DChangesininternalcontrolover_3625) | 160 |
| [Item 16A.](#Item16AAuditcommitteefinancial_46683) |  | [Audit committee financial expert](#Item16AAuditcommitteefinancial_46683) | 161 |
| [Item 16B.](#Item16BCodeofethics_875342) |  | [Code of ethics](#Item16BCodeofethics_875342) | 161 |
| [Item 16C.](#Item16CPrincipalaccountantfees_217824) |  | [Principal accountant fees and services](#Item16CPrincipalaccountantfees_217824) | 161 |
| [Item 16D.](#Item16DExemptionsfromthelisting_986491) |  | [Exemptions from the listing standards for audit committees](#Item16DExemptionsfromthelisting_986491) | 162 |
| [Item 16E.](#Item16EPurchaseofequitysecuritiesbytheis) |  | [Purchase of equity securities by the issuer and affiliated purchasers](#Item16EPurchaseofequitysecuritiesbytheis) | 162 |
| [Item 16F.](#Item16FChangeinregistrantscertifying_914) |  | [Change in registrant's certifying accountant](#Item16FChangeinregistrantscertifying_914) | 162 |
| [Item 16G.](#Item16GCorporategovernance_660989) |  | [Corporate governance](#Item16GCorporategovernance_660989) | 162 |
| [Item 16H.](#Item16HMinesafetydisclosure_802260) | N/A | [Mine safety disclosure](#Item16HMinesafetydisclosure_802260) | 169 |
| [Item 16I.](#Item16IDisclosureregardingforeignjurisdi) | N/A | [Disclosure regarding foreign jurisdictions that prevent inspections](#Item16IDisclosureregardingforeignjurisdi) | 170 |
| [Item 16J.](#Item16JInsidertradingpolicies_84285) |  | [Insider trading policies](#Item16JInsidertradingpolicies_84285) | 170 |
| [Item 16K.](#Item16KCybersecurity_903083) |  | [Cybersecurity](#Item16KCybersecurity_903083) | 170 |
| [**Part III**](#PartIII_76871) |  |  |  |
| [Item 17.](#Item17Financialstatements_987138) | N/A | [Financial statements](#Item17Financialstatements_987138) | 171 |
| [Item 18.](#Item18Financialstatements_487707) |  | [Financial statements](#Item18Financialstatements_487707) | 171 |
| [Item 19.](#Item19Exhibits_782434) |  | [Exhibits](#Item19Exhibits_782434) | 171 |

---

i

[**Table of Contents**](#TOC)

#### Certain defined terms
In this report, "FME AG," "Fresenius Medical Care," or the "Company," "we", "us," or "our" refers to Fresenius Medical Care AG or to Fresenius Medical Care AG and its subsidiaries on a consolidated basis, as the context requires. "FMCH" and "D-GmbH" refer, respectively, to Fresenius Medical Care Holdings, Inc., the holding company for our North American operations, and to Fresenius Medical Care Deutschland GmbH, one of our German subsidiaries. In addition, "Fresenius SE" and "Fresenius SE & Co. KGaA" refer to Fresenius SE & Co. KGaA. Fresenius SE owns 76,814,594, or 26.2%, of our 293,413,449 issued shares as of February 13, 2026, as reported herein. In this report, we use Fresenius SE to refer to that company as a partnership limited by shares, effective on and after January 28, 2011, as well as both before and after the conversion of Fresenius AG from a stock corporation under German law into a European Company (*Societas Europaea*) on July 13, 2007. "Management Board" and "our Management Board" refer to the members of the management board of FME AG and, except as otherwise specified, "Supervisory Board" and "our Supervisory Board" refer to the supervisory board of FME AG.

The term "Care Enablement" refers to the Company's Care Enablement operating segment, the term "Care Delivery" refers to the Care Delivery operating segment and the term "Value-Based Care" refers to the Company's new Value-Based Care operating segment. The Care Enablement segment is primarily engaged in the distribution of healthcare products and equipment, including research and development (R&D), manufacturing, supply chain, and commercial operations, as well as supporting functions such as regulatory and quality management. The Care Delivery segment is primarily engaged in providing healthcare services for the treatment of chronic kidney disease (CKD), end stage renal disease (ESRD), and other extracorporeal therapies. Care Delivery also includes the pharmaceutical products business and the income from equity method investees related to the sale of certain renal pharmaceuticals from Vifor Fresenius Medical Care Renal Pharma Ltd., which are used in the Company's clinics to provide healthcare services to its patients. As of June 1, 2025, a new reportable segment, "Value-Based Care," was created to align with recent changes to internal management reporting. The Value-Based Care operating segment is primarily focused on value-based kidney care, including contracting and performance management, clinical care models supported by a national network of nephrologists, and tech-enabled platforms that leverage proprietary informatics and patient engagement tools. Value and risk-based care arrangements with private payors or government programs may include shared savings or losses from reductions or increases in the overall medical spend of a population under management which are accounted for in accordance with IFRS<sup>®</sup> 15, Revenue from Contracts with Customers. Premiums and medical costs included in full risk arrangements, however, are accounted for in accordance with IFRS 17, Insurance Contracts. Premium revenue and claim costs are presented separately as insurance revenue and insurance costs of revenue, respectively, on the consolidated statements of income and constitute the majority of revenue and costs of revenue for the segment. Prior to June 1, 2025, discrete financial information was not provided to the chief operating decision maker on the basis of the new structure and the necessary systems and reporting changes to effect the new structure were not in place. The operating segments are determined based upon how the Company manages its businesses and allocates resources with responsibilities by products and services and is aligned to the financial information that is presented on a quarterly basis to the chief operating decision maker.

Our Global Medical Office, which seeks to optimize medical treatments and clinical processes within the Company and supports both Care Delivery and Care Enablement, is centrally managed and its profit and loss are allocated to those specific segments. Similarly, costs related primarily to headquarters overhead charges, including accounting and finance as well as certain human resources, legal, and IT costs, are allocated as these costs are attributable to the segments, and used in the allocation of resources to Care Delivery and Care Enablement. These costs are allocated at budgeted amounts, with the difference between budgeted and actual figures recorded at the corporate level. The Value-Based Care segment maintains its own separate finance, accounting, human resources, legal, medical office, and other administrative functions and is therefore excluded from the allocation process. Additionally, certain costs, which relate mainly to shareholder activities, management activities, global internal audit, and the remeasurement of certain investments and virtual power purchase agreements, are not allocated to a segment but are accounted for as corporate expenses. These activities do not fulfill the definition of a segment according to IFRS 8, Operating Segments, and are reported separately as Corporate (Corporate). Interest income, interest expense, and tax expense are neither included within the measure of segment profit or loss reviewed by the chief operating decision maker nor otherwise regularly provided to the chief operating decision maker by segment and are therefore not included in the presented segment information. While interest income, interest expense, and tax expense are not included in segment profit or loss, these items are reviewed and monitored at the consolidated level by management as part of its overall financial performance assessment. See note 29 of the notes to the consolidated financial statements included in this report for a further discussion on our operating segments.

[**Table of Contents**](#TOC)

At an extraordinary general meeting (EGM) of the Company held on July 14, 2023, the shareholders of the Company approved a proposal to change the legal form of the Company from a partnership limited by shares (*Kommanditgesellschaft auf Aktien* – KGaA) into a stock corporation (*Aktiengesellschaft* – AG), (the Conversion). Upon effectiveness of the Conversion, which occurred upon registration of the Conversion with the competent commercial register on November 30, 2023, Fresenius Medical Care Management AG, the Company's former general partner (Management AG) exited the Company, Fresenius SE ceased to control (as defined by IFRS 10, Consolidated Financial Statements) the Company and the Company ceased to be a member of the Fresenius SE consolidated group.

The abbreviations "K," "M," and "BN" are used to denote the presentation of amounts in thousands, millions, and billions, respectively. All references in this report to the notes to our financial statements are to the notes to the consolidated financial statements included in this report.

#### Forward-looking statements
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). When used in this report, the words "outlook," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "guidance," "target," and similar expressions are generally intended to identify forward looking statements. Although we believe that the assumptions and expectations reflected in such forward-looking statements are reasonable, forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy and some of which might not be anticipated. Additionally, subsequent events and actual results, financial and otherwise, have differed in the past and, going forward, could differ materially from those set forth in or contemplated by the forward-looking statements contained elsewhere in this report. We have based these forward-looking statements on current estimates and assumptions made to the best of our knowledge. By their nature, such forward-looking statements involve risks, uncertainties, assumptions, and other factors which could cause actual results, including our financial condition and profitability, to differ materially, positively or negatively, relative to the results expressly or implicitly described in or suggested by these statements. Moreover, forward-looking estimates or predictions derived from third parties' studies or information may prove to be inaccurate. Consequently, we cannot give any assurance regarding the future accuracy of the opinions set forth in this report or the actual occurrence of the projected developments described herein. In addition, even if our future results meet the expectations expressed here, those results may not be indicative of our performance in future periods.

These risks, uncertainties, assumptions, and other factors, including associated costs, could cause actual results to differ from our projected results and include, among others, the following:

● changes in governmental and private payor reimbursement for our complete products and services portfolio, including the United States (U.S. or USA) Medicare and Medicaid reimbursement systems for dialysis and other healthcare services, including potentially significant changes to the Patient Protection and Affordable Care Act of 2010 (Pub.L. 111-148), as amended by the Health Care and Education Reconciliation Act (Pub.L. 111-152) (collectively, ACA) that could result from the expiration of insurance premium subsidies previously available (until their expiration on December 31, 2025) for certain ACA coverage purchased through health care exchanges, which we assume will cause some of our patients to shift from private ACA exchange insurance to other types of reimbursement systems such as Medicare, Medicaid, or other commercial insurance which could lead to an overall decline in reimbursement, or future efforts to revise, repeal or replace the ACA, further legislative efforts to restrict eligibility for Medicaid and changes by regulators to certain reimbursement models, such as the Comprehensive Kidney Care Contracting (CKCC) model, which could significantly impact performance under these models in unanticipated ways;

[**Table of Contents**](#TOC)

● our ability to accurately interpret and comply with complex current and future government regulations applicable to our business including sanctions and export control laws and regulations, laws and regulations in relation to environmental, social, and governance topics, the impact of healthcare, tax and trade law reforms, in particular the Organisation for Economic Co-operation and Development (OECD) initiatives for the reallocation of taxation rights to market countries (Pillar one) and introduction of a global minimum tax (Pillar two) as well as potential countermeasures to OECD Global Tax deals, antitrust and competition laws in the countries and localities in which we operate, other government regulation including, in the U.S., the federal Medicare and Medicaid Fraud and Abuse Amendments of 1977, as amended (the Anti-Kickback Statute), the False Claims Act, the federal Physician Self-Referral Law (the Stark Law), the Civil Monetary Penalty Law, the Health Insurance Portability and Accountability Act, the Health Information Technology for Economic and Clinical Health Act, the Federal Trade Commission Unfair and Deceptive Trade Practices Rule, the Foreign Corrupt Practices Act (FCPA), state laws and judicial rulings prohibiting or limiting enforcement of non-compete clauses, the U.S. Securities and Exchange Commission ' s (SEC) climate disclosure rules (which are subject to litigation contesting their validity in the Eighth Circuit Court of Appeals, which has stayed the litigation and ordered the SEC to decide whether to defend the challenged rules or reconsider the rules by statutory notice-and-comment rulemaking) and other similar state laws, as well as the Food, Drug and Cosmetic Act, the U.S. Department of Justice Data Security Program, and, outside the U.S. (International), inter alia, the European Union (EU) Medical Device Regulation (MDR), the EU General Data Protection Regulation, the EU Taxonomy Regulation, the EU Corporate Sustainability Reporting Directive (CSRD), the EU Artificial Intelligence Act, the NIS 2 Directive (Directive (EU) 2022/2555), the German Act on Human Rights Due Diligence in Supply Chains, the EU Due Diligence Directive, the two invoice policy, " Buy China " policy, volume-based procurement policies and the Tendering and Bidding Law in China and other related local legislation, as well as other comparable regulatory regimes in many of the countries where we supply healthcare services and/or products.

● the influence of private payors (including integrated care organizations, commercial insurance, and Medicare Advantage plans, also known as Medicare Part C, offered by private health insurers approved by CMS to provide their members with Medicare Part A, Part B and usually Part D benefits (Medicare Advantage or MA plans), as well as efforts by these organizations to manage costs by limiting healthcare benefits, narrowing their networks, reducing provider reimbursement, implementing prior authorization requirements, and/or restricting options for patient funding of health insurance premiums, including efforts by employer group health plans (EGHPs) and commercial insurers to make dialysis reimbursement payments at a lower rate as a result of the U.S. Supreme Court's ruling in *Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc. et al. 142 S. Ct. 1968 (2022)* (Marietta), particularly if the U.S. Congress fails to enact legislation that would reverse the effects of that decision;

● the impact of worldwide pandemics (for example, the severe acute respiratory syndrome coronavirus 2 and the related Coronavirus disease (COVID-19) pandemic), including, without limitation, increased opposition to vaccinations that could mitigate the severity and spread such diseases, changes in government policies that have reduced the number of recommended vaccines and deferred the recommended timing of their administration, any or all of which could affect patient vaccine hesitancy and whether commercial insurers cover, without cost-sharing, vaccine costs for certain insureds and potentially reduce the vaccinated population, a significant increase in mortality of patients with chronic kidney diseases as well as an increase in persons experiencing renal failure, the impacts of global viruses on our patients, caregivers, employees, suppliers, supply chain, business, and operations, and consequences of economic downturns resulting from global pandemics;

[**Table of Contents**](#TOC)

● our ability to attract and retain skilled employees and risks that competition for labor, high turnover rates, and meaningfully higher personnel costs as well as legislative, union, or other labor-related activities or changes have and will continue to result in significant increases in our operating costs, decreases in productivity, and partial suspension of operations, and to impact our ability to address additional treatments and growth recovery;

● the increase in raw material, energy, labor, and other costs, including an impact from these cost increases and/or supply chain impacts on our cost savings initiatives and increases due to geopolitical conflicts in certain regions (for example, impacts related to the war between Russia and Ukraine (Ukraine War)) as well as the impact that inflation may have on a potential impairment of our goodwill, investments, or other assets as noted above;

● the outcome of litigation as well as government and internal investigations;

● launch of new technology, introduction of generic or new pharmaceuticals and medical devices that compete with our products or services, advances in medical therapies, including the increased utilization of pharmaceuticals that reduce the progression of CKD and its precursors, xenotransplantation research, and development and new market entrants that compete with our businesses (further information regarding the impact of certain pharmaceuticals that reduce the progression of CKD and our analysis of their impact on our cash flow projections and goodwill sensitivity assessments can be found in note 2 a) of the notes to the consolidated financial statements included in this report);

● product liability risks and the risk of recalls of our products by regulators;

● our ability to successfully launch our 5008X dialysis machine and related disposables and introduce high- volume hemodiafiltration (HVHDF) in the U.S. and otherwise to continue to grow our healthcare services and products businesses, organically and through acquisitions, including, with respect to acquisitions, the effects of increased enforcement of antitrust and competition laws, and to implement our strategy;

● the impact of currency and interest rate fluctuations, including the heightened risk of fluctuations as a result of geopolitical conflicts in certain regions, the impact of the current macroeconomic inflationary environment on interest rates, and a related effect on our borrowing costs;

● volatility in the valuation of financial instruments connected to energy prices or energy production volumes (such as virtual power purchase agreements (vPPAs)), including the heightened risk of volatility as a result of geopolitical conflicts in certain regions;

● potential impairment of our goodwill, investments, or other assets due to decreases in the recoverable amount of those assets relative to their book value, particularly as a result of sovereign rating agency downgrades coupled with an economic downturn in various regions, as a result of geopolitical conflicts in certain regions, or as a result of impacts from changes in government regulations affecting reimbursement;

● our ability to protect our information technology systems and protected health information and personally identifiable information against cyber-attacks and other unauthorized access and disclosure of personal data to prevent other data privacy or security breaches of our data (including data held by our third-party service providers), current and potential litigation arising from cybersecurity and privacy breaches, and the potential effects on our reputation, customer, or vendor relationships, business operations, or competitiveness of any cybersecurity incidents we or our service providers may incur, as well as our ability to effectively capture efficiency goals and align with contractual and other requirements related to data offshoring activities;

● changes in our costs of purchasing and utilization patterns for pharmaceuticals and our other healthcare products and supplies, the inability to procure raw materials, or disruptions in our supply chain;

● economic uncertainty resulting from the imposition of tariffs and proposals to impose tariffs (including, in each case, reciprocal retaliatory tariffs), and deferrals, modifications, and withdrawals of such tariffs and proposals, increases in tariffs and trade barriers that could result from withdrawal by single or multiple countries from multilateral trade agreements or the imposition of sanctions, and other countermeasures in the wake of trade disputes and geopolitical conflicts in certain regions along with the effects of global events, political and/or governmental volatility, and associated developments on healthcare systems, our patients or our business, as well as additional economic uncertainty resulting from budget impasses or government shutdowns;

[**Table of Contents**](#TOC)

● collectability of our receivables, which depends primarily on the efficacy of our billing practices, the financial stability, and liquidity of our governmental and private payors, services from third-party clearinghouses, customers, and intermediaries, as well as payor strategies to delay, dispute, or thwart the collection process;

● our ability to secure contracts and achieve cost savings and desired clinical outcomes in our operations, including in our value-based care operations and other healthcare risk management programs in which we participate or intend to participate;

● the greater size, market power, experience, and product offerings of certain competitors in certain geographic regions and business lines;

● the use of accounting estimates, judgments, and accounting pronouncement interpretations in our consolidated financial statements;

● our ability to continue to achieve projected cost savings and to implement our strategy to achieve higher margins. On June 17, 2025, we launched our new strategy, FME Reignite, announcing our increased profitability aspirations for 2030 and a new capital allocation framework to enhance value creation. Included within the announcement was the expansion of the transformation of our operating structure and steps to achieve cost savings (FME25 Program) by two years. The total program with its extension was renamed the FME25+ Program (FME25+ Program). The expanded program now targets a cumulative total of € 1.2 BN of sustainable savings by the end of 2027, including an additional € 400 M through operational efficiencies;

● our ability to improve our financial performance through the divestiture of non-core and dilutive assets; and

● our ability to achieve projected price increases for our products and corresponding services.

Important factors that could contribute to such differences are noted in Item 3.D, "Key Information — Risk factors," Item 4B, "Information on the Company — Business overview," and the notes to our audited consolidated financial statements included in this report.

Our business is also subject to other risks and uncertainties that we describe from time to time in our periodic public filings which can be accessed at the SEC website at www.sec.gov. Developments in any of these areas could cause our results to differ materially from the results that we or others have projected or may project.

The actual accounting policies, the judgments made in the selection and application of these policies, as well as the sensitivities of reported results to changes in accounting policies, assumptions, and estimates, are additional factors to be considered along with our financial statements and the discussion under "Results of operations" in Item 5 below, "Operating and financial review and prospects." For a discussion of our critical accounting policies, see note 2 of the notes to the consolidated financial statements included in this report.

Rounding adjustments applied to individual numbers and percentages shown in this and other reports may result in these figures differing immaterially from their absolute values. Some figures (including percentages) in this report have been rounded in accordance with commercial rounding conventions. In some instances, such rounded figures and percentages may not add up to 100% or to the totals or subtotals contained in this report. Furthermore, totals and subtotals in tables may differ slightly from unrounded figures contained in this report due to rounding in accordance with commercial rounding conventions. A dash (–) indicates that no data were reported for a specific line item in the relevant financial year or period, while a zero (0) is used when the pertinent figure, after rounding, amounts to zero.

#### Market and industry data
Except as otherwise specified herein, all patient and market data in this report have been derived using internal estimates and publicly available information collected by our internal market analysis tools. See Item 4.B, "Information on the Company — Business Overview — Major Markets and Competitive Position."

[**Table of Contents**](#TOC)

#### Part I

---

| | |
|:---|:---|
| **Item 1.** | **Identity of directors, senior management, and advisors** |

---

Not applicable

#### Item 2. Offer statistics and expected timetable
Not applicable

#### Item 3. Key information
We conduct our business on a global basis in various currencies with major operations located in the U.S. and Germany. We prepare our consolidated financial statements utilizing the euro as our reporting currency. We have converted the balance sheets of our non-euro denominated operations into euro at the exchange rates prevailing at the balance sheet date. Revenues and expenses are translated at the annual average exchange rates for the respective period, as shown.

A summary of the spot and annual average exchange rates for the euro to U.S. dollars for the last three years is set forth below. The European Central Bank (ECB) determines such rates (Reference Rates) based on the regular daily averaging of rates between central banks within and outside the European banking system. The ECB normally publishes the Reference Rates daily around 4 p.m. Central European Time (CET).

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exchange rates** |  |  |  |  |  |
|  | **December 31,** | **December 31,** |  |  |  |
|  | **2025** | **2024** | **2025** | **2024** | **2023** |
|  | spot exchange  | spot exchange  | average exchange | average exchange | average exchange |
|  | rate in € | rate in € | rate in € | rate in € | rate in € |
| 1 U.S. dollar | 0.85106 | 0.96256 | 0.88499 | 0.92386 | 0.92484 |

---

&nbsp;&nbsp;&nbsp;&nbsp;B. **Capitalization and indebtedness** 

Not applicable

&nbsp;&nbsp;&nbsp;&nbsp;C. **Reasons for the offer and use of proceeds** 

Not applicable

&nbsp;&nbsp;&nbsp;&nbsp;D. **Risk factors** 

Before you invest in our securities, you should be aware that the occurrence of any of the events described in the following risk factors or elsewhere in this report, and other events that we have not predicted or assessed could affect the outcome of forward-looking statements included in this report and/or have a material adverse impact on our business, financial condition, and results of operations. If the events described below or other unpredicted events occur, then the trading price of our securities could decline and you may lose all or part of your investment.

#### Risks relating to legal and regulatory matters
***We operate in a highly regulated industry such that the potential for legislative reform provides uncertainty and potential threats to our operating models and results.***

The delivery of healthcare services and products is highly regulated in virtually every country in which we operate. Proposals for legislative reform in these countries are often introduced to improve access to care, address quality of care issues and manage costs of the healthcare system. In the U.S., there have been efforts to pursue significant changes to existing healthcare programs, including efforts to repeal or replace the ACA which, while unsuccessful to date, continue. On June 17, 2021, the U.S. Supreme Court reversed lower court rulings that declared the ACA to be unconstitutional, holding that the states and other plaintiffs in the case did not have standing to challenge the law. If future efforts to limit or repeal the ACA are successful, such efforts could have significant effects on our businesses, both positive and negative, but the outcomes are impossible to predict.

[**Table of Contents**](#TOC)

In October 2017, the Trump administration discontinued making cost-sharing reduction (CSR) reimbursements to insurers, arguing that Congress failed to appropriate funding. In response, many state departments of insurance either allowed or required insurers to mitigate their losses by increasing the 2018 premiums on their ACA plans. Many insurers also mitigated the impact to themselves by "silver loading," a practice whereby the premiums for silver-level plans were increased to offset the loss of CSR payments. Silver loading may also have mitigated the impact of premium increases to some low-income consumers by increasing their premium tax credits. In 2019 and 2020, all states either permitted or required silver loading. In 2017, several insurers sued the U.S. federal government to reinstate CSR payments. On June 21, 2021, the U.S. Supreme Court denied requests from multiple insurers to review lower court decisions that held they were not entitled to full unpaid CSR payments. As a result, insurers are entitled to the unpaid CSRs, but the total amount they are owed must be offset by any excess premium tax credits received from premium increases for 2018 and beyond. As the expiration of ACA enhanced tax credits occurred on December 31, 2025 and was not extended, we assume that the resulting reduction in the availability of insurance through insurance exchanges established by the ACA and expiration of enhanced insurance premium subsidies previously available for certain ACA coverage purchased through health care exchanges will reduce the number of our patients with private ACA exchange insurance and shift such patients to Medicare and Medicaid. In addition, the Marietta ruling makes it easier for health plans to design plan benefits for Medicare eligible ESRD patients in a way that makes private health insurance relatively less attractive to ESRD patients and Medicare relatively more attractive. In the Marietta case, the questions presented involved whether the health plan violated the Medicare Secondary Payor Act (MSPA) by "taking into account" that plan beneficiaries are eligible for Medicare and/or by "differentiating" between the benefits that the plan offers to patients with dialysis versus others. On June 21, 2022, the U.S. Supreme Court reversed the Sixth Circuit decision and held that the EGHP for Marietta Memorial Hospital did not violate the MSPA.

The Restore Protections for Dialysis Patients Act, most recently introduced in the U.S. Congress in March 2025 but not enacted, would restore the interpretation of the Medicare Secondary Payer Act prior to the Marietta decision and ensure that patients cannot be discriminated against because of their need for dialysis. We cannot predict whether the U.S. Congress will enact this or any other proposed legislation that would reverse the potential effects of the Marietta decision. As Medicare and Medicaid reimbursement rates are generally lower than the reimbursement rates paid by commercial insurers, a shift of commercially insured patients to Medicare and Medicaid could have a material adverse impact on our business, financial condition, and results of operations. The Marietta ruling may also result in certain EGHPs reducing the benefits offered for dialysis, which could, depending on the number of patients impacted, have a material and adverse impact on our business, financial condition, and results of operation. There can be no assurance that this proposal or any other legislation to address the Marietta decision will be enacted. See "Changes in reimbursement, payor mix and/or governmental regulations for healthcare could materially decrease our revenues and operating profit" below.

#### Changes in reimbursement, payor mix and/or governmental regulations for healthcare could materially decrease our revenues and operating profit.
We receive reimbursement for our healthcare services from both public, government-sponsored payors and private, commercial payors. A large portion of our businesses is reimbursed by government payors, in particular the Medicare and Medicaid programs in the U.S. For the fiscal year ended December 31, 2025, approximately 16% of our consolidated revenues resulted from Medicare (excluding Medicare Advantage plans, also known as Medicare Part C, offered by private health insurers approved by CMS to provide their members with MA plans) and Medicaid reimbursement. The Medicare and Medicaid programs change their payment methodologies and funding from time to time in ways that are driven by changes in statute, economic conditions, and policy, but do not always keep pace with cost increases. For example, the Budget Control Act of 2011 (BCA) required a $1.2 trillion reduction in deficits through 2021. As a backup, if Congress could not agree on proposals to reach this target, sequestration or across-the-board spending cuts would go into effect (U.S. Sequestration). On April 1, 2013, a 2% reduction to Medicare payments took effect and continues in force. Additionally, the Statutory Pay-As-You-Go Act of 2010 (Statutory PAYGO) requires that if the Congressional Budget Office determines that Congress has passed legislation increasing the federal budget deficit, a 4% sequester cut for Medicare program payments would become effective. To date, Congress has passed legislation increasing the federal deficit on a number of occasions subsequent to the passage of Statutory PAYGO, but has always acted to prevent such sequestration from becoming effective. Spending cuts pursuant to the U.S. Sequestration have adversely affected our operating results in the past and will continue to do so. In addition, options to restructure the Medicare program in the direction of a defined contribution, "premium support" model, to shift Medicaid funding to a block grant or per capita arrangement, with greater flexibility for the states, have been proposed or considered from time to time. Changes in payment methodologies and funding or payment requirements of (without limitation) the End Stage Renal Disease Prospective Payment System (ESRD PPS), the Physician Fee Schedule, the Clinical Laboratory Fee Schedule, and the Ambulatory Surgical Center Payment System may have material effects on our operating results. We may also experience changes in the interpretation of government regulations by the courts. We have very little opportunity to influence or predict the magnitude of many of those changes. For further information regarding Medicare and Medicaid reimbursement, including new payment models proposed by executive order in July 2019 which are intended to encourage identification and earlier treatment of kidney disease, as well as increased home dialysis and transplants, see Item 4B, "Information on the Company — Business Overview — Regulatory and Legal Matters — Reimbursement."

[**Table of Contents**](#TOC)

The One Big Beautiful Bill Act (OBBBA) enacted in July 2025 includes provisions that limit coverage in Medicaid, Medicare, and the ACA exchanges. Medicaid provisions include approximately $1 trillion in funding cuts to Medicaid through 2034; limits on state-levied taxes on healthcare providers (so-called "provider taxes") (decreasing from 6% of provider revenues to 3.5% of net patient revenues by 2031) and limits on state-directed payment programs (from average commercial rates to either 100% (ACA expansion) or 110% (ACA non-expansion) of the Medicare payment rates, with certain exceptions), both often used to finance the states' share of Medicaid spending; increased eligibility verification; limitations on retroactive eligibility; prevention of certain non-citizens from enrolling or receiving benefits under Medicaid; requirement for states to implement cost-sharing for certain populations, among other provisions. Medicare provisions prohibit certain non-citizens from being eligible for Medicare. Revenues from Medicaid and other government sources (excluding Medicare and Medicare Advantage funds) represented 4.7% of U.S. patient service revenues for the year ended December 31, 2025. For further information regarding OBBBA, see Item 4B, "Information on the Company — Business Overview — Regulatory and Legal Matters — Healthcare reform."

Our patients make decisions about their insurance coverage among options that, depending on their personal circumstances and location, may include Medicare, Medicaid, Medicare Advantage plans, employer group health coverage, exchange plans, and other commercial coverage. Government reimbursement programs, including Medicare and Medicaid, generally pay less than commercial insurance, and Medicare Advantage plans generally pay less than other commercial plans. In addition, we may experience higher write-offs of Medicare deductibles and other cost-sharing amounts due to secondary uninsured and underinsured patients which would result in an increase in uncollectible accounts. As a result, the payments we receive from private payors generate a substantial portion of the profits we report. For further information, see the table "U.S. patient service revenue" detailing the percentage generated from government reimbursement and private payors in the U.S. in Item 4B, "Information on the Company — Business overview."

Any of the following events, among others, could have a material adverse impact on our business, financial condition, and results of operations:

● we may be subject to rejections of or reductions in reimbursement from private payors, including, for example, through their use of lower allowed charges rather than rates based on our billed charges;

● we may experience a reduction in our ability to obtain and retain commercially insured patients to utilize our healthcare services;

● efforts by private payors to continue to control the cost of and/or the eligibility for access to healthcare services, including relative to insurance products on and off the healthcare exchanges established by the ACA and potential efforts by employer group health plans and commercial insurers to limit benefits or reduce reimbursement for our services or eliminate reimbursement for some of our services;

● a portion of our business that is currently reimbursed by private insurers or hospitals may become reimbursed by integrated care organizations, which may use payment methodologies that reduce reimbursement for our services. There can be no assurance that we can achieve future price increases from private insurers and integrated care organizations offering private insurance coverage to our patients;

● if legislative or regulatory efforts or litigation to restrict or eliminate the charitable funding of patient insurance premiums are successful, our patients with coverage under publicly funded programs like Medicare may be unable to continue to pay the premiums for that coverage and may become uninsured for dialysis services. In addition, a portion of our patients who are currently covered by private insurers may be unable to continue to pay the premiums for that coverage and may become uninsured for dialysis services or may elect to transition to government funded reimbursement programs that reimburse us at lower rates for our services. See Item 4B, "Information on the Company – Business Overview – Regulatory and Legal Matters – Reimbursement – Potential changes impacting our private payors" for further information; or

● if we are unable to secure appropriate reimbursement arrangements for the pharmaceuticals we provide in our dialysis clinics, we could experience a material adverse effect on our operating results. An increased utilization of bundled pharmaceuticals as part of the ESRD PPS, the termination or expiration of certain payments made during a limited transitional period following incorporation of a pharmaceutical into the ESRD PPS, or decreases in reimbursement for pharmaceuticals outside the bundled rate may result in a material adverse impact on our results of operations.

For further information, see Item 4B, "Information on the Company — Business Overview — Regulatory and Legal Matters — Reimbursement."

[**Table of Contents**](#TOC)

In addition to the foregoing factors, the healthcare insurance industry is experiencing continuing consolidation among insurers and pharmacy benefit managers, including increasing buyer power and impacts on referral streams. Such consolidation could have a material adverse effect on our ability to negotiate favorable coverage terms and reimbursement rates.

***If we do not comply with the numerous governmental regulations applicable to our business, we could suffer adverse legal consequences, including exclusion from government healthcare programs or termination of our authority to conduct business, any of which would result in a material decrease in our revenue; this regulatory environment also exposes us to claims and litigation, including "whistleblower" suits.***

Our operations are subject to extensive governmental regulation in virtually every country in which we operate. We are also subject to other laws of general applicability, including antitrust, anti-bribery, and anti-corruption laws as well as sustainability requirements. The applicable regulations, which differ from country to country, cover areas that include:

● regulatory approvals for products or product improvements;

● regulatory approvals and oversight of clinical and certain non-clinical R&D activities;

● the quality, safety and efficacy of medical and pharmaceutical products and supplies;

● the operation and licensure of manufacturing facilities, laboratories, dialysis clinics, ambulatory surgery centers, and other healthcare facilities;

● product labeling, advertising, and other promotions;

● accurate reporting and billing for government and third-party reimbursement, including accurate and complete medical records to support such billing and, in the U.S., the obligation to report and return overpayments within 60 days of the time that the overpayment is identified and quantified;

● the discounting of reimbursed drug and medical device products and the reporting of drug prices to government authorities;

● limits on our ability to make acquisitions or certain investments and the terms of those transactions;

● the collection, dissemination, access, use, security, protection, and privacy of protected health information or other protected data, as well as requirements to report data breaches to regulatory agencies; and

● compensation of medical directors and other financial arrangements with physicians and other referral sources.

Failure to comply with one or more of these laws or regulations may give rise to a number of adverse legal consequences. These include, in particular, loss or suspension of federal certifications, loss or suspension of licenses under the laws of any state or governmental authority from which we generate substantial revenues, monetary and administrative penalties, product recalls, increased costs for compliance with government orders, complete or partial exclusion from government reimbursement programs, refunds of payments received from government payors and government healthcare program beneficiaries due to failures to meet applicable requirements, or complete or partial curtailment of our authority to conduct business. Any of these consequences could have a material adverse impact on our business, financial condition, and results of operations.

Our medical devices and drug products are subject to detailed, rigorous, and frequently changing regulation by numerous national, supranational, federal, and state authorities. In addition, our facilities and procedures and those of our suppliers are subject to periodic inspection by various regulatory authorities which may suspend, revoke, or adversely amend the authority necessary for research, manufacture, marketing, or sale of our products and those of our suppliers. We and our suppliers must incur expense and spend time and effort to ensure compliance with these complex regulations, and if such compliance is not maintained, we and our suppliers could be subject to significant adverse administrative and judicial enforcement actions in the future. These possible enforcement actions could include warning letters, injunctions, civil penalties, seizures of our products, and criminal prosecutions as well as dissemination of information to the public about such enforcement actions. These actions could result in, among other things, substantial modifications to our business practices and operations; refunds; a total or partial shutdown of production while the alleged violation is remedied; and recalls, withdrawals, or suspensions of current products from the market. Any of these events, in combination or alone, could disrupt our business and have a material adverse impact on our business, financial condition, and results of operations.

[**Table of Contents**](#TOC)

We operate many facilities and engage with other business associates to help conduct our healthcare activities. In such a widespread, global system, it is often difficult to maintain the desired level of oversight and control over the thousands of individuals employed by many affiliated companies and their business associates. We rely on our management structure, regulatory and legal resources, and the effective operation of our compliance programs to direct, manage, and monitor our operations, including the activities of our employees and their agents, to comply with government regulations. We cannot assure that our internal control policies and procedures will always protect us from intentional or inadvertent acts of our employees or agents that contravene our compliance policies or violate applicable laws. If employees were to deliberately, recklessly, or inadvertently fail to adhere to these regulations, then our authority to conduct business could be terminated and our operations could be significantly curtailed. Any such terminations or reductions could materially reduce our revenues. If we fail to identify in our diligence process or to promptly remediate any non-compliant business practices in companies that we acquire, we could be subject to penalties, claims for repayment, or other sanctions. Any such terminations or reductions could materially reduce our revenues, with a resulting material adverse impact on our business, financial condition, and results of operations. See also "Risks relating to internal control and compliance — We operate in many different jurisdictions and we could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar worldwide anti-corruption laws," below.

By virtue of this regulatory environment, our business activities and practices are subject to extensive review by regulatory authorities and private parties and continuing audits, subpoenas, other inquiries, claims, and litigation relating to our compliance with applicable laws and regulations. We may not always be aware that an inquiry or action has begun, particularly in the case of "qui tam" or "whistleblower" actions brought by private plaintiffs under the False Claims Act, which are initially filed under seal. We are the subject of a number of governmental inquiries and civil suits by governmental and private plaintiffs. For information about certain of these pending investigations and lawsuits, see note 25 of the notes to our consolidated financial statements included in this report.

In addition, future legislative or regulatory changes could affect procedures or decision making for approving medical devices or pharmaceuticals. Any such legislation or regulations, if enacted or promulgated, could result in a delay or denial of regulatory approval for our products. If any of our products do not receive regulatory approval, or there is a delay in obtaining approval, this also could have a material adverse impact on our business, financial condition, and results of operations.

#### Cyber-attacks or other privacy and data security incidents could disrupt our business and expose us to significant losses, liability, and reputational damage.
We and our third-party service providers routinely process, store and transmit substantial amounts of data in our operations, including sensitive personal information as well as proprietary or confidential information relating to our business or third parties. We may be subject to breaches of the information technology security systems we use both internally and externally with third-party service providers.

Cyber-attacks may penetrate our and our third-party service providers' security controls and result in the misappropriation or compromise of personal information or proprietary or confidential information, including such information which is stored or transmitted on the systems used by certain of our or their products, to create system disruptions, cause shutdowns (including disruptions to our production plants), or deploy viruses, worms, ransomware, denial-of-service attacks and other malicious software programs that attack our systems. We and our third-party service providers handle the personal information of our patients and beneficiaries, Patient Personal Data (PPD), throughout the U.S. and other parts of the world. We or our third-party service providers may experience a breach under the U.S. Health Insurance Portability and Accountability Act Privacy and Security Rules, the EU's General Data Protection Regulation and or other similar laws (Data Protection Laws), including the following events:

● impermissible use, access, or disclosure of unsecured PPD,

● a breach under Data Protection Laws when we or our business associates neglect to implement the required administrative, technical, and physical safeguards of its electronic systems and devices, or

● a data breach that results in impermissible use, access, or disclosure of personal identifying information of our employees, patients, and beneficiaries.

Our IT systems have been attacked in the past, resulting in certain patient data being illegally published. For information regarding our cybersecurity risk management and governance, see Item 16K. "Cybersecurity." For information regarding litigation relating to cybersecurity incidents we experienced in 2023, see note 25 of the notes to the consolidated financial statements included in this report.

[**Table of Contents**](#TOC)

When appropriate, we have filed complaints against the unknown attackers with the relevant authorities and we contacted the patients who were affected by the illegal data publication as well as other relevant regulatory agencies and stakeholders. While there has not been any material impact to our financial condition and results of operations as a result of these attacks, future cyber-attacks against our IT systems may result in a loss of financial data or interruptions of our operations that could have a material adverse impact on our business, financial condition, and results of operations in the future. The Ukraine War has increased the risk of cyber-attacks against our systems and data.

As we increase the amount of personal information or financial data that we store and share digitally, our exposure to these privacy and data breaches and cyber-attack risks increases (particularly as medical records are a high-value target), including the risk of undetected attacks, damage, loss or unauthorized disclosure or access, and the cost of attempting to protect against these risks also increases. While the availability of telehealth services is convenient and improves access to medical care, increased reliance on, and utilization of, telemedicine for delivery of healthcare services could also increase the risk of privacy violations and our vulnerability to data breaches and cyber-attacks. There are no assurances that our security technologies, processes, and procedures that we or our outside service providers have implemented to protect personal information and proprietary or confidential information and to build security into the design of our products will be effective. Any failure to keep our information technology systems, financial data and our patients' and customers' sensitive information secure from attack, damage, loss or unauthorized disclosure or access, whether as a result of our action or inaction or that of our third-party business associates or vendors that utilize and store such personal information on our behalf, could materially adversely affect our reputation and ability to continue normal operations. Additionally, such failure could expose us to mandatory public disclosure requirements, litigation and governmental enforcement proceedings, material fines, penalties and/or remediation costs, and compensatory, special, punitive and statutory damages, consent orders and other adverse actions, any of which could have a material adverse impact on our business, financial condition, and results of operations.

***If certain of our investments or value and risk-based care programs with healthcare organizations and healthcare providers are found to have violated the law, our business could be adversely affected.***

A number of the dialysis clinics and healthcare centers that we operate are owned, or managed, by entities in which one or more hospitals, physicians or physician practice groups hold an interest. Physician owners, who are usually nephrologists, may also provide medical director services and physician owners may refer patients to those centers or other centers we own and operate or to other physicians who refer patients to those centers or other centers we own and operate. We also have arrangements with physician practices to collaborate on our value and risk-based care programs with public and private payors. In the past, certain parties have attempted to utilize our disclosure of these arrangements as the basis for qui tam proceedings under the Anti-Kickback Statute and the Stark Law. Such attempts have not been successful to date. Because our relationships with physicians are governed by the federal and state anti-kickback statutes and other state fraud and abuse laws, we have structured our arrangements to comply with many of the criteria for safe harbor protection and waivers under the Anti-Kickback Statute; however, these arrangements do not always satisfy all elements of applicable safe harbors. While we have established comprehensive compliance policies, procedures and programs to ensure ethical and compliant business operations, if one or more of our arrangements, including value and risk-based care programs, were found to be in violation of the Anti-Kickback Statute, the Stark Law, analogous state laws, or other similar laws worldwide, we could be required to restructure or terminate them. We could also be required to repay Medicare, Medicaid as well as other federal healthcare program amounts pursuant to any prohibited referrals, and we could be subject to criminal and monetary penalties and exclusion from federal and state healthcare programs. Imposition of any of these penalties could have a material adverse impact on our business, financial condition, and results of operations. See note 25 of the notes to our consolidated financial statements included in this report.

***We are exposed to product liability, patent infringement and other claims which could result in significant costs and liability which we may not be able to insure on acceptable terms in the future.***

Healthcare companies are typically subject to claims alleging negligence, product liability, breach of warranty, malpractice and other legal theories that may involve large claims and significant defense costs whether or not liability is ultimately imposed. Healthcare products may also be subject to recalls, statutory or regulatory shipping holds and intellectual property rights (for example patents or trademarks) infringement claims which, in addition to monetary penalties, may restrict our ability to sell or use our products. We cannot assure that such claims will not be asserted against us, or, for example, that significant adverse verdicts will not be reached against us or that large scale recalls of our products will not become necessary. In addition, the laws of some of the countries in which we operate provide legal rights to users of pharmaceutical products that could increase the risk of product liability claims. Product liability and intellectual property rights infringement claims, other actions for negligence or breach of contract and product recalls or related sanctions could result in significant costs. These costs could have a material adverse impact on our business, financial condition, and results of operations.

[**Table of Contents**](#TOC)

While we have been able to obtain liability insurance in the past to partially cover our business risks, we cannot assure that such insurance will be available in the future either on acceptable terms or at all, or that our insurance carriers will not dispute their coverage obligations. In addition, FMCH, our largest subsidiary, is partially self-insured for professional, product and general liability, auto liability, and worker's compensation claims, up to pre-determined levels above which our third-party insurance applies. A successful claim for which we are self-insured or in excess of the limits of our insurance coverage could have a material adverse impact on our business, financial condition, and results of operations. Liability claims, regardless of their merit or eventual outcome, also may have a material adverse effect on our business and result in a loss of customer confidence in us or our products, which could have a material adverse impact on our business, financial condition, and results of operations. For information about certain of these pending investigations and lawsuits, see note 25 of the notes to our consolidated financial statements included in this report.

#### Risks relating to internal control and compliance
***We operate in many different jurisdictions and we could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar worldwide anti-corruption laws.***

The U.S. FCPA and similar worldwide anti-corruption laws generally prohibit companies and their intermediaries from making improper payments to public officials for the purpose of obtaining or retaining business. Our internal policies mandate compliance with these anti-corruption laws. We operate many facilities throughout the U.S. and other parts of the world. Our widespread, global operations have thousands of persons employed by many affiliated companies, and we rely on our management structure, regulatory and legal resources, and effective operation of our compliance program to direct, manage and monitor the activities of these employees and third-party intermediaries. On March 29, 2019, we entered into a non-prosecution agreement (NPA) with the U.S. Department of Justice (DOJ) and a separate agreement with the SEC in connection with its Cease and Desist Order (SEC Order) intended to resolve fully and finally the U.S. government allegations against us arising from DOJ and SEC investigations into conduct in countries outside the U.S. that violated the FCPA or other anti-bribery laws. As part of these agreements, we agreed to the appointment of an independent compliance monitor (the Monitor). On December 30, 2022, the Monitor certified to our implementation of an effective anti-corruption compliance program and submitted her final certification report on January 31, 2023. The DOJ and SEC accepted the Monitor's certification and the NPA and SEC Order expired on March 1, 2023 and March 29, 2023, respectively. While we continue to make significant investments in our compliance and financial controls and in our compliance, legal and financial organizations (including certain remaining recommendations of the Monitor) and are fully committed to compliance with the FCPA and other applicable anti-bribery laws, we cannot ensure that our internal control policies and procedures always will protect us from deliberate, reckless or inadvertent acts of our employees or third-party intermediaries that contravene our compliance policies or violate applicable laws. Our continued expansion, including in developing countries, could increase the risk of such violations in the future. Violations of these laws, or allegations of such violations, could disrupt our business and result in a material adverse impact on our business, financial condition, and results of operations.

In 2015, we self-reported to the German prosecutor conduct with a potential nexus to Germany and continued to cooperate with government authorities in Germany in their review of the conduct that prompted our and the U.S. government investigations.

For further information, see note 25 of the notes to our consolidated financial statements included in this report.

#### Risks relating to our business activities and industry
***If physicians and other referral sources cease referring patients to our healthcare service businesses and facilities or cease purchasing or prescribing our products, our revenues would decrease.***

In providing healthcare services, we depend upon patients choosing our healthcare facilities as the location for their care. Patients may select a facility based, in whole or in part, on the recommendation of their physician. Physicians and other clinicians typically consider a number of factors when recommending a particular dialysis facility, dialysis home program, pharmacy, physician practice, vascular surgery center, or cardiac catheterization center to an ESRD patient, including the quality of care, the competency of staff, convenient scheduling, and location and physical condition. Physicians may change their recommendations, which may result in the movement of new or existing patients to competing facilities, including facilities established by the physicians themselves. At most of our dialysis clinics and home programs, a relatively small number of physicians often account for the referral of all or a sizable portion of the patient base. We have no ability to dictate these recommendations and referrals. If a significant number of physicians or other referral sources cease referring their patients to our facilities and home programs or stop purchasing or prescribing our dialysis products, this would reduce our healthcare services and product business revenue and could materially adversely affect our overall operations.

[**Table of Contents**](#TOC)

#### As a company with operations spanning more than 140 countries, we face specific risks from our global operations.
We operate dialysis clinics in more than 30 countries and sell a range of products and services to customers in more than 140 countries. Our global operations are subject to a number of risks, including but not limited to the following:

● the economic and political situation in certain countries or regions could deteriorate, become unstable, or lead to armed conflict, as exemplified by the Ukraine War;

● geopolitical factors could intensify fluctuations in exchange rates, currency devaluations, and/or material increases in interest rates (for example, as a reaction from central banks to high inflation), any of which could adversely affect profitability and all of which have been heightened by the Ukraine War;

● sovereign rating agency downgrades coupled with an economic downturn in various regions or as a result of geopolitical conflicts in certain regions (for example, the Ukraine War) could result in impairment of our goodwill, investments or other assets due to decreases in the recoverable amount of those assets relative to their book value;

● we could face difficulties in enforcing and collecting accounts receivable under some countries' legal systems;

● local regulations could restrict our ability to obtain a direct ownership interest in dialysis clinics or other operations;

● some countries or economic unions may impose charges or restrictions, such as local content requirements, which restrict the importation of our products or give local manufacturers an advantage in tenders or provide large discounts to providers for certain purchases of our products;

● economic uncertainty resulting from the imposition of tariffs and proposals to impose tariffs (including, in each case, reciprocal retaliatory tariffs), and deferrals, modifications, and withdrawals of such tariffs and proposals, as well as actual increases in tariffs and trade barriers could affect both the sale of our products and importation of products and product components, including upon any withdrawal by the U.S. or other countries from multilateral trade agreements, or the imposition of sanctions, retaliatory tariffs and other countermeasures in the wake of trade disputes and geopolitical conflicts and wars in certain regions (for example the Ukraine War);

● we could experience transportation delays or interruptions or higher energy costs or energy shortages;

● growth and expansion into emerging markets could cause us difficulty due to greater regulatory barriers than in the U.S. or Western Europe, the necessity of adapting to new regulatory systems, and problems related to entering new markets with different economic, social, legal, and political systems and conditions; and

● we may not prevail in competitive contract tenders.

Any one or more of these or other factors relevant to global operations could increase our costs, reduce our revenues, or disrupt our operations, with possible material adverse impact on our business and financial condition.

Certain countries in which we market, manufacture or sell our products do not have laws which protect our intellectual property to the same degree as those in the U.S. or elsewhere and our competitors may gain market position by designing products that infringe upon our intellectual property rights. An inability to protect our intellectual property in these countries could have an adverse effect on our business, results of operations and financial condition.

[**Table of Contents**](#TOC)

We conduct humanitarian-related business and provide life-sustaining healthcare products and services directly or indirectly in sanctioned countries, such as Russia, Belarus, Iran, and Syria. We believe our humanitarian-related business is permitted by applicable sanctions regimes (or, in some cases is excluded from such regimes), and in light of the humanitarian nature of our products and services and the patient communities that benefit from our products, we expect to continue such activities, provided they continue to be permissible under or excluded from applicable export controls and economic sanctions. Life-sustaining healthcare products are usually not subject to trade sanctions/export controls. However, as a result of the escalation of EU, U.S., and other countries' trade sanctions targeting Russia and Belarus, certain spare parts and components for our products fall under product categories subject to restrictions. Sanctions programs often, but do not always, provide for certain exemptions or availability of licensure for medical or pharmaceutical purposes. Furthermore, product registration procedures may be affected in case technology/technical information on products or components to be submitted in such procedures is or becomes subject to export or transfer restrictions for a relevant country and in case relevant licenses cannot be obtained, which ultimately may also have an impact on marketability of affected products. At this time, we expect that such risk would mostly be limited to product registration procedures in Russia and Belarus as a result of the escalation of EU, U.S., and other countries' trade sanctions targeting Russia and Belarus, but it may also affect Eurasian Economic Union (EAEU) product registration procedures in other EAEU member states in case these involve an information exchange with Russian/Belarusian authorities of restricted technology/technical information and in case relevant licenses cannot be obtained. A violation of applicable economic sanctions or export controls laws and regulations could subject us to enforcement actions. Possible enforcement actions vary between jurisdictions and depend on the factual circumstances of the given violation, but could include criminal penalties, imprisonment of responsible individuals, administrative or civil penalties, restricted access to certain markets and reputational harm, among others. Our internal policies and procedures may not protect us from deliberate, reckless, or inadvertent acts of our employees or agents that contravene our compliance policies or violate applicable laws.

***If we fail to estimate, price for and manage medical costs in an effective manner, the profitability of our value and risk-based care programs could decline and could materially and adversely affect our results of operations, financial position and cash flows.***

Through our value and risk-based care programs, we assume the risk of both medical and administrative costs for certain patients in return for fixed periodic payments or potential reimbursement based on our achievement against set benchmark targets from governmental and commercial insurers. Specifically in the U.S., our participation in various value and risk-based care programs includes the CMS CKCC model and capitation, risk-based or shared savings agreements with commercial insurers in which FMCH receives fixed periodic payments against set benchmark targets to cover all or a defined portion of the medical costs of a defined population of patients. For information on the value-based programs in which we participate, see Item 4B, "Information on the Company — Business overview — Value-Based Care" and "— Regulatory and Legal Matters — Reimbursement."

Our profitability in our value-based agreements and risk products depends in part upon our ability to negotiate favorable financial terms, to manage a patient's care, to collaborate with our payor partners, to coordinate and collaborate effectively with other healthcare providers, to accurately document patients' health conditions for risk adjustment, and to find cost efficient, medically appropriate sites of service for our patients. Any failure to do so would limit our ability to improve the quality of patient care and health outcomes and to reduce medically unnecessary costs, which could lead to poorer performance under value and risk-based care programs.

The reserves that we establish in connection with the operation of our value and risk-based care programs are based upon assumptions and judgments concerning a number of factors, including trends in healthcare costs, expenses, patient hospitalization rates and other factors. To the extent the actual claims experience is less favorable than estimated based on our underlying assumptions, our incurred losses would increase, and future earnings could be adversely affected.

CMS relied on authority granted by the ACA to implement the CKCC model and seeks to deliver better health outcomes for ESRD patients while lowering CMS' costs. The current CKCC model is set to expire on December 31, 2027, which could adversely affect our business if not renewed or replaced with a new government program in 2028. In addition, efforts to repeal or replace the ACA, while unsuccessful to date, continue. For further information, see "We operate in a highly regulated industry such that the potential for legislative reform provides uncertainty and potential threats to our operating models and results" and Item 4B, "Information on the Company — Business Overview — Regulatory and Legal Matters — Reimbursement — Executive order-based models."

***Our sales and earnings growth depends, in part, on our ability to develop and expand our core kidney care business, efficiently manage costs and execute our portfolio optimization plan to exit non-core and dilutive assets, as well as realize anticipated cost savings within our expected timeframe.***

The healthcare industry experiences continuing consolidation, particularly among healthcare providers, as well as pressure on reimbursement and increasing costs, which requires us to identify both growth opportunities and efficiencies in the way we operate. Continuing consolidation in our industry could adversely affect our ability to find suitable acquisition targets and to increase future growth and product sales.

[**Table of Contents**](#TOC)

We also compete with other healthcare companies in seeking suitable acquisition targets and developing our core healthcare businesses. Our ability to make future acquisitions as well as develop our core kidney care business depends, in part, on the appropriate strategic target selection, the availability of financial resources and the current restrictions imposed by competition laws. The integration of acquired businesses may cause problems, e.g., by assuming unknown liabilities, underperformance subsequent to integration, associated requirements from competition authorities, or non-compliant business practices not disclosed by the seller or not uncovered during due diligence, any or all of which may result in our incurring unanticipated costs.

Our FME Reignite strategy includes the evolution of our business and reporting structure by creating three operating segments. As we continue to hone and optimize our business, we will continue assessing exiting unsustainable markets and non-core businesses and the cessation of certain R&D programs to enable more focused capital allocation towards areas in our core business that are expected to have higher profitable growth. In addition, in 2025 we began a limited launch of HVHDF to targeted Fresenius Kidney Care clinics with the aim of establishing HVHDF as a new standard of care in the U.S. dialysis industry, which we are expanding into a broader commercial launch in 2026 and beyond. While we believe the FME Reignite strategy, the FME25+ Program, and Legacy Portfolio Optimization (as defined in Item 4. "Information on the Company — A. History and development of the Company," below) are providing us with a more efficient way of both managing and growing the business, the amounts of anticipated cost savings and anticipated expenses related thereto as well as the effectiveness of the planned HVHDF launch in the U.S. involve risks, uncertainties, assumptions and other factors that may cause the timing of actual results, performance or achievements to be materially different. Assumptions relating to the FME25+ Program and the achievement of the aforementioned cost savings within the specified timeframe involve subjective decisions and judgments with respect to, among other things, the estimated impact of certain operational adjustments, labor management and labor relations (including our commitment to consult with works councils and other workplace representatives in good faith), and other cost and savings adjustments, as well as future economic, competitive, industry and market conditions and possible unanticipated effects from acquisitions, all of which are inherently uncertain and may not be completely within the control of our management. Although the Company's management believes these estimates and assumptions related to the timing of these savings to be reasonable, there can be no assurance that the estimates described herein will prove to be accurate, result in anticipated operational efficiencies or be implemented according to our previously announced timing. We expect that our security holders, investors, and other stakeholders will monitor both whether we achieve our anticipated FME25+ Program cost savings at our anticipated implementation cost levels and whether we meet our announced timing in doing so. Failure to realize the expected cost savings from the FME25+ Program within our announced timeframe described above could adversely impact the market for our securities and availability of financing, which, in addition, could limit our future growth, including growth in either our revenues or earnings. Lastly, investments in information systems and related projects are an important aspect and basis for the execution of our strategy. The inability to successfully complete such projects within the planned budget and timeframes could adversely affect our results of operations or otherwise impact the implementation of our strategic goals. Any or all of these factors could have an adverse effect on our business, financial condition, and results of operations. For further discussion on the impacts to our business in 2025 (see Item 5. "Operating and financial review and prospects — III. Results of operations, financial position and net assets").

#### Our pharmaceutical product business could lose sales to generic drug manufacturers or new branded drugs.
Our branded pharmaceutical product business is subject to significant risk as a result of competition from manufacturers of generic drugs and other new competing medicines or therapies. The expiration or loss of patent protection for one of our products, the "at-risk" launch by a generic manufacturer of a generic version of one of our branded pharmaceutical products or the launch of new branded drugs that compete with one or more of our products could result in the loss of a major portion of sales of that branded pharmaceutical product in a very short time period, which could materially and adversely affect our business, financial condition, and results of operations. See note 25 of the notes to the consolidated financial statements included in this report.

[**Table of Contents**](#TOC)

#### Our competitors could develop superior technology or otherwise take advantage of new competitive developments that impact our sales.
We face numerous competitors, some of whom may possess substantial financial, marketing, or R&D resources. Competition from new and existing competitors, and especially new competitive developments such as pharmaceuticals that reduce the progression of chronic kidney disease, and innovations in technology and care delivery models could materially adversely affect the future pricing and sale of our products and services. In 2023, a study on glucagon-like peptide 1 (GLP-1) receptor agonists, regarding its effectiveness in treating CKD experienced by diabetic patients was terminated early as a result of the study having met certain prespecified clinical endpoints. GLP-1 receptor agonist and sodium-glucose cotransporter 2 (SGLT2) inhibitor utilization in the CKD population suggest an increase in the total CKD population and a reduction in the ESRD population growth rate that remain materially consistent with the patient population forecasts which do not include the utilization of these drugs. Considering the positive cardiovascular effects of the drugs, reducing mortality, as well as the progression-delaying effect on the CKD population, the Company sees a balanced effect of the drugs on the patient population. However, we cannot ensure that further developments or changes in population will not lead to a material adverse effect on our business and results of operations. Additional information regarding the impact of certain pharmaceuticals that reduce the progression of chronic kidney disease and our analysis of their impact on our cash flow projections and goodwill sensitivity assessments can be found in note 2 a) of the notes to the consolidated financial statements included in this report. In particular, technological innovation has historically been a significant competitive factor in the dialysis products business. The introduction of new products or services by competitors could qualify them for certain additional payments for new and innovative equipment or render one or more of our products or services less competitive or even obsolete, which could also affect, among other items, our sales and distribution of pharmaceuticals for which, to some extent, we are obligated to make certain minimum annual royalty payments.

#### Global economic conditions as well as disruptions in financial markets could have an adverse effect on our businesses.
We are dependent on the conditions of the financial markets and the global economy. To pursue our business, we are reliant on capital markets, as are our renal product customers and commercial healthcare insurers. Limited or more expensive access to capital in the financial markets could adversely affect our business and profitability. Among other things, the potential decline in federal and state revenues in a prolonged economic slowdown or recession could create additional pressures to contain or reduce reimbursements for our services from public payors around the world, including Medicare and Medicaid in the U.S. and other government sponsored programs in the U.S. and other countries around the world. Devaluation of currencies such as the impact from hyperinflationary economies as well as fluctuations in currencies as a result of geopolitical conflicts, unfavorable interest rate changes and uncertainty regarding the direction of such changes, worsening economic conditions, uncertainty arising from geopolitical conflicts regarding a possible deterioration of the global macroeconomic outlook, including inflationary cost increases in various markets in connection with deteriorating country credit ratings increase the risk of a goodwill impairment, which could lead to a partial or total goodwill write-off in the affected cash generating units, or have a negative impact on our investments and external partnerships. In addition, uncertainty as well as volatility in global financial markets, including the banking sector, and inflation could adversely affect the valuations of certain of our investments, interest rate-sensitive assets or liabilities or variable interest rates payable under our credit facilities or could make it more difficult to obtain or renew such facilities or to obtain other forms of financing in the future should access to these capital markets become restricted.

We have seen challenges in the labor market, in particular in the U.S., resulting in staff shortages, high turnover rates and meaningfully higher costs, which have and could continue to impact our growth, specifically in U.S. healthcare services where labor constraints affected our ability to increase treatment volumes. These impacts, combined with uncertainty in the macroeconomic environment, driving inflationary cost increases and supply chain constraints, have had a materially adverse effect on our results of operations. The current uncertainty in the macroeconomic environment has also intensified the risk that price increases and restricted access related to energy commodities, including the costs of oil, gas and electricity, may occur. Our implemented countermeasures may not offset a significant increase in prices, which could result in an adverse effect on our results of operations going forward.

Job losses or increases in unemployment rates could result in a smaller percentage of our patients being covered by employer group health plans and a larger percentage being covered by lower paying government reimbursement programs. To the extent that our commercial payors are negatively impacted by a decline in the economy, we may experience further pressure on commercial rates, a further slowdown in collections and a reduction in the amounts we are able to collect. Any or all of these factors, or other consequences of the continuation, or worsening, of domestic and global economic conditions could continue to have a material adverse effect on our businesses and results of operations.

[**Table of Contents**](#TOC)

***We could be adversely affected if we experience shortages of goods or material price increases from our suppliers, or an inability to access new and improved products and technology.***

Our business is dependent on the reliable supply of several raw materials and finished components for production and service purposes. If we are unable to obtain sufficient quantities of these materials at times of limited availability of such materials, this could result in delays in production or loss of sales and hence have an adverse effect on our results of operations. Similarly, price increases by suppliers (including from the impact of tariffs, inflation, or both) and the inability to access new products or technology could also adversely affect our results of operations. In particular, the lingering macroeconomic inflationary environment, together with geopolitical conflicts, have resulted in and could continue to lead to, among other consequences, material increases in costs for energy, supplies and transportation. Disruptions in supply, coupled with labor shortages, absenteeism, and turnover as well as labor cost increases have resulted and could continue to result in a negative impact on our business. All of these factors introduce additional risk to our operations and exposure to legal liability in the delivery of our goods and services.

Our procurement risk mitigation efforts include (i) the development of partnerships with strategic suppliers through framework contracts, (ii) where reasonably practicable, at least two sources for all supply and price-critical primary products (*dual sourcing, multiple sourcing*), and (iii) measures to prevent loss of suppliers, such as risk analyses as well as continuous supply chain monitoring. Any failure of these measures to mitigate disruptive goods shortages and potential price increases or to allow access to favorable new product and technological developments could have an adverse impact on our business and financial condition. In some cases, for reasons of quality assurance, cost effectiveness, or availability, certain components or raw materials needed to manufacture our products are obtained from a sole supplier. The failure of any of our single-source suppliers to fulfil their contractual obligations in a timely manner or as a result of regulatory noncompliance or physical disruption at a manufacturing site could adversely affect our ability to manufacture and distribute our products in a timely or cost-effective manner, and our ability to make product sales. Due to the stringent regulations and requirements of regulatory agencies, including the U.S. FDA, regarding the manufacture of our products, we may not be able to quickly establish additional or replacement sources.

#### Any material disruption in government operations and funding could have a material adverse impact on our business, financial condition, and results of operations.
A substantial portion of our revenues depends on government healthcare program reimbursement, and any disruptions in government operations could have a material adverse impact on our business, financial condition, and results of operations. If the governments with which we do business default on their debts, there could be broad macroeconomic effects that could raise our cost of borrowing funds, and delay or prevent our future growth and expansion. Any government shutdown, government default on debt, decline in government revenues during a prolonged economic slowdown and/or failure of governments to enact annual appropriations could have a material adverse impact on our business, financial condition, and results of operations. Additionally, material disruptions in government operations may negatively impact regulatory approvals and guidance that are important to our operations and create uncertainty about the pace of upcoming healthcare regulatory developments.

***If we are unable to attract and retain skilled medical, technical, engineering or key strategic personnel, or if legislative, union, other labor-related activities or changes or employee absenteeism and turnover result in significant increases in our operating costs or decreases in productivity, we may be unable to manage our growth, continue our technological development or execute our strategy.***

Our continued growth will depend upon our ability to attract and retain a skilled workforce, including highly skilled nurses, technicians, and other medical personnel. Our healthcare products business depends on the development of new products, technologies, and treatment concepts to be competitive, and for that we need to attract the best and most talented people, especially in R&D. Competition for those employees is intense and shortages for these sought-after employees, such as nurses, or skilled engineers and R&D personnel, as well as increased reliance on contracted nurses and other personnel, have increased our personnel and recruiting costs and may continue to do so, and/or could impair our reputation for production of technologically advanced products. Inflationary cost increases have also had, and may continue to have, an unfavorable effect on our personnel costs (including elevated medical benefit costs). In recent years, we experienced and may continue to experience, greater employee absenteeism and turnover and longer recruiting cycles which negatively impact our ability to produce and deliver the goods and services that we provide to our customers and our patients, as well as increased personnel costs. Moreover, we believe that future success in the provider business will be significantly dependent on our ability to attract and retain qualified physicians to serve as employees of or consultants to our healthcare services businesses.

[**Table of Contents**](#TOC)

Additionally, in recruiting, employing, and retaining personnel, we may be exposed to risks relating to various labor and staffing laws, legislative, union, or other labor-related activities or changes, and potential safety risks to personnel. These factors could also impact the integration of acquired companies into our operations, which could increase our costs, decrease our productivity and prevent us from realizing synergies from acquisitions. If we are unable to manage the risks above, then our growth and results of operations could be adversely impacted.

***If we are unable to meet applicable legal requirements and/or market expectations with respect to sustainability, both our business and our reputation could suffer. We could be subject to fines and other financial burdens associated with global environmental, social and governance regulations, laws and activities, and we could alienate our patients, employees, customers, partners, investors, and the communities we serve. Furthermore, if we do not meet investors' or certain markets' ESG standards, the market for our securities could be adversely impacted. At the same time, any efforts to meet ESG standards involving diversity and equity could subject us to allegations of unlawful discrimination.***

Companies' environmental, social, and governance (ESG) activities are facing increased scrutiny from stakeholders such as institutional and other investors, regulatory bodies, and non-governmental organizations (NGOs). Failure to effectively identify, conduct and manage the necessary sustainability and related reporting activities as required or expected, as well as effectually manage the impact of factors beyond our control, could cause us to incur additional costs or damage our brand. We could also be subject to financial and other penalties imposed by the respective authorities in the jurisdictions in which we do business. For example, a rise in prices of carbon emission rights stemming from the requirements of European Climate Law could increase our production costs. Such cost increases could have an adverse effect on our operations and results if we do not accurately plan for, and effectively implement, necessary sustainable business practices. Additionally, we entered into several vPPAs with wind and solar energy project developers in Germany and in the U.S. in order to receive guarantees of origin and renewable energy certificates, respectively, to address our sustainability objectives. However, volatility in the valuation of financial instruments connected to energy prices or energy production volumes, including as a result of the heightened risk of volatility due to geopolitical conflicts in certain regions, could result in a material adverse effect on our business or results of operations.

In addition to environmental risks, we also face several social risks. High staff turnover is a risk, not only due to the expense associated with hiring and training new staff, but also because it could affect our ability to serve our patients. For further information on personnel risks, see the risk factor "If we are unable to attract and retain skilled medical, technical, engineering or key strategic personnel, or if legislative, union, other labor-related activities or changes or employee absenteeism and turnover result in significant increases in our operating costs or decreases in productivity, we may be unable to manage our growth, continue our technological development or execute our strategy." above. Furthermore, companies are increasingly expecting their suppliers to share their commitment to sustainability and demonstrate sustainable business practices across their supply chains, including the ability to identify and mitigate risks related to human rights in their entire value chain in connection with the requirements of the German Supply Chain Due Diligence Act (*Lieferkettensorgfaltspflichtengesetz*) and other regulations, especially those passed or proposed within the EU. If we fail to comply with our legal obligations related to supply chain due diligence, we could face significant fines and be excluded from public tenders and contracts. We could also suffer reputational damage, especially given that our performance in this area is closely monitored by NGOs, investors, and others.

Considering these expectations, among other aspects, we have incorporated sustainability as a performance target for the compensation of our Management Board. Should management fail to meet these outcomes, investors and/or debt providers may not deem us the correct fit for their investment or financing purposes, thereby negatively impacting our share price or our ability to source funding through debt financing. Our €2 BN syndicated multicurrency sustainability-linked revolving credit facility agreement entered in July 2021 (Syndicated Credit Facility), which serves as a backup facility, includes a sustainability component, pursuant to which the credit facility's margin for any outstanding borrowings will rise or fall depending on our sustainability performance.

Our sustainability efforts, including those on diversity, equity and inclusion, are designed to comply with any applicable laws, in particular anti-discrimination laws and other legal requirements of the various jurisdictions in which we operate. We are monitoring relevant legal developments, including 2025 Executive Orders issued in the U.S., the DOJ Civil Rights Fraud Initiative and related DOJ guidance positing that federal funding recipients commit fraud by certifying compliance with federal anti-discrimination laws in their payment or reimbursement requests while maintaining programs that encourage diversity, equity, and inclusion and will review our activities in relevant Company entities as appropriate to facilitate ongoing compliance with applicable laws, in particular anti-discrimination laws, and related risk mitigation efforts.

A heightened focus by certain regulators and other stakeholders on ESG topics may result in more extensive regulatory requirements aimed at mitigating the effects of climate change and other current and future ESG-related developments as well as possible challenges in complying with differing ESG standards and possible increased opposition to initiatives we undertake to meet our ESG goals. Should further regulation (such as climate disclosure requirements for entities with operations in California, U.S.) or stakeholder expectations be more stringent in the future, we may experience increased compliance burdens and costs to meet regulatory obligations and we cannot currently estimate what impact existing and future regulations will have on our business, financial condition, and results of operations.

[**Table of Contents**](#TOC)

#### We are subject to risks associated with unpredictable events, such as public health crises and epidemics/pandemics or other significant events beyond our control.
We operate dialysis and manufacturing facilities and provide other services in many regions of the world, with diverse geographic, societal, political and economic conditions and we are subject to unpredictable events beyond our control such as natural disasters, terrorist attacks, social unrest or public health crises such as epidemics or pandemics from, for example, virus infections. Given the already compromised health condition of our typical dialysis patients, our patients represent a heightened at-risk population, particularly, but not limited to, during an epidemic or a pandemic which could lead to decreased treatments and increases in mortality rates in our patient population, resulting in an adverse impact on our operations. The COVID-19 global pandemic resulted in higher costs incurred to address staffing shortages, implement preventive measures to protect patients, employees, and others, as well as a material deterioration of supply chains and the conditions of the global economy and financial markets. Any such unforeseeable events could have a material adverse effect on our business, financial condition, and results of operations.

#### Risks relating to taxation and accounting
***There are significant risks associated with estimating the amount of healthcare service revenues that we recognize that could impact the timing of our recognition of revenues or have a significant impact on our operating results and financial condition.***

There are significant risks associated with estimating the amount of revenues from healthcare services that we recognize in a reporting period.

● The billing and collection process is complicated due to a number of factors including insurance coverage changes, geographic coverage differences, differing interpretations of plan benefits and managed care contracts, and uncertainty about reimbursement from payors with whom we are not contracted.

● Laws and regulations governing Medicare, Medicaid and other federal programs are extremely complex, changing, and subject to interpretation.

● Determining applicable primary and secondary insurance coverage for an extensive number of patients at any point in time, together with the changes in patient coverage that occur each month or changes in plan benefits, requires complex, resource-intensive processes. Errors in determining the correct coordination of benefits may result in refunds to payors.

● The complexity of estimating revenues from a primary payor also brings complexity to estimating revenues from secondary payors and patients.

● Collections, refunds, and payor retractions may continue to occur for up to three years or longer after services are provided.

If our estimates of revenues are materially inaccurate, it could impact the timing and amount of our recognition of revenues and have a significant impact on our operating results and financial condition. For further information regarding our revenue recognition policies, see note 1 k) of the notes to the consolidated financial statements included in this report.

#### Diverging views of fiscal authorities or changes in tax legislation could require us to make additional tax payments.
***We are subject to potential changes in tax legislation as well as to ongoing tax audits in Germany, the U.S., and other jurisdictions. We have received notices of unfavorable adjustments and disallowances in connection with certain of these audits. Additionally, tax legislation in countries in which we operate is subject to constant change and development. For example, legislation seeking to impose additional income taxes against discriminatory or territorial tax of foreign jurisdictions could have negative effects on the amount of income tax expense which are currently unpredictable. If we are unsuccessful in contesting the above-mentioned notices or other unfavorable determinations or if tax legislation changes unfavorably in countries in which we operate, we could be required to make additional tax payments, which could have a material adverse impact on our business, financial condition, and results of operations. See Item 5, "Operating and financial review and prospects — IV. Financial position." For further information on the German tax authorities' objections to our previously filed tax returns, see note 25 of the notes to the consolidated financial statements included in this report.***

[**Table of Contents**](#TOC)

#### A dependency on the payment behavior and decision-making of our business partners can affect the collectability of accounts receivable and impact our operating results.
Our business differs across the regions in which we operate. In many cases, our products and services are paid for, either directly or indirectly, by government institutions. We believe the risk of default from a government payor is generally low to moderate worldwide which could, however, prove to be wrong, particularly in the event of a budget approval impasse or government shutdown which could result in significant payment delays even if it does not create a default. On a country level, the customer and payor mix is characterized by distinct customer or payor groups which can range in volume from a few customers to a considerable amount of customer types which have varying levels of risk associated with default or non-payment of receivables as well as risks for dependencies based upon the competition within low volume customer base environments. In certain cases, a resulting dependency on the payment behavior and decision-making of our business partners (for example, a decision to discontinue tender contracts or high-volume customer contracts) can affect the collectability of accounts receivable and can adversely affect our business, results of operations and financial condition. Our measures aiming to mitigate these risks by actively negotiating long-term contracts with major customers, targeted marketing activities, developing new product and pricing models as well as improving the quality of our services and products, could be insufficient or ineffective.

#### Risks relating to our financial condition and our securities

#### Our indebtedness may prevent us from fulfilling our debt-service obligations or implementing certain elements of our business strategy.
***At December 31, 2025, we had consolidated debt (including lease liabilities as well as debt and lease liabilities included within liabilities directly associated with assets held for sale) of €10,795 M and consolidated total shareholders' equity of €14,283 M (€10,988 M and €15,769 M, respectively at December 31, 2024). Our debt could jeopardize the successful execution of our business strategy, increase our vulnerability to general adverse economic conditions, limit our ability to obtain necessary financing to fund future working capital needs, capital expenditures, payment of dividends and other general corporate requirements, require us to dedicate a substantial portion of our cash flow from operations, as well as the proceeds of certain financings and asset dispositions, to payments on our indebtedness, thereby reducing the availability of our cash flow and such proceeds to fund other purposes, limit our flexibility in reacting to changes in our business and the industry in which we operate, place us at a competitive disadvantage compared to our competitors that have less debt, limit our ability to pursue possible future acquisitions and sell assets, make it more difficult for us to satisfy our obligations under our debt securities, and limit our ability to borrow additional funds. A deterioration of our current rating could lead to a reintroduction of financial covenants, could limit our financial flexibility, increase our financing costs, or limit access to funding. In addition, due to the financing structure of certain areas of our business, put options held by physician investors may have financial, legal, and operational effects that may also enhance other risk areas if the valuation of these put options fails to meet investors expectations.***

***Our leverage makes us vulnerable to a downturn in the operating performance of our business, larger than normal fluctuations or volatility in our cash flow, or a downturn in economic conditions. Our ability to make payments on and to refinance our indebtedness will depend on our ability to generate cash in the future, which is dependent on various factors. These factors include governmental and private insurer reimbursement rates for medical treatment and general economic, financial, competitive, legislative, regulatory, and other factors that are beyond our control. If our cash flow is not sufficient to meet our debt service and principal payment requirements, we could be required to refinance our obligations or to dispose of assets in order to meet such requirements. In addition, from time to time we need to refinance our existing debt as and when it matures. In either case, there is no guarantee that we will be able to refinance our existing indebtedness on terms comparable to those governing our existing indebtedness. If our cash flow is not sufficient to meet our debt service and principal payment requirements, or if we are unable to refinance our existing indebtedness on acceptable terms, it could have a material adverse effect on our business, financial condition, or results of operations. For information about our outstanding indebtedness, see note 16 and note 17 of the notes to our consolidated financial statements included in this report.***

***Our Syndicated Credit Facility and certain of our other financing instruments include covenants which, among other things, restrict or could have the effect of restricting our ability to dispose of assets and create liens, and restrict the indebtedness of our subsidiaries. These covenants may otherwise limit our activities as well. The breach of any of the covenants could result in a default and acceleration of the indebtedness under the respective financing agreements, which could, in turn, create additional defaults and acceleration of the indebtedness under the agreements relating to our other long-term indebtedness which would have an adverse effect on our business, financial condition, and results of operations.***

FME AG is not subject to any covenant that limits its ability to incur unsecured debt, regardless of our credit rating. If additional debt is added to our current debt levels, the related risks that we now face from our indebtedness could intensify.

[**Table of Contents**](#TOC)

For information regarding our new capital allocation policy, see "Item 4, "Information on the Company — B. Business overview — Corporate strategy and objectives."

***Although Fresenius SE no longer controls our Company through ownership of 100% of Management AG, its significant share of ownership, certain provisions of our Articles of Association and certain provisions of our trademark license from Fresenius SE enable Fresenius SE to retain significant influence over the management of the Company.***

Under our Articles of Association, Fresenius SE has the right to appoint two of the six shareholder representatives to our Supervisory Board for as long as it holds 30% or more of the Company's share capital and the right to appoint one of the six shareholder representatives to the Supervisory Board for as long as it holds at least 15% (but less than 30%) of the Company's share capital, and to dismiss those shareholder representatives. The chair of our Supervisory Board is one of the Fresenius SE representatives. In the case of a tie in the Supervisory Board, the Chair has two votes in a new vote on the same matter if this also results in a tie. Under German law and our Articles of Association, certain matters requiring a resolution at our general meeting of shareholders require a qualified majority of 75% of the share capital represented at the time of the vote, including capital increases and decreases, the creation of authorized and conditional capital, the issuance of convertible bonds, corporate measures such as mergers or spin-offs, the conclusion of intercompany agreements (*Unternehmensverträge*) such as domination and/or profit and loss transfer agreements (*Beherrschungs- und/oder Gewinnabführungsverträge*), amendments to the Articles of Association, dissolution of the Company, mergers, a change in the legal form of the stock corporation and other fundamental changes. By virtue of its ownership of our share capital, Fresenius SE therefore has a de facto veto right over any such resolution or resolutions if and when proposed for adoption by our shareholders. In addition, the Conversion and deconsolidation of the Company from the Fresenius SE Group resulted in the termination of certain voting restrictions on Fresenius SE's shares in the Company, including a restriction on voting in the election of members of the Company's Supervisory Board and members of Fresenius SE's management board are now eligible to seek election to and serve on the Company's Supervisory Board. The present Fresenius SE designees on our Supervisory Board are the Chief Executive Officer and Chief Financial Officer, respectively, of Fresenius SE.

We use "Fresenius" in our name and trademarks under a royalty-free license from Fresenius SE. Under amendments to that license entered into in connection with the Conversion, Fresenius SE has the right to terminate the license if, among other causes, a direct competitor of Fresenius SE acquires control of the Company or any other third party acquires control of the Company and Fresenius SE, acting reasonably, expects such acquisition to result in a not insignificant risk of negative impact on the Fresenius brand. In both cases, "control" is defined as acquisition of 30% or more of our shares. Such termination is with immediate effect, but we may continue using the "Fresenius" name for 18 months to facilitate rebranding efforts. These termination rights could serve to discourage third parties from attempting to acquire control of the Company, because any such change of control could risk the Company losing the right to use its corporate name, logo and related trademarks. Such impediments to a change of control could adversely affect the price of our shares.

As a result of its share ownership, its de facto veto right over shareholders' votes requiring a qualified majority and its representation on the Supervisory Board (including the chair), Fresenius SE will continue to have the ability to exercise significant influence over the management of the Issuer in its form as a German Stock Corporation (*Aktiengesellschaft*), and the interests and rights of Fresenius SE could deviate from those of the Issuer.

---

| | |
|:---|:---|
| **Item 4.** | **Information on the Company** |

---

&nbsp;&nbsp;&nbsp;&nbsp;**A.** **History and development of the Company** 

#### General
Fresenius Medical Care AG is a stock corporation (*Aktiengesellschaft* or *AG*) organized under the laws of Germany, formerly known as Fresenius Medical Care AG & Co. KGaA, a partnership limited by shares (*Kommanditgesellschaft auf Aktien* or *KGaA*). FME AG is registered with the commercial register of the local court (*Amtsgericht*) of Hof (Saale), Germany, under the registration number HRB 6841. Our registered office (*Sitz*) is Hof (Saale), Germany. Our registered business address, and our principal office, is Else-Kröner-Strasse 1, 61352 Bad Homburg, Germany, telephone +49-6172-609-0.

[**Table of Contents**](#TOC)

#### History
The Company was originally incorporated on August 5, 1996 as a stock corporation. On September 30, 1996, we completed a series of transactions to consummate an Agreement and Plan of Reorganization entered into on February 4, 1996 by Fresenius SE (then Fresenius AG) and W.R. Grace & Co. which we refer to as the "Merger" elsewhere in this report. Pursuant to that agreement, Fresenius SE contributed Fresenius Worldwide Dialysis, its global dialysis business, including its controlling interest in Fresenius USA, Inc., in exchange for 105,630,000 FME AG ordinary shares. Thereafter, subsidiaries of Fresenius SE merged with and into:

● W.R. Grace & Co., whose sole business at the time of the transaction consisted of National Medical Care, Inc., its global healthcare business; and into

● Fresenius USA, Inc.,

pursuant to which W.R. Grace & Co. and Fresenius USA, Inc. became wholly owned subsidiaries of the Company and the shareholders of W.R. Grace & Co. and the shareholders of Fresenius USA, Inc. (other than Fresenius SE) exchanged their shares for 94,080,000 FME AG ordinary shares, and 10,290,000 FME AG ordinary shares, respectively.

On February 10, 2006, the Company completed the transformation of its legal form under German law from a German AG to a KGaA with the name Fresenius Medical Care AG & Co. KGaA, as approved by its shareholders during the EGM held on August 30, 2005. The Company as a KGaA was the same legal entity under German law, rather than a successor to the stock corporation.

As noted in "Certain defined terms" above, on November 30, 2023, the Company's legal form was changed from a KGaA to an AG having the legal name Fresenius Medical Care AG with Management AG exiting the Company and Fresenius SE ceasing to have control of the Company (as defined in IFRS 10).

Information regarding authorizations granted by our Annual General Meeting (AGM) to conduct share buyback programs and reconciliations of any treasury share purchases, repurchases, and retirements under such programs can be found in note 20 of the notes to the consolidated financial statements included in this report. The most recent authorization granted in May 2021 was confirmed at our 2023 EGM. For further information, see Item 16E. "Purchase of equity securities by the issuer and affiliated purchasers" and note 20 of the notes to the consolidated financial statements included in this report.

Effective December 31, 2025, pursuant to an agreement signed on October 17, 2025, Fresenius Medical Care Deutschland GmbH purchased the Company's production sites in Schweinfurt and St. Wendel, Germany, which were previously leased from Fresenius SE and certain of its affiliates (collectively, Fresenius SE Companies), for a total transaction cost of €181 M (including a purchase price paid to Fresenius SE Companies in the amount of €171 M). For further information, see note 6 of the notes to the consolidated financial statements included in this report.

On August 24, 2022, we completed a business combination including Fresenius Health Partners, Inc. (FHP), the value-based care division of Fresenius Medical Care North America. The new company, which operates under the Interwell Health brand (Interwell Health) and comprises our Value-Based Care segment, combined FHP's expertise in kidney care value-based contracting and performance, InterWell Health LLC's clinical care models and network of around 1,700 nephrologists and Cricket Health, Inc.'s (Cricket) tech-enabled care model that utilizes its proprietary informatics, StageSmart™ and patient engagement platforms. We aim to significantly improve the care of patients with chronic kidney disease and further expand our leading position in value-based care. In the third quarter of 2025, we settled put options held by non-nephrologist investors in connection with the business combination, increasing our ownership of Interwell Health from 75% to 92%. For further information, see note 26 of the notes to the consolidated financial statements included in this report.

In December 2023, we completed the divestiture of National Cardiovascular Partners (NCP), comprising 21 facilities providing outpatient cardiac catheterization and vascular laboratory services, which were previously included in the Care Delivery segment of our U.S. healthcare service business. The NCP divestiture was effected as part of our review of our business portfolio, mainly due to exiting unsustainable markets and divesting non-core businesses, as well as the cessation of certain R&D programs to enable more focused capital allocation towards areas in our core business that are expected to have higher profitable growth (Legacy Portfolio Optimization). Additionally during 2025, we divested our renal dialysis clinic facilities in Brazil, Kazakhstan, and Malaysia and select assets of our wholly owned Spectra Laboratories while in 2024 we divested our service businesses in Chile, Ecuador, Sub-Saharan Africa, Türkiye, Guatemala, Curacao, Peru, Colombia, and the Cura Day Hospitals Group in Australia, all in connection with the Legacy Portfolio Optimization plan. Further information regarding our divestitures as well as assets classified as held for sale, see notes 3 and 4 of the notes to the consolidated financial statements included in this report.

[**Table of Contents**](#TOC)

For further information regarding important events in the development in our business, such as material mergers by us or our significant subsidiaries, acquisitions and dispositions of material assets outside the ordinary course of our business, material changes in the way we conduct our business, material changes in the products we produce and the services we provide, see Item 4, "Information on the Company," in this Annual Report on Form 20-F for the year ended December 31, 2025 and our reports for prior years, filed with the SEC and also available on our website www.freseniusmedicalcare.com. In furnishing our website address in this report, however, we do not intend to incorporate any information on our website into this report, and any information on our website should not be considered to be part of this report, except as expressly set forth herein.

For information regarding our principal capital expenditures and divestitures since the beginning of our last financial year, and information concerning our principal capital expenditures and divestitures currently in progress, see Item 4, "Information on the Company — B. Business overview — Capital expenditures" and "— Acquisitions and investments" as well as Item 5, "Operating and financial review and prospects — III. Financial position — Net cash provided by (used in) investing activities."

The SEC website contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The SEC's website is www.sec.gov. For additional information regarding the availability of periodic reports and other information concerning us, see Item 10.H, "Documents on Display."

&nbsp;&nbsp;&nbsp;&nbsp;B. **Business overview** 

#### Our business
Fresenius Medical Care is the world's leading provider of products and services for individuals with kidney diseases based on publicly reported revenue. As a vertically integrated medical technology (MedTech) and healthcare service company, Fresenius Medical Care combines medical device engineering and manufacturing expertise with comprehensive patient care.

The incidence of kidney disease is increasing worldwide. A significant rise in the drivers of kidney disease, such as obesity, diabetes, and hypertension, has elevated it to a global public health epidemic. According to estimates, the number of people requiring dialysis globally is increasing at a rate of 4% to 5% each year and is expected to reach around 7 M people by 2035.

Our care models, technologies, and partnerships position us to meet the growing demand for life-sustaining services and products that are vital to millions of people living with kidney disease worldwide. Kidney patients require therapy, pharmaceuticals, medical technologies, and products that meet their individual needs and preferences, regardless of where they receive treatment, whether in one of our treatment centers, a hospital setting, at home, or when traveling.

In the three operating segments, Care Delivery (CD), Value-Based Care (VBC), and Care Enablement (CE), Fresenius Medical Care provides the full spectrum of healthcare services, systems, devices, technologies, products, and pharmaceuticals to deliver high quality care to people living with kidney disease around the globe.

Through Fresenius Medical Care's vertical integration, scope, and scale, we develop, manufacture, and distribute medical devices, systems, pharmaceuticals, and products for kidney care to customers in more than 140 countries (2024: around 150). As of December 31, 2025, we operate 3,601 (2024: 3,675) dialysis centers in more than 30 countries worldwide (2024: around 40), serving 291,902 dialysis patients (2024: 299,352). Fresenius Medical Care manages the world's largest network of dialysis centers and has 35 production sites in 19 countries (2024: 39 production sites in 19 countries).

[**Table of Contents**](#TOC)

***Our products and services***

Our products and services for 2025 are shown in the following chart:

![Graphic](fms-20251231x20f004.jpg)

For information regarding the divestiture of business providing certain of these services during 2025, see note 3 and note 4 of the notes to the consolidated financial statements.

In 2025, approximately 4.5 M (2024: 4.3 M) patients worldwide regularly underwent dialysis treatment. Dialysis is a life-saving blood cleansing procedure that substitutes the function of the kidney in case of kidney failure. Healthy kidneys clean the blood of waste products, regulate water levels, and produce important hormones. Chronic kidney failure or end stage kidney disease (ESKD) (also referred to as ESRD) occurs when the kidneys are irreparably damaged and are no longer able to function adequately over a sustained period of time. Many diseases can lead to chronic kidney failure, particularly diabetes, chronic nephritis, or hypertension. There are currently two treatment options for ESKD: kidney transplant and dialysis.

For a summary of our revenues attributable to our major categories of activity, split by operating and reportable segments as well as by regions, for the three years ended December 31, 2025, 2024, and 2023, see notes 5 a) and 29 of the notes to the consolidated financial statements included in this report.

[**Table of Contents**](#TOC)

We receive a substantial portion of our Care Delivery revenue from the U.S. Medicare program and other government sources. The following table provides information for the years ended December 31, 2025, 2024, and 2023 regarding the percentage of our U.S. patient service revenue included in our healthcare service revenue from: (a) the Medicare program, (b) private/alternative payors, such as commercial insurance, Medicare Advantage, and private funds, (c) Medicaid and other government sources, and (d) hospitals.

---

| | | | |
|:---|:---|:---|:---|
| **U.S. patient service revenue** |  |  |  |
| *in % of U.S. patient service revenue* |  |  |  |
|  | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** |
|  | **2025** | **2024** | **2023** |
| Medicare program | 19.0 | 22.1 | 24.5 |
| Private / alternative payors | 72.4 | 69.2 | 67.2 |
| Medicaid and other government sources | 4.7 | 4.5 | 4.0 |
| Hospitals | 3.9 | 4.2 | 4.3 |
| Total | **100.0** | **100.0** | **100.0** |

---

Under the Medicare program, Medicare reimburses dialysis providers for the treatment of certain individuals who are diagnosed as having ESRD, regardless of age or financial circumstances. See "Regulatory and legal matters — Reimbursement."

***Dialysis treatment options for ESRD***

CKD is a global epidemic. The number of patients requiring kidney replacement therapy is increasing worldwide: At the end of 2025, about 5.5 M patients (2024: 5.3 M) underwent dialysis treatment or received a donor organ.

Further information can be found in the table below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Patients with end stage renal disease** |  |  |  |  |
| *in M (rounded)* |  |  |  |  |
|  | **2025** | **Share in %** | **2024** | **Share in %** |
| **Patients with end stage renal disease** | **5.5** | **100** | **5.3** | **100** |
| &nbsp;&nbsp;of which patients with transplants | 1.0 | 19 | 1.0 | 19 |
| **Of which dialysis patients** | **4.5** | **81** | **4.3** | **81** |
| &nbsp;&nbsp;In-center hemodialysis | 4.0 | 72 | 3.8 | 72 |
| &nbsp;&nbsp;Peritoneal dialysis | 0.5 | 9 | 0.5 | 9 |
| &nbsp;&nbsp;Home hemodialysis | <0.1 | <1 | <0.1 | <1 |

---

A successful kidney transplant is considered the most effective treatment for ESKD, offering those patients a chance for a longer, healthier life. However, the number of organs donated worldwide has been significantly lower than the number of patients on transplant waiting lists for many years. Despite extensive efforts, particularly in regional initiatives, to raise awareness of kidney donation and promote willingness to donate, the global proportion of patients receiving a kidney transplant compared to other treatment methods has remained relatively unchanged and comparatively low over the last ten years. (See "— Regulatory and legal matters — Reimbursement — Executive order-based models" for a discussion of recent proposed changes to the U.S. organ donation system.)

The prevalence of CKD varies between regions. There are several reasons for this:

● Countries differ in the demographics of their populations.

● Risk factors for kidney disease, such as obesity, diabetes and hypertension, varies widely.

● The genetic predisposition for kidney disease differs significantly around the world.

● Access to dialysis remains restricted in many countries, meaning that many patients suffering from CKD are not treated and therefore do not appear in available statistics.

● Cultural factors, such as nutrition, play a role.

[**Table of Contents**](#TOC)

The number of dialysis patients rose worldwide by around 4% to 5% in 2025 (2024: 4% to 5%). For information regarding new drug classes such as GLP-1 receptor agonists or SGLT2 inhibitors and their impact on patient populations, see note 2 a) of the notes to the consolidated financial statements included in this report.

*Comparison of dialysis treatment methods*

In 2025, most dialysis patients were treated in one of around 53,000 dialysis centers worldwide (2024: 52,000), with an average of approximately 80 patients per center (2024: 80). However, this figure varies considerably from country to country.

Hemodialysis (HD) is by far the most common form of therapy for ESKD. In 2025 89% (2024: 89%) of dialysis patients worldwide received hemodialysis at dialysis centers. During the same period, 11% of dialysis patients worldwide underwent treatment at home (2024: 11%), mostly using peritoneal dialysis. In 2025, 11% (2024: 11%) of all dialysis patients were treated with peritoneal dialysis. Currently, less than 1% (2024: less than 1%) of all dialysis patients globally are treated with home hemodialysis. In the U.S., the share of patients treated at home is higher, with 15% (2024: 15%) receiving home dialysis. See below for brief descriptions of HD and PD.

The following chart shows a comparison of in-center and home dialysis:

![Graphic](fms-20251231x20f005.jpg)

We also provide dialysis services under contract to hospitals in the U.S. on an "as needed" basis for hospitalized ESRD patients and for patients suffering from acute kidney failure. Acute kidney failure can result from infections, sepsis, hypotension, toxins, systemic diseases, trauma, or other causes, and requires dialysis until the patient's kidneys recover their normal function. We provide services to these patients either at their bedside, using portable dialysis equipment, or at the hospital's dialysis site. Contracts with hospitals provide for payment at negotiated rates that are generally higher than the Medicare reimbursement rates for chronic in-center outpatient treatments.

For acute kidney failure, the predominant treatment method is continuous kidney replacement therapy. Over 50% or around 1.1 M acute patients were treated with this method in 2025 (2024: over 50% or slightly more than 1 M). The number of patients requiring continuous kidney replacement therapy (CKRT) to treat acute kidney failure is set to rise from around 1.1 M patients in 2025 to over 1.5 M per year in 2035. In this field, we have a market share of approximately 30% (2024: 30%). For additional information regarding patient growth in this field, see "— Corporate strategy and objectives," below.

*Hemodialysis*. Hemodialysis removes toxins and excess fluids from the blood in a process in which the blood flows outside the body through plastic tubes known as bloodlines into a specially designed filter, called a dialyzer. The dialyzer separates waste products and excess water from the blood. Dialysis solution flowing through the dialyzer carries away the waste products and excess water and supplements the blood with solutes which must be added due to renal failure. The treated blood is returned to the patient. The hemodialysis machine pumps blood, adds anti-coagulants, regulates the purification process and controls the mixing of dialysis solution as well as the rate of its flow through the system. This machine can also monitor and record the patient's vital signs.

[**Table of Contents**](#TOC)

At our clinics, we provide hemodialysis treatments at individual stations through the use of dialysis machines and disposable products. In hemodialysis treatment, a nurse connects the patient to the dialysis machine via bloodlines and monitors the dialysis equipment and the patient's vital signs. The capacity of a clinic is a function of the number of stations and additional factors such as type of treatment, patient requirements, length of time per treatment, and local operating practices and ordinances regulating hours of operation.

As part of the dialysis therapy, we provide a variety of services to ESRD patients at our dialysis clinics in the U.S. These services include administering erythropoietin stimulating agents (ESAs), which are synthetic engineered hormones that stimulate the production of red blood cells. ESAs are used to treat anemia, a medical complication that ESRD patients frequently experience. We administer ESAs to most of our patients in the U.S. ESAs have historically constituted a material portion of our overall costs of treating our ESRD patients.

*Peritoneal dialysis*. Peritoneal dialysis removes toxins from the blood using the peritoneum, the membrane lining covering the internal organs located in the abdominal area, as a filter. Most peritoneal dialysis patients administer their own treatments in their own homes and workplaces, either by a treatment known as continuous ambulatory peritoneal dialysis (CAPD), or by a treatment known as continuous cycling peritoneal dialysis, also called automated peritoneal dialysis (APD). In both of these treatments, a surgically implanted catheter provides access to the peritoneal cavity. Using this catheter, the patient introduces a sterile dialysis solution from a solution bag through a tube into the peritoneal cavity. The peritoneum operates as the filtering membrane and, after a specified dwell time, the solution is drained and disposed. A typical CAPD peritoneal dialysis program involves the introduction and disposal of dialysis solution four times a day. With continuous cycling peritoneal dialysis, a machine pumps or "cycles" solution to and from the patient's peritoneal cavity while the patient sleeps. During the day, one and a half to two liters of dialysis solution remain in the abdominal cavity of the patient. The human peritoneum can be used as a dialyzer only for a limited period of time, ideally only if the kidneys are still functioning to some extent.

For our home dialysis patients, we provide materials, training and patient support services, including clinical monitoring, follow-up assistance and arranging for the delivery of supplies to the patient's residence. (See "— Regulatory and legal matters — Reimbursement — U.S." for a discussion of the ESRD PPS and billing for these products and services.)

***Care Delivery***

Our Care Delivery business segment encompasses our global network of dialysis clinics and includes services that address the complex healthcare needs and treatment choices for people living with kidney disease. In 2025, Fresenius Medical Care continued to support the entire spectrum of renal care for CKD and ESKD and are pioneers in dialysis as kidney replacement therapy. With our long history of kidney care and industry expertise, we leverage artificial intelligence (AI), analytics, technological capabilities, and platforms to support early interventions in care.

#### The service portfolio of Care Delivery is shown in the following chart:
![Graphic](fms-20251231x20f006.jpg)

[**Table of Contents**](#TOC)

The Company's dialysis clinic network comprises our 3,601 worldwide dialysis clinics (2024: 3,675), which provide various forms of in-center kidney replacement therapies. In 2025, we treated 70% (2024: 69%) of our patients in the U.S. and 30% (2024: 31%) internationally outside the U.S.

To help improve in-center treatment adherence, the Care Delivery organization initiated many programs to encourage patients to stay with their dialysis treatments as prescribed. For instance, our Fresenius Kidney Care team in the U.S. piloted a program with Uber Health, LLC, (hereinafter referred to as Uber Health) and expanded the partnership nationwide in 2025. Uber Health is a healthcare-focused service by Uber Technologies, Inc., that provides non-emergency medical transportation. The Fresenius Kidney Care team is partnering with Uber Health for this transportation program to provide additional access to care for patients in need of life-sustaining dialysis treatment when other transportation options have been exhausted.

As patients choose greater independence offered by home dialysis, two different options of home dialysis therapy – peritoneal dialysis (PD) and home hemodialysis (HHD) – are provided to meet different patient needs. Currently over 85,000 patients globally (2024: over 85,000) perform PD and HHD utilizing product solutions from Fresenius Medical Care.

Care Delivery provides different forms of dialysis therapies for people living with ESKD and transplant referral coordination for eligible patients where offered, as illustrated in the following chart.

![Graphic](fms-20251231x20f007.jpg)

***Although our dialysis clinic network is the heart of the Care Delivery segment, the overall Care Delivery portfolio includes a range of services that meet the immediate and long-term needs of individuals living with kidney disease:***

● Azura Vascular Care provides outpatient vascular care services to individuals requiring dialysis access management in the U.S.

● Frenova delivers a network of research sites, a diverse patient population, and the expertise to initiate clinical trials rapidly. This subsidiary works with partner sites to enroll suitable patients for renal trials and studies of adjacent conditions. Frenova also offers data analytics and licensing services, with access to one of nephrology's largest longitudinal databases.

● Fresenius Medical Care Renal Pharmaceuticals produces as well as distributes kidney-disease related drugs and pharmaceuticals and includes our investment in Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP).

● Fresenius Physician Solutions provides practice support for nephrologists in the U.S., including management, development, and technology solutions.

● Fresenius RX pharmacy provides dialysis medications, delivered directly to dialysis centers or to patients at home in the U.S., or even when traveling.

● Spectra Laboratories provides renal-specific laboratory testing and processing. In February 2025, Fresenius Medical Care announced the divestment of select laboratory and testing assets to Quest Diagnostics Inc. The transaction closed in the fourth quarter of 2025 and the transitional process will continue into 2026.

For additional information regarding our other healthcare services, see Item 3.D, "Key information — Risk factors and Item 4, "Information on the Company — Regulatory and legal matters — Reimbursement — U.S."

[**Table of Contents**](#TOC)

*High-volume hemodiafiltration*

In 2025, Fresenius Medical Care introduced HVHDF into clinical practice, with the goal of establishing it as a new standard of care in the U.S. dialysis industry. This therapy represents a significant opportunity to enhance patient outcomes and expand our presence in the U.S. dialysis market. In Europe and the Middle East, the Company has been treating patients successfully with HVHDF for more than a decade, underscoring its established benefits and potential for broader application.

HVHDF is a kidney replacement therapy that combines both convection and diffusion to remove solutes from the body. Unlike conventional hemodialysis, which primarily uses diffusion, HVHDF incorporates high-volume convective therapy, infusing additional fluid and removing larger middle molecules.

This therapy gained additional attention in 2023 with the release of the EU-funded CONVINCE study that compares the efficacy of HVHDF against high-flux hemodialysis (HF-HD). Starting in 2018, researchers observed more than 1,300 participants over two-and-a-half years. The results showed a 23% relative risk reduction in the hazard of all-cause mortality for patients treated with HVHDF versus HF-HD, as well as an improvement in patient-reported outcomes.

In February 2024, Fresenius Medical Care's 5008X hemodialysis system achieved a key milestone by becoming the first FDA-approved machine capable of delivering HVHDF in the U.S. Paired with our FX CorAL dialyzer, which was already available in the U.S., the 5008X combines advanced engineering and membrane technologies to enable HVHDF. In May 2025, the Company received FDA 510(k) clearance for the updated hemodiafiltration-capable 5008X CAREsystem.

In order to establish HVHDF as a new standard of care in the U.S. dialysis industry, Fresenius Medical Care conducted a limited launch in selected Fresenius Kidney Care clinics in 2025, with a broader commercial launch planned for 2026 and beyond. As part of our long-term strategy, we are committed to replacing the entire installed base at Fresenius Kidney Care with the 5008X CAREsystem by the end of 2030, reinforcing our market leadership and driving adoption of this advanced therapy.

***Value-Based Care***

In 2025, Fresenius Medical Care introduced a new operating segment, Value-Based Care, which was previously part of Care Delivery in the U.S., as a key component of our FME Reignite strategy. This segmentation enhances the transparency of financial reporting, offering greater insight into the performance and drivers of each reporting segment.

By leveraging Fresenius Medical Care's vertically integrated structure – encompassing Care Delivery, Value-Based Care, and Care Enablement – the Company aims to accelerate innovation, improve patient outcomes, drive growth, and reduce costs.

Value-Based Care drives innovation on the basis of risk-based delivery models that lower care costs by enhancing treatment quality and patient well-being, supporting planned (optimal) dialysis starts and fewer all-cause hospitalizations than the national average in the U.S. Our Value-Based Care entity, Interwell Health, leads the industry for value-based kidney care with three key differentiators:

● Connectivity to our U.S. clinic network

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●The largest nephrologist network in the U.S., with over 2,200 physician partnerships

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●The most widely adopted nephrology-specific electronic health record system in the U.S.

The Value-Based Care segment achieves exceptional clinical outcomes, with optimal start rates over twice as high as the U.S. national average. In the U.S. government's Kidney Care Choices (KCC) program, the majority of our aligned nephrology practices (called Kidney Contracting Entities or KCEs) are considered "high performers" by the program. Our KCEs contributed 80% of the entire KCC program's gross savings in 2022 (based on the latest publicly published data available).

[**Table of Contents**](#TOC)

***Care Enablement***

Our deep understanding of customer needs, combined with our profound engineering expertise, forms the foundation of Fresenius Medical Care's Care Enablement segment. To effectively serve a wide range of market segments, Care Enablement is organized around three main therapy areas: in-center dialysis, home dialysis, and critical care. Each of these units is responsible for the full product life cycle – from ideation and creation to value generation, supply chain management, and service – through to the end of the product's life. This comprehensive approach ensures the delivery of innovative and integrated therapies across all care settings.

The products in Care Enablement's portfolio are designed for blood purification as well as organ support and include medical devices for in-center hemodialysis and hemodiafiltration (HDF), dialyzers, concentrates for dialysate preparation, solutions and granulates, bloodlines, water treatment systems, home hemodialysis and peritoneal dialysis cyclers, peritoneal dialysis solutions, renal pharmaceuticals, acute cardiopulmonary products, apheresis products, data processing and analysis systems, and other medical devices.

Building on this broad portfolio, Care Enablement applies an integrated business model that combines product innovations with technical service, clinical training, and global commercial execution. By leveraging its global reach, operational excellence, and trusted customer relationships, Care Enablement capitalizes on synergies across the value chain, strengthens long-term partnerships, and drives sustainable growth worldwide.

Care Enablement offers healthcare products for acute and chronic kidney organ support in more than 140 countries globally, with a focus on the following therapies:

● Hemodialysis and hemodiafiltration: These are the most common therapies to support ESKD, the last stage of chronic kidney disease, and Care Enablement is recognized as the global leader in this field. Care Enablement provides a wide range of HD and HDF systems in dialysis centers as well as those designed for use at home. Enabled by Fresenius Medical Care's vertically integrated business model, Care Enablement plays a pivotal role in making HVHDF broadly available also in the U.S.; and by expanding its patented sodium management tool is also advancing precision medicine in dialysis at scale.

● Peritoneal dialysis: In PD the patient's peritoneum is used as a natural filter. Nearly all peritoneal dialysis is performed at home, and the Care Enablement portfolio includes systems and solutions for CAPD and APD.

● Acute dialysis: In case of a sudden loss of renal function, CKRT is used in intensive care units. Fresenius Medical Care also provides a comprehensive portfolio of products for this setting.

Care Enablement's portfolio includes dialysis systems and dialyzer options for kidney replacement therapies tailored to a wide range of clinical needs including low flux dialysis, high flux dialysis and hemodiafiltration, and offering solutions for diverse operational setups: covering every clinic, dialysis modality, patient segment, and every stage of life.

The comprehensive home dialysis portfolio, including both PD and HHD, reflects Care Enablement's strong commitment to this growing market.

Care Enablement is making significant progress in connected health solutions – digitally linking patients and care teams to enable remote monitoring, seamless communication, and more coordinated care – with a strong presence in the U.S. and across other international regions.

We also offer extracorporeal therapy options for patients who cannot be sufficiently treated through conventional pharmaceutical regimens, including the removal of metabolic products, toxins, autoantibodies, and immunocomplexes. Our Xenios AG (Xenios) products are used for a wide range of extracorporeal gas exchange and offer a wide range of heart and lung support from partial CO<sub>2</sub> removal up to full oxygenation. Xenios's Novalung<sup>®</sup> is the first extracorporeal membrane oxygenation system to be cleared for more than six hours of continuous use as extracorporeal life support.

[**Table of Contents**](#TOC)

For the fiscal year 2025, healthcare products accounted for 22% of our consolidated total revenue (2024: 22%). The following table shows the breakdown of our dialysis product revenues into sales of HD products, PD dialysis products and other healthcare products. The following amounts exclude intercompany product sales:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Healthcare product revenue** |  |  |  |  |  |  |
| *in € M* |  |  |  |  |  |  |
|  | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** |
|  | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
|  | **Total** |  | **Total** |  | **Total** |  |
|  | **product** |  | **product** |  | **product** |  |
|  | **revenues** | **% of total** | **revenues** | **% of total** | **revenues** | **% of total** |
| Hemodialysis products | 3453 | 78 | 3391 | 80 | 3253 | 80 |
| Peritoneal dialysis products | 358 | 8 | 358 | 8 | 359 | 9 |
| Other | 603 | 14 | 502 | 12 | 448 | 11 |
| Total | **4414** | **100** | **4251** | **100** | **4060** | **100** |

---

***Renal pharmaceuticals***

We continue to acquire and in-license renal pharmaceuticals to improve dialysis treatment for our patients. Below are the primary renal pharmaceuticals we have acquired or for which we have obtained licenses for use:

*PhosLo*<sup>®</sup>

In November 2006, we acquired PhosLo<sup>®</sup>, a calcium-based phosphate binder. Phosphate binders keep phosphorus levels in ESRD patients in a healthy range by preventing the body from absorbing phosphorus from foods and assisting the passing of excess phosphorous out of the body. We have received approval of PhosLo<sup>®</sup> in selected European countries. In October 2008, a competitive generic phosphate binder was introduced in the U.S. market, which reduced our PhosLo<sup>®</sup> sales in 2009. In October 2009, we launched an authorized generic version of PhosLo<sup>®</sup> to compete in the generic calcium acetate market. In April 2011, the FDA approved our New Drug Application for Phoslyra<sup>®</sup>, a liquid formulation of PhosLo<sup>®</sup>. In 2023, we discontinued the sale of Phoslyra in the U.S., and in 2024 we discontinued the sale of an authorized generic version of PhosLo.

*Venofer*<sup>®</sup> *and Ferinject*<sup>®</sup>

In 2008, we entered into two separate and independent license and distribution agreements, one for certain countries in Europe and the Middle East with Vifor (International) Ltd., a subsidiary of Swiss-based CSL Vifor (formerly Vifor Pharma Ltd.) and one for the U.S. (with American Regent, Inc. (formerly Luitpold Pharmaceuticals Inc.)), to market and distribute intravenous iron products; Venofer<sup>®</sup> (iron sucrose) and Ferinject<sup>®</sup> (ferric carboxymaltose) outside of the U.S. Both drugs are used to treat iron deficiency anemia experienced by non-dialysis CKD patients as well as dialysis patients. Venofer<sup>®</sup> is the originator intravenous iron sucrose product, a leading intravenous iron brand in terms of volume worldwide. Ferinject<sup>®</sup> is a leading intravenous iron therapy with market authorization in 87 countries as of October 2025 and more than 34 million patient years of experience.

The first agreement concerns all commercialization activities for these intravenous iron products in the field of dialysis and became effective on January 1, 2009. In North America, a separate license agreement effective November 1, 2008, provides our subsidiary Fresenius USA Manufacturing Inc. (FUSA) with exclusive rights to manufacture and distribute Venofer<sup>®</sup> to freestanding (non-hospital based) U.S. dialysis facilities and, in addition, grants FUSA similar rights for certain new formulations of the drug. In 2017, Fresenius Medical Care Canada acquired the license to distribute Venofer<sup>®</sup> for ESRD and all indications in Canada. The license agreement has a term of five years with two additional two-year options. The U.S. license agreement has a term of ten years and includes FUSA extension options. In 2023, the North American agreement with American Regent was renegotiated and extended through December 31, 2028. The international agreement which had a term of 20 years was terminated in 2010 as a consequence of the establishment of Vifor Fresenius Medical Care Renal Pharma Ltd.

In December 2010, we announced the expansion of our agreements with CSL Vifor by forming a new renal pharmaceutical company, VFMCRP, with the intention to develop and distribute products focused on addressing distinct complications and areas of chronic kidney disease; renal anemia management, mineral and bone management, kidney function preservation and improvement, conditions associated with kidney impairment and its treatment; and cardio-renal management. FME AG owns 45% of the company, which is headquartered in Switzerland. CSL Vifor contributed licenses (or the commercial benefit in the U.S.) to its Venofer<sup>®</sup> and Ferinject<sup>®</sup> products for use in the dialysis and pre-dialysis market (CKD stages III to V). CSL Vifor and its existing key affiliates or partners retain the responsibility for commercialization of both products outside the renal field. With effect as of November 2, 2021, Vifor Pharma Participations Ltd replaced Vifor Pharma Ltd as a shareholder of VFMCRP.

[**Table of Contents**](#TOC)

*Velphoro*<sup>®</sup>

As part of the agreement to create VFMCRP, CSL Vifor also contributed the asset Velphoro<sup>®</sup> (sucroferric oxyhydroxide), a novel iron-based phosphate binder, to the new company (excluding certain rights within Japan). We market the product on behalf of VFMCRP in the U.S. and commercial sales of Velphoro<sup>®</sup> commenced in the first quarter of 2014 in the U.S. market. In January 2025, the phosphate binder class, including Velphoro<sup>®</sup> has been integrated into the U.S. dialysis reimbursement bundle with the product being separately billable under a transitional drug add-on payment adjustment (TDAPA) in 2025 and 2026 (see additional information under "— Reimbursement" below). Velphoro<sup>®</sup> has been approved in 51 countries and commercially launched in 40 countries worldwide and the VFMCRP partner Kissei also received approval from the Ministry of Health, Labour and Welfare in Japan during 2015 for the product which is marketed in Japan under the brand name P-TOL. In China, we received New Drug Approval in February 2023. For further information, refer to note 25 of the notes to the consolidated financial statements included in this report.

*OsvaRen*<sup>®</sup> *and Phosphosorb*<sup>®</sup>

In June 2015, VFMCRP, with CSL Vifor, was developed further. In addition to the iron replacement products Ferinject<sup>®</sup> and Venofer<sup>®</sup> for use in nephrology indications and the phosphate binder Velphoro<sup>®</sup> in our shared product portfolio, VFMCRP acquired nephrology medicines commercialized by us, including the phosphate binders OsvaRen<sup>®</sup> and Phosphosorb<sup>®</sup>. The transfer of the marketing rights was largely completed during the fourth quarter of 2015, allowing the company to further develop its sales and marketing in key European markets. Since early 2025, these products are currently not being sold subject to further regulatory clearance.

*Shared product portfolio* 

The core of the VFMCRP model is to in-license products predominantly initiated or used by nephrologists as part of the following areas: renal anemia, mineral and bone and cardio-renal management, kidney function improvement and renal associated conditions in both dialysis dependent and non-dialysis dependent CKD. The in-licensed products are detailed below:

Mircera<sup>®</sup> (methoxy polyethylene glycol-epoetin beta) is a long-acting ESA licensed from F. Hoffmann-La Roche AG since 2015 to treat anemia associated with chronic kidney disease. A cornerstone of VFMCRP's franchise, Mircera<sup>®</sup> offers several dosing and administration benefits, making it a market-leading product in this category. The product is currently supplied to over 5,000 dialysis clinics in the U.S. and its territories.

Retacrit<sup>®</sup> (epoetin alfa-epbx) is a short-acting ESA approved in the US in 2018 for all indications of its reference drug, epoetin alfa. Retacrit<sup>®</sup> is licensed from Pfizer Inc. since 2015 for certain channels, primarily comprising the U.S. non-hospital dialysis market and nephrology office practices. It is the first, and only, biosimilar ESA approved for use in the U.S.

Rayaldee<sup>®</sup> (extended release calcifediol) is the first, and only, oral extended release formulation of calcifediol, a pro-hormone of the active form of vitamin D3, for the treatment of secondary hyperparathyroidism in CKD patients with vitamin D insufficiency. VFMCRP has an exclusive license agreement with OPKO Health, Inc., to co-develop and commercialize Rayaldee<sup>®</sup> in Europe (except Russia), Canada, Australia and Japan. In 2022, Rayaldee<sup>®</sup> was launched in Germany and Switzerland.

Tavneos<sup>®</sup> (avacopan) is a first-in-class rare disease treatment for anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) in adult patients. VFMCRP has licensed Tavneos<sup>®</sup> worldwide (except in the U.S., China, and other smaller Asian and Latin American countries) from ChemoCentryx, Inc., a wholly owned subsidiary of Amgen Inc. In the licensed territories, Tavneos<sup>®</sup> has been approved for the treatment of two main forms of AAV in Japan and, in combination with a rituximab or cyclophosphamide regimen, in the European Union (including Iceland, Liechtenstein and Norway), Canada, Great Britain, Switzerland, Australia, Kuwait, Israel, South Korea and Saudi Arabia. The therapy has been launched in over 20 countries across Europe, North America, Asia and the Middle East. Further launches are planned in the coming 36 months. In January 2026, the European Medicines Agency (EMA) has initiated a review of Tavneos<sup>®</sup> following concerns raised about integrity of data which had been provided with regard to a clinical trial which was the main study supporting the medicine's marketing authorization in the EU. EMA will now review all available data to assess whether this emerging information has an impact on the balance of benefits and risks of Tavneos<sup>®</sup>.

[**Table of Contents**](#TOC)

Korsuva<sup>®</sup>™/Kapruvia<sup>®</sup>™ (difelikefalin) is the first product approved in EU and U.S. for the treatment of moderate-to-severe pruritus associated with CKD for adults undergoing in-center hemodialysis. Since 2022, VFMCRP has had a license agreement with Cara Therapeutics, Inc. (Cara) to develop and commercialize Korsuva/Kapruvia worldwide, excluding Japan and South Korea. In April 2025, VFMCRP signed an asset purchase agreement with Cara which included the transfer of all rights for Korsuva/Kapruvia and associated intellectual property. Fresenius Renal Pharmaceuticals and CSL Vifor agreed that both organizations would stop promotion of Korsuva in the US market, in 2024, following the 2023 CMS ruling that phases out the add-on payment after 2026. Neither organization has received a marketing fee since January 2024. Korsuva/Kapruvia is approved in the U.S., the EU, and other countries. Further key launches are expected in the next 12 months.

VFMCRP also own the rights to Veltassa® (patiromer), a treatment for hyperkalaemia or elevated potassium levels, outside of the U.S. and Japan. In the licensed territories, Veltassa® was launched in 15 European markets as well as Israel, Saudi Arabia, United Arab Emirates, Kuwait, Australia, Canada (by partner Otsuka Canada Pharmaceutical, Inc.), and Japan (by partner Zeria Pharmaceutical Co., Ltd.).

***Global Medical Office***

Our Global Medical Office plays a pivotal role in contributing clinical expertise to Fresenius Medical Care's management, offering counsel to business leaders while maintaining close communication on the state of medicine and science in kidney disease care with the aim to connect the right care to the right person at the right time by leveraging advanced data analysis and research, as well as providing educational resources for physicians. By providing end-to-end medical-scientific leadership and clinical governance, including the generation and translation of clinical evidence, the Global Medical Office was pivotal in enabling the launch of HVHDF in the U.S. Its coordinated efforts established the clinical confidence and governance framework required to safely initiate HVHDF in U.S. practice, thereby demonstrating the clinical feasibility of implementing HVHDF in the U.S. healthcare setting. The planned rollout of hemodiafiltration therapy across the Company's U.S. Fresenius Kidney Care dialysis centers represent a critical advancement in kidney replacement therapy (KRT) to patients in the U.S., signifying a breakthrough for the nephrology community.

***Major markets and competitive position***

To obtain and manage information on the status and development of global, regional, and national markets, we have developed internal market analysis tools. We use these tools within the Company to collect, analyze, and communicate current and essential information on the dialysis market, developing trends, our market position, and those of our competitors. Except as otherwise specified herein, all market patient and other market data in this report has been derived using our internal market analysis tool.

For some of these tools, country by country surveys are performed annually which focus on the total number of patients treated for ESRD, the treatment modalities selected, products used, treatment location, the structure of ESRD patient care providers, and other metrics. These surveys have been refined since inception to facilitate access to more detailed information and to reflect changes in the development of therapies and products as well as changes to the structure of our competitive environment. Questionnaires are distributed to professionals in the field of dialysis who are in a position to provide ESRD-relevant country specific information themselves or who can coordinate appropriate input from contacts with the relevant know-how in each country. The surveys are then centrally validated and checked for consistency by cross-referencing them with the most recent publicly available sources of national ESRD information (e.g. registry data or publications, if available) and with the results of surveys performed in previous years. All information received is consolidated at a global and regional level and analyzed and reported together with publicly available information published by our competitors. New and updated information from countries, along with refinements to internal market analysis tools, may lead to retroactive adjustments of previously made statements and estimates concerning future developments. While we believe the information contained in our internal market analysis tools and competitor publications to be reliable, we have not independently verified the data or any assumptions from which our internal market analysis tools are derived or on which the estimates they contain are based, and we do not make any representation as to the accuracy of such information.

According to our estimates, the volume of the global dialysis market grew to around €81 to 85 BN in 2025 (2024: €80 to 84 BN). We estimate the following approximate breakdown for this market volume: around €16 BN (2024: €16 BN) for dialysis products and the remainder for dialysis services (including dialysis drugs).

[**Table of Contents**](#TOC)

The number of dialysis patients globally is increasing at a rate of 4% to 5% each year to around 4.5 M in 2025 (2024: 4.3 M) and is expected to reach around 7 M people by 2035, according to our estimates. Fresenius Medical Care is a global leader in dialysis care, providing treatment to about 7% of all dialysis patients (2024: 7%). At the end of 2025, we provided dialysis services for 291,902 people in our network of dialysis centers (2024: 299,352). The geographical breakdown according to patients treated can be found in the following chart:

![Graphic](fms-20251231x20f008.jpg)

Fresenius Medical Care is also the global market leader for dialysis products in general. Products made for use in our own dialysis centers or for sale to third-party customers accounted for a market share of around 35% in 2025 (2024: around 35%). Furthermore, in hemodialysis products alone, Fresenius Medical Care is the leading provider, holding over 40% of the global market share in 2025 (2024: over 40%).

Dialyzers for HD are the largest product group in the dialysis market with a worldwide sales volume of around 450 M units in 2025 (2024: 430 M). Approximately 171 M (around 38%) of these were made by Fresenius Medical Care (2024: 175 M or around 40%), giving us the biggest market share, by far. HD machines constitute another key component of our product business. Here, too, Fresenius Medical Care is the market leader. Of the estimated 110,000 machines installed in 2025 (2024: 100,000), around 56,000, or around 50% (2024: 51,000 or around 50%), were produced by Fresenius Medical Care. The Company holds the largest share of the HHD market. In 2025, more than 75% (2024: more than 75%) of all patients performing HHD utilized a dialysis machine from Fresenius Medical Care.

Furthermore, Fresenius Medical Care holds a strong position in the market for PD products: Around 14% (2024: around 14%) of all PD patients use products made by the Company.

The overall market for dialysis care services in the U.S. is consolidated. Across all market segments, Fresenius Medical Care treats around 37% of all dialysis patients here (2024: 37%). In the U.S., home dialysis is becoming increasingly important. In 2025, about 16% (2024: 16%) of our U.S. dialysis treatments were performed at home. Outside the U.S., the dialysis services business is much more fragmented. With 979 dialysis centers (2024: 1,051) and approximately 86,400 patients (2024: 92,900), Fresenius Medical Care operates the largest network of clinics.

[**Table of Contents**](#TOC)

Our competitive environment is described in more detail below:

*Healthcare Services.* We operate in a competitive, international market environment and are, therefore, subject to certain trends, risks, and uncertainties that could cause actual results to differ from our projected results. The major trends affecting the markets in which we operate are: the aging population and increased life expectancies, shortage of donor organs for kidney transplants, and increasing incidence and better treatment of and survival of patients with diabetes and hypertension, which frequently precede the onset of ESRD, all of which contribute to patient growth. In the U.S. and other markets in which dialysis is readily available, additional trends are:

Trends in the developed markets:

● improvements in treatment quality, which prolong patient life;

● stronger demand for innovative products and therapies;

● advances in medical technology;

● ongoing cost-containment efforts and ongoing pressure to decrease healthcare costs, resulting in limited reimbursement rate increases;

● reimbursement for the majority of treatments by governmental institutions, such as Medicare and Medicaid in the U.S.; and

● challenges in certain labor markets.

Trends in the emerging markets:

● increasing national incomes and hence higher spending on healthcare;

● improving standards of living in developing countries, which make life-saving dialysis treatment available;

● consolidation of providers (e.g. hospital chains);

● consolidation of healthcare insurers with pricing pressure on providers; and

● privatization of healthcare providers.

Our largest competitors in the dialysis services industry include DaVita, Inc., Diaverum AB, B. Braun SE, U.S. Renal Care, Inc., and Nephrocare Health Services Limited (NephroPlus).

U.S. government programs are the primary source of reimbursement for services to the majority of U.S. patients and, as such, competition for patients in the U.S. is based primarily on quality and accessibility of service and the ability to obtain referrals from physicians. However, the extension of periods during which commercial insurers are primarily responsible for reimbursement and the growth of managed care have placed greater emphasis on service costs for patients insured with private insurance.

In most countries other than the U.S., we compete primarily against individual freestanding clinics and hospital-based clinics. In many of these countries, especially the developed countries, governments directly or indirectly regulate prices and the opening of new clinics. Providers compete in all countries primarily on the basis of quality and availability of service and the development and maintenance of relationships with referring physicians.

[**Table of Contents**](#TOC)

*Products:* We compete globally in the product market which is largely segmented among in-center hemodialysis, peritoneal dialysis, home hemodialysis, and renal pharmaceuticals. Our competitors include:

---

| | | | |
|:---|:---|:---|:---|
| Akebia Therapeutics, Inc. | Guangdong Biolight Meditech Co., Ltd. | Nipro Corporation | Shandong Weigao Blood Purification Products Co., Ltd |
| Ardelyx Inc. | JMS Co., Ltd | Outset Medical, Inc. | Takeda Pharmaceutical Company Limited |
| Asahi Kasei Medical Co., Ltd | Mozarc Medical Holding LLC | Physidia SAS | Toray Medical Co., Ltd. |
| B. Braun SE | Nikkiso Co., Ltd. | Quanta Dialysis Technologies Inc. | Vantive Health LLC |
| Bain Medical Equipment (Guangzhou) Co., Ltd | Ningbo Tianyi Medical Appliance Co., Ltd. | Sanofi S.A. |  |

---

We have invested significantly in developing proprietary processes, technologies, and manufacturing equipment which we believe provide a competitive advantage in manufacturing our products.

#### Corporate strategy and objectives
**Introducing the new strategy**

At its Capital Markets Day in June 2025, Fresenius Medical Care introduced its new FME Reignite strategy. FME Reignite sets the ambition to deliver both industry-leading outcomes and margins with above-market growth, positioning the Company to lead kidney care through exceptional patient care and innovation.

FME Reignite is based on three strategic priorities: strengthening our core operations, driving profitable growth and innovation, and developing and strengthening our culture. It reflects a greater focus on our overall portfolio, which has now been reorganized into three reporting segments including Value-Based Care as a new stand-alone segment. Our strategy is guided by our vision of "Creating a future worth living. For patients. Worldwide. Every day." This takes Fresenius Medical Care from the successful transformation and turnaround phase of recent years to a new chapter of accelerated growth and innovation, designed to build on and strengthen our role as a leader in kidney care.

![Graphic](fms-20251231x20f009.jpg)

**Leveraging the power of vertical integration**

*Vertical integration as the foundation for FME Reignite*

Vertical integration is at the root of Fresenius Medical Care's business model and our FME Reignite strategy. It creates a basis to deliver industry-leading treatment, outcomes, and economics across our three operating segments, Care Delivery, Value-Based Care, and Care Enablement, as well as improve patient outcomes, unlock efficiencies, and reinforce synergies across kidney care. The Company is taking vertical integration to the next level and harnessing its capabilities across the different businesses. This means bringing together different parts of our organization with the goal of providing best-in-class products and services for our patients and customers. By doing so, Fresenius Medical Care is uniquely positioning itself to create value through a powerful cycle of innovation and care.

[**Table of Contents**](#TOC)

*Introducing Value-Based Care as a new operating segment*

As part of the new strategy and in recognition of the growing importance of this field, Fresenius Medical Care introduced Value-Based Care as a separate segment, with the aim of sharpening the segment´s profile and boosting transparency. The segment comprises Fresenius Medical Care´s Interwell Health value- and risk-based care programs with public and private payors in the U.S. to provide long-term care to patients with CKD and ESKD. It leverages vertical integration through the company-wide use of patient and clinic data, treatment insights and medical innovation, and supports practice management and relationships with over 2,200 partner nephrologists, while aiming to reduce total medical cost.

*Transforming the standard of care with high-volume hemodiafiltration in the U.S.*

High-volume hemodiafiltration provided by Fresenius Medical Care's 5008X CAREsystem aims to set a new standard in the treatment of kidney patients and is a good example of the benefits of vertical integration. With Food and Drug Administration (FDA) clearance secured, the Company prepared for commercialization in the U.S. in the course of 2025, with full market launch planned for 2026. HVHDF is supported by extensive international clinical evidence, e.g., the European-funded CONVINCE study, and results in improved patient outcomes compared with conventional hemodialysis.

![Graphic](fms-20251231x20f010.jpg)

[**Table of Contents**](#TOC)

**Three key strategic priorities**

FME Reignite is founded on three levers to implement the strategy throughout the Company:

● Strengthening core operations: By delivering operational excellence with the Company's core assets in its leading market positions, it will drive scalable, high-quality care to further enhance patient health and increase agility and operational efficiency through more standardized and improved operations as well as focused investments in technology and special programs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●Driving profitable growth and innovation: By increasing R&D efficiency with a global product platform and products, targeting a new standard of care with the U.S. launch of high-volume hemodiafiltration, growing the clinic network in selected international markets, and driving AI-powered transformation in patient care, we will further drive profitable growth and enhance clinic outcomes and patient safety.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●Developing together and advancing our culture: By focusing on its people, Fresenius Medical Care intends to become the employer of choice in healthcare, attracting, retaining and engaging the best talent with a passion to make an impact, while living its new core values: We care. We connect. We commit.

![Graphic](fms-20251231x20f011.jpg)

**New capital allocation framework**

Alongside its FME Reignite strategy, Fresenius Medical Care has introduced a new capital allocation framework which allows the Company to balance and achieve three objectives: investing in the core business, optimizing the capital structure, and returning excess capital to shareholders. The framework foresees a dividend payout ratio of 30% to 40%, complemented by a share buyback program with a total volume of €1 BN, which is expected to be completed in less than a year, significantly earlier than originally planned. The Company earmarks annual capital expenditures of around €0.8 BN to €1.0 BN between 2025 and 2030 to drive profitable growth in the core businesses and support innovation. Through 2030, the Company expects to generate operating cash flow of at least €2.5 BN annually to support the capital allocation framework. A strong balance sheet, financial flexibility, and a commitment to a sustainable investment grade rating are key aspects of the financial policy. As part of this consistent focus on our new dividend policy, Fresenius Medical Care lowered its self-imposed target band for the net financial leverage to between 2.5x and 3.0x (previously: 3.0x to 3.5x). This supports our stated goal of enabling attractive returns of excess capital to our shareholders.

[**Table of Contents**](#TOC)

**Portfolio update**

Overall, Fresenius Medical Care is making strategic decisions about the market segments it invests in and how to ensure success in those segments, ensuring that the portfolio remains aligned with our strategy and supports the future direction of the Company.

Measures undertaken to optimize our portfolio in 2025 included the divestment of clinic operations in a few countries, including Brazil, Malaysia, and Kazakhstan. Furthermore, we divested select assets of Spectra Laboratories in the U.S. in the fourth quarter 2025.

***Integrating sustainability***

In line with our FME Reignite strategy, sustainability continues to be an integral part of our business approach and supports our efforts across each of our strategic priorities. Sustainability is embedded in the Company's vision, mission, and strategic planning, reflecting our commitment to addressing global healthcare challenges and maximizing the impact. Fresenius Medical Care manages sustainability risks and opportunities by prioritizing areas such as operational efficiency, customer needs and employer attractiveness. Our strategic sustainability goals are designed to create value for our business and stakeholders, with a focus on advancing care for patients, empowering people to contribute to a sustainable future, and driving sustainable operations and design. Sustainability performance related to patients and employees is directly tied to the short-term incentives for the Management Board and senior executives, while the long-term incentive plan is linked to our environmental performance.

For further information, see "— Environmental Management" and Item 6.B, "Directors, senior management and employees — Compensation," below.

**Medium-term aspirations**

The FME Reignite strategy is designed to enable Fresenius Medical Care to enter a phase of accelerated growth and innovation that builds on the Company's successful turnaround and transformation processes. By leveraging vertical integration within our Company, focusing on our three strategic priorities, and allocating capital in a disciplined way, we aim to achieve superior outcomes for patients, supported by a strong physician network, and create sustainable value for our shareholders. The FME Reignite strategy supports our aspiration to achieve industry-leading profitability with an operating income margin in the mid-teens percentage range by 2030.

***Customers, marketing, distribution and service***

We sell most of our products to dialysis clinics, hospitals, and other specialized treatment clinics. A synergistic relationship among our sales, marketing, and R&D personnel enables real-world insights from the field to be incorporated into our product development process. We maintain a direct sales force of trained salespersons engaged in the sale of hemodialysis and peritoneal dialysis as well as acute dialysis products and products for critical care. International sales teams engage directly with healthcare professionals and, together with marketing, represent us at industry events, while our clinical nurses provide support, training, and assistance to customers. We offer customer service, training, and education in the applicable local language, and technical support such as field service, repair shops, maintenance, and warranty regulation for each country in which we sell dialysis products.

Our distribution network is designed for efficiency, with products moving from factories to central warehouses, then to regional facilities. We also provide direct-to-patient delivery for home dialysis products and offer direct shipping to healthcare facilities for certain product lines. To maximize our reach, we employ a combination of local sales forces, independent distributors, dealers, and sales agents to ensure our products are accessible worldwide.

[**Table of Contents**](#TOC)

***Sales of dialysis products to Iran***

We actively employ comprehensive policies, procedures, and systems to ensure compliance with applicable controls and economic sanctions laws. We allocate resources to design, implement, and maintain a compliance program specific to our U.S. and non-U.S. activities. Additionally, our dedication to providing its life-saving dialysis products to patients and sufferers of ESRD extends worldwide, including conducting humanitarian-related business with distributors in Iran in compliance with applicable law. In particular, our product sales to Iran from Germany are not subject to the EU's restrictive measures against Iran established by Council Regulation (EU) No. 267/2012 of March 23, 2012, as last amended by Council Implementing Regulation (EU) 2025/1559 of July 25, 2025 implementing Regulation (EU) No 267/2012 concerning restrictive measures against Iran, as the Company's products sold to Iran do not fall within the scope of the EU sanctions and none of the end users or any other person or organization involved is listed on the relevant EU sanctions lists. Because our sales to Iran were and are made solely by our German subsidiaries, the sales are not subject to the Iranian Transactions and Sanctions Regulations, 31 C.F.R Part 560 (ITSR) and are not eligible for licenses from the U.S. Treasury Department's Office of Foreign Assets Control (OFAC) pursuant to the Trade Sanctions Reform and Export Enhancement Act of 2000. Also, ITSR § 560.215(a) is not applicable in the present case because we do not have a U.S. parent company and are not in any other way owned or controlled by a U.S. person, as those terms are used in ITSR § 560.215(a), and our affiliates involved in Iran-related transactions are also not "owned or controlled" by a U.S. person. That we have a U.S. subsidiary does not cause the ITSR to apply to our Iran-related transactions (because the sales by our non-U.S. affiliates are outside the scope of ITSR §560.215(a)). In any case, OFAC's public guidance provides that sales of medical devices to Iran by non-U.S. companies are generally subject to humanitarian exceptions under U.S. sanctions targeting Iran.

During the year ended December 31, 2025, we sold approximately €11.8 M of dialysis products to an independent distributor. This distributor further distributes the products to other foreign distributors for resale, processing, and assembling in Iran. The products included fiber bundles, dialysis concentrates, dialysis machines, parts, and related disposable supplies. The sales of these products generated approximately €6.8 M in operating income for the year ended December 31, 2025. All such sales were made by our German subsidiaries. Based on information available to us, we believe that most products were eventually sold to hospitals in Iran through state purchasing organizations affiliated with the Iranian Ministry of Health and were therefore sales to the "Government of Iran" as defined in ITSR § 560.304. Our 2025 sales to Iran represent approximately 0.06% of our total revenues. We have no subsidiaries, affiliates, or offices, nor do we have any direct investment or own any assets, in Iran. In light of the humanitarian nature of our products and the patient communities that benefit from our products, we expect to continue selling dialysis products to Iran, provided such sales continue to be permissible under, or excluded from, applicable export control and economic sanctions laws and regulations.

***Patient, physician and other relationships***

We believe that our success in establishing and maintaining healthcare centers, both in the U.S. and in other countries, depends significantly on our ability to obtain the acceptance of and referrals from local physicians, hospitals, and integrated care organizations. Our ability to provide high-quality dialysis care and to fulfill the requirements of patients and doctors depends significantly on our ability to enlist nephrologists as medical directors for our dialysis clinics and receive referrals from nephrologists, hospitals, post-acute care facilities, and general practitioners.

Medicare program regulations rely on Conditions for Coverage rules for ESRD facilities which require that each dialysis clinic shall have a medical director who is responsible for overseeing the delivery of patient care and outcomes at the dialysis clinic. The medical director must be board-certified or board eligible in internal medicine or pediatrics, have completed a board-approved training program in nephrology, and have at least twelve months of experience providing care to patients undergoing dialysis. We have engaged physicians or physician practices to serve as medical directors for our outpatient dialysis centers, home dialysis programs, and inpatient dialysis service relationships with hospitals. The compensation of our medical directors and other contracted physicians is negotiated individually in arm's length negotiations and is based on the anticipated workload for each clinic or program the medical director will oversee, as well as any unique market factors such as, for example, the lack of availability of alternative options within the market. The total annual compensation of the medical directors is to be in place for a term of at least one year and the medical directors agree to seek to continue to improve quality, safety, and efficiency. We have developed internal processes with the goal of setting the compensation of our medical directors at fair market value.

Almost all contracts we enter into with our medical directors in the U.S., as well as the typical contracts which we obtain when acquiring existing clinics, contain non-compete clauses concerning certain activities in defined areas for a defined period of time. These non-compete agreements restrict the physicians from owning or providing medical director services to other outpatient dialysis centers, but these clauses do not restrict the physicians from performing patient services directly at other locations/areas or referring patients to other facilities. We do not require physicians to send patients to us or to specific clinics.

[**Table of Contents**](#TOC)

In addition to our dialysis clinics, a number of our other healthcare centers employ or contract with physicians to provide professional and administrative services. We have financial relationships with these physicians in the form of compensation arrangements for the services rendered. We have processes in place to negotiate these contractual arrangements in compliance with federal and state laws applicable to financial relationships with physicians, such as the Stark Law and the Anti-Kickback Statute.

A number of the dialysis clinics and other healthcare centers we operate are owned or managed by entities in which we hold a controlling interest and one or more hospitals, physicians, or physician practice groups hold a minority interest. We have granted holders of these minority interests put options or similar rights under which we could be required to purchase all or part of the minority owners' noncontrolling interests. See notes 1 a) and 26 of the notes to our audited consolidated financial statements included in this report.

We also have agreements with physicians to provide management and administrative services at healthcare centers in which physicians or physician groups hold an ownership interest and agreements with physicians to provide professional services at such healthcare centers. Our relationships with physicians and other referral sources relating to these entities must comply with the federal Anti-Kickback Statute and Stark Law. There is a safe harbor under the Anti-Kickback Statute for certain investment interests in small entities. Investments by physicians and other referral sources in these entities have been designed to comply with the federal Anti-Kickback Statute and Stark Law, but they do not satisfy all of the requirements for safe harbor protection under the Anti-Kickback Statute. Failure to comply with a safe harbor does not render an arrangement illegal under the federal Anti-Kickback Statute and, therefore, physician-owned entities that fall outside the safe harbors are not, by definition, prohibited by law but continue to be subject to legal scrutiny.

Our contractual and other relationships with physicians and other referral sources are subject to numerous legal requirements. While we operate under procedures and policies regarding compliance with these requirements, and in some respects, we follow the guidance under safe harbors, there is no assurance that our interpretations of legal requirements will always be accurate or that our execution of legal requirements will always be sufficient or complete.

We have received civil investigative demands from the U.S. Federal Trade Commission (FTC), the Florida Attorney General, and the Washington Attorney General requesting information regarding our conduct in acquiring medical director services and providing dialysis service, including information related to restrictive covenants such as non-competes with physicians. For further information, see Item 3.D, "Key information — Risk factors" and note 25 of the notes to our audited consolidated financial statements included in this report.

#### Capital expenditures
We invested, by operating segment, the gross amounts shown in the table below during the years ended December 31, 2025, 2024, and 2023.

---

| | | | |
|:---|:---|:---|:---|
| **Capital expenditures (gross)** |  |  |  |
| *in € M* |  |  |  |
|  | **2025** | **2024** | **2023** |
| **Capital expenditures for property, plant and equipment and capitalized development costs** |  |  |  |
| Care Delivery | 323 | 355 | 332 |
| Value-Based Care | 0 | 1 | 1 |
| Care Enablement | 592 | 343 | 352 |
| **Total** | **915** | **699** | **685** |
| **Acquisitions, investments, purchases of intangible assets and investments in debt securities** |  |  |  |
| Care Delivery | 50 | 35 | 55 |
| Value-Based Care | 0 | 2 | 0 |
| Care Enablement | 60 | 68 | 83 |
| **Total** | **110** | **105** | **138** |

---

For additional information regarding our capital expenditures, see Item 5.IV, "Operating and financial review and prospects — Financial position."

[**Table of Contents**](#TOC)

#### Acquisitions and investments
A significant factor in the growth in our revenue and operating earnings in prior years has been our ability to acquire healthcare businesses, particularly dialysis clinics, on mutually beneficial terms. In the U.S., physicians and others who own dialysis operations might decide to sell their clinics (or investment interests in their clinics) to obtain relief from day-to-day administrative responsibilities and changing governmental regulations, to focus on patient care, and to realize a return on their investment. Outside the U.S., doctors might determine to sell to us and/or enter into certain relationships with us to achieve the same goals and to gain a partner with extensive expertise in dialysis products and services. Privatization of healthcare in Eastern Europe and Asia could present additional acquisition opportunities. We believe we are also viewed as a valuable strategic healthcare partner outside the dialysis business due to our experience in managing chronic disease for dialysis patients, our record of improving quality and patient satisfaction, reducing the overall cost of care, and our leadership in advancing innovation and improvement in healthcare.

For a discussion of our 2025, 2024, and 2023 acquisitions and investments, see Item 5, "Operating and financial review and prospects — IV. Financial position — Net cash provided by (used in) investing activities."

#### Production
We operate modern development, production, and distribution facilities worldwide to meet the demand for our dialysis products and other healthcare products. We have invested significantly in developing proprietary processes, technologies, and manufacturing equipment resulting in a competitive advantage in manufacturing our products. Production facilities and distribution centers are located around the world, with many strategically positioned to reduce transportation cost and facilitate the distribution of products to our customers.

The following table describes the countries in which we produce, manufacture or assemble products globally:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Production overview by country** |  |  |  |  |  |  |
|  |  |  |  |  |  | **Home** |
|  |  | **Peritoneal** |  |  |  | **hemodialysis** |
|  | **Hemodialysis** | **dialysis** |  | **Polysulfone** |  | **products and** |
|  | **machines** | **cyclers** | **Dialyzers** | **membranes** | **Bloodlines** | **components** |
| China | ✔ |  | ✔ |  | ✔ |  |
| France |  |  | ✔ | ✔ |  |  |
| Germany | ✔ | ✔ | ✔ | ✔ |  | ✔ |
| Italy |  |  |  |  |  | ✔ |
| Japan |  |  | ✔ | ✔ |  |  |
| Mexico | ✔ | ✔ |  |  | ✔ | ✔ |
| Serbia |  |  |  |  | ✔ |  |
| Türkiye |  |  |  |  | ✔ |  |
| U.S. |  |  | ✔ | ✔ |  |  |

---

In addition, we manufacture hemodialysis concentrate products and PD solutions at various facilities worldwide.

***Procurement***

We manage the procurement of raw materials and semi-finished goods used in the manufacturing of renal products globally. This global approach enables us to:

● enhance the efficiency of our processes,

● optimize cost structures,

● improve returns on our capital invested in manufacturing,

● respond quickly,

● maintain high quality and safety standards, and

● lessen risks in our supply chain to ensure supply availability.

[**Table of Contents**](#TOC)

Our procurement risk mitigation efforts include the development of partnerships with strategic suppliers through framework contracts, maintaining, where reasonably practicable, at least two sources for all supply and price-critical primary products (dual sourcing, multiple sourcing), incorporating measures to prevent loss of suppliers such as continuous supply chain monitoring, and the creation of risk mitigation strategies to increase supply chain resilience, particularly for primary and secondary suppliers located in countries with unpredictable geopolitical landscapes.

Our procurement policy combines worldwide sourcing of high-quality materials with the establishment of long-term supplier relationships. Additionally, we have processes in place to ensure that purchased materials comply with the quality specifications and safety standards required for our dialysis products. We outsource only after we have qualified suppliers, ensuring they meet our requirements. Interactive supplier relationship management and risk management systems connect all our global procurement activities to enhance global transparency, ensure compliance with our Global Code of Conduct for Business Partners, standardize processes, and enable the constant monitoring of our projects and supplier-related activities.

With close to €8.0 BN of addressable spend per year purchased from over 70,000 external suppliers, procurement is a function having a significant operational and financial impact on the Company. Effective January 1, 2025, ProCure Medical GmbH (PMG), our subsidiary, commenced operations as our global procurement company. PMG focuses on global category management, strategic sourcing, and supplier partnering in spend areas that we believe provide opportunities to capture incremental value through leveraging our procurement scale and skills above the country and regional levels. Overall, we anticipate that PMG will strengthen procurement's strategic role within the Company and sharpen alignment with the goals and ambitions of the FME25+ Program.

***Quality assurance and quality management in dialysis care***

With a focus on quality, costs and availability, we introduced an improved organizational infrastructure with efficient processes and systems over the last several years. All production sites follow the Lean Manufacturing approach which, in our plants in North America and most of our plants in the European, Middle East and African regions, includes the "Lean Six Sigma" management system. The focus of Lean Manufacturing and Six Sigma is the continuous improvement of manufacturing processes in order to achieve a low defect rate resulting in improved product quality, while reducing manufacturing time. Our production of renal pharmaceuticals and medical devices must comply with current Good Manufacturing Practices under the applicable regulations of the U.S. FDA, the EU, the Brazilian Health Regulatory Agency (ANVISA) and other jurisdictions. See "— Regulatory and legal matters — Product Regulation," below.

We have been successful in the continued harmonization of the major management systems in all manufacturing and development sites outside the U.S., the International Organization for Standardization (ISO)-certified marketing and sales sites in the EMEA region and the EU legal manufacturer under one globally harmonized management system (GMS). The GMS fulfills ISO 13485:2016, ISO 9001:2015 and ISO 14001 standards, the Medical Device Single Audit Program (MDSAP) underlying regulatory requirements, the Medical Device Directive 93/42/EEC as well as Regulation (EU) 2017/745 of April 5, 2017 on MDR, which have been implemented in the design, manufacture and distribution sites outside the U.S. (See also "Regulatory and Legal Matters — Facilities and Operational Regulation" below). Every medical device plant outside the U.S. has a local quality management system (QMS) directed by GMS that is certified either to ISO 13485:2016 and/or ISO 9001:2015 under MDSAP. Our operations in the U.S. continue to be governed under our North American Management System in compliance with U.S. FDA regulations. Where applicable, each site also complies to the Medical Device Directive 93/42/EEC, the MDSAP underlying regulatory requirements and additional national requirements based upon target markets and countries of manufacturing. Plants producing products with the Conformité Européene mark are in compliance with the EU MDR and our product portfolio is in the transition process to obtain EU MDR conformity in line with legal timelines until May 2028. The QMS of each site is reviewed through periodic corporate and local management reviews as well as internal audits.

All certified plants have successfully passed the annual ISO 13485, ISO 9001, MDSAP underlying regulatory requirements, external QMS audits and authority inspections for maintaining their required certifications and licenses.

Our dialysis clinics work in conformance with the generally accepted quality standards of the industry, particularly the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines from the U.S., the European Renal Best Practice standard and increasingly, Kidney Disease: Improving Global Outcomes (KDIGO), an industry initiative for global clinical practice guidelines. Clinical data management systems are used to routinely collect certain medical parameters, which we evaluate in anonymized form in compliance with these guidelines.

[**Table of Contents**](#TOC)

At each of our dialysis clinics in the U.S., a quality assurance committee is responsible for reviewing quality of care data, choosing local quality improvement projects and monitoring the progress towards achieving the quality targets which are informed by KDOQI, KDIGO and the Quality Agenda established by the Fresenius Medical Care North America (FMCNA) Medical Office. A rigorous scoring system, Clinical Quality Score, reports trends in outcomes and performance comparison among all levels of the organization. Visual representation of key performance indicators can be viewed in increasing levels of detail to provide transparency of results. We continue to develop and implement programs and tools to assist in achieving our quality goals. These include treatment algorithms based on best medical evidence, outlier management teams, and technology to highlight opportunities for improvement at the dialysis chairside.

The Medicare Improvements for Patients and Providers Act of 2008 created the ESRD quality incentive program under which dialysis facilities in the U.S. that fail to achieve annual quality standards established by CMS could have base payments reduced in a subsequent year by up to 2%. These programs blend the CMS quality standard measures with industry baselines in an effort to improve quality of care through a pay-for-performance program that operates as a part of the ESRD PPS. See Item 5. "Operating and financial review and prospects — II. Financial condition and results of operations — Overview."

Outside the U.S., the Care Delivery International (CDI) Clinic Quality Management Department (CQM) is responsible for establishing and maintaining our internal quality management systems in the EMEA and Asia Pacific (APAC) regions. Currently established QMS play a critical role in meeting quality and safety, legal and normative requirements in country organizations and dialysis clinics. As the dialysis industry-related requirements are highly regulated in the EMEA region, the establishment and maintenance of a quality management system is a mandatory requirement to maintain the validity of clinic licenses. CDI QMS performs its scoping procedures according to local legal requirements and Company requirements across EMEA and APAC. As such, both CDI CQM and country quality managers share responsibilities for defining, controlling and mitigating the quality, safety and clinical risks during the audit process as well as ensuring a continuously improving system. The CDI QMS audit program is performed at both the country and clinic level by systems, environmental, health and safety, nursing and medical expert auditors. The audit program has a non-conformity rating strategy focusing on risk assessment and, by utilizing regular audits, our clinical compliance status can be monitored regularly. We use different tools and systems together with CDI QMS to monitor our compliance status and performance of countries and clinics, including performance management tools such as balanced scorecards. In EMEA and APAC, respectively, 601 and 125 dialysis centers clinical and operational performance are measured via the CDI Balanced Scorecard. We also utilize a Power BI tool to monitor non-conformities and respective corrective actions by all levels of the organization. Additionally, regular management and operational review meetings are held at both corporate and country levels to address and respond to risks.

Specific to our Value-Based Care operating segment, we partner with payors, the Centers for Medicare and Medicaid Innovation (CMMI), nephrology practices, dialysis clinics, and transplant providers across the U.S. to help improve efficiency, health outcomes, and quality of care for aligned CKD and ESRD patients. Performance in each contract is measured by our ability to meet specific quality metrics, such as optimal starts, patient engagement, and delaying disease progression, as well as our ability to lower the total cost of care, through deploying care management tactics that help avoid hospitalizations and ensure that patients are receiving timely, holistic care and are appropriately connected to a nephrologist. To monitor our progress in meeting Value-Based Care contract performance and quality savings goals, our Value-Based Care segment aligns its company sub-goals to patient outcomes and quality improvement. These sub-goals are routinely assessed and evaluated by all levels of the Company, ensuring Value-Based Care's focus remains on delivering quality outcomes for patients that lower the total cost of care. In addition, Value-Based Care also uses tactics such as call monitoring, patient surveys and feedback, and data science to monitor and improve the quality of care provided throughout the year as well.

#### Environmental management
Environmental management in the healthcare sector involves balancing environmental responsibility with high-quality patient care. Providing patient care and the manufacturing of our life-sustaining products require significant amounts of energy, water, and other resources. We develop strategies that minimize environmental impact while maintaining safety and efficiency.

To verify compliance with environmental laws, local regulations, certifications, and internal guidelines, our production sites, distribution centers, laboratories, and dialysis clinics undergo both internal and external audits. Our employees are kept informed about environmental topics through internal articles, workshops, Q&A sessions, and targeted training.

The Management Board oversees strategic environmental matters, including the approval of the overarching environmental strategy and global targets. It supervises global environmental policies and receives updates from the Global Head of Sustainability on the implementation of measures and progress toward global targets throughout the year. The Management Board, relevant business units, and global functions support resource allocation, and identify, prepare, and implement sustainability projects at all levels. The Supervisory Board also receives updates during the year on implementation and progress related to the environment.

[**Table of Contents**](#TOC)

In recent years, there have been price increases and volatility in energy markets that could impact our financial position, for example, through the impact of vPPAs. While energy risks can be managed, they cannot be entirely eliminated, especially given potential supply challenges. Additionally, growing regulatory and market pressures may require a faster transition to renewable energy sources, potentially driving up operational costs. Generating and procuring renewable electricity in the markets where we operate can lead to cost savings, positive cash flows, and operational improvements. Examples include vPPAs, extending energy efficiency projects, and replacing energy sources, such as transitioning from gas to electricity. As a global healthcare company with production sites and clinics worldwide, we could be subject to potential physical risks posed by climate change. These may include floods, storms, heatwaves, droughts, and water stress, which could disrupt operations, affect infrastructure, and impact service continuity.

We continue to evaluate the potential financial impact of transition scenarios on our assets and our business model. We anticipate being able to secure access to financing, retain options for asset deployment flexibility, adapt our product and service offerings as market conditions evolve, and develop workforce capabilities aligned with climate transition requirements. This assessment is based on professional judgment, considering our climate targets, including actions such as our renewable electricity purchasing strategy, water strategy, and our forward-looking environmental risks management.

We generate and source renewable electricity in the markets where we operate. This can lower costs and improve cash flow. In 2024, we entered into five vPPAs, which are long-term purchase agreements with wind and solar parks. Three sites started producing electricity in 2024. Since January 2025, all sites have been operational and supplied electricity for the entire year. The contracts have terms ranging from 10 to 15 years. For further information regarding the impact of vPPAs on our consolidated financial statements, see note 26 of the notes to the consolidated financial statements included in this report.

In 2025, our Management Board extended our climate targets to include a net-zero goal, which has been validated by the Science Based Targets initiative (SBTi). Alongside existing climate targets, we now aim to achieve net-zero across our entire value chain by 2050, based on SBTi criteria. According to our validated net-zero target, we need to reduce our combined scope 1 and market-based scope 2 emissions, as well as our combined scope 3 emissions, by 90% compared to their respective base years by latest 2050.

In addition to the long-term target noted above, we have also established near-term and interim targets. By 2030, we plan to reduce our scope 1 and 2 emissions by 50% (457,866 tCO2e) compared to our 2020 base year (915,732 tCO2e) across our global operations. We have set two near-term scope 3 targets, covering six scope 3 categories and over 72.5% of total scope 3 emissions. With the first target we aim to reduce our combined scope 3 emissions from the following three categories by 25% compared to our scope 3 baseline year 2024: fuel- and energy-related activities, business travel, and use of sold products. As a second target, we have set a supplier engagement target to actively involve suppliers in reducing their scope 1 and 2 emissions. We expect the suppliers responsible for 70% of our scope 3 emissions in the three categories – purchased goods and services, capital goods, and upstream transportation and distribution – to set science-based emission reduction targets. Our target covers 1,206,929 tCO2e from these categories (around 39% of scope 3 emissions). In 2025, we verified that 11% of emissions in these categories were covered by suppliers that have set SBTi targets. We remain committed to our more ambitious scope 1 and 2 target established in 2022. We aim to achieve a 90% reduction of our combined scope 1 and market-based scope 2 emissions by 2040 and expect to meet the SBTi validated target ten years in advance.

Management Board and managerial staff member compensation has also been directly linked to our emissions targets and its effect on our financial statements is described in note 23 of the notes to the consolidated financial statements included in this report. Management Board compensation is also described in Item 6.B, "Directors, senior management and employees — Compensation," below.

In 2025, our scope 1 and 2 emissions totaled 649,608 tCO2e (2024: 687,439 tCO2e), a reduction of over 29% from our baseline (annual average reduction of 5.8% since 2020). Scope 1 emissions increased by 1.2% and market-based scope 2 emissions decreased by 12.9%. This decrease is mainly due to renewable electricity from our vPPAs. In 2025, the scope 3 emissions covered by our emissions reduction target increased by around 3% compared to our baseline. This is the result of increased sales and the resulting emissions from the use of sold products.

#### Patents and patent licenses
As the owner of patents or licensee under patents throughout the world, we currently hold rights in over 7,800 patents and patent applications in major markets.

Technologies that are the subject of granted patents or pending patent applications include aspects of our hemodialysis, peritoneal dialysis, and critical care treatment systems, relating to both single-use products and treatment machines.

[**Table of Contents**](#TOC)

Other parts of the patent portfolio relate to platform and future technologies, such as digital and data management.

We believe that our success will continue to depend significantly on our technology. As a standard practice, we obtain the legal protections we believe are appropriate for our intellectual property. Nevertheless, we are in a position to successfully market a significant number of products for which patent protection has lapsed or where only particular features are patented. We believe that even after the expiration of some of our patents, our proprietary know how for the manufacturing of our products and our continuous efforts to obtain targeted patent protection for newly developed upgraded products will continue to provide us with a competitive advantage. From time to time, our patents may be infringed by third parties and, in such cases, we will assert and enforce our rights. Registered patents may also be subject to invalidation claims made by competitors in formal proceedings (oppositions, trials, re-examinations, invalidation action, etc.) either in part or in whole. In addition, technological developments could suddenly and unexpectedly reduce the value of some of our existing intellectual property (see Item 3.D, "Key Information – Risk Factors").

#### Trademarks
As the owner of trademarks or licensee of trademarks throughout the world, we currently hold rights in over 3,600 registered trademarks or trademark applications covering inter alia our key product branding in major markets.

Our principal trademarks and corporate names are or comprise the designation "Fresenius Medical Care" which we use stand-alone or together with the V-shaped design element (the FME super-sign) in our corporate logo. The use of the "Fresenius" name in our trademarks and corporate logo is based on a perpetual, royalty-free license from Fresenius SE, our major shareholder.

The original Trademark License Agreement dated September 27, 1996 (Original Trademark License Agreement) remains in force after our Conversion and related deconsolidation from Fresenius SE as amended by the Long Form of Amendment to the Original Trademark License Agreement dated December 23, 2025 (Trademark License Agreement). The amended scope of the rights to use the Licensed Marks and/or the "Fresenius" name in the Worldwide Territory for products and/or services in different business fields shall only be governed by the Trademark License Agreement and reflects the current scope of business of Fresenius SE and the Company. Other amendments/clarifications concern, inter alia, standards regarding the use of the "Fresenius" name (details to be defined in Branding Guidelines, jointly developed by Fresenius SE and the Company), limits on the current and future stand-alone use of the "Fresenius" name by us, the introduction of customary termination rights and the introduction of reporting obligations regarding any harmful use of the Licensed Marks and/or of "Fresenius" name. See Item 7.B, "Related party transactions — Trademarks." The Trademark License Agreement has been filed as an exhibit to this report.

***Risk management***

We see risk management as the ongoing task of determining, analyzing and evaluating the spectrum of actual and potential risks arising from our business operations in our environment and, where possible, taking preemptive and corrective measures. Our risk management system provides us with a basis for these activities. It enables management to identify risks that could jeopardize the achievement of our strategic objectives or going concern and to take steps to minimize any negative impact. Accordingly, it is a vital component of our management and governance.

**Risk management system**

The main objective of the risk management system is to identify potential risks as early as possible to assess their impact on business activities and enable us, where necessary, to take appropriate countermeasures. Due to the constantly changing external and internal environment, our risk management system is continuously evolving. In the past fiscal year, we expanded our enterprise risk management system to include new functions and segments. In addition, we developed a new training concept to further improve the effectiveness and outcomes of the enterprise risk management system.

[**Table of Contents**](#TOC)

The organizational structure of our corporate risk management as well as the processes described below are shown in the following overview:

![Graphic](fms-20251231x20f012.jpg)

The structure of the risk management system is based on the internationally recognized framework for company-wide risk management, the "Enterprise Risk Management - Integrated Framework" of the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Additionally, sustainability-related risk management is part of our risk management system.

As part of the risk management system, risk coordinators, utilizing risk management software, assume the task of coordinating risk management activities within our risk management segments, in particular for risk identification and assessment with individual risk owners by means of, among other things, workshops, interviews and queries. These activities relate to existing and potential emerging short-term as well as mid-term risks. Semi-annually, identified risk information is processed by the risk coordinators and reviewed by the respective heads of general and administrative (G&A) functions, which is followed by further discussion and review in risk committees. Subsequently, the corporate risk management function gathers the risks and risk responses from risk management segments, analyzes and discusses them in the corporate risk committee, and communicates the compiled results to the Management Board. The analysis of the risk situation also includes determining the degree of a potential threat to our going concern by aggregating all risks with the aid of a software-supported risk simulation.

The Management Board and corporate risk management are promptly informed of new risks that are estimated to be high or develop into high risks in order to ensure appropriate responses (see Item 5. "Operating and financial review and prospects — VI. Risk matrix" regarding the classification of risks). The effectiveness of the risk management system is monitored by the Audit Committee of the Supervisory Board which also receives risk reporting information. Finally, the Supervisory Board is also informed about the risk situation.

In addition to risk reporting, standard reporting to management is a crucial tool for managing and controlling risks as well as for taking preventive measures in a timely manner. Therefore, our Management Board is informed monthly about the industry situation, our operating and non-operating business, and the outcome of analyses of our earnings and financial position, as well as of our assets position on a quarterly basis.

[**Table of Contents**](#TOC)

The Global Internal Audit department is regularly informed about the results of the risk management system. This department determines risk focus areas and audits a selected number of our end-to-end processes, management systems, departments, subsidiaries, and information technology (IT) processes worldwide each year. Determined risk focus areas are audited across all business segments. The department works according to the internationally accepted standards of the Institute of Internal Auditors, which was confirmed by a quality assessment in 2022. The next quality assessment is planned for 2026, based on the revised standards of the Institute of Internal Auditors. The scope of individual audit engagements is risk-focused and involves, among other activities, periodic assessment of the effectiveness of controls (including legal and compliance controls) over business processes, IT security, the reliability of financial reporting, and compliance with accounting regulations and internal policies. Since 2021, Global Internal Audit has conducted third-party audits of selected sales intermediaries to give assurance that business transactions with our products are in accordance with applicable compliance standards.

The "objects" to be audited are determined annually based on an audit universe, i.e. a selection model taking various risks and materiality into consideration. This annual audit plan is reviewed and approved by the Management Board and the Audit Committee of the Supervisory Board. All audit reports with material observations are presented to the Management Board.

The Global Internal Audit department is also responsible for monitoring the implementation of measures mitigating identified deficiencies. The Management Board is informed about the mitigation status on a quarterly basis. The Audit Committee of the Supervisory Board is also informed of the audit results. In 2025, a total of 24 audits and 15 sales intermediary audits conducted. Risk focus areas were compliance, FCPA, governance and ESG.

Nevertheless, it is important to note that a functioning and adequate risk management system cannot guarantee that all risks are fully identified and controlled.

For information regarding our risk management processes relating to environmental matters, including climate change, see "— Environmental Management" above. For information regarding our risk management processes relating to cybersecurity, see Item 16K, "Cybersecurity" in this report.

#### Internal control and risk management system for the Company's accounting process
Our internal control system over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB). Our reporting process is designed for reliable recording, processing, and control of financial data and key disclosures. In addition, the Management Board and the departments responsible for preparing the consolidated financial statements discuss key parameters, assumptions, and estimates that substantially affect the externally reported consolidated and segment results. The Audit Committee of the Supervisory Board also reviews current quarterly results and compares them with budgets and projections.

The internal control system contains guidelines and instructions designed for the appropriate and accurate recording and presentation of Company transactions within financial reporting.

Further control mechanisms aimed at achieving reliable financial reporting and correct recording of transactions within the accounting and the consolidation process include automated and manual reconciliations as well as the organizational separation of certain functions to prevent potential conflicts of interest. Furthermore, several preventive approval steps as well as detective plausibility checks are in place in various core finance and finance-related processes to ensure correct financial reporting. All process owners identify and assess the risks of their respective processes in terms of the implications for accounting and financial reporting. These process owners also determine that corresponding controls are in place to minimize these risks. Changes to accounting standards are discussed on an ongoing basis and considered in the preparation of the financial statements. Employees responsible for financial reporting are provided with regular training regarding changes in accounting standards. The consolidation is performed by a central department. The basis for the consolidation is derived from reporting packages and sub-group consolidated financial statements prepared and submitted by group entities. The preparation of reporting packages and sub-group consolidated financial statements is performed according to central requirements and guidelines.

[**Table of Contents**](#TOC)

As we are also listed on the NYSE, we are required to adhere to the requirements of the U.S. Sarbanes-Oxley Act of 2002 (SOX). Section 404 of this federal law stipulates that management of companies listed in the U.S. are responsible for implementing and adhering to an effective internal control system to produce reliable financial reporting. Yearly risk assessment and scoping take place to determine entities, processes, and controls which are subject to SOX requirements. The design and operating effectiveness of the internal control system over financial reporting are routinely assessed and considered in the regular testing cycle. Control testing results are regularly discussed with the respective stakeholders and remediation of control deficiencies is monitored. These criteria are also included in the annual audit by our independent registered public accounting firm. A quarterly certification process has been implemented as a formal accountability and responsibility mechanism for countries, segments, shared services centers, and corporate entities which aims at the accuracy of financial reporting and the associated disclosure controls and procedures.

The internal control system over financial reporting follows the criteria of the COSO model, *Internal Control – Integrated Framework* (2013), which was developed by COSO and is recognized as a standard by the SEC. In accordance with the COSO model, the internal control system over financial reporting is divided into five components: control environment, risk assessment, control activities, information and communication, and the monitoring of the internal control system. Each of these components is regularly documented, tested, and assessed. We aligned our internal controls to fulfill the requirements of the COSO model.

Our internal review of the internal control system over financial reporting complies with a specific SEC guideline (Guidance Regarding Management's Report on Internal Control Over Financial Reporting) and is conducted with software support. The global internal control team coordinates the assessment of the controls in scope for assessment, after which the results are consolidated for information and communication to those charged with governance. Based upon this assessment, management evaluates the effectiveness of the internal control system for the current fiscal year. External advisors are consulted for the review as needed. A steering committee meets at least twice per year to review regulatory developments and changes of relevant internal control requirements, to discuss control deficiencies, and derive further measures. In addition, in its meetings, the Audit Committee of the Supervisory Board is informed regularly of the key results of management's assessment.

Internal control systems over financial reporting are subject to inherent limitations, irrespective of how carefully these systems are designed. As a result, there is no absolute assurance that objectives for financial reporting can be met, nor that misstatements will always be prevented or detected.

For further information on these requirements, limitations and management's assessment of the Company's internal control over financial reporting for 2025, see Items 15.A. and 15.B, "Disclosure controls and procedures" and "Management's annual report on internal control over financial reporting."

#### Regulatory and legal matters

#### Regulatory and compliance overview
Our operations are subject to extensive governmental regulation by virtually every country in which we operate including, most notably, in the U.S., at the federal, state and local levels. Although these regulations differ from country to country, in general, non-U.S. regulations are designed to accomplish the same objectives as U.S. regulations governing the operation of healthcare centers, laboratories and manufacturing facilities for healthcare products, the provision of high quality healthcare for patients, compliance with labor and employment laws, the maintenance of occupational, health, safety and environmental standards and the provision of accurate reporting and billing for payments and/or reimbursement. In the U.S., some states establish regulatory processes that must be satisfied prior to the establishment of new healthcare centers. Outside the U.S., each country has its own payment and reimbursement rules and procedures, and some countries prohibit private ownership of healthcare providers or establish other regulatory barriers to direct ownership by foreign companies.

Any of the following matters could have a material adverse effect on our business, financial condition, and results of operations:

● failure to receive required licenses, certifications, clearances or other approvals for new or existing services, facilities, or products or significant delays in such receipt;

● complete or partial loss of various certifications, licenses, or other permits required under governmental authority by withdrawal, revocation, suspension, or termination or restrictions of such certificates and licenses by the imposition of additional requirements or conditions, or the initiation of proceedings possibly leading to such restrictions or the partial or complete loss of the required certificates, licenses or permits;

[**Table of Contents**](#TOC)

● recoupment or required refunding of payments received from government and private payors as well as government healthcare program beneficiaries because of any failures to meet applicable requirements;

● a non-appealable finding of material violations of applicable healthcare or other laws; and

● changes resulting from healthcare reform or other government actions that restrict our operations, reduce reimbursement or reduce or eliminate coverage for particular products or services we provide.

We must comply with all U.S., German and other legal and regulatory requirements under which we operate, including the U.S. federal Medicare and Medicaid Fraud and Abuse Amendments of 1977, as amended, generally referred to as the "Anti-Kickback Statute," the federal False Claims Act, the federal Physician Self-Referral Law, commonly known as the "Stark Law," the U.S. Civil Monetary Penalties Law, including the prohibition on inducements to patients to select a particular healthcare provider and the federal FCPA, as well as other fraud and abuse laws and similar state statutes, as well as similar laws in other countries.

As a global healthcare company, we are subject to laws and regulations including privacy and data protection. These laws and regulations govern, amongst other elements, the collection, use, disclosure, retention, and transfer of personal data. For example, the EU's General Data Protection Regulation, which became effective in May 2018, imposes substantial worldwide obligations on the processing and disclosure of personal data. Additional requirements are imposed by U.S. federal rules protecting the privacy and security of patient medical information, as promulgated under the Health Insurance Portability and Accountability Act of 1996 and, as amended by the Health Information Technology for Economic and Clinical Health Act (enacted as part of the American Recovery and Reinvestment Act of 2009), among other rules promulgated by individual state legislatures. These laws continue to develop globally and differ from jurisdiction to jurisdiction, which increases the complexity and costs of our global data protection and security compliance programs. Because of varying legal requirements across the world, the Fresenius Medical Care Global Privacy Foundation (the Foundation) establishes a set of requirements to help ensure appropriate use of personal data throughout its life cycle. While the Foundation creates a baseline compliance requirement for all of our subsidiaries and personnel, we are also obligated to comply with the requirements of all applicable local laws that impose other or stricter standards.

A number of U.S. states in which we operate have laws that prohibit business entities, such as the Company and our subsidiaries, from practicing medicine, employing physicians to practice medicine or exercising control over medical decisions by physicians (known collectively as the corporate practice of medicine prohibition). These states also prohibit entities from engaging in certain arrangements, such as fee-splitting, with physicians. Additional state and local laws and regulations require us to maintain certain licenses and certifications to operate our facilities and/or manufacture and distribute our products and services.

Our merger and acquisition activity, as well our business operations in both products and services, are regulated by antitrust and competition laws in the countries and localities in which we operate. Some of our transactions are subject to prior review and clearance by competition authorities, while others do not require any such review or clearance. Violations of competition laws may result in government enforcement action as well as private lawsuits. We develop and execute strategies in conformity with these laws to drive innovation and appropriate competition in our businesses and we provide regular internal training on appropriate business strategies under the competition laws.

In the U.S., a significant number of our patients receive healthcare coverage through federal health care programs, such as Medicare, Medicaid, and the ACA's individual market exchanges. There can be no assurance that applicable laws, or the regulations thereunder, will not be amended, or that enforcement agencies or the courts will not make interpretations inconsistent with our own, any one of which could have a material adverse effect on our business, reputation, financial condition and operating results. Sanctions for violations of these statutes may include criminal or civil penalties, such as imprisonment, fines or forfeitures, denial of payments, and suspension or exclusion from the Medicare, Medicaid and other federal health programs. In the U.S., some of these laws have been broadly interpreted by a number of courts, and significant government funds and personnel have been devoted to their enforcement because such enforcement has become a high priority for the federal government and some states. We, and the healthcare industry in general, will continue to be subject to extensive federal, state and foreign (i.e., non-U.S.) regulation, the full scope of which cannot be predicted. In addition, the U.S. Congress and federal and state regulatory agencies continue to consider modifications to healthcare laws that may create further restrictions. Proposals to restructure the Medicare program in the direction of a defined contribution, "premium support" model, to shift Medicaid funding to a block grant or per capita arrangement with greater flexibility for the states have previously been proposed and could have significant effects on our businesses. There also continue to be legal challenges to the ACA, and the outcomes and impact of such changes on our business, financial condition, and results of operations are currently impossible to quantify or predict.

[**Table of Contents**](#TOC)

We maintain a comprehensive worldwide compliance program under the overall supervision of our chief compliance officer. The program includes a compliance staff, a written code of business conduct applicable worldwide and available on our website, training programs, regulatory compliance policies and procedures including corrective action for failure to follow policies, provisions for anonymous reporting of suspected violations of applicable laws or Company policies, and periodic internal audits of our compliance procedures. We operate many facilities throughout the U.S. and other countries in which we do business. In such a widespread, global system, it is often difficult to maintain the desired level of oversight and control over the thousands of individuals employed by many affiliated companies. We rely on our management structure, regulatory and legal resources, and the effective operation of our compliance program to direct, manage and monitor the activities of these employees. If our employees or their agents or subcontractors, deliberately or inadvertently, were to submit inadequate or incorrect billings to any federally-funded healthcare program, or engage in unlawful conduct with physicians or other referral sources or vendors with which we do business, the actions of such persons could subject us and our subsidiaries to liability under the Federal Food, Drug, and Cosmetic Act, Anti-Kickback Statute, the Stark Law, the False Claims Act or the Foreign Corrupt Practices Act, among other laws. See note 25 of the notes to our audited consolidated financial statements included in this report.

While we operate under procedures and policies developed in response to the regulatory environment in which we conduct our business, there is no assurance that our interpretations of legal requirements will always be accurate or that our execution of legal requirements will always be sufficient or complete. Any failure to comply with legal requirements could result in repayment obligations, civil and criminal penalties, loss of licenses and certifications required to conduct business, limitations on our operations and greater governmental oversight.

#### Product regulation
*U.S. pharmaceuticals*

In the U.S., numerous regulatory bodies, including the FDA and comparable state regulatory agencies impose requirements on certain of our subsidiaries as a manufacturer, distributor and/or a seller of drug products under their respective jurisdictions. Some of the products our subsidiaries manufacture and/or distribute are subject to regulation under the Federal Food, Drug, and Cosmetic Act of 1938, as amended (FDCA) and FDA's implementing regulations. These products include our peritoneal dialysis and saline solutions, PhosLo<sup>®</sup> (calcium acetate), Phoslyra<sup>®</sup> (calcium acetate oral solution), Venofer<sup>®</sup> (iron sucrose injection, USP), and Velphoro (sucroferric oxyhydroxide). Distribution of PhosLo<sup>®</sup> and Phoslyra<sup>®</sup> was discontinued in 2024. Many of these requirements are similar to those for devices, as described below. We are required to register as an establishment with the FDA, submit listings for drug products in commercial distribution and comply with regulatory requirements governing product approvals, drug manufacturing, labelling, promotion, distribution, post market safety reporting and recordkeeping. We are subject to periodic inspections by the FDA and other authorities for compliance with inspections as well as with federal CMS average sales price reporting, medical drug rebate program and other requirements. Our pharmaceutical products must be manufactured in accordance with current Good Manufacturing Practices (cGMP). We are required to provide information to the FDA whenever we become aware of a report of an adverse drug experience associated with the use of one of our drug products that is both serious and unexpected, as defined in FDA regulations and guidance. We are required to notify the FDA of certain product quality issues. In addition, as with the marketing of our medical devices, in order to obtain marketing approval of our drug products, we must satisfy mandatory procedures and safety and efficacy requirements. Furthermore, the FDA prohibits our products division from marketing or promoting our pharmaceutical products in a false or misleading manner and from otherwise misbranding or adulterating them. Finally, if the FDA believes that a company is not in compliance with applicable drug regulations, it has similar enforcement authorities as those discussed below with respect to medical devices, including under the administrative, civil, and criminal penalty provisions of the FDA. Other state and federal regulatory and enforcement agencies have authority to enforce related fraud, consumer protection, privacy, and other laws.

*Pharmaceuticals outside the U.S.*

Some of our products, such as peritoneal dialysis and acute dialysis solutions as well as phosphate binders and other orally administered drugs, are considered medicinal products subject to the specific drug law provisions in various countries. The EU has issued several directives and regulations on medicinal products, including a directive on medicinal products for human use, like Regulation (EC) 726/2004 (March 31, 2004) and Directive 2001/83/EC (November 6, 2001), as amended. Each member of the EU is responsible for conforming its law to comply with the latter directive. In Germany, the German Drug Law (*Arzneimittelgesetz* or AMG), which implements several EU requirements, is the primary regulation applicable to medicinal products.

[**Table of Contents**](#TOC)

The provisions of the AMG are comparable with the legal standards in all other European Union countries. As in many other countries, the AMG generally provides that a medicinal product may only be placed on the market if it has been granted a corresponding marketing authorization. Such marketing authorization is granted by the licensing authorities only if the quality, efficacy and safety of the medicinal product have been scientifically proven. Medicinal products marketed on the basis of a corresponding marketing authorization are subject to ongoing control by the competent authorities. The marketing authorization may also be subsequently restricted or made subject to specific requirements.

The production of medicinal products requires a manufacturing license which is granted by the competent authorities of the relevant EU Member State for a specific manufacturing facility and for specific medicinal products and forms of medicinal products. The manufacturing license is granted only if the manufacturing facility, production techniques and production processes comply with the national drug law requirements, with the principles and guidelines of EU-Good Manufacturing Practice (EU-GMP). International guidelines also govern the manufacture of medicinal products and, in many cases, overlap with national requirements. Material regulations concerning manufacture and registration related to medicinal products have been issued by the European Commission (EC) and the International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The Pharmaceutical Inspection Co-operation Scheme (PIC/S), an international informal cooperative arrangement between regulatory authorities, aims at harmonizing inspection procedures by developing common standards in the field of good manufacturing practices and by providing training opportunities to inspectors. Among other things, the EC, PIC/S and ICH establish requirements for good manufacturing practices, many of which are then adopted at the national level.

Another international standard, which is non-binding for medicinal products, is the ISO9001:2015 system for assuring quality management system requirements. This system has a broader platform than EU-GMP, which is more detailed and is primarily acknowledged outside the field of medicinal products, e.g., with respect to medical devices.

*U.S. medical devices*

Our subsidiaries engaged in the manufacture of medical devices are required to register with the FDA as device manufacturers and submit listing information for devices in commercial distribution. As a manufacturer of medical devices, we are subject to requirements governing premarket approval and clearance, labelling, promotion, clinical research, medical device adverse event reporting, manufacturing practices, reporting of corrections and removals, and recordkeeping, and we are subject to periodic inspection by the FDA for compliance with these requirements. With respect to manufacturing, we are subject to FDA's Quality System Regulation (21 C.F.R. Part 820) and related FDA guidance, which requires us to manufacture products in accordance with cGMP, including standards governing product design. The medical device reporting regulations and guidance require that we report to the FDA whenever we receive or become aware of information that reasonably suggests that a device may have caused or contributed to a death or serious injury, or that a device has malfunctioned and a device or similar device would be likely to cause or contribute to a death or serious injury if the malfunction were to recur. FDA regulations also may require us to conduct product recalls and take certain other product corrective actions in response to potential quality issues. In addition, the FDA prohibits our products division from promoting our manufactured products for unapproved or uncleared indications or in a false or misleading manner. We are also prohibited from promoting unapproved or uncleared drugs or devices more generally. Finally, as with our pharmaceutical products, states impose additional requirements on our drug and device manufacturing and distribution activities, including requiring additional state licenses. We are subject to periodic inspections by the FDA and other authorities for compliance with these requirements.

In January 2023, SEIU-United Healthcare Workers West, a labor union, submitted a petition requesting that the U.S. FDA issue a recall of certain of our dialysis machines to address certain purported safety matters raised by their petition. The Company believes that the claims raised by the union's petition are without merit. The FDA has not responded to the petition. If and when the FDA acts on the petition, the Company will respond appropriately.

*Medical devices outside the U.S.*

In the European Union, medical devices are subject to their own regulatory requirements. Since May 26, 2021, the Medical Device Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5, 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU have replaced former acts and set out the main regulatory framework. Although the MDR is self-binding in all Member States of the EU, numerous acts of the EC and of national legislation in each Member State are necessary to fully implement the legal provisions. These provisions essentially include higher safety standards to be met by medical devices and, therefore, require a new conformity assessment procedure and re-certification of all medical devices regardless of whether they have already been placed on the market.

[**Table of Contents**](#TOC)

Originally, the transitional provisions according to Article 120 of the MDR allowed manufacturers until May 2024, at the latest, to continue to place their medical devices on the EU market based on a valid EC certificate according to the former directives and local laws for medical devices.

However, on March 15, 2023, the European Parliament published Regulation (EU) 2023/607 (2<sup>nd</sup> amendment to the MDR), with major relevance for certification and products which are already on the market in compliance with the Medical Devices Directive (MDD). MDD certificates shall be considered valid until end of the new transition dates. We have met all requirements of the 2<sup>nd</sup> amendment enabling us to continuously place MDD products on the market until December 31, 2027 or December 31, 2028, depending on the specific products' individual risk class. The corresponding manufacturer's declaration and confirmation letters by the notified body have been issued accordingly.

Conformity of our QMS with the applicable MDR requirements was assessed and confirmed by our notified body during an initial certification audit in 2019 and surveillance audits in 2020 through 2023. During 2024, the MDR recertification audit was successfully passed, followed by the successfully passed surveillance audit in 2025. After the additionally required successful assessment of the submitted technical documentation, the first EU certificate, pursuant to the MDR, was issued mid 2020 by our notified body. For each extension of the product scope of the EU certificate, a review of a sample of the technical documentation from the respective product group is required. Following this step-wise approach, our EU MDR certificates have been extended in 2023, 2024, and 2025, resulting in greater than 97% coverage of those product categories required to certify our product portfolio. In alignment with our product business, one remaining product category is currently in the certification process with our notified body with planned finalization in 2026.

According to the current EU regulations, the Conformité Européene mark serves as a general product passport for all Member States of the EU and the European Economic Area (EEA). Upon receipt of an EU certificate for a product according to the applicable conformity assessment procedure, e.g. a certified full quality management system for medical devices according to ISO 13485:2016, and the documented declaration and proof of conformity of our products to the harmonized European norms (Declaration of Conformity), we as the legal manufacturer are able to mark products as being in compliance with the EU requirements. If able to do so, the manufacturer must place a Conformité Européene mark on the products. Medical devices that do not bear the Conformité Européene mark cannot be sold or distributed within the EU.

*Clinical Research*

Our subsidiaries engaged in the manufacture and sale of medicinal products and medical devices, when engaged in clinical research involving investigational products, are subject to many requirements governing the conduct of clinical research, including Good Clinical Practice (GCP) standards. Similarly, our subsidiaries involved in the provision of clinical research services may also be subject to those requirements governing the conduct of clinical research depending on the nature of the research involved.

*FDA and other regulatory bodies' enforcement action*

If the FDA or other regulatory bodies believe that a regulated company is not in compliance with applicable laws and regulations, they can pursue various administrative and enforcement actions, including, for example, issuing an untitled or warning letter, initiating a seizure action, or seeking an injunction. Among other things, these actions can result in the assessment of administrative penalties, product recalls and civil or criminal enforcement. Such actions could also lead to additional enforcement by other state or federal government agencies as well as lawsuits by patients or shareholders.

On December 4, 2023, the FDA issued a warning letter to us citing several deficiencies of the cGMP requirements of the Quality System regulation and alleging possible corrective and preventive action failures, among other things, in connection with the use of silicone tubing used in certain of our dialysis machines that was previously reported to the FDA. We have responded and continue to update the FDA about continuing remediation efforts. For a description of the status of outstanding FDA warning letters related to our operations, see note 25 of the notes to the consolidated financial statements included in this report.

We cannot assure that all necessary regulatory clearances or approvals, including those for new products or product improvements, will be granted on a timely basis, if at all. Delays in or failure to receive clearance or approval or delays in or failures to carry out product recalls may result in liability and reputational harm and may materially adversely affect our operating results. If at any time the FDA or other regulatory bodies believe we are not in compliance with applicable laws and regulations, they could take administrative, civil, or criminal enforcement action, resulting in liability and reputational harm, which could materially affect our operating results.

[**Table of Contents**](#TOC)

***Potential changes impacting our private payors in the U.S.***

The operation of charitable insurance premium assistance programs such as that offered by the American Kidney Fund (AKF) has received increased attention over the last few years by CMS and state insurance regulators and legislators. The result may be a regulatory framework that differs from the current framework or that varies from state to state. Even in the absence of actions by CMS or state regulators and legislatures to restrict the access that patients currently have to premium assistance programs, insurers are likely to continue efforts to thwart charitable premium assistance by premium assistance programs to our patients. If successful in a material area or scope of our U.S. operations, these efforts would have a material adverse impact on our business and operating results.

One such law that was enacted is AB290 in California (U.S.). Upon enactment, we, along with other providers and the AKF, filed suit challenging the validity of the law. *Jane Doe, et al. v. Xavier Becerra, et al.,* 8:19-cv-02105, U.S. District Court for the Central District of California, Southern Division. In December 2019, the court issued a preliminary injunction staying implementation of the law. On January 9, 2024, the court issued a summary judgment decision which, among other things, upheld the provisions limiting reimbursement paid to providers who donate to the AKF when such reimbursement relates to services provided to patients who receive AKF support. On May 9, 2024, the court issued a final judgment, but stayed entry of such judgment while the parties appeal. See "— Regulatory and legal matters — Reimbursement — Possible changes in statutes or regulations" for further information on charitable premium assistance programs.

*Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc. et al.* No. 20-1641: On November 5, 2021, the U.S. Supreme Court granted certiorari of an appeal by an employer group health plan, the plan sponsor, and the plan's advisor of the U.S. Court of Appeals for the Sixth Circuit (Sixth Circuit) decision in DaVita Inc.'s favor. The questions presented involved whether the health plan violated the MSPA by "taking into account" that plan beneficiaries are eligible for Medicare and/or by "differentiating" between the benefits that the plan offers to patients with dialysis versus others. On June 21, 2022, the U.S. Supreme Court reversed the Sixth Circuit decision and held that the EGHP for Marietta Memorial Hospital did not violate the MSPA. The Marietta ruling makes it easier for health plans to design plan benefits for Medicare eligible ESRD patients in a way that makes private health insurance relatively less attractive to ESRD patients and Medicare relatively more attractive. The Restore Protections for Dialysis Patients Act, most recently introduced in the U.S. Congress in March 2025 but not enacted, would restore the interpretation of the Medicare Secondary Payer Act prior to the Marietta decision and ensure that patients cannot be discriminated against because of their need for dialysis. We cannot predict whether the U.S. Congress will enact this or any other proposed legislation that would reverse the potential effects of the Marietta decision. As Medicare and Medicaid reimbursement rates are generally lower than the reimbursement rates paid by commercial insurers, a shift of commercially insured patients to Medicare and Medicaid could have a material adverse impact on our business, financial condition, and results of operations. The Marietta ruling may also result in certain EGHPs reducing the benefits offered for dialysis, which could, depending on the number of patients impacted, have a material and adverse impact on our business, financial condition, and results of operation. There can be no assurance that this proposal or any other legislation to address the Marietta decision will be enacted.

***U.S. ballot initiatives and other legislation***

Further federal or state legislation or regulations may be enacted in the future through legislative and public referendum processes, which could substantially modify or reduce the amounts paid for services and products offered by us and our subsidiaries, mandate new or alternative operating models and payment models, and/or increase our operating expenses that could present more risk to our healthcare service operations. Ballot initiatives that are successfully introduced at the state level in the U.S. require the vote of state citizens to directly adopt or reject proposed new legislation. These ballot initiatives require a material expenditure of resources by us to participate in public discourse regarding the proposed new legislation underlying the initiatives, which if passed, could further regulate multiple aspects of our operations including, for instance, clinic staffing requirements, state inspection requirements and profit margins on commercial business. Efforts to enact new state laws regarding our operations are continuing. State regulation at this level would introduce an unprecedented level of oversight and additional expense at the clinic level which could have a material adverse effect on our business in the impacted states. It is also possible that statutes may be adopted or regulations may be promulgated in the future that impose additional eligibility requirements for participation in the federal and state healthcare programs. Such new legislation or regulations could, depending upon the detail of the provisions, have positive or adverse effects, possibly material, on our businesses and results of operations. See "— Regulatory and legal matters — Reimbursement – Possible changes in statutes or regulations," below.

[**Table of Contents**](#TOC)

#### Environmental regulation
We are subject to a broad range of federal, foreign, state and local laws and regulations relating to pollution and the protection of the environment. These laws regulate, among other things, the discharge of materials into the environment, the handling and disposal of medical and other wastes, remediation of contaminated sites and other matters relating to worker, public and consumer health and safety as well as to the protection of the environment. In addition, the Company uses substances regulated under U.S. and EU environmental laws, primarily in product design as well as manufacturing and sterilization processes. Noncompliance with these regulations can result in significant fines or penalties or limitations on our operations. The applicable environmental, health and safety laws and regulations, and any changes to them or their enforcement, may require us to make material expenditures with respect to ongoing compliance with or remediation under these laws and regulations or require that we modify our products or processes in a manner that increases our costs or reduces revenues. For information regarding our activities in the areas of energy and climate protection, water management, waste management and biodiversity and pollution, see "Environmental Management," above.

#### Facilities and operational regulation
Operational conditions in recent years had an impact on the standard operating practices at our manufacturing facilities, distribution operations, and global clinic network and resulted in changes to these practices through the implementation of additional best practice procedures along with procedures required by the jurisdictions in which we operate. Within our production facilities and clinic network, we defined and implemented further hygiene and infection control measures and precautions in order to maintain sufficient clinical staff and available space to treat all of our patients, including those who are or may be infected with communicable diseases, while not unnecessarily exposing our care teams or other patients to whom we provide dialysis services, and who are among the groups most vulnerable to such infections. Vaccination is the top priority for our clinic network where vaccines for such diseases are available.

*U.S.*

Federal, state and local regulations (implemented by CMS, FDA, the Occupational Health and Safety Administration (OSHA), the Drug Enforcement Administration, and state departments or boards of public health, public welfare, medicine, nursing, pharmacy, and medical assistance, among others) require us to meet various standards relating to, among other things, the management, licensing, safety, security and operation of facilities (including, e.g., laboratories, pharmacies, and clinics), personnel qualifications and licensing, the maintenance of proper records, equipment, and quality assurance programs, and the dispensing, storage, and administration of controlled substances. All of our operations in the U.S. are subject to periodic inspection by federal, state and local agencies to determine if the operations, premises, equipment, personnel and patient care meet applicable standards. To receive Medicare/Medicaid reimbursement, our healthcare centers, renal diagnostic support business and laboratories must be certified by CMS. While all of our entities that furnish Medicare or Medicaid services maintain and renew the required certifications, material adverse effects on our business, financial condition, and results of operations could potentially occur if certain of those entities lose or are delayed in renewing a certification.

Our operations are subject to various U.S. Department of Transportation, Nuclear Regulatory Commission, Environmental Protection Agency, and OSHA requirements and other federal, state and local hazardous and medical waste disposal laws. As currently in effect, laws governing the disposal of hazardous waste do not classify most of the waste produced in connection with the provision of our healthcare services as hazardous, although disposal of non-hazardous medical waste is subject to specific state regulation. Our operations are also subject to various air emission and wastewater discharge regulations.

Several states have certificate of need programs regulating the establishment or expansion of healthcare facilities, including dialysis centers. We believe that we have obtained all necessary approvals for the operation of our healthcare facilities in accordance with all applicable state certificate of need laws. In states that also have certificate of need programs, the licensing requirements are separate and in addition to the need for certificates of need.

[**Table of Contents**](#TOC)

*Non-U.S.*

We are subject to a broad spectrum of regulation in almost all countries. Our operations must comply with various environmental and transportation regulations in the various countries in which we operate. Our manufacturing facilities and dialysis clinics are also subject to various standards relating to, among other things, facilities, management, personnel qualifications and licensing, maintenance of proper records, equipment, quality assurance programs, the operation of pharmacies, the protection of workers from blood-borne diseases, and the dispensing of controlled substances. All of our operations may be subject to periodic inspection by various governmental authorities to determine if the operations, premises, equipment, personnel, and patient care meet applicable standards. Our dialysis clinic operations and our related activities generally require licenses, which may be subject to periodic renewal and may be revoked for violation of applicable regulatory requirements.

In addition, many countries impose various investment restrictions on foreign companies. For instance, government approval may be required to enter into a joint venture with a local partner. Some countries do not permit foreign investors to own a majority interest in local companies or require that companies organized under their laws have at least one local shareholder. Investment restrictions may therefore affect the operating procedures and other characteristics of our subsidiaries and joint ventures in these and other countries.

We believe our facilities are currently in compliance in all material respects with the applicable national and local requirements in the jurisdictions in which they operate.

#### Reimbursement
As a global company delivering healthcare and dialysis products, we are represented in more than 140 countries worldwide. Consequently, we face the challenge of addressing the needs of a wide variety of stakeholders, such as patients, customers, payors, regulators, and legislators in very different economic environments and healthcare systems.

Healthcare systems and reimbursement structures for ESRD treatment vary significantly by country. In general, the government (in some countries in coordination with private insurers) or social and private insurance programs pay for healthcare. Funding is achieved through taxes and other sources of government income, from social security contributions, or a combination of those sources. However, not all healthcare systems provide for dialysis treatment. In some developing countries, only limited subsidies from government, social insurances, or charitable institutions are available, and typically dialysis patients must personally finance all or a substantial share of the treatment cost. Irrespective of the funding structure, in some countries patients needing dialysis do not receive treatment on a regular basis but rather only when financial resources allow.

*U.S.*

Our dialysis clinics provide outpatient hemodialysis treatment and related services for ESRD patients. In the U.S., Medicare pays as the primary insurer for Medicare-eligible individuals under many circumstances. Some patients pay for their healthcare services primarily through commercial insurance coverage. For Medicare primary patients, Medicare pays 80% of the prospective payment amount for the ESRD Prospective Payment system items and services. The beneficiary or third-party insurance payors (including employer-sponsored health insurance plans, commercial insurance carriers, including Medicare Advantage, Medicaid Risk plans and the Medicaid program) on behalf of the beneficiary are responsible for paying the beneficiary's cost-sharing obligations (typically an annual deductible and 20% co-insurance), subject to the specific coverage policies of such payors. Each third-party payor, including Medicaid, makes payment under contractual or regulatory reimbursement provisions that may or may not cover the full 20% co-payment or annual deductible. Where the beneficiary has no third-party insurance or the third-party insurance does not fully cover the co-payment or deductible, the beneficiary is responsible for paying the co-payments or the deductible, which we frequently cannot fully collect despite collection efforts.

*Medicare's ESRD Prospective Payment System.* Under the ESRD PPS, CMS reimburses dialysis facilities with a single payment for each dialysis treatment, inclusive of (i) all items and services included in the former composite rate, (ii) calcimimetics (as of January 1, 2021), oral vitamin D analogues, oral levocarnitine, ESAs and other ESRD-related pharmaceuticals (other than vaccines and oral-only drugs) furnished to ESRD patients that were previously reimbursed separately under Part B or Part D of the Medicare program, (iii) most dialysis-related diagnostic laboratory tests and (iv) certain other items and services furnished to individuals for the treatment of ESRD.

[**Table of Contents**](#TOC)

Payment rates vary by both patient and facility. CMS subjects a base ESRD PPS payment rate to case-mix adjustments that take into account individual patient characteristics (e.g., age, body surface area, body mass) and certain co-morbidities. The base payment rate is also adjusted for (i) certain high cost patient outliers reflecting unusual variations in medically necessary care, (ii) disparately high costs incurred by low volume facilities relative to other facilities, (iii) provision of home dialysis training and (iv) wage-related costs in the geographic area in which the provider is located. The Protecting Access to Medicare Act of 2014 (PAMA) provides that rates will be updated by the market basket rate of increase net of multifactor productivity adjustment. The ESRD PPS also provides for: (i) a training add-on payment for home and self-dialysis modalities, (ii) a transitional drug add-on payment adjustment, (iii) a transitional add-on payment adjustment for new and innovative equipment and supplies (TPNIES), and (iv) beginning in 2024, for new renal dialysis drugs or biological products used to treat or manage a condition for which there is already an existing ESRD PPS functional category, a 3-year post-TDAPA add-on payment adjustment on all ESRD PPS claims, which provides increased payment following the end of the TDAPA period for those products. New renal dialysis drugs or biological products used to treat or manage a condition for which there is not an ESRD PPS functional category are not considered included in the ESRD PPS bundled payment. Such new renal dialysis drugs or biological products are paid for using the TDAPA. At the conclusion of that TDAPA period, CMS undertakes rulemaking to modify the ESRD PPS base rate, if appropriate, to account for the new renal dialysis drug or biological in the ESRD PPS bundled payment. The post-TDAPA add-on payment adjustment does not apply for these drugs or biological products.

On November 20, 2025, CMS issued a final rule for the 2026 ESRD PPS, which CMS projects will increase the total aggregate payments to all ESRD facilities by 2.2%. For CY 2026, the ESRD PPS base rate is $281.71, an increase of $7.89 from the current CY 2025 base rate of $273.82. This amount reflects application of the final CY 2026 ESRD Bundled market basket update of 2.1%, which is the result of a 2.9% market basket increase offset by a 0.8% productivity adjustment, as well as applicable budget-neutrality adjustment factors. CMS notes in the final rule that the 1.0 percent target for outlier payments was not achieved in CY 2024 as outlier payments represented approximately 0.8 percent of total Medicare payments. The final Acute Kidney Injury payment rate for CY 2026 is equal to the CY 2026 ESRD PPS base rate. CMS also finalized a budget-neutral payment increase for ESRD facilities in Alaska, Hawaii, and the U.S. Pacific Territories. CMS also finalized the termination of the ESRD Treatment Choices (ETC) Model effective December 31, 2025.

*Sequestration of Medicare payments.* On August 2, 2011, the BCA was enacted, raising the U.S. debt ceiling and putting into effect a series of actions for deficit reduction. The BCA, in effect, required automatic across-the-board spending cuts for most government programs over nine fiscal years (2013-2021); these cuts were projected to total $1.2 trillion. The first cuts for Medicare payments to providers and suppliers were initially implemented on April 1, 2013. As a result of subsequent legislation, these cuts have been extended through FY 2032. Under the BCA, as amended, the reduction in Medicare payments to providers and suppliers (the U.S. Sequestration) is limited to one adjustment of no more than 2% in each year through 2031, and in 2032 there will be an adjustment of 2% for the first half of FY 2032, dropping to 0.0% for the second half of FY 2032. The U.S. Sequestration is independent of Medicare's annual inflation update mechanisms, such as the market basket update pursuant to the ESRD PPS.

*TDAPA and oral-only drugs.* PAMA also included a provision addressing ESRD-related drugs with only an oral form, which are referred to as "oral-only" drugs and which have previously been paid separately. Subsequently, the Stephen Beck, Jr., Achieving a Better Life Experience Act of 2014 delayed inclusion of oral-only drugs in the ESRD PPS until January 1, 2025. Under the CY 2025 ESRD PPS Final Rule, oral-only drugs were approved for the TDAPA under the ESRD PPS.

CMS will utilize the TDAPA for at least two years to collect utilization data before adding these drugs to the ESRD PPS base rate. The TDAPA is generally based on 100% of average sales price. If ASP is not available, then the TDAPA is based on 100% of wholesale acquisition cost (WAC). If WAC is unavailable, then the payment is based on the drug manufacturer's invoice. As finalized in the CY 2025 ESRD PPS Final Rule, CMS will apply a fixed increase to the calculation of the monthly TDAPA amount during this transition period for claims that include the applicable new oral-only drugs, to cover the incremental operational costs of making these medications available to patients. At the end of this transition period, CMS will initiate rulemaking to modify the base rate, if appropriate, to account for these drugs in the ESRD PPS bundled payment, as CMS did in the CY 2021 final rule for calcimimetics.

[**Table of Contents**](#TOC)

In addition to the TDAPA payments for these oral-only drugs, CMS will continue the TDAPA payments for two additional drugs. Effective July 1, 2024, taurolidine and heparin sodium, a catheter lock solution instilled into the central venous catheter at the conclusion of each hemodialysis session, qualified for the TDAPA as a drug or biological product used to treat or manage a condition for which there is an existing ESRD PPS functional category. The TDAPA payment period began on July 1, 2024 and will continue through June 30, 2026, at which point the product will both become outlier eligible and also be included in the post-TDAPA add-on payment adjustment calculation. Additionally, effective January 1, 2025, vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor indicated for treating anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, qualified for the TDAPA as a drug or biological used for anemia management, an existing ESRD PPS functional category. Vadadustat is eligible for the TDAPA throughout CY 2026 but does not qualify for outlier payments.

*Revisions to Medicare's Physician Fee Schedule.* The Medicare and CHIP Reauthorization Act of 2015 (MACRA) removed the periodic threat of substantial reductions in payment rates under the Physician Fee Schedule (PFS) that could have, if they had been permitted to take effect, significantly affected our businesses and those of our affiliated physicians. MACRA permanently removed the "sustainable growth rate" provision and in its place specified modest increases in PFS payment rates for the next several years. MACRA creates an elaborate scheme of incentive payments and penalty adjustments that started in 2019 based on 2017 physician performance as reflected in various measures of cost, use of health information technology, practice improvement activities, and quality of care and on possible participation in "advanced alternative payment models," such as some accountable care organizations. We cannot predict whether this scheme is likely to have material effects on our revenues and profitability in our nephrology, urgent care, vascular, cardiovascular and endovascular specialty services. Through an annual rule-making cycle, CMS revises PFS payment rates to account for across-the-board updates as well as, from time to time, changes in the evaluation of physician work and practice expenses used to set rates for individual services paid under the PFS. While impacts of large changes are usually spread out over several years, such changes have the potential to affect the rates for specific services that are extensively furnished in our physician businesses and hence to affect materially the revenues of those businesses.

On October 31, 2025, CMS released the final Physician Fee Schedule for CY 2026. As required by statute, beginning in CY 2026, there will be two separate conversion factors: one for alternative payment model (APM) qualifying participants (QPs) and one for physicians and practitioners who are not QPs. The final CY 2026 qualifying APM conversion factor of $33.57 represents a projected increase of $1.22 (+3.8%) from the current conversion factor of $32.35. Similarly, the final CY 2026 non-qualifying APM conversion factor of $33.40 represents a projected increase of $1.05 (+3.3%) from the current conversion factor of $32.35. The final updates are inclusive of the OBBBA one-time adjustment for 2026. The impacts of the final updates are expected to vary by specialty and site of service. On November 21, 2025, CMS released the CY 2026 final rule for hospital outpatient and ambulatory surgery center (ASC) payment systems. For CY 2026, CMS finalized an update factor to the ASC rates of 2.6%.

*ESRD PPS quality incentive program.* The ESRD PPS's Quality Incentive Program (QIP) affects Medicare payments based on performance of each facility on a set of quality measures. Based on a prior year's performance, dialysis facilities that fail to achieve the established quality standards have payments for a particular year reduced by up to 2 percent. CMS updates the set of quality measures each year, adding, revising or retiring measures.

Under the ESRD QIP, CMS assesses the total performance of each facility on a set of quality measures specified per payment year and applies up to a 2% payment reduction to facilities that do not meet a minimum total performance score. Beginning with QIP Payment Year (PY) 2027, CMS has removed the Facility Commitment to Health Equity reporting measure, Screening for Social Drivers of Health reporting measure and Screen Positive Rate for Social Drivers of Health reporting measure. CMS also finalized changes to In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems intended to reduce patient and facility burden. CMS has retained the COVID-19 Vaccination Coverage Among Healthcare Personnel measure and summarized responses to its requests for information on Health IT and potential quality measures related to nutrition and wellness.

[**Table of Contents**](#TOC)

*Affordable Care Act.* ACA provides for broad healthcare system reforms, including (i) provisions to facilitate access to private health insurance, (ii) expansion of the Medicaid program, (iii) industry fees on device and pharmaceutical companies based on sales of brand name products to government healthcare programs, (iv) increases in Medicaid prescription drug rebates, (v) commercial insurance market reforms that protect consumers, such as bans on lifetime and annual limits, coverage of pre-existing conditions, and limits on waiting periods, (vi) provisions encouraging integrated care, efficiency and coordination among providers (vii) provisions for reduction of healthcare program waste and fraud and (viii) a 2.3% excise tax on manufacturers' medical device sales starting in 2013. However, pursuant to the Consolidated Appropriations Act of 2016, enacted December 18, 2015, the medical device excise tax was suspended for all sales of such devices in 2016 and 2017. On January 22, 2018, Congress passed a continuing resolution that further extended this moratorium for 2018 and 2019. In December 2019, Congress passed, and President Trump signed, a full FY 2020 domestic appropriations package that permanently repeals the medical device tax. In 2017, Congress considered legislation to "repeal and replace" ACA and may return to these issues in the future. The Biden administration did not support policies that it viewed as undermining ACA access, coverage and payment provisions and issued an executive order to review and examine policies or practices that may undermine the health insurance marketplace or the individual, small group, or large group markets for health insurance in the U.S. The Trump administration rescinded that executive order and has begun to pursue its own policies to address the cost of healthcare, focusing on policies related to lowering the cost of prescription drugs through "most-favored nation" policies and direct negotiations with pharmaceutical companies.

The ACA included a provision referred to as the individual mandate, which requires most U.S. citizens and noncitizens to have health insurance that meets certain specified requirements or be subject to a tax penalty. On December 22, 2017, sweeping changes to the U.S. Tax Code were signed into law. Among the provisions included in the law was an amendment to this ACA provision that reduced to zero the excise tax penalty imposed on individuals who do not obtain minimum essential healthcare coverage. The provision became effective in 2019. The Congressional Budget Office estimated in November of 2017 that elimination of the mandate had the potential to decrease the number of individuals with health insurance by approximately 4 million in 2019 and premiums were likely to increase because healthier individuals were likely to opt out of paying for health insurance without the influence of a penalty. On February 26, 2018, the Texas and Wisconsin Attorneys General, leading a 20-state coalition, filed a lawsuit challenging the constitutionality of the ACA in the Northern District of Texas titled Texas and Wisconsin, et al v. United States, et al (N.D. Tex). The plaintiffs argued that because the amendment "renders legally *impossible* the Supreme Court's prior savings construction of the Affordable Care Act's core provision – the individual mandate – the Court should hold that the ACA is unlawful and enjoin its operations." On December 14, 2018, the Court granted a partial summary judgment finding the individual mandate unconstitutional and the remaining provisions of the ACA inseparable, and therefore invalid, and granted the plaintiffs' claim for declaratory relief in Count 1 of the amended complaint. On December 30, 2018, the Court issued a final judgment on Count 1, which enabled the decision to be appealed. In December 2019, a three-judge panel from the U.S. Court of Appeals for the Fifth Circuit affirmed a district court ruling that found the individual mandate to be unconstitutional because it can no longer be read as a tax, and there is no other constitutional provision that justifies this exercise of congressional power. The Supreme Court issued an opinion in the case, *California v. Texas v. Azar*, on June 17, 2021 denying the plaintiffs' constitutional challenge to the ACA on the grounds that they lacked standing.

*Pharmaceuticals*. We participate in the federal Medicaid rebate program established by the Omnibus Budget Reconciliation Act of 1990, as well as other government reimbursement programs including Medicare Part D Gap, TriCare and state pharmacy assistance programs established according to statutes, government regulations and policy. We make our pharmaceutical products available to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs. Under our license to market and distribute the intravenous iron medication Venofer<sup>®</sup> to freestanding dialysis clinics, we also are considered, for statutory price reporting purposes, to be the manufacturer of Venofer<sup>®</sup> (when sold by us under one of our national drug codes (NDCs)), which is reimbursed under Part B of the Medicare program. Our products are also subject to a federal requirement that any company participating in the Medicaid rebate or Medicare program charge prices to Medicare comparable to the rebates paid by State Medicaid agencies on purchases under the Public Health Services (PHS) pharmaceutical pricing program managed by the Department of Health and Human Services (also known as the "340B program" by virtue of the section of the Public Health Service Act that created the program). The PHS pricing program extends these deep discounts on outpatient drugs to a variety of community health clinics and other entities that receive health services grants from the PHS, certain "look alikes," as well as various other providers. ACA expanded the 340B program to include additional providers.

[**Table of Contents**](#TOC)

Under the Medicaid rebate program, we pay a rebate to each state Medicaid program based upon sales of our covered outpatient drugs that are separately reimbursed by those programs. ACA increased the minimum federal Medicare rebate percentages, effective January 1, 2010. Rebate calculations and price reporting rules are complex and, in certain respects, subject to interpretations of law, regulation, or policy guidance by us, government or regulatory agencies and the courts. The Medicaid rebate amount is computed each quarter based on our submission to CMS of our current Average Manufacturer Price and Best Price for our pharmaceutical products. The Veterans Health Care Act imposes a requirement that the prices we charge to certain federal entities under the FSS must be no greater than the Federal Ceiling Price, which is determined by applying a statutory discount to the average price charged to non-federal customers through wholesalers. Because the amount the government pays to reimburse the cost of a drug under Part B of the Medicare program is ordinarily based on the drug's average sales price (ASP), additional price calculation and reporting obligations are imposed on the manufacturers of Part B drugs under that program (to the extent these manufacturers participate in the Medicaid rebate program, from which an obligation to report Part B drug prices flows). Since Venofer<sup>®</sup> is covered under Part B, we are responsible for compiling and utilizing a wide range of sales data elements to determine the ASP of Venofer<sup>®</sup> marketed under our NDCs and reporting it to CMS. The Medicare ESRD PPS system incorporates payment for Venofer<sup>®</sup> at dialysis facilities.

Government agencies may make changes in program interpretations, requirements or conditions of participation, and retain the right to audit the accuracy of our computations of rebates and pricing, some of which may result in implications (such as recoupment) for amounts previously estimated or paid which may have a material adverse effect on our operating results.

*Laboratory tests*. Spectra obtains a portion of its revenue from Medicare, which pays for clinical laboratory services provided to dialysis patients in two ways. Payment for most tests is included in the ESRD PPS bundled rate paid to dialysis clinics. The dialysis clinics obtain the laboratory services from laboratories and pay the laboratories for the services. In accordance with industry practice, Spectra usually provides such testing services under capitation agreements with its customers pursuant to which it bills a fixed amount per patient per month to cover the laboratory tests included in the ESRD PPS rate designated in the capitation agreement. Second, the few laboratory tests performed by Spectra for Medicare beneficiaries that are not included in the ESRD PPS bundled rate are billed separately to Medicare. Such tests are paid at 100% of the payment amounts on Medicare's Clinical Laboratory Fee Schedule (CLFS), although payment rates are further reduced by a 2% sequestration adjustment that remains in place until further notice.

PAMA required CMS to substantially revise how payment rates are determined under the CLFS. The new rates, effective January 1, 2018, were determined based on the median of rates paid by private payors for these tests in the period before the new rates took effect. The new rates are effective for most tests for a three-year period, with no updates during that period for inflation or other factors. PAMA provided that rate declines were limited to 10% in each of the first three years. The Continuing Appropriations and Extensions Act of 2026 is the latest in a series of legislation which extended the phase-in of payment reductions. There is no reduction for 2021-January 30, 2026 and payment may not be reduced by more than 15% from January 31, 2026 through 2028. Payment rates for the majority of tests paid on the CLFS were reduced under PAMA. These declines are not expected to directly affect Spectra's principal source of revenue, payments from dialysis facilities for laboratory tests included in the ESRD PPS. For information regarding our sale of select assets of our wholly owned Spectra Laboratories, see note 4 of the notes to our audited consolidated financial statements included in this report.

*Coordination of benefits.* Medicare entitlement begins for most patients at least three months after the initiation of chronic dialysis treatment at a dialysis center. During the first three months, considered to be a waiting period, the patient or patient's insurance, Medicaid or a state renal program is generally responsible for payment.

Patients who are covered by Medicare and are also covered by an EGHP are subject to a 30-month coordination period during which the EGHP is the primary payor and Medicare the secondary payor. During this coordination period, the EGHP pays a negotiated rate or in the absence of such a rate, our standard rate or a rate defined by its plan documents. The EGHP payments are generally higher than the Medicare payment. EGHP insurance, when available, will therefore generally cover as the primary payor for a total of 33 months, including the 3-month waiting period plus the 30-month coordination period. Any significant decreases in EGHP reimbursement rates could have material adverse effects on our provider business and, because the demand for our products is affected by provider reimbursement, on our products business.

[**Table of Contents**](#TOC)

*Participation in other Medicare payment arrangements.*

We conduct a broad range of value and risk-based care programs spanning CKD and ESRD patient populations with both private and public payors. Value and risk-based care programs include shared risk arrangements in which private payors or government programs share the savings or losses from reductions or increases in the overall medical spend of a population under management assuming that certain quality thresholds are also met. Full risk arrangements include capitated arrangements and shared saving arrangements in which private payors or government programs reimburse us based on savings generated in the management of such members. Since capitation arrangements often can be recognized as premium revenue and the full medical premium for ESRD beneficiaries generally is very large, capitation programs can drive significant revenue and, when costs are effectively managed, profit opportunities. We participate in value and risk-based care programs with private payors to provide care to commercial and Medicare Advantage ESRD and CKD patients. Under these payment arrangements, our financial performance is based on our ability to manage a defined scope of medical costs within certain parameters for clinical outcomes. Other programs, such as the ESRD Treatment Choices model and the Comprehensive Kidney Care Contracting model, are described in more detail below.

*Executive order-based models.* On July 10, 2019, an Executive Order on advancing kidney health was signed in the United States. Among other things, the order instructed the Secretary of the HHS to develop new Medicare payment models to encourage identification and earlier treatment of kidney disease as well as increased home dialysis and transplants. One of those models, for which the rule was finalized on September 29, 2020 and later amended through finalized changes on October 29, 2021, the ETC model, is a mandatory model that creates financial incentives for home treatment and kidney transplants with a start date in January 2021 and an originally scheduled ending in June 2027. On November 20, 2025, CMS finalized the termination of the ETC model as of December 31, 2025 and modified the duration during which CMS will apply payment adjustments. This model applied both upside and downside payment adjustments to claims submitted by physicians and dialysis facilities for certain Medicare home dialysis patients over the model's tenure. Participants in this model were based on a random selection of 30% of in certain randomly selected geographic regions (specifically, Hospital Referral Regions) that comprised approximately 30% of adult ESRD beneficiaries in all 50 states and the District of Columbia. As of December 31, 2025, 970 of our U.S. dialysis facilities, representing approximately 35% of our U.S. dialysis facilities, were within the random selection of Hospital Referral Regions and therefore are in areas selected for participation in the model. An initial upside-only payment, Home Dialysis Payment Adjustment (HDPA), was applied for the first three years of the model, beginning in January 2021, in decreasing payment adjustments ranging from 3% in the first HDPA payment year, to 2% in the second HDPA payment year, and to 1% in the final HDPA payment year. This model also includes a Performance Payment Adjustment (PPA) beginning in July 2022. PPA payments will be a combined calculation of home dialysis (home, self-dialysis and nocturnal in-center) and transplant (living donor transplants and transplant waitlist) rates based upon a participant's historic performance and/or increasingly weighted benchmark data from comparison geographic areas. CMS utilizes a two-tiered approach in PPA scoring to stratify participants with a high volume of beneficiaries who are dual-eligible for Medicare and Medicaid or Low Income Subsidy recipients.

On October 31, 2022, CMS finalized refinements to the ETC model, including a change to the improvement in scoring methodology and a change to the requirements related to flexibilities regarding furnishing and billing kidney disease patient education services under the ETC model. CMS also discussed its intent to publish participant-level performance data. These changes did not result in additional estimated savings to the Medicare program. At this time, our payment adjustments from the ETC model have resulted in a net positive adjustment. With the early termination of the ETC model at December 31, 2025, the PPAs will be discontinued, and all dialysis facilities will return to standard Medicare reimbursement rates in 2026.

Pursuant to the Executive Order, the Secretary of HHS also announced voluntary payment models, Kidney Care First (KCF) and CKCC models (graduated, professional and global), aim to build on the existing Comprehensive ESRD Care model. These voluntary models create financial incentives for healthcare providers to manage care for Medicare beneficiaries with CKD stages 4 and 5 and with ESRD, to delay the start of dialysis, and to incentivize kidney transplants. The voluntary models allow healthcare providers to take on various amounts of financial risk by forming an entity known as a KCE. Two options, the CKCC global and professional models, allow renal healthcare providers to assume upside and downside financial risk. A third option, the CKCC graduated model, is limited to assumption of upside risk, but is unavailable to KCEs that include large dialysis organizations such as the Company. Under the global model, the KCE is responsible for 100% of the total cost of care for all Medicare Part A and B services for aligned beneficiaries, and under the professional model, the KCE is responsible for 50% of such costs. As of December 31, 2025, we participated in 21 KCEs. Twenty KCEs began assuming financial risk within the first performance year that commenced January 1, 2022, and four began assuming financial risk within the second performance year that commenced January 1, 2023. Subsequently, three KCEs ended performance. The CKCC model is expected to run through 2027. In September 2025, CMS released the performance scores for the 2024 performance year in which the majority of the KCEs organized in Value-Based Care qualified as high performers in various quality metrics. As of December 2025, approximately 52,000 patients were aligned to KCEs in which we participated.

[**Table of Contents**](#TOC)

*Federal surprise billing statute and regulations.* The No Surprises Act was enacted on December 27, 2020 as part of the 2021 Budget Act. The No Surprises Act aims to address surprise, balance billing to patients at the national level (many states already had laws regulating balance billing). Effective January 1, 2022, the legislation limits patient payment responsibility for certain unavoidable out-of-network services, prohibits certain providers and facilities (not including dialysis facilities) from balance billing patients for those services, establishes price transparency disclosure requirements for providers and insurers and mandates creation of dispute resolution processes for patients, providers and insurers to address unanticipated medical bills. The Department of Labor, HHS and the Department of the Treasury have collectively issued several Final Rules to implement the requirements of the statute. The statute and regulations have only limited applicability to our business: our ASCs and certain providers of services ancillary to ASC services (such as anesthesia) are subject to certain requirements of the statute and regulations; and our dialysis facilities are subject to certain requirements of the statute and regulations with respect to price transparency for individuals who are uninsured or "self-pay" (i.e., individuals who plan to pay out of pocket without using insurance).

*Possible changes in statutes or regulations.* Further federal or state legislation or regulations may be enacted in the future that could substantially modify or reduce the amounts paid for services and products offered by us and our subsidiaries and/or implement new or alternative payment models for dialysis that could present more risk sharing for dialysis clinics. For example, ballot initiatives introduced at the state level which could further regulate clinic staffing requirements, state inspection requirements and commercial reimbursement rates. Additionally, in response to the COVID-19 pandemic, the federal and state governments implemented wide-ranging, temporary measures that have affected the regulatory and legal landscape in which we operate. These measures included temporary waivers and modifications to certain statutes, regulations, government reimbursement and funding programs and the governments' enforcement priorities. While the public health emergency has ended, certain of the emergency measures such as certain telehealth services remain in effect. To the extent we rely on such measures, in certain circumstances we could be forced to change our operations if reliance upon those measures that continue to exist is terminated.

*Non-U.S.*

A country's approach to reimbursement and market pricing is markedly influenced by the type of healthcare funding system it employs. In the major European and British Commonwealth countries, healthcare systems are generally based on one of two funding models. The healthcare systems of countries such as Germany, France, Belgium, Austria, Czech Republic and Poland are based on the Bismarck-type system; where mandatory employer and employee contributions dedicated to healthcare financing are required. Countries such as the United Kingdom, Canada, Denmark, Finland, Portugal, Sweden and Italy established their national health services using the Beveridge-type system, which provides a national healthcare system financed by taxes. However, during the last decade, healthcare financing under many social security systems has also been significantly subsidized with tax money.

In the Asia-Pacific region, Universal Health Care (UHC) is at varying stages of implementation and, as such, reimbursement mechanisms may vary significantly between countries (including variances at the state, provincial or city level). Tax-based healthcare funding systems are mostly seen in New Zealand, Malaysia and Thailand where governments have more direct levers to manage the provision of healthcare. Other countries, such as Japan and South Korea, finance healthcare through social health insurance mandating citizens to make contributions into a pooled fund. In Taiwan, dialysis costs for all patients with ESRD are reimbursed by national health insurance, with the government covering premiums in the case of low-income citizens. Singapore has a multi-tier system with mandatory medical savings account alongside means-tested subsidies to cover catastrophic illnesses. Indonesia and India continue their effort to achieve UHC amidst system challenges.

India has a fragmented and complex payer landscape involving both government and private payors. Out-of-pocket expenses remain a large contribution of the overall healthcare expenditure in the country. The Pradhan Mantri National Dialysis Programme launched the Ayushman Bharat Yojana, a national health insurance scheme aimed at providing free access to healthcare for low-income earners, in 2018. Coverage is expanding, but payors and providers are also increasingly implementing cost containment strategies across the region to manage the rising demand for healthcare. On September 11, 2024, the prime minister approved a major expansion of the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY), whereby all senior citizens aged 70 and above will receive health coverage regardless of their income. As per the latest estimate, dialysis is the most available therapy, accounting for 14% of overall disbursement. South Korea has a universal national health insurance system with a fee-for-service payment scheme in place based on employee taxes, government subsidies, tobacco surcharges and other contributions. For dialysis specifically, a 9:1 ratio exists where the insurance scheme covers 90% of the dialysis costs and 10% must be paid by the patient out-of-pocket.

[**Table of Contents**](#TOC)

China has achieved UHC by establishing a tiered healthcare system nationwide and a multi-layer medical insurance system (MLMIS) covering approximately 95% of its population. For the MLMIS, the main coverage scheme is Basic Medical Insurance (BMI) composed of employees' BMI and residents' BMI (the basic insurance every citizen receives independent of employment status), administrated by the National Healthcare Security Administration (NHSA). The system includes reimbursement for drugs listed in the National Reimbursement Drug List (NRDL) and partial medical services listed in the National Basic Medical Insurance Diagnostic and Treatment Programs.

For employees' BMI, the pooled funds come from employer contribution and employee payroll tax and is much more prominent than the contribution of the residents' BMI, leading to more comprehensive healthcare coverage.

For residents' BMI, the NHSA merged the insurance schemes for urban and rural residents at the national level in 2019 and began applying the terminology of "basic medical insurance for urban and rural residents" as one statistical item in the NHSA annual report. However, the threshold and compensation level remain different between urban and rural residents.

Given the large geographical disparity in terms of economic development and BMI pooled funds, the specific reimbursement policies issued by local Health Security Administration vary, although general guidance of the NHSA is followed.

Similarly to national standards of healthcare coverage and reimbursement, there is a clear trend for volume-based procurement of medical technologies.

In the Latin America region, healthcare systems are funded by public payors, private payors or a combination of both. For countries such as Argentina, Brazil, Chile, Colombia, Curaçao, Ecuador, Guatemala and Peru, UHC covers ESRD for all citizens, funded by employers as well as individual compulsory contributions. In general, UHC is not yet fully implemented. Even though most countries in the region legally guarantee treatment in practice, access remains uneven. Regional budget limitations and differences in service availability often create significant gaps. Most countries in Latin America in which we operate have differentiated reimbursement between therapies and differences between public and private reimbursement. Value-based healthcare initiatives are starting, but limited due to the many countries that have significant economic constraints. Private insurers complement healthcare coverage, particularly in Argentina, Brazil and Colombia, and may be preferred by patients for a better quality of treatment or convenience. Each payor (public or private) defines its own tariff, subject to a yearly revision to restore the value eroded by inflation. In Colombia, competition bids for lower prices without regard to adjusted tariffs and in Brazil, where public payors represent more than 80% of the share. High inflation and currency fluctuations continue to affect dialysis costs, often without matching adjustments in reimbursement rates. For information regarding our divestitures of businesses in certain Latin American countries, see note 5 e) of the notes to our audited consolidated financial statements included in this report.

Remuneration for ESRD treatments widely differs between countries but there are three broad types of reimbursement modalities: global budget, fee-for-service reimbursement and a bundled payment or capitation rate paid at predetermined periods. In some cases, reimbursement modalities may also vary within the same country depending on the type of healthcare provider (public or private). Budget allocation is a reimbursement modality used mainly for public providers in most European countries where the funding is based on taxation and in some of the countries where it is based on social security. Fee-for-service, which used to be the most common reimbursement modality for private providers in European and Asia-Pacific countries, is increasingly being replaced by periodic reimbursement bundles. These include different components of the ESRD treatment and level of payment is linked to certain quality parameters.

Additionally, in all countries, operations are increasingly subject to cost management strategies (also due to inflation) as a significant increase in logistic cost, personnel cost, raw materials and other costs are not fully reflected in reimbursement changes. Additionally, many health systems apply health technology assessments methods (a strict analysis on the entry of new products and services), which require additional data, reviews and administrative processes, all of which increase the complexity, timing and costs of obtaining reimbursement for products and services, simultaneously putting continuous downward pressure on available reimbursement. In June 2021, the EU approved the EU Health Technology Assessments Regulation which will fully enter into force in 2025 and is expected to unify and further reinforce the trend. In addressing these cost containment pressures, the Company is developing more expertise in the Health Economics, Market Access and Political Affairs fields in order to respond, counteract and proactively anticipate health system funding changes that impact our business. The main aim of this development is to demonstrate that our products and services create value for patients and for those who pay for healthcare. The Company advocates to encourage a long-term partnership for sustainable healthcare financing and value-based payment programs.

[**Table of Contents**](#TOC)

Generally, in European countries with established dialysis programs, reimbursements range from €70 to more than €400 per treatment. In Asia-Pacific and Latin America, reimbursement rates can be significantly lower. Where treatment is reimbursed on a fee-for-service basis, reimbursement rates are sometimes allocated in accordance with the type of treatment performed. However, because the services and costs that are reimbursed differ widely between countries, calculation of an average global reimbursement amount would likely bear little relation to the actual reimbursement system in any one country. Hence, country comparison will be relevant only if it includes an analysis of the cost components covered, including their individual costs, services rendered and the structure of the dialysis clinic in the countries being compared.

In light of the inflationary environment and geopolitical volatility, the medical device industry is facing significant cost increases which cannot be easily transferred as price increases to healthcare customers that need to operate under a fixed budget. Nevertheless, reimbursement and price increases have been acknowledged and granted in some health systems already and discussions are ongoing in most countries.

#### Anti-kickback statutes, False Claims Act, Stark Law and other fraud and abuse laws in the United States
Some of our operations are subject to federal and state statutes and regulations governing financial relationships between healthcare providers and potential referral sources and reimbursement for services and items provided to patients with Medicare, Medicaid and other types of U.S. Government and state government health insurance. Our operations are also subject to federal statutes that govern the relationships and assistance that we may provide to our patients. Such laws include the Anti-Kickback Statute, the False Claims Act, the Stark Law, the Civil Monetary Penalty Law and other federal healthcare fraud and abuse laws and similar state laws. The U.S. Government, many individual states and private third-party risk insurers have devoted increasing resources to combat fraud, waste, and abuse in the healthcare sector.

The Office of the Inspector General of HHS (OIG), state Medicaid fraud control units, and other enforcement agencies have dedicated substantial resources to their efforts to detect arrangements and practices that may violate fraud and abuse laws.

The government's ability to pursue actions against potential violators has been enhanced over the past years, by expanding the government's investigative authority, expanding criminal and administrative penalties, by increasing funding for enforcement and providing the government with expanded opportunities to pursue actions under the federal Anti-Kickback Statute, the False Claims Act, and the Stark Law. For example, the ACA narrowed the public disclosure bar under the False Claims Act, allowing increased opportunities for whistleblower litigation. In addition, the legislation modified the intent standard under the federal Anti-Kickback Statute, making it easier for prosecutors to prove that alleged violators had met the requisite knowledge requirement. The ACA and implementing regulations also require providers and suppliers to report any Medicare or Medicaid overpayment and return the overpayment on the later of 60 days of identification of the overpayment or the date the cost report is due (if applicable), or else all claims associated with the overpayment will become false claims. The ACA also provides that any claim submitted from an arrangement that violates the Anti-Kickback Statute is a false claim.

In late 2020, both CMS and the OIG issued final rules that implemented changes to the regulations for the Stark Law, Anti-Kickback statute and Civil Monetary Penalty Law. These rules were aimed at easing the burden of compliance and promoting coordinated care and value-based care.

[**Table of Contents**](#TOC)

#### Healthcare reform
In response to increases in healthcare costs in recent years, there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control these costs and reform the U.S. healthcare system. The ACA, enacted in 2010, contained broad healthcare system reforms, including (i) provisions to facilitate access to affordable health insurance for all Americans, (ii) expansion of the Medicaid program, (iii) an industry fee on pharmaceutical companies starting in 2011 based on sales of brand name pharmaceuticals to government healthcare programs, (iv) increases in Medicaid prescription drug rebates effective January 1, 2010, (v) commercial insurance market reforms that protect consumers, such as bans on lifetime and annual limits, coverage of pre-existing conditions, and limits on waiting periods, (vi) provisions encouraging integrated care, efficiency and coordination among providers (vii) provisions for reduction of healthcare program waste and fraud and (viii) a 2.3% excise tax on manufacturers' medical device sales starting in 2013. However, pursuant to the Consolidated Appropriations Act of 2016, which was signed into law on December 18, 2015, the medical device excise tax was suspended for all sales of such devices in 2016 and 2017. On January 22, 2018, Congress passed a continuing resolution that further extended this moratorium for 2018 and 2019. In December 2019, Congress passed, and former President Trump signed, a full FY 2020 domestic appropriations package that permanently repeals the medical device tax. Throughout the years of the Obama Administration, the Republicans in Congress attempted on several occasions to repeal the ACA, recognizing that any such effort would be rejected by a Presidential veto. Similarly, during the 2016 Presidential campaign, President Trump called for a repeal and replacement of the ACA, though no legislation to repeal the ACA passed during his first term in office. In the 2020 Presidential campaign, President Biden called for further expansions of the ACA, the potential for a reduction in Medicare eligibility age, and a so-called "public option." In 2021, Congress passed the America Rescue Plan which increased the subsidies available under the ACA's individual market exchanges to further decrease the cost of coverage. These enhanced subsidies expired at the end of 2025. We cannot predict what actions Congress or current administration will implement to address a potential reduction in insurance coverage as a result of this expiration.

In *National Federation of Independent Business v. Sebelius,* the U.S. Supreme Court affirmed the right of individual states to elect whether or not to participate in the ACA's Medicaid expansion. As of November 2025, forty states (and the District of Columbia) elected to expand their programs. Because 10 states have so far declined to participate, the number of uninsured individuals is greater than originally expected when the ACA was passed. We cannot predict whether additional states will agree to participate in the expansion in future years, presuming that there is no change in the current law.

The first Trump administration and several states led by Republican Governors filed suit to challenge the constitutionality of the ACA and, in particular, its requirement that all U.S. citizens purchase health coverage, known as the "individual mandate." In December 2019, a three-judge panel from the U.S. Court of Appeals for the Fifth Circuit affirmed a district court ruling that found the mandate to be unconstitutional because, after elimination of the excise tax penalty imposed on individuals who do not obtain minimum essential healthcare coverage, there is no other constitutional provision that justifies this exercise of congressional power. On June 17, 2021, the Supreme Court issued an opinion in the case, *California v. Texas,* upholding the ACA. For additional information, see "—Reimbursement – U.S. – ESRD PPS quality incentive program" above.

The first Trump administration revised regulations to the implementation of various provisions of the ACA and, in 2017, halted CSR payments to insurers, prompting premium increases as insurers were still required to offer reduced cost-sharing to low-income enrollees. Although the Trump administration later sought authority to fund CSRs in its FY 2019–2021 budgets, Congress did not authorize the payments. The Biden administration likewise requested CSR appropriations for FY 2023 and FY 2024, but Congress did not include them. Litigation over the previous administration's non-payment is ongoing: courts have held the government owes CSRs for 2017 and must determine amounts owed for subsequent years, and the U.S. Supreme Court declined further review in 2021. President Biden's 2021 Executive Order directed agencies to reverse policies undermining the ACA and suggested renewed support for CSR funding. There continue to be discussions in Congress and within the Trump administration about funding the CSRs, but it is unclear if efforts to appropriate the CSRs will be successful.

To encourage health insurers to participate in the public exchanges, the ACA created the Risk Corridors Program, a temporary framework to compensate insurers for unexpectedly unprofitable plans during the ACA's first three years. Pursuant to a formula, insurers with profits exceeding a certain amount were required to pay to the government a portion of the excess profits, and insurers that experienced higher than expected loses would be reimbursed by the government. Rather than paying the amounts owed, Congress, through appropriations riders, prevented CMS from paying these amounts for each year of the program. On April 27, 2020, the U.S. Supreme Court ruled in *Maine Community Health Options v. United States that* that the federal government must pay over $12 BN to health insurers that sold consumer policies on public exchanges and had claimed losses under the Risk Corridors Program established by the ACA.

[**Table of Contents**](#TOC)

In addition, further regulations may be promulgated in the future that could substantially change the Medicare and Medicaid reimbursement systems, or that could impose additional eligibility requirements for participation in the federal and state healthcare programs. Moreover, such regulations could alter the current responsibilities of third-party insurance payors (including employer-sponsored health insurance plans, commercial insurance carriers and the Medicaid program) including, without limitation, with respect to cost-sharing. Changes of this nature could have significant effects on our businesses, but the outcomes and impact of such changes on our business, financial condition, and results of operations are impossible to quantify or predict.

On March 31, 2023, the continuous Medicaid enrollment provision of the Families First Coronavirus Response Act (FFCRA) expired. This provision allowed Medicaid beneficiaries to maintain continuous coverage during the COVID-19 pandemic without affirmatively renewing coverage each year. Since the expiration of the continuous enrollment provision of the FFCRA, a number of states have disenrolled Medicaid beneficiaries who have not elected to renew their Medicaid enrollment. These actions by states have resulted in a number of previous Medicaid beneficiaries losing coverage.

The One Big Beautiful Bill Act (P.L. 119-21) was signed into law on July 4, 2025. Focused on extending President Trump's 2017 tax cuts and other domestic policy priorities, the OBBBA includes provisions that limit coverage in Medicaid, Medicare, and the ACA exchanges. Medicaid provisions include approximately $1 trillion in funding cuts to Medicaid through 2034; limits on state-levied taxes on healthcare providers (so-called "provider taxes") (decreasing from 6% of provider revenues to 3.5% of net patient revenues by 2031) and limits on state-directed payment programs (from average commercial rates to either 100% (ACA expansion) or 110% (ACA non-expansion) of the Medicare payment rates, with certain exceptions), both often used to finance the states' share of Medicaid spending; increased eligibility verification; limitations on retroactive eligibility; prevention of certain non-citizens from enrolling or receiving benefits under Medicaid; requirement for states to implement cost-sharing for certain populations, and work requirements for certain "able-bodied" beneficiaries (excludes beneficiaries with Medicare Part A/B and with a serious, complex medical condition), among other provisions. Medicare provisions prohibit certain non-citizens from being eligible for Medicare; provide a 2.5% increase in the Medicare Physician Fee Schedule for 2026 as a one-time adjustment; and expand the exemption of certain orphan drugs from the Medicare Drug Price Negotiation Program. The OBBBA also established a $50 BN Rural Health Transformation Program to help fund rural hospitals and other providers over 5 years in an effort to offset decreases in Medicaid funding. ACA-related provisions of the OBBBA limit the availability of premium tax credits for plans through the ACA marketplace to certain non-citizens, shorten the open enrollment period, and eliminate automatic re-enrollment. Overall, the OBBBA includes significant changes involving funding, enrollments, and eligibility. While it is too early to predict the magnitude of the changes or the cumulative effect on the Company, it is important to note that revenues from Medicaid and other government sources (excluding Medicare and Medicare Advantage funds) represented 4.7% of U.S. patient service revenues for the year ended December 31, 2025 (2024: 4.5%). We do not expect the changes resulting from the tax provisions in OBBBA to have a material impact on our effective tax rate or on our cash tax position.

&nbsp;&nbsp;&nbsp;&nbsp;C. **Organizational structure** 

The following chart shows our organizational structure and our significant subsidiaries as of December 31, 2025. Fresenius Medical Care Holdings, Inc. conducts its business as "Fresenius Medical Care North America." For additional discussion regarding the Company's principal subsidiaries, see note 1 a) of the notes to our audited consolidated financial statements included in this report.

![Graphic](fms-20251231x20f013.jpg)

[**Table of Contents**](#TOC)

&nbsp;&nbsp;&nbsp;&nbsp;D.  ***Property, plant and equipment*** 

#### Property
The table below describes our principal facilities. We own the land and buildings comprising our principal production facilities in Schweinfurt and St. Wendel, Germany and we lease our corporate headquarters in Bad Homburg, Germany on a long-term basis from Fresenius SE or one of its affiliates. These leases and the purchase of our principal production facilities from Fresenius SE companies are described in note 6, "Related party transactions," of the notes to the consolidated financial statements included in this report.

---

| | | | | |
|:---|:---|:---|:---|:---|
| <br>**Location** | **Floor area**<br>**(approximate**<br>**square meters)** | **Currently**<br>**owned or**<br>**leased** | <br>**Lease**<br>**expiration** | <br>**Use** |
| Suzhou, China (Changshu Plant) | 119516 | leased / owned | August 2055 / December 2056 | Manufacture of hemodialysis bloodline sets & AV Fistula set, HD dialyzer and peritoneal dialysis solutions |
| St. Wendel, Germany | 113285 | owned |  | Manufacture of polysulfone membranes, dialyzers and peritoneal dialysis solutions; research and development |
| Ogden, Utah,U.S. | 102193 | owned |  | Manufacture of polysulfone membranes and dialyzers and peritoneal dialysis solutions; research and development |
| Biebesheim / Gernsheim, Germany | 65000 | leased | December 2026 / December 2028 | Central distribution Europe, Asia-Pacific and Latin America |
| L´Arbresle, France | 47765 | owned |  | Manufacture of polysulfone dialyzers, special filters, dry & liquid hemodialysis concentrates, empty pouches, injection molding |
| Schweinfurt, Germany | 38100 | owned |  | Manufacture of hemodialysis machines and peritoneal dialysis cyclers; research and development |
| Fukuoka, Japan (Buzen Plant) | 37092 | owned |  | Manufacture of peritoneal dialysis bags and dialyzers |
| Bogota, Colombia | 37979 | owned |  | Manufacture of dry and liquid concentrates, CAPD and APD bags, intravenous solutions, empty Biofine bags |
| Waltham, Massachusetts,U.S. | 36473 | leased | April 2029 | Corporate headquarters and administration - U.S. |
| Enstek, Malaysia | 28778 | owned |  | Manufacture of peritoneal dialysis solutions and hemodialysis concentrate |
| Fukuoka, Japan (Buzen Plant) | 27943 | owned |  | Manufacture of peritoneal dialysis bags and dialyzers |
| Knoxville, Tennessee,U.S. | 27637 | owned |  | Manufacture of peritoneal dialysis solutions |
| Palazzo Pignano, Italy | 27435 | owned |  | Manufacture of bloodlines and tubing, office |
| São Paulo, Brazil | 20159 | owned |  | Manufacture of hemodialysis concentrate solutions, dry hemodialysis concentrates, peritoneal dialysis bags, intravenous solutions bags, peritoneal dialysis and blood lines sets and warehouse |
| Guadalajara, México | 24234 | owned |  | Manufacture of saline, sodium citrate and liquid acids |
| Oita, Japan (Inukai Plant) | 24084 | owned |  | Manufacture of fiber bundles |
| Bad Homburg, Germany | 15214 | leased | December 2026 /December 2029 | Corporate headquarters and administration |
| Antalya,Türkiye | 22161 | leased | December 2037 | Manufacture of bloodlines, warehousing and sterilization plant |
| Tijuana, Mexico | 22126 | leased | May 2029 / September 2026 | Manufacturing of NxStage Medical, Inc. (NxStage) System One equipment and related disposables |
| Southaven, Mississippi,U.S. | 19666 | leased | November 2040 | Clinical laboratory testing and administration |
| Rockleigh, New Jersey,U.S. | 17742 | leased | December 2028 | Clinical laboratory testing and administration |
| Reynosa, Mexico | 15746 | leased | October 2027 | Manufacture of bloodlines |
| Vrsac, Serbia | 15365 | owned |  | Administration, production and warehouse building |
| Bad Homburg (OE), Germany | 10300 | leased / owned | December 2026 | Manufacture of hemodialysis concentrate solutions / technical services / logistics services |

---

We lease most of our dialysis clinics, manufacturing, laboratory, warehousing and distribution, and administrative and sales facilities in the U.S. and other countries on terms which we believe are customary in the industry. We own those dialysis clinics and manufacturing facilities that we do not lease.

For information regarding our capital expenditures, see "Item 4.B. Business Overview – Capital Expenditures."

#### Item 4A. Unresolved staff comments
Not applicable

[**Table of Contents**](#TOC)

#### Item 5. Operating and financial review and prospects
You should read the following discussion and analysis of the results of operations of the Company and its subsidiaries in conjunction with our historical consolidated financial statements and related notes contained elsewhere in this report. Some of the statements contained below, including those concerning future revenue, costs, and capital expenditures, and possible changes in our industry, competition, and financial condition include forward-looking statements. We made these forward-looking statements based on the expectations and beliefs of management concerning future events which may affect us, but we cannot assure that such events will occur or that the results will be as anticipated. Because such statements involve risks and uncertainties, actual results may differ materially from the results which the forward-looking statements express or imply. Such statements include the matters and are subject to the uncertainties that we described in the discussion in this report entitled "Introduction - Forward-looking statements." See also Item 3.D, "Key Information – Risk factors."

Our business is also subject to other risks and uncertainties that we describe from time to time in our public filings. Developments in any of these areas could cause our results to differ materially from the results that we or others have projected or may project.

Our reported financial condition and results of operations are sensitive to accounting methods, assumptions, and estimates that are the basis for our financial statements.

For information about our discretionary accounting policies and estimations, see note 2 of the notes to our consolidated financial statements included in this report. The critical accounting policies, judgments made in the creation and application of these policies, and sensitivities of reported results to changes in accounting policies, assumptions, and estimates are factors to be considered along with our financial statements and the discussion below in III. Results of operations, financial position and net assets - "Results of operations."

&nbsp;&nbsp;&nbsp;&nbsp;I. **Performance management system** 

The Management Board oversees our Company by setting strategic and operational targets and measuring various financial key performance indicators used for internal management determined in euro based upon IFRS Accounting Standards and other measures, as described below.

The key performance indicators used for internal management are identical in the individual operating segments. Each operating segment is evaluated based on target figures that reflect the revenue and expenses they control. For a discussion of items that we believe are within or are outside of operating segment control, see "II. Financial condition and results of operations — Company Structure," below).

Certain of the following financial measures and other financial information as well as discussions and analyses set out in this report include measures that are not defined by IFRS Accounting Standards (Non-IFRS Measures). We believe this information, along with comparable IFRS Accounting Standards financial measurements, is useful to our investors as it provides a basis for assessing our performance, payment obligations related to performance-based compensation, our compliance with covenants, and enhanced transparency and comparability of our results. Non-IFRS financial measures should not be viewed or interpreted as a substitute for financial information presented in accordance with IFRS Accounting Standards.

Our presentation of some financial measures used in this report such as changes in revenue, operating income, and net income attributable to shareholders of FME AG (or net income) includes the impact of translating local currencies to our reporting currency for financial reporting purposes. We calculate and present these financial measures using both IFRS Accounting Standards and at constant exchange rates to show changes in these metrics and other items without giving effect to period-to-period currency fluctuations. Under IFRS Accounting Standards, amounts received in local (non-euro) currency are translated into euro at the average exchange rate for the period presented. Once we translate the local currency for the constant currency, we then calculate the change, as a percentage, of the current period calculated using the prior period exchange rates versus the prior period. This resulting percentage is a Non-IFRS Measure referring to a change as a percentage at constant currency. These currency-adjusted financial measures are identifiable by the designated terms "Constant Exchange Rates" or "Constant Currency."

The primary key performance indicators are presented both in accordance with IFRS Accounting Standards and at Constant Currency. Each of these indicators presented at Constant Currency is considered a non-IFRS measure. For the purposes of management compensation, these metrics are also benchmarked at the underlying exchange rates used in the calculation of our incentive compensation targets.

[**Table of Contents**](#TOC)

We believe that the measures at Constant Currency are useful to investors, lenders, and other creditors because such information enables them to gauge the impact of currency fluctuations on our revenue, operating income, net income attributable to shareholders of FME AG, and other items from period to period. In addition, under our long-term incentive plans, we measure the attainment of certain predetermined financial targets for revenue growth and net income growth in Constant Currency. However, we limit our use of Constant Currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency into euro. We do not evaluate our results and performance without considering both:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) period-over-period changes in revenue, operating income, net income attributable to shareholders of FME AG, and other items prepared in accordance with IFRS Accounting Standards, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Constant Currency changes in revenue, operating income, net income attributable to shareholders of FME AG, and other items.

We caution the readers of this report not to consider these measures in isolation, but to review them in conjunction with changes in revenue, operating income, net income attributable to shareholders of FME AG, and other items prepared in accordance with IFRS Accounting Standards. We present the growth rate derived from non-IFRS measures next to the growth rate derived from IFRS Accounting Standards measures such as revenue, operating income, net income attributable to shareholders of FME AG, and other items. As the reconciliation is inherent in the disclosure included within "Results of operations, financial position and net assets," below, we believe that a separate reconciliation would not provide any additional benefit.

**Financial performance indicators**

#### Primary key performance indicators
*Revenue and revenue growth*

We use revenue and revenue growth as key performance indicators as we believe that the key to continue growing our revenue is to attract new patients and increase the number of treatments performed each year. The number of treatments performed each year is therefore an indicator of both the absolute amount of revenue as well as continued revenue growth. For further information regarding revenue recognition and measurement, refer to note 1 k) of the notes to the consolidated financial statements included in this report. Revenue and revenue growth are also benchmarked based on movement at Constant Exchange Rates (Non-IFRS Measures).

*Operating income*

Operating income is the most appropriate measure for evaluating the profitability of the operating segments and therefore is also a key performance indicator. Operating income is also benchmarked based on movement at Constant Exchange Rates (Non-IFRS Measure).

***Secondary financial performance indicators***

*Return on invested capital (ROIC) (Non-IFRS Measure)*

ROIC is the ratio of operating income, for the last twelve months, after tax (net operating profit after tax or NOPAT) to the average invested capital of the last five quarter closing dates, including adjustments for acquisitions and divestitures made during the last twelve months with a purchase price above a €50 M threshold, consistent with the respective adjustments made in the determination of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) below (see "Net leverage ratio (Non-IFRS Measure)"). ROIC expresses how efficiently we allocate the capital under our control or how well we employ our capital with regard to investment projects. For further adjustments to ROIC used in the calculation of Management Board compensation, see Item 6.B, "Directors, senior management and employees — Compensation," below. The following tables show the reconciliation of average invested capital to total assets, which we believe to be the most directly comparable IFRS Accounting Standards financial measure, and how ROIC is calculated:

[**Table of Contents**](#TOC)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** |
| *in € M, except where otherwise specified* |  |  |  |  |  |
|  | **December 31,** | **September 30,** | **June 30,** | **March 31,** | **December 31,** |
| **2025** | **2025** | **2025** | **2025** | **2025** | **2024** |
| Total assets | 31002 | 30887 | 31291 | 32735 | 33567 |
| Plus: Cumulative goodwill amortization and impairment loss | 379 | 380 | 465 | 494 | 504 |
| Minus: Cash and cash equivalents<sup>(1)</sup> | (1599) | (1256) | (1720) | (1079) | (1185) |
| Minus: Deferred tax assets<sup>(1)</sup> | (237) | (231) | (232) | (225) | (230) |
| Minus: Accounts payable to unrelated parties<sup>(1)</sup> | (738) | (726) | (687) | (771) | (906) |
| Minus: Accounts payable to related parties | (85) | (92) | (48) | (106) | (55) |
| Minus: Provisions and other current liabilities<sup>(2)</sup> | (2699) | (3235) | (2496) | (2637) | (2803) |
| Minus: Income tax liabilities<sup>(1)</sup> | (248) | (256) | (247) | (238) | (222) |
| **Invested capital** | **25775** | **25471** | **26326** | **28173** | **28670** |
| **Average invested capital as of December 31, 2025** | **26883** |  |  |  |  |
| Operating income | 1827 |  |  |  |  |
| Income tax expense<sup>(3)</sup> | (451) |  |  |  |  |
| **NOPAT** | **1376** |  |  |  |  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Adjustments to average invested capital and ROIC** | **Adjustments to average invested capital and ROIC** | **Adjustments to average invested capital and ROIC** | **Adjustments to average invested capital and ROIC** | **Adjustments to average invested capital and ROIC** | **Adjustments to average invested capital and ROIC** |
| *in € M, except where otherwise specified* |  |  |  |  |  |
|  | **December 31,** | **September 30,** | **June 30,** | **March 31,** | **December 31,** |
| **2025** | **2025** | **2025**<sup>(4)</sup> | **2025**<sup>(4)</sup> | **2025**<sup>(4)</sup> | **2024**<sup>(4)</sup> |
| Total assets |  |  | (56) | (58) | (57) |
| Plus: Cumulative goodwill amortization and impairment loss |  |  | (76) | (78) | (76) |
| Minus: Cash and cash equivalents |  |  | 4 | 5 | 4 |
| Minus: Deferred tax assets |  |  |  |  |  |
| Minus: Accounts payable to unrelated parties |  |  | 1 | 1 | 2 |
| Minus: Accounts payable to related parties |  |  |  |  |  |
| Minus: Provisions and other current liabilities <sup>(2)</sup> |  |  | 12 | 13 | 12 |
| Minus: Income tax liabilities |  |  | 2 | 2 | 2 |
| **Invested capital** | **—** | **—** | **(113)** | **(115)** | **(113)** |
| **Adjustment to average invested capital as of December 31, 2025** | **(68)** |  |  |  |  |
| Adjustment to operating income<sup>(4)</sup> | (35) |  |  |  |  |
| Adjustment to income tax expense<sup>(4)</sup> | 9 |  |  |  |  |
| **Adjustment to NOPAT** | **(26)** |  |  |  |  |

---

[**Table of Contents**](#TOC)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** |
| *in € M, except where otherwise specified* |  |  |  |  |  |
|  | **December 31,** | **September 30,** | **June 30,** | **March 31,** | **December 31,** |
| **2025** | **2025** | **2025**<sup>(4)</sup> | **2025**<sup>(4)</sup> | **2025**<sup>(4)</sup> | **2024**<sup>(4)</sup> |
| Total assets | 31002 | 30887 | 31235 | 32677 | 33510 |
| Plus: Cumulative goodwill amortization and impairment loss | 379 | 380 | 389 | 416 | 428 |
| Minus: Cash and cash equivalents<sup>(1)</sup> | (1599) | (1256) | (1716) | (1074) | (1181) |
| Minus: Deferred tax assets<sup>(1)</sup> | (237) | (231) | (232) | (225) | (230) |
| Minus: Accounts payable to unrelated parties<sup>(1)</sup> | (738) | (726) | (686) | (770) | (904) |
| Minus: Accounts payable to related parties | (85) | (92) | (48) | (106) | (55) |
| Minus: Provisions and other current liabilities<sup>(2)</sup> | (2699) | (3235) | (2484) | (2624) | (2791) |
| Minus: Income tax liabilities<sup>(1)</sup> | (248) | (256) | (245) | (236) | (220) |
| **Invested capital** | **25775** | **25471** | **26213** | **28058** | **28557** |
| **Average invested capital as of December 31, 2025** | **26815** |  |  |  |  |
| Operating income<sup>(4)</sup> | 1792 |  |  |  |  |
| Income tax expense<sup>(3), (4)</sup> | (442) |  |  |  |  |
| **NOPAT** | **1350** |  |  |  |  |
| **ROIC in %** | **5.0** |  |  |  |  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure, unadjusted)** |
| *in € M, except where otherwise specified* | *in € M, except where otherwise specified* | *in € M, except where otherwise specified* | *in € M, except where otherwise specified* | *in € M, except where otherwise specified* | *in € M, except where otherwise specified* |
|  | **December 31,** | **September 30,** | **June 30,** | **March 31,** | **December 31,** |
| **2024** | **2024** | **2024** | **2024** | **2024** | **2023** |
| Total assets | 33567 | 32511 | 33896 | 34336 | 33930 |
| Plus: Cumulative goodwill amortization and impairment loss | 504 | 519 | 565 | 519 | 629 |
| Minus: Cash and cash equivalents<sup>(1)</sup> | (1185) | (1387) | (1112) | (1192) | (1427) |
| Minus: Deferred tax assets<sup>(1)</sup> | (230) | (296) | (281) | (279) | (292) |
| Minus: Accounts payable to unrelated parties<sup>(1)</sup> | (906) | (779) | (793) | (748) | (775) |
| Minus: Accounts payable to related parties | (55) | (73) | (100) | (110) | (123) |
| Minus: Provisions and other current liabilities<sup>(2)</sup> | (2803) | (2671) | (3062) | (3026) | (2936) |
| Minus: Income tax liabilities<sup>(1)</sup> | (222) | (227) | (189) | (280) | (231) |
| **Invested capital** | **28670** | **27597** | **28924** | **29220** | **28775** |
| **Average invested capital as of December 31, 2024** | **28637** |  |  |  |  |
| Operating income | 1392 |  |  |  |  |
| Income tax expense<sup>(3)</sup> | (502) |  |  |  |  |
| **NOPAT** | **890** |  |  |  |  |

---

[**Table of Contents**](#TOC)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Adjustments to average invested capital and ROIC** | **Adjustments to average invested capital and ROIC** | **Adjustments to average invested capital and ROIC** | **Adjustments to average invested capital and ROIC** | **Adjustments to average invested capital and ROIC** | **Adjustments to average invested capital and ROIC** |
| *in € M, except where otherwise specified* |  |  |  |  |  |
|  | **December 31,** | **September 30,** | **June 30,** | **March 31,** | **December 31,** |
| **2024** | **2024** | **2024**<sup>(4)</sup> | **2024**<sup>(4)</sup> | **2024**<sup>(4)</sup> | **2023**<sup>(4)</sup> |
| Total assets |  | (38) | (47) | (622) | (709) |
| Plus: Cumulative goodwill amortization and impairment loss |  | (2) | (2) | (50) | (84) |
| Minus: Cash and cash equivalents |  | 3 | 5 | 24 | 35 |
| Minus: Deferred tax assets |  | 2 | 2 | 3 | 10 |
| Minus: Accounts payable to unrelated parties |  | 2 | 2 | 13 | 12 |
| Minus: Accounts payable to related parties |  |  |  | 1 | 1 |
| Minus: Provisions and other current liabilities<sup>(2)</sup> |  | 8 | 7 | 29 | 39 |
| Minus: Income tax liabilities |  |  |  | 1 | 3 |
| **Invested capital** | **—** | **(25)** | **(33)** | **(601)** | **(693)** |
| **Adjustment to average invested capital as of December 31, 2024** | **(270)** |  |  |  |  |
| Adjustment to operating income<sup>(4)</sup> | 139 |  |  |  |  |
| Adjustment to income tax expense<sup>(4)</sup> | (50) |  |  |  |  |
| **Adjustment to NOPAT** | **89** |  |  |  |  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** | **Reconciliation of average invested capital and ROIC (Non-IFRS Measure)** |
| *in € M, except where otherwise specified* |  |  |  |  |  |
|  | **December 31,** | **September 30,** | **June 30,** | **March 31,** | **December 31,** |
| **2024** | **2024** | **2024**<sup>(4)</sup> | **2024**<sup>(4)</sup> | **2024**<sup>(4)</sup> | **2023**<sup>(4)</sup> |
| Total assets | 33567 | 32473 | 33849 | 33714 | 33221 |
| Plus: Cumulative goodwill amortization and impairment loss | 504 | 517 | 563 | 469 | 545 |
| Minus: Cash and cash equivalents<sup>(1)</sup> | (1185) | (1384) | (1107) | (1168) | (1392) |
| Minus: Deferred tax assets<sup>(1)</sup> | (230) | (294) | (279) | (276) | (282) |
| Minus: Accounts payable to unrelated parties<sup>(1)</sup> | (906) | (777) | (791) | (735) | (763) |
| Minus: Accounts payable to related parties | (55) | (73) | (100) | (109) | (122) |
| Minus: Provisions and other current liabilities<sup>(2)</sup> | (2803) | (2663) | (3055) | (2997) | (2897) |
| Minus: Income tax liabilities<sup>(1)</sup> | (222) | (227) | (189) | (279) | (228) |
| **Invested capital** | **28670** | **27572** | **28891** | **28619** | **28082** |
| **Average invested capital as of December 31, 2024** | **28367** |  |  |  |  |
| Operating income<sup>(4)</sup> | 1531 |  |  |  |  |
| Income tax expense<sup>(3), (4)</sup> | (552) |  |  |  |  |
| **NOPAT** | **979** |  |  |  |  |
| **ROIC in %** | **3.5** |  |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes amounts related to assets, and associated liabilities, classified as held for sale (see note 4 of the notes to the consolidated financial statements included in this report).

&nbsp;&nbsp;&nbsp;&nbsp;(2) Including non-current provisions, non-current labor expenses, and variable payments outstanding for acquisitions and excluding pension liabilities and noncontrolling interests subject to put provisions.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Adjusted for noncontrolling partnership interests.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Including adjustments for acquisitions and divestitures made during the last twelve months with a purchase price above a €50 M threshold.

*Operating income margin*

Operating income margin represents the ratio of operating income to revenue. We believe operating income margin shows the profitability of each of our operating segments and our company on a consolidated basis.

[**Table of Contents**](#TOC)

*Net income and net income growth*

As net income represents the profitability of our business after all costs including operating costs, interest income and expense, taxes, and the impacts of noncontrolling interests in our subsidiaries, this metric shows our profit for the period after taking into account all aspects of our business. On a consolidated level, we also use percentage growth in net income (net income attributable to shareholders of FME AG) at Constant Currency as an additional performance indicator used for internal management. Net income and net income growth are also benchmarked based on movement at Constant Exchange Rates (Non-IFRS Measures).

*Basic earnings per share growth*

Percentage growth in basic earnings per share at Constant Currency (Non-IFRS Measure) is a performance indicator used to evaluate our profitability. This indicator helps to manage our overall performance. Basic earnings per share is calculated by dividing net income attributable to shareholders by the weighted-average number of outstanding shares over the course of the year.

*Net cash provided by (used in) operating activities in % of revenue*

Our consolidated statement of cash flows indicates how we generated and used cash and cash equivalents. In conjunction with our other primary financial statements, it provides information that helps us evaluate changes to our net assets and our financial structure (including liquidity and solvency). Net cash provided by (used in) operating activities is applied to assess whether a business can internally generate the cash required to make the necessary replacement and expansion of investments. This indicator is impacted by the profitability of our business and the development of working capital, mainly receivables. Net cash provided by (used in) operating activities in percent of revenue shows the percentage of our revenue that is available in terms of financial resources. This measure is an indicator of our operating financial strength.

*Free cash flow in % of revenue (Non-IFRS Measure)*

Free cash flow (which we define as net cash provided by (used in) operating activities after capital expenditures, before acquisitions and investments) refers to the cash flow we have at our disposal, including cash flows that may be restricted for other uses. This indicator shows the percentage of revenue available for acquisitions and investments, dividends to shareholders, debt servicing, reductions in debt financing, and for repurchasing shares.

For a reconciliation of cash flow performance indicators for the years ended 2025, 2024, and 2023, which reconciles free cash flow and free cash flow in percent of revenue to Net cash provided by (used in) operating activities and Net cash provided by (used in) operating activities in percent of revenue, see "Item 5. Operating and financial review and prospects — IV. Financial position — Sources of liquidity."

*Capital expenditures*

We manage our investments using a detailed coordination and evaluation process. The Management Board sets our complete investment budget and targets. Before realizing specific investment projects or acquisitions, our internal Acquisition & Investment Committee examines, based on certain thresholds, the individual projects and measures considering the expected return on investment and potential yield. Investment projects are evaluated using common methods such as net present value, internal interest rate methods, and return on invested capital. We utilize this evaluation methodology to ensure that we only make and implement investments and acquisitions that increase shareholder value. Capital expenditures for property, plant, and equipment and capitalized development costs is an indicator used for internal management. The measure influences the capital invested for replacement and expansion.

*Net leverage ratio (Non-IFRS Measure)*

The net leverage ratio is a performance indicator used for capital management. To determine the net leverage ratio, debt and lease liabilities less cash and cash equivalents (net debt) is compared to adjusted EBITDA, which we define as EBITDA adjusted for:

● the effects of acquisitions and divestitures made during the year with a purchase price above a €50 M threshold as defined in our Syndicated Credit Facility (See note 17 of the notes to the consolidated financial statements included in this report),

● non-cash charges,

[**Table of Contents**](#TOC)

● impairment loss (including any impairment losses associated with the FME25+ Program and Legacy Portfolio Optimization, as defined below), and

● special items, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. costs related to our FME25+ Program,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. the impact from the remeasurement of our investment in Humacyte, Inc. and receivables related to a royalty stream that we are entitled to base on sales made by Humacyte, Inc. in the U.S. (Humacyte Remeasurements),

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. certain costs associated with the Conversion, primarily related to the requisite relabeling of our products, transaction costs (such as costs for external advisors and conducting an extraordinary general meeting) and costs related to the establishment of dedicated administrative functions required to manage certain services which have historically been administered at the Fresenius SE group level and paid by the Company through corporate charges (Legal Form Conversion Costs), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. costs incurred in relation to strategic divestitures identified during our Legacy Portfolio Optimization review. For further information regarding these costs during the years ended December 31, 2025, 2024, and 2023, see notes 4 and 5 e) of the notes to the consolidated financial statements included in this report).

The ratio is an indicator of the length of time the Company needs to service the net debt out of its own resources. We believe that the net leverage ratio provides alternative information that management believes to be useful in assessing our ability to meet our payment obligations in addition to considering the absolute amount of our debt. We have a strong market position in a growing, global, and mainly non-cyclical market. Furthermore, most of our customers have a high credit rating as the dialysis industry is characterized by stable and sustained cash flows. We believe this enables us to work with a reasonable proportion of debt.

Adjusted EBITDA, a non-IFRS Measure, is used in our capital management and is also relevant in major financing instruments, including the Syndicated Credit Facility. You should not consider adjusted EBITDA to be an alternative to net earnings determined in accordance with IFRS Accounting Standards or to cash flow from operating, investing, or financing activities. In addition, not all funds depicted by adjusted EBITDA are available for management's discretionary use. For example, a substantial portion of such funds are subject to contractual restrictions and functional requirements to fund debt service, capital expenditures, and other commitments as described in more detail elsewhere in this report.

**For our self-set target range for the net leverage ratio and a reconciliation of adjusted EBITDA and net leverage ratio as of December 31, 2025 and 2024, see "Item 5. Operating and financial review and prospects — IV. Financial position — Financing strategy."** 

*Business metrics for Value-Based Care*

The metrics outlined below represent performance indicators utilized by management to evaluate the Value-Based Care operating segment. Value and risk-based care programs include shared risk arrangements in which private payors or government programs share the savings or losses from reductions or increases in the overall medical spend of a population under management assuming that certain quality thresholds are also met. Full risk arrangements include capitated arrangements and shared saving arrangements in which private payors credit us periodic, fixed payments based on expected medical expenses of such members. Since capitation arrangements often can be recognized as premium revenue and the full medical premium for ESRD beneficiaries generally is very large, capitation programs can drive significant revenue and, when costs are effectively managed, profit opportunities; however, these programs also carry significant costs and potential risk of loss due to the full-risk nature of these arrangements. See "Item 4B, "Information on the Company — Business Overview — Regulatory and Legal Matters — Reimbursement — Executive order-based models."

Our financial performance in this segment is directly linked to our ability to manage a defined scope of medical costs within specific parameters for clinical outcomes. Due to the time required for CMS and private payors to review data for programs, we utilize estimates in order to report certain metrics on a timely basis. The key metrics currently used to evaluate performance in the Value-Based Care operating segment include member months under medical cost management (Member Months) and membership.

[**Table of Contents**](#TOC)

These metrics are intended for discussion and internal evaluation purposes and may be further refined or expanded in future reporting periods. Because these measures are not derived from financial measures, they do not constitute measures determined in accordance with IFRS Accounting Standards or non-IFRS financial measures, and accordingly, are not reconciled to IFRS Accounting Standards metrics.

**Member Months**

Member Months is calculated by multiplying the number of members included in value-based reimbursement programs by the corresponding number of months these members participate in those programs. Under certain value-based care programs, we assume both the risk associated with generating savings and the risk related to the total cost of care for attributed patients. The financial results are recorded in earnings as our performance is determined. A change in patient membership may indicate future earnings or losses as our performance is determined through these managed care programs.

**Membership**

Membership refers to the total number of individuals who are enrolled in a plan or program for which they receive care under a value-based care model. The metric represents the population of patients whose health outcomes, utilization of services and cost of care are measured under value-based care programs and, we believe, is an indicator of the revenue generated.

&nbsp;&nbsp;&nbsp;&nbsp;**II.** **Financial condition and results of operations** 

#### Overview
We are the world's leading provider of products and services for individuals with renal diseases, based on publicly reported revenue. We provide dialysis and related services for individuals with renal diseases, including through value and risk-based care programs, as well as other healthcare services. We also develop, manufacture, and distribute a wide variety of healthcare products. Our healthcare products include hemodialysis machines, peritoneal dialysis cyclers, dialyzers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, as well as acute cardiopulmonary and apheresis products. We supply dialysis clinics we own, operate, or manage with a broad range of products and also sell dialysis products to other dialysis service providers. Our other healthcare services include pharmacy services, vascular specialty services, ambulatory surgery center services, and physician nephrology practice management.

Dialysis patient growth results from factors such as:

● aging populations and increased life expectancies;

● shortage of donor organs for kidney transplants;

● increasing incidence of kidney disease;

● better treatment and survival of patients with diabetes, hypertension, and other illnesses, which frequently lead to the onset of CKD;

● improvements in treatment quality, new pharmaceuticals, and product technologies, which prolong patient life; and

● improving standards of living in developing countries, which make life-saving dialysis treatment available.

[**Table of Contents**](#TOC)

We are also engaged in different areas of healthcare product therapy research.

As a global company delivering healthcare services and products, we face the challenge of addressing the needs of a wide variety of stakeholders, such as patients, customers, payors, regulators, and legislators in many different economic environments and healthcare systems. In general, government-funded programs (in some countries in coordination with private insurers) pay for certain healthcare items and services provided to their citizens. Not all healthcare systems provide payment for dialysis treatment. Therefore, the reimbursement systems and ancillary services utilization environment in various countries significantly influence our business.

#### Company structure
For a description of our structure, especially as it relates to our operating segments, see "Certain defined terms," above, as well as note 29 of the notes to the consolidated financial statements included in this report.

#### Significant U.S. reimbursement, legislative matters, and other Medicare payment arrangements
**A significant portion of healthcare services we provide is paid for by governmental institutions. For the year ended December 31, 2025, approximately 16% of our consolidated revenue was attributable to U.S. federally-funded healthcare benefit programs, such as Medicare and Medicaid, under which reimbursement rates are set by CMS. Legislative or regulatory changes could affect reimbursement rates for a significant portion of the services we provide. The stability of reimbursement in the U.S. has been affected by the ESRD PPS and the U.S. federal government across the board spending cuts in payments to Medicare providers commonly referred to as "U.S. Sequestration."**

Presently, there is considerable uncertainty regarding possible future additional changes in healthcare regulation, including the regulation of reimbursement for dialysis services. As a consequence of the pressure to decrease healthcare costs, government reimbursement rate increases in the U.S. have historically been limited and are expected to continue in this fashion. However, any significant decreases in reimbursement under Medicare, Medicaid, Medicare Advantage plans, or from commercial insurance (which could result from changes in legislation, regulation, or other federal pressure on insurers to decrease rates), or in patient access to commercial insurance (as the result, e.g., of the termination of enhanced premium tax credits that expired at the end of 2025), or Medicare Advantage plans could have material adverse effects on our healthcare services business and, because the demand for dialysis products is similarly affected by reimbursement and coverage rates, on our products business. To the extent that increases in operating costs that are affected by inflation, such as labor and supply costs, are not fully reflected in a compensating increase in reimbursement rates, our business and results of operations would be adversely affected. For additional information regarding reimbursement and other regulatory matters, including the Marietta decision and impacts from OBBBA, as well as a description of the other Medicare programs, initiatives, and arrangements that we participate (or have participated) in, each with specific reimbursement models, see Item 3.D, "Key information — Risk factors," Item 4.B, "Information on the Company — B. Business Overview — Regulatory and Legal Matters — Health care Reform" and "— Reimbursement," above.

&nbsp;&nbsp;&nbsp;&nbsp;**III.** **Results of operations, financial position and net assets** 

**Highlights**

The following items represent notable impacts or trends in our business and/or industry for the year ended December 31, 2025:

***Legacy Portfolio Optimization and FME25+ Program***

We continue to review our business portfolio, specifically with a view to exiting unsustainable markets and divesting non-core businesses and the cessation of certain R&D programs to enable more focused capital allocation towards areas in our core business that are expected to have higher profitable growth. During the year ended December 31, 2025, the impacts from Legacy Portfolio Optimization mainly related to the completed divestitures in Brazil, Malaysia, and Kazakhstan as well as the select assets of our wholly owned Spectra Laboratories, and impairment losses primarily related to right-of-use assets as described in notes 4 and 5 e) of the notes to the consolidated financial statements included in this report.

[**Table of Contents**](#TOC)

On June 17, 2025, we launched our new strategy, FME Reignite, announcing our increased profitability aspirations for 2030 and a new capital allocation framework to enhance value creation. Included within the announcement was the expansion of the transformation of our operating structure into a significantly simplified structure embodying a more centralized approach and steps to achieve cost savings, originally named FME25 Program, by two years. The total program with its extension was renamed the FME25+ Program. We continue to target sustainable savings, including operational efficiencies, under our FME25+ Program, which was based on the successful implementation of the original FME25 Program. The FME25 Program introduced Care Enablement - the consolidation of our previously decentralized healthcare products business (including research and development, manufacturing, supply chain and commercial operations as well as supporting functions, such as regulatory and quality management) under a global MedTech umbrella, and Care Delivery, combining our global healthcare services businesses. These two operating segments were further expanded to include Value-Based Care under FME Reignite. The majority of the costs and recurring savings are included in costs of revenue and selling, general and administrative expense within our consolidated statements of income.

The following table shows the overall impact from Legacy Portfolio Optimization on our operating income as well as the costs and recurring savings associated with the FME25+ Program for the years ended December 31, 2025, 2024, and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Legacy Portfolio Optimization and FME25+ Program impacts on operating income** | **Legacy Portfolio Optimization and FME25+ Program impacts on operating income** | **Legacy Portfolio Optimization and FME25+ Program impacts on operating income** | **Legacy Portfolio Optimization and FME25+ Program impacts on operating income** |
| *in € M* | *in € M* | *in € M* | *in € M* |
|  | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2025** | **2024** | **2023** |
| **Legacy Portfolio Optimization** | (97) | (288) | (204) |
| **FME25+ Program** |  |  |  |
| &nbsp;&nbsp;Costs | (194) | (180) | (153) |
| &nbsp;&nbsp;Recurring savings | 804 | 567 | 346 |

---

In the discussion of our results below, the effects of the costs and savings related to the FME25+ Program are presented on a net basis.

***Settlement of Interwell Health put options***

During the second quarter of 2025, the Company entered into an agreement with shareholders of Interwell Health (our value and risk-based care subsidiary) to accelerate the settlement of put options held by non-physician investors originally granted as part of the 2022 merger of Cricket Health, InterWell Health LLC and Fresenius Health Partners, Inc. that created Interwell Health (the 2022 Interwell Health Transaction). The settlement in the amount of $362 M (€312 M) for this transaction occurred during September 2025 and represented a transaction with noncontrolling interests without loss of control. The settlement also resulted in the derecognition of certain deferred tax liabilities initially established in connection with the 2022 Interwell Health Transaction (Interwell Health Deferred Tax Reversal). For further information, see "Net cash provided by (used in) financing activities" below and note 26 of the notes to the consolidated financial statements included in this report.

***Purchase of production sites***

Effective December 31, 2025, pursuant to an agreement signed on October 17, 2025, Fresenius Medical Care Deutschland GmbH purchased the Company's production sites in Schweinfurt and St. Wendel, Germany, which were previously leased from Fresenius SE and certain of its affiliates (collectively, Fresenius SE Companies), for a total transaction cost of €181 M (including a purchase price paid to Fresenius SE Companies in the amount of €171 M). For further information, see note 6 of the notes to the consolidated financial statements included in this report.

***Share buyback***

We launched our €1 BN share buyback program (excluding ancillary transaction costs) in two tranches to be completed within two years by August 10, 2027. Under the first tranche, shares were to be acquired up to a maximum of €600 M including any true-ups over a period ending latest April 30, 2026. The first tranche was initiated on August 11, 2025 and completed ahead of schedule on December 29, 2025, under which 14,124,564 shares were repurchased for €586 M (including true-ups). On January 9, 2026, we announced that we would accelerate our share buyback program and start the repurchase of the second tranche. Under the second tranche, we plan to repurchase a total amount of around €414 M from January 12 to May 8, 2026. The share buyback program is expected to be completed significantly earlier than originally planned, in less than a year. As of December 31, 2025, 14,124,564 shares have been repurchased resulting in cash outflows of €585 M. For further information, see note 20 of the notes to the consolidated financial statements included in this report.

[**Table of Contents**](#TOC)

***Other Trends***

Recent changes in global trade policy, including new tariffs on most products imported into the U.S. and the possibility of additional trade restrictions, have created increased uncertainty and potential risk within the healthcare industry and to our business operations and financial performance. While we have implemented measures to mitigate these risks, we may see further increased costs for supplies depending on the nature and scope of these shifts on the affected goods and materials we use. In addition to tariffs, additional macroeconomic factors continue to present challenges as inflation remains elevated, which contributes to higher labor and production costs, as well as ongoing disruptions of global supply chains and new or potential export/import restrictions across key markets. Resulting cost increases have and could continue to adversely impact our financial condition and results of operations, especially if we are unable to absorb these costs through increased reimbursement (which is largely dependent on government action and contractual terms) and increased prices for our products or offset them through supply chain adjustments, product redesign (which could require regulatory approvals), or other operational efficiencies. We are closely monitoring these developments and identifying additional strategies to mitigate potential financial and operational impacts and have experienced a limited impact in 2025. However, given the continuously changing nature of these challenges and their broader economic implications, we cannot accurately predict the full extent of their impact on our business in the medium to long-term. Additionally, for the year ended December 31, 2025, the euro to U.S. dollar exchange rate experienced moderate volatility, with the euro generally strengthening against the U.S. dollar. Influences on currency markets via geopolitical developments such as the changes in trade policy noted above and corrective actions taken by central banks may cause such exchange rate developments to differ significantly in the future.

As described in Item 4.B, "Information on the Company — B. Business Overview — Regulatory and Legal Matters — Health care Reform" and "— Reimbursement," above, we are facing regulatory challenges that we assume will impact earnings development in future quarters. In the U.S., the elimination of the ACA premium tax credits (absent any future extension) and certain Medicaid-related provisions of the OBBBA are anticipated to adversely affect reimbursement levels and patient volumes. Additionally, certain pharmaceutical products are reimbursed under TDAPA, which provides for separate payment under the ESRD PPS for a limited transitional period. Upon expiration of the applicable TDAPA period, reimbursement for these pharmaceutical products transitions to either a post-TDAPA add-on under the ESRD PPS for dialysis drugs or biologicals for which there is an existing functional category or via a modification to the ESRD PPS rate, if applicable, after CMS undertakes additional rulemaking for dialysis drugs or biologicals for which there is not an existing functional category. The impacts from such changes in reimbursement on our results of operations, financial position, and net assets are described in the following discussions as "Impacts from TDAPA Reimbursement Regulation." These U.S. regulatory impacts, together with other evolving global regulatory and reimbursement developments such as volume-based procurement and other regulatory policies in China, could continue to place pressure on our business in future periods and result in a negative impact on our revenues and operating income.

On July 11, 2025, the German legislature approved an investment program for economic growth which increases depreciation for machinery and equipment used in the calculation of income tax as well as implemented a gradual reduction of the corporate tax rate from 15% to 10% from 2028 until 2032. We do not expect a material impact on our business, financial position and results of operations as a result of the new regulation.

The following sections summarize our consolidated results of operations, financial position and net assets as well as key performance indicators by reporting segment, as well as Corporate, for the periods indicated. We prepared the information consistent with the manner in which management internally disaggregates financial information to assist in making operating decisions and evaluating management performance.

**Results of operations**

Revenue and operating income generated in countries outside the eurozone are subject to currency fluctuations. As a significant portion of our operations are derived from our businesses in the U.S., the development of the euro against the U.S. dollar can have a material impact on our results of operations, financial position and net assets and the impacts of foreign currency transaction and translation effects are included in the discussion of our key and secondary performance indicators below.

[**Table of Contents**](#TOC)

#### Year ended December 31, 2025 compared to year ended December 31, 2024

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Results of operations** | **Results of operations** | **Results of operations** | **Results of operations** | **Results of operations** | **Results of operations** |
| *in € M* |  |  |  |  |  |
|  |  |  | **Change in %** | **Change in %** | **Change in %** |
|  |  |  |  | **Currency**  |  |
|  |  |  |  | **translation**  | **Constant**  |
|  | **2025** | **2024** | **As reported** | **effects** | **Currency**<sup>(1)</sup> |
| Revenue | 19628 | 19336 | 2 | (3) | 5  |
| Costs of revenue | (14599) | (14579) | 0 | 4 | 4  |
| Selling, general and administrative costs | (3033) | (3143) | (4) | 4 | 0  |
| Research and development | (158) | (183) | (14) | 1 | (13) |
| Income from equity method investees | 181 | 135 | 34 | 1 | 35  |
| Other operating income | 528 | 760 | (31) | (2) | (29) |
| Other operating expense | (720) | (934) | (23) | 2 | (21) |
| Operating income | 1827 | 1392 | 31 | (5) | 36  |
| Operating income margin | 9.3 | 7.2 |  |  |  |
| Interest income | 70 | 72 | (3) | (5) | 2 |
| Interest expense | (385) | (407) | (6) | 4  | (2) |
| Income tax expense | (321) | (316) | 2 | 2  | 4  |
| Net income | 1191 | 741 | 61 | (5) | 66  |
| Net income attributable to noncontrolling interests | (213) | (203) | 5 | 4  | 9  |
| Net income attributable to shareholders of FME AG | 978 | 538 | 82 | (6) | 88 |
| Basic and diluted earnings per share in € | 3.36 | 1.83 | 83 | (6) | 89  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) For further information on Constant Exchange Rates, see "I. Performance management system" above.

**Key Performance Indicators**

The following discussions include our operating and reportable segments and the measures we use to manage these segments. Due to the change in our operating structure as of June 1, 2025, we have restated the financial information for 2024 for our operating segments in order to conform to the current year's presentation. For further information, see note 1 and note 29 of the notes to the consolidated financial statements included in this report.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** |  |  |
| *in € M, except dialysis treatment, patient and clinic data* |  |  |  |  |  |  |  |
|  |  |  | **Change in %** | **Change in %** | **Change in %** | **Change in %** | **Change in %** |
|  |  |  |  | **Currency**  |  |  | **Same Market** |
|  |  |  |  | **translation**  | **Constant**  | **Organic** | **Treatment** |
|  | **2025** | **2024** | **As reported** | **effects** | **Currency**<sup>(1)</sup> | **growth** | **Growth**<sup>(2)</sup> |
| Revenue | 19628 | 19336 | 2 | (3) | 5 | 8 |  |
| &nbsp;&nbsp;Care Delivery segment | 13736 | 14003 | (2) | (4) | 2 | 5 | 0.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Thereof: U.S. | 11507 | 11526 | 0 | (4) | 4 | 5 | 0.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Thereof: International | 2229 | 2477 | (10) | (1) | (9) | 4 | 2.0 |
| &nbsp;&nbsp;Value-Based Care segment | 2247 | 1752 | 28 | (6) | 34 | 34 |  |
| &nbsp;&nbsp;Care Enablement segment | 5476 | 5557 | (1) | (3) | 2 | 2 |  |
| &nbsp;&nbsp;Inter-segment eliminations | (1831) | (1976) | (7) | 3 | (4) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Thereof: Care Delivery <sup>(3)</sup> | (497) | (480) | 4 | 4 | 8 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Thereof: Care Enablement <sup>(3)</sup> | (1334) | (1496) | (11) | 3 | (8) |  |  |
| Dialysis treatments | 44746884 | 47617071 | (6) |  |  |  |  |
| Patients | 291902 | 299352 | (2) |  |  |  |  |
| Clinics | 3601 | 3675 | (2) |  |  |  |  |
| Member Months | 1788951 | 1534053 | 17 |  |  |  |  |
| Membership | 162697 | 131750 | 23 |  |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) For further information on Constant Exchange Rates, see "I. Performance management system" above.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Same market treatment growth represents growth in treatments, adjusted for certain reconciling items including (but not limited to) treatments from acquisitions, closed or sold clinics and differences in dialysis days (Same Market Treatment Growth).

&nbsp;&nbsp;&nbsp;&nbsp;(3) Services provided by the Care Delivery segment in the U.S. for patients managed under the Value-Based Care segment are provided at fair market value. We also transfer products from the Care Enablement segment to the Care Delivery segment at fair market value.

[**Table of Contents**](#TOC)

#### Consolidated
**Revenue increased as compared to the year ended December 31, 2024, primarily driven by an increase in organic growth in all segments, partially offset by a negative impact from foreign currency translation, the effect of closed or sold operations (primarily related to Legacy Portfolio Optimization) and a decrease in dialysis days.**

#### Care Delivery
**The decrease in Care Delivery revenue as compared to the year ended December 31, 2024 was driven by a negative impact from foreign currency translation and the effect of closed or sold operations (primarily related to Legacy Portfolio Optimization), partially offset by an increase in organic growth. Organic growth was supported by favorable Impacts from TDAPA Reimbursement Regulation, reimbursement rate increases, and favorable payor mix effects. As of December 31, 2025, the number of patients treated in dialysis clinics that we own or operate in Care Delivery decreased as compared to December 31, 2024, primarily driven by divestitures in connection with Legacy Portfolio Optimization. Treatments in our Care Delivery segment decreased as compared to the year ended December 31, 2024, mainly due to the effect of closed or sold clinics (primarily related to Legacy Portfolio Optimization) and a decrease in dialysis days, partially offset by Same Market Treatment Growth. During the year ended December 31, 2025, we acquired 6, opened 27, and combined, closed, or sold 107 dialysis clinics.**

#### U.S.
**In the U.S., revenue remained stable as an increase in organic growth was offset by a negative impact from foreign currency translation and a decrease in dialysis days. Organic growth in the U.S. was supported by favorable Impacts from TDAPA Reimbursement Regulation, reimbursement rate increases, and favorable payor mix effects. In the U.S., the number of patients we treated in dialysis clinics that we own or operate remained relatively stable at 205,483 patients (December 31, 2024: 206,436). Treatments remained relatively stable at 31,069,465 for the year ended December 31, 2025 as compared to 31,213,447 for the year ended December 31, 2024. We owned or operated 2,622 dialysis clinics in the U.S. at December 31, 2025 as compared to 2,624 dialysis clinics at December 31, 2024. During the year ended December 31, 2025, we acquired 2, opened 15 and combined, closed, or sold 19 dialysis clinics.**

#### International
**In International, the decrease in revenue was driven by the effect of closed or sold operations (primarily related to Legacy Portfolio Optimization) and a negative impact from foreign currency translation, partially offset by an increase in organic growth. There were 86,419 patients treated in dialysis clinics that we own or operate in International, a decrease of 7% (December 31, 2024: 92,916) primarily driven by divestitures in connection with Legacy Portfolio Optimization. Treatments in International decreased by 17% to 13,677,419 for the year ended December 31, 2025 as compared to 16,403,624 for the year ended December 31, 2024, driven by the effect of closed or sold operations (primarily related to Legacy Portfolio Optimization), partially offset by Same Market Treatment Growth. We owned or operated 979 dialysis clinics in International at December 31, 2025 as compared to 1,051 dialysis clinics at December 31, 2024. During the year ended December 31, 2025, we acquired 4, opened 12 and combined, closed, or sold 88 dialysis clinics.**

#### Value-Based Care
**Value-Based Care revenue increased as compared to the year ended December 31, 2024, primarily due to an increase in organic growth, driven by an increase in Member Months mainly due to contract expansion, partially offset by a negative impact from foreign currency translation.**

[**Table of Contents**](#TOC)

#### Care Enablement
**Care Enablement revenue decreased as compared to the year ended December 31, 2024, primarily driven by a negative impact from foreign currency translation, partially offset by higher revenues related to critical care products (including products for acute care treatment and acute cardiopulmonary products), machines for chronic treatment, home hemodialysis products, and peritoneal dialysis products. Apart from the negative foreign currency translation impact, the development of revenue was driven by volume increases and positive pricing momentum despite a negative impact from volume-based procurement and other regulatory policies in China.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Operating income (loss)** | **Operating income (loss)** | **Operating income (loss)** | **Operating income (loss)** | **Operating income (loss)** | **Operating income (loss)** |
| *in € M* | *in € M* | *in € M* | *in € M* | *in € M* | *in € M* |
|  |  |  | **Change in %** | **Change in %** | **Change in %** |
|  |  |  |  | **Currency** |  |
|  |  |  |  | **translation**  | **Constant** |
|  | **2025** | **2024** | **As reported** | **effects** | **Currency**<sup>(1)</sup> |
| Operating income (loss) | 1827 | 1392 | 31 | (5) | 36 |
| &nbsp;&nbsp;Care Delivery segment | 1614 | 1218 | 33 | (7) | 40 |
| &nbsp;&nbsp;Value-Based Care segment | 1 | (28) | n.a. |  | n.a. |
| &nbsp;&nbsp;Care Enablement segment | 326 | 267 | 22 | (1) | 23 |
| &nbsp;&nbsp;Inter-segment eliminations | 5 | (17) | n.a. |  | n.a. |
| &nbsp;&nbsp;Corporate | (119) | (48) | 148 | (58) | 206 |
| Operating income (loss) margin | 9.3 | 7.2 |  |  |  |
| &nbsp;&nbsp;Care Delivery segment | 11.8 | 8.7 |  |  |  |
| &nbsp;&nbsp;Value-Based Care segment | 0.1 | (1.6) |  |  |  |
| &nbsp;&nbsp;Care Enablement segment | 6.0 | 4.8 |  |  |  |

---

(1)For further information on Constant Exchange Rates, see "I. Performance management system" above.

***Consolidated***

The increase in our operating income was largely driven by a positive impact from business growth (across all operating segments), net savings associated with the FME25+ Program, and reduced expenses from Legacy Portfolio Optimization, partially offset by higher personnel expense (including elevated medical benefit costs), a negative impact from Humacyte Remeasurements, inflationary cost increases, a negative impact from foreign currency translation, and an unfavorable impact from foreign currency transaction effects.

***Care Delivery***

Care Delivery operating income increased primarily as a result of a favorable impact from business growth (driven by favorable Impacts from TDAPA Reimbursement Regulation, reimbursement rate increases, and favorable payor mix effects), reduced expenses from Legacy Portfolio Optimization, and net savings associated with the FME25+ Program, partially offset by higher personnel expense (including elevated medical benefit costs), a negative impact from foreign currency translation, and inflationary cost increases.

***Value-Based Care***

For the year ended December 31, 2025, Value-Based Care recorded operating income as compared to an operating loss for the year ended December 31, 2024, mainly driven by a favorable savings rate for certain contracts, partially offset by an unfavorable effect from CKCC programs.

***Care Enablement***

Care Enablement operating income increased primarily due to net savings from the FME25+ Program and a favorable impact from business growth (driven by higher volumes and positive pricing developments, despite volume-based procurement and other regulatory policies in China). The increase in operating income was partially offset by inflationary cost increases, a negative impact from the remeasurement of receivables related to a royalty stream that we are entitled to base on sales made by Humacyte, Inc. in the U.S., and an unfavorable impact from foreign currency transaction effects.

[**Table of Contents**](#TOC)

**Secondary performance indicators and other contributors to profit and loss**

Costs of revenue remained stable as compared to the year ended December 31, 2024 as higher costs associated with business growth (mainly related to higher membership in our Value-Based Care segment), higher personnel expense in Care Delivery, and inflationary cost increases were mostly offset by a positive impact from foreign currency translation and net savings from the FME25+ Program. Costs of revenue by segment for the years ended December 31, 2025 and 2024 are provided in the following table:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Costs of revenue** | **Costs of revenue** | **Costs of revenue** | **Costs of revenue** | **Costs of revenue** | **Costs of revenue** |
| *in € M* |  |  |  |  |  |
|  |  |  | **Change in %** | **Change in %** | **Change in %** |
|  |  |  |  | **Currency** |  |
|  |  |  |  | **translation** | **Constant**  |
|  | **2025** | **2024** | **As reported** | **effects** | **Currency**<sup>(1)</sup> |
| Care Delivery segment | 10517 | 10922 | (4) | 4 | 0 |
| Value-Based Care segment | 2132 | 1679 | 27 | 6 | 33 |
| Care Enablement segment | 3780 | 3915 | (3) | 4 | 1 |
| Inter-segment eliminations | (1836) | (1952) | (6) | 3 | (3) |
| Corporate | 6 | 15 | (68) | 0 | (68) |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) For further information on Constant Exchange Rates, see "I. Performance management system" above.

Selling, general and administrative (SG&A) expense decreased for the year ended December 31, 2025 as compared to the prior year comparable period, primarily driven by net savings from the FME25+ Program and a positive impact from foreign currency translation, partially offset by higher personnel expense (including elevated medical benefit costs).

The decrease in research and development expense was largely driven by higher capitalization of development costs, partially offset by higher personnel costs for R&D projects.

The increase in income from equity method investees was primarily driven by higher earnings attributable to VFMCRP.

The decrease in other operating income was primarily driven by lower gains from divestitures in connection with Legacy Portfolio Optimization, a decline in the contribution from the remeasurement of our investment in Humacyte, Inc., and an unfavorable impact from the phasing of income attributable to a consent agreement on certain pharmaceuticals, partially offset by higher foreign exchange gains.

The decrease in other operating expense was primarily driven by reduced expenses from Legacy Portfolio Optimization, partially offset by a negative impact from the remeasurement of our investment in Humacyte, Inc. and higher foreign exchange losses.

For additional information regarding other operating income and expense, see note 5 e) of the notes to the consolidated financial statements included in this report.

Net interest expense decreased by 6% from €335 M to €315 M, primarily due to a favorable impact from refinancing activities (mainly driven by lower debt) and lower interest expense resulting from lease liabilities, partially offset by unfavorable effects from foreign currency swaps.

The effective tax rate decreased from 29.9% to 21.2%, primarily driven by a positive impact from Legacy Portfolio Optimization, the Interwell Health Deferred Tax Reversal, and an increase in tax-free income related to equity method investees, partially offset by lower tax provisions in 2024 related to the release of certain valuation allowances which did not recur in 2025.

The increase in net income attributable to noncontrolling interests was primarily due to higher earnings from entities in which we have less than 100% ownership and are fully consolidated.

The increase in net income attributable to shareholders of FME AG resulted from the combined effects of the items discussed above.

Basic earnings per share increased primarily due to the increase in net income attributable to shareholders of FME AG described above. The average weighted number of shares outstanding for the period decreased to 291.2 M in 2025 as compared to 293.4 M in 2024, primarily driven by purchases of treasury stock under our share buyback program.

[**Table of Contents**](#TOC)

We employed 109,698 people (total headcount) as of December 31, 2025 (December 31, 2024: 111,513). This 2% decrease was largely due to the divestiture of certain businesses in connection with Legacy Portfolio Optimization.

***Year ended December 31, 2024 compared to year ended December 31, 2023***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Results of operations** | **Results of operations** | **Results of operations** | **Results of operations** | **Results of operations** | **Results of operations** |
| *in € M* | *in € M* | *in € M* | *in € M* | *in € M* | *in € M* |
|  |  |  | **Change in %** | **Change in %** | **Change in %** |
|  |  |  |  | **Currency** |  |
|  |  |  |  | **translation** | **Constant** |
|  | **2024** | **2023** | **As reported** | **effects** | **Currency**<sup>(1)</sup> |
| Revenue | 19336 | 19454 | (1) | (1) | 0 |
| Costs of revenue | (14579) | (14529) | 0 | 1 | 1 |
| Selling, general and administrative costs | (3143) | (3196) | (2) | 1 | (1) |
| Research and development | (158) | (232) | (32) | 0 | (21) |
| Income from equity method investees | 181 | 122 | 48 | 37 | 11 |
| Other operating income | 528 | 515 | 3 | 45 | 48 |
| Other operating expense | (720) | (765) | (6) | 29 | 23 |
| Operating income | 1827 | 1369 | 33 | 30 | 3 |
| Operating income margin | 7.2 | 7.0 |  |  |  |
| Interest income | 70 | 88 | (19) | (1) | (18) |
| Interest expense | (385) | (424) | (9) | 5 | (4) |
| Income tax expense | (321) | (301) | 7 | (1) | 6 |
| Net income | 1191 | 732 | 63 | 61 | 2 |
| Net income attributable to noncontrolling interests | (213) | (233) | (13) | 0 | (13) |
| Net income attributable to shareholders of FME AG | 978 | 499 | 96 | 87 | 9 |
| Basic and diluted earnings per share in € | 3.36 | 1.70 | 98 | 89 | 9 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) For further information on Constant Exchange Rates, see "I. Performance management system" above.

**Key Performance Indicators**

The following discussions include our operating and reportable segments and the measures we use to manage these segments. Due to the change in our operating structure as of June 1, 2025, as mentioned above, we have restated the financial information for 2024 and 2023 for our operating segments in order to conform to the current year's presentation. For further information, see note 1 and note 29 of the notes to the consolidated financial statements included in this report.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** |
| *in € M, except dialysis treatment, patient and clinic data* | *in € M, except dialysis treatment, patient and clinic data* | *in € M, except dialysis treatment, patient and clinic data* | *in € M, except dialysis treatment, patient and clinic data* | *in € M, except dialysis treatment, patient and clinic data* | *in € M, except dialysis treatment, patient and clinic data* | *in € M, except dialysis treatment, patient and clinic data* | *in € M, except dialysis treatment, patient and clinic data* |
|  |  |  | **Change in %** | **Change in %** | **Change in %** | **Change in %** | **Change in %** |
|  |  |  |  |  |  |  | **Same** |
|  |  |  |  | **Currency** |  |  | **Market** |
|  |  |  |  | **translation** | **Constant** | **Organic** | **Treatment** |
|  | **2024** | **2023** | **As reported** | **effects** | **Currency**<sup>(1)</sup> | **growth** | **Growth**<sup>(2)</sup> |
| Revenue | 19336 | 19454 | (1) | (1) | 0 | 4 |  |
| &nbsp;&nbsp;Care Delivery segment | 14003 | 14749 | (5) | 0 | (5) | 1 | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Thereof: U.S. | 11526 | 11836 | (3) | 0 | (3) | 0 | (0.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Thereof: International | 2477 | 2913 | (15) | (2) | (13) | 4 | 1.4 |
| &nbsp;&nbsp;Value-Based Care segment | 1752 | 1277 | 37 | 0 | 37 | 37 |  |
| &nbsp;&nbsp;Care Enablement segment | 5557 | 5345 | 4 | (1) | 5 | 5 |  |
| &nbsp;&nbsp;Inter-segment eliminations | (1976) | (1918) | 3 | 0 | 3 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Thereof: Care Delivery <sup>(3)</sup> | (480) | (448) | 7 | 0 | 7 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Thereof: Care Enablement <sup>(3)</sup> | (1496) | (1469) | 2 | 0 | 2 |  |  |
| Dialysis treatments | 47617071 | 51654540 | (8) |  |  |  |  |
| Patients | 299352 | 332548 | (10) |  |  |  |  |
| Clinics | 3675 | 3925 | (6) |  |  |  |  |
| Member Months | 1534053 | 1330582 | 15 |  |  |  |  |
| Membership | 131750 | 122242 | 8 |  |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) For further information on Constant Exchange Rates, see "I. Performance management system" above.

[**Table of Contents**](#TOC)

&nbsp;&nbsp;&nbsp;&nbsp;(2) Same market treatment growth represents growth, in percent, in treatments, adjusted for certain reconciling items including (but not limited to) treatments from acquisitions, closed or sold clinics and differences in dialysis days (Same Market Treatment Growth).

&nbsp;&nbsp;&nbsp;&nbsp;(3) Services provided by the Care Delivery segment in the U.S. for patients managed under the Value-Based Care segment are provided at fair market value. We also transfer products from the Care Enablement segment to the Care Delivery segment at fair market value.

#### Consolidated
**Revenue decreased as compared to the year ended December 31, 2023, primarily driven by the effect of closed or sold operations (primarily related to Legacy Portfolio Optimization), the absence, in 2024, of a settlement agreement in 2023 related to a previous complaint we filed against the U.S. government in 2019 which sought to recover amounts owed to us under the Tricare program (Tricare Settlement) and a negative impact from foreign currency translation, partially offset by an increase in organic growth in both all segments.**

#### Care Delivery
**The decrease in Care Delivery revenue as compared to the year ended December 31, 2023 was driven by the effect of closed or sold operations (primarily related to Legacy Portfolio Optimization) and the absence, in 2024, of the Tricare Settlement. Organic growth was supported by reimbursement rate increases and a favorable payor mix, which were offset by increased implicit price concessions. As of December 31, 2024, the number of patients treated in dialysis clinics that we own or operate in Care Delivery decreased as compared to December 31, 2023, primarily driven by divestitures in connection with our Legacy Portfolio Optimization plan. Treatments in our Care Delivery segment decreased as compared to the year ended December 31, 2023, mainly due to the effect of closed or sold clinics (primarily related to Legacy Portfolio Optimization). During the year ended December 31, 2024, we acquired 3, opened 30 and combined, closed or sold 283 dialysis clinics.**

#### U.S.
**In the U.S., the decrease in revenue was driven by the absence, in 2024, of the Tricare Settlement and the effect of closed or sold operations (primarily related to Legacy Portfolio Optimization). Organic growth in the U.S. was supported by reimbursement rate increases and a favorable payor mix, which were offset by increased implicit price concessions. In the U.S., 206,436 patients (December 31, 2023: 205,308) were treated in dialysis clinics that we own or operate. Treatments remained relatively stable at 31,213,447 for the year ended December 31, 2024 as compared to 31,210,375 for the year ended December 31, 2023, primarily as Same Market Treatment Growth was limited by the cancellation of less profitable acute care contracts (-0.2%). We owned or operated 2,624 dialysis clinics in the U.S. at December 31, 2024 as compared to 2,615 dialysis clinics at December 31, 2023. During the year ended December 31, 2024, we opened 27 and combined, closed or sold 18 dialysis clinics.**

#### International
**In International, the decrease in revenue was driven by the effect of closed or sold operations (primarily related to Legacy Portfolio Optimization) and a negative impact from foreign currency translation, partially offset by an increase in organic growth and an increase in dialysis days. There were 92,916 patients, a decrease of 27% (December 31, 2023: 127,240) treated in dialysis clinics that we own or operate in International, primarily driven by divestitures in connection with Legacy Portfolio Optimization. Treatments in International decreased by 20% to 16,403,624 for the year ended December 31, 2024 as compared to 20,444,165 for the year ended December 31, 2023, driven by the effect of closed or sold operations (primarily related to Legacy Portfolio Optimization), partially offset by Same Market Treatment Growth and an increase in dialysis days. We owned or operated 1,051 dialysis clinics in International at December 31, 2024 as compared to 1,310 dialysis clinics at December 31, 2023. During the year ended December 31, 2024, we acquired 3, opened 3, and combined, closed, or sold 265 dialysis clinics.**

***Value-Based Care***

Value-Based Care revenue increased as compared to the year ended December 31, 2023 primarily due to an increase in organic growth, driven by an increase in Member Months mainly due to contract expansion and membership growth.

[**Table of Contents**](#TOC)

#### Care Enablement
**Care Enablement revenue increased as compared to the year ended December 31, 2023, primarily driven by higher revenues related to in-center disposables, machines for chronic treatment, home hemodialysis products, and products for acute care treatments, partially offset by a negative impact from foreign currency translation. The development was driven by volume increases for our products across all of our geographical regions. Additionally, pricing momentum outside of China remained positive. In China, pricing was negatively impacted by volume-based procurement.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Operating income (loss)** | **Operating income (loss)** | **Operating income (loss)** | **Operating income (loss)** | **Operating income (loss)** | **Operating income (loss)** |
| *in € M* |  |  |  |  |  |
|  |  |  | **Change in %** | **Change in %** | **Change in %** |
|  |  |  |  | **Currency**  |  |
|  |  |  |  | **translation**  | **Constant** |
|  | **2024** | **2023** | **As reported** | **effects** | **Currency**<sup>(1)</sup> |
| Operating income (loss) | 1392 | 1369 | 2 | (1) | 3 |
| &nbsp;&nbsp;Care Delivery segment | 1218 | 1612 | (24) | 0 | (24) |
| &nbsp;&nbsp;Value-Based Care segment | (28) | (96) | (71) | 0 | (71) |
| &nbsp;&nbsp;Care Enablement segment | 267 | (67) | n.a. |  | n.a. |
| &nbsp;&nbsp;Inter-segment eliminations | (17) | (13) | 30 | 5 | 25 |
| &nbsp;&nbsp;Corporate | (48) | (67) | (29) | (1) | (28) |
| Operating income (loss) margin | 7.2 | 7.0 |  |  |  |
| &nbsp;&nbsp;Care Delivery segment | 8.7 | 10.9 |  |  |  |
| &nbsp;&nbsp;Value-Based Care segment | (1.6) | (7.5) |  |  |  |
| &nbsp;&nbsp;Care Enablement segment | 4.8 | (1.2) |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) For further information on Constant Exchange Rates, see "I. Performance management system" above.

***Consolidated***

The increase in our operating income was largely driven by a positive impact from business growth, net savings associated with the FME25+ Program, and a positive impact from value and risk-based care programs, partially offset by higher personnel expense, the absence, in 2024, of the Tricare Settlement, inflationary cost increases, and an unfavorable impact from Legacy Portfolio Optimization.

***Care Delivery***

Care Delivery operating income decreased primarily as a result of an unfavorable impact from Legacy Portfolio Optimization, the absence, in 2024, of the Tricare Settlement, higher personnel expense and inflationary cost increases, partially offset by a positive impact from business growth, a positive impact from value and risk-based care programs and net savings associated with the FME25+ Program.

***Value-Based Care***

The operating loss for Value-Based Care decreased primarily due to a favorable savings rate and an increase in Member Months, mainly due to contract expansion and membership growth.

***Care Enablement***

For the year ended December 31, 2024, Care Enablement recorded operating income as compared to an operating loss for the year ended December 31, 2023, primarily due to a favorable impact from business growth (driven by positive volume and pricing developments which were partially offset by volume-based procurement in China), a favorable impact from Legacy Portfolio Optimization, net savings from the FME25+ Program, and a positive impact from the remeasurement of receivables related to a royalty stream that we are entitled to base on sales made by Humacyte, Inc. in the U.S., partially offset by inflationary cost increases and unfavorable foreign currency transaction effects.

[**Table of Contents**](#TOC)

**Secondary performance indicators and other contributors to profit and loss**

Costs of revenue remained relatively stable as compared to the year ended December 31, 2023 as increased value and risk-based care program expenses (contract expansion and membership growth) in Value-Based Care, higher personnel expense in Care Delivery and inflationary cost increases were mostly offset by lower costs associated with business growth in Care Delivery (partially offset by higher costs in Care Enablement), the absence, in 2024, of the results of operations for businesses previously divested under Legacy Portfolio Optimization primarily within Care Delivery, net savings from the FME25+ Program and a positive impact from foreign currency translation. Costs of revenue by segment for the year ended December 31, 2024 and 2023 are provided in the following table:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Costs of revenue** | **Costs of revenue** | **Costs of revenue** | **Costs of revenue** | **Costs of revenue** | **Costs of revenue** |
| *in € M* | *in € M* | *in € M* | *in € M* | *in € M* | *in € M* |
|  |  |  | **Change in %** | **Change in %** | **Change in %** |
|  |  |  |  | **Currency** |  |
|  |  |  |  | **translation**  | **Constant** |
|  | **2024** | **2023** | **As reported** | **effects** | **Currency**<sup>(1)</sup> |
| Care Delivery segment | 10922 | 11350 | (4) | 1 | (3) |
| Value-Based Care segment | 1679 | 1250 | 34 | 0 | 34 |
| Care Enablement segment | 3915 | 3834 | 2 | 1 | 3 |
| Inter-segment eliminations | (1952) | (1905) | 2 | 1 | 3 |
| Corporate | 15 | 0 | n.a. |  | n.a. |

---

(1)For further information on Constant Exchange Rates, see "I. Performance management system" above.

SG&A expense decreased for the year ended December 31, 2024 as compared to the prior year comparable period driven by lower costs associated with business growth.

The decrease in research and development expense for the year ended December 31, 2024 as compared to the year ended December 31, 2023 was largely driven by lower personnel costs for R&D projects, higher capitalization of development costs, and lower costs related to activities in the field of regenerative medicine, partially offset by increased R&D activity.

The increase in income from equity method investees was primarily driven by higher earnings attributable to VFMCRP.

The increase in other operating income was primarily driven by foreign exchange gains, a positive impact from Humacyte Remeasurements, and the impacts from Legacy Portfolio Optimization.

The increase in other operating expense was primarily driven by the impacts from Legacy Portfolio Optimization, foreign exchange losses, and an unfavorable impact from the valuation of vPPAs, partially offset by the absence, in 2024, of the results of operations for businesses previously divested under Legacy Portfolio Optimization.

For additional information regarding other operating income and expense, see note 5 e) of the notes to the consolidated financial statements included in this report.

Net interest expense remained relatively stable at €335 M from €336 M as a favorable impact from refinancing activities and favorable effects from foreign currency swaps were mostly offset by higher net interest expense on taxes related to a settlement, lower interest associated with receivables related to a royalty stream that we are entitled to base on sales made by Humacyte, Inc. in the U.S., a negative impact from the cyber attack on one of our third party service providers leading to a shutdown of its financial clearinghouse service systems resulting in a delay in claims processing (the Third-party Cyber Incident), and unfavorable foreign currency translation effects.

The effective tax rate increased to 29.9% from 29.1% for the same period of 2023, primarily driven by a negative impact from Legacy Portfolio Optimization, partially offset by lower tax provisions related to the recognition of a previously unrecognized deferred tax asset and tax law changes. For information regarding the impact of Pillar Two tax legislation, see note 5 g) of the notes to the consolidated financial statements included in this report.

[**Table of Contents**](#TOC)

The decrease in net income attributable to noncontrolling interests was primarily due to lower earnings in fully consolidated entities in which we have less than 100% ownership, partially offset by a favorable impact from Legacy Portfolio Optimization.

The increase in net income attributable to shareholders of FME AG resulted from the combined effects of the items discussed above.

Basic earnings per share increased primarily due to the increase in net income attributable to shareholders of FME AG described above. The average weighted number of shares outstanding for the period was unchanged at 293.4 M in 2024 (2023: 293.4 M).

We employed 111,513 people (total headcount) as of December 31, 2024 (December 31, 2023: 119,845). This 7% decrease was largely due to the divestiture of certain businesses in connection with Legacy Portfolio Optimization.

**IV.** **Financial position**

Our investment and financing strategy did not change substantially in the past fiscal year as our business model, which is based on stable and high cash flows, allows for a reasonable proportion of debt. We regard our refinancing options as being very stable and flexible. During the past fiscal year, the focus of our investing activities was on our healthcare products business.

***Financing strategy***

Our financing strategy aims at ensuring financial flexibility, managing financial risks, and optimizing financing costs. Financial flexibility is ensured through maintaining sufficient liquidity. Refinancing risks are limited due to the Company's balanced maturity profile, which is characterized by a wide range of maturities of up to 2032. Corporate bonds in euro and U.S. dollar form the basis of our mid- and long-term financing instruments. Corporate bonds in euro are issued under our €10 BN debt issuance program. For short-term financing we use our €1.5 BN commercial paper program and bilateral credit lines. The €2 BN Syndicated Credit Facility serves as a backup facility and was undrawn at December 31, 2025.

[**Table of Contents**](#TOC)

The following chart summarizes our main financing debt mix as of December 31, 2025:

![Graphic](fms-20251231x20f014.jpg)

In our long-term capital management, we focus primarily on the net leverage ratio, a Non-IFRS measure, and manage against our self-imposed target of 2.5x - 3.0x (see "I. Performance management system — Net leverage ratio (Non-IFRS Measure)," above). The following table shows the reconciliation of net debt and adjusted EBITDA and the calculation of the net leverage ratio as of December 31, 2025 and 2024.

[**Table of Contents**](#TOC)

---

| | | |
|:---|:---|:---|
| **Reconciliation of adjusted EBITDA and net leverage ratio to the most directly comparable IFRS Accounting Standards financial measure** | **Reconciliation of adjusted EBITDA and net leverage ratio to the most directly comparable IFRS Accounting Standards financial measure** | **Reconciliation of adjusted EBITDA and net leverage ratio to the most directly comparable IFRS Accounting Standards financial measure** |
| *in € M, except for net leverage ratio* |  |  |
|  | **December 31,** | **December 31,** |
|  | **2025** | **2024** |
| Debt and lease liabilities <sup>(1)</sup> | 10795 | 10988 |
| Minus: Cash and cash equivalents <sup>(2)</sup> | (1599) | (1185) |
| **Net debt** | **9196** | **9803** |
| Net income | 1191 | 741 |
| Income tax expense | 321 | 316 |
| Interest income | (70) | (72) |
| Interest expense | 385 | 407 |
| Depreciation and amortization | 1463 | 1536 |
| Adjustments <sup>(3)</sup> | 447 | 450 |
| **Adjusted EBITDA** | **3737** | **3378** |
| **Net leverage ratio** | **2.5** | **2.9** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Debt includes the following balance sheet line items: short-term debt, current portion of long-term debt, long-term debt, less current portion, and debt and lease liabilities included within liabilities directly associated with assets held for sale.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Includes cash and cash equivalents included within assets held for sale (see note 4 of the notes to the consolidated financial statements included in this report).

&nbsp;&nbsp;&nbsp;&nbsp;(3) Acquisitions and divestitures made for the last twelve months with a purchase price above a €50 M threshold as defined in the Syndicated Credit Facility (2025: €1 M; 2024: -€23 M), non-cash charges, primarily related to pension expense (2025: €47 M; 2024: €52 M), impairment loss (2025: €37 M; 2024: €207 M), and special items, including costs related to the FME25+ Program (2025: €185 M; 2024: €164 M), Legacy Portfolio Optimization (2025: €83 M; 2024: €113 M), Legal Form Conversion Costs (2025: €4 M; 2024: €9 M), and Humacyte Remeasurements (2025: €90 M; 2024: -€72 M).

The key financial risks we are exposed to include foreign exchange risk and interest rate risk. To manage these risks, we enter into various hedging transactions that have been authorized by the Management Board. Counterparty risks are managed via internal credit limits, taking into account the external credit ratings of the respective hedging counterparty. We do not use financial instruments for trading or other speculative purposes (for financial risks as well as information regarding vPPAs, see Item 11. "Quantitative and qualitative disclosures about market risk — Management of foreign exchange and interest rate risks" below as well as note 26 of the notes to the consolidated financial statements included in this report). For information on our credit ratings, see note 21 of the notes to the consolidated financial statements included in this report. A rating is not a recommendation to buy, sell, or hold securities of the Company, and may be subject to suspension, change, or withdrawal at any time by the assigning rating agency.

We have established guidelines for risk management procedures and controls which govern the use of financial instruments. These guidelines include a clear segregation of duties with regards to execution on the one hand and administration, accounting, and controlling on the other.

#### Effect of off-balance-sheet financing instruments on our financial position, assets and liabilities
We are not involved in off-balance-sheet transactions that have or are reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, cash requirements, or capital resources.

#### Sources of liquidity
Our primary sources of liquidity are typically cash provided by operating activities, cash provided by short-term debt, proceeds from the issuance of long-term debt, and divestitures. We require this capital primarily to finance working capital needs, fund the FME25+ Program and acquisitions, operate clinics, develop free-standing renal dialysis clinics and other healthcare facilities, purchase equipment for existing or new renal dialysis clinics and production sites, repay debt, pay dividends, repurchase shares (see "Net cash provided by (used in) investing activities" and "Net cash provided by (used in) financing activities" below), and to satisfy put option obligations to holders of minority interests in our majority-owned subsidiaries (see note 26 of the notes to the consolidated financial statements included in this report).

As of December 31, 2025, our available borrowing capacity under unutilized credit facilities amounted to approximately €3.3 BN, including €2.0 BN under the Syndicated Credit Facility, which we maintain as a backup for general corporate purposes (see note 17 of the notes to the consolidated financial statements included in this report).

At December 31, 2025, we had cash and cash equivalents of €1,599 M (December 31, 2024: €1,180 M).

[**Table of Contents**](#TOC)

Free cash flow (Net cash provided by (used in) operating activities, after capital expenditures, before acquisitions and investments) is a Non-IFRS Measure, see "— I. Performance management system — Net cash provided by (used in) operating activities in % of revenue" and "— Free cash flow in % of revenue (Non-IFRS Measure)" above.

The following table shows the cash flow performance indicators for the years ended December 31, 2025, 2024, and 2023 and reconciles free cash flow to Net cash provided by (used in) operating activities, the most directly comparable IFRS Accounting Standards measure, and free cash flow in percent of revenue to Net cash provided by (used in) operating activities in percent of revenue:

---

| | | | |
|:---|:---|:---|:---|
| **Cash flow measures** |  |  |  |
| *in € M, except where otherwise specified* |  |  |  |
|  | **2025** | **2024** | **2023** |
| **Revenue** | 19628 | 19336 | 19454 |
| **Net cash provided by (used in) operating activities** | 2681 | 2386 | 2629 |
| &nbsp;&nbsp;Capital expenditures | (915) | (699) | (685) |
| &nbsp;&nbsp;Proceeds from sale of property, plant and equipment | 16 | 14 | 16 |
| **Capital expenditures, net** | (899) | (685) | (669) |
| **Free cash flow** | 1782 | 1701 | 1960 |
| **Net cash provided by (used in) operating activities in % of revenue** | 13.7 | 12.3 | 13.5 |
| **Free cash flow in % of revenue** | 9.1 | 8.8 | 10.1 |

---

#### Net cash provided by (used in) operating activities
Net cash provided by (used in) operating activities is impacted by the profitability of our business, the development of our working capital, principally inventories and receivables, and cash outflows that occur due to a number of specific items as discussed below. The increase in net cash provided by operating activities in percent of revenue for the year ended December 31, 2025 as compared to the year ended December 31, 2024 was driven by an increase in net income, an improvement in cash collections and the combined positive prior year impacts of the phasing of income tax payments, particularly in the U.S., (positive) and cash received in 2024 from our former general partner, Fresenius Medical Care Management AG, related to pension obligations for management board members as a result of the Conversion, which did not recur in 2025 (negative), further muted by a negative impact in 2025 from the development of certain other working capital items (driven by the development of inventories). The decrease in net cash provided by operating activities in percent of revenue for the year ended December 31, 2024 as compared to the year ended December 31, 2023 was driven by a negative impact from the phasing of dividend payments received from equity method investments and the absence, in 2024, of the Tricare Settlement, partially offset by a favorable effect from certain working capital items (mainly accounts receivable from related parties and inventories). Delays in collections of trade accounts receivable in the U.S. (including significant delays in the first half of 2024 from the Third-party Cyber Incident) were partially mitigated by the substantial resolution of the impacts related to the Third-party Cyber Incident during the second half of 2024.

The profitability of our business depends significantly on reimbursement rates for our services. For the year ended December 31, 2025, approximately 78% of our revenue was generated by providing healthcare services (including insurance services), a major portion of which is reimbursed by either public healthcare organizations or private insurers. In 2025, approximately 16% of our consolidated revenue was attributable to reimbursements from U.S. federal healthcare benefit programs such as Medicare and Medicaid. Legislative changes could affect Medicare reimbursement rates for a significant portion of the services we provide as well as the scope of Medicare coverage. A decrease in reimbursement rates or the scope of coverage could have a material adverse effect on our business, financial position and results of operations and thus on our capacity to generate cash flow. See "II. Financial condition and results of operations — Overview," above.

We intend to continue to address our current cash and financing requirements using net cash provided by operating activities, issuances under our commercial paper program (see note 16 of the notes to the consolidated financial statements included in this report), as well as from the use of our bilateral credit lines. We expect that we will have adequate sources of financing available to us. Our Syndicated Credit Facility is also available for backup financing needs. In addition, to finance acquisitions or meet other needs, we expect to utilize long-term financing arrangements, such as the issuance of bonds (see "Net cash provided by (used in) financing activities" and note 17 of the notes to the consolidated financial statements included in this report).

[**Table of Contents**](#TOC)

Net cash provided by (used in) operating activities depends on the collection of accounts receivable. Commercial customers and government institutions generally have different payment cycles. Lengthening their payment cycles could have a material adverse effect on our capacity to generate cash flow. In addition, we could face difficulties enforcing and collecting accounts receivable under the legal systems of, and due to the economic conditions in, some countries. Accounts receivable balances, net of expected credit losses, represented Days Sales Outstanding (DSO) (Non-IFRS Measure) of 59 days at December 31, 2025 (December 31, 2024: 63 days).

DSO by segment is calculated by dividing the respective segment's trade accounts and other receivables from unrelated parties (including receivables related to assets held for sale) less contract liabilities, converted to euro using the average exchange rate for the period presented by the average daily sales for the last twelve months of that segment, including sales or value-added tax, converted to euro using the average exchange rate for the period. In order to ensure comparability of line items included in the consolidated balance sheets and consolidated statements of income, trade accounts and other receivables from unrelated parties (including receivables related to assets held for sale) and contract liabilities as of December 31, 2025 are adjusted for an increase in the amount of €101.3 M and €3.7 M, respectively (December 31, 2024: a decrease of €78.5 M and an increase of €1.5 M, respectively), which represents the impact on these line items from foreign currency translation. Additionally, daily revenues in the amount of €(0.1) M and €(0.6) M for the twelve months ended December 31, 2025 and December 31, 2024, respectively, are adjusted in relation to amounts related to acquisitions and divestitures made within the reporting period with a purchase price above a €50 M threshold, to increase consistency with the respective adjustments in the determination of adjusted EBITDA (See "— I. Performance management system — Net leverage ratio (Non-IFRS Measure)" above) and in the amount of €1.1 M and €1.0 M for the twelve months ended December 31, 2025 and December 31, 2024, respectively to include sales or value-added tax and other smaller effects.

The development of DSO by reporting segment is shown in the table below:

---

| | | | |
|:---|:---|:---|:---|
| **Development of days sales outstanding (Non-IFRS Measure)** | **Development of days sales outstanding (Non-IFRS Measure)** | **Development of days sales outstanding (Non-IFRS Measure)** | **Development of days sales outstanding (Non-IFRS Measure)** |
| *in days* |  |  |  |
|  | **December 31,** | **December 31,** |  |
|  | **2025** | **2024** | **Explanation of movement** |
| Care Delivery | 54 | 56 | Improvement in cash collections |
| Value-Based Care | 33 | 33 | Remained stable |
| Care Enablement | 86 | 95 | Improvement through sharpened focus on credit management and cash collection |
| **FME AG** | **59** | **63** |  |

---

Due to the fact that a large portion of our reimbursement is provided by public healthcare organizations and private payors, we expect that most of our accounts receivable will be collectible.

For information regarding litigation exposure as well as ongoing and future tax audits, see note 25 of the notes to the consolidated financial statements included in this report.

[**Table of Contents**](#TOC)

#### Net cash provided by (used in) investing activities
Net cash used in investing activities in 2025, 2024, and 2023 was €723 M, €85 M, and €544 M, respectively. The following table shows a breakdown of our investing activities for 2025, 2024, and 2023:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Cash flows relating to investing activities** | **Cash flows relating to investing activities** | **Cash flows relating to investing activities** | **Cash flows relating to investing activities** | **Cash flows relating to investing activities** | **Cash flows relating to investing activities** | **Cash flows relating to investing activities** | **Cash flows relating to investing activities** | **Cash flows relating to investing activities** | **Cash flows relating to investing activities** |
| *in € M* |  |  |  |  |  |  |  |  |  |
|  |  |  |  | **Acquisitions, investments,** | **Acquisitions, investments,** | **Acquisitions, investments,** |  |  |  |
|  | **Capital expenditures, net, including**  | **Capital expenditures, net, including**  | **Capital expenditures, net, including**  | **purchases of intangible assets and** | **purchases of intangible assets and** | **purchases of intangible assets and** | **Proceeds from divestitures and the** | **Proceeds from divestitures and the** | **Proceeds from divestitures and the** |
|  | **capitalized development costs** | **capitalized development costs** | **capitalized development costs** | **investments in debt securities** | **investments in debt securities** | **investments in debt securities** | **sale of debt securities** | **sale of debt securities** | **sale of debt securities** |
|  | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** |
| Care Delivery | 321 | 352 | 329 | 49 | 35 | 55 | 226 | 658 | 194 |
| Value-Based Care | 1 | 1 | 1 | 0 | 2 |  | 0 |  | 1 |
| Care Enablement | 577 | 332 | 339 | 60 | 68 | 82 | 59 | 47 | 67 |
| **Total** | **899** | **685** | **669** | **109** | **105** | **137** | **285** | **705** | **262** |

---

The majority of our capital expenditures was used for the expansion of production capacity (including the purchase of previously leased facilities), capitalization of certain development costs, capitalization of machines provided to our customers, maintaining existing clinics and centers, and equipping new clinics and centers. Capital expenditures accounted for approximately 5%, 4%, and 3% of total revenue in 2025, 2024, and 2023, respectively.

Acquisitions in 2025 relate primarily to the purchase of clinics and centers. Investments in 2025 were primarily comprised of purchases of debt securities. Divestitures in 2025 mainly related to the divestment of equity investments and debt securities, including divestitures under our Legacy Portfolio Optimization program as well as cash received related to the sale of select assets of the Company's wholly owned Spectra Laboratories (see note 4 of the notes to the consolidated financial statements included in this report).

Investments in 2024 were primarily comprised of purchases of debt securities and equity investments. Divestitures in 2024 were mainly related to the divestment of equity investments (including divestitures under our Legacy Portfolio Optimization program) and debt securities.

Investments in 2023 were primarily comprised of purchases of debt securities. Divestitures in 2023 were mainly related to the divestment of equity investments (including divestitures under our Legacy Portfolio Optimization program) and debt securities. Acquisitions in 2023 related primarily to the purchase of dialysis clinics. Additionally, purchases of intangibles in 2023 related primarily to emission rights certificates.

In 2026, we anticipate capital expenditures around €0.8 BN to €1.0 BN and will remain disciplined with regard to acquisition and investment spending, while focusing on the organic growth of our business. Our anticipated capital expenditures are driven by the need to position us well to capture growth opportunities, including the large-scale rollout of our HVHDF-capable 5008X CAREsystem (for which we are targeting to replace around 20% of our machines in 2026 with the ultimate goal of replacing 100% by 2030), as well as to maintain quality levels and patient experience. Additionally, we plan accelerated capital expenditures in new production facilities as well as into R&D activities for a more globalized product portfolio.

Further information regarding our acquisitions, investments and divestitures, see notes 3, 4, and 5 e) of the notes to the consolidated financial statements included in this report.

#### Net cash provided by (used in) financing activities
In 2025, 2024, and 2023, net cash used in financing activities was €1,403 M, €2,569 M and €1,859 M, respectively.

In 2025, cash was mainly used in the repayment of debt and lease liabilities, the purchase of our shares through the share buyback program, distributions to noncontrolling interests (including the settlement of Interwell Health put options), and the payment of dividends, partially offset by proceeds from debt (including the issuance of bonds during the second quarter of 2025).

In 2024, cash was mainly used in the repayment of debt (including short and long-term debt, the accounts receivable securitization program as well as lease liabilities), payment of dividends and distributions to noncontrolling interests.

[**Table of Contents**](#TOC)

In 2023, cash was mainly used in the repayment of lease liabilities (including lease liabilities from related parties), the repayment of long-term debt (including the repayment at maturity of bonds in an aggregate principal amount of €650 M), the payment of dividends, distributions to noncontrolling interests and the repayment of short-term debt (including borrowings under our commercial paper program and short-term debt from related parties), partially offset by proceeds from long-term debt and short-term debt (including borrowings under our commercial paper program and short-term debt from related parties).

On May 27, 2025, we paid a dividend with respect to 2024 of €1.44 per share (€1.19 per share for 2023 paid in 2024 and €1.12 per share for 2022 paid in 2023). The total dividend payments in 2025, 2024, and 2023 were €423 M, €349 M and €329 M, respectively.

The following chart summarizes our significant long-term financing instruments as well as their maturity structure at December 31, 2025:

![Graphic](fms-20251231x20f015.jpg)

For a description of our short-term debt, long-term sources of liquidity, and contractual cash flows (including interest) resulting from recognized financial liabilities and derivative financial instruments recorded in the consolidated balance sheets, see notes 16, 17, and 26 of the notes to the consolidated financial statements included in this report.

The following table summarizes our available sources of liquidity at December 31, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Available sources of liquidity** |  |  |  |  |  |
| *in € M* |  |  |  |  |  |
|  |  | **Expiration per period of** | **Expiration per period of** | **Expiration per period of** | **Expiration per period of** |
|  |  | **Less than 1**  |  |  |  |
|  | **Total** | **year** | **1-3 years** | **3-5 years** | **Over 5 years** |
| Syndicated Credit Facility | 2000 |  | 2000 |  |  |
| Other unused lines of credit | 1307 | 997 | 310 |  |  |
|  | 3307 | 997 | 2310 |  |  |

---

An additional source of liquidity is our commercial paper program, under which up to €1,500 M of short-term notes can be issued on a flexible and continuous basis. As of December 31, 2025 and 2024, we did not utilize the commercial paper program.

At December 31, 2025, we had short-term debt from unrelated parties (excluding the current portion of long-term debt) in the total amount of €17 M.

For information regarding other contractual commitments, see note 25 of the notes to the consolidated financial statements included in this report.

[**Table of Contents**](#TOC)

Although current and future economic conditions could adversely affect our business and our profitability, we believe that we are well positioned to continue to operate our business while meeting our financial obligations as they come due, and to resume growing our business as macroeconomic conditions improve and headwinds subside. Because of the non-discretionary nature of the healthcare services we provide, the need for healthcare products utilized to provide such services, and the availability of government reimbursement for a substantial portion of our healthcare services, our business is generally not cyclical. A substantial portion of our accounts receivable is generated by governmental payors. While payment and collection practices vary significantly between countries and even between agencies within one country, government payors usually represent low to moderate credit risk. However, limited or expensive access to capital could make it more difficult for our customers to do business with us, or to do business generally, which could adversely affect our business by causing our customers to reduce or delay their purchases of our healthcare products (see "III. Results of operations, financial position and net assets" and Item 3.D, "Key Information — Risk factors," above). If the conditions in the capital markets worsen, this could increase our financing costs and limit our financial flexibility.

At our AGM scheduled to be held on May 21, 2026, our Supervisory Board intends to propose to the shareholders a dividend of €1.49 per share for 2025, payable in 2026. The total expected dividend payment is approximately €416 M based on shares outstanding as of December 31, 2025. This amount considers the 14,124,564 treasury shares held by the Company as of December 31, 2025, which are not entitled to dividends.

Our principal financing needs in 2026 relate to the repayment of bonds at maturity and to repurchase shares under our share buyback program. The dividend payment in May 2026, anticipated capital expenditures as well as further acquisition payments are expected to be covered by our cash flow, including the use of existing credit facilities and, if required, additional debt financing. We have sufficient flexibility to meet our financing needs in 2026.

&nbsp;&nbsp;&nbsp;&nbsp;V. **Balance sheet structure** 

Total assets as of December 31, 2025 decreased by 8% to €31.0 BN from €33.6 BN as compared to 2024. Apart from a 9% negative impact resulting from foreign currency translation, total assets increased by 1% to €34.1 BN primarily due to increases in certain working capital items such as cash and cash equivalents, inventories, and other receivables from unrelated parties.

Current assets as a percent of total assets increased to 25% at December 31, 2025 as compared to 24% at December 31, 2024, primarily due to decreased goodwill, right of use assets and property, plant and equipment driven by the impact from foreign currency translation. The equity ratio, the ratio of our equity divided by total liabilities and shareholders' equity, decreased to 46% at December 31, 2025 as compared to 47% at December 31, 2024, primarily due to a decrease in shareholders' equity driven by a negative impact from foreign currency translation adjustments and purchases of treasury stock under our share buyback program, partially offset by the impact of net income on shareholders' equity and the impact from the settlement of Interwell Health put options. The decrease in the equity ratio was mitigated by a decrease in lease liabilities (mainly due to impacts from foreign currency translation) and other financial liabilities (including a decrease related to the settlement of Interwell Health put options). ROIC increased to 5.0% at December 31, 2025 as compared to 3.5% at December 31, 2024 primarily driven by an overall increase in our operating income, a decrease in costs related to Legacy Portfolio Optimization, the impact from the Interwell Health Deferred Tax Reversal, and a decrease in average invested capital (mainly due to impacts from foreign currency translation). Goodwill, included in the item "Invested capital," has a significant impact on the calculation of ROIC. The weighted average cost of capital (WACC), including weighted risk premiums for country risks, was 7.0%. See "— I. Performance management system — Return on invested capital (ROIC) (Non-IFRS Measure)" above.

For supplementary information on capital management and our capital structure, see note 21 of the notes to the consolidated financial statements included in this report.

&nbsp;&nbsp;&nbsp;&nbsp;VI. **Risk Matrix** 

In addition to the consolidated financial statements prepared in accordance with IFRS Accounting Standards included in this report, we are subject to home country reporting requirements in Germany. These require that we provide an assessment of the probability and impact of certain risks and uncertainties that could materially affect our outlook. A summary of such risk assessment is set forth below.

[**Table of Contents**](#TOC)

Although we believe our FY 2026 outlook, which we issued in connection with the announcement of our results for the 2025 fiscal year, is based on reasonable assumptions, it is subject to risks and uncertainties that may materially impact the achievement of the outlook. In the following table, we have listed certain risks and the corresponding risk factor (or other discussion of such risks) within this report as well as our assessment of the reasonable probability and potential impact of these known risks on our results for the FY 2026. The risks and their related risk factors or other disclosure headings have been paired together to provide further information on the risks as well as provide an indication of the locations at which they are discussed in this report. The assessment below should be read together with the discussions of such risks and uncertainties contained in Item 3.D, "Key Information — Risk factors" and Item 11, "Quantitative and qualitative disclosures about market risk." Our Litigation risk represents an assessment of material litigation currently known or threatened and is discussed in note 25 of the notes to the consolidated financial statements included in this report. These assessments by their nature do not purport to be a prediction or assurance as to the eventual resolution of such risks. As with all forward-looking statements, actual results may vary materially. See "Forward-looking Statements" immediately following the **Table of Contents** to this report. Other risks discussed in Item 3.D, "Key Information — Risk factors," that are not included in the table below were deemed to have a medium to long-term potential effect on our business, financial condition, and results of operations. The classification of potential impact and likelihood as well as the localization of the risks within the risk matrix are depicted below:

---

| | | | |
|:---|:---|:---|:---|
| **Potential impact** | **Description of impact** | **Classification** | **Likelihood** |
| **Severe** | Material negative impact | **Almost certain** | > 90% to 100 |
| **Major** | Significant negative impact | **Likely** | > 50% to 90 |
| **Medium** | Moderate negative impact | **Possible** | > 10% to 50 |
| **Low** | Small negative impact | **Unlikely** | 0% to 10 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Likelihood** | **Almost Certain**<br>|  |  |  |  |
| **Likelihood** |  |  |  |  |  |
| **Likelihood** | **Likely**<br>|  | **9, 10, 16**<br>|  |  |
| **Likelihood** |  |  |  |  |  |
| **Likelihood** | **Possible**<br>| **1, 2, 7, 8, 13**<br>| **3, 4, 5, 6, 12, 14, 15, 18, 20**<br>| **17, 19**<br>|  |
| **Likelihood** |  |  |  |  |  |
| **Likelihood** | **Unlikely**<br>|  |  | **11**<br>|  |
|  |  | **Low** | **Medium** | **Major** | **Severe** |

---

---

| |
|:---|
| **High Risk**<br>|
| **Medium Risk**<br>|
| **Low Risk**<br>|

---

[**Table of Contents**](#TOC)

---

| | |
|:---|:---|
| **Risk Number** | **Risk factor (or other related disclosure) within the report** |
| 1 | If we do not comply with the numerous governmental regulations applicable to our business, we could suffer adverse legal consequences, including exclusion from government healthcare programs or termination of our authority to conduct business, any of which would result in a material decrease in our revenue; this regulatory environment also exposes us to claims and litigation, including "whistleblower" suits. |
| 2 | If certain of our investments or value and risk-based care programs with healthcare organizations and healthcare providers are found to have violated the law, our business could be adversely affected. |
| 3 | If we fail to estimate, price for and manage medical costs in an effective manner, the profitability of our value and risk-based care programs could decline and could materially and adversely affect our results of operations, financial position and cash flows. |
| 4 | There are significant risks associated with estimating the amount of healthcare service revenues that we recognize that could impact the timing of our recognition of revenues or have a significant impact on our operating results and financial condition. |
| 5 | Any material disruption in government operations and funding could have a material adverse impact on our business, financial condition, and results of operations. |
| 6 | A dependency on the payment behavior and decision-making of our business partners can affect the collectability of accounts receivable and impact our operating results. |
| 7 | Changes in reimbursement, payor mix and/or governmental regulations for healthcare could materially decrease our revenues and operating profit. |
| 8 | We operate in a highly regulated industry such that the potential for legislative reform provides uncertainty and potential threats to our operating models and results. |
| 9 | We could be adversely affected if we experience shortages of goods or material price increases from our suppliers, or an inability to access new and improved products and technology. |
| 10 | If we are unable to attract and retain skilled medical, technical, engineering or key strategic personnel, or if legislative, union, other labor-related activities or changes or employee absenteeism and turnover result in significant increases in our operating costs or decreases in productivity, we may be unable to manage our growth, continue our technological development or execute our strategy. |
| 11 | We operate in many different jurisdictions and we could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar worldwide anti-corruption laws. |
| 12 | Cyber-attacks or other privacy and data security incidents could disrupt our business and expose us to significant losses, liability, and reputational damage. |
| 13 | Our indebtedness may prevent us from fulfilling our debt-service obligations or implementing certain elements of our business strategy. |
| 14 | Foreign currency and interest rate exposure. See Item 5, "Operating and financial review and prospects – IV. Financial position," Item 11, "Quantitative and qualitative disclosures about market risk – Market risk" and note 26 of the notes to the consolidated financial statements included in this report. |
| 15 | Legal and regulatory matters (see note 25 of the notes to the consolidated financial statements included in this report). |
| 16 | Diverging views of fiscal authorities or changes in tax legislation could require us to make additional tax payments. |
| 17 | As a company with operations spanning more than 140 countries, we face specific risks from our global operations. |
| 18 | We are subject to risks associated with unpredictable events, such as public health crises and epidemics/pandemics or other significant events beyond our control. |
| 19 | Global economic conditions as well as disruptions in financial markets could have an adverse effect on our businesses. |
| 20 | If we are unable to meet applicable legal requirements and/or market expectations with respect to sustainability, both our business and our reputation could suffer. We could be subject to fines and other financial burdens associated with global environmental, social and governance regulations, laws and activities, and we could alienate our patients, employees, customers, partners, investors, and the communities we serve. Furthermore, if we do not meet investors' or certain markets' ESG standards, the market for our securities could be adversely impacted. At the same time, any efforts to meet ESG standards involving diversity and equity could subject us to allegations of unlawful discrimination. |

---

VII. Research and development

Healthcare systems face major financial challenges. With the R&D activities, Fresenius Medical Care therefore aims to develop innovative products and therapies that not only meet high quality standards and improve clinical outcomes but are also cost efficient. As an operator of proprietary dialysis clinics and a provider of comprehensive dialysis solutions – including equipment, services, and support for both clinical and home settings – the Company believes that these goals are entirely compatible.

[**Table of Contents**](#TOC)

***Global research and development strategy***

Our R&D strategy contributes to our corporate strategy, which aims to provide healthcare for chronically and critically ill patients by developing adjacent products and therapies across the full spectrum of renal care (e.g., digital health solutions, AI-supported care models, and home-based renal therapies), as well as by developing and acquiring complementary assets such as data platforms and service offerings that support value-based integrated renal care. Furthermore, our globally oriented R&D strategy enables us to respond effectively to the worldwide rise in demand for high-quality yet cost-efficient treatment and therapy methods. In so doing, Fresenius Medical Care takes regional and local market conditions into account and offers a differentiated product portfolio in line with its strategic goal of achieving industry-leading treatment outcomes. See Item 4B "Business overview — Major markets and competitive position" and "— Corporate strategy and objectives" above. In conjunction with the R&D activities, Fresenius Medical Care actively collaborates with a broad range of external partners to strengthen the global innovation and technology ecosystem. These partnerships include numerous academic institutions and research institutes at prestigious universities across the U.S. and beyond. The Renal Research Institute (RRI), our wholly owned subsidiary, is an important player in data-driven research, artificial intelligence, mathematical modeling, and other advanced analytics research. The Renal Research Institute explores critical scientific questions related to all aspects of CKD and renal therapies. In addition, the Renal Research Institute fosters collaborations with nephrology societies and technology-focused organizations to jointly explore and implement digital health innovations, AI-enabled tools, and evidence-based solutions that enhance patient care.

In 2025, the global Clinical Research team supported commercialization of products and services within Fresenius Medical Care, including company-sponsored clinical trials and investigator-initiated clinical studies globally. In addition, Fresenius Medical Care Ventures (FMCV) collaborates with start-ups and early-stage companies with the objective of promoting an open culture of innovation and enabling access to the latest technologies.

***R&D highlights in 2025***

In 2025, the Renal Research Institute and Clinical Research within the Global Medical Office undertook several R&D initiatives. These efforts highlighted Fresenius Medical Care's commitment to improving care for patients with ESKD and advancing the field of nephrology. A unifying theme across all these initiatives is the enhancement of patient care through personalized and precision medicine.

*Advancements in dialysis technology and personalized therapy*

The global Clinical Research team plays a pivotal role in validating and advancing technologies and practices, ensuring the implementation of safer, more personalized treatments that enhance patient experience and outcomes.

**High-Volume hemodiafiltration and clinical validation**

Following the 2024 publication of the CONVINCE study (Kidney International, 2024 Nov;106(5):961-971), our research in 2025 has centered on translating its findings into clinical practice through the widespread adoption of HVHDF. Over the past year, we have consolidated the evidence base by validating HVHDF's cognitive benefits through real-world data collected across our European network. Most recently, analyses of 2025 Fresenius Medical Care clinic data confirmed sustained reductions in mortality and hospitalization rates. These latest results, presented at international scientific congresses during the autumn of 2025, highlight the transition from clinical trial achievement to the establishment of HVHDF as a new standard of care in advanced dialysis treatment.

**Clinical trial outcomes and progress**

Our registration and post-market studies demonstrate our commitment to rigorous clinical validation across our product portfolio.

The SAfety of Regional Citrate Anticoagulation (SARCA) Study is aiming to support the introduction of the multiFiltratePRO acute dialysis machine and citrate anticoagulation procedure to the U.S. market. This open-label, prospective, multi-center registration study successfully enrolled 31 patients across ten U.S. clinics, confirming that all components of the therapy can be considered both safe and effective, with no unexpected safety events observed. Based on these strong results, Fresenius Medical Care remains on track to submit the registration for our citrate solution in the U.S. in December 2025, with market launch expected in 2026.

[**Table of Contents**](#TOC)

A retrospective, multi-center analysis known as the MFT PRO Adult Study confirmed the performance and safety of the multiFiltratePRO device for continuous kidney replacement therapy in adult patients with acute kidney injury (AKI). The study successfully met performance and safety objectives, demonstrating that the target for effluent dose – set by the Kidney Disease: Improving Global Outcomes (KDIGO) initiative was consistently achieved. These findings support the continued Conformité Européenne (CE) mark certification of the device for routine clinical use.

In critical care, the multicenter, prospective, interventional multiECCO2R Study investigated the safety and effectiveness of the multiECCO2R gas exchanger in 28 patients with combined renal insufficiency and hypercapnia due to acute lung failure. Patients were treated for up to 72 hours, and a comprehensive analysis of the study data is currently being prepared. Additionally, the SEPIAR Study, which evaluated the safety and effectiveness of the CE-certified Immunoglobulin G (IgG) immunoadsorber GLOBAFFIN® in routine clinical practice, has been completed, and data analyses are currently ongoing.

**Artificial intelligence applications**

The Renal Research Institute is also developing AI applications in the dialysis space. These applications underscore the Renal Research Institute´s commitment to harnessing data-driven insights to address complications and improve care delivery.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Nutrition plays a vital role in the well-being of patients with kidney disease, necessitating a personalized approach to address their unique dietary needs. The Renal Research Institute is leveraging generative AI to enhance precision nutrition strategies, considering medical, socio-economic, and cultural factors for a highly diverse patient population. The results from this work have been published in the Journal of Renal Nutrition (Bergling K, Wang LC, Shivakumar O, Nandorine Ban A, Moore LW, Ginsberg N, Kooman J, et al. From bytes to bites: application of large language models to enhance nutritional recommendations. Clin Kidney J. 2025 Mar 17;18(4):sfaf082. doi: 10.1093/ckj/sfaf082. PMID: 40226366; PMCID: PMC11992566.) and presented at international conferences, showcasing the potential of AI-driven solutions to improve dietary guidance and overall patient care.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Home dialysis offers significant clinical and lifestyle benefits to patients with kidney failure, yet adoption is increasing slowly due to multifactorial barriers. In a study, conducted by the Renal Research Institute, advanced machine learning techniques were applied to develop a predictive model that identifies ideal candidates for home dialysis, using a wide range of demographic, clinical, and treatment-related variables. Published in the Journal of Kidney Medicine (Monaghan CK, Willetts J, Han H, Chaudhuri S, Ficociello LH, Kraus MA, Giles HE, Usvyat L, Turk J. Home Dialysis Prediction Using Artificial Intelligence. Kidney Med. 2024 Dec 16;7(2):100949. doi:10.1016/j.xkme.2024.100949), this work demonstrates the potential of AI-driven tools to enhance individualized modality selection and support shared decision-making between patients and care teams. These innovations aim to improve home dialysis penetration by matching the right therapy to the right patient, advancing both quality of care and patient empowerment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Understanding the clinical impact of AI-driven decision support is crucial. Hence, this study from the Renal Research Institute evaluates the association between the use of an AI-based Anemia Control Model (ACM) and patient outcomes in dialysis care. Published in BMC Nephrology (2025), the analysis demonstrates that consistent use of ACM tools was associated with both economic and patient improvements. These findings highlight the potential for AI-driven clinical support to meaningfully improve care delivery and patient outcomes, while also offering a scalable approach to integrating predictive analytics into everyday nephrology practice (Gandjour A, Apel C, Kendzia D, Neri L, Bellocchio F, Usvyat L, Larkin J, Petrovic Vorkapic J. Health-economic evaluation of an AI-powered decision support system for anemia management in in-center hemodialysis patients. BMC Nephrol. 2025 Aug 28;26(1):496. doi: 10.1186/s12882-025-04298-7. PMID: 40877797; PMCID: PMC12392536.).

For information on the impact of AI as it relates to cybersecurity and our response to managing those impacts, see Item 16K. "Cybersecurity."

[**Table of Contents**](#TOC)

**Biomarker research and lab sciences**

Metabolomics and proteomics provide insights into a patient's condition. In 2025 the Renal Research Institute Research Lab continues to focus on the following projects within the field of dialysis-related multiomics:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Studies on peritoneal dialysis: Spent peritoneal dialysate contains thousands of metabolites that provide valuable information about the function of the peritoneal membrane. The Renal Research Institute Research Lab is leveraging advanced laboratory techniques and machine learning to analyze these metabolomic patterns in greater detail, aiming to assess the membrane's ability to remove fluid and waste products efficiently. This continued approach seeks to replace some of the current testing methods, which are often cumbersome and time-consuming, with faster, more precise evaluations. By streamlining the assessment process, the Renal Research Institute aims to enhance the management and outcomes of PD therapy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Identification of a uremic toxin: When the kidneys fail, waste products known as uremic solutes accumulate in the body, contributing to various complications. In collaboration with academic partners, the Renal Research Institute has identified a specific solute, uremic solute 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), which is believed to play a role in the development of anemia in patients with kidney disease. Our current research is now focused on developing real-world methods to enhance the removal of CMPF, aiming to mitigate its impact on anemia and improve patient outcomes. This work represents a significant step toward better understanding and managing the complex effects of uremic solutes in kidney failure, as well as translating research into viable ways to improve therapy.

**Strengthening global research partnerships**

In 2025, the Renal Research Institute strengthened its global collaborations with academic and clinical partners, driving innovation in kidney care through expanded initiatives. Highlights include the growth of the MONDO (MONitoring Dialysis Outcomes) International Network and partnerships with leading institutions such as Mayo Clinic, Imperial College London, Massachusetts General Hospital, Utrecht University, the University of Maryland, the University of California, Santa Barbara, and Maastricht University. Additional collaborative initiatives include ApolloDialDB<sup>TM</sup>, Inspire initiative, and others.

These collaborations promote data-sharing and knowledge exchange, fostering a dynamic ecosystem for research and development. These R&D highlights reflect the multifaceted approach by the Renal Research Institute and Clinical Research to enhance ESKD treatment and patient quality of life, from advanced technologies to translational research. The developments set a foundation for ongoing innovation in renal care.

#### Innovations in 2025
***In 2025, Fresenius Medical Care worked on several new products that are now close to market launch or have already launched, and maintains an extensive portfolio of innovation projects with a focus on technologies in our core business as well as related areas of strategic interest.***

***The digitalization of healthcare products and processes is a key aspect of innovation at Fresenius Medical Care. Our primary objectives are to connect patients, physicians, and nursing staff, improve nursing documentation at the point of care, and enhance water treatment technologies through automation. To this end, we leverage data and know-how from our Care Enablement MedTech segment, our Care Delivery clinics, and Global Medical Office to identify innovative medical products and services, as well as to harness the potential to enhance our product portfolio with digital solutions and data analytics. Our goal in doing so is to achieve better treatment results for patients on dialysis and other organ support therapies, enable seamless connectivity, optimize the workflow for healthcare professionals, and attain sustainable savings in treatment-related costs for our customers.***

#### Home dialysis
***Home dialysis is a growing part of our overall business. In 2025, more than 15,300 U.S.-based patients used the NxStage portable HHD system designed with home use in mind (2024: more than 14,500). This was enabled by the introduction of the new FDA-approved GuideMe software on the NxStage VersiHD cycler to the U.S. market. GuideMe's digital technology leverages the touchscreen interface to offer enhanced user experience for patients and nurses, with walk-through graphical guidance that makes it easier to learn and retain skills while facilitating the transition to home dialysis. This is why all of Fresenius Kidney Care's home hemodialysis patients in the U.S. now use our NxStage systems. Its 100% adoption rate underscores the integral role of NxStage technology in enabling patient-centered at-home care.***

[**Table of Contents**](#TOC)

#### VersiHD with GuideMe also recently received EU MDR approval for CE markets and will soon be rolled out in Europe.
***In addition, we continued our drive to optimize the cost of the NxStage portfolio by insourcing pre-mixed dialysate bags. These were cleared by the FDA in January 2024.***

***Furthermore, we introduced the Liberty Select Cycler with kinexus PD bidirectional remote therapy management in the U.S. in 2024. This technology makes it possible for clinical teams to remotely access and monitor patient treatment data and programs or update patient prescriptions.***

***In 2025, approximately 58,000 therapy prescription programs were delivered remotely, and data for over 7.7 M patient treatments digitally transmitted. In May 2024, we introduced kinexus PD remote therapy management in certain European countries for both continuous ambulatory peritoneal dialysis patients and automated peritoneal dialysis patients who use the sleep.safe harmony cycler. Rollout to additional countries in Europe and Asia started in 2025.***

***Fresenius Kidney Care also expanded its automated peritoneal dialysis APD portfolio for home patients with the introduction of a mobile version of the Silencia system in Latin America, Asia, and selected countries in Europe.***

#### In-center dialysis
In June 2025, we received 510(k) clearance from the FDA for the latest version of the hemodiafiltration-capable 5008X CAREsystem. Following a successful user experience on an earlier version of the CAREsystem – which had received 510(k) clearance from the FDA in February 2024 – we continued to roll out the program to Fresenius Kidney Care dialysis centers across the United States ahead of its planned commercial launch in 2026.

With FDA clearance secured, the first HDF therapies were conducted in 2025, marking a major milestone in the evolution of end stage renal disease treatment – the biggest leap in innovation the industry has seen in decades. The learnings from the initial pilot program at Fresenius Kidney Care clinics will be applied as the Company moves forward with its plan to offer this treatment modality to more of its dialysis patients as well as other dialysis providers in the U.S. in the coming years.

During 2025, we launched updated versions of the 5008S CorDiax and 6008 CAREsystems in line with recent MDR requirements. We continued expanding both systems into new markets in collaboration with healthcare organizations (HCOs) to establish multiple centers of excellence dedicated to HVHDF.

We continued roll out our patented sodium management tool, a unique add-on treatment option that enables precision medicine in dialysis at scale. This will help boost sales of our 6008 CAREsystem in new and existing markets while supporting healthcare professionals in leveraging sodium management as an important therapy-enhancing option.

We also accelerated our activities to develop and implement fluid management and body composition monitoring for dialysis patients, with a particular emphasis on enhancing the user experience and strengthening the value proposition of our product portfolio.

In the area of digitalization, Fresenius Kidney Care continued to roll out and implement its digital product portfolio with a focus on therapy data management system (TDMS) and industrial data management system (IDMS) for water quality monitoring, as well as 7Connect for connectivity and interoperability. This was in response to increasing demand for digitalization in the area of core therapy management (e.g., for patients transitioning to HVHDF) and clinic processes with the aim of driving efficiency. As digitalization is an important pillar of our in-center product strategy, in 2025 we laid the foundation for the next generation of digital products with increased automation, ease of use, improved patient outcomes, and sustainability.

Within our dialyzer portfolio we made important strides forward in terms of both sustainability and treatment. We continued to broaden patient access to high-quality care. At the same time, we expanded FX CorAL, our most advanced dialyzer, into new markets, including the U.S., where it is already reaching a growing number of patients and receiving very positive customer feedback.

Increasing the sustainability of our dialysis products is a very important goal for us. In 2025, we lowered our environmental impact by reducing the material consumption of our 5008 bloodline portfolio, among other measures.

[**Table of Contents**](#TOC)

The introduction of the 5008X CAREsystem together with HVHDF in the U.S. will allow us to further reduce our environmental impact by removing the need for most saline bags for dialysis while enabling a more efficient use of water, energy, and dialysis concentrates in dialysis clinics.

*Critical care*

Fresenius Kidney Care provides hospitals and intensive care units (ICUs) with a comprehensive portfolio of technologies to offer extracorporeal organ support for critically ill patients.

Our multiFiltratePRO platform gives ICU staff a wide range of features to support patients undergoing continuous renal replacement therapy. In 2025, we obtained the CE mark for hemoperfusion (HP) mode. The software update enables clinicians to perform stand-alone hemoperfusion using validated adsorbers and a blood-gas exchanger, supported by a dedicated HP workflow. This gives ICU teams access to an additional extracorporeal therapy.

Further technological developments include an advanced monitor and the Secure Connectivity Board (SCB) to bolster cybersecurity, scheduled for release in 2026. We also stepped up production of the domestic multiFiltratePRO in China designed specifically for this market after obtaining approval from the Chinese authorities and successfully delivering the first machines to our Chinese customers in August 2024.

The introduction of Fresenius Kidney Care's own, PVC-free Biofine® foil for our Ci-Ca® dialysate bags in 2025, which went into production at the end of 2024, led to cost reductions. In 2024, we obtained 510(k) clearance for our pureFLOW fluids 400, 401, 402, and 407, as well as Special 510(k) clearance for the multiFlux 1000 filter for use in acute renal failure. We now manufacture pureFLOW fluids in-house and made them widely available across the United States in 2025. The multiFlux 1000 filter, cleared in 2024, will play an important role in our acute renal care portfolio in the future.

The Apheresis Pathogen Reduction Device (APRΞD) represents a next-generation platform for therapeutic apheresis, designed to deliver enhanced performance and operational efficiency in clinical settings. CE MDR certification was granted in August 2024, followed by the start of lipoprotein apheresis treatments in September 2024 and re-approval by the notified body in October 2025. APRΞD was introduced to the market at the end of 2025 prior to commercial launch in January 2026.

A key development in clinician education was the continued evolution of Fresenius Kidney Care's Augmented Reality (AR) training application Ready4 multiFiltratePRO AR. Originally launched to support ICU teams in mastering the multiFiltratePRO acute dialysis device, the scope of this digital tool was extended in 2025 to offer expanded educational modules that deepen users' clinical understanding and confidence. Through immersive 3D anatomy and physiology models, they can explore the kidney and nephron structure in detail. Dynamic AR visuals also bring continuous kidney replacement therapy principles such as diffusion, convection, and modality differences to life, bridging theory and practice in a vivid, interactive format. With ongoing updates and new content, the Ready4 multiFiltratePRO AR experience ensures clinicians have access to the latest insights, reinforcing its value as a continuously evolving training resource.

In 2025, Fresenius Kidney Care focused on significant improvements to manufacturing operations for its heart and lung business. Through process optimization, automation, and targeted investments, we successfully removed key bottlenecks and streamlined production workflows. As a result, we more than doubled our manufacturing capacity and output, increasing the reliability and flexibility of supply to meet the growing global demand for extracorporeal life support (ECLS) systems.

A key milestone in our heart and lung business in 2025 was the successful regulatory approval of synchronized cardiac support therapy. This innovative, synchronized, and pulsatile extracorporeal membrane oxygenation (ECMO) therapy represents a breakthrough in extracorporeal life support. By actively synchronizing blood flow with the patient's cardiac cycle, it improves end-organ perfusion and reduces cardiac afterload, potentially improving myocardial recovery and overall patient outcomes. The approach combines the benefits of mechanical circulatory support with physiological pulsatility, bringing ECMO therapy one step closer to natural heart function.

In addition, Fresenius Kidney Care developed multiHL7 in 2024, a connectivity solution for multiFiltratePRO devices. Connectivity was a key driver in upgrading our Xenios 2.0 console, which we launched in April 2025. The system simplifies the implementation of standards-based medical data, allowing machine data to be incorporated flexibly into a variety of patient monitoring systems. Medical information is automatically transferred to patient data management systems (PDMS) or electronic medical records (EMR), significantly reducing the workload for healthcare providers by streamlining documentation and data management processes.

[**Table of Contents**](#TOC)

*Access to transplants*

As a patient's path to a transplant starts with a referral, Fresenius Medical Care launched its ReferralReady program in 2023 to redesign the process. Historically, the fragmentation of referral policies led to process bottlenecks, extra work, and lengthy delays that eroded patients' belief in the transplant system.

Based on extensive feedback from transplant intake personnel and dialysis social workers, we developed a semi-automated workflow to create the industry's most comprehensive referral program with two specific aims:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Quality: ReferralReady draws on more than 167 data points across Fresenius Medical Care systems to provide a highly transparent system that enables transplant intake teams to make timely decisions for each patient.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Efficiency: The semi-automated workflow saves dialysis social workers two hours of administration per referral, giving them more time to help patients become stronger transplant candidates.

ReferralReady has strengthened the working relationship between transplant centers and dialysis teams, laying the foundation to continue increasing the number of our patients placed on the kidney transplant waitlist.

#### R&D resources
R&D expenditure corresponded to 4% (2024: 4%) of our healthcare product revenue. At the end of 2025, our patent portfolio comprised some 7,890 property rights across approximately 1,498 patent families, i.e. groups of patents linked to the same invention. In 2025, we produced around 67 additional patent families. Our broad portfolio of patents provides us with a wide range of treatment options in this competitive field.

As of December 31, 2025, 1,488 employees (total headcount) worked for the Company in R&D worldwide (December 31, 2024: 1,384). These employees come from diverse backgrounds, with professionals from medical, business, and technical fields working alongside software, data, and AI specialists on interdisciplinary teams. The majority of our R&D staff, over 940 employees, are based in Europe. Most R&D activities are carried out at our facilities in Schweinfurt and Bad Homburg v. d. Höhe (Germany). Other development sites are in St. Wendel (Germany) and Palazzo Pignano (Italy).

In the U.S., we maintain a center of excellence for the development of dialyzers and other disposable products in Ogden, Utah. In China, development activities in Shanghai and Changshu focus on the growing demand for cost-effective dialysis systems in Asia and emerging markets. The Global R&D organization coordinates collaboration and knowledge-sharing across all these sites.

More information is shown in the table below:

---

| | | | |
|:---|:---|:---|:---|
| **Research and development expenditures** | **Research and development expenditures** | **Research and development expenditures** | **Research and development expenditures** |
| *in € M* |  |  |  |
|  | **2025** | **2024** | **2023** |
| Total | 158 | 183 | 232 |

---

---

| | | | |
|:---|:---|:---|:---|
| **Employees** | **Employees** | **Employees** | **Employees** |
| *Total headcount, as of December 31, for the respective period presented* |  |  |  |
|  | **2025** | **2024** | **2023** |
| Total | 1488 | 1384 | 1358 |

---

---

| | | | |
|:---|:---|:---|:---|
| **Number of patents** | **Number of patents** | **Number of patents** | **Number of patents** |
| *As of December 31, for the respective period presented* |  |  |  |
|  | **2025** | **2024** | **2023** |
| Total | 7890 | 9529 | 9537 |

---

VIII. Trend information

For information regarding significant trends in our business see Item 5, "Operating financial review and prospects."

[**Table of Contents**](#TOC)

&nbsp;&nbsp;&nbsp;&nbsp;IX. **Tabular disclosure of contractual obligations** 

The information required by this item may be found in Item 5B under the caption "– IV. Financial position – net cash provided by (used in) financing activities."

#### Item 6. Directors, senior management, and employees
&nbsp;&nbsp;&nbsp;&nbsp;A. **Directors and senior management** 

#### General
Under the German Stock Corporation Act (*Aktiengesetz or AktG*), our corporate bodies are our Management Board, Supervisory Board and general meeting of shareholders. For a detailed discussion of our legal and management structure, see Item 16G, "Corporate governance — The legal structure of the Company." The business address of all members of our Management Board and our Supervisory Board, as described below, is Else-Kröner-Strasse 1, 61352 Bad Homburg, Germany.

#### Supervisory Board
Pursuant to Article 8 paragraph 1 of the Articles of Association of the Company, the Supervisory Board of the Company consists of twelve members, of whom, subject to the existence of the appointment right pursuant to Article 8 paragraph 2 of the Articles of Association, six are to be elected by the general meeting of shareholders (shareholder representatives) and six are to be elected by the employees (employee representatives) in accordance with the provisions of the German Co-Determination Act (MitbestG). Pursuant to Article 8 paragraph 2 of the Articles of Association, Fresenius SE & Co. KGaA, if it holds shares in the Company with a proportionate amount of the share capital of the Company of at least 15%, is entitled to appoint one of the Supervisory Board members representing the shareholders; if Fresenius SE & Co. KGaA holds shares in the Company with a proportionate amount of the share capital of the Company of at least 30%, it is entitled to appoint two of the Supervisory Board members representing the shareholders.

Mr. Shervin J. Korangy, Dr. Marcus Kuhnert, Mr. Gregory Sorensen, MD, and Ms. Pascale Witz have been elected by our shareholders as members of the Supervisory Board of the Company. Fresenius SE & Co. KGaA, which holds shares in the Company with a proportionate amount of the share capital of the Company of approximately 26.2% as of February 13, 2026, appointed Mr. Michael Sen and Ms. Sara Hennicken to the Supervisory Board.

Upon motion of the Management Board of the Company, the competent local court in Hof (Saale), Germany, appointed Ms. Stefanie Balling, Ms. Beate Haßdenteufel, Mr. Frank Michael Prescher, Dr. Manuela Stauss-Grabo, Mr. Ralf Erkens and Ms. Regina Karsch as employee representatives to the Supervisory Board of the Company. Ms. Stefanie Balling, Ms. Beate Haßdenteufel and Mr. Frank Michael Prescher are employees of the Company in accordance with Section 7 paragraph 2 no. 1, paragraph 4 MitbestG. Dr. Manuela Stauss-Grabo was appointed as a representative of the executive employees of the Company in accordance with Section 7 paragraph 2 no. 1, paragraph 4 MitbestG in combination with Section 15 paragraph 1 sentence 2 MitbestG. Mr. Ralf Erkens and Ms. Regina Karsch are representatives of the trade union IGBCE in accordance with Section 7 paragraph 2 no. 1 MitbestG. IGBCE is the trade union represented in the Company within the meaning of Section 7 paragraph 5 MitbestG.

The Supervisory Board of the Company thus includes the number of members representing each constituency (shareholders and employees) as required by law and by our Articles of Association. The judicial appointment of the employee representatives is effective for the period until the election of the employee representatives by the employees of the Company entitled to vote have been completed in accordance with the relevant statutory provisions.

[**Table of Contents**](#TOC)

Unless the General Meeting specifies a shorter term of office, the Supervisory Board members are elected in accordance with Article 8 paragraph 3 of the Articles of Association of the Company until the end of the ordinary General Meeting which resolves on the discharge of the Supervisory Board members for the fourth fiscal year after commencement of the term of office. The fiscal year in which the term of office commences is not considered for this calculation. The same applies for the Supervisory Board members to be elected by the employees. However, the election of the first Supervisory Board of the Company in the form of an AG by the EGM and the appointment by Fresenius SE & Co. KGaA each took place for the period until the end of the General Meeting of the Company which resolves on the ratification of actions of the members of the Supervisory Board of the Company for fiscal year 2026. This deviation was effected in line with the Articles of Association of the Company with a view to preferences that had been expressed by investors and proxy advisors. The term of office of those members of the Supervisory Board to be elected by the employees who must be employees of the Company is subject to additional requirements in accordance with Sections 7 paragraph 4, 6 paragraph 2 sentence 1 MitbestG. Among other things, they must have reached the age of 18 and have been with the Company for one year. If a Supervisory Board member who must be an employee of the Company in accordance with Section 7 paragraph 2 MitbestG loses his or her eligibility for election, that board member's office expires.

The elections of the shareholder representatives are conducted in accordance with recommendation C.15 of the German Corporate Governance Code (GCGC) as individual elections. In case of election proposals to the General Meeting, a curriculum vitae is provided for each candidate in accordance with recommendation C.14 of the GCGC, and any personal or business relationship of a candidate with the enterprise, the corporate bodies of the Company or a significant shareholder of the Company are disclosed in accordance with recommendation C.13 of the GCGC.

The Supervisory Board has resolved a standard age limit for its members and shall, as a rule, only include persons who have not reached the age of 75 years at the time of their election or appointment. Before the expiration of their term, any member of the Supervisory Board may be removed by court upon formal request of a simple majority of the Supervisory Board if there is good cause for such removal (for example, a severe breach of duty as a Supervisory Board member). Members elected by the shareholders may also be removed by a resolution of the general meeting of shareholders with a majority of three quarters of the votes cast at such general meeting. The employee representatives may also be removed by a voting decision by all employees of the Company in Germany requiring a 75% majority of the votes cast; the motion for removal must be submitted by the relevant employee group (non-executive employees, executive employees or union).

Our Supervisory Board ordinarily passes resolutions by a simple majority of the votes cast. The Chair, who is typically selected from among the Supervisory Board members elected by the shareholders, has a tie-breaking vote in case of any deadlock. The principal function of the Supervisory Board is to oversee the management of the Company, including to appoint and to supervise the Management Board in its management of the Company, to be involved in involved in strategy and planning, to approve dividend payments and other matters which are not in the ordinary course of business or are of fundamental importance to us. The Supervisory Board is also responsible for determining the compensation for the individual members of the Management Board as well as determining and reviewing the compensation system for the members of the Management Board.

The table below provides the names of the current members of the Supervisory Board and their ages:

---

| | |
|:---|:---|
| **Name** | **Current Age** |
| ***Shareholder Representatives*** |  |
| Mr. Michael Sen, Chair<sup>(1), (2),</sup> <sup>(5)</sup> | 57 |
| Ms. Sara Hennicken<sup>(2)</sup> | 45 |
| Mr. Shervin J. Korangy<sup>(2), (3)</sup> | 51 |
| Dr. Marcus Kuhnert<sup>(1), (4)</sup> | 57 |
| Mr. Gregory Sorensen, MD<sup>(4), (5)</sup> | 63 |
| Ms. Pascale Witz<sup>(2), (3)</sup> | 59 |
| ***Employee Representatives*** |  |
| Ms. Stefanie Balling<sup>(1), (4), (5)</sup> | 57 |
| Mr. Ralf Erkens<sup>(1)</sup> | 60 |
| Ms. Beate Haßdenteufel<sup>(5)</sup> | 55 |
| Ms. Regina Karsch<sup>(3)</sup> | 42 |
| Mr. Frank Michael Prescher<sup>(4)</sup> | 62 |
| Dr. Manuela Stauss-Grabo<sup>(3)</sup> | 57 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Member of the Presiding Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Member of the Nomination Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Member of the Compensation Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Member of the Audit Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Member of the Mediation Committee.

[**Table of Contents**](#TOC)

For information regarding the Supervisory Board committees, see "Board Practices," below.

*Shareholder representatives*

MR. MICHAEL SEN has been Chair of the Supervisory Board since the Conversion (previously Chair of the supervisory board of Management AG since October 1, 2022). Mr. Sen has also been the Chief Executive Officer of Fresenius SE and Chair of the Management Board of Fresenius Management SE since October 1, 2022. Mr. Sen joined the management board of Fresenius Management SE in April 2021 as the Chair of the Management Board of Fresenius Kabi AG, a wholly owned subsidiary of Fresenius SE specializing in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Mr. Sen served as CEO of Fresenius Kabi AG until a successor was appointed in March 2023 and has served as Chair of Fresenius Kabi AG's supervisory board since March 2023. Before joining Fresenius Kabi AG, Mr. Sen was a member of the Management Board of Siemens AG, where he was responsible for the healthcare business Siemens Healthineers and for Siemens' energy business. Prior to that, he was Chief Financial Officer of E.ON SE. At the start of his professional career, Mr. Sen completed an apprenticeship at Siemens in Berlin and then studied business administration at the Technical University of Berlin.

MS. SARA HENNICKEN has been the Chief Financial Officer of Fresenius SE since September 1, 2022. Ms. Hennicken became a member of the Company's Supervisory Board upon the Conversion (previously Ms. Hennicken had been a member of the supervisory board of Management AG since September 1, 2022). She is also a member of the supervisory board of Fresenius Kabi AG since September 1, 2022 and, after having served as its Chair, became its Deputy Chair on March 8, 2023. Since December 14, 2022, Ms. Hennicken also serves as a member of the supervisory board of VIACAMA AG (which changed its name from VAMED AG as of September 16, 2025) and became its Deputy Chair on July 12, 2023. In May 2024, Ms. Hennicken was appointed a member of the supervisory board of Deutsche Lufthansa AG. Ms. Hennicken joined Fresenius SE in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Previously, she spent 14 years in investment banking, including nine years at Deutsche Bank, lastly as Managing Director and Senior Client Executive in Corporate Finance Coverage before moving to Fresenius. Between 2005 and 2010 she worked for Citigroup in Frankfurt and London. Ms. Hennicken studied economics in Germany and in the United States.

MR. SHERVIN J. KORANGY became a member of the Supervisory Board upon effectiveness of the Conversion. Mr. Korangy became a senior advisor to TPG Inc. (TPG Capital Fund), a leading global alternative asset management firm, in January 2026. Mr. Korangy served as the President and the Chief Executive Officer and a member of the board of directors of BVI Medical, Inc. (BVI) (a TPG Capital Fund portfolio company), a global developer, manufacturer, and marketer of devices for ophthalmic surgery, and continues to serve as an advisor to BVI. Prior to his current role at BVI, Mr. Korangy served as the Chief Financial Officer and Chief Strategy Officer from 2017 to 2019. Prior to joining BVI, Mr. Korangy served as a senior executive of Novartis AG, a diversified healthcare products company, from 2010 until March 2017. During his seven years at Novartis, he served in various international capacities spanning strategy, mergers & acquisitions, integrations, sales & marketing and general management, including serving as the Global Head of Corporate Finance based in Switzerland. In 2011, Mr. Korangy co-founded Sight Sciences, Inc., a medical device company. Previously, he was a Managing Director at the Blackstone Group, one of the largest global investment firms, which he joined in 1996. During his more than 14 years at Blackstone, he served as both an advisor in the Restructuring/Special Situations business and as an investor in the Private Equity business. Mr. Korangy currently serves as a member of the Board of Directors for The Hain Celestial Group, Inc., a leading marketer, manufacturer and seller of organic and natural, "better-for-you" consumer products. He is Chair of the compensation committee and a member of the nominating and governance committee at Hain. Mr. Korangy serves on the Undergraduate Board of the Wharton School since July 2024. Mr. Korangy has served on the Wharton McNulty Leadership Advisory Board, established by the Center for Leadership and Change Management, since January 2019. Mr. Korangy is a graduate of The Wharton School at the University of Pennsylvania.

DR. MARCUS KUHNERT became a member of the Supervisory Board upon effectiveness of the Conversion. Dr. Kuhnert was a member of the Executive Board and Chief Financial Officer of Merck KGaA, a global science and technology company headquartered in Darmstadt, Germany, from August 2014 until June 30, 2023. Dr. Kuhnert continued to serve as a member of the Executive Board of E. Merck KG until July 31, 2024. In September 2017, Dr. Kuhnert additionally took over the responsibility for the newly-founded Business Services of Merck KGaA, Darmstadt, Germany. Dr. Kuhnert also assumed the accountability for Group Procurement in October 2018 and for IT in July 2020. Before joining Merck KGaA, Dr. Kuhnert worked for Henkel AG & Co. KGaA (a global chemical and consumer goods company headquartered in Düsseldorf, Germany), most recently as Chief Financial Officer of the Laundry & Home Care business unit. Dr. Kuhnert studied Business Administration and Mechanical Engineering at the Technical University of Darmstadt from which he received a PhD. Dr. Kuhnert is a member of the Board of Directors of Döhler Group SE, a global producer and provider of technology-based ingredients and ingredient systems for the food and beverage industries based in Darmstadt, Germany. He is also a member of the supervisory board of MEWA Textil-Service SE, Germany, and maxingvest GmbH & Co. KGaA, Germany.

[**Table of Contents**](#TOC)

MR. GREGORY SORENSEN, MD, became a member of the Supervisory Board of the Company on May 20, 2021. Until effectiveness of the Conversion, he was also a member of the supervisory board of Management AG since May 2021. Mr. Sorensen holds an MD degree from Harvard Medical School, an MS in Computer Science from Brigham Young University and a BS in Biology from the California Institute of Technology. Since August 2023, Mr. Sorensen is a member of the Board of Directors and the Chief Science Officer of RadNet, Inc. Mr. Sorensen has been President of DeepHealth, Inc. (a subsidiary of RadNet, Inc.) and Executive Chair of the Board of Directors of IMRIS (Deerfield Imaging, Inc.) since 2015. From 2011 until 2015, he was President and Chief Executive Officer of Siemens Medical Solutions USA, Inc. Mr. Sorensen was a member of the supervisory board of Siemens Healthineers AG from April 2018 until February 2023.

MS. PASCALE WITZ became a member of the Supervisory Board of the Company on May 12, 2016. Until effectiveness of the Conversion, she was also a member of the supervisory board of Management AG since May 2021. Ms. Witz is currently president of PWH Advisors, a strategic advisory firm serving life sciences companies. Ms. Witz was a member of the Executive Committee of Sanofi S.A., serving as Executive Vice President, Diabetes and Cardiovascular, after serving as Executive Vice President, Global Pharmaceutical Divisions. From 2009 to 2013, Ms. Witz was President and CEO of GE Healthcare Pharmaceutical Diagnostics. Previously, Ms. Witz held a number of other executive positions at GE Healthcare and Becton Dickinson. Ms. Witz has served on the Board of Directors of Regulus Therapeutics Inc. from June 1, 2017 until June 25, 2025 and Revvity, Inc. (formerly known as Perkin Elmer Inc.) since October 30, 2017.

*Employee representatives*

MS. STEFANIE BALLING became a member of the Supervisory Board on January 26, 2024. Ms. Balling also currently serves as Chair of the general works council of the Company and has been chair of the Schweinfurt works council of D-GmbH since 2010. Since 2006, Ms. Balling has worked as a strategic buyer for D-GmbH and has also served as a member of the examination committee of the Wuerzburg-Schweinfurt Chamber of Industry and Commerce since 2014. From 2018 to 2023, Ms. Balling served as Chair of the general works council of Fresenius SE.

MR. RALF ERKENS became a member of the Supervisory Board on January 26, 2024. As of November 2024, Mr. Erkens is a Specialist Secretary of the Industrial Union for Mining, Chemical and Energy (IGBCE). Previously, he was the District Manager of the Rhine-Main union district for the IGBCE since 2013. Mr. Erkens also served as District Manager of the IGBCE's Schleswig-Holstein district from 2010 to 2013 and Deputy District Manager of its Hamburg/Harburg district from 2005 to 2010. Mr. Erkens is a member of the supervisory board of Abbott GmbH in Wiesbaden, Germany.

MS. BEATE HAßDENTEUFEL became a member of the Supervisory Board on January 26, 2024. Ms. Haßdenteufel has served as Chair of the representative body for the severely disabled employees at our St. Wendel facility since 2013 and Deputy Chair of the St. Wendel works council since 2012 and has been a member of the works council since 2006. Ms. Haßdenteufel has also served as the First Deputy of the cross company representative body of severely disabled people of the Company since 2024. From 2022 to 2023, Ms. Haßdenteufel served as Second Deputy of the joint representative body for disabled employees at Fresenius SE.

MS. REGINA KARSCH became a member of the Supervisory Board on January 26, 2024. Ms. Karsch has been the Board Secretary to the Deputy Chair of the IGBCE in Hanover, Germany since 2022, the Head of the Competence Center for Education at the IGBCE since 2024, and the District Manager in Hanover for the IGBCE since 2025. Prior to her current position, Ms. Karsch served as a Trade Union Secretary of the IGBCE from 2020 to 2021, Head of the Diversity & Anti-Discrimination Department of the IGBCE from 2018 to 2020, and in other IGBCE positions from 2015 to 2017. Ms. Karsch holds a Master of Arts of Political Science and History degree from Gottfried Wilhelm Leibniz University in Hanover, Germany.

MR. FRANK MICHAEL PRESCHER became a member of the Supervisory Board on January 26, 2024. Mr. Prescher has been employed since 2017 as a Nursing Service Manager at Nephrocare Mönchengladbach GmbH and has served as Chair of the works council of Nephrocare Mönchengladbach GmbH since 2016. From 1993 to 2016, Mr. Prescher worked in Technical Management at Dialysis Center Dr. Ropertz u. Dr. Jennessen. Mr. Prescher trained as a registered nurse at Franziskus Hospital in Mönchengladbach, Germany.

DR. MANUELA STAUSS-GRABO became a member of the Supervisory Board on January 26, 2024. Dr. Stauss-Grabo has been Senior Vice President and Head of Global Clinical Research in the Global Medical Office of the Company since 2023. From 2015 to 2023, Dr. Stauss-Grabo held various management and research positions in the Company's Global Medical Office, including Vice President and Head of Biomedical Evidence Generation (global and outside the U.S.) as well as Vice President and Head of Clinical Research for the EMEA region. Dr. Stauss-Grabo obtained a diploma in Biology from Julius-Maximilians University in Wuerzburg, Germany, and a PhD in Pharmacy from Phillips-University in Marburg, Germany.

[**Table of Contents**](#TOC)

#### Management Board
Each member of the Management Board is appointed by the Supervisory Board for a maximum term of five years and is eligible for reappointment thereafter. Initial appointments are typically limited to a term of three years. Our Supervisory Board has resolved a standard age limit for the Management Board members. Board members shall, as a rule, retire from the Management Board at the end of the calendar year in which they reach the age of 65 years. The Management Board adopts resolutions at meetings by simple majority of votes cast, and outside the meetings by simple majority of its members. In case of a tie, the Chair of the Management Board has the casting vote.

The table below provides names, positions and terms of office of the current members of the Management Board and their ages:

---

| | | | |
|:---|:---|:---|:---|
| <br>**Name** | <br>**Current Age** | <br>**Position** | **Year term** <br>**expires** |
| Ms. Helen Giza | 58 | Chief Executive Officer | 2027 |
| Mr. Martin Fischer | 49 | Chief Financial Officer | 2026 |
| Mr. Craig Cordola, EdD | 54 | Management Board Member responsible for Care Delivery | 2026 |
| Dr. Jörg Häring | 55 | Management Board Member responsible for Legal, Compliance and Human Resources | 2027 |
| Mr. Joseph E. (Joe) Turk | 58 | Management Board Member responsible for Care Enablement | 2028 |
| Mr. Charles Hugh-Jones, MD, FRCP | 56 | Global Chief Medical Officer | 2028 |

---

**MS. HELEN GIZA was appointed Chief Executive Officer of the Company and Chair of the Management Board upon effectiveness of the Conversion. Previously, Ms. Giza was Chief Executive Officer and Chair of the management board of Management AG effective December 6, 2022 and Chief Financial Officer of the management board of Management AG effective November 1, 2019. Ms. Giza continued to serve as acting Chief Financial Officer of the management board of Management AG until a successor, Mr. Martin Fischer, was appointed for the position effective October 1, 2023. Prior to joining Fresenius Medical Care, she was Chief Integration and Divestiture Management Officer at Takeda Pharmaceuticals. Before joining the Takeda Corporate Executive Team, she served as Chief Financial Officer of Takeda's U.S. business unit from 2008 to 2018. Prior to that, she held a number of key international finance and controlling positions, amongst others, at TAP Pharmaceuticals and Abbott Laboratories. On August 22, 2023, Ms. Giza was appointed a non-executive director on the Board of Directors of Resonetics, LLC. Ms. Giza is a U.K. Chartered Certified Accountant and holds a Master of Business Administration from the Kellogg School of Management at Northwestern University in Evanston, Illinois, U.S.**

**MR. MARTIN FISCHER was appointed Chief Financial Officer and member of the management board of Management AG as of October 1, 2023 and became Chief Financial Officer and a member of the Management Board of the Company upon effectiveness of the Conversion. Prior to his appointment, Mr. Fischer was Head of Finance for Siemens Healthineers' Diagnostics division based in Tarrytown, NY, USA since 2019. Previously, he headed the Board Office and Organizations function for Siemens Healthineers after leading the business plan and operating model development for the company's initial public offering in March 2018. Prior to that, Mr. Fischer held a number of key international operational and finance positions in healthcare within Siemens AG. Mr. Fischer holds a degree in business informatics from the Reutlingen University of Applied Sciences and an MBA from Friedrich Alexander University, Nuremberg, Germany. He completed the Chief Financial Officer Program at Columbia Business School in New York, USA.**

MR. CRAIG CORDOLA, EdD was appointed Chief Executive Officer of Care Delivery and member of the Management Board of the Company as of January 1, 2024. Prior to joining the Company in 2024, he served in several executive roles with Ascension from 2017 through 2023, including Executive Vice President for Ascension Capital, Executive Vice President and Chief Operating Officer as well as President and Chief Executive Officer for Ascension Texas. Mr. Cordola has almost 30 years of experience in the healthcare industry, holding Chief Executive Officer roles and other senior leadership positions at several healthcare organizations. He holds an EdD in Leadership and Learning in Organizations from Peabody College at Vanderbilt University, an MHA/MBA from the University of Houston at Clear Lake and a Bachelor of Arts from The University of Texas.

DR. JÖRG HÄRING was appointed member of the Management Board responsible for Legal, Compliance, and Human Resources and Labor Relations Director as of June 1, 2024. Prior to joining Fresenius Medical Care, Dr. Jörg Häring was a member of the Management Committee, Chief Legal & Assurance Officer, and Secretary of the Board at the Spanish energy company Compañía Española de Petróleos (CEPSA), overseeing Legal, Corporate Audit, Risk Management, and Compliance globally. He previously spent 18 years with the Siemens Group, including nearly 13 years as General Counsel. Before joining Siemens, he worked at the law firm Cleary, Gottlieb, Steen & Hamilton in Frankfurt, Germany and Brussels, Belgium. Dr. Häring holds a PhD in law and a degree in economics from the University of Tübingen, Germany.

[**Table of Contents**](#TOC)

MR. JOSEPH E. (JOE) TURK was appointed Chief Executive Officer of Care Enablement and Management Board member of the Company responsible for Care Enablement as of January 1, 2026. Prior to this appointment, he served as Executive Vice President of Global Home and Critical Care Therapies and Head of U.S. Commercial Operations of the Company. Mr. Turk joined the Company in 2019 following the acquisition of NxStage Medical, Inc. Before joining the Company, he held positions at Boston Scientific Corporation, McKinsey & Company, Inc., and Deloitte LLP. Mr. Turk holds a master's degree in marketing, finance, and operations from the Northwestern University Kellogg School of Management, and a degree in economics from Wabash College.

MR. CHARLES HUGH-JONES, MD, FRCP was appointed Global Chief Medical Officer and a member of the Management Board effective January 1, 2026. Mr. Hugh-Jones most recently served as CEO of Volastra Therapeutics, Inc. (Volastra) from its inception as a discovery-stage startup to a clinical-stage biotech company, advancing novel oncology assets. Prior to Volastra, he served as Chief Medical Officer at Allergan plc, later acquired by AbbVie Inc., overseeing global medical operations and leading major product launches across multiple therapeutic areas. Mr. Hugh-Jones also held senior leadership roles at Pfizer Inc. and Sanofi-Aventis Groupe S.A., driving innovation in chronic disease care, diabetes, cardiovascular, and other therapeutic areas, held medical roles at Enzon Pharmaceuticals, Inc. and Bayer Schering Pharma AG, and was a practicing physician in the United Kingdom. Mr. Hugh-Jones holds an MD from Charing Cross and Westminster Medical School, University of London, and is a Fellow of the Royal College of Physicians of the United Kingdom.

&nbsp;&nbsp;&nbsp;&nbsp;**B.** **Compensation** 

As a foreign private issuer, we are not subject to the compensation disclosure provisions of SEC Regulation S-K, which include requirements for disclosure of executive compensation that are significantly more detailed than Form 20-F. Regulation S-K also includes a requirement to provide a "Compensation Discussion and Analysis" explaining the material elements of the compensation paid to a company's CEO, CFO and certain other highly-compensated executive officers or employees. See Item 16G, "Corporate Governance." Instead, as a German publicly-held company, we prepare a Compensation Report in accordance with the requirements of the German statutory provisions referred to below. Set forth below is a convenience translation of the Compensation Report of FME AG for the fiscal year 2025, substantially in its entirety. Definitions expressly set forth in this Compensation Report are applicable solely to the Compensation Report.

By referring to our German Annual Report (Geschäftsbericht or our Annual Report 2025) and to our and other websites throughout this Compensation Report, we do not intend to incorporate into this report any information in our Annual Report 2025 or on our and other websites, and any information on our and other websites should not be considered to be part of this report, except as expressly set forth herein.

**Introduction**

The Compensation Report of Fresenius Medical Care AG for the fiscal year 2025 was prepared in accordance with the requirements of Section 162 of the German Stock Corporation Act (Aktiengesetz – AktG). In this Compensation Report, "Company" refers to Fresenius Medical Care AG, and "Group" refers to the Fresenius Medical Care group of companies. "Fiscal year" refers to the fiscal year 2025, unless expressly stated or indicated by the context otherwise. The Compensation Report includes individualized and comprehensive information on compensation within the meaning of Section 162(1) AktG awarded or due to current and former members of the Company's Management Board and Supervisory Board in the fiscal year and on benefits within the meaning of Section 162(2) AktG awarded or promised to Management Board members.

The Company's 2025 Annual General Meeting of shareholders (AGM) approved the Compensation Report for the fiscal year 2024 with a majority of 88.57% of the votes cast. The Management Board and the Supervisory Board see the vote of the 2025 AGM as confirmation of their approach to reporting. The structure of the Compensation Report for the fiscal year and the level of detail of the information provided are essentially the same as in the previous year.

Unless stated otherwise, the information on the compensation of Management Board members pertains to those who held office during the fiscal year. For the amounts, see the section "Compensation tables for the Management Board members in office in the fiscal year."

For information on compensation of former Management Board members and the amounts of such compensation, see the section "Former Management Board members' compensation." This section also contains relevant information on former members of the Management Board of the Company's former general partner, which managed the Company's affairs until the change in the Company's legal form took effect on November 30, 2023.

[**Table of Contents**](#TOC)

Certain disclosures in this Compensation Report fulfill reporting obligations from Fresenius Medical Care's "Sustainability statement" resulting from the application of the European Sustainability Reporting Standards (ESRS). These disclosures are marked by reference such as [ESRS 2, 40g], and are provided within or at the end of the respective sections where the related information appears.

**The fiscal year in retrospect**

The compensation awarded or due to the Management Board members in the fiscal year rewarded their performance, particularly in achieving the Company's strategic objectives. At the same time, the compensation provided effective incentives for the Company's long-term value creation – taking into account the interests of patients, shareholders, employees and other stakeholders as well as compensation practices in relevant comparable markets. Consequently, the compensation of the Management Board members made a significant contribution to promoting the Company's business strategy and the long-term sustainable development of the Company and the Group.

***Business performance and economic environment***

See Item 5, "Operating and financial review and prospects," above.

***Short-term incentive target achievement***

The business performance in the fiscal year was reflected by an overall target achievement of 56.01% to 101.58% for the short-term variable compensation component (short-term incentive – STI) for the fiscal year. For further details, see the section "Short-term incentive – MBBP 2024+."

***Long-term incentive target achievement for the performance period ending at the end of the fiscal year***

The performance period of the allocation made in 2023 under the Management Board Long-Term Incentive Plan 2020 (MB LTIP 2020) as a long-term variable compensation component (long-term incentive – LTI) ended upon the end of the fiscal year 2025. The performance periods for the allocations made in 2024 and 2025 will only end in the coming years.

The target achievement for the allocation made in 2023 was to be determined based on the performance in the fiscal years 2023, 2024 and 2025. The target achievement levels of the performance targets "revenue growth" and "net income growth" were calculated based on a compound annual growth rate (CAGR) over the entire three-year performance period. Annual target values applied to the performance target "return on invested capital" (ROIC).

[**Table of Contents**](#TOC)

The target values and the target achievement were each as shown in the following table:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Target values and target achievement for the allocation 2023 under the MB LTIP 2020** | **Target values and target achievement for the allocation 2023 under the MB LTIP 2020** | **Target values and target achievement for the allocation 2023 under the MB LTIP 2020** | **Target values and target achievement for the allocation 2023 under the MB LTIP 2020** | **Target values and target achievement for the allocation 2023 under the MB LTIP 2020** | **Target values and target achievement for the allocation 2023 under the MB LTIP 2020** | **Target values and target achievement for the allocation 2023 under the MB LTIP 2020** | **Target values and target achievement for the allocation 2023 under the MB LTIP 2020** | **Target values and target achievement for the allocation 2023 under the MB LTIP 2020** | **Target values and target achievement for the allocation 2023 under the MB LTIP 2020** | **Target values and target achievement for the allocation 2023 under the MB LTIP 2020** |
|  |  | **Target values** | **Target values** | **Target values** | **Actual values** | **Actual values** | **Actual values** | **Actual values** | **Actual values** | **Target achievement** |
|  |  |  |  |  |  |  | **Adjusted for** |  |  |  |
|  |  |  |  |  |  |  | **target** |  |  |  |
|  |  | **0%** | **100%** | **200%** | **As reported** <sup>(1)</sup> | **Adjustments** <sup>(2)</sup> | **achievement** |  | **CAGR** |  |
| **Revenue growth** | **Revenue growth** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;2023 | } |  |  |  | 0.3% | 5.2% | 5.5% | } |  |  |
| &nbsp;&nbsp;2024 | } | ≤ 2% | = 5% | ≥ 10% | (0.6)% | 0.6% | 0.0% | } | **3.6%**  | **54%** |
| &nbsp;&nbsp;2025 | } |  |  |  | 1.5%  | 3.9%  | 5.4%  | } |  |  |
| **Net income growth** | **Net income growth** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;2023 | } |  |  |  | (25.9)% | 0.7% | (25.2)% | } |  |  |
| &nbsp;&nbsp;2024 | } | ≤ 31% | = 34% | ≥ 39% | 7.8% | 14.9% | 22.7% | } | **24.4%**  | **0%** |
| &nbsp;&nbsp;2025 | } |  |  |  | 81.9%  | 28.0%  | 109.9%  | } |  |  |
| **Return on invested capital (ROIC)** | **Return on invested capital (ROIC)** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;2023 | } |  |  |  | 2.8% | (0.1)% | **2.7%**  |  |  | **0%** |
| &nbsp;&nbsp;2024 | } | ≤ 4.0% | = 4.5% | ≥ 7.0% | 3.5% | 0.0% | **3.5%**  |  |  | **0%** |
| &nbsp;&nbsp;2025 | } |  |  |  | 5.0%  | 0.5%  | **5.5%**  |  |  | **142%** |
| **Overall target achievement** | **Overall target achievement** |  |  |  |  |  |  |  |  | **34%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) ROIC is a Non-IFRS measure. For a description of ROIC and how the measure is calculated, see Item 5, "Operating and financial review and prospects," above.

&nbsp;&nbsp;&nbsp;&nbsp;(2) According to the plan terms, revenue growth and net income growth were determined at Constant Currency. In addition, net income growth and ROIC were adjusted for the effects from one-time costs related to the FME25+ program to ensure comparability of the underlying performance targets for the variable compensation with the Company's operating performance, and adequately compensate the actual performance of the members of the Management Board. This was done in the context of the expansion of the FME25+ program to the extent the one-time cost effects deviate from the respective effects that had been assumed when the target values were defined. In the ROIC calculation, operating income and net operating profit after tax were adjusted by -€71 M and -€45 M, respectively, for the 2023 fiscal year, by €5 M and €3 M, respectively, for the 2024 fiscal year, and by €182 M and €136 M, respectively, for the 2025 fiscal year. For the 2023 fiscal year, FME25+ related one-time costs were lower than originally assumed, which is why operating income and net operating profit after tax were correspondingly reduced by the lower costs when determining the ROIC target achievement.

The compensation under the MB LTIP 2020 vests on the third anniversary after the respective allocation. The Company pays the compensation to a financial institution that invests the compensation in shares of the Company. The shares are to be acquired on the stock exchange and to be held by the respective Management Board members for at least one year. In accordance with recommendation G.10 of the German Corporate Governance Code (GCGC), the Management Board members therefore cannot dispose of the corresponding amounts before four years have passed since the respective allocation.

The specific amounts to be invested in shares of the Company from the allocation for 2023 can be determined only after vesting in 2026 and will be disclosed in the Compensation Report for the fiscal year 2026.

Details on the vested amounts to be invested in shares of the Company in the fiscal year 2025 from the allocation for 2022 under the MB LTIP 2020 can be found in the section "Vested amounts (Allocation 2022)."

Information on the outstanding LTI tranches, including a temporal profile of the individual tranches, can be found in the section "Outstanding share-based compensation components."

[**Table of Contents**](#TOC)

***No relevant changes to the basics for compensation***

The amount of the target total direct compensation (consisting of base salary as well as the STI target and LTI allocation amounts) of the Management Board members remained unchanged to the previous year both overall and in terms of its individual components.

Fresenius Medical Care began implementing its FME Reignite strategy in the fiscal year. The basis for the compensation of the Management Board members and the system currently used for this purpose, the Compensation System 2024+, remain unaffected by this new strategy. The compensation components provided for under the Compensation System 2024+ and the financial and non-financial performance criteria for the variable compensation components continue to create relevant incentives under the new strategy and make an important contribution to promoting the company's business strategy and long-term development. For further information on the FME Reignite strategy, see Item 4, "Corporate strategy and objectives," above.

The agreements concluded in 2024 with Helen Giza and Franklin W. Maddux, MD, to retroactively cancel their respective pension commitments took effect in the fiscal year as planned. As announced and described in the Compensation Report for the fiscal year 2024, Helen Giza and Franklin W. Maddux, MD, each received compensation during the fiscal year 2025 in the amount of the total insurance contributions paid until the cancellation of their respective pension commitments took effect. Since both the insurance contributions for financing the pension commitments and the pension allowance each correspond to an amount of 40% of the annual base salary, this change is neutral in terms of amount for the Management Board members. Further information on this can be found in the section "Pension-related obligations."

Franklin W. Maddux, MD, and Dr. Katarzyna Mazur-Hofsäß each left the Management Board at the end of the fiscal year. Charles Hugh-Jones, MD, FRCP, and Joseph E. Turk have been appointed as their respective successors effective January 1, 2026. More detailed information on the agreements concluded with Franklin W. Maddux, MD, and Dr. Katarzyna Mazur-Hofsäß in connection with their departure from the Management Board can be found in the section "Agreements with members of the Management Board who resigned from office at the end of the fiscal year." The compensation for Franklin W. Maddux, MD, and Dr. Katarzyna Mazur-Hofsäß is reported together with the compensation of the current members of the Management Board because they each were members of the Management Board for the entire fiscal year. This is in line with previous practice in comparable cases.

**Compensation governance for Management Board**

Compensation for the Management Board members is awarded on the basis of the respective compensation system submitted by the Supervisory Board to the Company's general meeting of shareholders for approval. The compensation system must be submitted to the Company's general meeting of shareholders for approval in case of relevant changes and at least every four years.

The Supervisory Board is responsible for determining the compensation of the Management Board members. The resolutions of the Supervisory Board are prepared by the Compensation Committee, which is formed among the Supervisory Board's members. In the fiscal year, the Compensation Committee consisted of Pascale Witz (Chair), Dr. Manuela Stauss-Grabo (Deputy Chair), Regina Karsch, and Shervin J. Korangy. [ESRS 2, 29e]

***Relevant compensation systems***

The Supervisory Board determined the compensation of the Management Board members for the fiscal year in accordance with the Compensation System 2024+, which was approved by the Company's 2024 AGM with a majority of 87.58% of the votes cast. The Compensation System 2024+ has been implemented in the service agreements of the Management Board members and in general applies to the compensation as from 2024. [ESRS 2, 29e]

Compensation components allocated before 2024 generally continue to be subject to the compensation system applied at the time. This applies in particular to LTI allocations made in previous years under the Compensation System 2020+, which was approved by the Company's 2020 AGM with a majority of 95.05% of the votes cast. Further information on this can be found in the sections "Long-term incentive – MB LTIP 2020", "Overview of outstanding share-based compensation components" and "Temporal profile of the share-based compensation components." There are no outstanding performance-based variable compensation components from the period before the Compensation System 2020+.

The compensation components awarded or due in the fiscal year are in accordance with the respective compensation systems.

[**Table of Contents**](#TOC)

The Compensation System 2024+ and the Compensation System 2020+ as well as the compensation awarded or due in the fiscal year are in each case in accordance with the relevant recommendations of the GCGC in the version dated April 28, 2022.

The main elements of the Compensation System 2024+ are set out in this Compensation Report in the section "Components of the Compensation System 2024+." The main elements of the Compensation System 2020+ are set out in the Compensation Reports for the fiscal years 2023, 2022 and 2021. These main elements are also set out in this Compensation Report insofar as they are relevant to compensation awarded or due in the fiscal year 2025.

***Guiding principles of the Compensation System 2024+***

The Compensation System 2024+ aims to reward the Management Board members based on their duties and performance as well as their success in managing the economic and financial position of Fresenius Medical Care giving due regard to the peer environment. In addition, the Compensation System 2024+ aims to enable the Management Board members to participate reasonably in a sustainable and long-term development of Fresenius Medical Care's business and to make a significant contribution to the implementation and further development of the business strategy. [ESRS 2, 29c]

***Components of the Compensation System 2024+***

The following chart shows the compensation components and further design elements of the Compensation System 2024+, which are described in more detail below: [ESRS 2, 29a]

![Graphic](fms-20251231x20f016.jpg)

[**Table of Contents**](#TOC)

***Compensation structure (target compensation)***

Under the Compensation System 2024+, the Supervisory Board sets the STI target amount for each fiscal year and the LTI allocation amount for each allocation.

The STI target amount or the LTI allocation amount is the amount that is earned if the target achievement is 100%. The STI target amount can be set within a range of 100% (multiplier of 1) to 125% (multiplier of 1.25) of the relevant base salary of the respective Management Board member and generally amounts to 105% (multiplier of 1.05). The LTI allocation amount of the Chairperson of the Management Board can be set within a range of 105% (multiplier of 1.05) to 200% (multiplier of 2) and for the other Management Board members can be set within a range of 105% (multiplier of 1.05) to 150% (multiplier of 1.5) of the relevant base salary and generally amounts to 135% (multiplier of 1.35). The multiplier is determined at the beginning of each performance period. The LTI allocation amount must exceed the STI target amount.

For the fiscal year 2025, the Supervisory Board applied a multiplier of 1.05 for the STI target amount and a multiplier of 1.35 for the LTI allocation amount for all Management Board members. This corresponds to the multipliers that were applied in the previous year and were to be applied before under the Compensation System 2020+. The compensation structure of the target total direct compensation for the fiscal year 2025 therefore consists of 29% base salary, 31% STI and 40% LTI.

![Graphic](fms-20251231x20f017.jpg)

With a 71% share of performance-based variable compensation components in the target total direct compensation, the compensation of the Management Board is predominantly performance-based. With a 40% LTI share (i.e., 56% of performance-based variable compensation components) in the target total direct compensation, the compensation of the Management Board is geared to promoting sustainable and long-term corporate development.

[**Table of Contents**](#TOC)

The target total direct compensation for the fiscal year was as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Target total direct compensation of the members of the Management Board in office in the fiscal year** | **Target total direct compensation of the members of the Management Board in office in the fiscal year** | **Target total direct compensation of the members of the Management Board in office in the fiscal year** | **Target total direct compensation of the members of the Management Board in office in the fiscal year** | **Target total direct compensation of the members of the Management Board in office in the fiscal year** | **Target total direct compensation of the members of the Management Board in office in the fiscal year** | **Target total direct compensation of the members of the Management Board in office in the fiscal year** |
| in € K |  |  |  |  |  |  |
|  |  | **Craig Cordola,** |  |  | **Franklin W.**  | **Dr. Katarzyna**  |
|  | **Helen Giza** | **EdD** | **Martin Fischer** | **Dr. Jörg Häring** | **Maddux, MD** | **Mazur-Hofsäß** |
|  | Chief Executive |  |  |  |  |  |
|  | Officer and Chair of | Chief Executive  |  | Legal, Compliance |  | Chief Executive |
|  | the Management | Officer for Care  | Chief Financial  | and Human | Global Chief | Officer for Care |
|  | Board | Delivery | Officer | &nbsp;&nbsp;&nbsp;&nbsp;Resources | Medical Officer | Enablement |
| Base salary | 1593 | 1283 | 800 | 700 | 938 | 1064 |
| STI target amount (105% of base salary) | 1673 | 1347 | 840 | 735 | 985 | 1117 |
| LTI allocation amount (135% of base salary) | 2151 | 1732 | 1080 | 945 | 1266 | 1436 |
| **Target total direct compensation** | **5417** | **4362** | **2720** | **2380** | **3189** | **3617** |

---

Information on the relative shares of the fixed and the variable compensation components in the compensation awarded or due in the fiscal year can be found in the tables in the sections "Compensation tables for the Management Board members in office in the fiscal year" and "Former Management Board members' compensation", respectively.

***Compensation reviews***

The Supervisory Board determines the value of the total target compensation for each Management Board member in line with the Compensation System 2024+. The Supervisory Board in compliance with the requirements of the German Stock Corporation Act and the recommendations of the GCGC also ensures that the compensation is commensurate with the duties and performance of each Management Board member and the Company's situation, is geared toward the long-term, sustainable development of Fresenius Medical Care, and does not exceed customary compensation without any special justification. To this end, both external and internal compensation comparisons are conducted. As a result, the respective total compensation may differ among the Management Board members, diligently considering the respective Management Board member's function and responsibilities as well as differences in international pay practices. The specific total compensation for each Management Board member also takes into account the Company's interests in retaining current members and attracting qualified candidates for the Management Board.

*Horizontal comparison (peer group)*

In order to assess the appropriateness of the Compensation System 2024+ and the individual compensation of the Management Board members, the Supervisory Board conducts a horizontal review of the respective compensation amounts and structures (external comparison). The comparison is made at a national level with other companies from the most relevant German benchmark index in which the Company is listed. Supplementary comparisons are made at an international level with companies operating in a similar industry and having a similar size as well as with European companies of a similar size with U.S.-resident management board members.

– For the fiscal year, the DAX companies as of December 31, 2024, were used for the comparison at national level.

---

| | |
|:---|:---|
| – | For the supplementary comparison at international level with companies operating in a similar industry (life science industry including MedTech) and having a similar size – depending on the specific tasks of the relevant Management Board member – the following companies were used: Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Boston Scientific Corporation, DaVita Inc., Encompass Health Corporation, The Ensign Group Inc., HCA Healthcare Inc., Koninklijke Philips N.V., Labcorp Holding Inc., Medtronic plc, Merck KGaA, Quest Diagnostics Inc., Sartorius AG, Siemens Healthineers AG, Smith & Nephew plc, Tenet Healthcare Corporation, and Universal Health Services Inc.  |

---

For the supplementary comparison with European companies of a similar size (regardless of the industry) with U.S.-resident management board members, the following companies were used: 4imprint Group, Alcon Inc., ArcelorMittal S.A., Ashtead Group plc, BAE Systems plc, Compass Group plc, Experian plc, Glencore plc, Heidelberg Materials AG, HelloFresh SE, KION Group AG, Lanxess AG, Pearson plc, Qiagen N.V., Sage Group plc, Siemens Energy AG, Smith & Nephew plc, STMicroelectronics N.V., TeamViewer SE, and Traton SE.<br>

[**Table of Contents**](#TOC)

The peer groups were adjusted compared to the previous year to reflect as best as possible the evolving international competitive landscape for qualified candidates for the Company's Management Board, considering industry and company size comparability. At the same time, greater emphasis was placed on U.S. peer companies and the proportion of German companies was slightly increased, while the weighting of other European markets was reduced.

*Vertical comparison (intra-company)*

The Supervisory Board also considers a vertical review of the compensation levels of the Group's employees when determining the compensation system and the compensation of the Management Board members (internal comparison). The compensation of the Management Board members and of the members of the Group's senior management (currently Management Level 8 or higher) as well as of the global staff (in general all employees with the exception of the Group's senior management) is set in relation. When conducting the vertical review, the Supervisory Board in accordance with recommendation G.4 of the GCGC also considers the development of compensation levels over time.

*Result of the review of the appropriateness of the compensation*

Based on of the compensation reviews carried out in the fiscal year, the Supervisory Board reached the conclusion that the compensation of the Management Board is appropriate in terms of both its structure and amount.

***Caps and maximum compensation***

The total compensation of each Management Board member is limited by caps on each variable compensation component and by a maximum compensation amount.

For the STI, the target achievement is capped at 150%. The amounts payable are accordingly capped at 150% of the relevant target amount.

For the LTI, the target achievement is capped at 200% for each allocation. In addition, the amounts payable from each LTI allocation are capped at 400% of the allocation amount. This also limits the opportunity to benefit from the share price performance in the respective vesting period, which is relevant for the LTI amount to be paid out. This applies irrespective of whether the LTI is paid out in cash or, as provided for alternatively under the Compensation System 2024+, settled in shares of the Company.

The Supervisory Board has further agreed a cap option for the variable compensation components in the event that extraordinary developments occur. In the fiscal year, there was no reason for the Supervisory Board to make use of this cap option.

In addition, there is a maximum amount of total compensation for each Management Board member (maximum compensation). This maximum compensation limits the benefits that a Management Board member can receive as compensation for a fiscal year, irrespective of when the actual payment accrues. The maximum compensation includes the base salary for the relevant fiscal year (paid out during the relevant fiscal year), the STI for the relevant fiscal year (paid out in the following fiscal year) and the LTI for the relevant fiscal year (paid out in later fiscal years) and all fringe benefits, sign-on bonuses and other compensation for the relevant fiscal year such as a pension allowance for the relevant fiscal year (generally paid out during the relevant fiscal year). Any pension service costs incurred in a fiscal year under a pension commitment are also included in the calculation of the maximum compensation. A Management Board member's maximum compensation may be lower than the sum of the potentially achievable payouts from the individual compensation components determined or allocated for a fiscal year.

[**Table of Contents**](#TOC)

The caps and maximum compensation are shown in the following chart:

![Graphic](fms-20251231x20f018.jpg)

The maximum compensation for a fiscal year is determined based on the currency of the base salary as specified in the relevant Management Board member's service agreement. Under the Compensation System 2024+ and the allocation of responsibilities on which it is based, and in accordance with the respective service agreement, the maximum compensation amounts to €12,000 K or $12,975 K for the Chairperson of the Management Board (CEO), €9,500 K or $10,272 K for the Management Board member responsible for the Care Delivery operating segment, and €7,000 K or $7,569 K for any other Management Board function. The aforementioned amounts in euros for the maximum compensation are identical to those under the Compensation System 2020+. The aforementioned U.S. dollar amounts were based on an updated exchange rate compared to the Compensation System 2020+.

---

| | | |
|:---|:---|:---|
| **Amount of the maximum compensation under the Compensation System 2024+** | **Amount of the maximum compensation under the Compensation System 2024+** | **Amount of the maximum compensation under the Compensation System 2024+** |
| in K |  |  |
|  |  | **Contractually agreed maximum** |
|  | **Function** | **compensation** |
| Helen Giza | Chief Executive Officer and Chair of the Management Board | $12975  |
| Craig Cordola, EdD | Chief Executive Officer for Care Delivery | $10272  |
| Martin Fischer | Chief Financial Officer | 7000 |
| Dr. Jörg Häring | Legal, Compliance and Human Resources | 7000 |
| Franklin W. Maddux, MD | Global Chief Medical Officer | $7569  |
| Dr. Katarzyna Mazur-Hofsäß | Chief Executive Officer for Care Enablement | 7000 |

---

Information on compliance with the maximum compensation can be found in the section "Compliance with maximum compensation (Allocations 2022)."

[**Table of Contents**](#TOC)

***Malus and clawback***

The Supervisory Board in accordance with the details of the relevant contractual provisions is entitled to withhold or reclaim variable compensation components in whole or in part in cases of a Management Board member's misconduct or non-compliance with such member's duties or internal Company guidelines, considering the characteristics of the individual case.

Also, the Supervisory Board has adopted a policy that in accordance with applicable U.S. regulatory requirements provides that the Company may recover excess incentive-based compensation if it is required to prepare an accounting restatement due to material noncompliance with relevant financial reporting requirements under U.S. federal securities laws.

In the fiscal year, there was no reason for the Supervisory Board to make use of these authorizations.

**Management Board members' compensation**

The compensation awarded or due in the fiscal year to the Management Board members in office in the fiscal year will be described in more detail below. Tables showing their respective total compensation are set out in the section "Compensation tables for the Management Board members in office in the fiscal year."

Compensation awarded or due to the Management Board members in the fiscal year consisted of fixed and variable, incentive-based components:

– fixed compensation, consisting of a base salary, fringe benefits and, if applicable, a pension allowance in cash

– one-year variable compensation (STI)

– multi-year variable compensation (LTI), consisting of payments under share-based cash-settled compensation allocated in 2022.

***Fixed compensation components***

The fixed compensation components comprise a base salary and fringe benefits as well as a pension allowance or a pension commitment as fixed compensation components. The pension commitment does not, however, constitute compensation within the meaning of Section 162(1) AktG.

The amount of the base salary is set out in the service agreements of the Management Board members. In line with standard local practice, the base salary is generally paid in twelve monthly installments for Management Board members resident in Germany and in biweekly installments for Management Board members resident in the U.S.

Fringe benefits are awarded or due individually based on the service agreements. In the fiscal year, the fringe benefits consisted mainly of the private use of company cars, the payment of a mobility allowance or the use of rental cars, housing and rent payments, reimbursement of fees for the preparation of tax returns, contributions to pension schemes (other than the pension commitments or the cash pension allowance set out herein), contributions to accident, life and health insurances or other insurances as well as tax equalization compensation due to varying tax rates applicable in Germany and the country in which the relevant Management Board member is personally taxable. See the section "Further information" for details of such tax equalization compensation.

[**Table of Contents**](#TOC)

In addition, Management Board members in general receive a pension allowance in cash amounting to 40% of their base salary for their own pension provision. For one Management Board member in office in the fiscal year and for former Management Board members, pension commitments exist instead. Payments under the pension commitments will in general only become due when the covered event occurs. The pension allowance and the pension commitments are set out in the section "Pension-related obligations."

***Short-term incentive – MBBP 2024+***

Under the Compensation System 2024+, the Management Board members are entitled to receive an STI in accordance with the Management Board Bonus Plan 2024+ (MBBP 2024+). The STI rewards the Management Board members for the Company's performance in the relevant fiscal year. The STI is linked to the achievement of three financial targets and one non-financial, sustainability-related performance target.

The STI target amount for the fiscal year 2025 (i.e., the amount paid out at a target achievement level of 100%) equaled 105% (multiplier of 1.05) of the relevant base salary of each Management Board member.

*Functioning*

The functioning of the MBBP 2024+ is shown in the following chart:

![Graphic](fms-20251231x20f019.jpg)

[**Table of Contents**](#TOC)

The STI is measured based on the achievement of four performance targets: 20% relate to revenue, 40% to operating income, 20% to net income and 20% to the achievement of a measurable sustainability target, which can also consist of various sub-targets. [ESRS 2, 29d]

The Supervisory Board defines for each performance target the specific target values that lead to a target achievement of 0% (lower threshold), 100% and 150% (cap). The Supervisory Board may also set additional target values leading to a target achievement of between 0% and 150%. The following applies to each performance target: If the lower threshold of a target value is not exceeded, the target achievement is 0%. If the upper target value is reached or exceeded, the target achievement is 150%. Target achievement in the range between two adjacent target values is generally determined by linear interpolation.

The STI is paid out in cash in the year following the year of target achievement.

*Link to strategy*

The financial performance targets (revenue, operating income, net income) reflect key operating figures of the Company and support Fresenius Medical Care's strategy of achieving sustainable and profitable growth. The non-financial, sustainability-related performance target underlines Fresenius Medical Care's commitment to implement its global sustainability targets.

The respective weightings of the individual performance targets for the STI and their link to Fresenius Medical Care's strategy are shown in the following chart:

![Graphic](fms-20251231x20f020.jpg)

*Financial performance targets*

The underlying financial figures of the financial performance targets for the STI are at constant currency. The financial figures may be adjusted for certain effects to ensure comparability of these financial figures with respect to the operational performance. This relates, e.g., to effects from certain acquisitions and divestments or effects from changes in IFRS accounting standards.

[**Table of Contents**](#TOC)

In order to promote collaboration across the operating segments and at the same time incentivize the Management Board members with respect to their individual responsibilities, some financial performance targets are measured at group level, whereas others are measured at the level of the area of responsibility of the individual Management Board member. The "net income" performance target for all Management Board members is measured at group level. The performance targets "revenue" and "operating income" are in general measured at group level. For the Management Board members with responsibility for the Care Delivery and Care Enablement operating segments, these performance targets are measured at the level of the segment for which such members are responsible. By measuring certain performance targets at group level as well as at the level of the operating segments, the financial performance of both the group and that of the relevant operating segments is reflected.

The determination of the target achievement for the performance targets "revenue" and "operating income" for the Care Delivery operating segment, for which Craig Cordola, EdD, is responsible, for the fiscal year also included the corresponding contributions from the Value-Based Care operating segment, which was formerly part of the Care Delivery operating segment. This is consistent with the financial reporting structure in place when the performance targets for Craig Cordola, EdD, were set and is in accordance with the target values and comparison parameters defined at that time. Further, this appropriately takes into account that Craig Cordola, EdD, throughout the entire fiscal year – both before and after Value-Based Care was established as a separate operating segment – significantly contributed to the success of the underlying business.

The target values applied to the financial performance targets in the fiscal year for the STI and the target achievement are set out in the table below:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Short-term incentive – Target values and target achievement in the fiscal year (financial performance targets)** | **Short-term incentive – Target values and target achievement in the fiscal year (financial performance targets)** | **Short-term incentive – Target values and target achievement in the fiscal year (financial performance targets)** | **Short-term incentive – Target values and target achievement in the fiscal year (financial performance targets)** | **Short-term incentive – Target values and target achievement in the fiscal year (financial performance targets)** | **Short-term incentive – Target values and target achievement in the fiscal year (financial performance targets)** | **Short-term incentive – Target values and target achievement in the fiscal year (financial performance targets)** | **Short-term incentive – Target values and target achievement in the fiscal year (financial performance targets)** | **Short-term incentive – Target values and target achievement in the fiscal year (financial performance targets)** |
|  | **Target values** <sup>(1)</sup> | **Target values** <sup>(1)</sup> | **Target values** <sup>(1)</sup> | **Target values** <sup>(1)</sup> | **Actual values** | **Actual values** | **Actual values** | **Target**<br>**achievement** |
|  |  |  |  |  |  | **Adjust-**  | **Adjusted for** |  |
|  | **0%** | **30%** | **100%** | **150%** | **As reported** | **ments** <sup>(2)</sup> | **target achievement** |  |
|  | in € M | in € M | in € M | in € M | in € M | in € M | in € M | in % |
| **Revenue** |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Group | ≤ 17,459 | = 18,429 | = 19,399 | ≥ 20,369 | 19628 | 294 | **19922** | **126.96** |
| &nbsp;&nbsp;Care Delivery (incl. Value-Based Care) | ≤ 13,630 | = 14,387 | = 15,145 | ≥ 15,902 | 15486<br> <sup>(3)</sup> | 231 | **15717** | **137.77** |
| &nbsp;&nbsp;Care Enablement | ≤ 4,996 | = 5,273 | = 5,551 | ≥ 5,829 | 5476 | 79 | **5555** | **100.69** |
| **Operating income** |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Group | ≤ 1,816 |  | = 2,136 | ≥ 2,457 | 1827 | 213 | **2040** | **69.80** |
| &nbsp;&nbsp;Care Delivery (incl. Value-Based Care) | ≤ 1,521 |  | = 1,789 | ≥ 2,057 | 1615<br> <sup>(3)</sup> | 178 | **1793** | **100.84** |
| &nbsp;&nbsp;Care Enablement | ≤ 366 |  | = 430 | ≥ 495 | 326 | 43 | **369** | **5.46** |
| **Net income** | ≤ 1,019 |  | = 1,199 | ≥ 1,379 | 978 | 137 | **1115** | **53.44** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) According to the plan terms, the financial figures underlying the target values had to be adjusted by effects resulting from strategic portfolio divestments. The target values shown here already include these adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;(2) According to the plan terms, the financial figures underlying the target achievement were translated at the exchange rates that were applied for the determination of the target values to ensure comparability. The relevant financial figures were adjusted according to the plan terms for one-time effects in connection with strategic portfolio divestments and, in addition, for the effects from one-time costs related to the FME25+ program, in each case to the extent such effects deviate from the respective effects included in the target values. This was done in the context of the expansion of the FME25+ program to ensure the comparability of the underlying financial figures of the performance targets for the variable compensation with the Company's operating performance, and adequately compensate the actual performance of the members of the Management Board.

&nbsp;&nbsp;&nbsp;&nbsp;(3) The amount set out herein represents the consolidated contributions of the Care Delivery and the Value-Based Care operating segments. The amount set out for revenue consists of €13,736 M revenue of the Care Delivery operating segment, €2,247 M revenue of the Value-Based Care operating segment and -€498 M from inter-segment eliminations. The amount set out for operating income consists of €1,614 M operating income of the Care Delivery operating income and €1 M operating income of the Value-Based Care operating segment.

*Sustainability target*

The sustainability target for the STI relates to strategic focus areas of the Group in the areas of Environment, Social and Governance (ESG). The sustainability target is defined by the Supervisory Board for each fiscal year and can consist of various sub-targets. The sustainability target is measured at group level for all Management Board members in order to ensure close collaboration among them in the context of the Company's sustainability efforts.

[**Table of Contents**](#TOC)

For the fiscal year, the Supervisory Board defined two equally weighted sub-targets as sustainability target for the STI: "Patient Satisfaction" and "Employee Satisfaction." Both sub-targets have already been used for the sustainability target for the fiscal years 2023 and 2024. These sub-targets are in line with the topics of quality of care and employee engagement relevant to the Group, which emerged from the most recent materiality analysis in 2023. To determine the target achievement, the values reported in Fresenius Medical Care's "Sustainability statement" for the fiscal year 2025 were used for each sub-target. [ESRS 2, 29b]

"Patient Satisfaction" was determined using the Net Promoter Score (NPS). The NPS is a strategically relevant measure of patient satisfaction with the Group's services, measured as the patient's likelihood to recommend Fresenius Medical Care to others for dialysis treatment. The NPS is determined based on patient surveys conducted as part of the Group's global Patient Experience Program. Fresenius Medical Care has set itself the corporate target of achieving an NPS value of at least 70 every year. For a target achievement for the sustainability sub-target "Patient Satisfaction" of 100%, an even more ambitious target value has been set for the fiscal year. The NPS is calculated in integers.

The target achievement for the sustainability sub-target "Patient Satisfaction" was 120.00%.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Short-term incentive – Sustainability sub-target Patient Satisfaction** | **Short-term incentive – Sustainability sub-target Patient Satisfaction** | **Short-term incentive – Sustainability sub-target Patient Satisfaction** | **Short-term incentive – Sustainability sub-target Patient Satisfaction** | **Short-term incentive – Sustainability sub-target Patient Satisfaction** | **Short-term incentive – Sustainability sub-target Patient Satisfaction** | **Short-term incentive – Sustainability sub-target Patient Satisfaction** | **Short-term incentive – Sustainability sub-target Patient Satisfaction** | **Short-term incentive – Sustainability sub-target Patient Satisfaction** | **Short-term incentive – Sustainability sub-target Patient Satisfaction** | **Short-term incentive – Sustainability sub-target Patient Satisfaction** |
|  | **Target values** | **Target values** | **Target values** | **Target values** | **Target values** | **Target values** | **Target values** | **Target values** | **Target achievement** | **Target achievement** |
|  | **0%** | **50%** | **100%** | **110%** | **120%** | **130%** | **140%** | **150%** | **Absolute** | **Relative** |
|  | in points | in points | in points | in points | in points | in points | in points | in points | in points | in % |
| **Net Promoter Score** | ≤ 61 | =66 | =71 | =72 | =73 | =74 | =75 | ≥ 76 | 73 | 120.00 |

---

The sustainability sub-target "Employee Satisfaction" is another strategically relevant indicator and was measured using the Global Employee Engagement Score (GEES). As part of a group-wide survey, Fresenius Medical Care evaluated employee feedback on positive aspects of the working environment as well as opportunities for improvement. Fresenius Medical Care determined the GEES by asking employees to indicate the extent to which they agree that they a) would recommend Fresenius Medical Care as a great place to work, b) rarely think about looking for a new job with another company, and c) are inspired by Fresenius Medical Care to do their best work. Employees responded on a scale from one (I strongly disagree) to five (I strongly agree). The GEES represents the "percent favorable" score, which is the percentage of responses across the three engagement questions that are either 4 ("agree") or 5 ("strongly agree"). The methodology for determining the GEES has been revised compared to previous years. The target values and scales have been adjusted compared to previous years accordingly.

The target achievement for the sustainability sub-target "Employee Satisfaction" was 110.00%.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Short-term incentive – Sustainability sub-target Employee Satisfaction** | **Short-term incentive – Sustainability sub-target Employee Satisfaction** | **Short-term incentive – Sustainability sub-target Employee Satisfaction** | **Short-term incentive – Sustainability sub-target Employee Satisfaction** | **Short-term incentive – Sustainability sub-target Employee Satisfaction** | **Short-term incentive – Sustainability sub-target Employee Satisfaction** | **Short-term incentive – Sustainability sub-target Employee Satisfaction** |
|  | **Target values** | **Target values** | **Target values** | **Target values** | **Target achievement** | **Target achievement** |
|  | **0%** | **50%** | **100%** | **150%** | **Absolute** | **Relative** |
|  | in % | in % | in % | in % | in % | in % |
| **Global Employee Engagement Score** | ≤ 55 | = 60 | = 65 | ≥ 70 | 66 | 110.00 |

---

The overall target achievement for the sustainability target was 115.00%. The target achievement for the sustainability target and the individual, equally weighted sustainability sub-targets are shown in the following table:

---

| | | |
|:---|:---|:---|
| **Short-term incentive – Sustainability target achievement in the fiscal year** | **Short-term incentive – Sustainability target achievement in the fiscal year** | **Short-term incentive – Sustainability target achievement in the fiscal year** |
| in % |  |  |
| **Target achievement per sustainability sub-target** | **Target achievement per sustainability sub-target** | **Sustainability target achievement** |
| **Patient Satisfaction (50%)** | **Employee Satisfaction (50%)** |  |
| 120.00 | 110.00 | 115.00 |

---

[**Table of Contents**](#TOC)

*Overall target achievement*

The degree of the overall target achievement for the STI is determined based on the weighted arithmetic mean of the target achievement level of each performance target. Multiplying the degree of the overall target achievement with the relevant target amount results in the amount to be paid out. Since the overall target achievement is capped at 150%, the payout amount is also capped at 150% of the relevant target amount.

The following table shows the target achievement per performance target as well as the overall target achievement for the fiscal year:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Short-term incentive – Overall target achievement in the fiscal year** | **Short-term incentive – Overall target achievement in the fiscal year** | **Short-term incentive – Overall target achievement in the fiscal year** | **Short-term incentive – Overall target achievement in the fiscal year** | **Short-term incentive – Overall target achievement in the fiscal year** | **Short-term incentive – Overall target achievement in the fiscal year** |
| in % |  |  |  |  | **Overall target** |
|  | **Target achievement (weighting)** | **Target achievement (weighting)** | **Target achievement (weighting)** | **Target achievement (weighting)** | **achievement** |
|  | **Revenue**  | **Operating income** | **Net income** | **Sustainability target** |  |
|  | **(20%)** | **(40%)** | **(20%)** | **(20%)** |  |
| Helen Giza | 126.96 | 69.80 | 53.44 | 115.00 | 87.00 |
| Craig Cordola, EdD | 137.77 | 100.84 | 53.44 | 115.00 | 101.58 |
| Martin Fischer | 126.96 | 69.80 | 53.44 | 115.00 | 87.00 |
| Dr. Jörg Häring | 126.96 | 69.80 | 53.44 | 115.00 | 87.00 |
| Franklin W. Maddux, MD | 126.96 | 69.80 | 53.44 | 115.00 | 87.00 |
| Dr. Katarzyna Mazur-Hofsäß | 100.69 | 5.46 | 53.44 | 115.00 | 56.01 |

---

The amounts to be paid out in 2026 based on the overall target achievement for the fiscal year 2025 can be found in the following table:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Short-term incentive – Amounts to be paid in 2026 for the performance in the fiscal year** | **Short-term incentive – Amounts to be paid in 2026 for the performance in the fiscal year** | **Short-term incentive – Amounts to be paid in 2026 for the performance in the fiscal year** | **Short-term incentive – Amounts to be paid in 2026 for the performance in the fiscal year** | **Short-term incentive – Amounts to be paid in 2026 for the performance in the fiscal year** | **Short-term incentive – Amounts to be paid in 2026 for the performance in the fiscal year** | **Short-term incentive – Amounts to be paid in 2026 for the performance in the fiscal year** |
| in € K |  |  |  |  |  |  |
|  |  |  |  |  | **Overall** |  |
|  |  |  |  |  | **target** |  |
|  |  |  | **Target** |  | **achievement** | **Payout** |
|  | **Base salary** | **Multiplier** | **amount** | **Cap (150%)** | **in %** | **amount** |
| Helen Giza <sup>(1)</sup> | 1593 | 1.05 | 1673 | 2510 | 87.00 | 1455 |
| Craig Cordola, EdD <sup>(1)</sup> | 1283 | 1.05 | 1347 | 2021 | 101.58 | 1369 |
| Martin Fischer | 800 | 1.05 | 840 | 1260 | 87.00 | 731 |
| Dr. Jörg Häring | 700 | 1.05 | 735 | 1103 | 87.00 | 639 |
| Franklin W. Maddux, MD <sup>(1)</sup> | 938 | 1.05 | 985 | 1478 | 87.00 | 857 |
| Dr. Katarzyna Mazur-Hofsäß | 1064 | 1.05 | 1117 | 1676 | 56.01 | 626 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The compensation benefits for Helen Giza, Craig Cordola, EdD, and Franklin W. Maddux, MD, are denominated in U.S. dollars. The amounts were therefore subject to currency fluctuations. The translation of U.S. dollar amounts was done at the average exchange rate for the applicable calendar year.

The corresponding information on the STI to be paid out in the fiscal year for the performance in the fiscal year 2024 was disclosed in the Compensation Report for the fiscal year 2024, a convenience translation of which was included in our Annual Report on Form 20-F for 2024.

***Long-term incentive – MB LTIP 2020***

Based on the Compensation System 2020+, Performance Shares were allocated in previous years to the Management Board members in office at the time under the MB LTIP 2020 as performance-based LTI compensation. In the fiscal year, the compensation from the Performance Shares allocated for 2022 was earned.

Performance Shares under the MB LTIP 2020 are virtual (i.e., not backed by equity), cash-settled compensation instruments. Any amounts to be received from the Performance Shares are subject to the achievement of three equally weighted performance targets and further depend on the development of the stock exchange price of the Company's shares. The performance period for the performance targets covers three fiscal years.

The allocation amount for the Performance Shares equaled 135% (multiplier of 1.35) of the relevant base salary of the respective Management Board member. To determine the number of Performance Shares to be allocated to the relevant Management Board member, the relevant allocation amount was divided by the value per Performance Share determined in accordance with IFRS 2 and considering the average price of the Company's shares over a period of 30 calendar days prior to each relevant allocation date. The number of Performance Shares to vest for each Management Board member depended on the achievement of the performance targets.

[**Table of Contents**](#TOC)

*Functioning*

The functioning of the MB LTIP 2020 is shown in the following chart:

![Graphic](fms-20251231x20f021.jpg)

The Supervisory Board defined for each performance target the specific target values that lead to a target achievement of 0% (lower threshold), 100% and 200% (cap). The following applies to each performance target: If the lower target value is not exceeded, a target achievement of 0% applies. If the upper target value is reached or exceeded, a target achievement of 200% applies. Target achievement in the range between two adjacent target values is determined by linear interpolation. At the end of the three-year performance period, the Supervisory Board determines the overall target achievement by taking the average of the target achievement levels for the three performance targets in the applicable three-year performance period. The three performance targets are equally weighted.

Based on the degree of the overall target achievement, the number of Performance Shares to vest is determined for each Management Board member. The number of Performance Shares may increase or decrease over the performance period. A total loss as well as (at most) doubling of the allocated Performance Shares in case of a target achievement of 200% (cap) is possible. After the determination of the overall target achievement, the number of Performance Shares to vest is multiplied by the average price of the Company's shares over the 30 calendar days preceding the relevant vesting date to calculate the corresponding amount received from the Performance Shares to vest. The total proceeds from the Performance Shares (i.e., the amount that can be earned under an allocation) are capped at 400% of the relevant allocation amount.

The proceeds from the Performance Shares (after taxes and duties) are transferred to a bank, which uses them to purchase shares of the Company on the stock exchange. The shares acquired in this way are subject to a holding period of at least one year. In accordance with recommendation G.10 of the GCGC, the Management Board members can therefore only dispose of the LTI after a period of at least four years.

*Link to strategy*

The three performance targets revenue growth, net income growth and return on invested capital (ROIC) were selected because they provide effective incentives that the Company's investments achieve a certain return, thereby supporting long-term, profitable growth and an attractive total return for shareholders. These performance targets form part of the Company's primary key performance indicators or secondary financial performance indicators and support the execution of the Company's long-term strategy.

[**Table of Contents**](#TOC)

The respective weightings of the individual performance targets for the LTI and their link to Fresenius Medical Care's strategy are shown in the following chart:

![Graphic](fms-20251231x20f022.jpg)

*Target values and target achievement (Allocation 2022)*

In the fiscal year 2025, the LTI from the allocation for 2022 was earned. The performance period from 2022 to 2024 was determinative for target achievement. The target values for the performance targets and the target achievement are shown in the following table:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Target values and target achievement for the Allocation 2022 under the MB LTIP 2020** | **Target values and target achievement for the Allocation 2022 under the MB LTIP 2020** | **Target values and target achievement for the Allocation 2022 under the MB LTIP 2020** | **Target values and target achievement for the Allocation 2022 under the MB LTIP 2020** | **Target values and target achievement for the Allocation 2022 under the MB LTIP 2020** | **Target values and target achievement for the Allocation 2022 under the MB LTIP 2020** | **Target values and target achievement for the Allocation 2022 under the MB LTIP 2020** | **Target values and target achievement for the Allocation 2022 under the MB LTIP 2020** | **Target values and target achievement for the Allocation 2022 under the MB LTIP 2020** | **Target values and target achievement for the Allocation 2022 under the MB LTIP 2020** | **Target values and target achievement for the Allocation 2022 under the MB LTIP 2020** |
|  |  | **Target values** | **Target values** | **Target values** | **Actual values** | **Actual values** | **Actual values** | **Actual values** | **Actual values** | **Target achievement** |
|  |  |  |  |  |  | **Currency** | **At Constant** |  |  |  |
|  |  |  |  |  |  | **translation** | **Currency according** |  |  |  |
|  |  | **0%** | **100%** | **200%** | **As reported** <sup>(1)</sup> | **adjustment** | **to plan terms** |  | **CAGR** |  |
| **Revenue growth** | **Revenue growth** |  |  |  |  |  |  |  |  |  |
| 2022 | } |  |  |  | 10.1% | (8.0)% | 2.1% | } |  |  |
| 2023 | } | ≤ 2% | = 5% | ≥ 8% | 0.3% | 5.2% | 5.5% | } | **2.5%**  | **17%** |
| 2024 | } |  |  |  | (0.6)%  | 0.6%  | 0.0%  | } |  |  |
| **Net income growth** | **Net income growth** |  |  |  |  |  |  |  |  |  |
| 2022 | } |  |  |  | (30.5)% | (6.1)% | (36.6)% | } |  |  |
| 2023 | } | ≤ 10% | = 17% | ≥ 20% | (25.9)% | 1.6% | (24.3)% | } | **(19.3)%**  | **0%** |
| 2024 | } |  |  |  | 7.8%  | 1.6%  | 9.4%  | } |  |  |
| **Return on invested capital (ROIC)** | **Return on invested capital (ROIC)** |  |  |  |  |  |  |  |  |  |
| 2022 | } |  |  |  | 3.3% | —% | **3.3%**  |  |  | **0%** |
| 2023 | } | ≤ 5.5% | = 6.0% | ≥ 6.5% | 2.8% | —% | **2.8%**  |  |  | **0%** |
| 2024 | } |  |  |  | 3.5%  | —%  | **3.5%**  |  |  | **0%** |
| **Overall target achievement** | **Overall target achievement** |  |  |  |  |  |  |  |  | **6%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) ROIC is a Non-IFRS measure. For a description of ROIC and how the measure is calculated, see Item 5, "Operating and financial review and prospects," above.

[**Table of Contents**](#TOC)

*Vested amounts (Allocation 2022)*

The following table shows the amounts that vested in the fiscal year 2025 from the allocation for 2022 and were awarded within the meaning of Section 162(1), first sentence AktG:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Long-term incentive – Vested amount from the Allocation 2022 of the MB LTIP 2020** | **Long-term incentive – Vested amount from the Allocation 2022 of the MB LTIP 2020** | **Long-term incentive – Vested amount from the Allocation 2022 of the MB LTIP 2020** | **Long-term incentive – Vested amount from the Allocation 2022 of the MB LTIP 2020** | **Long-term incentive – Vested amount from the Allocation 2022 of the MB LTIP 2020** | **Long-term incentive – Vested amount from the Allocation 2022 of the MB LTIP 2020** | **Long-term incentive – Vested amount from the Allocation 2022 of the MB LTIP 2020** |
|  | <br>**Fair Value at** <br>**allocation** | **Number of** <br>**allocated** <br>**Performance** <br>**Shares** | <br>**Overall target** <br>**achievement** | <br>**Number of final** <br>**Performance** <br>**Shares** | <br>**Share price at** <br>**vesting** | <br>**Vested amount** |
|  | in € K |  | in % |  | in € | in € K |
| **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** |  |  |  |  |
| Helen Giza <sup>(1)</sup> | 1688 | 32279 | 6 | 1936 | 46.04 | **97** |
| Franklin W. Maddux, MD <sup>(1)</sup> | 1110 | 20974 | 6 | 1258 | 46.04 | **63** |
| Dr. Katarzyna Mazur-Hofsäß | 1359 | 26074 | 6 | 1564 | 46.04 | **72** |
| **Former members of the Management Board** |  |  |  |  |  |  |
| Rice Powell <sup>(1)</sup> | 2425 | 45841 | 6 | 2750 | 46.04 | **138** |
| William Valle <sup>(1)</sup> | 1888 | 35678 | 6 | 2141 | 46.04 | **107** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The compensation benefits for Helen Giza, Franklin W. Maddux, MD, Rice Powell and William Valle are denominated in U.S. dollars. The amounts concerned were therefore subject to currency fluctuations. The translation of vested U.S. dollar amounts was done at the closing rate of the vesting date.

The amounts that vested in the fiscal year 2025 (after taxes and duties) were not paid out but in accordance with the plan terms transferred to a bank, which used them to purchase shares of the Company on the stock exchange. The shares acquired in this way are subject to a holding period of at least one year.

***Compliance with maximum compensation (Allocations 2022)***

In the fiscal year, compliance with the maximum compensation from allocations from 2022 could be conclusively assessed since the vesting period for the LTI allocated in 2022 under the MB LTIP 2020 ended and the amount earned in this respect was determined. The individual maximum compensation limits for the respective Management Board members for 2022 were in each case complied with. No reduction of the LTI payout amount was necessary (as provided for to avoid exceeding the maximum compensation if necessary). The details are shown in the following table:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Compliance with the maximum compensation of the members of the Management Board then in office for 2022** | **Compliance with the maximum compensation of the members of the Management Board then in office for 2022** | **Compliance with the maximum compensation of the members of the Management Board then in office for 2022** | **Compliance with the maximum compensation of the members of the Management Board then in office for 2022** | **Compliance with the maximum compensation of the members of the Management Board then in office for 2022** | **Compliance with the maximum compensation of the members of the Management Board then in office for 2022** | **Compliance with the maximum compensation of the members of the Management Board then in office for 2022** | **Compliance with the maximum compensation of the members of the Management Board then in office for 2022** | **Compliance with the maximum compensation of the members of the Management Board then in office for 2022** |
| in € K | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** |
|  | **Helen Giza** |  | **Franklin W. Maddux, MD** <sup>(1)</sup> |  | **Dr. Katarzyna Mazur-Hofsäß** | **Dr. Carla Kriwet** | **Rice Powell** <sup>(1)</sup> | **William Valle** <sup>(1)</sup> |
| &nbsp;&nbsp;Base salary | 1302 |  | 866 |  | 1064 | 2250<br> <sup>(6)</sup> | 1894 | 1474 |
| &nbsp;&nbsp;Fringe benefits | 39 |  | 164 |  | 57 | 1044<br> <sup>(6)</sup> | 203 | 267 |
| &nbsp;&nbsp;Pension expense | 1245 | <sup>(2)</sup> | 961 | <sup>(4)</sup> | 808<br> <sup>(5)</sup> |  |  | 1469<br> <sup>(8)</sup> |
| Total fixed components | 2586 |  | 1991 |  | 1929 | 3294 | 2097 | 3210 |
| &nbsp;&nbsp;Short-term incentive | 510 |  | 339 |  | 416 | 176 | 741 | 577 |
| &nbsp;&nbsp;Long-term incentive (MB LTIP 2020) | 90 |  | 59 |  | 72 |  | 128 | 100 |
| Total variable components | 600 |  | 398 |  | 488 | 176 | 869 | 677 |
| **Total compensation for 2022** | **3186** |  | **2389** |  | **2417** | **3470** | **2966** | **3887** |
| *Cap short-term incentive* | *1641* |  | *1091* |  | *1341* | *567* | *2386* | *1857* |
| *Cap long-term incentive* | *7031* |  | *4676* |  | *5746* | *2430* | *10228* | *7960* |
| ***Maximum compensation*** |  ***12000*** | <sup>(3)</sup> |  ***7000*** |  |  ***7000*** |  ***12000*** |  ***10750***<br> <sup>(7)</sup> |  ***9500*** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The maximum compensation of Franklin W. Maddux, MD, Rice Powell and William Valle for 2022 is denominated in U.S. dollars. For the presentation in this table, the U.S. dollar amounts were translated with the exchange rate of €1/$1.11947 used when the maximum compensation in the Compensation System 2020+ was determined. The amounts set out herein may therefore deviate from the amounts set out in other tables of this Compensation Report or in tables of previous Compensation Reports.

[**Table of Contents**](#TOC)

&nbsp;&nbsp;&nbsp;&nbsp;(2) The pension expense set out herein for 2022 relates to the pension commitment granted in 2022 and includes the past service cost which relates to the service period rendered since the appointment as a Management Board member effective October 1, 2019. The pension commitment was cancelled in the fiscal year 2025 (see the section "Cash pension allowance instead of defined contribution pension commitments").

&nbsp;&nbsp;&nbsp;&nbsp;(3) Helen Giza has been Chair since December 6, 2022. Therefore, the maximum compensation amount applicable to the Chairperson applies to Helen Giza's maximum compensation for 2022.

&nbsp;&nbsp;&nbsp;&nbsp;(4) The pension expense set out herein for 2022 relates to the pension commitment granted in 2022 and includes the past service cost which relates to the service period rendered since the appointment as a Management Board member effective January 1, 2020. The pension commitment was cancelled in the fiscal year 2025 (see the section "Cash pension allowance instead of defined contribution pension commitments").

&nbsp;&nbsp;&nbsp;&nbsp;(5) Dr. Katarzyna Mazur-Hofsäß was Chief Executive Officer for the Europe, Middle East and Africa region until December 31, 2021. The base salary was increased in 2022 with a view to Dr. Katarzyna Mazur-Hofsäß' new responsibilities as Chief Executive Officer for Care Enablement. The pension expense set out herein includes the past service cost recognized in 2022 to account for the salary adjustment.

&nbsp;&nbsp;&nbsp;&nbsp;(6) Dr. Carla Kriwet was Chair from October 1, 2022, until December 5, 2022. The base salary set out herein includes a severance payment in connection with Dr. Carla Kriwet's departure from the Management Board in the amount of €1,800 K; the fringe benefits include an inaugural bonus in the amount of €100 K as well as payments for forfeited benefits from a previous service relationship in the amount of €885 K.

&nbsp;&nbsp;&nbsp;&nbsp;(7) Rice Powell was a member of the Management Board until December 31, 2022, and until September 30, 2022, also its Chair. The maximum compensation amount agreed with Rice Powell for 2022 reflects these responsibilities on a pro-rated basis.

&nbsp;&nbsp;&nbsp;&nbsp;(8) William Valle was Chief Executive Officer for the North America region until December 31, 2021. The base salary was increased in 2022 with a view to William Valle's new responsibilities as Chief Executive Officer for Care Delivery. The pension expense set out herein includes the past service cost recognized in 2022 to account for the salary adjustment.

***Compensation tables for the Management Board members in office in the fiscal year***

The following tables show the individualized compensation awarded or due in the fiscal year to each Management Board member in office in the fiscal year. In addition, the pension expense incurred for pension commitments is disclosed.

For the purposes of the following tables, compensation is deemed to have been awarded in the fiscal year if it has vested in the fiscal year. For this purpose, compensation is deemed to have vested in the year in which the underlying activity has been fully performed and the entitlement to payment of the compensation is no longer subject to any conditions precedent or conditions subsequent. For the LTI, this corresponds to the year in which the compensation is paid out. The LTI earned under the MB LTIP 2020 is to be regarded as awarded irrespective of the fact that the amounts earned are to be invested in shares of the Company to be acquired on the stock exchange in accordance with the applicable plan terms.

Based on this understanding, the STI is considered to have vested in the year and is shown in the following tables for the respective years, in which the underlying activity was performed. This facilitates comparison of the Management Board members' performance with the Company's performance in the same year and allows the STI to be allocated on an accrual basis to the year in which the performance was achieved. The columns for 2025 therefore contain the STI for the fiscal year 2025, which will be paid out in 2026, and the columns for 2024 contain the STI for 2024, which was paid out in the fiscal year 2025.

Compensation for forfeited compensation benefits from a previous employment relationship is reported under fringe benefits. The respective amount to be paid was determined taking into account the estimated value of the forfeited compensation benefits at the time of termination of the previous employment relationship. The amount to be paid does not exceed the market value of the forfeited compensation benefit determined at the time and is also limited to an amount that is less than the amount that the Management Board member would have received under the previous employment relationship in case of a 100% target achievement. Such payments were or are only made if the Management Board member has not resigned from office and the Company has not terminated such member's service agreement and would not be entitled to terminate it when the payment becomes due.

[**Table of Contents**](#TOC)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** |
| in € K |  |  |  |  |  |  |  |  |
|  | **Helen Giza** | **Helen Giza** | **Helen Giza** | **Helen Giza** | **Craig Cordola, EdD** | **Craig Cordola, EdD** | **Craig Cordola, EdD** | **Craig Cordola, EdD** |
|  | Chief Executive Officer and Chair of the Management Board | Chief Executive Officer and Chair of the Management Board | Chief Executive Officer and Chair of the Management Board | Chief Executive Officer and Chair of the Management Board | Chief Executive Officer for Care Delivery | Chief Executive Officer for Care Delivery | Chief Executive Officer for Care Delivery | Chief Executive Officer for Care Delivery |
|  | Management Board member since November 1, 2019 | Management Board member since November 1, 2019 | Management Board member since November 1, 2019 | Management Board member since November 1, 2019 | Management Board member since January 1, 2024 | Management Board member since January 1, 2024 | Management Board member since January 1, 2024 | Management Board member since January 1, 2024 |
|  | **2025** | **2025** | **2024** <sup>(1)</sup> | **2024** <sup>(1)</sup> | **2025** | **2025** | **2024** <sup>(1)</sup> | **2024** <sup>(1)</sup> |
|  | Absolute | Ratio in % | Absolute | Ratio in % | Absolute | Ratio in % | Absolute | Ratio in % |
| &nbsp;&nbsp;&nbsp;&nbsp;Base salary | 1593 |  | 1663 |  | 1283 |  | 1340 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Fringe benefits | 76 |  | 80 |  | 82 |  | 447<br> <sup>(3)</sup> |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash pension allowance | 3236<br> <sup>(2)</sup> |  |  |  | 513 |  | 536 |  |
| &nbsp;&nbsp;Total non-performance-based compensation | 4905 | 76 | 1743 | 47 | 1878 | 58 | 2323 | 62 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term incentive | 1455 | 23 | 1844 | 50 | 1369 | 42 | 1395 | 38 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term incentive | 97 | 2 | 121 | 3 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allocation 2021 (MB LTIP 2020) |  |  | 121 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allocation 2022 (MB LTIP 2020) | 97 |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total variable compensation | 1552 |  | 1965 |  | 1369 |  | 1395 |  |
| &nbsp;&nbsp;Total compensation according to Section 162 (1) sent. 2 No. 1 AktG | 6457 |  | 3708 |  | 3247 |  | 3718 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension expense |  |  | 729 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cancellation of pension commitment | (2599)<br> <sup>(2)</sup> |  |  |  |  |  |  |  |
| **Total compensation including pension commitment** | **3858** |  | **4437** |  | **3247** |  | **3718** |  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Martin Fischer** | **Martin Fischer** | **Martin Fischer** | **Martin Fischer** | **Dr. Jörg Häring** | **Dr. Jörg Häring** | **Dr. Jörg Häring** | **Dr. Jörg Häring** |
|  | Chief Financial Officer | Chief Financial Officer | Chief Financial Officer | Chief Financial Officer | Legal, Compliance and Human Resources | Legal, Compliance and Human Resources | Legal, Compliance and Human Resources | Legal, Compliance and Human Resources |
|  | Management Board member since October 1, 2023 | Management Board member since October 1, 2023 | Management Board member since October 1, 2023 | Management Board member since October 1, 2023 | Management Board member since June 1, 2024 | Management Board member since June 1, 2024 | Management Board member since June 1, 2024 | Management Board member since June 1, 2024 |
|  | **2025** | **2025** | **2024** <sup>(1)</sup> | **2024** <sup>(1)</sup> | **2025** | **2025** | **2024** <sup>(1)</sup> | **2024** <sup>(1)</sup> |
|  | Absolute | Ratio in % | Absolute | Ratio in % | Absolute | Ratio in % | Absolute | Ratio in % |
| &nbsp;&nbsp;&nbsp;&nbsp;Base salary | 800 |  | 800 |  | 700 |  | 408 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Fringe benefits | 329<br><sup>(4)</sup> |  | 437<br><sup>(4)</sup> |  | 30 |  | 354<br><sup>(6)</sup> |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash pension allowance | 320 |  | 400<br><sup>(5)</sup> |  | 280 |  | 163 |  |
| &nbsp;&nbsp;Total non-performance-based compensation | 1449 | 66 | 1637 | 65 | 1010 | 61 | 925 | 67 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term incentive | 731 | 34 | 887 | 35 | 639 | 39 | 453 | 33 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term incentive |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allocation 2021 (MB LTIP 2020) |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allocation 2022 (MB LTIP 2020) |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total variable compensation | 731 |  | 887 |  | 639 |  | 453 |  |
| &nbsp;&nbsp;Total compensation according to Section 162(1) sent. 2 No. 1 AktG | 2180 |  | 2524 |  | 1649 |  | 1378 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension expense |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cancellation of pension commitment |  |  |  |  |  |  |  |  |
| **Total compensation including pension commitment** | **2180** |  | **2524** |  | **1649** |  | **1378** |  |

---

[**Table of Contents**](#TOC)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** | **Compensation of the members of the Management Board in office in the fiscal year** |
|  | **Franklin W. Maddux, MD** | **Franklin W. Maddux, MD** | **Franklin W. Maddux, MD** | **Franklin W. Maddux, MD** | **Dr. Katarzyna Mazur-Hofsäß** | **Dr. Katarzyna Mazur-Hofsäß** | **Dr. Katarzyna Mazur-Hofsäß** | **Dr. Katarzyna Mazur-Hofsäß** |
|  | Global Chief Medical Officer | Global Chief Medical Officer | Global Chief Medical Officer | Global Chief Medical Officer | Chief Executive Officer for Care Enablement | Chief Executive Officer for Care Enablement | Chief Executive Officer for Care Enablement | Chief Executive Officer for Care Enablement |
|  | Management Board member since January 1, 2020 | Management Board member since January 1, 2020 | Management Board member since January 1, 2020 | Management Board member since January 1, 2020 | Management Board member since September 1, 2018 | Management Board member since September 1, 2018 | Management Board member since September 1, 2018 | Management Board member since September 1, 2018 |
|  | **2025** | **2025** | **2024** <sup>(1)</sup> | **2024** <sup>(1)</sup> | **2025** | **2025** | **2024** <sup>(1)</sup> | **2024** <sup>(1)</sup> |
|  | Absolute | Ratio in % | Absolute | Ratio in % | Absolute | Ratio in % | Absolute | Ratio in % |
| &nbsp;&nbsp;&nbsp;&nbsp;Base salary | 938 |  | 979 |  | 1064 |  | 1064 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Fringe benefits | 156 |  | 187 |  | 73 |  | 57 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash pension allowance | 2151<br><sup>(2)</sup> |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Total non-performance-based compensation | 3245 | 78 | 1166 | 49 | 1137 | 62 | 1121 | 42 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term incentive | 857 | 21 | 1086 | 46 | 626 | 34 | 1429 | 54 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term incentive | 63 | 2 | 107 | 5 | 72 | 4 | 116 | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allocation 2021 (MB LTIP 2020) |  |  | 107 |  |  |  | 116 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allocation 2022 (MB LTIP 2020) | 63 |  |  |  | 72 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total variable compensation | 920 |  | 1193 |  | 698 |  | 1545 |  |
| &nbsp;&nbsp;Total compensation according to Section 162 (1) sent. 2 No. 1 AktG | 4165 |  | 2359 |  | 1835 |  | 2666 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension expense |  |  | 397 |  | 621 |  | 611 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cancellation of pension commitment | (1776)<br><sup>(2)</sup> |  |  |  |  |  |  |  |
| **Total compensation including pension commitment** | **2389** |  | **2756** |  | **2456** |  | **3277** |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Note for purposes of comparison between the amounts indicated for the fiscal year 2024 and those of the fiscal year 2025 that the compensation is subject to foreign exchange rate fluctuations depending on whether it is contractually denominated in euros (Martin Fischer, Dr. Jörg Häring and Dr. Katarzyna Mazur-Hofsäß) or U.S. dollars (Helen Giza, Craig Cordola, EdD, and Franklin W. Maddux, MD). In general, the translation of U.S. dollar amounts was done at the average exchange rate for the applicable calendar year. For the long-term incentive the translation of U.S. dollar amounts was done at the closing rate of the applicable vesting date.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The previously existing pension commitment was retroactively cancelled in the fiscal year 2025. The amount paid for the financing of the pension commitment for the period since the appointment as a Management Board member was reimbursed to the Company in the amount of the surrender value, less transaction costs. The amount reported in previous years as "Pension expense," which corresponds to the insurance contributions paid by the Company at that time, is reported in the line "Cancellation of pension commitment" with the cumulative amount for previous years with a negative sign. The line "Cash pension allowance" includes both the amounts that were payable on a pro rata temporis basis as cash pension allowance amounting to 40% of the base salary in the fiscal year 2025 since the cancellation of the pension commitment took effect, and the amount that was payable in the fiscal year 2025 in implementation of the agreed cancellation of the pension commitment (i.e., the sum of the insurance contributions that were paid until the cancellation of the pension commitment took effect).

&nbsp;&nbsp;&nbsp;&nbsp;(3) The fringe benefits of Craig Cordola, EdD, for the fiscal year 2024 include a payment of $450 K (€416 K), which he received as compensation for forfeited compensation benefits from a previous employment relationship. As agreed, Craig Cordola, EdD, invested 50% of the net amount of this compensation in shares of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Martin Fischer's fringe benefits for the fiscal year 2024 and for the last time for the fiscal year 2025 each include a payment of €300 K, which he received as compensation for forfeited compensation benefits from a previous employment relationship.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Since October 1, 2024, Martin Fischer has received the pension allowance described in this Compensation Report. The defined contribution pension commitment previously promised to Martin Fischer in the event of the conclusion of a corresponding reinsurance policy was canceled in view of the new pension regulations under the Compensation System 2024+. The amount reported for the fiscal year 2024 includes an amount of €320 K (corresponding to 40% of his annual base salary), which Martin Fischer received in 2024 as compensation for the insurance contributions that would otherwise have to be paid for the period from October 1, 2023, to September 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;(6) Dr. Jörg Häring's fringe benefits for the fiscal year 2024 include a payment of €300 K, which he received as compensation for forfeited compensation benefits from a previous employment relationship.

**Outstanding share-based compensation components**

The following information concerns outstanding share-based compensation components. These relate solely to allocations of Performance Shares under the MB LTIP 2020 and the Management Board Long-Term Incentive Plan 2024+ (MB LTIP 2024+).

[**Table of Contents**](#TOC)

***MB LTIP 2024+ (Allocation in the fiscal year)***

In the fiscal year 2025, the Management Board members were allocated Performance Shares under the MB LTIP 2024+ as LTI compensation under the Compensation System 2024+.

Any amounts to be received from the Performance Shares are subject to the achievement of three performance targets and further depend on the development of the stock exchange price of the Company's shares. The performance period for the performance targets covers three fiscal years, the vesting period four years from the date of allocation.

Based on the degree of the overall target achievement, the number of Performance Shares to vest is determined for each Management Board member. The number of Performance Shares may increase or decrease over the performance period. A total loss as well as (at most) doubling of the allocated Performance Shares in case of a target achievement of 200% (cap) is possible. After the determination of the overall target achievement, the number of Performance Shares to vest is multiplied by the average price of the Company's shares over the 30 calendar days preceding the relevant vesting date in order to calculate the corresponding amount received from the Performance Shares to vest. The total proceeds from the Performance Shares (i.e., the amount that can be earned under an allocation) are capped at 400% of the relevant allocation amount.

The functioning of the MB LTIP 2024+ is shown in the following chart: [ESRS 2, 29a, d]

![Graphic](fms-20251231x20f023.jpg)

[**Table of Contents**](#TOC)

As in previous years, return on invested capital (ROIC) has been set as the profitability target.

Total shareholder return (TSR) compared to competitors (Relative TSR) is used as capital market target under the Compensation System 2024+. The capital markets target addresses investor-specific requirements for the inclusion of a relative performance measurement in comparison to relevant competitors and ties the compensation of the Management Board to the Company's long-term capital market performance. The target achievement of the Relative TSR is determined based on the percentile ranking of the Company's TSR performance in comparison to the TSR performance of companies in one or more comparison groups determined by the Supervisory Board. In general, STOXX® Europe 600 Health Care and S&P 500 Health Care indices are determined as comparison groups.

As in the previous year, the reduction in market-based CO<sub>2</sub> equivalents (CO<sub>2</sub>e) emissions has been set as the sustainability target. This target is in line with the topic of climate protection relevant to the Group, which emerged from the most recent materiality analysis in 2023. Sustainability is an essential and integral part of the Fresenius Medical Care's corporate strategy. Considering non-financial, sustainability-related objectives in the areas of Environment, Social and Governance (ESG) in the context of the LTI is derived from the Company's commitment toward maintaining a responsible corporate culture, meets investor-specific and social requirements, and also promotes the Group's long-term, sustainable development. [ESRS 2, 29b]

Information on the target values and the respective performance target achievement will be disclosed after the end of the performance period in the Compensation Report for the relevant fiscal year.

Compensation claims arising from Performance Shares under the MB LTIP 2024+ may be paid in cash or settled in shares of the Company. The Supervisory Board has decided that the compensation claims arising from the Performance Shares allocated for the fiscal year 2025 shall be settled in shares of the Company after vesting.

The allocation amount for the Performance Shares equals 135% (multiplier of 1.35) of the relevant base salary of the respective Management Board member. The number of Performance Shares allocated for the fiscal year is shown in the following table:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Performance Shares allocated in the fiscal year under the MB LTIP 2024+** | **Performance Shares allocated in the fiscal year under the MB LTIP 2024+** | **Performance Shares allocated in the fiscal year under the MB LTIP 2024+** | **Performance Shares allocated in the fiscal year under the MB LTIP 2024+** | **Performance Shares allocated in the fiscal year under the MB LTIP 2024+** | **Performance Shares allocated in the fiscal year under the MB LTIP 2024+** | **Performance Shares allocated in the fiscal year under the MB LTIP 2024+** |
|  | <br>**Base salary** | <br>**Multiplier** | <br>**Allocation amount** | **Value per** <br>**Performance**<br>**Share**<br>**at allocation** <sup>(1)</sup> | <br>**Number of** <br>**Performance** <br>**Shares** | <br>**Cap (400%)** |
|  | in € K |  | in € K | in € |  | in € K |
| Helen Giza <sup>(2)</sup> | 1593 | 1.35 | 2151 | 39.20 | 59543 | 8604 |
| Craig Cordola, EdD <sup>(2)</sup> | 1283 | 1.35 | 1732 | 39.20 | 47965 | 6928 |
| Martin Fischer | 800 | 1.35 | 1080 | 39.20 | 27551 | 4320 |
| Dr. Jörg Häring  | 700 | 1.35 | 945 | 39.20 | 24107 | 3780 |
| Franklin W. Maddux, MD <sup>(2), (3)</sup> | 938 | 1.35 | 1266 | 39.20 | 35064 | 5064 |
| Dr. Katarzyna Mazur-Hofsäß <sup>(4)</sup> | 1064 | 1.35 | 1436 | 39.20 | 36643 | 5744 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The value per Performance Share as set out herein and relevant for the number of Performance Shares to be allocated is determined according to the plan terms considering the average price of the Company's shares over a period of 30 calendar days prior to the allocation date and assuming a 100% target achievement for the performance target "Relative TSR", which is why it may deviate from the Fair Value according to IFRS 2.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The compensation benefits for Helen Giza, Craig Cordola, EdD, and Franklin W. Maddux, MD, are denominated in U.S. dollars. The amounts concerned are therefore subject to currency fluctuations. The translation of U.S. dollar amounts was done at the average exchange rate for the applicable calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;(3) The Performance Shares allocated to Franklin W. Maddux, MD, can be earned in accordance with the plan conditions of the MB LTIP 2024+ also after termination of his service agreement at the end of the fiscal year. Further information on the agreements made with Franklin W. Maddux, MD, can be found in the section "Agreements with members of the Management Board who resigned from office at the end of the fiscal year."

&nbsp;&nbsp;&nbsp;&nbsp;(4) The Performance Shares allocated to Dr. Katarzyna Mazur-Hofsäß forfeited in accordance with the plan conditions of the MB LTIP 2024+ upon termination of her service agreement at the end of the fiscal year. Further information on the agreements made with Dr. Katarzyna Mazur-Hofsäß can be found in the section "Agreements with members of the Management Board who resigned from office at the end of the fiscal year."

[**Table of Contents**](#TOC)

***Overview of outstanding share-based compensation components***

The status of the outstanding Performance Shares of the current and former Management Board members as of the end of the fiscal year and further information on this are shown in the following table:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Overview of outstanding Performance Shares allocated under the MB LTIP 2020 and under the MB LTIP 2024+** | **Overview of outstanding Performance Shares allocated under the MB LTIP 2020 and under the MB LTIP 2024+** | **Overview of outstanding Performance Shares allocated under the MB LTIP 2020 and under the MB LTIP 2024+** | **Overview of outstanding Performance Shares allocated under the MB LTIP 2020 and under the MB LTIP 2024+** | **Overview of outstanding Performance Shares allocated under the MB LTIP 2020 and under the MB LTIP 2024+** | **Overview of outstanding Performance Shares allocated under the MB LTIP 2020 and under the MB LTIP 2024+** | **Overview of outstanding Performance Shares allocated under the MB LTIP 2020 and under the MB LTIP 2024+** |
|  |  |  |  |  |  | **Number of** |
|  |  |  |  | **Number of** |  | **Performance** |
|  |  |  |  | **allocated** | **Overall target** | **Shares as of** |
|  |  |  | **Fair Value at** | **Performance** | **achievement** | **December 31,** |
|  | **Allocation date** | **Vesting date** | **allocation** <sup>(1)</sup> | **Shares** | **(if final)** | **2025** |
|  |  |  | in € K |  | in % |  |
| **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** |
| Helen Giza |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Allocation 2023 | March 1, 2023 | March 1, 2026 | 2177 | 67568 | 34 | 22973 |
| &nbsp;&nbsp;&nbsp;Allocation 2024 | March 1, 2024 | March 1, 2028 | 2182 | 71358 |  | 71358 |
| &nbsp;&nbsp;&nbsp;Allocation 2025 | March 1, 2025 | March 1, 2029 | 2152 | 59543 |  | 59543 |
| &nbsp;&nbsp;&nbsp;**Total** |  |  |  | **198469** |  | **153874** |
| Craig Cordola, EdD |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Allocation 2024 | March 1, 2024 | March 1, 2028 | 1758 | 57483 |  | 57483 |
| &nbsp;&nbsp;&nbsp;Allocation 2025 | March 1, 2025 | March 1, 2029 | 1733 | 47965 |  | 47965 |
| &nbsp;&nbsp;&nbsp;**Total** |  |  |  | **105448** |  | **105448** |
| Martin Fischer |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Allocation 2023 | October 1, 2023 | October 1, 2026 | 264 | 7037 | 34 | 2393 |
| &nbsp;&nbsp;&nbsp;Allocation 2024 | March 1, 2024 | March 1, 2028 | 1049 | 34242 |  | 34242 |
| &nbsp;&nbsp;&nbsp;Allocation 2025 | March 1, 2025 | March 1, 2029 | 1035 | 27551 |  | 27551 |
| &nbsp;&nbsp;&nbsp;**Total** |  |  |  | **68830** |  | **64186** |
| Dr. Jörg Häring |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Allocation 2024 | June 1, 2024 | June 1, 2028 | 546 | 15850 |  | 15850 |
| &nbsp;&nbsp;&nbsp;Allocation 2025 | March 1, 2025 | March 1, 2029 | 906 | 24107 |  | 24107 |
| &nbsp;&nbsp;&nbsp;**Total** |  |  |  | **39957** |  | **39957** |
| Franklin W. Maddux, MD <sup>(2)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Allocation 2023 | March 1, 2023 | March 1, 2026 | 1282 | 39790 | 34 | 13529 |
| &nbsp;&nbsp;&nbsp;Allocation 2024 | March 1, 2024 | March 1, 2028 | 1285 | 42022 |  | 42022 |
| &nbsp;&nbsp;&nbsp;Allocation 2025 | March 1, 2025 | March 1, 2029 | 1267 | 35064 |  | 35064 |
| &nbsp;&nbsp;&nbsp;**Total** |  |  |  | **116876** |  | **90615** |
| Dr. Katarzyna Mazur-Hofsäß (3) |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Allocation 2023 | March 1, 2023 | March 1, 2026 | 1375 | 42852 | 34 |  |
| &nbsp;&nbsp;&nbsp;Allocation 2024 | March 1, 2024 | March 1, 2028 | 1395 | 45542 |  |  |
| &nbsp;&nbsp;&nbsp;Allocation 2025 | March 1, 2025 | March 1, 2029 | 1377 | 36643 |  |  |
| &nbsp;&nbsp;&nbsp;**Total** |  |  |  | **125037** |  | **—** |
| **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** |
| William Valle |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Allocation 2023 | March 1, 2023 | March 1, 2026 | 1995 | 61938 | 34 | 21059 |
| &nbsp;&nbsp;&nbsp;**Total** |  |  |  | **61938** |  | **21059** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The IFRS 2 Fair Value in general reflects all market conditions. The amounts set out for the Allocations 2024 and 2025 are based on a 100% target achievement for the performance target "Relative TSR" to avoid the allocation value being influenced by short-term volatility in the development of the Company's Relative TSR and to enable comparability of the allocation value with those from previous years.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The Performance Shares allocated to Franklin W. Maddux, MD, can be earned in accordance with the plan conditions of the MB LTIP 2020 and of the MB LTIP 2024+ also after termination of his service agreement at the end of the fiscal year. Further information on the agreements made with Franklin W. Maddux, MD, can be found in the section "Agreements with members of the Management Board who resigned from office at the end of the fiscal year."

&nbsp;&nbsp;&nbsp;&nbsp;(3) The Performance Shares allocated to Dr. Katarzyna Mazur-Hofsäß forfeited in accordance with the plan conditions of the MB LTIP 2020 and of the MB LTIP 2024+ upon termination of her service agreement at the end of the fiscal year. Further information on the agreements made with Dr. Katarzyna Mazur-Hofsäß can be found in the section "Agreements with members of the Management Board who resigned from office at the end of the fiscal year."

[**Table of Contents**](#TOC)

***Temporal profile of the share-based compensation components***

The following chart shows a simplified, schematic representation of the temporal profile of the share-based compensation components outstanding in the fiscal year. The details can be found in the explanations above.

![Graphic](fms-20251231x20f024.jpg)

**Share ownership guidelines and shareholdings**

The Compensation System 2024+ introduced formal Share Ownership Guidelines (SOG) to tie the Management Board members' compensation even more closely to the interests of the shareholders and the Group's sustainable development.

The SOG provide that the Chairperson of the Management Board must invest an amount equaling 200% and the other Management Board members must invest an amount equaling 150% of their relevant annual base salary in shares of the Company. The highest annual base salary during the period in which the shares are to be acquired applies. The shares must in general be acquired within four years of the start of the respective service agreement, but no earlier than January 1, 2024, (build-up period) and must be held for a period of at least two years after the end of the respective service agreement. If the service agreement ends before the end of the build-up period, the amount to be invested until the end of the service agreement refers to 100% of the relevant annual base salary and is reduced on a pro rata temporis basis depending on the duration of the build-up period.

Should the relevant amount not be invested in full, the Supervisory Board may determine consequences in accordance with the SOG. This may include the Management Board member being ineligible for further LTI allocations.

Existing acquisition or shareholding requirements, such as from the MB LTIP 2020, remain unaffected. Shares acquired prior to the beginning of the investment period relevant for the SOG or as part of an equity settlement under an LTI are credited to the investment obligation under the SOG. Changes in the value of the shares after acquisition are not taken into account for purposes of the fulfillment of the investment obligation under the SOG.

[**Table of Contents**](#TOC)

The shareholdings notified to the Company as of the end of the fiscal year of the Management Board members as well as the status of the fulfillment of the SOG are shown in the following table. The investment obligation under the SOG may be satisfied by acquisition of shares or American Depositary Shares (ADSs) representing shares. For simplification purposes, the number of shares and ADSs have been combined in the following table. Where ADSs are held, two ADSs represent one share.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Overview on the SOG requirements and on the status** | **Overview on the SOG requirements and on the status** | **Overview on the SOG requirements and on the status** | **Overview on the SOG requirements and on the status** | **Overview on the SOG requirements and on the status** | **Overview on the SOG requirements and on the status** | **Overview on the SOG requirements and on the status** | **Overview on the SOG requirements and on the status** | **Overview on the SOG requirements and on the status** |
|  | | **SOG requirements** | **SOG requirements** | **SOG requirements** | **SOG requirements** | **Status as of December 31, 2025** | **Status as of December 31, 2025** | **Status as of December 31, 2025** |
|  | <br>**Management Board** <br>**member since** | <br>**Annual base**<br>**salary** | **SOG amount** <br>**in % of base**<br>**salary** | <br>**SOG amount** | <br>**To fulfill until (build-**<br>**up period)** | <br>**Amount** <br>**invested** <sup>(3)</sup> | <br>**Status of** <br>**fulfillment** | <br>**Number of**<br>**shares** |
|  |  | in € K | in % | in € K |  | in € K | in % |  |
| Helen Giza <sup>(1)</sup> | November 1, 2019  | 1593 | 200 | 3186 | December 31, 2027 | 785 | 25 | 18221 |
| Craig Cordola, EdD <sup>(1)</sup> | January 1, 2024 | 1283 | 150 | 1925 | December 31, 2027 | 1321 | 69 | 39448 |
| Martin Fischer | October 1, 2023 | 800 | 150 | 1200 | December 31, 2027 |  |  |  |
| Dr. Jörg Häring | June 1, 2024 | 700 | 150 | 1050 | May 31, 2028 |  |  |  |
| Franklin W. Maddux, MD <sup>(1),</sup> <sup>(2)</sup> | January 1, 2020 | 938 | 50 | 469 | December 31, 2025 | 1171 | 250 | 24463 |
| Dr. Katarzyna Mazur-Hofsäß <sup>(2)</sup> | September 1, 2018 | 1064 | 50 | 532 | December 31, 2025 | 592 | 111 | 13829 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The annual base salary and consequently also the SOG amount and the amount invested for Helen Giza, Craig Cordola, EdD, and Franklin W. Maddux, MD, is denominated in U.S. dollars. For the presentation in this table, the U.S. dollar amounts were translated with the average exchange rate of the calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The build-up period applicable to Franklin W. Maddux, MD, and Dr. Katarzyna Mazur-Hofsäß ended early due to the termination of their service agreements at the end of the fiscal year. Under the SOG, Franklin W. Maddux, MD, and Dr. Katarzyna Mazur-Hofsäß were therefore required to invest 50% of their respective last annual base salary on a pro rata temporis basis until then.

&nbsp;&nbsp;&nbsp;&nbsp;(3) To the extent the acquisition is made in a currency other than that of the agreed base salary and consequently also of the SOG amount, the translation of the invested amounts is done at the exchange rate of the respective acquisition date.

**Other benefits and commitments**

The following information concerns benefits and commitments to Management Board members within the meaning of Section 162(2) AktG and related disclosures as, for instance, on the cash pension allowance.

***Benefits from third parties***

Unless otherwise stated in this Compensation Report, no benefits were awarded or promised to the Management Board members by a third party in the fiscal year with regard to their activities as Management Board members, and compensation awarded to Management Board members for management activities or supervisory board mandates in Group companies is offset against the compensation of the respective Management Board member. If the Supervisory Board resolves that compensation awarded to Management Board members for supervisory board activities outside the Group shall be deducted in full or in part from the compensation of the respective Management Board member, this will be made transparent accordingly.

***Pension-related obligations***

The pension arrangements with the Management Board members in general consist of a pension allowance. For individual Management Board members who were appointed before January 1, 2019, individual, performance-based (i.e., defined benefit) contractual pension commitment exist instead.

*Cash pension allowance instead of defined contribution pension commitments*

Helen Giza, Craig Cordola, EdD, Martin Fischer, Dr. Jörg Häring, and Franklin W. Maddux, MD, receive a cash pension payment allowance in the amount of 40% of their respective base salary in accordance with the Compensation System 2024+. The pension allowance is generally paid in the same cycle as the base salary.

[**Table of Contents**](#TOC)

The defined contribution pension commitments for Helen Giza and Franklin W. Maddux, MD, were retroactively canceled in the fiscal year in accordance with the agreements concluded with them in 2024. To compensate for the cancellation of the pension commitments, Helen Giza and Franklin W. Maddux, MD, each received a payment in the fiscal year, as agreed, in the amount equal to the total insurance contributions that had been made to finance the respective pension commitments until the cancellation took effect. The amounts recorded as pension expense, which had been paid by the Company to finance the pension commitments, were reimbursed to the Company in the amount of the surrender value after deduction of transaction costs. There are no longer any defined contribution pension commitments for Management Board members.

*Defined benefit pension commitments*

Dr. Katarzyna Mazur-Hofsäß and individual former Management Board members were each made a defined benefit pension commitment.

The defined benefit pension commitments each provide for a retirement pension and survivor benefits (Hinterbliebenenversorgung) as of the time of conclusively ending active work (at age 65 at the earliest) or upon occurrence of disability or incapacity to work (Berufs- oder Erwerbsunfähigkeit) or of a full or partial reduction in earning capacity (Erwerbsminderung), calculated by reference to the amount of the most recent base salary.

The retirement pension in general amounts to 30% of the pensionable income. The percentage increases by 1.5 percentage points for each full year of service, up to a maximum of 45%. The pensionable income is determined based on the average base salary in the last five years before the occurrence of the insured event. Current retirement pensions increase according to statutory requirements (Section 16 of the German Act on the Improvement of Company Pension Plans (Gesetz zur Verbesserung der betrieblichen Altersversorgung – BetrAVG)). In general, 30% of the gross amount of any post-retirement income from an activity of the Management Board member is to be offset against the pension.

If the Management Board member dies, the surviving spouse receives a pension amounting to 60% of the pension claim applicable at that time. Furthermore, the deceased Management Board member's natural legitimate children (leibliche eheliche Kinder) receive an orphan's pension amounting to 20% of the pension claim applicable at that time until they complete their education, but no longer than they reach 25 years of age. However, all orphans' pensions and the surviving spouse's pension, taken together, may not exceed 90% of the Management Board member's pension claim.

If the Management Board member leaves the Management Board before reaching the age of 65, the rights to the aforementioned benefits survive. In such case, however, the pension to be paid is reduced – unless the Management Board member ceases to hold office because a covered event occurs (disability or incapacity to work, payment of a survivor's pension in case of death or, if applicable, early retirement) – in proportion to the ratio of the actual years of service as a Management Board member to the potential years of service until reaching the age of 65.

According to IAS 19, the pension commitment for Dr. Katarzyna Mazur-Hofsäß has increased by €332 K in the fiscal year and amounted to €3,992 K on December 31, 2025 (December 31, 2024: €3,660 K).

*U.S.-based 401(k) Savings Plan*

Based on individual contractual commitments, Helen Giza and Craig Cordola, EdD, participated in the U.S.-based 401(k) savings plan in the fiscal year. In this context, an amount of $10,500 (€9,292) for each of Helen Giza and Craig Cordola, EdD, was earned in the fiscal year. This plan generally allows employees in the U.S. to invest a limited portion of their gross salaries in retirement pension programs. Fresenius Medical Care supports its employees at this with matching contributions of up to 50% of the annual payments.

***Post-*** ***contractual non-competition clause***

A post-contractual non-competition clause was agreed with each Management Board member. If such clause becomes applicable, the Management Board member will receive, for a period of up to two years, non-compete compensation amounting to half of the respective annual base salary for each year the non-competition clause is applied.

***Change of control***

The service agreements of the Management Board members contain no express provisions for the event of a change of control.

[**Table of Contents**](#TOC)

***Severance payment cap***

The service agreements of the Management Board members provide for a severance payment cap. Under this cap, payments in connection with the early termination of a Management Board activity may not exceed the value of two years' compensation and may not compensate for more than the remaining term of the service agreement. To calculate the relevant annual compensation, only the fixed compensation components are applied. If the Company has terminated the service agreement for good cause or would be entitled to do so, no severance payments will be made.

***Continued compensation in cases of sickness***

The Management Board members have received individual contractual commitments to obtain continued compensation in cases of sickness for a maximum of twelve months; after six months of sick leave, insurance benefits may be offset against such payments. If a Management Board member dies, the surviving dependents will be paid three more monthly installments after the month of death, not to exceed, however, the amount due for the period until the scheduled expiration of the relevant service agreement.

***Agreements with members of the Management Board who resigned from office at the end of the fiscal year***

Franklin W. Maddux, MD, left the Management Board early at the end of the fiscal year after informing the Supervisory Board of his intention to retire. It was agreed with Franklin W. Maddux, MD, that his service agreement is terminated at the end of the fiscal year and that he is entitled to compensation for the period until the end of the fiscal year in accordance with his service agreement (including STI for the fiscal year). Performance Shares allocated to Franklin W. Maddux, MD, as LTI will continue to vest due to his age in accordance with the retirement clause of the applicable plan conditions. It was agreed with Franklin W. Maddux, MD, that he will receive a net reimbursement of up to €10 K in connection with relocation costs. Further, a post-contractual non-competition clause was agreed with Franklin W. Maddux, MD, for the period from January 1, 2026 to December 31, 2027. The annual compensation Franklin W. Maddux, MD, is entitled to receive for the post-contractual non-competition clause amounts to $530 K (€469 K). Since his pension commitment was canceled in the fiscal year as agreed, Franklin W. Maddux, MD, is not entitled to a pension.

Dr. Katarzyna Mazur-Hofsäß left the Management Board early at the end of the fiscal year after informing the Supervisory Board of her intention to retire. It was agreed with Dr. Katarzyna Mazur-Hofsäß that her service agreement is terminated at the end of the fiscal year and that she is entitled to compensation for the period until the end of the fiscal year in accordance with her service agreement (including the STI for the fiscal year). Performance Shares allocated to Dr. Katarzyna Mazur-Hofsäß as LTI and not vested by the end of the fiscal year have been forfeited in accordance with the applicable plan conditions. It was agreed with Dr. Katarzyna Mazur-Hofsäß that she is entitled to the fringe benefits agreed in her service agreement (including the use of her company car) as severance payment for the period until March 31, 2026. Further, a post-contractual non-competition clause was agreed with Dr. Katarzyna Mazur-Hofsäß for the period from January 1, 2026 to December 31, 2027. The annual compensation that Dr. Katarzyna Mazur-Hofsäß is entitled to receive for the post-contractual non-competition clause amounts to €532 K and is to be offset against her severance payment. Dr. Katarzyna Mazur-Hofsäß is entitled to a pension from age 65 in accordance with her pension commitment described above. As agreed, no further entitlements under the pension commitment have been acquired since the end of the fiscal year.

The respective above agreements with Franklin W. Maddux, MD, and Dr. Katarzyna Mazur-Hofsäß are in line with the applicable Compensation System 2024+ and the relevant recommendations of the GCGC.

The compensation awarded or due to Dr. Katarzyna Mazur-Hofsäß for the years 2023, 2024 and 2025 is disclosed in the Compensation Reports for the relevant fiscal years and in each case does not exceed the applicable maximum compensation. Dr. Katarzyna Mazur-Hofsäß cannot earn any further compensation for the aforementioned years, as all non-vested LTI entitlements have been forfeited at the end of the fiscal year. Compliance with the maximum compensation for Franklin W. Maddux, MD, for the aforementioned years will be reported in the Compensation Reports for the fiscal years in which his LTI entitlements are earned, as applicable.

[**Table of Contents**](#TOC)

***Further information***

Compensation of the U.S. members of the Management Board Helen Giza, Craig Cordola, EdD, and Franklin W. Maddux, MD, was paid or taxed partly in the U.S. (in U.S. dollars) and partly in Germany (in euros). With respect to the amount paid in Germany, it was agreed with the aforementioned Management Board members that, due to varying tax rates in both countries, the increased or lower tax burden to such Management Board members arising from German tax rates in comparison to U.S. tax rates will be balanced or will be paid back by them (net compensation). Pursuant to a modified net compensation agreement, these Management Board members will be treated as if they were taxed in the U.S. only. Since the actual tax burden can be calculated only in connection with the preparation of the Management Board members' tax returns, subsequent adjustments may have to be made, which will then be retroactively covered in future Compensation Reports.

The Company has taken out Directors & Officers insurance for members of the Management Board against whom claims are made on the basis of their activities for the Company and the Group companies. The Directors & Officers insurance includes a deductible that complies with the provisions of the German Stock Corporation Act.

In accordance with applicable legal requirements, no loans or advance payments on future compensation components were awarded to Management Board members in the fiscal year.

**Former Management Board members' compensation**

The compensation awarded or due to former Management Board members in the fiscal year is shown individually in the following table, unless the respective member left before the end of 2015. Management Board members who left before the end of 2015 received pension payments totaling €652 K in the fiscal year. Otherwise, no compensation was awarded or due to former Management Board members in the fiscal year.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Compensation of the former members of the Management Board** | **Compensation of the former members of the Management Board** | **Compensation of the former members of the Management Board** | **Compensation of the former members of the Management Board** | **Compensation of the former members of the Management Board** | **Compensation of the former members of the Management Board** | **Compensation of the former members of the Management Board** |
| in € K | in € K | in € K | in € K | in € K | in € K | in € K |
|  | **Michael Brosnan** <sup>(1)</sup> | **Michael Brosnan** <sup>(1)</sup> | **Roberto Fusté** | **Roberto Fusté** | **Ronald Kuerbitz** <sup>(1)</sup> | **Ronald Kuerbitz** <sup>(1)</sup> |
|  | Management Board | Management Board | Management Board | Management Board | Management Board | Management Board |
|  | member until  | member until  | member until  | member until  | member until  | member until  |
|  | October 31, 2019 | October 31, 2019 | March 31, 2016 | March 31, 2016 | February 17, 2017 | February 17, 2017 |
|  | Absolute | Ratio in % | Absolute | Ratio in % | Absolute | Ratio in % |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension payments | 382 |  | 337 |  | 130 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Fringe benefits |  |  |  |  |  |  |
| &nbsp;&nbsp;Total non-performance-based compensation | 382 | 100 | 337 | 100 | 130 | 100 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term incentive – Allocation 2022 (MB LTIP 2020) |  |  |  |  |  |  |
| &nbsp;&nbsp;Total variable compensation |  |  |  |  |  |  |
| **Total compensation according to Sec. 162 para. 1 sent. 2 no. 1 AktG** | **382** |  | **337** |  | **130** |  |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Rice Powell** <sup>(1)</sup> | **Rice Powell** <sup>(1)</sup> | **William Valle** <sup>(1)</sup> | **William Valle** <sup>(1)</sup> | **Kent Wanzek** <sup>(1)</sup> | **Kent Wanzek** <sup>(1)</sup> |
|  | Management Board | Management Board | Management Board | Management Board | Management Board | Management Board |
|  | member until | member until | member until | member until | member until | member until |
|  | December 31, 2022 | December 31, 2022 | December 31, 2023 | December 31, 2023 | December 31, 2021 | December 31, 2021 |
|  | Absolute | Ratio in % | Absolute | Ratio in % | Absolute | Ratio in % |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension payments | 699 |  | 60<br> <sup>(2)</sup> |  | 278 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Fringe benefits |  |  |  |  |  |  |
| &nbsp;&nbsp;Total non-performance-based compensation | 699 | 84 | 60 | 36 | 278 | 100 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term incentive – Allocation 2022 (MB LTIP 2020) | 138 |  | 107 |  |  |  |
| &nbsp;&nbsp;Total variable compensation | 138 | 16 | 107 | 64 |  |  |
| **Total compensation according to Sec. 162 para. 1 sent. 2 no. 1 AktG** | **837** |  | **167** |  | **278** |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The compensation benefits for Michael Brosnan, Ronald Kuerbitz, Rice Powell, William Valle and Kent Wanzek are denominated in U.S. dollars. The amounts were therefore subject to currency fluctuations. In general, the translation of U.S. dollar amounts was done at the average exchange rate for the applicable calendar year. For the long-term incentive the translation of U.S. dollar amounts was done at the closing rate of the applicable vesting date.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The payment of the entitlement to the pension payment set out herein was reduced, as agreed, in the full amount by the amount that William Valle was entitled to receive as compensation for the post-contractual non-competition clause agreed with him in 2023 for the fiscal year.

For an explanation as to how the compensation components correspond to the relevant compensation system, as to how compensation promotes the long-term development of the Company, as to how the performance criteria were applied and as to under what conditions compensation is regarded to have been awarded in the fiscal year, see the respective aforementioned statements regarding the compensation for the Management Board members in office in the fiscal year.

[**Table of Contents**](#TOC)

**Remuneration of the members of the Supervisory Board**

The Supervisory Board advises and monitors the Management Board and is involved in the strategy and planning and in all matters of fundamental importance to Fresenius Medical Care. In view of these tasks, which carry a high degree of responsibility, the members of the Supervisory Board are intended to receive appropriate remuneration, which also takes sufficient account of the time required to hold the Supervisory Board office. In addition, Supervisory Board remuneration that is appropriate also with respect to the market environment ensures that the Company will continue to have qualified candidates for the Supervisory Board in the future. Appropriate remuneration of the Supervisory Board members thus contributes to the promotion of the business strategy and the long-term development of the Company.

The remuneration for the members of the Supervisory Board is granted based on the Company's Articles of Association, which is resolved by the Company's general meeting of shareholders. [ESRS 2, 29e] According to Article 14 of the Articles of Association, the members of the Supervisory Board receive fixed remuneration and, if they serve on committees of the Supervisory Board, in general remuneration for these committee activities.

The fixed remuneration for service on the Supervisory Board or committees of the Supervisory Board is payable in four equal installments at the end of a calendar quarter. The members of the Supervisory Board in accordance with suggestion A.18, first sentence, of the GCGC do not receive variable remuneration; the remuneration awarded and due to them exclusively comprises fixed remuneration components. No sustainability targets are therefore taken into account in the remuneration of the members of the Supervisory Board. [ESRS 2, 29d]

If a fiscal year is not a complete calendar year, the remuneration relating to a full fiscal year is paid on a pro rata temporis basis. This in general applies accordingly if members of the Supervisory Board hold their office in the Supervisory Board or in a committee of the Supervisory Board or hold the office as Chairperson or Deputy Chairperson only during a part of a fiscal year.

The members of the Supervisory Board are reimbursed for the expenses incurred in the exercise of their office, including any statutory value-added tax owed by them. The Company has taken out Directors & Officers insurance for the members of the Supervisory Board.

***Changes to the remuneration in previous year***

The Company's 2024 AGM resolved with a majority of 99.49% of the votes cast to amend the corresponding provisions of the Articles of Association with effect from July 1, 2024. The remuneration of the members of the Supervisory Board was increased moderately overall to appropriately take into account the further increased demands regarding the responsibilities of the Supervisory Board and certain Supervisory Board committees as well as the corresponding increase in time expenditure. At the same time, it should be ensured that the Company remains competitive in attracting highly qualified Supervisory Board candidates. The currency of the remuneration was changed from U.S. dollars to euros.

Since July 1, 2024, remuneration for work on the Supervisory Board and its committees has been as follows:

The fixed remuneration for each Supervisory Board member amounts to €170 K per year. The Chairperson receives double this amount (i.e., €340 K) and the Deputy Chairperson receives one and a half times this amount (i.e., €255 K).

The members of the Audit Committee and the Presiding Committee receive €55 K per year for their work in each of these committees. The Chairperson of each of these committees receives double this amount (i.e., €110 K).

The members of the Compensation Committee and the Nomination Committee as well as any other committee receive €40 K per year for their work in each of these committees. The Chairperson of each of these committees receives double this amount (i.e., €80 K).

No additional remuneration is paid for serving as a member of the Mediation Committee or for serving as a Deputy Chairperson in the committees of the Supervisory Board.

[**Table of Contents**](#TOC)

***Remuneration awarded and due in the fiscal year***

The remuneration awarded or due in the fiscal year to the members of the Company's Supervisory Board is shown in the following table. No remuneration was awarded or due to former Supervisory Board members in the fiscal year.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Remuneration of the members of the Supervisory Board in office in the fiscal year** | **Remuneration of the members of the Supervisory Board in office in the fiscal year** | **Remuneration of the members of the Supervisory Board in office in the fiscal year** | **Remuneration of the members of the Supervisory Board in office in the fiscal year** | **Remuneration of the members of the Supervisory Board in office in the fiscal year** | **Remuneration of the members of the Supervisory Board in office in the fiscal year** |  |
| in € K | in € K | in € K | in € K | in € K | in € K |  |
|  | **Remuneration for**  | **Remuneration for**  |  |  |  |  |
|  | **supervisory board** | **supervisory board** | **Remuneration for**  | **Remuneration for**  |  |  |
|  | **activities**  | **activities**  | **committee services** | **committee services** | **Total remuneration** | **Total remuneration** |
|  | **2025** | **2024** <sup>(1)</sup> | **2025** | **2024** <sup>(1)</sup> | **2025** | **2024** <sup>(1)</sup> |
| Michael Sen <sup>(2)</sup> | 340 | 318 | 190 | 191 | **530** | **509** |
| Stefanie Balling <sup>(3)</sup> | 255 | 215 | 110 | 105 | **365** | **320** |
| Ralf Erkens <sup>(4)</sup> | 170 | 150 | 55 | 39 | **225** | **189** |
| Beate Haßdenteufel <sup>(5)</sup> | 170 | 150 |  | 11 | **170** | **161** |
| Sara Hennicken <sup>(6)</sup> | 170 | 174 | 40 | 38 | **210** | **212** |
| Regina Karsch <sup>(7)</sup> | 170 | 150 | 40 | 31 | **210** | **181** |
| Shervin J. Korangy <sup>(8)</sup> | 170 | 159 | 80 | 86 | **250** | **245** |
| Dr. Marcus Kuhnert <sup>(9)</sup> | 170 | 159 | 165 | 138 | **335** | **297** |
| Frank Michael Prescher <sup>(10)</sup> | 170 | 150 | 55 | 39 | **225** | **189** |
| Gregory Sorensen, MD <sup>(11)</sup> | 170 | 159 | 55 | 54 | **225** | **213** |
| Dr. Manuela Stauss-Grabo <sup>(12)</sup> | 170 | 150 | 40 | 37 | **210** | **187** |
| Pascale Witz <sup>(13)</sup> | 170 | 172 | 120 | 127 | **290** | **299** |
| **Total** | **2295** | **2106** | **950** | **896** | **3245** | **3002** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The currency of the remuneration was changed from U.S. dollars to euros effective July 1, 2024. The translation of U.S. dollar amounts for the period from January 1, 2024, to June 30, 2024, was made using the average exchange rate for the first half of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Member and Chair of the Supervisory Board as well as of the Presiding Committee and the Nomination Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Since January 26, 2024, member of the Supervisory Board. Since March 14, 2024, Deputy Chair of the Supervisory Board as well as member and Deputy Chair of the Audit Committee and the Presiding Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Since January 26, 2024, member of the Supervisory Board. Since March 14, 2024, member of the Presiding Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Since January 26, 2024, member of the Supervisory Board.

&nbsp;&nbsp;&nbsp;&nbsp;(6) Member of the Supervisory Board and of the Nomination Committee. Until March 14, 2024, Deputy Chair of the Supervisory Board.

&nbsp;&nbsp;&nbsp;&nbsp;(7) Since January 26, 2024, member of the Supervisory Board. Since March 14, 2024, member of the Compensation Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(8) Member of the Supervisory Board, member of the Compensation Committee as well as member and Deputy Chair of the Nomination Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(9) Member of the Supervisory Board, member and Chair of the Audit Committee as well as member of the Presiding Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(10) Since January 26, 2024, member of the Supervisory Board. Since March 14, 2024, member of the Audit Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(11) Member of the Audit Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(12) Since January 26, 2024, member of the Supervisory Board. Since March 14, 2024, member and Deputy Chair of the Compensation Committee.

&nbsp;&nbsp;&nbsp;&nbsp;(13) Member and Chair of the Compensation Committee as well as member of the Nomination Committee. Until March 14, 2024, also member and Deputy Chair of the Audit Committee.

**Comparative presentation of the development of the compensation**

The development of the compensation awarded or due to the current and former members of the Management Board and the Supervisory Board, the development of the Company's earnings and the development of the average compensation of employees on a full-time equivalent (FTE) basis are shown comparatively in the following table. The disclosures are also made for the former members of the management board of the Company's former general partner. The disclosures are only made for persons to whom compensation was awarded or due in the fiscal year.

***Metrics for the performance of the Company***

The Company's earnings development pursuant to German commercial law is shown in the Company's annual results for the year under German commercial law. For the comparative presentation of the Company's performance, revenue and net income as well as operating income and return on invested capital (ROIC) are also used. These figures also serve as primary key performance indicators or secondary financial performance indicators of the group and as performance targets for the Management Board members' variable compensation.

[**Table of Contents**](#TOC)

***Financial figures***

The figures set out in the compensation comparison are disclosed at current currency, while the growth rates relating to the Management Board members' LTI are determined at constant currency and the figures relating to the Management Board members' STI are translated at the exchange rates that were applied for the determination of the target values.

As disclosed in the Compensation Reports for the relevant years, the figures used for determining the level of target achievement and for determining the Management Board members' compensation were and are, in some cases, adjusted for certain effects to ensure comparability of the figures with respect to the operational performance.

Consequently, there is only a limited degree of comparability between the figures relating to each year shown in the following table and the corresponding amounts of the Management Board members' compensation and, in particular, between these figures in terms of their respective annual change.

***Compensation of the Management Board***

In accordance with the applicable plan terms, an award within the meaning of this Compensation Report from the LTI to the Management Board members is generally made only after expiry of the multi-year vesting period. As a result, compensation awarded or due to Management Board members is usually lower in the first years of their Management Board activity than in subsequent years.

The vesting periods for the various LTIs included in the following table are not identical. This means that more than one LTI tranche could be earned in certain years and is therefore deemed to have been awarded. This applies, for example, to the 2019 allocation under the Management Board Long-Term Incentive Plan 2019 (MB LTIP 2019) and the 2020 allocation under the MB LTIP 2020, which each vested in 2023.

The pension allowance introduced with effect from January 1, 2024, for individual Management Board members is compensation within the meaning of Section 162(1), second sentence, No. 1 AktG and is therefore – unlike the pension expense for pension commitments of other Management Board members – included in the amounts shown in the following table. The retroactive cancellation of the pension commitments for Helen Giza and Franklin W. Maddux, MD, with compensation for the payments made in this respect, means that the amount reported as pension allowance for Helen Giza and Franklin W. Maddux, MD, for the fiscal year 2025 in addition to the amounts for the fiscal year 2025 also includes the amounts that relate to the period of time from the appointment as Management Board member until the cancellation of the pension commitments took effect. This also results in a higher CEO pay ratio for the fiscal year 2025 compared to previous years, although from an economic perspective this is not based on a corresponding increase in compensation costs for the Company.

***Compensation of the Supervisory Board***

The compensation for the members of the Supervisory Board and its committees was changed with effect as of July 1, 2024, and increased moderately overall to appropriately take into account the further increased demands regarding the responsibilities of the Supervisory Board and certain Supervisory Board committees as well as the corresponding increase in time expenditure.

***Compensation of the employees***

Employee compensation is based on the average wages and salaries of all employees on an FTE basis at the Company and its group companies worldwide in the respective year.

[**Table of Contents**](#TOC)

***Table on the development of the compensation***

The comparative presentation of the development of the compensation over the past five years is shown in the following table:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Comparative presentation of the development of the compensation** | **Comparative presentation of the development of the compensation** | **Comparative presentation of the development of the compensation** | **Comparative presentation of the development of the compensation** | **Comparative presentation of the development of the compensation** | **Comparative presentation of the development of the compensation** | **Comparative presentation of the development of the compensation** | **Comparative presentation of the development of the compensation** | **Comparative presentation of the development of the compensation** | **Comparative presentation of the development of the compensation** |
|  | **2025** | **Change** | **2024** | **Change** | **2023** | **Change** | **2022** | **Change** | **2021** |
|  | in € K | in % | in € K | in % | in € K | in % | in € K | in % | in € K |
| **Revenue** | 19627602 | **2** | 19335909 | **(1)** | 19453617 | **0** | 19398017 | **10** | 17618685 |
| **Operating income** | 1827036 | **31** | 1392395 | **2** | 1369438 | **(9)** | 1511755 | **(18)** | 1852290 |
| **Net income** | 978367 | **82** | 537913 | **8** | 498997 | **(26)** | 673405 | **(31)** | 969308 |
| **ROIC** | 5.0% | **43** | 3.5% | **25** | 2.8% | **(15)** | 3.3% | **(33)** | 4.9% |
| **Annual result according to the statutory financial statements of Fresenius Medical Care AG** | 1371795 | **42** | 966458 | **21** | 798197 | **n.a.** | (1141219) | **n.a.** | 1737017 |
| **Average employees' compensation** | 60.7 | **(0)** | 60.8 | **17** | 51.9 | **(1)** | 52.3 | **15** | 45.4 |
| **CEO pay ratio (CEO in office at year-end to average employees)** | 106:1 | **n.a.** | 61:1 | **n.a.** | 83:1 | **n.a.** | 89:1 | **n.a.** | 119:1 |
| **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** | **Members of the Management Board in office in the fiscal year** |
| &nbsp;&nbsp;Helen Giza | 6457 | **74** | 3708 | **(14)** | 4304 | **119** | 1969 | **11** | 1781 |
| &nbsp;&nbsp;Craig Cordola, EdD | 3247 | **(13)** | 3718 | **n.a.** |  | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Martin Fischer | 2180 | **(14)** | 2524 | **185** | 887 | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Dr. Jörg Häring | 1649 | **20** | 1378 | **n.a.** |  | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Franklin W. Maddux, MD | 4165 | **77** | 2359 | **(13)** | 2708 | **61** | 1683 | **(15)** | 1986 |
| &nbsp;&nbsp;Dr. Katarzyna Mazur-Hofsäß | 1835 | **(31)** | 2666 | **(17)** | 3210 | **69** | 1903 | **2** | 1872 |
| **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** | **Former members of the Management Board** |
| &nbsp;&nbsp;Michael Brosnan | 382 | **2** | 374 | **(38)** | 601 | **57** | 382 | **(41)** | 651 |
| &nbsp;&nbsp;Roberto Fusté | 337 | **15** | 293 | **—** | 293 | **—** | 293 | **7** | 274 |
| &nbsp;&nbsp;Ronald Kuerbitz | 130 | **1082** | 11 | **n.a.** |  | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Rice Powell | 837 | **(10)** | 930 | **(64)** | 2574 | **(45)** | 4658 | **(14)** | 5424 |
| &nbsp;&nbsp;William Valle | 167 | **(8)** | 182 | **(97)** | 6387 | **85** | 3457 | **(7)** | 3709 |
| &nbsp;&nbsp;Kent Wanzek | 278 | **(27)** | 382 | **(66)** | 1137 | **54** | 740 | **(71)** | 2554 |
| **Members of the Supervisory Board in office in the fiscal year** | **Members of the Supervisory Board in office in the fiscal year** | **Members of the Supervisory Board in office in the fiscal year** | **Members of the Supervisory Board in office in the fiscal year** | **Members of the Supervisory Board in office in the fiscal year** | **Members of the Supervisory Board in office in the fiscal year** | **Members of the Supervisory Board in office in the fiscal year** | **Members of the Supervisory Board in office in the fiscal year** | **Members of the Supervisory Board in office in the fiscal year** | **Members of the Supervisory Board in office in the fiscal year** |
| &nbsp;&nbsp;Michael Sen | 530 | **4** | 509 | **15** | 444 | **289** | 114 | **n.a.** |  |
| &nbsp;&nbsp;Stefanie Balling | 365 | **14** | 320 | **n.a.** |  | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Ralf Erkens | 225 | **19** | 189 | **n.a.** |  | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Beate Haßdenteufel  | 170 | **6** | 161 | **n.a.** |  | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Sara Hennicken | 210 | **(1)** | 212 | **34** | 158 | **216** | 50 | **n.a.** |  |
| &nbsp;&nbsp;Regina Karsch | 210 | **16** | 181 | **n.a.** |  | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Shervin J. Korangy | 250 | **2** | 245 | **1125** | 20 | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Dr. Marcus Kuhnert | 335 | **13** | 297 | **1314** | 21 | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Frank Michael Prescher | 225 | **19** | 189 | **n.a.** |  | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Gregory Sorensen, MD | 225 | **6** | 213 | **41** | 151 | **(1)** | 152 | **77** | 86 |
| &nbsp;&nbsp;Dr. Manuela Stauss-Grabo | 210 | **12** | 187 | **n.a.** |  | **n.a.** |  | **n.a.** |  |
| &nbsp;&nbsp;Pascale Witz  | 290 | **(3)** | 299 | **30** | 230 | **10** | 209 | **12** | 187 |

---

**Compensation outlook for 2026**

The Supervisory Board has again set the two equally weighted sub-targets "Patient Satisfaction" and "Employee Satisfaction" as the sustainability target for the STI for 2026 and the reduction in market-based CO<sub>2</sub>e emissions as the sustainability target for the LTI allocation for 2026. The other performance targets for the STI for 2026 and for the allocation of the LTI for 2026 as well as the weightings for the individual performance targets also correspond to those of the fiscal year. Information on the target values and the respective performance target achievement will be disclosed after the end of the performance period in the Compensation Report for the relevant fiscal year.

[**Table of Contents**](#TOC)

C. Board practices

For information relating to the terms of office of the Management Board and of the Supervisory Board, and the periods in which the members of those bodies have served in office, see Item 6.A, "Directors, senior management and employees — Directors and senior management," above.

The Supervisory Board has formed an Audit Committee consisting of Dr. Marcus Kuhnert (Chair), Ms. Stefanie Balling (Deputy Chair), Mr. Gregory Sorensen, MD, and Mr. Frank Michael Prescher. Dr. Kuhnert and Mr. Sorensen are independent directors for purposes of SEC Rule 10A-3 and NYSE Rule 303A.06. For details on the exemption from the independence requirements of those rules relied upon with respect to Ms. Balling and Mr. Prescher, who are employee representatives, see Item 16D, "Exemptions from the listing standards for audit committees." The primary function of the Audit Committee is to assist FME AG's Supervisory Board in fulfilling its oversight responsibilities, primarily through:

● overseeing FME AG's accounting and financial reporting processes, the performance of the internal audit function and the effectiveness of the internal control system;

● overseeing the auditing of FME AG's financial statements;

● overseeing FME AG's sustainability related objectives and the auditing or assurance of the Company's sustainability reporting required by law;

● overseeing the independence and performance of FME AG's outside auditors;

● overseeing the effectiveness of our risk management system;

● overseeing the effectiveness of our systems and processes utilized to comply with relevant legal and regulatory standards for global healthcare companies;

● overseeing our relationship with Fresenius SE and its affiliates as well as overseeing related party transactions generally;

● reporting by FME AG's outside auditors directly to the Audit Committee; and

● performing such other functions and exercising such other responsibilities as are required to be performed or exercised by audit committees by applicable law or as may be delegated to the Audit Committee by the Supervisory Board.

The Supervisory Board has formed a Presiding Committee consisting of Mr. Michael Sen (Chair), Ms. Stefanie Balling (Deputy Chair), Dr. Marcus Kuhnert, and Mr. Ralf Erkens. The Presiding Committee is responsible in particular for administrative matters relating to the Supervisory Board and for various Management Board matters including recommendations to the Supervisory Board on the appointment or dismissal of Management Board members and on the allocation of responsibilities among the Management Board members. The Presiding Committee further reviews and assesses the Company's corporate governance.

[**Table of Contents**](#TOC)

The Supervisory Board has formed a Compensation Committee consisting of Ms. Pascale Witz (Chair), Dr. Manuela Stauss-Grabo (Deputy Chair), Mr. Shervin J. Korangy, and Ms. Regina Karsch. The Compensation Committee is responsible for preparing the decisions of the Supervisory Board regarding the compensation of the members of the Management Board. This includes the preparation of the determination of the compensation system and of the short-term and long-term incentive plans for the Management Board as well as the definition of the targets for variable compensation components and the definition of target values as well as of the determination of the target achievement. The Compensation Committee also prepares the regular review by the Supervisory Board of the appropriateness of the compensation system and of the total compensation of the individual Management Board members. The Compensation Committee also reviews the annual compensation report.

The Nomination Committee of the Supervisory Board of the Company consists of Mr. Michael Sen (Chair), Mr. Shervin J. Korangy (Deputy Chair), Ms. Sara Hennicken, and Ms. Pascale Witz. The Nomination Committee recommends suitable candidates to the Supervisory Board for its proposals to the General Meeting for the election of Supervisory Board members or, if required, for judicial appointment of shareholder representatives on the Supervisory Board. The Nomination Committee also, in certain cases, makes recommendations to the Supervisory Board on members of the shareholder representatives to be elected to the committees of the Supervisory Board.

The Supervisory Board has formed a Mediation Committee (*Vermittlungsausschuss*) consisting of Mr. Michael Sen (Chair), Ms. Stefanie Balling (Deputy Chair), Ms. Beate Haßdenteufel, and Mr. Gregory Sorensen, MD. The Mediation Committee, in accordance with the German Co-Determination Act, convenes to resolve any disputes among the members of the Supervisory Board that may arise in connection with the appointment or dismissal of members of the Management Board.

We are exempt from the NYSE rule requiring companies listed on that exchange to maintain compensation committees and nominating committees consisting solely of independent directors. See Item 16G, "Corporate governance."

&nbsp;&nbsp;&nbsp;&nbsp;D. **Employees** 

At December 31, 2025, we had 109,698 employees (total headcount) as compared to 111,513 at December 31, 2024 and 119,845 at December 31, 2023. For further information on the movement in employees, see Item 5, "Operating and financial review and prospects — III. Results of operations, financial position and net assets," above. The following table shows the number of employees by our major category of activities for the last three fiscal years.

---

| | | | |
|:---|:---|:---|:---|
|  | **December 31,**<br>**2025** | **December 31,**<br>**2024** | **December 31,**<br>**2023** |
| **Total Company** | 109698 | 111513 | 119845 |
| **U.S.** | 58973 | 60516 | 60868 |
| &nbsp;&nbsp;Care Delivery | 54297 | 54753 | 54360 |
| &nbsp;&nbsp;Value-Based Care | 654 | 684 | 687 |
| &nbsp;&nbsp;Care Enablement | 3999 | 5024 | 5805 |
| &nbsp;&nbsp;Corporate | 23 | 55 | 16 |
| **Germany** | 7855 | 7658 | 7581 |
| &nbsp;&nbsp;Care Delivery | 2432 | 2545 | 2394 |
| &nbsp;&nbsp;Care Enablement | 5362 | 5025 | 5125 |
| &nbsp;&nbsp;Corporate | 61 | 88 | 62 |
| **Rest of the world** | 42870 | 43339 | 51396 |
| &nbsp;&nbsp;Care Delivery | 23105 | 25161 | 33556 |
| &nbsp;&nbsp;Care Enablement | 19764 | 18168 | 17839 |
| &nbsp;&nbsp;Corporate | 1 | 10 | 1 |

---

During 2025 and the prior two fiscal years, we have not suffered any protracted labor-related work disruptions. Collective bargaining agreements apply to different groups of employees within the Company, depending on local laws and practices.

[**Table of Contents**](#TOC)

We respect the principles of freedom of association and the right to collective bargaining, including the rights of our employees to freely choose whether or not to be represented by a particular trade union, and engage in collective bargaining in accordance with applicable law and practice globally. In cases where our employees are represented by unions or works councils, we manage these relationships responsibly, following local laws and practices.

Starting in late 2022, we experienced union organizing activity in the state of California (U.S.) and we expect this union campaign to continue in 2026.

&nbsp;&nbsp;&nbsp;&nbsp;E. **Share ownership** 

As of December 31, 2025, no member of our Supervisory Board or our Management Board beneficially owned 1% or more of our shares, according to the most recent information available. See Item 6.B, "Directors, senior management and employees — Compensation" for information regarding share-based compensation, including the grants of cash-settled virtual performance shares and provisions of the compensation system providing for mandatory share retention to promote share ownership. Additionally, share-based plans are discussed in detail in note 23 of the notes to our consolidated financial statements included in this report.

&nbsp;&nbsp;&nbsp;&nbsp;F. **Disclosure of a registrant's action to recover erroneously awarded compensation** 

During 2025, we did not have an accounting restatement that required recovery of erroneously awarded incentive-based compensation pursuant to our incentive-based compensation recovery policy. As of December 31, 2025, there were no outstanding balances of erroneously awarded incentive-based compensation to be recovered from the application of the policy to a prior restatement. Our Incentive-based Compensation Recover Policy is included as Exhibit 97 to this Report.

#### Item 7. Major shareholders and related party transactions
&nbsp;&nbsp;&nbsp;&nbsp;A. **Major shareholders** 

#### Security ownership of certain beneficial owners of the Company
Our outstanding share capital consists of shares issued only in bearer form. Accordingly, unless we receive information regarding acquisitions of our shares through a filing with the SEC or through the German statutory requirements referred to below, or except as described below with respect to our shares held in American Depositary Receipt (ADR) form, we, despite a right to request depositaries to disclose corresponding information, face difficulties precisely determining who our shareholders are at any specified time or how many shares any particular shareholder owns.

Commencing March 18, 2026, our directors and officers will be required to report their ownership of our equity securities and their transactions in our equity securities pursuant to Section 16 of the Securities and Exchange Act of 1934 but, because we are a foreign private issuer, they are not required to do so before that date. However, persons who become "beneficial owners" of more than 5% of our shares are required to report their beneficial ownership pursuant to Section 13(d) of the Securities and Exchange Act of 1934.

In addition, under Article 19(1) of the Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014 on market abuse (Market Abuse Regulation or MAR), persons discharging managerial responsibilities within an issuer of shares, as well as persons closely associated with them, are obliged to notify the issuer and the competent authority, i.e. for the Company as issuer, the German Federal Financial Supervisory Authority (*Bundesanstalt für Finanzdienstleistungsaufsicht* or BaFin), of every transaction conducted on their own account relating to the shares or debt instruments of the issuer or to derivatives or other financial instruments linked thereto no later than three business days after the date of the transaction. This notification obligation applies once the volume of all transactions of such person conducted within a calendar year exceeds a total amount of €50,000. Persons discharging managerial responsibilities include, inter alia, the members of management as well as supervisory boards.

[**Table of Contents**](#TOC)

In addition, holders of voting securities of a German company listed on the regulated market (*Regulierter Markt*) of a German stock exchange or a corresponding trading segment of a stock exchange within the EU are, under Sections 33, 34 of the German Securities Trading Act (*Wertpapierhandelsgesetz* or WpHG), obligated to notify the company of held or attributed holding whenever such holding reaches, exceeds or falls below certain thresholds, which have been set at 3%, 5%, 10%, 15%, 20%, 25%, 30%, 50% and 75% of a company's outstanding voting rights. Such notification obligations will also apply pursuant to Section 38 of the WpHG to the direct or indirect holder of instruments granting an unconditional right to acquire voting rights when due or providing discretion as to the acquisition of shares or instruments that have a similar economic effect as well as pursuant to Section 39 of the WpHG to the aggregate of held or attributed voting rights and instruments (in each case excluding the 3% threshold). For threshold notifications furnished to us by third parties, see note 20 of the notes to the consolidated financial statements included in this report.

We have been informed that as of February 13, 2026, Fresenius SE owned 76,814,594, or 26.2%, of our issued shares. Subject to any applicable statutory limitations and the provisions of our Articles of Association granting Fresenius SE the right to designate up to two members of our Supervisory Board, all of our outstanding shares have the same voting rights.

On March 7, 2025, Else Kröner-Fresenius-Stiftung, Bad Homburg v.d.Höhe, Germany, with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 28.55% of the voting rights of the Company were held as of March 4, 2025.

On January 21, 2026, BlackRock, Inc., Wilmington, Delaware, U.S., with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 4.74% of the voting rights of the Company and pursuant to Section 38 of the WpHG that instruments relating to 0.34% of the voting rights of the Company were held as of January 16, 2026.

On August 22, 2025, Artisan Partners Asset Management Inc., Wilmington, Delaware, U.S., with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 2.99% of the voting rights of the Company were held as of August 19, 2025.

On July 9, 2025, Dodge & Cox International, San Francisco, California, U.S., disclosed pursuant to Section 33 of the WpHG that 4.98% of the voting rights of the Company were held as of July 3, 2025. According to an amended Schedule 13G filed with the SEC on February 13, 2024, Dodge & Cox, an investment adviser registered under the U.S. Investment Advisers Act of 1940, is the beneficial owner of 7.4% of the Company's shares. The Schedule 13G states that Dodge & Cox has sole voting power and sole dispositive power over such shares, and that clients of Dodge & Cox, including investment companies registered under the U.S. Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, such shares.

On April 16, 2025, Harris Associates L.P., Wilmington, Delaware, U.S., with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 2.98% of the voting rights of the Company were held as of April 14, 2025.

On February 28, 2025, Dodge & Cox International Stock Fund, San Francisco, California, U.S., disclosed pursuant to Section 33 of the WpHG that 5.00% of the voting rights of the Company were held as of February 24, 2025.

On January 7, 2025, Harris Associates Investment Trust, Boston, Massachusetts, U.S., disclosed pursuant to Section 33 of the WpHG that 3.00% of the voting rights of the Company were held as of January 3, 2025.

On October 28, 2022, Richard Pzena, with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 5.20% of the voting rights of the Company were held as of October 24, 2022.

Bank of New York Mellon, our ADR depositary, informed us, that as of December 31, 2025, 38,572,325 American Depositary Shares (ADS) were held of record by 2,007 U.S. holders. Two ADSs represent one share. Exhibit 2.1, "Description of Securities," provides additional information regarding our ADRs and ADSs.

#### Security ownership of certain beneficial owners of Fresenius SE
Fresenius SE's share capital consists solely of ordinary shares, issued only in bearer form. Accordingly, Fresenius SE has, despite a right to request depositaries to disclose corresponding information, difficulties precisely determining who its shareholders are at any specified time or how many shares any particular shareholder owns. However, under the WpHG, holders of voting securities of a German company listed on the regulated market *(Regulierter Markt)* of a German stock exchange or a corresponding trading segment of a stock exchange within the EU are obligated to notify a company of certain levels of holdings, as described above.

[**Table of Contents**](#TOC)

The Else Kröner-Fresenius-Stiftung is the sole shareholder of Fresenius Management SE, the general partner of Fresenius SE, and has sole power to elect the supervisory board of Fresenius Management SE. In addition, based on the most recent information available, the Else Kröner-Fresenius-Stiftung owns approximately 27% of the Fresenius SE ordinary shares. See Item 7.B, "Related party transactions – Other interests," below.

&nbsp;&nbsp;&nbsp;&nbsp;B. **Related party transactions** 

In connection with the formation of FME AG, and the combination of the dialysis businesses of Fresenius SE and W.R. Grace & Co. in 1996, Fresenius SE and its affiliates and FME AG and its affiliates entered into several agreements for the purpose of giving effect to the Merger and defining our ongoing relationship. Fresenius SE and W.R. Grace & Co. negotiated these agreements. The information below summarizes the material aspects of certain agreements, arrangements and transactions between FME AG and Fresenius SE, their affiliates and with certain of our equity method investees. For further information, see note 6 of the notes to the consolidated financial statements included in this report. The following descriptions are not complete and are qualified in their entirety by reference to those agreements, which have been filed with the SEC. We believe that the leases, the supply agreements and the service agreements summarized below are no less favorable to us and no more favorable to Fresenius SE than would have been obtained in arm's-length bargaining between independent parties. The trademark and other intellectual property agreements summarized below were negotiated by Fresenius SE and W.R. Grace & Co., and, taken independently, are not necessarily indicative of market terms.

In the discussion below regarding our contractual and other relationships with Fresenius SE:

● the term "we (or us) and our affiliates" refers only to FME AG and its subsidiaries; and

● the term "Fresenius SE and its affiliates" refers only to Fresenius SE and affiliates of Fresenius SE other than FME AG and its subsidiaries.

#### Real property leases
For information with respect to our principal properties, see "Item 4.D. Property, plant and equipment." For discussion of related party leases, see note 6 of the notes to the consolidated financial statements included in this report.

#### Trademarks
Fresenius SE owns the name "Fresenius" and several marks containing "Fresenius" (Fresenius Marks) also after our Conversion and related deconsolidation from Fresenius SE. Fresenius SE and Fresenius Medical Care Deutschland GmbH (D-GmbH) entered into the original Trademark License Agreement dated September 27, 1996 (Original Trademark License Agreement), which remains in force after our Conversion and related deconsolidation from Fresenius SE. The parties agreed to some amendments/clarifications set out in the Long Form of Amendment to the Original Trademark License Agreement dated December 23, 2025 (as amended, Trademark License Agreement).

Fresenius SE has granted D-GmbH for our benefit and that of our affiliates, a worldwide, royalty-free, perpetual license to use the Licensed Marks (including the Fresenius Marks) and/or the "Fresenius" name in our company names and as a trademark for products and services with an intended use or for medical indications in the field of extra-corporeal blood treatment and peritoneal dialysis. In the field of renal care, the license is generally exclusive. For renal pharmaceuticals exclusivity only applies to pharmaceuticals falling into specific categories. This amended scope of the license shall only be governed by the Trademark License Agreement and reflects the current scope of business of Fresenius SE and the Company.

We and our affiliates have the right to use the Licensed Marks, including the Fresenius Marks and/or the "Fresenius" name outside the field of extra-corporeal blood treatment and peritoneal dialysis only with the consent of Fresenius SE. Regardless of whether or not exclusivity applies, Fresenius SE or its affiliates shall not use or license third parties to use the designations "Fresenius Medical Care", "a Fresenius Medical Care company", or one of the terms "renal", "kidney", "nephro," or "dialysis" (incl. corresponding translations) as addition to the Fresenius Mark or the "Fresenius" name or any confusingly similar designations.

[**Table of Contents**](#TOC)

The "Fresenius" Name and Fresenius Marks (details to be defined in Branding Guidelines jointly developed by Fresenius SE and the Company) may only be used by us in combination with Medical Care, any of the terms Kidney, Renal, Dialysis, Nephro, or the addition "a Fresenius Medical Care company". In the Trademark License Agreement customary termination rights for Fresenius SE in case of a material breach, in the event of a change of control and in the event we decide to change our legal company name were introduced. Furthermore, reporting obligations were introduced regarding any harmful use of the Licensed Marks and/or the "Fresenius" name.

#### Services agreements and products
For information on our services agreements and products, see note 6 of the notes to the consolidated financial statements included in this report.

#### Financing
For information on our related party financing arrangements, see note 6 and note 16 of the notes to the consolidated financial statements included in this report.

#### Key management personnel
For information on transactions involving our key management personnel, see Item 6.B, "Directors, senior management and employees – Compensation" and notes 6, 23, and 31 of the notes to the consolidated financial statements included in this report.

***Settlements with former directors***

For information regarding settlements with certain former members of the General Partner's Management Board in connection with their respective resignations from the Management Board, see "Item 6.B, "Directors, senior management and employees — Compensation — Management Board members' compensation — Other benefits and commitments — Agreements with a member of the Management Board who resigned from office at the end of the Fiscal Year."

#### General Partner reimbursement
For information on reimbursement obligations to our former General Partner, see note 6 of the notes to the consolidated financial statements included in this report.

#### Item 8. Financial information
The information called for by parts 8.A.1 through 8.A.6 of this item is in the section beginning on Page F-1.

#### 8.A.7. Legal and regulatory matters
The information in note 25 of the notes to the consolidated financial statements of this report is incorporated by this reference in response to this item.

#### 8.A.8. Dividend policy
We generally pay annual dividends on our shares in amounts that we determine on the basis of FME AG's prior year's balance sheet profit (*Bilanzgewinn*) as shown in the statutory unconsolidated financial statements that we prepare under German law on the basis of the accounting principles of the German Commercial Code (*Handelsgesetzbuch* or HGB). The payment of dividends is subject to approval by a resolution of the general meeting of shareholders. Our dividend policy foresees a stable and predictable dividend development, resulting in a 30% to 40% payout ratio, based on net income attributable to shareholders of FME AG excluding special items, to return excess capital to shareholders. For a description of special items, see Item 5, "Operating and financial review and prospects — I. Performance management system," above.

Our Management Board and Supervisory Board propose dividends to the AGM and the AGM approves dividends. The dividends are paid in respect of the fiscal year preceding the respective AGM. Since all of our shares are in bearer form, we remit dividends to the depositary bank (*Depotbank*) on behalf of the shareholders.

[**Table of Contents**](#TOC)

The table below provides information regarding the annual dividend per share that we paid on our shares. These payments were made in the years shown in the table. They relate to the results of operations in the year preceding the payment.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| **Per share amount** | € | 1.44 | € | 1.19 | € | 1.12 |

---

For the proposed dividend for 2025 payable in 2026, see Item 5. IV. "Operation and financial review and prospects – Financial position – Net cash provided by (used in) financing activities."

Except as described in the Description of Securities filed as Exhibit 2.1 to this report, holders of ADSs will be entitled to receive dividends on the shares represented by the respective ADSs. We will pay any cash dividends payable to such holders to the depositary in euros and, subject to certain exceptions, the depositary will convert the dividends into U.S. dollars and, after deduction of its fees and any taxes, distribute the dividends to ADS holders. For additional information regarding the distribution of dividends to ADS holders, see part D. "American Depositary Shares," in the "Description of Securities" filed as Exhibit 2.1 to this report. Fluctuations in the exchange rate between the U.S. dollar and the euro will affect the amount of dividends that ADS holders receive. Dividends paid to holders and beneficial holders of the ADSs will be subject to deduction of German withholding tax. You can find a discussion of German withholding tax below in "Item 10.E. Taxation."

#### Item 9. The offer and listing
The information required by Items 9.A.3, 9.A.5 and 9.A.6 is incorporated herein by reference to the information under the heading "Information pertaining to Item 9. The offer and listing details" in Exhibit 2.1 to this report.

#### A.4. and C. Information regarding the trading markets for of our stock

#### Trading markets

#### Trading on the Frankfurt Stock Exchange
The principal trading market for our shares is the Frankfurt Stock Exchange (*FWB*<sup>®</sup> *Frankfurter Wertpapierbörse*). wherein our shares are listed and traded under the symbol FME.

Our shares have been listed on the Regulated Market (*Regulierter Markt*) of the Frankfurt Stock Exchange and on the Prime Standard of the Regulated Market, which is a sub-segment of the Regulated Market with additional post-admission obligations. Admission to the Prime Standard requires the fulfillment of the following transparency criteria: publication of quarterly reports, in both German and English; preparation of financial statements in accordance with international accounting standards; publication of a company calendar; convening of at least one analyst conference per year; and publication of ad-hoc notifications (i.e., certain announcements of certain price-relevant material developments and events required to be made as soon as possible) in English. Companies aiming to be listed in this segment have to apply for admission. Listing in the Prime Standard is a prerequisite for inclusion of shares in the selection indices of the Frankfurt Stock Exchange. We are included in the DAX® 40, the index representing the performance of the 40 largest publicly traded companies listed on the Frankfurt Stock Exchange.

Deutsche Börse AG operates the Frankfurt Stock Exchange, which is the largest of the German stock exchanges by value of shares traded. Our shares are traded on Xetra, the electronic trading system of the Deutsche Börse. The trading hours for Xetra are between 9:00 a.m. and 5:30 p.m. CET. Only brokers and banks that have been admitted to Xetra by the Frankfurt Stock Exchange have direct access to the system and may trade on it. Private investors can trade on Xetra through their banks and brokers.

Deutsche Börse AG publishes information for all traded securities on the Internet, www.deutsche-boerse.com.

Transactions on Xetra and the Frankfurt Stock Exchange settle on the second business day following the trade. The Frankfurt Stock Exchange can suspend a quotation if orderly trading is temporarily endangered or if a suspension is deemed to be necessary to protect the public.

The Hessian Stock Exchange Supervisory Authority (*Hessische Börsenaufsicht*) and the Trading Monitoring Unit of the Frankfurt Stock Exchange (*HÜSt – Handelsüberwachungsstelle*) both monitor trading on the Frankfurt Stock Exchange.

The Federal Financial Supervisory Authority (*BaFin*), an independent federal authority, is responsible for the general supervision of securities trading pursuant to the provisions of the Regulation (EU) No. 596/2014 of the European Parliament and of the Council (*Market Abuse Regulation* or *MAR*), the *WpHG* and other applicable laws.

[**Table of Contents**](#TOC)

#### Trading on the New York Stock Exchange
ADSs representing our shares are listed on the NYSE and traded under the symbol FMS. Effective December 3, 2012, we effected a two-for-one split of our outstanding ADSs, which changed the ratio of our ADSs to shares from one ADSs representing one share to two ADSs representing one share. The Depositary for the ADSs is Bank of New York Mellon (the Depositary). For information regarding the terms of ADSs representing shares of FME AG, see Exhibit 2.1.

#### Item 10. Additional information
&nbsp;&nbsp;&nbsp;&nbsp;A. **Share Capital** 

#### General information regarding our share capital
As of February 13, 2026, our share capital consists of 293,413,449 outstanding bearer shares without par value (*Stückaktien*) and a nominal value of €1.00 each. Our share capital has been fully paid in. For additional information see Exhibit 2.1, "Description of Securities" and note 20 of the notes to the consolidated financial statements included in this report.

&nbsp;&nbsp;&nbsp;&nbsp;B. **Articles of Association** 

---

| | |
|:---|:---|
| **B2.** | **Certain provisions relating to directors** |

---

Our Articles of Association do not contain any provisions with respect to the power of a member of the Supervisory Board or the Management Board to vote on a proposal, arrangement or contract in which he or she is materially interested, their power to vote compensation to themselves or any members of the Supervisory Board or the Management Board, borrowing powers exercisable by the board members, or their retirement or non-retirement under a standard age limit requirement. The Supervisory Board, however, itself set a standard age limit for members of the Supervisory Board and of the Management Board, but this standard age limit may be waived by the Supervisory Board. See Item 6.A., "Directors, senior management and employees — Directors and senior management — "Supervisory Board" and "— Management Board." Transactions in which a related party of the Company (which includes members of the Management Board and the Supervisory Board) is interested are required to be entered into at market conditions. Such transactions may be subject to review by the Supervisory Board. See Item 6.C, "Directors, senior management and employees — Board practices." The compensation of members of our Supervisory Board is fixed by the Articles of Association. The Supervisory Board, assisted by its Compensation Committee, is responsible for determining the compensation of members of the Management Board. See Item 6.B, "Directors, senior management and employees — Compensation — The Company's structure and corporate bodies' compensation — Management Board members' compensation" and Item 6.C, "Directors, senior management and employees — Board practices." The Articles of Association do not require ownership of our shares for director qualification. For share ownership requirements applying to our Management Board members, see Item 6.B, "Directors, senior management and employees — Compensation. For information regarding the provisions of our Articles of Association and applicable law requiring that our Supervisory Board be composed on a parity basis of six supervisory board members representing our shareholders and six supervisory board members representing our employees, see Item 6. Directors, senior managers and employees and Item 16G, "Corporate Governance."

---

| | |
|:---|:---|
| **B.5** | **Provisions relating to shareholder meetings** |

---

The Articles of Association provide that a general meeting is to be called at least thirty days prior to the day of the general meeting (excluding the call date and the meeting date), unless a shorter period is permitted by law. This notice period shall be extended by the days of the period for registration, i.e. the six days prior to the general meeting, unless a shorter period is provided in the meeting invitation, excluding the meeting date and the date that registration is received. Under the Articles of Association, the general meeting shall be held at the place where the Company's registered office is located, in a German city where a stock exchange is situated or at the place where the registered office of a domestic affiliated company is located. Only shareholders who have registered and provided evidence of their entitlement to exercise shareholder rights are entitled to attend and vote at the general meeting. As evidence of entitlement, evidence of the shareholding by the ultimate intermediary is required. Such evidence must relate to the close of business on the 22nd day prior to the general meeting. At our 2025 AGM, our shareholders approved amendments to our Articles of Association to authorize our Management Board, with the approval of our Supervisory Board, for a period of two years to convene general meetings as virtual meetings.

[**Table of Contents**](#TOC)

The remaining information required by Item 10, comprising Items 10.B.3 and 10.B.4, and Items 10.B.6 through 10.B.10, including a description of our ordinary shares, is contained in Exhibit 2.1 to this report, and is incorporated by reference to said exhibit. The description of our ordinary shares contained in Exhibit 2.1 is qualified in its entirety by reference to the complete text of our Articles of Association, which are available at the locations referred to therein.

C. Material contracts

For information regarding certain of our material contracts, see "Item 7.B. Major shareholders and related party transactions — Related party transactions" and note 6 of the notes to the consolidated financial statements included in this report. For a description of our share-based compensation plans, see Item 6.B. "Directors, senior management and employees — Compensation" and note 23 of the notes to the consolidated financial statements included in this report. For a description of our Syndicated Credit Facility and our agreements relating to our long-term and short-term indebtedness, see note 16 and note 17 of the notes to the consolidated financial statements included in this report.

D. Exchange controls

#### Exchange controls and other limitations affecting security holders.
Germany, in principle, does not restrict the export or import of capital. However, there are restrictions on transactions based on sanctions, international embargoes or terror prevention resolutions. These concern, for example, North Korea, Russia, Crimea/Sevastopol, non-government controlled areas of Ukraine in the oblasts of Donetsk, Kherson, Luhansk and Zaporizhzhia and Syria. Restrictions of this nature are adopted at the EU level and, where required, enforced by German national authorities. Furthermore, the Federal Ministry for Economic Affairs and Climate Action (*Bundesministerium für Wirtschaft und Klimaschutz*) may review and restrict or prohibit the direct or indirect acquisition of 25% or more of the voting rights in any German company by a person or company with residency outside of the EU and the European Free Trade Area if such acquisition is likely to impair public security or order. This threshold is 20% for investments in companies active in specific sectors deemed particularly important (e.g. development of personal protective equipment, vaccines, medicinal products, in-vitro diagnostics), and 10% for investments in further defined companies (e.g. operators of critical infrastructure, providers of software for critical infrastructure) or companies active in other sectors deemed essential (e.g. media, certain IT security functions). The 10% threshold also applies to the so-called sector-specific review (including acquisitions by non-German persons and companies) concerning, in particular, German defense companies. The relevant provisions also apply to other means of acquisition, e.g. asset deals, and mergers. Further, for statistical purposes, resident individuals or corporations residing in Germany must report payments of more than €50,000 (or the corresponding amount in other currencies) received from/for account of or made to/for account of an individual or a corporation resident outside of Germany to the German Federal Bank (*Deutsche Bundesbank)*. Certain payments (for example, for the import, export or transfer of goods) are exempt. Specific reporting requirements apply if reports must be lodged for transit trade transactions relating, inter alia, to the designation of the good. In addition, residents (excluding natural persons, monetary financial institutions, investment stock corporations and capital management companies regarding the claims and liabilities of their investment funds) must report (i) monthly any claims against, or any liabilities payable to, non-resident individuals or corporations, if such claims or liabilities, in the aggregate exceed €6 M at the end of any month, and (ii) quarterly claims against, or liabilities payable to, non-residents arising under derivative financial instruments (*derivative Finanzinstrumente*) if the claims, or liabilities, exceed €500 M at the end of the quarter. Further, in principle, residents must report yearly the value (*Stand*) of the assets (*Vermögen*) (i) of non-resident companies in which either 10% or more of the shares or of the voting rights in a company are to be attributed to the resident, (ii) of non-resident companies if more than 50% of the shares or of the voting rights are to be attributed to one or more non-resident companies which are controlled by the resident, and (iii) of the resident's non-resident branch offices and permanent establishments of a domestic company, and the assets which are ascribed to foreign branches and permanent establishments of a foreign company which fulfills the conditions mentioned under (ii). Likewise, equivalent to the conditions described with regard to assets of German residents abroad, residents must report yearly the value of the assets of foreigners in Germany.

Except as described above, there are no limitations imposed by German law or our Articles of Association (*Satzung*) on the right of a non-resident to hold our shares or the ADSs evidencing shares.

[**Table of Contents**](#TOC)

&nbsp;&nbsp;&nbsp;&nbsp;E. **Taxation** 

#### U.S. and German tax consequences of holding ADSs
The discussion below is intended only as a descriptive summary and does not purport to be a complete analysis of all potential German tax and U.S. federal income tax consequences relating to the ownership and disposition of ADSs of the Company. Each holder of ADSs should consult its own tax advisors with respect to the particular German and U.S. federal income tax consequences of the ownership and disposition of ADSs in light of its particular circumstances, including the application of the German and U.S. federal income tax considerations discussed below, as well as the application of state, local, foreign or other laws.

This summary is based on the current tax laws of Germany and the U.S., including the current "Convention between the United States of America and the Federal Republic of Germany for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with respect to Taxes on Income and Capital and to Certain Other Taxes", as amended through the 2006 Protocol to the conventions which entered into force on December 28, 2007 (the Treaty). The 2006 Protocol is effective in respect of withholding taxes for amounts paid on or after January 1, 2007. Changes related to other taxes on income became effective on January 1, 2008.

#### German taxation
For German tax purposes, a holder of ADSs is generally treated as the economic owner of the underlying shares and, therefore, is generally treated as a shareholder of the Company (Federal Ministry of Finance circular dated May 24, 2013, as updated on December 18, 2018) for tax purposes. Differences may, however, apply when the holder of the ADSs seeks to obtain treaty relief from dividend withholding tax in Germany (e.g., in terms of requirements to provide evidence regarding the actual ownership of the ADS and entitlement to economic ownership in the underlying shares).

*Tax treatment of dividends*

Dividend distributions by German corporations paid to resident and non-resident shareholders are generally subject to dividend withholding tax at a rate of 25% (plus solidarity surcharge). The tax withholding obligation in general applies regardless of whether and, if so, to what extent the dividend is exempt from tax at the shareholder's level.

For non-resident shareholders, the withholding tax rate of 25% may be reduced up to 0%, e.g. on the basis of a double tax treaty. For corporate non-German holders, 40% of the withheld and remitted withholding tax may be refunded upon application at the German Federal Tax Office (at the address noted below), which would generally result in a net dividend tax of 15% (plus solidarity surcharge). The entitlement of corporate non-German holders to further reductions of the withholding tax under an applicable income tax treaty remains unaffected. A partial refund of this withholding tax can be obtained by U.S. Holders under the Treaty (see discussion below). Foreign corporations will generally have to meet certain activity or substance criteria defined by applicable law in order to receive an exemption from or a (partial) refund of German dividend withholding tax.

Under the Treaty, the refund of German tax, including the withholding tax, Treaty payment and solidarity surcharge, will not be granted when the ADSs are part of the business property of a U.S. Holder's permanent establishment located in Germany or are part of the assets of an individual U.S. Holder's fixed base located in Germany and used for the performance of independent personal services. In this case, however, withholding tax and solidarity surcharge may be credited against German income tax liability.

*Taxation of capital gains*

If the shares are not held as business assets of a domestic business, capital gains realized by a non-German holder are only taxable in Germany if the disposing holder holds (or has held at any time in the last five years) 1% or more of the Company's stated capital. Under the Treaty, a U.S. Holder who is not a resident of Germany for German tax purposes will not be liable for German tax on capital gains realized or accrued on the sale or other disposition of ADSs unless the ADSs are part of the business property of a permanent establishment located in Germany or are part of the assets of a fixed base of an individual located in Germany and used for the performance of independent personal services.

[**Table of Contents**](#TOC)

*Refund procedures*

To claim a refund under the Treaty, the U.S. Holder, as defined below, must submit an application for refund to the German tax authorities, with the original bank voucher, or certified copy thereof issued by the paying entity documenting the tax withheld or a withholding tax certificate (*Steuerbescheinigung*), as the case may be, within four years from the end of the calendar year in which the dividend is received.

Claims for refund are made on a special German claim for refund form, which must be filed with the German Federal Tax Office: Bundeszentralamt für Steuern, An der Küppe 1, D-53225 Bonn, Germany. The claim refund forms may be obtained from the German Federal Tax Office at the same address where the applications are filed, or from the Embassy of the Federal Republic of Germany, 4645 Reservoir Road, N.W., Washington, D.C. 20007-1998, or can be downloaded from the homepage of the Bundeszentralamt für Steuern (www.bzst.de).

U.S. Holders must also submit to the German tax authorities a certification (on IRS Form 6166) with respect to their last filed U.S. federal income tax return. Requests for IRS Form 6166 are made on IRS Form 8802, which requires payment of a user fee. IRS Form 8802 and its instructions can be obtained from the Internal Revenue Service (IRS) website at www.irs.gov*.*

*German Gift or Inheritance Tax; Other German taxes*

The transfer of ADSs to another person by way of gift or inheritance is generally subject to German gift or inheritance tax only if (i) the decedent, the donor, the heir, donee or any other beneficiary maintained a domicile or his/her habitual abode in Germany, or has its place of management or statutory seat in Germany at the time of the transfer, or is a German citizen who has spent no more than five consecutive years outside Germany without maintaining a residence in Germany (special rules apply to certain former German citizens who neither maintain their domicile nor have their habitual abode in Germany), (ii) the ADSs were held by the decedent or donor as part of business assets for which a permanent establishment or other fixed place of business was maintained in Germany or for which a permanent representative in Germany had been appointed, or (iii) the decedent or donor, at the time of the inheritance or gift, held either individually or collectively with related parties, directly or indirectly, at least 10% of the Company's registered share capital.

The U.S.-Germany estate, inheritance and gift tax treaty provides that an individual whose domicile is determined to be in the U.S. for purposes of such treaty will not be subject to German inheritance and gift tax, the equivalent of the U.S. federal estate and gift tax, on the individual's death or making of a gift unless the ADSs are part of the business property of a permanent establishment located in Germany or are part of the assets of a fixed base of an individual located in Germany and used for the performance of independent personal services. An individual's domicile in the U.S., however, does not prevent imposition of German inheritance and gift tax with respect to an heir, donee, or other beneficiary who is domiciled in Germany at the time the individual died or the gift was made.

Such U.S.-Germany estate, inheritance and gift tax treaty also provides a credit against U.S. federal estate and gift tax liability for the amount of inheritance and gift tax paid in Germany, subject to certain limitations, in a case where ADSs are subject to German inheritance or gift tax and U.S. federal estate or gift tax.

There are no German transfer, stamp or other similar taxes that would apply to U.S. Holders who purchase or sell ADSs.

[**Table of Contents**](#TOC)

#### U.S. taxation
The following discussion describes the material U.S. federal income tax considerations relating to the ownership and disposition of the ADSs by a U.S. Holder (as defined below) who holds ADSs as capital assets for tax purposes, based on the Internal Revenue Code of 1986, as amended (the Code), IRS rulings and pronouncements, judicial decisions, final, temporary and proposed Treasury regulations, and the Treaty, all as now in effect and all of which are subject to change or differing interpretations, possibly with retroactive effect. The discussion below is intended only as a descriptive summary and does not purport to be a complete analysis of all of the potential U.S. tax consequences of holding ADSs of the Company. In particular, this discussion does not address all of the tax consequences that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special tax rules, such as certain financial institutions, insurance companies, regulated investment companies, real estate investment trusts, grantor trusts, traders that have elected the "mark-to-market" method of accounting, a U.S. expatriate within the meaning of Sections 877 or 877A of the Code, tax-exempt entities (including a private foundation, an "individual retirement account" or a Roth IRA), persons subject to special tax accounting rules as a result of any item of gross income with respect to ADSs being taken into account in an applicable financial statement, persons who directly, indirectly, or constructively own 10% or more, by vote or value, of the equity of the Company, investors holding ADSs through partnerships or other fiscally transparent entities, investors liable for the alternative minimum tax, investors that hold ADSs as part of a straddle or a hedge, investors whose functional currency is not the U.S. dollar, dealers in securities and persons holding ADSs in connection with a trade or business conducted outside of the U.S. or in connection with a permanent establishment or other fixed place of business outside of the United States. Moreover, this description does not address the U.S. federal estate and gift tax or alternative minimum tax, or state and local tax consequences of the acquisition, ownership or disposition of ADSs. U.S. Holders should consult their tax advisors regarding U.S. federal, state and local tax consequences of owning and disposing of ADSs.

For purposes of this discussion, a "U.S. Holder" is a beneficial owner of ADSs that for U.S. federal income tax purposes, is (1) an individual who is a citizen or resident of the U.S.; (2) a corporation created or organized under the laws of the U.S., any state thereof or the District of Columbia; (3) an estate, the income of which is subject to U.S. federal income tax regardless of its source; or (4) a trust, if it (i) is subject to the primary supervision of a U.S. court and one or more U.S. persons control all substantial decisions of the trust or (ii) has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. If a partnership (including for this purpose any entity treated as a partnership for U.S. federal income tax purposes) is a beneficial owner of ADSs, the U.S. federal income tax consequences to a partner in the partnership will generally depend on the status of the partner and the activities of the partnership. A holder of ADSs that is a partnership and the partners in such partnership should consult their own tax advisors regarding the U.S. federal income tax consequences of the ownership and disposition of ADSs.

*Ownership of ADSs in general*

For U.S. federal income tax purposes, a holder of ADSs generally will be treated as the owner of the shares represented by such ADSs. The U.S. Treasury Department has expressed concern that depositaries for ADSs, or other intermediaries between the holders of shares of an issuer and the issuer, may be taking actions that are inconsistent with the claiming of U.S. foreign tax credits by U.S. Holders of such receipts or shares. Accordingly, the analysis regarding the availability of a U.S. foreign tax credit for German taxes and sourcing rules described below could be affected by future actions that may be taken by the U.S. Treasury Department.

*Tax treatment of distributions*

Subject to the discussion below under "Passive Foreign Investment Company considerations," a U.S. Holder that receives a distribution with respect to ADSs generally will be required to include the U.S. dollar value of the gross amount of such distribution (before reduction for any German withholding taxes) in gross income as a dividend when actually or constructively received to the extent of the U.S. Holder's pro rata share of the Company's current or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder's pro rata share of the Company's current and accumulated earnings and profits, the distribution will be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder's ADSs. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder's ADSs, the remainder will be taxed as capital gain. We do not intend to maintain calculations of earnings and profits, as determined for U.S. federal income tax purposes. Consequently, any distributions generally will be treated as dividend income.

[**Table of Contents**](#TOC)

With respect to non-corporate U.S. Holders, certain dividends received from a qualified foreign corporation ("qualified dividend income") will be subject to U.S. federal income tax at preferential rates applicable to long-term capital gains (the maximum rate which under current law is 20%), rather than the higher rates of tax generally applicable to items of ordinary income, provided that the ADSs in respect of which such dividend is paid have been held for at least 61 days during the 121 day period beginning 60 days before the ex-dividend date and certain other requirements are met. Periods during which you hedge a position in our ADSs or related property may not count for purposes of the holding period test. The dividends would also not be eligible for the lower rate if you elect to take dividends into account as investment income for purposes of limitations on deductions for investment income. Provided (i) the ADSs of the Company are readily tradable on the NYSE (or certain other stock exchanges) or the Company qualifies for benefits under the Treaty and (ii) the Company was not, in the taxable year prior to the year in which the dividend was paid, and is not, in the taxable year in which the dividend is paid, a passive foreign investment company (discussed below), the Company will be treated as a qualified foreign corporation for this purpose. This reduced rate will not be available in all situations, and U.S. Holders should consult their tax advisors regarding the application of the relevant rules to their particular circumstances.

Subject to certain complex limitations, it is possible that any German tax withheld from distributions in accordance with the Treaty and paid over to Germany will be deductible or creditable against your U.S. federal income tax liability. Special rules apply in determining the foreign tax credit limitation with respect to dividends that are subject to the preferential tax rates. To the extent a reduction or refund of the tax withheld is reasonably certain to be refunded under German law or under the Treaty, the amount of tax withheld would not be expected to be eligible for credit against your U.S. federal income tax liability.

Furthermore, if the dividends are taxed as qualified dividend income (as discussed above), the amount of the dividend taken into account for purposes of calculating the foreign tax credit limitation will in general be limited to the gross amount of the dividend, multiplied by a fraction, the numerator of which is the reduced tax rate applicable to qualified dividend income and denominator of which is the highest tax rate normally applicable to dividends. However, such foreign tax credit may be disallowed if the U.S. Holder held such ADSs or equity shares for less than a minimum period during which the U.S. Holder is not protected from risk of loss or is obligated to make payments related to the dividends. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, any dividends distributed by us with respect to ADSs or equity shares will generally constitute "passive category income" but could, in the case of certain U.S. Holders, constitute "general category income." The rules relating to the determination of the foreign tax credit are complex and U.S. Holders should consult their tax advisors to determine whether and to what extent a credit would be available in their particular circumstances, including the effects of any applicable income tax treaties.

Dividends will generally constitute foreign source income for foreign tax credit limitation purposes. However, if we are a "United States-owned foreign corporation," solely for foreign tax credit purposes, a portion of the dividends allocable to our U.S. source earnings and profits may be re-characterized as U.S. source. A "United States-owned foreign corporation" is any foreign corporation in which U.S. persons own, directly or indirectly, 50% or more (by vote or by value) of the stock. In general, United States-owned foreign corporations with less than 10% of earnings and profits attributable to sources within the U.S. are exempted from these rules. Although we don't believe we are currently a "United States-owned foreign corporation," we may become one in the future. In such case, if 10% or more of our earnings and profits are attributable to sources within the U.S., a portion of the dividends paid on the ADSs allocable to our U.S. source earnings and profits will be treated as U.S. source, and as such, a U.S. Holder may not offset any foreign tax withheld as a credit against U.S. federal income tax imposed on that portion of dividends.

The U.S. dollar value of any distribution on the ADSs made in euros generally should be calculated by reference to the spot exchange rate between the U.S. dollar and the euro in effect on the date the distribution is actually or constructively received by the U.S. Holder regardless of whether and when the Euros so received are in fact converted into U.S. dollars. A U.S. Holder who receives payment in Euros and converts those Euros into U.S. dollars at an exchange rate other than the rate in effect on such day may have a foreign currency exchange gain or loss, which would generally be treated as ordinary income or loss from sources within the U.S. for U.S. foreign tax credit purposes.

[**Table of Contents**](#TOC)

*Sales, exchange, or other dispositions of ADSs*

Subject to the discussion below under "Passive foreign investment company considerations," upon a sale, exchange, or other disposition of the ADSs, a U.S. Holder will generally recognize a capital gain or loss for U.S. federal income tax purposes in an amount equal to the difference between the amount realized and the U.S. Holder's tax basis in the ADSs. Such gain or loss will generally be long-term capital gain or loss if the U.S. Holder's holding period for the ADSs exceeds one year. Individual U.S. Holders are generally taxed at a preferential rate on long-term capital gains (the maximum rate which under current law is 20%). The deductibility of capital losses is subject to limitations. Any such gain or loss that you recognize will generally be treated as U.S. source income or loss for foreign tax credit limitation purposes. You should consult your own tax advisor regarding the availability of a foreign tax credit or deduction in respect of any German tax imposed on a sale or other disposition of ADSs.

In the case of a cash-basis U.S. Holder who receives Euros in connection with the sale or other disposition of ADSs, the amount realized will be calculated based on the U.S. dollar value of the Euros received as determined by reference to the spot rate in effect on the settlement date of such exchange. A U.S. Holder who receives payment in Euros and converts Euros into U.S. dollars at a conversion rate other than the rate in effect on the settlement date may have foreign currency exchange gain or loss that would be treated as ordinary income or loss from sources within the U.S. for U.S. foreign tax credit purposes.

An accrual-basis U.S. Holder may elect the same treatment required of cash-basis taxpayers with respect to a sale or disposition of ADSs, provided that the election is applied consistently from year to year. Such election may not be changed without the consent of the IRS. In the event that an accrual-basis U.S. Holder does not elect to be treated as a cash-basis taxpayer (pursuant to the Treasury regulations applicable to foreign currency transactions), such U.S. Holder may have foreign currency gain or loss for U.S. federal income tax purposes because of differences between the U.S. dollar value of the currency received prevailing on the trade date and the settlement date. Any such currency gain or loss would be treated as ordinary income or loss from sources within the U.S. for U.S. foreign tax credit purposes. However, if foreign currency is converted into U.S. dollars on the date received by the U.S. Holder, a cash-basis or electing accrual-basis U.S. Holder should not recognize any gain or loss on such conversion.

*Taxation of foreign currency gains upon refund of German withholding taxes*

U.S. Holders of ADSs who receive a refund attributable to reduced withholding taxes under the Treaty may be required to recognize foreign currency gain or loss, which will be treated as ordinary income or loss, to the extent that the dollar value of the refund on the date it is received by the U.S. Holders differs from the dollar equivalent of the refund on the date the dividend on which such withholding taxes were imposed was received by the depositary or the U.S. Holder, as the case may be.

*Passive Foreign Investment Company considerations*

Special adverse U.S. federal income tax rules apply to U.S. Holders owning shares of a Passive Foreign Investment Company (PFIC). In general, if you are a U.S. Holder, we will be a PFIC with respect to you if for any taxable year in which you held our ADSs or shares: (i) at least 75% of our gross income for the taxable year is passive income or (ii) at least 50% of the value, determined on the basis of a quarterly average, of our assets is attributable to assets that produce or are held for the production of passive income. The determination of whether we are a PFIC will be made annually. Accordingly, it is possible that we may become a PFIC in the current or any future taxable year due to changes in our asset or income composition. The value of assets for purposes of the asset test, including the value of our goodwill and other unbooked intangibles, will generally be determined by reference to the market price of our ADSs or shares, which may fluctuate considerably, especially in times of high market volatility. Accordingly, fluctuations in the market price of our ADSs or shares may affect our PFIC status for any taxable year.

Passive income generally includes dividends, interest, royalties, rents (other than certain rents and royalties derived in the active conduct of a trade or business), annuities and gains from the disposition of assets that produce passive income. Any cash we hold generally will be treated as held for the production of passive income for the purpose of the PFIC test, and any income generated from cash or other liquid assets generally will be treated as passive income for such purpose. If a non-U.S. corporation owns at least 25% by value of the shares of another corporation, the non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation, and as receiving directly its proportionate share of the other corporation's income.

Although we do not believe that we are currently a PFIC, the determination of PFIC status is highly factual and based on technical rules that are difficult to apply. Accordingly, there can be no assurances that we will not be a PFIC for the current year or any future taxable year. U.S. Holders should consult their own tax advisors regarding the application of the PFIC rules to their investment in our ADSs.

[**Table of Contents**](#TOC)

*Tax on net investment income*

In addition to regular U.S. federal income tax, certain U.S. Holders that are individuals, estates, or trusts are subject to a 3.8% tax on all or a portion of their "net investment income," which may include all or a portion of their dividend income and net gain from the sale, exchange or other disposition of their ADSs.

*U.S. information reporting and backup withholding*

Dividends paid on, and proceeds on a sale or other dispositions of, ADSs paid to a U.S. Holder within the U.S. or through U.S.-related financial intermediaries are subject to information reporting and may be subject to backup withholding at a current rate of 24% unless you (1) are a corporation or other exempt recipient or (2) provide a taxpayer identification number and certify (on IRS Form W-9) that no loss of exemption from backup withholding has occurred.

Backup withholding is not an additional tax, and any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against a U.S. Holder's U.S. federal income tax liability, provided the required information is furnished to the IRS in a timely manner.

Holders other than U.S. Holders are generally not subject to backup withholding. However, such a non-U.S. Holder may be required to provide a certification (generally on IRS Form W-8BEN or W-8BEN-E) of its non-U.S. status in connection with payments received in the U.S. or through a U.S.-related financial intermediary in order to establish its exemption from backup withholding.

Individuals who are U.S. Holders, and who hold "specified foreign financial assets" (as defined in section 6038D of the Code) whose aggregate value exceeds certain thresholds during the tax year, including debt or ordinary shares of a non-U.S. corporation that are held for investment and are not held in an account maintained by a financial institution, may be required to attach to their tax returns for the year certain specified information. An individual who fails to timely furnish the required information may be subject to a penalty. Additionally, in the event a U.S. Holder does not file the required information, the statute of limitations may not close before such information is filed. Under certain circumstances, an entity may be treated as an individual for purposes of the foregoing rules.

U.S. and non-U.S. Holders may be subject to other U.S. information reporting requirements. U.S. and non-U.S. Holders should consult their own advisors regarding the application of U.S. information reporting rules in light of their particular circumstances.

The above summary is not intended to constitute a complete analysis of all tax consequences relating to the ownership and disposition of ADSs. U.S. Holders should consult their own tax advisors concerning the tax consequences of the ownership and disposition of ADSs in light of their particular circumstances, including the application of the U.S. federal income tax considerations discussed above, as well as the application of state, local, non-U.S. or other laws.

&nbsp;&nbsp;&nbsp;&nbsp;H. **Documents on display** 

We file periodic reports and furnish other information with the SEC. You may obtain copies of these reports without charge from the Internet site maintained by the SEC, which contains reports, proxy and information statements, and other information regarding registrants that file electronically with the SEC. The SEC's website is www.sec.gov. The reports and other documents that we filed in our legal form of a partnership limited by shares before the Conversion will continue to be available on the SEC's website on the same page as the reports and other documents that we file in our corporate form as Fresenius Medical Care AG. You can also obtain copies of these reports on the "Investors" page under "Publications" on our own website, www.freseniusmedicalcare.com. In furnishing our website address in this report, however, we do not intend to incorporate any information on our website into this report, and any information on our website should not be considered part of this report, except as expressly set forth herein.

The NYSE currently lists American Depositary Shares representing our shares. As a result, we are subject to the periodic reporting requirements of the Exchange Act and we file reports with, and furnish other information to, the SEC. We are not subject to the SEC proxy rules but, in accordance with the rules of NYSE, we provide for voting by proxy at our general meetings. These reports, proxy statements, and other information and exhibits and schedules thereto may be inspected without charge at, and copies thereof may be obtained at prescribed rates from, the public reference facilities of the SEC and the electronic sources listed in the preceding paragraph.

[**Table of Contents**](#TOC)

In addition to the reports and other information that we file with or furnish to the SEC, we prepare annual and quarterly reports. Our annual reports contain financial statements examined and reported upon, with opinions expressed by our independent auditors. Our consolidated financial statements included in our reports are prepared in conformity with IFRS Accounting Standards as issued by the IASB. For information regarding ESG matters, see "Introduction — Forward-looking statements." Our annual and quarterly reports to our shareholders are posted under "Publications" on the "Investors" page of our website at www.freseniusmedicalcare.com.

We will also furnish the ADR depositary with all notices of shareholder meetings and other reports and communications that are made generally available to our shareholders. The depositary, to the extent permitted by law, shall arrange for the transmittal to the registered holders of American Depositary Receipts of all notices, reports, and communications, together with the governing instruments affecting our shares and any amendments thereto. Such documents are also available for inspection by registered holders of American Depositary Receipts at the principal office of the depositary. For additional information regarding the dissemination of such notices, reports and communications, see the information under the heading "D. American Depositary Shares — Description of American depositary receipts — Voting rights" in Exhibit 2.1.

Documents referred to in this report which relate to us as well as future annual and interim reports prepared by us may also be inspected at our offices, Else-Kröner-Strasse 1, 61352 Bad Homburg v. d. Höhe, Germany.

#### Item 11. Quantitative and qualitative disclosures about market risk

#### Market risk
Our businesses operate in highly competitive markets and are subject to changes in business, economic, and competitive conditions. Our business is subject to:

● changes in reimbursement rates;

● intense competition;

● inflation;

● foreign exchange rate and interest rate fluctuations;

● varying degrees of acceptance of new product introductions;

● technological developments in our industry;

● uncertainties in litigation or investigative proceedings and regulatory developments in the healthcare sector; and

● the availability of financing.

The information required by this Item is contained in note 26 of the notes to the consolidated financial statements included in this report and is incorporated by this reference in response to this Item. We also enter into non-speculative derivative contracts to hedge these risks which are also discussed in detail in note 26 of the notes to the consolidated financial statements included in this report. Additional information related to interest rates is discussed in note 17 of the notes to the consolidated financial statements included in this report.

#### Additional factors and further information
Our business is also subject to other risks and uncertainties that we describe from time to time in our public filings. See Item 3.D, "Key information – Risk factors." Developments in any of these areas could cause our results to differ materially from the results that we or others have projected or may project.

[**Table of Contents**](#TOC)

*Reimbursement rates*

Approximately 16% of our worldwide revenue for 2025 was for services rendered to patients covered by Medicare's ESRD program and Medicaid. In order to be eligible for reimbursement by Medicare, ESRD facilities must meet conditions for coverage established by CMS. Additionally, government agencies may make changes in program interpretations, requirements, or conditions of participation, and retain the right to audit the accuracy of our computations of rebates and pricing, some of which may result in implications (such as recoupment) for amounts previously estimated or paid which may have a material adverse effect on the Company's revenues, profitability, and financial condition. See Item 4.B, "Information on the Company – Business overview – Regulatory and legal matters – Reimbursement" and "– Health care reform" and Item 5, "Operating and financial review and prospects – II. Financial Condition and Results of Operations – Significant U.S. Reimbursement Developments."

We also obtain a significant portion of our revenues from reimbursement by non-government payors. Historically, these payors' reimbursement rates generally have been higher than government program rates in their respective countries. However, non-governmental payors are imposing cost containment measures that are creating significant downward pressure on reimbursement levels that we receive for our services and products. See Item 3.D, "Key information – Risk factors."

*Inflation*

A major portion of our revenues from healthcare are subject to reimbursement rates regulated by governmental authorities, and a significant portion of other revenues, especially revenues from the U.S., is received from customers whose revenues are subject to these regulated reimbursement rates. Non-governmental payors are also exerting downward pressure on reimbursement rates. Increased operation costs that are subject to inflation may not be recoverable through price increases in the absence of a compensating increase in reimbursement rates payable to us and our customers, and could materially adversely affect our business, financial condition, and results of operations.

Recent changes in global trade policy, including new tariffs on most products imported into the U.S. and the possibility of additional trade restrictions, have created increased uncertainty and potential risk within the healthcare industry and to our business operations and financial performance. While we have implemented measures to mitigate these risks, we may see further increased costs for supplies depending on the nature and scope of these shifts on the affected goods and materials we use. In addition to tariffs, additional macroeconomic factors continue to present challenges as inflation remains elevated, which contributes to higher labor and production costs, as well as ongoing disruptions of global supply chains and new or potential export/import restrictions across key markets. Resulting cost increases have and could continue to adversely impact our financial condition and results of operations, especially if we are unable to absorb these costs through increased reimbursement (which is largely dependent on government action and contractual terms) and increased prices for our products or offset them through supply chain adjustments, product redesign (which could require regulatory approvals), or other operational efficiencies. We are closely monitoring these developments and identifying additional strategies to mitigate potential financial and operational impacts and have experienced a limited impact in 2025. However, given the continuously changing nature of these challenges and their broader economic implications, we cannot accurately predict the full extent of their impact on our business in the medium to long-term.

For further information regarding the effects of inflation on our results of operations, see Item 5, "Operating and financial review and prospects – III. Results of operations, financial position and net assets."

[**Table of Contents**](#TOC)

#### Item 12. Description of securities other than equity securities
D. American depositary shares

Items 12A, 12B, and 12C are not applicable to the Company. The information required by Items 12.D.1 and 12.D.2 is incorporated herein by reference to Exhibit 2.1 to this report. The description of our American Depositary Shares contained in Exhibit 2.1 is qualified in its entirety by reference to the complete text of the Amended and Restated Deposit Agreement referred to below, which is available on the SEC website, www.sec.gov.

Information regarding the fees and charges that a holder of our American Depositary Receipts may have to pay, either directly or indirectly, and the fees and other direct and indirect payments made by the depositary to the Company, is set forth in Items 12.D.3 and 12.D.4 below.

---

| | |
|:---|:---|
| **D.3.** | **Fees and expenses** |

---

Under the Amended and Restated Deposit Agreement dated as of November 30, 2023, between the Company and The Bank of New York Mellon, as depositary, ADS holders will be charged a fee for each issuance of ADSs, including issuances resulting from distributions of shares, rights and other property, and for each surrender of ADSs in exchange for deposited securities. The fee in each case is up to $5.00 for each 100 ADSs (or any portion thereof) issued or surrendered.

The following additional charges shall be incurred by the ADS holders, by any party depositing or withdrawing shares or by any party surrendering ADSs or to whom ADSs are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by the Company or an exchange of stock regarding the ADSs or the deposited securities or a distribution of ADRs), whichever is applicable:

● a fee of $0.05 or less per ADS (or portion thereof) for any cash distribution made pursuant to the deposit agreement;

● a fee of $0.05 per ADS (or portion thereof) per year for services performed by the depositary in administering our ADS program (which fee shall be assessed against holders of ADSs as of the record date set by the depositary not more than once each calendar year and shall be payable in the manner described in the next succeeding provision);

● any other charge payable by any of the depositary or the custodian, any of the depositary's or custodian's agents, or the agents of the depositary's or custodian's agents in connection with the servicing of our shares or other deposited securities (which charge shall be assessed against registered holders of our ADSs as of the record date or dates set by the depositary and shall be payable at the sole discretion of the depositary by billing such registered holders or by deducting such charge from one or more cash dividends or other cash distributions);

● a fee for the distribution of securities or of rights where the depositary will not exercise or sell those rights on behalf of holders (or the sale of securities in connection with a distribution), such fee being in an amount equal to the fee for the execution and delivery of ADSs which would have been charged as a result of the deposit of such securities (treating all such securities as if they were ordinary shares) but which securities or the net cash proceeds from the sale thereof are instead distributed by the depositary to those holders entitled thereto;

● stock transfer or other taxes and other governmental charges;

● cable, (including SWIFT) and facsimile transmission and delivery charges as are expressly provided for in the deposit agreement;

● transfer or registration fees for the registration of transfer of deposited securities on any applicable register in connection with the deposit or withdrawal of deposited securities; and

● expenses of the depositary in connection with the conversion of foreign currency into U.S. dollars.

[**Table of Contents**](#TOC)

The depositary may collect any of its fees by deduction from any cash distribution payable, or by selling a portion of any securities to be distributed, to holders that are obligated to pay those fees. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions. The depositary may own and deal in any class of securities of the Company and its affiliates and in the ADSs.

The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

We will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian) pursuant to agreements from time to time between us and the depositary. The fees described above may be amended from time to time. If an amendment adds or increases fees or charges, except for taxes or other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudice a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment.

---

| | |
|:---|:---|
| **D.4.** | **Amounts payable by the depositary to the Company** |

---

Under the fee agreement for the ADS program between us and The Bank of New York Mellon, the depositary has agreed to waive and/or pay its standard out-of-pocket facility administrative and maintenance expenses and registered ADR holder services expenses, as defined by the agreement. Moreover, the depositary has agreed to pay us 100% of the net cash dividend fee collected by the depositary during each contract year. Net cash dividend fees are defined as gross cash dividend fees collected by the depositary less any expenses incurred by the depositary relating to the collection of such fees. For 2025, we received € 1.0 M in aggregate payments from the depositary for such fees and expenses.

[**Table of Contents**](#TOC)

#### Part II

#### Item 13.&nbsp;&nbsp;&nbsp;&nbsp;Defaults, dividend arrearages, and delinquencies
None.

#### Item 14.&nbsp;&nbsp;&nbsp;&nbsp;Material modifications to the rights of security holders and use of proceeds
Not applicable.

#### Item 15A.&nbsp;&nbsp;&nbsp;&nbsp;Disclosure controls and procedures
The Company's management, including the members of the Management Board performing the functions of Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of December 31, 2025. Based on such evaluation, the persons performing the functions of Chief Executive Officer and Chief Financial Officer have concluded that as of December 31, 2025, the Company's disclosure controls and procedures were effective.

#### Item 15B.&nbsp;&nbsp;&nbsp;&nbsp;Management's annual report on internal control over financial reporting
Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f). The Company's internal control over financial reporting is a process designed by or under the supervision of the members of the Management Board performing the functions of Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company's financial statements for external reporting purposes in accordance with IFRS Accounting Standards as issued by the IASB. Internal control over financial reporting includes policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of our assets; (2) provide reasonable assurance that the Company's transactions are recorded as necessary to permit preparation of the consolidated financial statements in accordance with IFRS Accounting Standards as issued by the IASB, and that the Company's receipts and expenditures are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the Company's financial statements.

The Company's management assessed the effectiveness of the Company's internal control over financial reporting based on the criteria established in *Internal Control – Integrated Framework* (2013) issued by COSO as of December 31, 2025. Based on such assessment, management has concluded that the Company's internal control over financial reporting as of December 31, 2025 was effective.

*Inherent limitations of internal control over financial reporting*

Because of its inherent limitations, internal control over financial reporting, no matter how well designed, cannot provide absolute assurance of achieving financial reporting objectives and may not prevent or detect misstatements. Therefore, even if the internal control over financial reporting is determined to be effective it can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

#### Item 15C.&nbsp;&nbsp;&nbsp;&nbsp;Attestation report of the independent registered public accounting firm
The effectiveness of our internal control over financial reporting as of December 31, 2025 has been audited by PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft, an independent registered public accounting firm, as stated in their report included on page F-2.

#### Item 15D.&nbsp;&nbsp;&nbsp;&nbsp;Changes in internal control over financial reporting
There were no changes in our internal control over financial reporting during the year ended December 31, 2025 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

[**Table of Contents**](#TOC)

#### Item 16A.&nbsp;&nbsp;&nbsp;&nbsp;Audit committee financial expert
Our Supervisory Board has determined that each of Dr. Marcus Kuhnert and Mr. Gregory Sorensen, MD qualifies as an audit committee financial expert and is "independent" as defined in Rule 10A-3 under the Exchange Act, in accordance with the instructions in Item 16A of Form 20-F.

#### Item 16B.&nbsp;&nbsp;&nbsp;&nbsp;Code of ethics
On October 14, 2020, we adopted a revised Code of Ethics and Business Conduct. As adopted, the revised Code applies to members of the Management Board, including its Chair and the member responsible for Finance & Controlling, other senior officers, and all Company employees.

A copy of our Code of Ethics and Business Conduct is available on our website under "About Us – Compliance" at: www.freseniusmedicalcare.com/en/about-us/compliance/our-code-of-ethics-and-business-conduct/

#### Item 16C.&nbsp;&nbsp;&nbsp;&nbsp;Principal accountant fees and services
At the AGM held on May 21, 2025, our shareholders approved the appointment of PwC to serve as our independent auditors for the 2025 fiscal year, for the potential review of interim financial information for fiscal year 2025 prepared after the AGM in 2025 and as auditor for the potential review of interim financial information for fiscal year 2026 prepared prior to the AGM in 2026. At the AGM held on May 16, 2024 our shareholders approved the appointment of PwC to serve as our independent auditors for the 2024 fiscal year, for the potential review of interim financial information for fiscal year 2024 prepared after the AGM in 2024 and as auditor for the potential review of interim financial information for fiscal year 2025 prepared prior to the AGM in 2025.

For the fees billed by our principal accountant for the last three years, comprising audit fees, audit related fees, tax fees and other fees, see note 32 of the notes to the consolidated financial statements included in this report.

#### Audit Committee's pre-approval policies and procedures
As a German company, we prepare statutory financial statements under German law on the basis of the accounting principles of the German Commercial Code (*Handelsgesetzbuch* or *HGB*) and consolidated financial statements in accordance with IFRS Accounting Standards. Our Supervisory Board engages our independent auditors to audit these financial statements, in consultation with our Audit Committee and subject to election by our shareholders at our AGM in accordance with German law.

Our financial statements are also included in registration statements and reports that we file with the SEC. Our Audit Committee engages our independent auditors to audit these financial statements in accordance with Rule 10A-3 under the Exchange Act and Rule 303A.06 of the NYSE Governance Rules. See also the description in "Item 6C. Directors, senior management and employees – Board practices."

Our Audit Committee also adopted a policy requiring management to obtain the committee's approval before engaging our independent auditors to provide any permitted non-audit services to us or our subsidiaries. Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the Audit Committee pre-approves a catalog of specific non-audit services that may be performed by our auditors. The policy also provides for additional approval requirements based on fee amount.

The Chief Financial Officer reviews or is informed of all individual management requests to engage our auditors as a service provider in accordance with this catalog and, if the requested services are permitted pursuant to the catalog, approves the request according to thresholds defined in the policy. Services that are not included in the catalog or are included but exceed applicable fee levels are passed on either to the chair of the Audit Committee or to the full committee for approval on a case-by-case basis. In addition, the Audit Committee is informed about all approvals on a quarterly basis. Neither the chair of our Audit Committee nor the full committee is permitted to approve any engagement of our auditors if the services to be performed either fall into a category of services that are not permitted by applicable law or would be inconsistent with maintaining the auditors' independence.

[**Table of Contents**](#TOC)

#### Item 16D.&nbsp;&nbsp;&nbsp;&nbsp;Exemptions from the listing standards for audit committees
SEC Rule 10A-3 under the Exchange Act requires that all members of the Audit Committee of our Supervisory Board be independent, as defined by that rule, subject to certain exceptions. Our Audit Committee consists of both board members elected by our shareholders and board members elected by our employees. Under Rule 10A-3, a company employee is ordinarily not considered independent. However, Rule 10A-3 provides an exception for an employee of a foreign private issuer who is not an executive officer of that issuer and who is elected to the supervisory board or audit committee of that issuer, *inter alia,* pursuant to the issuer's governing law. In such a case, the employee is exempt from the independence requirements of Rule 10A-3 and is permitted to serve on the audit committee.

We rely on this exemption. Our Audit Committee includes two employee representatives, Ms. Stefanie Balling and Mr. Frank Michael Prescher, who were appointed to our Supervisory Board pursuant to the provisions of the German Stock Corporation Act (AktG) and the German Co-Determination Act (MitbestG). See Item 6A, "Directors, Senior Management and Employees - Directors and senior management" and Item 16G, "Corporate Governance" for additional information. We believe that our reliance on this exemption does not materially adversely affect the ability of our Audit Committee to act independently and to satisfy the other requirements of Rule 10A-3.

#### Item 16E.&nbsp;&nbsp;&nbsp;&nbsp;Purchase of equity securities by the issuer and affiliated purchasers
By resolution of the Company's AGM on May 20, 2021, amended by the Company's EGM on July 14, 2023 in its wording with respect to the Company's change of legal form, the Management Board is authorized until May 19, 2026 to purchase treasury shares up to a maximum amount of 10% of the registered share capital existing at the time of this resolution. On the basis of this authorization, we launched our €1 BN share buyback program (excluding ancillary transaction costs) in two tranches to be completed within two years by August 10, 2027. Under the first tranche, shares were to be acquired up to a maximum of €600 M including any true-ups over a period ending latest April 30, 2026. The first tranche was initiated on August 11, 2025 and completed ahead of schedule on December 29, 2025, under which 14,124,564 shares were repurchased for €586 M (including true-ups). On January 9, 2026, we announced that we would accelerate our share buyback program and start the repurchase of the second tranche. Under the second tranche, we plan to repurchase a total amount of around €414 M from January 12 to May 8, 2026. The share buyback program is expected to be completed significantly earlier than originally planned, in less than a year. As of December 31, 2025, we hold 14,124,564 treasury shares. These shares will be used predominantly to reduce the registered share capital of the Company by cancellation of the acquired shares and, to a significantly lesser extent, may be used for allocations under incentive-based compensation plans.

See note 20 of the notes to the consolidated financial statements included in this report for information on the authorization of our Management Board to purchase treasury shares, as well as information on purchases made pursuant to our share buyback program during the fiscal year, which is provided in substantially the columnar format required by Item 16E. We did not purchase any shares outside of our share buyback program.

#### Item 16F.&nbsp;&nbsp;&nbsp;&nbsp;Change in registrant's certifying accountant
Not applicable.

#### Item 16G.&nbsp;&nbsp;&nbsp;&nbsp;Corporate governance

#### Introduction
ADSs representing our shares are listed on the NYSE. However, because we are a "foreign private issuer," as defined in the rules of the SEC, we are exempt from substantially all of the governance rules set forth in Section 303A of the NYSE's Listed Companies Manual, other than the obligations to:

● maintain an audit committee in accordance with Rule 10A-3 under the Exchange Act,

● maintain (and enforce, if required) an incentive-based compensation recovery policy,

● notify the NYSE if any of our executive officers becomes aware of any material non-compliance with any applicable provisions of Section 303A,

[**Table of Contents**](#TOC)

● file annual and interim written affirmations, on forms mandated by the NYSE, relating to our compliance with applicable NYSE governance rules, and

● disclose the significant ways in which the governance standards that we follow differ from those applicable to U.S. companies under the NYSE governance rules.

Many of the governance reforms instituted by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, including the requirements to provide shareholders with "say-on-pay" and "say-on-when" advisory votes related to the compensation of certain executive officers, are implemented through the SEC's proxy rules. Because foreign private issuers are exempt from the proxy rules, these governance rules are not applicable to us. Under German law, our compensation system must be submitted for approval to the general meeting of shareholders if relevant amendments to the system are made and every four years, at a minimum. Each of the Compensation System 2020+ and the Compensation System 2024+ for our Management Board was submitted to, and was approved by, our AGM on August 27, 2020, and May 16, 2024, respectively. The compensation system is also reviewed by an independent external compensation expert if relevant amendments to the system are made. Similarly, the more detailed disclosure requirements regarding management compensation applicable to U.S. domestic companies (including requirements to provide pay ratio disclosure and a "Compensation Discussion and Analysis," as well as disclosure of the relationship between executive compensation actually paid and a registrant's financial performance) are found in SEC Regulation S-K, whereas compensation disclosure requirements for foreign private issuers are set forth in Form 20-F. Item 6.B of Form 20-F generally requires foreign private issuers to disclose executive compensation on an individual basis for all officers unless the issuer does not disclose individual compensation pursuant to home country law or otherwise. We disclose the compensation paid to members of the Management Board and the Supervisory Board on an individual basis in the Compensation Report that we prepare and disclose under German law. A convenience translation of our Compensation Report for 2025, which discloses the compensation received by these board members and describes our compensation system and the performance targets included in the system, is included in this Form 20-F. See Item 6.B, "Directors, senior management and employees — Compensation." We submit the Compensation Report to our shareholders for approval at our AGM.

In October 2022, the SEC issued its final compensation "clawback" (recovery) rule. That rule directs U.S. stock exchanges to establish listing standards requiring their listed issuers to adopt, implement and disclose policies providing for the recovery, under certain circumstances, of incentive-based compensation paid on the basis of financial information that is subsequently restated. In addition, if a company prepares such an accounting restatement, it will be required to disclose information regarding the enforcement of its recovery policy, including whether the company has foregone any such recovery under the limited conditions permitted by the rule and whether any executive officer owes any amounts of recoverable compensation to the company. See Item 6.F, "Directors, senior management and employees — Disclosure of a registrant's action to recover erroneously awarded compensation." The clawback rule and related disclosure requirements apply to both U.S. domestic and foreign private issuers and impose clawback requirements without fraud or other misconduct as a necessary prerequisite. Our incentive-based compensation recovery policy is available at www.sec.gov. Under the terms and conditions of our long-term incentive plans and the service agreements concluded with the members of the Management Board, the Company is entitled to reclaim certain previously earned and paid compensation components. Such right to reclaim exists in case of relevant violations of internal guidelines or undutiful conduct. The SEC's clawback rule does not affect our rights to seek recovery under these compensation plans and service agreements, but any such recovery could not be applied to offset amounts due under our incentive-based compensation recovery policy unless such violation or undutiful conduct were directly related to an accounting restatement.

In addition to the comparative governance disclosure requirements of this Item 16.G, as a German company, we disclose certain governance matters in a Declaration on Corporate Governance (*Erklärung zur Unternehmensführung*) that we prepare and make available pursuant to German law as well as certain other governance-related information that we prepare and make available pursuant to German and EU law, as described in the Introduction to this Form 20-F. Our Declaration on Corporate Governance, in addition to the information in Item 6.A, "Directors, senior management and employees — Directors and senior management" and Item 6.C "Directors, senior management and employees — Board practices," each above, in particular includes information on the composition and practices of the Management Board, our Supervisory Board and the committees of our Supervisory Board. Our Declaration on Corporate Governance for 2024 is posted on our website at www.freseniusmedicalcare.com/en/investors/corporate-governance/declaration-on-corporate-governance. We will post our 2025 Declaration on Corporate Governance on our website when it becomes available following the filing of this report on Form 20-F.

[**Table of Contents**](#TOC)

In contrast, SEC rules require certain sustainability-related information in reports filed with the SEC. See Item 16K, "Cybersecurity." In March 2024 the SEC adopted disclosure requirements regarding climate-related matters in SEC reports and registration statements filed with the SEC, including information about a company's climate-related risks, disclosure of a company's GHG emissions, and inclusion of certain climate-related financial metrics in a company's audited financial statements. Similar to the cybersecurity rules, the SEC's climate disclosure rules apply to both U.S. domestic and foreign private issuers. The SEC has stayed the effectiveness of these rules which are subject to litigation contesting their validity in the Eighth Circuit Court of Appeals, which has stayed the litigation and ordered the SEC to decide whether to defend the challenged rules or reconsider the rules by statutory notice-and-comment rulemaking.

As a German company, FME AG follows German corporate governance practices. German corporate governance practices generally derive from the provisions of the AktG, capital market related laws, the German Co-Determination Act (*Mitbestimmungsgesetz,* or MitBestG) and the German Corporate Governance Code. Our Articles of Association also include provisions relevant to our corporate governance. German standards differ from the corporate governance listing standards applicable to U.S. domestic companies which have been adopted by the NYSE. The discussion below provides certain information regarding our organizational structure, management arrangements and governance. It should be noted that the information in the discussion below relating to the voting and other rights of our shareholders under our Articles of Association and German law applies only to persons who actually hold our shares, but not to holders of our ADSs. Holders of our ADSs have only the rights provided under the deposit agreement governing the terms of the ADSs. For detailed information regarding those rights, including information regarding how holders of ADSs may instruct the depositary to vote the shares represented by their ADSs, see the information under the heading "D. American Depositary Shares — Description of American depositary receipts" in Exhibit 2.1 to this report.

#### The legal structure of the Company
The Company is a stock corporation under German law. The corporate bodies of a German stock corporation are its management board, its supervisory board and its general meeting of shareholders.

#### Management and oversight
The governance structure of FME AG is illustrated as follows:

![Graphic](fms-20251231x20f025.jpg)

#### Management Board
The Management Board manages the Company and conducts its business.

[**Table of Contents**](#TOC)

#### Supervisory Board
The Supervisory Board supervises and advises the Management Board and performs the other duties assigned to it by law and the Articles of Association. In accordance with principle 6 of the German Corporate Governance Code, supervision and advice include sustainability matters. The Supervisory Board is further involved in strategy and planning as well as all matters of fundamental importance for the Company.

Pursuant to the applicable statutory provisions of the German Stock Corporation Act (*Aktiengesetz* — AktG), the German Co-Determination Act (*Mitbestimmungsgesetz* – MitbestG) and in accordance with the more detailed provisions of the Articles of Association of the Company, the Supervisory Board of the Company consists of twelve members, of whom, subject to Fresenius SE's appointment right pursuant to Article 8 paragraph 2 of the Articles of Association, six are to be elected by the General Meeting (shareholder representatives) and six are to be elected by the employees (employee representatives) in accordance with the provisions of the MitbestG. See Item 6A, "Directors, senior management and employees — Directors and senior management - Supervisory Board."

The Supervisory Board does not include any members who were previously members of the Management Board.

German regulations have several rules applicable to supervisory board members which are designed to ensure that the supervisory board in its entirety possesses the knowledge, ability and expert experience to properly fulfill its tasks as well as to ensure a certain degree of independence of the board's members. German law prohibits members of the management board from contemporaneously serving on the supervisory board. This may be contrasted with the U.S. practice under which executive officers may, and often do, serve as both officers and directors of a company, subject to stock exchange rules requiring listed U.S. domestic companies (but not foreign private issuers such as the Company) to have a majority of independent directors (further subject to certain additional exceptions). German law requires members of the supervisory board to act in the best interest of the company. They do not have to follow directions or instructions from third parties. Any service, consulting or similar agreements between an AG and any of its supervisory board members require approval by the supervisory board and are only permitted in such cases where the subject matter is beyond the scope of a supervisory board member's duties.

#### General meeting
The general meeting is the resolution body of the Company's shareholders. The rules of the NYSE require companies with voting securities listed on the NYSE to solicit proxies for all meetings of shareholders; however, such solicitations by foreign private issuers need not comply with the SEC's proxy rules. Shareholders can exercise their voting rights at the general meeting themselves, by proxy via a representative of their choice, or by a company-nominated proxy acting on their instructions. Instructions for voting by proxy are included in the invitation for the general meeting. The agenda and resolution proposals for the general meeting are prepared by the Management Board and the Supervisory Board. The Management Board, however, cannot propose nominees for election as members of the Supervisory Board or make proposals for the Company's auditors.

#### The Articles of Association of FME AG
For information regarding our Articles of Association, including information regarding the Company's authorized share of capital, see Exhibit 2.1. The information about our Articles of Association summarized in Exhibit 2.1 is not complete and is qualified in its entirety by reference to the complete form of Articles of Association of FME AG. A convenience English translation of our Articles of Association is on file with the SEC and can also be found on the Company's website under www.freseniusmedicalcare.com.

[**Table of Contents**](#TOC)

#### Managers' transactions
According to Article 19(1) of the MAR, persons discharging managerial responsibilities within an issuer of shares, as well as persons closely associated with them, are obligated to notify the issuer and the competent authority, i.e. for the Company as issuer, *BaFin*, of every transaction conducted on their own account relating to the shares or debt instruments of the issuer or to derivatives or other financial instrument linked thereto no later than three business days after the date of the transaction, once the volume of all transactions conducted within a calendar year exceeds a total amount of € 50,000. Persons discharging managerial responsibilities include, inter alia, the members of management boards and supervisory boards. We make public the information received through these notifications and publish them on our website in accordance with the MAR. We must make public the information contained in a notification received from a person discharging managerial responsibilities within two business days of receipt of such a notification. Pursuant to Article 19(11) of the MAR, a person discharging managerial responsibilities within an issuer must not either conduct any transactions on its own account or for the account of a third party, directly or indirectly, relating to, *inter alia*, the shares or debt instruments of the issuer during a closed period of 30 calendar days before the announcement of an interim financial report or a year-end report which the issuer is obliged to make public.

Holders of more than 5% of our voting securities are, however, required to comply with the reporting requirements of Section 13(d) of the Exchange Act. See Item 7A, "Major shareholders and related party transactions – Major shareholders. The reporting requirements of Section 16 of the Exchange Act do not apply to holders of more than 10% of the equity securities of a foreign private issuer, but commencing March 18, 2026, the members of our Management Board and our Supervisory Board will become subject to such requirements with respect to their ownership of and transactions in our shares. Transactions in our shares are not subject to "short-swing" profit recovery by us or our shareholders. As a foreign private issuer, we are also exempt from the SEC proxy rules. Therefore, we are also not subject to rules adopted by the SEC that require U.S. domestic public companies to disclose in their proxy statements their practices or policies regarding the ability of their directors, officers or employees (or their respective designees) to purchase financial instruments that are designed to hedge or offset any decrease in the market value of equity securities granted to them as compensation or directly or indirectly held by them. However, our Insider Policy provides that persons subject to the policy are discouraged from engaging in such transactions.

We are subject to SEC rules requiring disclosure in annual reports whether or not (and if not, why not) a company has adopted insider trading policies and procedures and requiring a company that has adopted such policies and procedures to disclose such policies and to file its policies as an exhibit to its annual report. Our Insider Policy is available on the SEC's website, www.sec.gov and on our website, www.freseniusmedicalcare.com.

[**Table of Contents**](#TOC)

#### Certain share issuances
Under the listing rules of the NYSE, the issuance of securities of the same class as the listed class, or of securities convertible into or exchangeable for the listed securities, may require shareholder approval as a condition to the listing of such additional securities on the NYSE. Subject to certain exceptions (including the issuance of shares in public offerings for cash and issuances for cash at a price equal to or exceeding a defined minimum), shareholder approval may be required for the listing of shares to be issued to certain related parties, issuances of shares having voting power equal to or in excess of 20% of the voting power outstanding before the issuance of such securities, and issuances pursuant to share-based incentive compensation plans. However, under NYSE policy, such approval is not required for issuances of securities by foreign private issuers if it is not required by the issuer's home country law and the NYSE receives an opinion of counsel in the issuer's home jurisdiction to that effect. Subject to shareholder approval requirements under the stock exchange listing rules referred to above, companies organized under the corporate statutes of the states of the U.S. may generally issue shares solely by action of a company's board of directors, assuming, in the case of common shares, the availability of a sufficient number of authorized but unissued and unreserved shares or, in the case of preferred stock, the inclusion of "blank-check" preferred authorization in a company's charter document. In contrast, under the AktG, the issuance of new shares requires a capital increase (*Kapitalerhöhung*) of the Company by way of an approval by the shareholders requiring the affirmative vote of a majority of three quarters of the capital represented at the vote. Next to a capital increase against contribution (*Kapitalerhöhung gegen Einlagen*), a capital increase may also be conducted from Authorized Capital (*genehmigtes Kapital*) or Conditional Capital (*bedingtes Kapital*). The resolution creating Authorized Capital may authorize the Management Board to issue new shares up to a stated amount for a period of up to five years. The nominal value of any proposed increase of the Authorized Capital may not exceed half of the issued capital stock at the time of the authorization. In addition, Conditional Capital may be created for the purpose of issuing (i) new shares to holders of convertible bonds or other securities which grant a right to shares, (ii) new shares as the consideration in a merger with another company, or (iii) new shares offered to management or employees. The nominal value for any Conditional Capital may not exceed 60% of the Company's issued capital at the time of the resolution. The nominal value for any Conditional Capital created for the purpose of issuing new shares to holders of convertible bonds or other securities which grant a right to shares may not exceed 50% of the Company's issued capital at the time of the resolution. The nominal value for any Conditional Capital created for the purpose of issuing shares to management and employees may not exceed 20% of the Company's issued capital at the time of the resolution. For information regarding our authorized capital, including provisions permitting the exclusion of shareholder subscription (pre-emptive) rights, and our conditional capital, see Exhibit 2.1 to this report.

#### Comparison with U.S. and NYSE governance standards and practices
Although, as noted above, our status as a foreign private issuer exempts us from most of the NYSE requirements, several of the concepts addressed by the NYSE rules are also addressed (but not mandated) by the German Corporate Governance Code. The most recent applicable version of the German Corporate Governance Code is dated April 28, 2022 which became effective June 27, 2022 (German Corporate Governance Code). The German Corporate Governance Code's governance rules applicable to German corporations are not legally binding. However, companies that do not comply with the German Corporate Governance Code's recommendations must disclose publicly whether and for what reason their practices differ from the recommendations of the German Corporate Governance Code. Under the German Corporate Governance Code, a well justified deviation from a recommendation may be in the interest of good corporate governance. A convenience translation of our most recent annual "Declaration of Compliance" with the recommendations of the German Corporate Governance Code, including certain deviations, is posted on our website, www.freseniusmedicalcare.com in the section "Corporate Governance" of the Investor Relations page under "Declaration of Compliance" at www.freseniusmedicalcare.com/en/investors/corporate-governance/declaration-of-compliance/, together with our declarations for prior years.

[**Table of Contents**](#TOC)

The listing standards of the NYSE require that a U.S. domestic listed company have a majority of independent board members and that the independent directors meet in regularly scheduled sessions without management. U.S. listed companies must also adopt corporate governance guidelines that address director qualification standards, director responsibilities, director access to management and independent advisors, director compensation, director orientation and continuing education, management succession, and an annual performance evaluation of the board. Some of the German Corporate Governance Code's recommendations address the independence and qualifications of supervisory board members. Specifically, the German Corporate Governance Code recommends that the supervisory board shall determine specific objectives regarding its composition and shall prepare a profile of skills and expertise for the entire board while taking the principle of diversity into account. Our Supervisory Board has determined concrete objectives for its composition and prepared such a profile of skills and expertise, which is posted on our website at www.freseniusmedicalcare.com/en/about-us/supervisory-board. Proposals by the supervisory board to the general meeting shall take these objectives into account, while simultaneously aiming at fulfilling the overall profile of required skills and expertise of the supervisory board. The objectives regarding its composition shall, inter alia, also take into account potential conflicts of interest. Further, information shall be provided about what the supervisory board regards as the appropriate number of independent supervisory board members, and the names of those members. Our independent shareholder representatives on the Supervisory Board within the meaning of the German Corporate Governance Code are Mr. Shervin J. Korangy, Dr. Marcus Kuhnert, Mr. Gregory Sorensen, MD, and Ms. Pascale Witz. Similarly, if a substantial and not merely temporary conflict of interest between a company and a member of its supervisory board arises, the German Corporate Governance Code recommends that the term of that member be terminated. The German Corporate Governance Code further recommends that at any given time not more than two former members of the management board shall serve on the supervisory board. Presently, no member of our Supervisory Board is a former member of our Management Board. As previously noted, we are exempt from the SEC proxy rules, which require U.S. issuers to include in SEC filings a discussion of the specific experience, qualifications, attributes or skills that led to directors' inclusion as board members. However, Form 20-F requires that we disclose, inter alia, the business experience, functions and areas of experience in the Company of our directors and their principal business activities performed outside the Company. Under the German Corporate Governance Code, the composition of the supervisory board has to ensure that its members collectively have the knowledge, skills, and professional expertise required to properly perform all duties. For information regarding the professional backgrounds of our board members, see Item 6. Directors, senior management and employees.

Since the Company's change of legal form to that of an AG took effect and the German Co-Determination Act (*Mitbestimmungsgesetz*) became applicable to the Company, at least 30% of the members of the Supervisory Board must be women and at least 30% must be men in accordance with Section 7 paragraph 3 sentence 1 MitbestG, Section 96 paragraph 2 AktG. For a twelve-member supervisory board, this corresponds to at least four women and at least four men. This requirement was met during 2025.

Gender requirements for the composition of the Management Board are also applicable to the Company's Management Board. According to Section 76 paragraph 3a AktG, if the Management Board of the Company consists of more than three persons, it must include at least one woman and at least one man. This requirement was met at all times during 2025 and continues to be met as of the date of this report.

The NYSE, on which ADSs representing our shares are listed, does not impose specific diversity requirements for boards of directors of NYSE-listed companies, and has noted that in at least one state, laws mandating diversity have been struck down.

As noted above, as a company listed on the NYSE, we are required to maintain an audit committee in accordance with Rule 10A-3 under the Exchange Act. The NYSE's governance rules applicable to U.S. domestic listed companies also require that such companies also maintain a nominating committee to select nominees to the board of directors and a compensation committee, each consisting solely of directors who are "independent" as defined in the NYSE's governance rules. While we maintain a nominating committee and a compensation committee of our Supervisory Board, we are exempt from the NYSE rules requiring such committees and that they consist solely of independent directors.

[**Table of Contents**](#TOC)

In contrast to U.S. practice, with two exceptions, German corporate law does not mandate the creation of specific supervisory board committees, independent or otherwise. As a company subject to the MitbestG, we are required to establish a mediation committee with a charter to resolve any disputes among the members of the supervisory board that may arise in connection with the appointment or dismissal of members of the management board. In addition, the AktG provides that the supervisory board of public interest entities within the meaning of the German Commercial Law must establish an audit committee that supervises the monitoring of the accounting process, the effectiveness of the internal control system, the risk management system and the internal audit function as well as the annual auditing, in particular the selection and the independence of the external auditor, the quality of the audit, and the additional services rendered by the external auditor. Most of these functions are also the responsibility of the audit committee under the NYSE and SEC audit committee rules. Our Audit Committee within the Supervisory Board, which functions in each of these areas, also serves as our audit committee required by SEC Rule 10A-3 and the NYSE rules. The Rules of Procedure of our Audit Committee, and the SEC and NYSE rules all require that the Audit Committee consist solely of "independent" directors, except that committee members may serve in reliance on an applicable exemption from such independence requirements. Under the Audit Committee Rules of Procedure and the German Corporate Governance Code, an Audit Committee member is independent if such member has no significant business, professional or personal relationship with the Company or its affiliates and satisfies the SEC and NYSE independence requirements, is independent from the Company, the Management Board and from any controlling shareholder as defined by the German Corporate Governance Code and, in case of a conflict of interest, the Supervisory Board determines that such conflict does not interfere with the exercise of such member's independent judgment as a member of the Audit Committee. Under the SEC and NYSE rules, an audit committee member is not independent if he or she receives any compensation other than fees for board and committee service and certain permitted retirement compensation. Co-determination requires that our Supervisory Board include employee representatives. However, under the SEC and NYSE audit committee rules, Supervisory Board members who are also employees would not be independent because, in addition to any fees they receive for service on the board and the Audit Committee, they receive compensation as employees. The SEC and NYSE audit committee rules recognize our co-determination obligations and provide that employees of a foreign private issuer who serve on the issuer's board of directors or audit committee pursuant to the issuer's governing law or documents, a collective bargaining or similar agreement or other home country legal or listing requirements, and who are not "executive officers" (as defined in SEC Rule 3c-7 under the Exchange Act) of the foreign private issuer are exempt from those rules' independence requirements. See Item 16D. "Exemptions from the listing standards for audit committees." In accordance with Rule 303A.12 of the NYSE listing rules, we also report our reliance on this exemption in an Annual Affirmation to the NYSE.

In addition to the Audit Committee, our Supervisory Board has formed a Presiding Committee, a Compensation Committee, a Nomination Committee and a Mediation Committee. For information regarding the members of our Audit Committee as well as the functions of the Audit Committee, the Presiding Committee, the Compensation Committee, the Nomination Committee and the Mediation Committee, see Item 6.C, "Directors, senior management and employees — Board practices."

Under the NYSE compensation committee rule, as adopted to implement SEC Rule 10C-1 adopted under the Dodd-Frank Act, NYSE-listed companies must maintain a compensation committee consisting solely of independent directors. Unlike the SEC Audit Committee Rule, which identifies specific factors that preclude independence, Rule 10C-1 provides that independence is to be determined considering "all relevant factors." Under SEC Rule 10C-1, a compensation committee is a committee with functions that include "oversight" of executive compensation on behalf of the board of directors. NYSE Rule 303A.05 provides that a NYSE-listed company's compensation committee must have, *inter alia*, "direct responsibility" to determine and approve the CEO's compensation level and make recommendations to the board with respect to non-CEO executive officer compensation. Under the NYSE rules, foreign private issuers such as FME AG continue to be exempt from all requirements to maintain an independent compensation committee. Our Compensation Committee prepares proposals for the Supervisory Board regarding the compensation of the Management Board, but the Supervisory Board itself must decide upon such compensation.

The SEC's incentive compensation "clawback" rule permits a company to refrain from pursuing recovery of incentive compensation if it would be "impracticable" to do so (see Item 6.F, "Disclosure of a registrant's actions to recover erroneously awarded compensation"). The rule requires that the impracticability determination must be made by a company's independent committee responsible for executive compensation or, in the absence of such a committee, a majority of the independent directors on the company's board. For foreign private issuers, recovery may be "impracticable" if (in addition to other bases available to all issuers) recovery would violate the issuer's home country law where that law was adopted prior to November 28, 2022. In such a case, the issuer must obtain an opinion of home country counsel to that effect and provide such opinion to the stock exchange on which it is listed.

#### Item 16H. Mine safety disclosure
Not applicable.

[**Table of Contents**](#TOC)

#### Item 16I. Disclosure regarding foreign jurisdictions that prevent inspections
Not applicable.

#### Item 16J. Insider trading policies
Our insider trading policy, as contemplated by Item 16J. of Form 20-F, is available on the SEC website, www.sec.gov, as Exhibit 11.3 to this report.

#### Item 16K. Cybersecurity
***Risk Management and Strategy***

Our cybersecurity program is designed to protect our information, and that of our patients, our business partners and our employees, from unauthorized access, manipulation and data misuse. Cybersecurity is an integral aspect of our enterprise digital program. Our goal is to continuously enhance our global cybersecurity capabilities to safeguard sensitive information and facilitate strategic initiatives. The Cybersecurity & Privacy Solutions department is responsible for overseeing information security and privacy assurance. Additionally, as cybersecurity is part of our overall risk management system, such risks are monitored and semi-annually reported to the Management Board within our risk management system. Our Global Internal Audit Department audits a selected number of our technology applications worldwide each year (see Item 4. "Information on the Company — B. Business Overview — Risk management" for further information on this system). Routine program updates are provided to our Management Board and we provide a program review for our Supervisory Board on an annual basis. Our goal is to continuously respond to changes in the global security landscape through consistent monitoring and analysis practices.

During 2025, we successfully delivered the key initiatives outlined in our security roadmap, including improving our risk management and global cybersecurity operations. We increased our cybersecurity effectiveness by implementing strategic initiatives focused on cybersecurity governance, risk and compliance, cyber operations, third-party risk and data security programs. For example, we have implemented a new monthly cybersecurity risk metrics process, allowing standard metrics to be discussed during our monthly Cybersecurity Council Meeting. Additionally, we completed the migration of our security incident & event management platform to an enterprise-integrated solution, enabling us to keep pace with modern cybersecurity threats.

In managing and measuring performance as part of our global cybersecurity program, we have adopted the standards set out in the globally recognized U.S. National Institute of Standards and Technology (NIST) Cyber Security Framework. These standards guide our activities in identifying, protecting, detecting, responding to and recovering from cybersecurity incidents. In 2025, we continued to update and implement new policies and controls based on the NIST Cybersecurity Framework.

We aim to continue to prevent, detect and react to security incidents with layered controls and training programs. In 2025, our privacy, cybersecurity and legal teams collaborated to streamline cyber and privacy incident response procedures. Internal audits are in place to evaluate the effectiveness of our internal controls, identify vulnerabilities in our IT security processes and maintain compliance with our regulatory requirements. Additionally, we engage third party experts to assess the effectiveness of our framework implementation and program. We also perform third-party cybersecurity risk assessments for service providers and others outside the organization. For instance, when a third-party vendor is involved in processing personal data, we assess their administrative, physical and technical to evaluate their compliance with our company policies and applicable regulatory requirements. We also review and assess internal initiatives that involve the processing of personal data.

Employee awareness and training are essential to our ability as a company to thwart cyber-attacks. In 2025, we continued to raise employees' risk awareness with mandatory, regular online training for all employees and complimentary awareness campaigns. We conducted a month-long global campaign to promote cybersecurity awareness among our employees. The event's primary objective was to apprise our staff members of the measures and protocols in place for the safety of our company, patients and employees in the digital realm. The event also aimed to educate our employees on best practices and steps to mitigate the risks of cyber threats, including techniques and clues to recognize various forms of "phishing" and efforts to deploy viruses and malware in our systems.

[**Table of Contents**](#TOC)

Our organization increasingly leverages AI and other emerging technologies to improve our patient outcomes and enhance our productivity. It is essential that we maintain the highest level of cybersecurity to safeguard our confidential information, patient health information, personally identifiable information and intellectual property. Recent developments involving AI chat applications have exposed potential risks and vulnerabilities in handling sensitive information. In light of these risks, we have issued guidelines for the appropriate use of AI-powered capabilities to all employees. In addition, we have established an AI Oversight Committee which was commissioned by the Management Board.

For additional information regarding risks from cybersecurity threats, see Item 3. "Key information — D. Risk Factors — Risks relating to legal and regulatory matters — Cyber-attacks or other privacy and data security incidents could disrupt our business and expose us to significant losses, liability, and reputational damage." For information regarding lawsuits filed against FME AG related to previously reported cybersecurity incidents, see note 25 of the notes to the consolidated financial statements included in this report.

***Governance***

We aim to continuously improve our global cybersecurity capabilities to secure sensitive information and support strategic initiatives. We employ a Global Chief Information Security Officer (CISO), who reports to the Global Chief Information Officer (CIO) who in turn reports to the CFO. The CIO and CISO are accountable and responsible for overseeing information security and managing the Global Information Security Program to reduce cybersecurity risk. If necessary, the CISO has direct access to the Management Board.

Our Management Board and other executive-level teams are regularly updated on our IT and cybersecurity programs, while our Supervisory Board receives an annual review of the performance of the information security program. In addition, Cybersecurity & Privacy Solutions partners with our legal department to jointly manage privacy assurance and records management.

Managing and measuring performance is an integral part of our global cybersecurity program oversight. As noted above, we have adopted the standards of the NIST Cyber Security Framework. This framework is risk-driven and helps us to identify, protect, detect, respond to and recover from cybersecurity incidents.

In late 2025, we engaged external cybersecurity experts to evaluate the effectiveness of our cybersecurity program on a global scale. Based on this analysis, we are targeting adjustments to our multi-year security roadmap. This roadmap prioritizes our program goals and investments by risk, ensuring that we focus our efforts on the most critical areas of our cybersecurity program.

As part of our cybersecurity roadmap, we set annual maturity targets based on the NIST Cyber Security Framework. We use these metrics to measure our effectiveness in improving risk management and global cybersecurity processes. In 2025, we continued to enhance the effectiveness of our cybersecurity program with a focus on areas such as cybersecurity governance, risk management and cyber operations.

The cybersecurity team manages the risk program for IT and Cybersecurity. Our IT and cybersecurity risk reporting follows enterprise risk management methods required by the corporate risk team. This reporting ensures that key IT and cybersecurity risks and management plans are visible to our enterprise risk management committee. We also communicate our top risks and management plans to the Management Board and Supervisory Board.

#### Part III

#### Item 17.&nbsp;&nbsp;&nbsp;&nbsp;Financial statements
Not applicable. See Item 18. "Financial statements."

#### Item 18.&nbsp;&nbsp;&nbsp;&nbsp;Financial statements
The information called for by this item commences on Page F-1.

#### Item 19.&nbsp;&nbsp;&nbsp;&nbsp; Exhibits
A listing of our exhibits can be found immediately following the notes to the consolidated financial statements included in this report.

[**Table of Contents**](#TOC)

#### Signatures
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

DATE: February 24, 2026

---

| | |
|:---|:---|
| FRESENIUS MEDICAL CARE AG | FRESENIUS MEDICAL CARE AG |
| By: | /s/ HELEN GIZA |
| Name: | Helen Giza |
| Title: | Chief Executive Officer and Chair of the Management Board |
| By: | /s/ MARTIN FISCHER |
| Name: | Martin Fischer |
| Title: | Chief Financial Officer and member of the Management Board |

---

[**Table of Contents**](#TOC)

#### Index of financial statements

#### Audited consolidated financial statements

---

| | |
|:---|:---|
| [Report of independent registered public accounting firm](#Reportof_876766) (PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft) (PCAOB ID: 1275) | F-2 |
| [Consolidated statements of income for the years ended December 31, 2025, 2024 and 2023](#Consolidatedstatementsofincome_951214) | F-5 |
| [Consolidated statements of comprehensive income for the years ended December 31, 2025, 2024 and 2023](#Consolidatedstatementsofcomprehensiveinc) | F-6 |
| [Consolidated balance sheets as of December 31, 2025 and 2024](#Consolidatedbalancesheets_455830) | F-7 |
| [Consolidated statements of cash flows for the years ended December 31, 2025, 2024 and 2023](#Consolidatedstatementsofcashflows_714055) | F-8 |
| [Consolidated statements of shareholders' equity for the years ended December 31, 2025, 2024 and 2023](#Consolidatedstatementsofshareholders_723) | F-9 |
| [Notes to the consolidated financial statements](#a1TheCompanybasisofpresentation_38021) | F-10 |

---

[**Table of Contents**](#TOC)

#### Report of Independent Registered Public Accounting Firm
To the Shareholders and Supervisory Board of Fresenius Medical Care AG

***Opinions on the Financial Statements and Internal Control over Financial Reporting***

We have audited the accompanying consolidated balance sheets of Fresenius Medical Care AG and its subsidiaries (the "Company") as of December 31, 2025 and 2024, and the related consolidated statements of income, comprehensive income, shareholders' equity and cash flows for each of the three years in the period ended December 31, 2025, including the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with International Financial Reporting Standards (IFRS Accounting Standards) as issued by the International Accounting Standards Board (IASB). Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the COSO.

***Basis for Opinions***

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 15B. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

***Definition and Limitations of Internal Control over Financial Reporting***

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

[**Table of Contents**](#TOC)

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

***Critical Audit Matter***

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

*Goodwill Impairment Assessment – Care Delivery, Care Enablement and Value-Based Care*

As described in Notes 1g), 2a) and 12 to the consolidated financial statements, the Company's consolidated goodwill balance as of December 31, 2025 was € 13,571,394k, thereof € 11,212,997k related to the group of cash generating units ("CGUs") that comprise the Care Delivery segment, € 1,989,734k related to the group of cash generating units ("CGUs") that comprise the Care Enablement segment, and € 368,663k related to the group of CGUs that comprise the Value-Based Care segment. Management conducts an impairment test as of October 1 of each year, or more frequently if events or circumstances indicate that the carrying value of goodwill may be impaired. In addition to its annual test, in connection with the decision of the Company's management board to update the Company's globalized operating model by introducing a new operating segment, the company performed a reallocation of goodwill to the Care Delivery and Value-Based Care segments using a relative value approach and evaluated the effects of this reallocation on the recoverability of Goodwill as of June 1, 2025 before and after the reallocation. Management identified its groups of CGUs and determined their carrying value by assigning the operating assets and liabilities, including the existing goodwill and intangible assets, to those groups of CGUs. Groups of CGUs reflect the lowest level on which goodwill is monitored for internal management purposes. To comply with IFRS to determine possible impairments of these assets, the value in use of each group of CGUs is first compared to the group of CGUs' carrying amount. In cases where the value in use of the group of CGUs is less than its carrying amount and the fair value less cost of disposal is not estimated to be higher than the value in use, the difference is recorded as an impairment of the carrying amount of the group of CGUs. The goodwill impairment tests performed did not result in any impairment. The value in use of each group of CGUs is determined using estimated future cash flows for the unit discounted by a pre-tax discount rate ("WACC") specific to that group of CGUs.

The principal considerations for our determination that performing procedures relating to the goodwill impairment assessments of the Care Delivery, Care Enablement, and Value-Based Care groups of CGUs is a critical audit matter are (i) the significant judgment by management when developing the value in use estimate of the Care Delivery, Care Enablement, and Value-Based Care groups of CGUs, and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management's significant assumptions related to revenue growth rates, projected operating income margins, residual value growth rates, and the pre-tax discount rates; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

[**Table of Contents**](#TOC)

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management's goodwill impairment assessments and goodwill reallocation between Care Delivery and Value-Based Care, including controls over the valuation of the Company's groups of CGUs. These procedures also included, among others (i) testing management's process for reallocating goodwill between Care Delivery and Value-Based Care and for developing the value in use estimates of the Care Delivery, Care Enablement and Value-Based Care groups of CGUs; (ii) evaluating the appropriateness of the discounted cash flow models used by management; (iii) testing the completeness and accuracy of underlying data used in the discounted cash flow models; and (iv) evaluating the reasonableness of the significant assumptions used by management related to revenue growth rates, projected operating income margins, residual value growth rates, and the pre-tax discount rates. Evaluating management's assumptions related to revenue growth rates and projected operating income margins involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the Care Delivery, Care Enablement, and Value-Based Care groups of CGUs; (ii) the consistency with external market and industry data; and (iii) whether the assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating the appropriateness of the Company's valuation model and the pre-tax discount rate for all groups of CGUs.

Frankfurt am Main, Germany

February 24, 2026

PricewaterhouseCoopers GmbH

Wirtschaftsprüfungsgesellschaft

---

| | |
|:---|:---|
| /s/ Thomas Tilgner<br>| /s/ Dominik Höhler<br>|
| Wirtschaftsprüfer<br>| Wirtschaftsprüfer<br>|
| (German Public Auditor)<br>| (German Public Auditor)<br>|

---

We have served as the Company's auditor since 2020.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Consolidated statements of income** |  |  |  |  |
| *in € thousands (K), except per share data* |  |  |  |  |
|  | **Note** | **2025** | **2024** | **2023** |
| **Revenue:** |  |  |  |  |
| &nbsp;&nbsp;Healthcare services | 5 a, 29 | 13097267 | 13471363 | 14166796 |
| &nbsp;&nbsp;Healthcare products | 5 a, 29 | 4413625 | 4250522 | 4059681 |
| &nbsp;&nbsp;Insurance contracts | 5 a, 29 | 2116710 | 1614024 | 1227140 |
|  | 5 a, 29 | **19627602** | **19335909** | **19453617** |
| **Costs of revenue:** |  |  |  |  |
| &nbsp;&nbsp;Healthcare services |  | 10134231 | 10555770 | 10993302 |
| &nbsp;&nbsp;Healthcare products |  | 2399741 | 2419939 | 2349766 |
| &nbsp;&nbsp;Insurance contracts |  | 2064701 | 1603548 | 1185544 |
|  |  | **14598673** | **14579257** | **14528612** |
| **Operating (income) expenses:** |  |  |  |  |
| &nbsp;&nbsp;Selling, general and administrative | 5 b | 3032728 | 3142819 | 3196336 |
| &nbsp;&nbsp;Research and development |  | 157975 | 183493 | 231970 |
| &nbsp;&nbsp;Income from equity method investees | 29 | (181368) | (134875) | (121785) |
| &nbsp;&nbsp;Other operating income | 5 e | (528099) | (760118) | (515247) |
| &nbsp;&nbsp;Other operating expense | 5 e | 720657 | 932938 | 764293 |
| **Operating income** |  | **1827036** | **1392395** | **1369438** |
| **Other (income) expense:** |  |  |  |  |
| &nbsp;&nbsp;Interest income | 5 f | (69611) | (71575) | (88217) |
| &nbsp;&nbsp;Interest expense | 5 f | 384409 | 407044 | 424640 |
| **Income before income taxes** |  | **1512238** | **1056926** | **1033015** |
| &nbsp;&nbsp;Income tax expense | 5 g | 320971 | 316056 | 300557 |
| **Net income** |  | **1191267** | **740870** | **732458** |
| &nbsp;&nbsp;**Net income attributable to noncontrolling interests** |  | **212900** | **202957** | **233461** |
| **Net income attributable to shareholders of FME AG** |  | **978367** | **537913** | **498997** |
| **Basic earnings per share** | 22 | **3.36** | **1.83** | **1.70** |
| **Diluted earnings per share** | 22 | **3.36** | **1.83** | **1.70** |

---

The following notes are an integral part of the consolidated financial statements.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Consolidated statements of comprehensive income** |  |  |  |  |
| *in € K* |  |  |  |  |
|  | **Note** | **2025** | **2024** | **2023** |
| **Net income** |  | **1191267** | **740870** | **732458** |
| **Other comprehensive income (loss):** |  |  |  |  |
| **Components that will not be reclassified to profit or loss:** |  |  |  |  |
| FVOCI equity investments | 27 | 6537 | (15586) | 18046 |
| Actuarial gain (loss) on defined benefit pension plans | 19, 27 | 72462 | 15990 | (58455) |
| Income tax (expense) benefit related to components of other comprehensive income not reclassified | 27 | (22958) | (2941) | 16196 |
|  |  | 56041 | (2537) | (24213) |
| **Components that may be reclassified subsequently to profit or loss:** |  |  |  |  |
| Gain (loss) related to foreign currency translation, net of reclassification adjustments resulting from deconsolidation | 27 | (1544634) | 727473 | (607873) |
| FVOCI debt securities | 27 | 7639 | (857) | 7299 |
| Gain (loss) related to cash flow hedges | 26, 27 | 22433 | (12817) | (4307) |
| Cost of hedging | 27 | (1141) | 2045 | (1171) |
| Income tax (expense) benefit related to components of other comprehensive income that may be reclassified | 27 | (6745) | 2595 | 254 |
|  |  | (1522448) | 718439 | (605798) |
| **Other comprehensive income (loss), net of tax** |  | **(1466407)** | **715902** | **(630011)** |
| **Total comprehensive income** |  | **(275140)** | **1456772** | **102447** |
| **Comprehensive income attributable to noncontrolling interests** |  | **81591** | **272235** | **190022** |
| **Comprehensive income (loss) attributable to shareholders of FME AG** |  | **(356731)** | **1184537** | **(87575)** |

---

The following notes are an integral part of the consolidated financial statements.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

---

| | | | |
|:---|:---|:---|:---|
| **Consolidated balance sheets** |  |  |  |
| *in € K, except share data* |  |  |  |
|  | **Note** | **2025** | **2024** |
| **Assets** |  |  |  |
| Cash and cash equivalents | 7 | 1599113 | 1180187 |
| Trade accounts and other receivables from unrelated parties | 8 | 3142298 | 3367111 |
| Accounts receivable from related parties | 6 | 32683 | 40936 |
| Inventories | 9 | 2140771 | 2067922 |
| Other current assets | 10 | 533436 | 671835 |
| Other current financial assets | 10 | 446504 | 433740 |
| Assets held for sale | 4 | 3595 | 161013 |
| **Total current assets** |  | **7898400** | **7922744** |
| Property, plant and equipment | 11 | 3486293 | 3646126 |
| Right-of-use assets | 24 | 3013502 | 3612456 |
| Intangible assets | 12 | 1254489 | 1370080 |
| Goodwill | 12 | 13571394 | 15170652 |
| Deferred taxes | 5 g | 236547 | 229509 |
| Investment in equity method investees | 13 | 663652 | 620831 |
| Other non-current assets |  | 218225 | 198325 |
| Other non-current financial assets | 14 | 659831 | 795856 |
| **Total non-current assets** |  | **23103933** | **25643835** |
| **Total assets** |  | **31002333** | **33566579** |
| **Liabilities** |  |  |  |
| Accounts payable to unrelated parties |  | 737595 | 904278 |
| Accounts payable to related parties | 6 | 97951 | 80044 |
| Current provisions and other current liabilities | 15 | 1471113 | 1499934 |
| Other current financial liabilities | 15 | 1601517 | 1787373 |
| Short-term debt from unrelated parties | 16 | 17015 | 2099 |
| Current portion of long-term debt | 17 | 1596029 | 575283 |
| Current portion of lease liabilities from unrelated parties |  | 577392 | 615983 |
| Current portion of lease liabilities from related parties | 6 | 6896 | 24901 |
| Income tax liabilities |  | 139595 | 142654 |
| Liabilities directly associated with assets held for sale | 4 |  | 27511 |
| **Total current liabilities** |  | **6245103** | **5660060** |
| Long-term debt, less current portion | 17 | 5691852 | 6260825 |
| Lease liabilities from unrelated parties, less current portion |  | 2895215 | 3411855 |
| Lease liabilities from related parties, less current portion | 6 | 11206 | 87962 |
| Non-current provisions and other non-current liabilities | 18 | 320914 | 374163 |
| Other non-current financial liabilities | 18 | 182166 | 538685 |
| Pension liabilities | 19 | 574807 | 678673 |
| Income tax liabilities |  | 108738 | 76953 |
| Deferred taxes | 5 g | 689523 | 708890 |
| **Total non-current liabilities** |  | **10474421** | **12138006** |
| **Total liabilities** |  | **16719524** | **17798066** |
| **Shareholders' equity:** |  |  |  |
| Ordinary shares, no par value, €1.00 nominal value, 382,754,793 shares authorized, 293,413,449 issued and 279,288,885 outstanding as of December 31, 2025 (December 31, 2024: 362,370,124 shares authorized, 293,413,449 issued and outstanding) | 20 | 293413 | 293413 |
| Treasury stock, at cost | 20 | (586094) |  |
| Additional paid-in capital | 20 | 3079368 | 3345408 |
| Retained earnings | 20 | 12207913 | 11266287 |
| Accumulated other comprehensive income (loss) | 27 | (1684768) | (328545) |
| **Total FME AG shareholders' equity** |  | **13309832** | **14576563** |
| Noncontrolling interests | 20 | 972977 | 1191950 |
| **Total equity** |  | **14282809** | **15768513** |
| **Total liabilities and equity** |  | **31002333** | **33566579** |

---

The following notes are an integral part of the consolidated financial statements.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Consolidated statements of cash flows** |  |  |  |  |
| *in € K* |  |  |  |  |
|  |  | **For the twelve months ended December 31,**  | **For the twelve months ended December 31,**  | **For the twelve months ended December 31,**  |
|  | **Note** | **2025** | **2024** | **2023** |
| **Operating activities** |  |  |  |  |
| &nbsp;&nbsp;Net income |  | 1191267 | 740870 | 732458 |
| &nbsp;&nbsp;**Adjustments to reconcile net income to net cash provided by operating activities:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation, amortization and impairment loss | 11, 12, 24, 29 | 1500409 | 1742257 | 1751971 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in deferred taxes, net |  | (27213) | (72672) | (122149) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss from the sale of fixed assets, right-of-use assets, investments and divestitures |  | 123235 | (12168) | (12902) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income from equity method investees |  | (181368) | (134875) | (121785) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 5 f | 314798 | 335469 | 336423 |
| &nbsp;&nbsp;**Changes in assets and liabilities, net of amounts from businesses acquired:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade accounts and other receivables from unrelated parties |  | (76448) | (197918) | (125593) |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories |  | (248658) | 107897 | (13140) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current and non-current assets |  | 206897 | (227970) | 145697 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable from related parties |  | 7387 | 124441 | (26251) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable to related parties |  | 27214 | (46200) | (10905) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable to unrelated parties, provisions and other current and non-current liabilities |  | (14766) | 201789 | 119384 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax liabilities |  | 236612 | 482274 | 472084 |
| &nbsp;&nbsp;Received dividends from investments in equity method investees |  | 139211 | 100663 | 219953 |
| &nbsp;&nbsp;Paid interest |  | (359982) | (381226) | (394535) |
| &nbsp;&nbsp;Received interest |  | 68155 | 68099 | 88217 |
| &nbsp;&nbsp;Paid income taxes |  | (225751) | (444586) | (410126) |
| &nbsp;&nbsp;**Net cash provided by (used in) operating activities** |  | **2680999** | **2386144** | **2628801** |
| &nbsp;&nbsp;**Investing activities** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment and capitalized development costs |  | (915369) | (699358) | (684596) |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisitions, net of cash acquired, investments and purchases of intangible assets | 3, 28 | (21972) | (23066) | (35202) |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments in debt securities | 3 | (87521) | (81501) | (102363) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of property, plant and equipment |  | 16695 | 14103 | 16138 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from divestitures, net of cash disposed | 3, 28 | 202140 | 629749 | 172201 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of debt securities | 3 | 83497 | 75134 | 89595 |
| &nbsp;&nbsp;**Net cash provided by (used in) investing activities** |  | **(722530)** | **(84939)** | **(544227)** |
| &nbsp;&nbsp;**Financing activities** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from short-term debt from unrelated parties |  | 156457 | 84812 | 55133 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of short-term debt from unrelated parties |  | (140805) | (540499) | (230771) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from short-term debt from related parties |  |  |  | 10204 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of short-term debt from related parties |  |  |  | (14204) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from long-term debt |  | 1622553 | 61513 | 417877 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of long-term debt |  | (839585) | (834462) | (700663) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of lease liabilities from unrelated parties | 24 | (623323) | (651686) | (702212) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of lease liabilities from related parties | 24 | (25715) | (24827) | (25157) |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) of accounts receivable facility |  |  | (23096) | (69363) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of treasury stock | 20 | (585285) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends paid | 20 | (422515) | (349162) | (328623) |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions to noncontrolling interests |  | (573971) | (313691) | (313365) |
| &nbsp;&nbsp;&nbsp;&nbsp;Contributions from noncontrolling interests |  | 28982 | 21798 | 42615 |
| &nbsp;&nbsp;**Net cash provided by (used in) financing activities** |  | **(1403207)** | **(2569300)** | **(1858529)** |
| &nbsp;&nbsp;**Effect of exchange rate changes on cash and cash equivalents** |  | **(141477)** | **26198** | **(72607)** |
| &nbsp;&nbsp;**Cash and cash equivalents:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net increase (decrease) in cash and cash equivalents |  | 413785 | (241897) | 153438 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents at beginning of period |  | 1185328 | 1427225 | 1273787 |
| &nbsp;&nbsp;**Cash and cash equivalents at end of period** | 7 | **1599113** | **1185328** | **1427225** |
| &nbsp;&nbsp;**Thereof: cash and cash equivalents within the disposal groups** | 4 | **—** | **5141** | **23733** |

---

The following notes are an integral part of the consolidated financial statements.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

---

| | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Consolidated statements of shareholders' equity** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| *in € K, except share data* |  |  |  |  |  |  |  | **Accumulated**  | **Accumulated**  | **Accumulated**  | **Accumulated**  |  |  |  |
|  |  | **Ordinary shares** | **Ordinary shares** | **Treasury stock** | **Treasury stock** |  |  | **other comprehensive income (loss)** | **other comprehensive income (loss)** | **other comprehensive income (loss)** | **other comprehensive income (loss)** |  |  |  |
|  |  |  |  |  |  | **Additional** |  | **Foreign** |  |  |  | **Total FME AG**  |  |  |
|  |  | **Number of** |  | **Number of** |  | **paid-in** | **Retained** | **currency**  | **Cash flow**  |  | **Fair value** | **shareholders'** | **Noncontrolling** |  |
|  | **Note** | **shares** | **No par value** | **shares** | **Amount** | **capital** | **earnings**  | **translation** | **hedges** | **Pensions** | **changes** | **equity** | **interests** | **Total equity** |
| **Balance at December 31, 2022** |  | 293413449 | 293413 | **—** | **—** | 3372799 | 10711709 | (207210) | (627) | (155526) | (25105) | 13989453 | 1459726 | 15449179 |
| Proceeds from exercise of options and related tax effects | 23 |  |  |  |  | (1190) |  |  |  |  |  | (1190) |  | (1190) |
| Dividends paid | 20 |  |  |  |  |  | (328623) |  |  |  |  | (328623) |  | (328623) |
| Transactions with noncontrolling interests without loss of control |  |  |  |  |  | 8722 |  |  |  |  |  | 8722 | (14684) | (5962) |
| Noncontrolling interests due to changes in consolidation group |  |  |  |  |  |  |  |  |  |  |  |  | (182488) | (182488) |
| Contributions from/ to noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  | (246302) | (246302) |
| Put option liabilities | 26 |  |  |  |  |  | 39474 |  |  |  |  | 39474 |  | 39474 |
| Transfer of cumulative gains/losses of equity investments | 26 |  |  |  |  |  | 129 |  |  |  | (129) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Income |  |  |  |  |  |  | 498997 |  |  |  |  | 498997 | 233461 | 732458 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) related to: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation, net of reclassification adjustments resulting from deconsolidation | 5 e, 27 |  |  |  |  |  |  | (558371) | (55) | 5086 | (11094) | (564434) | (43439) | (607873) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flow hedges, net of related tax effects | 27 |  |  |  |  |  |  |  | (3903) |  |  | (3903) |  | (3903) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pensions, net of related tax effects | 19 |  |  |  |  |  |  |  |  | (42050) |  | (42050) |  | (42050) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value changes, net of related tax effects | 27 |  |  |  |  |  |  |  |  |  | 23815 | 23815 |  | 23815 |
| Comprehensive income |  |  |  |  |  |  |  |  |  |  |  | (87575) | 190022 | 102447 |
| **Balance at December 31, 2023** |  | **293413449** | **293413** | **—** | **—** | **3380331** | **10921686** | **(765581)** | **(4585)** | **(192490)** | **(12513)** | **13620261** | **1206274** | **14826535** |
| Dividends paid | 20 |  |  |  |  |  | (349162) |  |  |  |  | (349162) |  | (349162) |
| Transactions with noncontrolling interests without loss of control | 20 |  |  |  |  | (34923) |  |  |  |  |  | (34923) | (20982) | (55905) |
| Noncontrolling interests due to changes in consolidation group | 20 |  |  |  |  |  |  |  |  |  |  |  | (40013) | (40013) |
| Contributions from/ to noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  | (225564) | (225564) |
| Put option liabilities | 26 |  |  |  |  |  | 155850 |  |  |  |  | 155850 |  | 155850 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Income |  |  |  |  |  |  | 537913 |  |  |  |  | 537913 | 202957 | 740870 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) related to: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation, net of reclassification adjustments resulting from deconsolidation | 5 e, 27 |  |  |  |  |  |  | 723617 | (265) | (8715) | (56442) | 658195 | 69278 | 727473 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flow hedges, net of related tax effects | 27 |  |  |  |  |  |  |  | (8448) |  |  | (8448) |  | (8448) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pensions, net of related tax effects | 19 |  |  |  |  |  |  |  |  | 13147 |  | 13147 |  | 13147 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value changes, net of related tax effects | 27 |  |  |  |  |  |  |  |  |  | (16270) | (16270) |  | (16270) |
| Comprehensive income |  |  |  |  |  |  |  |  |  |  |  | 1184537 | 272235 | 1456772 |
| **Balance at December 31, 2024** |  | **293413449** | **293413** | **—** | **—** | **3345408** | **11266287** | **(41964)** | **(13298)** | **(188058)** | **(85225)** | **14576563** | **1191950** | **15768513** |
| Equity-settled share-based payment transactions | 23 |  |  |  |  | 8182 |  |  |  |  |  | 8182 |  | 8182 |
| Purchase of treasury stock | 23 |  |  | (14124564) | (586094) |  |  |  |  |  |  | (586094) |  | (586094) |
| Dividends paid | 20 |  |  |  |  |  | (422515) |  |  |  |  | (422515) |  | (422515) |
| Transactions with noncontrolling interests without loss of control | 20 |  |  |  |  | (274222) |  |  |  |  |  | (274222) | (85806) | (360028) |
| Noncontrolling interests due to changes in consolidation group | 20 |  |  |  |  |  |  |  |  |  |  |  | 603 | 603 |
| Contributions from/ to noncontrolling interests | 20 |  |  |  |  |  |  |  |  |  |  |  | (215361) | (215361) |
| Put option liabilities | 3, 26 |  |  |  |  |  | 364649 |  |  |  |  | 364649 |  | 364649 |
| Transfer of cumulative gains/losses of equity investments | 26 |  |  |  |  |  | 21125 |  |  |  | (21125) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Income |  |  |  |  |  |  | 978367 |  |  |  |  | 978367 | 212900 | 1191267 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) related to: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation, net of reclassification adjustments resulting from deconsolidation | 5 e, 27 |  |  |  |  |  |  | (1430922) | 461 | 17094 | 42 | (1413325) | (131309) | (1544634) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flow hedges, net of related tax effects | 27 |  |  |  |  |  |  |  | 15812 |  |  | 15812 |  | 15812 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pensions, net of related tax effects | 19 |  |  |  |  |  |  |  |  | 49289 |  | 49289 |  | 49289 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value changes, net of related tax effects | 27 |  |  |  |  |  |  |  |  |  | 13126 | 13126 |  | 13126 |
| Comprehensive income |  |  |  |  |  |  |  |  |  |  |  | (356731) | 81591 | (275140) |
| **Balance at December 31, 2025** |  | **293413449** | **293413** | **(14124564)** | **(586094)** | **3079368** | **12207913** | **(1472886)** | **2975** | **(121675)** | **(93182)** | **13309832** | **972977** | **14282809** |

---

The following notes are an integral part of the consolidated financial statements.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**1.**The Company, basis of presentation and significant accounting policies

#### The Company
Fresenius Medical Care AG (FME AG or the Company) is a German stock corporation (*Aktiengesellschaft* — AG) registered with the commercial register of Hof (Saale) under HRB 6841, with its business address at Else-Kröner-Str. 1, 61352 Bad Homburg v. d. Höhe, Germany. The Company is the world's leading provider of products and services for individuals with renal diseases, based on publicly reported revenue. The Company provides dialysis and related services for individuals with renal diseases, including through value and risk-based care programs, as well as other healthcare services. The Company also develops, manufactures, and distributes a wide variety of healthcare products. The Company's healthcare products include hemodialysis machines, peritoneal dialysis cyclers, dialyzers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, as well as acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates, or manages with a broad range of products and also sells dialysis products to other dialysis service providers. The Company's other healthcare services include pharmacy services, vascular specialty services, ambulatory surgery center services, and physician nephrology practice management.

In these notes, "FME AG," the "Company" or the "Group" refers to Fresenius Medical Care AG or Fresenius Medical Care AG and its subsidiaries on a consolidated basis, as the context requires. "Management AG" and the "General Partner" refer to Fresenius Medical Care Management AG (renamed Fresenius Vermögensverwaltung GmbH), which was the Company's general partner prior to the Conversion (as defined below) and is wholly owned by Fresenius SE. Management AG ceased to be a General Partner of the Company when the Conversion took effect. "Management Board" refers to the members of the management board of the Company (or of Management AG, prior to the Conversion) and, except as otherwise specified, "Supervisory Board" refers to the supervisory board of the Company.

At an extraordinary general meeting (EGM) of the Company held on July 14, 2023, the shareholders of the Company approved a proposal to change the legal form of the Company from a partnership limited by shares (*Kommanditgesellschaft auf Aktien* – KGaA) into an AG (the Conversion). Upon effectiveness of the Conversion, which occurred upon registration of the Conversion with the competent commercial register on November 30, 2023, Management AG exited the Company, Fresenius SE & Co. KGaA (Fresenius SE or Fresenius SE & Co. KGaA) ceased to control (as defined by IFRS 10, Consolidated Financial Statements) the Company and the Company ceased to be a member of the Fresenius SE consolidated group. Fresenius SE continues to have significant influence over the Company.

The term "Care Enablement" refers to the Company's Care Enablement operating segment, the term "Care Delivery" refers to the Care Delivery operating segment and the term "Value-Based Care" refers to the Company's new Value-Based Care operating segment. Prior to June 1, 2025, discrete financial information was not provided to the chief operating decision maker on the basis of the new structure and the necessary systems and reporting changes to effect the new structure were not in place. Due to the change in the Company's operating structure, the Company has adjusted the prior year financial information for its operating segments in order to conform to the current year's presentation. For further discussion of the Company's operating and reportable segments, see note 29. The abbreviations "K," "M," and "BN" are used to denote the presentation of amounts in thousands, millions, and billions, respectively.

#### Basis of presentation
The consolidated financial statements and other financial information included in the Company's Annual Report on Form 20-F are prepared solely in accordance with International Financial Reporting Standards (IFRS® Accounting Standards) as issued by the International Accounting Standards Board (IASB), using the euro as the Company's reporting and functional currency. At December 31, 2025, there were no IFRS Accounting Standards or IFRS Interpretations Committee interpretations as endorsed by the European Union relevant for the Company's reporting that differed from IFRS Accounting Standards as issued by the IASB.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The preparation of consolidated financial statements in conformity with IFRS Accounting Standards requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Such financial statements reflect all adjustments that, in the opinion of management, are necessary to provide a fair statement of the results of the periods presented. All such adjustments are of a normal recurring nature. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in all future periods affected.

In order to improve clarity of presentation, various items are aggregated in the consolidated balance sheets and consolidated statements of income. These items are analyzed separately in the notes where this provides useful information to the users of the consolidated financial statements.

The consolidated balance sheets contain all information required to be presented by IAS 1, Presentation of Financial Statements (IAS 1) and is classified on the basis of the liquidity of assets and liabilities. The consolidated statements of income are classified using the cost-of-sales accounting format.

Due to the increased significance of Value-Based Care and its insurance operations, the Company reclassified €1,614,024 and €1,227,140 for the years ended December 31, 2024 and 2023, respectively, to Insurance contract revenue from Healthcare services revenue within its consolidated financial statements. Insurance contract costs of revenue in the amount of €1,603,548 and €1,185,544 for the years ended December 31, 2024 and 2023, respectively, were also reclassified and were previously reported within the Healthcare services costs of revenue line item.

At February 23, 2026, the Management Board and Supervisory Board authorized the consolidated financial statements for issue.

**Significant accounting policies**

**a)** **Principles of consolidation and composition of the group**

The financial statements of consolidated entities have been prepared using uniform accounting methods in accordance with IFRS 10, Consolidated Financial Statements (IFRS 10). Acquisitions of companies are accounted for under the acquisition method.

Besides FME AG, the consolidated financial statements include all material subsidiaries according to IFRS 10 over which the Company has control. The Company controls an entity if it has power over the entity through existing rights that give the Company the current ability to direct the activities that significantly affect the entity's return. In addition, the Company is exposed to, or has rights to, variable returns from the involvement with the entity and the Company has the ability to use its power over the entity to affect the amount of the Company's return. In most cases, control is achieved when the Company has the majority of a subsidiary's equity ownership and voting rights.

For certain subsidiaries in which the Company has the majority of the equity ownership and voting rights and does not consolidate, an assessment of materiality is made in order to determine that the subsidiary is insignificant to the Company's results based on qualitative and quantitative factors. Such factors include quantitative analyses noting that the sum of these unconsolidated subsidiaries is less than 1% of the Company's total assets, revenue, and operating income or qualitative factors such as such a subsidiary's dormancy, impending liquidation, or other factors are considered.

The equity method is applied in accordance with IAS 28, Investments in Associates and Joint Ventures (IAS 28). Generally, equity method investees are entities in which the Company, directly or indirectly, holds 50% or less of the voting power and can exercise significant influence over their financial and operating policies. For information on the Company's investment in Vifor Fresenius Medical Care Renal Pharma Ltd., which makes up a large portion of its equity method investees, see note 13.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Acquisitions of companies are accounted for in accordance with IFRS 3, Business Combinations (IFRS 3) at the date of acquisition using, in general, the full goodwill method. Initially, all identifiable assets acquired and liabilities assumed as well as the noncontrolling interests, when applicable, are recognized at their fair values. The fair value of the consideration transferred and the amount of any noncontrolling interest measured at fair value is then compared with the fair value of the assets acquired and liabilities assumed. Any remaining balance is recognized as goodwill and is tested at least once a year for impairment. Generally, adjustments made to the fair value of identifiable assets and liabilities during the measurement period are recorded as an offset to goodwill. Any adjustments made subsequent to the measurement period are recognized immediately in profit or loss.

Intercompany revenues, expenses, income, receivables, payables, accruals, provisions, and commitments and contingencies are eliminated. Profits and losses on items of property, plant and equipment and inventory acquired from other group entities are also eliminated.

Deferred tax assets and liabilities are recognized due to temporary differences resulting from consolidation procedures.

Noncontrolling interest (NCI) is the portion of equity in a subsidiary not attributable, directly or indirectly, to a parent and is recognized at its fair value at the date of first consolidation using the full goodwill method. Profits and losses attributable to the noncontrolling interests are separately disclosed in the consolidated statements of income.

The Company writes put options on certain noncontrolling interests. A portion of these put options relates to equity interests in dialysis clinics owned by nephrologists or nephrology groups. Generally, the put options associated with this business model are valid for an unlimited time. In addition, as part of the transaction with Cricket Health, Inc. (Cricket), and InterWell Health LLC, the Company also granted put options to noncontrolling interest owners of the newly created value-based kidney care entity. The options held by non-physician investors were subsequently settled during 2025 (see note 26 for further information). Accordingly, the put options represent a long-term investment into a dialysis clinic for the NCI holder. The put options provide for settlement in cash. For these put options, IAS 32, Financial Instruments: Presentation (IAS 32) paragraph 23 requires the Company to recognize a liability for the present value of the exercise price of the option. The put option liability is recorded in other current financial liabilities and other non-current financial liabilities at present value of the redemption amount at the balance sheet date. The Company believes the accounting treatment of the changes to the put option liability under IFRS Accounting Standards to this date has not been finally clarified. In the absence of IFRS Accounting Standards guidance specifically applicable to the accounting for put options on NCI, the Company, in line with IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors (IAS 8) paragraph 10, applied the present access method. According to the present access method, NCI are recorded in equity when the risks and rewards of ownership reside with the NCI holders. The initial recognition, valuation differences, and the derecognition of the put option liability are recorded in equity with no impact to the income statement (see note 1 h)). For exercises of put options, the Company additionally recognizes any difference between the amount of noncontrolling interests derecognized and the fair value of consideration paid within additional paid - in capital as such transactions do not result in a loss of control (see note 20). At the same time, retained earnings are adjusted accordingly. This presentation results in information that is relevant to the economic decision-making needs of the users of the Company's financial statements and to provide reliable financial information as the Company considers these NCI with written put options as equity holders and accordingly attributes net income to NCI. For further information regarding the valuation of the put option liabilities, see note 26.

The consolidated financial statements for 2025 include FME AG as well as 2,142 companies (2024: 2,158). In 2025, 41 companies were first-time consolidations (2024: 39), 57 companies were deconsolidated (2024: 108), while no entity changed from consolidated to equity method investees during the year (2024: 0). In 2025, 57 companies were accounted for by the equity method (2024: 57).

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The principal subsidiaries of the Company are those with the most significant contribution to the Company's revenue, net income, or net assets. The Company's interest in these subsidiaries for the years ended December 31, 2025 and 2024 are listed in the table below:

---

| | | | |
|:---|:---|:---|:---|
| **Principal subsidiaries** | **Principal subsidiaries** | **Principal subsidiaries** | **Principal subsidiaries** |
| **Name** | **Country** | **Main activity** | **Ownership** |
| Fresenius Medical Care Australia Pty. Ltd. | Australia | Provision of healthcare services | 100% |
|  |  | Sale of healthcare products |  |
| Fresenius Medical Care Deutschland GmbH | Germany | Sale of healthcare products | 100% |
|  |  | Production of healthcare products |  |
|  |  | Research and development |  |
| Fresenius Medical Care France S.A.S. | France | Sale of healthcare products | 100% |
| Fresenius Medical Care GmbH | Germany | Sale of healthcare products | 100% |
| Fresenius Medical Care Holdings, Inc. (FMCH) | USA | Provision of healthcare services | 100% |
|  |  | Sale of healthcare products |  |
|  |  | Production of healthcare products |  |
|  |  | Research and development |  |
| Fresenius Medical Care Italia S.p.A. | Italy | Sale of healthcare products | 100% |
| Fresenius Medical Care Korea Ltd. | South Korea | Sale of healthcare products | 100% |
| Fresenius Medical Care Ltda. | Brazil | Sale of healthcare products | 100% |
| Fresenius Medical Care Shanghai Ltd. | China | Sale of healthcare products | 100% |
| Fresenius Medical Care (U.K.) Ltd. | United Kingdom | Provision of healthcare services | 100% |
|  |  | Sale of healthcare products |  |
|  |  | Production of healthcare products |  |
| National Medical Care of Spain, S.A.U. | Spain | Provision of healthcare services | 100% |
| NephroCare Portugal, S.A. | Portugal | Provision of healthcare services | 100% |
|  |  | Sale of healthcare products |  |
| Fresenius Nephrocare Polska Sp. z.o.o. | Poland | Provision of healthcare services | 100% |
| Fresenius Nephrocare Romania S.r.l. | Romania | Provision of healthcare services | 100% |

---

The complete list of participations in affiliated and associated companies of FME AG will be submitted to the electronic companies register.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

For 2025, the following fully consolidated German subsidiaries of the Company will apply the exemption provided in Section 264 (3) or Section 264b of the HGB and therefore will be exempt from applying certain legal requirements to prepare notes to the statutory standalone financial statements and a management report as well as the requirements of an independent audit and public disclosure.

---

| | |
|:---|:---|
| **Companies exempt from applying certain legal requirements** | |
| **Name of the company** | **Registered office of the company** |
| DiZ München Nephrocare GmbH | Munich, Germany |
| ET Software Developments GmbH | Sandhausen, Germany |
| Fresenius Medical Care Beteiligungsgesellschaft mbH | Bad Homburg v. d. Höhe, Germany |
| Fresenius Medical Care Data Solutions GmbH | Berlin, Germany |
| Fresenius Medical Care Deutschland GmbH | Bad Homburg v. d. Höhe, Germany |
| Fresenius Medical Care GmbH | Bad Homburg v. d. Höhe, Germany |
| Fresenius Medical Care Investment GmbH | Bad Homburg v. d. Höhe, Germany |
| Fresenius Medical Care US Vermögensverwaltungs GmbH & Co. KG | Bad Homburg v. d. Höhe, Germany |
| Fresenius Medical Care US Zwei Vermögensverwaltungs GmbH & Co. KG | Bad Homburg v. d. Höhe, Germany |
| Fresenius Medical Care Ventures GmbH | Bad Homburg v. d. Höhe, Germany |
| MVZ Gelsenkirchen-Buer GmbH | Gelsenkirchen, Germany |
| Nephrocare Ahrensburg GmbH | Ahrensburg, Germany |
| Nephrocare Augsburg GmbH | Augsburg, Germany |
| Nephrocare Berlin-Weißensee GmbH | Berlin, Germany |
| Nephrocare Betzdorf GmbH | Betzdorf, Germany |
| Nephrocare Bielefeld GmbH | Bielefeld, Germany |
| Nephrocare Buchholz GmbH | Buchholz, Germany |
| Nephrocare Daun GmbH | Daun, Germany |
| Nephrocare Deutschland GmbH | Bad Homburg v. d. Höhe, Germany |
| Nephrocare Döbeln GmbH | Döbeln, Germany |
| Nephrocare Dortmund GmbH | Dortmund, Germany |
| Nephrocare Friedberg GmbH | Friedberg, Germany |
| Nephrocare Grevenbroich GmbH | Grevenbroich, Germany |
| Nephrocare Hagen GmbH | Hagen, Germany |
| Nephrocare Hamburg-Altona GmbH | Hamburg, Germany |
| Nephrocare Hamburg-Barmbek GmbH | Hamburg, Germany |
| Nephrocare Hamburg-Süderelbe GmbH | Hamburg, Germany |
| Nephrocare Ingolstadt Schrobenhausen GmbH | Ingolstadt, Germany |
| Nephrocare Kaufering GmbH | Kaufering, Germany |
| Nephrocare Krefeld GmbH | Krefeld, Germany |
| Nephrocare Lahr GmbH | Lahr, Germany |
| Nephrocare Leverkusen GmbH | Leverkusen, Germany |
| Nephrocare Ludwigshafen GmbH | Ludwigshafen am Rhein, Germany |
| Nephrocare Mettmann GmbH | Mettmann, Germany |
| Nephrocare Mönchengladbach GmbH | Mönchengladbach, Germany |
| Nephrocare Mühlhausen GmbH | Mühlhausen, Germany |
| Nephrocare München-Ost GmbH | Munich, Germany |
| Nephrocare Münster GmbH | Münster, Germany |
| Nephrocare MVZ Aalen GmbH | Aalen, Germany |
| Nephrocare Oberhausen GmbH | Oberhausen, Germany |
| Nephrocare Papenburg GmbH | Papenburg, Germany |
| Nephrocare Pirmasens GmbH | Pirmasens, Germany |
| Nephrocare Püttlingen GmbH | Püttlingen, Germany |
| Nephrocare Recklinghausen GmbH | Recklinghausen, Germany |
| Nephrocare Rostock GmbH | Rostock, Germany |
| Nephrocare Salzgitter GmbH | Salzgitter, Germany |
| Nephrocare Schwandorf-Regenstauf GmbH | Schwandorf, Germany |
| Nephrocare Wetzlar GmbH | Wetzlar, Germany |
| Nephrocare Witten GmbH | Witten, Germany |
| Nova Med GmbH Vertriebsgesellschaft für medizinischtechnische Geräte und Verbrauchsartikel | Bad Homburg v. d. Höhe, Germany |
| ProCure Medical GmbH | Bad Homburg v. d. Höhe, Germany |
| VIVONIC GmbH | Sailauf, Germany |

---

**b)** **Cash and cash equivalents**

Cash and cash equivalents comprise cash funds and all short-term investments (measured at fair value through profit and loss) with original maturities of up to three months. Short-term investments are highly liquid and readily convertible into known amounts of cash. The risk of changes in value is insignificant.

**c)** **Trade accounts and other receivables from unrelated parties**

Trade accounts and other receivables from unrelated parties are recognized initially at fair value and subsequently at amortized cost. For information regarding expected credit losses, see note 2 c).

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The Company provides reinsurance to a healthcare insurer of end stage renal diseases and has entered into renal care coordination agreements to arrange and provide healthcare services to patients with chronic kidney disease (CKD). The Company accounts for both its reinsurance contract and renal care coordination agreement as insurance contracts, classified as separate portfolios, under IFRS 17, Insurance Contracts (IFRS 17) as significant insurance risk for these arrangements is transferred and the Company does not apply the optional exemption of IFRS 17 to account for these contracts under IFRS 15.

Premium revenue is received throughout the year based on claims experience. For both insurance and reinsurance portfolios, the Company applies the premium allocation approach (PAA) under IFRS 17 as the contract boundary of the cash flows is one year or less. On initial recognition of the liabilities for incurred claims, the estimation and valuation processes remain unchanged as compared to the application of IFRS 4, Insurance Contracts (IFRS 4). The subsequent measurement of insurance liabilities is based on the estimated cost of settling the claims incurred, but not yet recorded (IBNR). IBNR is estimated using actual paid claim data and applying historical claim completion factors, which may include the effects of both inflationary and socio-economic factors as well as using past experience adjusted for current trends and any other factors that would modify past experience. Regarding the measurement of the liabilities for the remaining coverage, the liabilities are equal to the premiums received less any insurance acquisition cash flows. Any insurance acquisition cash flows will be expensed when incurred. The Company does not consider the effects and time value of money when measuring the liabilities for the remaining coverage as the related cash flows are expected to be paid or received within one year or less from the date the claims are incurred. The Company does not receive any premiums in advance. As a result, the liabilities for the remaining coverage is zero.

The Company has applied the modified retrospective approach at the date of transition due to the impracticability of collecting cash flow estimations and risk adjustments for non-financial risk at the date of initial recognition of the reinsurance contract. Insurance premium revenues are recognized based upon the passage of time. For additional information see note 5 a) and note 8.

**d)** **Inventories**

Inventories are stated at the lower of cost (determined by using the average or first-in, first-out method) or net realizable value (see note 9). Costs included in inventories are based on invoiced costs and/or production costs as applicable. Included in production costs are material, direct labor, production overhead, and applicable depreciation charges.

**e)** **Property, plant and equipment**

Property, plant and equipment are stated at cost less accumulated depreciation (see note 11). Maintenance and repair costs (day-to-day servicing) are expensed as incurred. The Company recognizes in the carrying amount of an item of property, plant and equipment the cost of replacing parts and major inspections if it is probable that the future economic benefits associated with the item will flow to the Company and the cost can be measured reliably. Depreciation on property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets ranging from 4 to 60 years for buildings and improvements with a weighted average life of 18 years, 3 to 19 years for machinery and equipment with a weighted average life of 12 years, and 4 to 12 years for rented and loaned equipment with a weighted average life of 8 years. Internal use platform software that is integral to the computer equipment it supports is included in property, plant and equipment.

**f)** **Leases**

A lease is defined as a contract that conveys the right to use an underlying asset for a period of time in exchange for consideration. According to IFRS 16, a contract is or contains a lease if:

● the underlying asset is identified in the contract, and

● the customer has both the right to direct the identified asset's use and to obtain substantially all the economic benefits from that use.

*The Company as lessee:*

Under IFRS 16, the Company is required to recognize a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments for almost all leases.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The Company applies both the short-term and low-value lease exemption. These leases are exempt from balance sheet recognition and lease payments will be recognized as expenses over the lease term.

IFRS 16 is not applied to leases of intangible assets.

*Lease liabilities*

Lease liabilities are initially recognized at the present value of the following payments:

● fixed lease payments (including in-substance fixed payments), less any lease incentives receivable,

● variable lease payments (linked to an index or interest rate),

● expected payments under residual value guarantees,

● the exercise price of purchase options, where exercise is reasonably certain,

● lease payments in optional renewal periods, where exercise of extension options is reasonably certain, and

● penalty payments for the termination of a lease, if the lease term reflects the exercise of the respective termination option.

Lease payments are discounted using the implicit interest rate underlying the lease if this rate can be readily determined. Otherwise, the incremental borrowing rate of the lessee is used as the discount rate.

Lease liabilities are subsequently measured at amortized cost using the effective interest method. Furthermore, lease liabilities may be remeasured due to lease modifications or reassessments of the lease.

For lease contracts that include both lease and non-lease components that are not separable from lease components, no allocation is performed. Each lease component and any associated non-lease components are accounted for as a single lease. If the lease contracts include lease and non-lease costs that are separable, the lease contract costs are divided into lease and non-lease components.

*Right-of-use assets*

The Company recognizes right-of-use assets at the commencement date of the respective lease. Right-of-use assets are stated at cost less accumulated depreciation. Upon initial recognition, cost comprises of:

● the initial lease liability amount,

● initial direct costs incurred when entering into the lease

● (lease) payments before commencement date of the respective lease, and

● less any lease incentives received.

Right-of-use assets are depreciated over the shorter of the lease term or the useful life of the underlying asset using the straight-line method. Where a lease agreement includes a transfer of ownership at the end of the lease term or the exercise of a purchase option is deemed reasonably certain, right-of-use assets are depreciated over the useful life of the underlying asset using the straight-line method. In addition, right-of-use assets are reduced by impairment losses, if any, and adjusted for certain remeasurements.

Right-of-use assets are classified into right-of-use assets relating to land, buildings and improvements or machinery and equipment. In addition, prepayments on right-of-use assets are presented separately (see note 24).

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

*The Company as lessor:*

Under IFRS 16, leases for which the Company is the lessor are classified as finance or operating leases. Where the terms of a lease agreement transfer substantially all the risks and rewards of ownership of the asset to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

For a lease agreement classified as a finance lease, the Company initially recognizes a finance lease receivable in the amount of its net investment in the lease, which comprises the present value of the minimum lease payments and any unguaranteed residual accruing to the lessor. Initial direct costs are included in the calculation of the finance lease receivable (see note 8). Subsequently, the Company recognizes profit or loss on the transaction, as well as interest income, over the lease term. For a lease agreement classified as an operating lease, the Company records rental revenue on a straight - line basis unless another systematic and rational basis is more representative of the revenue earned. Assets leased under operating leases are included in property, plant, and equipment in the Company's consolidated balance sheets (see note 11)

**g)** **Intangible assets and goodwill**

Intangible assets such as non-compete agreements, technology, distribution agreements, patents, licenses to treat, licenses to manufacture, distribute and sell pharmaceutical drugs, exclusive contracts and exclusive licenses, trade names, management contracts, application software, acute care agreements, customer relationships, and emission certificates are recognized and reported apart from goodwill (see note 12). If acquired, those intangible assets are recorded at estimated fair value at the date of the acquisition. Patient relationships, however, are not reported as separate intangible assets due to the missing contractual basis but are part of goodwill.

Expenditures related to application software, either hosted by the Company or within a software as a service arrangement, that fully meet the criteria for the recognition of an intangible asset set out in IAS 38, Intangible Assets (IAS 38) are capitalized as intangible assets.

Goodwill, identifiable intangibles with indefinite useful lives, and intangible assets not yet available for use are not amortized but tested for impairment annually or when an event becomes known that could trigger an impairment. The Company identified certain trade names and qualified management contracts as intangible assets with indefinite useful lives because there is no foreseeable limit to the period over which those assets are expected to generate net cash inflows for the Company.

Intangible assets with finite useful lives are amortized over their respective useful lives to their residual values on a straight-line basis. The Company amortizes non-compete agreements over their useful lives which, on average, are 7 years. Technology is amortized over its average useful lives of 12 years. Internally developed intangibles are amortized over their average useful lives of 8 years. Licenses to manufacture, distribute, and sell pharmaceutical drugs, exclusive contracts, and exclusive licenses are amortized over their useful lives which on average is 11 years. Customer relationships are amortized over their average useful lives of 18 years. All other intangible assets are amortized over their weighted average useful lives of 8 years. The weighted average useful life of all amortizable intangible assets is 11 years. Intangible assets with finite useful lives are evaluated for impairment when events have occurred that may give rise to an impairment (see note 1 o)).

To perform the annual impairment test of goodwill, the Company identified its groups of cash generating units (CGUs) and determined their carrying value by assigning the operating assets and liabilities, including the existing goodwill and intangible assets, to those groups of CGUs. Groups of CGUs reflect the lowest level on which goodwill is monitored for internal management purposes.

One group of CGUs was identified in each of the Company's operating segments. For the purpose of goodwill impairment testing, all corporate assets and liabilities are allocated to the groups of CGUs. At least once a year, the Company compares the recoverable amount of each group of CGUs to the group of CGUs' carrying amount. The recoverable amount is defined as the higher of the value in use or the fair value less cost of disposal of a group of CGUs. In the first step, the value in use of the group of CGUs is determined using a discounted cash flow approach based upon the cash flow expected to be generated by the group of CGUs. In case that the value in use of the group of CGUs is less than its carrying amount and the fair value less cost of disposal is not estimated to be higher than the value in use, the difference is first recorded as an impairment of the carrying amount of the goodwill.

For further information see note 2 a).

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**h)** **Financial instruments**

The Company classifies its financial instruments in accordance with IFRS 9 in the following measurement categories: at amortized cost, at fair value through profit and loss (FVPL), and at fair value through other comprehensive income (FVOCI).

Financial assets are classified depending on the business model in which the financial assets are held and the contractual terms of the cash flows. Financial assets are only reclassified when the business model for managing those assets changes. During the reporting period, no financial instruments were reclassified. Purchases and sales of financial assets are recognized or derecognized on the trading date. The Company makes use of the fair value option, which allows financial instruments to be classified at FVPL upon initial recognition, in very rare cases. At initial recognition financial assets and financial liabilities are measured at fair value. Subsequent measurement is either at cost, FVPL, or FVOCI.

In general, financial liabilities are classified and subsequently measured at amortized cost, with the exception of contingent consideration resulting from a business combination, put option liabilities, and derivative financial liabilities. For debt instruments, accrued interest is included in the line items on the consolidated balance sheets where the borrowing is presented.

Investments in equity instruments are recognized and subsequently measured at fair value. The Company's equity investments are not held for trading. In general, changes in the fair value of equity investments are recognized in the income statement. However, at initial recognition the Company elected, on an instrument-by-instrument basis, to represent subsequent changes in the fair value of individual strategic equity investments in other comprehensive income (loss) (OCI).

The Company invested in several debt securities, with the objective to achieve both collecting contractual cash flows and selling the financial assets. All debt securities are consequently measured at fair value. Some of these securities give rise on specified dates to cash flows that are solely payments of principal and interest. These securities are subsequently measured at FVOCI. All other securities are measured at FVPL.

The Company, as option writer of existing put options, can be obligated to purchase the noncontrolling interests held by third parties. The obligations are in the form of put liabilities and are exercisable at the third-party owners' discretion within specified periods or upon the occurrence of certain events as outlined in each specific put option. If these put option liabilities were exercised, the Company would be required to purchase all or part of third-party owners' noncontrolling interests at the appraised fair value at the time of exercise. The initial recognition, subsequent measurement, and derecognition of put option liabilities are recognized in equity of the Company. For further information related to the estimation of these fair values, see note 26.

Certain put option arrangements contain contingent triggers based on changes in legislation, which the Company has concluded are not genuine using the guidance in IFRS 9 B4.1.18 and IAS 32.25. The Company considers this subset of contracts as being non-genuine as the trigger in these clauses is considered to be an event that is extremely rare, highly abnormal and very unlikely to occur. Therefore, the Company has not recorded a liability on the balance sheet relating to this subset of put option contracts.

Derivative financial instruments which primarily include foreign currency forward contracts are recognized as assets or liabilities at fair value in the balance sheet (see note 26). From time to time, the Company may enter into other types of derivative instruments, such as interest rate swaps and derivatives embedded in Virtual Power Purchase Agreements (vPPAs), which are dealt with on a transaction-by-transaction basis.

Changes in the fair value of derivative financial instruments designated and qualifying as cash flow hedges are recognized in accumulated OCI (AOCI) in shareholders' equity. The Company only designated the change in fair value of the spot element of foreign exchange forward contracts as the hedging instrument in cash flow hedging relationships and uses a hedge ratio for designated risks of 1:1. The forward elements are separately accounted for as cost of hedging in a separate component within AOCI. The ineffective portion of cash flow hedge is recognized in the income statement.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The amounts recorded in AOCI are subsequently reclassified into earnings as a component of revenue for those foreign exchange contracts, entered into with financial institutions, that hedge forecasted sales or as an adjustment of costs of revenue for those contracts that hedge forecasted intercompany product purchases. In connection with intercompany loans in foreign currency, the Company uses foreign exchange swaps with third parties to assure that no foreign exchange risks arise from those loans, which, if they qualify for cash flow hedge accounting, are also reported in AOCI and subsequently reclassified to other operating income or other operating expense. The amounts recorded in AOCI are reclassified in the same period in which the hedged transaction affects earnings. Amounts recorded in AOCI for cash flow hedges related to product purchases from third parties are removed from AOCI and included directly in the carrying amount of the asset at initial recognition. Product purchases and sales designated in a cash flow hedging relationship are expected to affect profit and loss in the same period in which the cash flows occur. The critical terms of the forward exchange contracts generally align with the hedged item. The economic relationship between forward exchange contracts and the hedged forecast transaction is based on the timing, currency and amount of the hedged cash flows. Ineffectiveness could arise in case the timing of the hedged transaction or the credit default risk changes.

From time to time, the Company enters into derivatives (particularly interest rate swaps and, to a certain extent, interest rate options) to protect against the risk of rising interest rates. When applicable, these interest rate derivatives are designated as cash flow hedges and have been entered into in order to effectively convert payments based on variable interest rates into payments at a fixed interest rate. The Company determines the existence of an economic relationship between the hedging instrument and hedged item based on the reference interest rates, maturities, and the notional amounts. As applicable, the effective portion of gains and losses of derivatives designated as cash flow hedges is deferred in AOCI; the amount of gains and losses reclassified from AOCI are recorded in interest income and interest expenses.

The change in fair value of derivatives that do not qualify for hedge accounting is recorded in the income statement and usually offsets the change in value recorded in the income statement for the underlying asset or liability.

Derivatives embedded in host contracts, such as derivatives embedded in vPPAs, are accounted for as separate derivatives if their economic characteristics and risks are not closely related to those of the host contracts. Currently, these embedded derivatives are limited to those embedded in vPPAs which are measured at fair value with changes in fair value recognized in the income statement within other operating income or other operating expense.

**i)** **Impairment of financial assets**

The impairment of financial assets is based on the expected credit loss approach in accordance with IFRS 9. The expected credit loss approach requires that all impacted financial assets will carry a loss allowance based on their expected credit losses. Expected credit losses are a probability-weighted estimate of credit losses over the contractual life of the financial assets.

This model comprises a three-stage approach. Upon recognition, the Company shall recognize expected lifetime losses. When assessing for significant increases in credit risk, the Company shall compare the risk of a default occurring on the financial instrument at the reporting date with the risk of a default occurring on the financial instrument at the date of initial recognition. The Company should consider reasonable and supportable information including historic loss rates, present developments such as liquidity issues, and information about future economic conditions to ensure foreseeable changes in the customer-specific or macroeconomic environment are considered. Separately, there is the rebuttable presumption that the credit risk has increased significantly since the initial recognition when contractual payments are overdue by more than 30 days.

In case of objective evidence of impairment there is an assignment to stage 3. The assignment of a financial asset to stage 3 should rely on qualitative knowledge on the customers' unfavorable financial position (for example bankruptcy, lawsuits with private or public payers), or quantitative criteria, based on an individual maturity analysis. Independently, there is an assignment to stage 3 if the contractual payments are overdue by more than 360 days. When a counterparty defaults, all financial assets against this counterpart are considered impaired. The definition of default is mainly based on payment practices specific to individual regions and businesses.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The Company recognizes a loss allowance for expected credit losses on financial assets measured at amortized cost, contract assets and lease receivables, and on investments in debt securities measured at fair value through other comprehensive income. The financial assets mainly comprise of accounts receivable as well as cash and cash equivalents. The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective instrument. Financial assets with expected credit losses not assessed individually are grouped on the basis of geographical regions and impairment is generally assessed on the basis of macroeconomic indicators such as credit default swaps.

For accounts receivable, the Company uses the simplified method which requires recognizing lifetime expected credit losses at inception. However, expected credit losses on cash and cash equivalents are measured according to the general method based on IFRS 9.

Based on the external credit ratings of the counterparties, which are generally investment grade, the Company considers that its cash and cash equivalents have a low credit risk. A significant increase in credit risk will be assessed based on qualitative and quantitative information.

**j)** **Foreign currency translation**

For purposes of these consolidated financial statements, the euro is the reporting and functional currency. The requirement to report in euro arises from Section 244 HGB. Substantially all assets and liabilities of foreign subsidiaries that use a functional currency other than the euro are translated at year-end exchange rates, while profit and loss positions are translated at annual average exchange rates. Adjustments for foreign currency translation fluctuations are excluded from net earnings and are reported in AOCI. In addition, the translation adjustments of certain intercompany borrowings, which are of a long-term nature, are reported in AOCI. Transactions in foreign currencies recorded by subsidiaries are accounted for at the prevailing spot rate on the date of the respective transaction. Foreign exchange gains and losses resulting from the settlement of such transactions are generally recognized in profit and loss. Financial instruments denominated in a foreign currency are revalued at the spot rate as of the date of the consolidated statement of financial position. On the disposal of a foreign operation, all of the foreign currency translation differences accumulated in AOCI in respect of that disposed operation are reclassified to the consolidated statements of income. On a partial disposal of a subsidiary that includes a foreign operation that does not result in the loss of control over the subsidiary, the proportionate share of accumulated foreign currency translation differences is re-attributed to noncontrolling interests.

The exchange rates of the U.S. dollar affecting foreign currency translation developed as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exchange rates**  |  |  |  |  |  |
|  | **December 31, 2025** | **December 31, 2024** | **2025** | **2024** | **2023** |
|  | spot exchange | spot exchange | average exchange | average exchange | average exchange |
|  | rate in € | rate in € | rate in € | rate in € | rate in € |
| 1 U.S. dollar | 0.85106 | 0.96256 | 0.88499 | 0.92386 | 0.92484 |

---

**k)** **Revenue recognition**

For both healthcare services revenue and healthcare products revenue, amounts billed to patients, third party payors and customers are recorded net of contractual allowances, discounts or rebates to reflect the estimated amounts to be receivable from these payors.

*Healthcare services*

Healthcare services revenue, other than insurance revenues discussed below, are recognized on the date the patient receives treatment and includes amounts related to certain services, products and supplies utilized in providing such treatment at an amount to which the Company expects to be entitled. The patient is obligated to pay for healthcare services at amounts estimated to be receivable based upon the Company's standard rates or at rates determined under reimbursement arrangements. In the U.S., these arrangements are generally with third party payors, such as Medicare, Medicaid or commercial insurers. Outside the U.S., the reimbursement is usually made through national or local government programs with reimbursement rates established by statute or regulation.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

For services performed for patients where the collection of the billed amount or a portion of the billed amount cannot be determined at the time services are performed, the Company concludes that the consideration is variable (implicit price concession) and records the difference between the billed amount and the amount estimated to be collectible as a reduction to healthcare services revenue. Implicit price concessions include such items as amounts due from patients without adequate insurance coverage, patient co-payment and deductible amounts due from patients with healthcare coverage. The Company determines implicit price concessions based primarily upon historical collections, denials, delays, refunds, payment adjustments, and regulatory compliance. Upon receipt of new information relevant for the determination of the implicit price concession, the Company constrains, or adjusts the constraints for the variable consideration of the transaction price. Furthermore, collections, refunds, and payment adjustments often continue for up to three years or more following the provision of services.

*Healthcare products* 

In the healthcare product business, major revenues are generated from the sale of dialysis machines, water treatment systems, home hemodialysis products, disposable products, and maintenance agreements for the Company´s healthcare products. Revenues from the sale of dialysis machines and water treatment system are typically recognized upon installation and provision of the necessary technical instructions as only thereafter the customer obtains control of the medical device. A small portion of the Company´s revenue is recognized from sales of dialysis machines, home hemodialysis products, and other products used for in-center hemodialysis treatment to distributors. When the distributor is the principal in the contract, the revenue allocated to the machine or the products will be recognized upon transfer of control to the distributor. In case the Company is committed to perform the installation, revenue allocated to the installation, as a separate performance obligation, would be recorded upon installation of the machine at the end-customers' premises. In case the distributor is only an agent in the contract, revenue for sale of the machine would be recorded upon installation.

Under consignment arrangements revenue is recognized upon withdrawal of the products by the customer.

Maintenance is provided over time, and as such revenue is typically recognized on a straight-line basis as the customer is simultaneously receiving and consuming the benefits provided by the Company's performance.

All other dialysis and non-dialysis product revenues are recognized upon transfer of control to the customer. Product revenues are normally based upon pre-determined rates that are established by contractual arrangement.

A portion of dialysis product revenues is generated from arrangements which give the customer, typically a healthcare provider, the right to use dialysis machines. In the same contract the customer agrees to purchase the related treatment disposables at a price marked up from the standard price list. If the right to use the machine is conveyed through an operating lease and the customer agrees to purchase a minimum number of related treatment disposables, the Company does not recognize revenue upon delivery of the dialysis machine but recognizes revenue on the sale of disposables upon transfer of control with revenue for the use of dialysis machines recognized straight-line over the term of the lease contract. When there is no such agreement that the customer purchases a minimum number of related treatment disposables, revenue is recognized only on the sale of disposables unless the timing of the first purchase order of related treatment disposables justifies a combination of contracts according to IFRS 15.

If the lease of the machines is a finance lease, ownership of the dialysis machine is transferred to the user upon installation of the dialysis machine at the customer site. In this type of contract, revenue is recognized in accordance with the accounting principles for finance leases under IFRS 16. The allocation of the transaction price to lease and non-lease components is based on stand-alone selling prices.

For certain home-dialysis products the Company offers month-to-month rental arrangements, where revenue is recognized on a monthly basis.

In addition, for some licensing agreements and equipment sales to dialysis clinic customers in the area of home-dialysis, the Company recognizes upfront fees received as lease revenue on a straight-line basis over the term of the contract.

IFRS 15 specifically excludes leases from the scope of the revenue standard. The transaction price of contracts which include lease components is allocated in accordance with IFRS 15. Revenue is recognized separately for the lease and the non-lease components of the contract.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

"Revenue from lease contracts" is disclosed separately from "Revenue from contracts with customers" in the notes to the consolidated financial statements.

*Insurance contracts*

In the U.S., the Company generates revenue from insurance (including reinsurance) contracts, such as sub-capitation arrangements, for which the Company applies IFRS 17 as significant insurance risk for these arrangements is transferred and the Company does not apply the optional exemption of IFRS 17 to account for these contracts under IFRS 15. Insurance premium revenue is recognized as earned each month and risk adjustments are offset against revenue.

The Company has entered into shared savings arrangements with certain payors to provide care and care coordination services to certain end stage renal disease (ESRD) and chronic kidney disease patients. Under these arrangements, the Company may earn variable reimbursement or may owe the payor reimbursement.

"Revenue from insurance contracts" is disclosed separately from "Revenue from contracts with customers" in the notes to the consolidated financial statements.

**l)** **Capitalized interest**

For significant construction projects exceeding six months, the Company includes capitalized interest costs that are directly attributable to the construction or the production of a qualifying asset as part of the cost of the asset. For the fiscal years 2025, 2024, and 2023, interest of €1,577, €2,149, and €2,500, based on an average interest rate of 2.45%, 2.24%, and 2.88%, respectively, was recognized as a component of the cost of assets.

**m)** **Research and development (R&D) expense**

Research is the original and planned investigation undertaken with the prospect of gaining new scientific or technical knowledge. Development is the technical and commercial implementation of research results and takes place before the start of commercial production or use. Research costs are expensed as incurred. Development costs that fully meet the criteria for the recognition of an intangible asset, as set out in IAS 38, are capitalized and are primarily development projects related to dialysis machines. Such costs are capitalized when the Company's commitment to finalize the project has been formalized and approved by management, the design input of the project or machine has been finalized and, based on experience with similar projects, the Company has determined that technical feasibility has been achieved and future economic benefits are probable.

**n)** **Income taxes**

Current taxes are calculated based on the profit (loss) of the fiscal year and in accordance with local tax rules of the respective tax jurisdictions. Expected and executed additional tax payments and tax refunds for prior years are also taken into account.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the single entity's financial statement carrying amounts of existing assets and liabilities and their respective tax basis, tax credits, and tax loss carryforwards which are probable to be utilized. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates that have been enacted or substantially enacted by the end of the reporting period. A change in tax rate for the calculation of deferred tax assets and liabilities is recognized in the period the new laws are enacted or substantively enacted. The effects of the adjustment are generally recognized in the income statement. The effects of the adjustment are recognized in equity, if the temporary differences are related to items directly recognized in equity.

Deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill and are not tax deductible. In addition, deferred tax assets and liabilities are not recognized if they arise from the initial recognition of an asset or a liability in a transaction other than a business combination that at the time of the transaction affects neither accounting profit nor taxable profit or loss and does not give rise to equal taxable and deductible temporary differences.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The carrying amount of a deferred tax asset is reviewed at each balance sheet date. A deferred tax asset is recognized to the extent that the utilization of parts or all of it is probable because sufficient taxable profit will be available (see note 5 g). The determination of future taxable income is based on assumptions on future market conditions and future profits of FME AG and considers all currently available information as well as the level of historical taxable income. In addition, the determination of the recoverable amount of deferred tax assets considers implemented tax strategies.

With respect to the interpretation of tax laws, the amount, and the timing of future taxable income, complex tax rules may lead to uncertainties in tax treatments. The Company recognizes assets and liabilities for uncertain tax treatments based on reasonable estimates to the extent it is probable the tax will be recovered or that the tax will be payable, respectively.

In the U.S. and Germany, interest and penalties related to income taxes, including uncertain tax treatments, do not meet the definition of income taxes and therefore are accounted for under IAS 37. All other jurisdictions account for interest and penalties related to income taxes in accordance with local tax rules of the respective tax jurisdiction either under IAS 37 or as income tax expense under IAS 12. Under IAS 37, penalties related to income taxes, including uncertain tax treatments, are recorded within selling, general and administrative expense. Additionally, in accordance with IAS 37, interest related to income taxes, including uncertain tax treatments, are recorded within other (income) expense.

The Company's Global Intercompany Service Charging initiative established a standardized and simplified global framework for intercompany service charging. Consistent with Organisation for Economic Co-operation and Development Transfer Pricing Guidelines, service fees are charged based on associated costs and arm's length mark-ups using allocation keys which reflect the benefits received by the service recipients.

Due to the size of the Company's revenue, the Company is within the scope of the Organisation for Economic Co-operation and Development's Inclusive Framework on Base Erosion Profit Shifting (BEPS) Global Anti-Base Erosion Model Rules (GloBE): Global Minimum Taxation (Pillar Two) legislation. In Germany, the jurisdiction in which the Company resides, the legislation became effective on January 1, 2024. The Company applies the exception not to recognize or disclose deferred taxes in connection with Pillar Two income taxes. Income tax expenses related to Pillar Two income taxes are included within the income tax expense line item in the Company's consolidated statements of income.

**o)** **Impairment**

The Company reviews the carrying amount of its property, plant and equipment, intangible assets with definite useful lives, right-of-use assets, and other non-current assets for impairment whenever events or changes in circumstances indicate that the carrying amount is higher than the asset's recoverable amount in accordance with IAS 36, Impairment of Assets (IAS 36). The fair value less cost of disposal of an asset is estimated as its net realizable value. The value in use is the present value of future cash flows expected to be derived from the relevant asset. If it is not possible to estimate the future cash flows from the individual assets, impairment is tested on the basis of the corresponding group of CGUs.

Impairment losses, except impairment losses recognized on goodwill, are reversed up to the amount of the amortized acquisition cost as soon as the reasons for impairment no longer exist.

Non-current assets to be disposed of by sale are reported at the lower of carrying value or fair value less cost to sell and depreciation is ceased. Non-current assets to be disposed of other than by sale are considered to be held and used until disposal.

**p)** **Debt issuance costs**

Debt issuance costs related to a recognized debt liability are presented on the balance sheet as a direct deduction from the carrying amount of that debt liability. Debt issuance costs related to undrawn credit facilities are presented in Other assets. These costs are amortized over the term of the related obligation or credit facility.

For further information see note 17.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**q)** **Concentration of risk**

The Company is engaged in the manufacture and sale of products for all forms of kidney dialysis, principally to healthcare providers throughout the world, and in providing kidney dialysis treatment as well as providing other healthcare services. The Company performs ongoing evaluations of its customers' financial condition and, generally, requires no collateral.

Revenues which were earned and subject to regulations under Medicare and Medicaid (excluding Medicare Part C, also known as Medicare Advantage plans), governmental healthcare programs administered by the U.S. government, were approximately 16%, 18%, and 18% of the Company's worldwide revenues in 2025, 2024, and 2023, respectively.

See note 2 c) for concentration risks of debtors or group of debtors as well as note 9 for discussion of suppliers with long-term purchase commitments.

**r)** **Other provisions**

In accordance with IAS 37, provisions are recognized when there is a present obligation to a third party arising from past events, it is probable that the obligation will be settled in the future and the required amount can be reliably estimated. Provisions by their nature are more uncertain than most other items in the statement of financial position.

Non-current provisions with a remaining period of more than one year are discounted to the present value of the expenditures expected to settle the obligation. The applied discount rate is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.

**s)** **Earnings per share**

Basic earnings per share is calculated in accordance with IAS 33, Earnings per Share (IAS 33). Basic earnings per share is calculated by dividing net income attributable to shareholders by the weighted average number of shares outstanding during the year. Diluted earnings per share include the effect of all potentially dilutive instruments on shares that would have been outstanding during the years presented had the dilutive instruments been issued. For the calculation of basic earnings per share, treasury stock is not considered outstanding and is therefore deducted from the number of shares outstanding.

Equity-settled awards granted under the Company's share-based plans (see note 23) might be potentially dilutive equity instruments.

**t)** **Treasury stock**

The Company may, from time to time, acquire its own shares (Treasury Stock) as approved by its shareholders. The acquisition, sale or retirement of its Treasury Stock is recorded separately in equity. The value of such Treasury Stock is shown as a reduction of the Company's equity.

**u)** **Employee benefit plans**

Pension obligations for post-employment benefits are measured in accordance with IAS 19, Employee Benefits (IAS 19), using the projected unit credit method, taking into account future salary and trends for pension increase.

The Company uses December 31 as the measurement date when measuring the net pension liability.

For the Company's funded benefit plans the defined benefit obligation is offset against the fair value of plan assets (net pension liability). Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. A pension liability is recognized in the consolidated balance sheet if the defined benefit obligation exceeds the fair value of plan assets. A pension asset is recognized (and reported under "Other non-current assets" in the consolidated balance sheet) if the fair value of plan assets exceeds the defined benefit obligation and if the Company has a right of refund against the fund or a right to reduce future payments to the fund.

Net interest costs are calculated by multiplying the benefit obligation (fair value of plan assets) at beginning of the year with the discount rate utilized in determining the benefit obligation.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Remeasurements include actuarial gains and losses resulting from the evaluation of the defined benefit obligation as well as from the difference between actual investment returns and the return implied by the net interest cost. In the event of a surplus for a defined benefit pension plan remeasurements can also contain the effect from asset ceiling, as far as this effect is not included in net interest costs.

Remeasurements are recognized in AOCI completely. Remeasurements may not be reclassified in subsequent periods. Components of net periodic benefit cost are recognized in profit and loss of the period.

**v)** **Share-based plans**

The fair value of cash-settled performance shares and of performance shares that will be settled in shares of the Company granted to the Management Board and executive employees of the Company is calculated using the Monte Carlo pricing model in accordance with IFRS 2, Share-based Payment (IFRS 2). For cash-settled performance shares, the corresponding liability based on the balance sheet date fair value is accrued over the vesting periods of the performance share plans. For performance shares that will be settled in shares of the Company, the corresponding increase in equity based on the grant date fair value is allocated over the vesting periods of the performance share plans. For certain exceptions, a shorter vesting period may apply after which the performance shares will not forfeit in any way. In such cases the vesting period is shortened accordingly.

**w)**Impacts of climate change on accounting

The Company continually analyzes potential sustainability risks in the areas of climate change, water scarcity, and resource usage. In particular, during 2024, we entered into several vPPAs with wind and solar energy project developers in Germany and in the U.S. in order to receive guarantees of origin and renewable energy certificates, respectively, to address our sustainability objectives. Volatility in the valuation of financial instruments connected to energy prices or energy production volumes, including as a result of the heightened risk of volatility due to geopolitical conflicts in certain regions, could result in a material adverse effect on our business or results of operations. Other than the aforementioned risk, the Company has not identified any significant risks for its business model in 2025.

**x)**Recent pronouncements

#### Recently implemented accounting pronouncements
The Company has prepared its consolidated financial statements at and for the year ended December 31, 2025 in conformity with IFRS Accounting Standards that must be applied for fiscal years starting on or after January 1, 2025. For the year ended December 31, 2025, there were no recently implemented accounting pronouncements that materially affect the business.

**Recent accounting pronouncements not yet adopted**

The following new accounting standards and amendments to accounting standards have been published that are not mandatory as of and for the year ended December 31, 2025 and will not be early adopted by the Company.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

***IFRS 18, Presentation and Disclosure in Financial Statements***

On April 9, 2024, the IASB issued IFRS 18, Presentation and Disclosure in Financial Statements (IFRS 18). IFRS 18 aims to improve how information is communicated in financial statements to give investors a more comparable basis to analyze companies' performance. The standard introduces three sets of new requirements: new categories and subtotals in the consolidated statements of income, disclosure regarding management-defined performance measures, and guidance related to the aggregation and disaggregation of certain information. The consolidated statements of income will be split into three newly defined categories (operating, investing, and financing) and will include two newly defined subtotals (operating profit and profit before financing and income taxes). Management-defined performance measures are subtotals of income and expense used in public communication outside the financial statements and communicate management's view of certain aspects of a company's performance. Such measures will be required to be described in a clear and understandable manner in a single note explaining how the measure is calculated, why it is useful, providing a reconciliation to the most directly comparable subtotal noted above, the income tax and the effect on noncontrolling interest for each item will be presented in the reconciliation and how the income tax effect is determined. Lastly, companies will be required to disaggregate items if such information is material and to avoid using the label "other" in financial statements. Certain additional details for depreciation and amortization, impairment and other expense classifications may be required. Additionally, IFRS 18 will introduce limited changes to IAS 7, Statement of Cash Flows. Operating profit will be the starting point for reporting cash flows from operating activities using the indirect method and the option for classifying interest and dividend cash flows as operating activities will be eliminated. Dividends and interest paid will be classified in cash flows from financing activities whereas dividends and interest received will be classified in cash flows from investing activities. An entity shall apply those amendments when it applies IFRS 18. IFRS 18 is effective for fiscal periods commencing on or after January 1, 2027, while earlier adoption is permitted. The standard must be applied retrospectively. The standard is expected to impact the Company's presentation of items within the consolidated financial statements and its notes disclosures once implemented, though the standard is not expected to change how the Company recognizes or measures items in its consolidated financial statements. In order to comply with the extended disclosure requirements under IFRS 18, the Company will expand the disclosures in the notes to the consolidated financial statements, including the disclosure of expenses by function according to their cost type. The Company continues to investigate the appropriate level of disaggregation in accordance with IFRS 18 and the associated effects of IFRS 18 on the consolidated financial statements.

Notably, foreign exchange gains and losses are currently presented in other operating income and other operating expense, but will be presented within the newly defined operating, investing, and financing categories under IFRS 18 which would have an impact on certain related subtotals and key performance indicators for the Company. Similarly, items such as income from equity method investees and the revaluation of certain investments held by the Company, currently presented within operating income, will be shown within the consolidated statement of income in the investing category. Quantitative impacts cannot yet be adequately estimated at this time.

In the Company's view, no other pronouncements issued by the IASB are expected to have a material impact on the consolidated financial statements.

**2.**Significant judgments and sources of estimation uncertainties

The Company's reported results of operations, financial position, and net assets are sensitive to significant judgments, assumptions, and estimates that are the basis for its financial statements. The critical accounting policies, the judgments made in the creation and application of these policies, and the sensitivities of reported results to changes in accounting policies, significant judgments, and estimates are factors to be considered along with the Company's financial statements. In the opinion of the Management of the Company, the following accounting policies, significant judgments, and sources of estimation uncertainties are critical for the consolidated financial statements in the present economic environment.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**a)**Recoverability of goodwill and intangible assets

The growth of the business through acquisitions has created a significant amount of intangible assets, including goodwill, trade names, management contracts, non-compete agreements, technology and customer relationships as well as licenses and distribution agreements. In addition, the Company recognizes internally developed intangible assets related to R&D and software development projects. At December 31, 2025, the carrying amount of goodwill and non-amortizable intangible assets amounted to €13,826,378 (€15,461,434 at December 31, 2024) representing approximately 45% and 46% of the Company's total assets at December 31, 2025 and 2024, respectively.

In accordance with IAS 36, the Company performs an impairment test of goodwill and non-amortizable intangible assets at least once a year for each group of CGUs or more frequently if the Company becomes aware of events that occur or if circumstances change that would indicate the carrying value may not be recoverable (see also note 1 g).

To comply with IFRS Accounting Standards to determine possible impairments of these assets, the value in use of the group of CGUs is first compared to the group of CGUs' carrying amount. In cases where the value in use of the group of CGUs is less than its carrying amount and the fair value less cost of disposal is not estimated to be higher than the value in use, the difference is recorded as an impairment of the carrying amount of the group of CGUs.

To evaluate the recoverability of intangible assets with indefinite useful lives, the Company compares the recoverable amounts of the smallest identifiable group of assets that generate largely independent cash inflows with their carrying values. An intangible asset's fair value is determined using a discounted cash flow approach or other methods, if appropriate.

The value in use of each group of CGUs is determined using estimated future cash flows for the unit discounted by a pre-tax discount rate (WACC) specific to that group of CGUs. The Company's WACC consists of a basic rate in which costs of debt and capital structure are derived from the market data of the respective peer group companies. The basic rate is adjusted by a weighted average country risk rate and, if appropriate, by a factor to reflect higher risks associated with the cash flows from recent material acquisitions within each group of CGUs, until they are appropriately integrated as well as country- and business-specific risks identified within a group of CGUs. The Company's WACC is impacted by macro-economic and other specific uncertainties. Estimating the future cash flows involves significant assumptions, especially regarding future reimbursement rates and sales prices, number of treatments, sales volumes and costs. The estimates were largely impacted by the continuing deterioration of the macroeconomic environment in recent years.

In connection with the decision of the Management Board to update the Company's globalized operating model by introducing a new operating segment, Value-Based Care, as of June 1, 2025, the Company performed a reallocation of goodwill to the segments under its new operating structure and evaluated the effects of this reallocation on the recoverability of goodwill. At the date of the reorganization, goodwill was reallocated to the CGUs Care Delivery and Value-Based Care using a relative value approach. As there was no change in the composition of the operating segment Care Enablement, the goodwill of this CGU remained unchanged. Based on the new operating model, one group of CGUs was identified in each of the Company's operating segments (Care Delivery, Value-Based Care and Care Enablement) as of June 1, 2025 with no impairment as indicated by impairment tests before and after the reallocation.

The Company performed an analysis in connection with the annual goodwill impairment test as of October 1, 2025, which included qualitative and quantitative simulations to assess the potential impact of GLP-1 receptor agonists and the potential impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the CKD and ESRD populations, specifically in relation to cash flow projections and goodwill sensitivity assessments based on the analysis of the population impact model (a computational tool to predict the size and age distribution of future patient populations with kidney disease for the coming decade, based on various public-health scenarios). In the Company's population impact model the sensitivity bands of the various scenarios of GLP-1 receptor agonist and SGLT2 inhibitor utilization in the CKD population suggest an increase in the total CKD population and a reduction in the ESRD population growth rate that remain materially consistent with the patient population forecasts which do not include the utilization of these drugs. Considering the positive cardiovascular effects of the drugs, reducing mortality, as well as the progression-delaying effect on the CKD population, the Company sees a balanced effect of the drugs on the patient population. The Company's assessment concluded that underlying patient growth assumptions used in its cash flow projections reflect the current understanding of treatment developments.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The key assumptions represent management's assessment of future trends and have been based on historical data from both external and internal sources, including the population impact model as described above. The Company's projections include its estimation of the impacts resulting from changes in healthcare and tax legislation as well as uncertainty regarding global trade policy (including the impact of tariffs). While the Company utilizes its three-year budgets for all CGUs, projections for years four to ten and a representative growth rate for all remaining years in determining discounted cash flows are used for the CGUs Care Delivery and Care Enablement. For the CGU Value-Based Care, projections for years four to five and a representative growth rate for all remaining years in determining discounted cash flows are applied, given the nascent character of the business. The projections for the first three years were prepared based on the status of current initiatives without considering any growth and improvement from initiatives which have not commenced related to the transformation of the Company's operating structure and steps to achieve cost savings (FME25+ Program). Projections for up to ten years are possible due to the non-discretionary nature of the healthcare services the Company provides, the need for healthcare products utilized to provide such services and the availability of government reimbursement for a substantial portion of its services. The simulations regarding the potential impacts of GLP-1 and SGLT2, as described above, underlined the Company's determination of using projections for up to ten years as the full potential impacts on the Company's revenue, operating income, and cash flow streams are not expected to be realized within a shorter time period.

The annual impairment test performed as of October 1, 2025 did not result in an impairment.

The market capitalization of the Company decreased by 12% to €11,383,815 as of December 31, 2025, from €12,957,138 as of December 31, 2024. Total FME AG shareholders' equity decreased by 8% to €13,309,832 as of December 31, 2025, from €14,576,563 as of December 31, 2024, driven primarily by a decrease in other comprehensive income (loss), including foreign currency translation effects in the amount of €1,544,634, and purchases of treasury stock under our share buyback program, partially offset by the impact of net income on shareholders' equity and the impact from the settlement of Interwell Health put options.

Due to the carrying amount of net assets exceeding the Company's market capitalization, the Company performed an impairment test as of December 31, 2025, in addition to the annual impairment test as of October 1, 2025. WACC parameters were updated as of December 31, 2025, while CGU residual value growth rates remained unchanged as compared to the annual impairment test performed as of October 1, 2025. The goodwill impairment test performed as of December 31, 2025 did not result in any impairment.

A prolonged downturn in the healthcare industry with lower than expected increases in reimbursement rates and/or higher than expected costs for providing healthcare services and for procuring and selling healthcare products, a significant increase of mortality of patients with chronic kidney diseases, changes in global trade policy, including new tariffs on most products imported into the U.S. and the possibility of additional trade restrictions, or changes to Medicare and Medicaid funding, enrollment, and eligibility effected by the One Big Beautiful Bill Act, could adversely affect the Company's estimated future cash flows. Future adverse changes in a cash-generating unit's economic environment of a group of CGUs could affect the country specific risk rate and therefore the discount rate. Equally an increase of the general interest rate level could affect the base rate and therefore the discount rate. Additionally, changing market conditions and new market entrants could have a negative impact on the estimated future cash flows and/or a decline in the cash-generating units economic environment, both of which are, by their nature, difficult to predict. As noted in the sensitivity analysis below, if the Company's assumptions change or actual future performance is lower than expected, the Company could record goodwill impairments in the future, and such impairments could be material to its net income.

The following table shows the amount of goodwill recognized, the amount by which the recoverable amount of each of the Company's CGUs exceeded its carrying amount, key assumptions of value-in-use calculations (presented based upon the goodwill impairment test performed as of December 31, 2025, October 1, 2025 and June 1, 2025) and the reasonable amounts by which the key assumptions would need to change individually that the recoverable amount equals the carrying amount. There are no reasonably possible changes in assumptions that would lead to an impairment in these groups of CGUs.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Goodwill recognized** |  |  |  |  |  |
| *in € K* |  |  |  |  |  |
|  | **December 31, 2025** | **October 1, 2025** | **June 1, 2025**<sup>(1)</sup> | **December 31, 2024** | **October 1, 2024** |
| Goodwill | 13571394 | 13585362 | 14035273 | 15170652 | 14227152 |
| &nbsp;&nbsp;thereof Care Delivery | 11212997 | 11227831 | 11613650 | 13014925 | 12171616 |
| &nbsp;&nbsp;thereof Value-Based Care | 368663 | 368945 | 382025 | n.a. | n.a. |
| &nbsp;&nbsp;thereof Care Enablement | 1989734 | 1988586 | 2039598 | 2155727 | 2055536 |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Excess of recoverable amount over carrying amount** |  |  |  |  |  |
| *in € K* |  |  |  |  |  |
|  | **December 31, 2025** | **October 1, 2025** | **June 1, 2025**<sup>(1)</sup> | **December 31, 2024** | **October 1, 2024** |
| Care Delivery | 6521602 | 5606349 | 5110313 | 6757218 | 7454490 |
| Value-Based Care | 172260 | 89670 | 424898 | n.a. | n.a. |
| Care Enablement | 2732309 | 2672471 | 8661306 | 3290699 | 3360527 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Key assumptions** | **Key assumptions** | **Key assumptions** | **Key assumptions** | **Key assumptions** | **Key assumptions** |
| *in %* |  |  |  |  |  |
|  | **Care Delivery** | **Care Delivery** | **Care Delivery** | **Care Delivery** | **Care Delivery** |
|  | **December 31,**  | **October 1,** | **June 1,** | **December 31,**  | **October 1,** |
|  | **2025** | **2025** | **2025**<sup>(1)</sup> | **2024** | **2024** |
| Average revenue growth in projection period | low-single-digit | low-single-digit | low-single-digit | mid-single-digit | mid-single-digit |
| Average operating income growth in projection period | mid-single-digit | mid-single-digit | low-single-digit | mid-single-digit | mid-single-digit |
| Residual value growth | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Pre-tax WACC | 8.90 | 9.09 | 9.06 | 8.55 | 8.50 |
| After-tax WACC | 7.21 | 7.39 | 7.37 | 6.46 | 6.45 |
| **Sensitivity analysis** |  |  |  |  |  |
| *Change in percentage points* |  |  |  |  |  |
| Pre-tax WACC | 2.69 | 2.36 | 2.18 | 2.46 | 2.77 |
| After-tax WACC | 2.11 | 1.86 | 1.51 | 1.80 | 2.05 |
| Residual value growth | (8.53) | (7.40) | (6.83) | (7.55) | (9.37) |
| Operating income margin of each projection year | (3.18) | (2.88) | (2.39) | (2.86) | (3.20) |

---

---

| | | | |
|:---|:---|:---|:---|
| **Key assumptions** | **Key assumptions** | **Key assumptions** | **Key assumptions** |
| *in %* |  |  |  |
|  | **Value-Based Care** | **Value-Based Care** | **Value-Based Care** |
|  | **December 31, 2025** | **October 1, 2025** | **June 1, 2025**<sup>(1)</sup> |
| Average revenue growth in projection period | high-single-digit | high-single-digit | low-double-digit |
| Average operating income growth in projection period | low-triple-digit | low-triple-digit | low-triple-digit |
| Residual value growth | 2.80 | 2.80 | 2.80 |
| Pre-tax WACC | 8.53 | 9.00 | 9.45 |
| After-tax WACC | 7.20 | 7.57 | 7.97 |
| **Sensitivity analysis** |  |  |  |
| *Change in percentage points* |  |  |  |
| Pre-tax WACC | 1.71 | 0.97 | 6.07 |
| After-tax WACC | 1.32 | 0.75 | 4.67 |
| Residual value growth | (2.36) | (1.32) | (11.17) |
| Operating income margin of each projection year | (0.41) | (0.24) | (0.99) |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Key assumptions** | **Key assumptions** | **Key assumptions** | **Key assumptions** | **Key assumptions** | **Key assumptions** |
| in % |  |  |  |  |  |
|  | **Care Enablement** | **Care Enablement** | **Care Enablement** | **Care Enablement** | **Care Enablement** |
|  | **December 31,**  | **October 1,**  | **June 1,** | **December 31,**  | **October 1,**  |
|  | **2025** | **2025** | **2025**<sup>(1)</sup> | **2024** | **2024** |
| Average revenue growth in projection period | mid-single-digit  | mid-single-digit  | mid-single-digit  | mid-single-digit | mid-single-digit |
| Average operating income growth in projection period | high-single-digit | high-single-digit | high-single-digit | low-double-digit | low-double-digit |
| Residual value growth | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Pre-tax WACC | 8.43<br><sup>(3)</sup>  | 8.52<br><sup>(3)</sup>  | 5.85<br><sup>(2)</sup>  | 7.78 | 7.79 |
| After-tax WACC | 6.42<br><sup>(3)</sup>  | 6.51<br><sup>(3)</sup>  | 4.6<br><sup>(2)</sup>  | 6.00 | 6.03 |
| **Sensitivity analysis** |  |  |  |  |  |
| *Change in percentage points* |  |  |  |  |  |
| Pre-tax WACC | 2.02 | 2.01 | 4.35 | 2.30 | 2.39 |
| After-tax WACC | 1.41 | 1.42 | 3.05 | 1.67 | 1.75 |
| Residual value growth | (4.74) | (4.84) | (13.02) | (5.70) | (6.16) |
| Operating income margin of each projection year | (2.62) | (2.64) | (5.24) | (2.90) | (3.02) |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Information as of June 1, 2025 is presented in alignment with the aforementioned changes in the Company's operating segments. The Company performed an impairment analysis at the date of the reallocation in both the current and prior CGU structure, neither of which indicated any impairment in our operating segments. The key assumptions and sensitivities under both the current and prior CGU structures are not materially different.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The decrease of the after-tax and pre-tax WACC of Care Enablement compared to the status as of December 31, 2024 was mainly driven by a lower beta factor due to peer group changes and lower beta factors of the majority of the remaining peer entities.

&nbsp;&nbsp;&nbsp;&nbsp;(3) The increase of the after-tax and pre-tax WACC of Care Enablement compared to the status as of June 1, 2025 was mainly driven by a refined methodology of WACC calculation in regards to country risk premiums.

A further overview of the carrying amounts of goodwill and an overview of intangibles with indefinite useful life for each group of CGUs is shown in note 12.

**b)** **Legal contingencies**

From time to time, during the ordinary course of operations as well as due to acquisitions, the Company is party to litigation and arbitration and is subject to investigations relating to various aspects of its business (see note 25). The Company regularly analyzes current information about such claims for probable losses and provides accruals for such matters, including the estimated legal expenses and consulting services in connection with these matters, as appropriate. The Company utilizes its internal legal department as well as external resources for these assessments. In making the decision regarding the need for loss accrual, the Company considers the degree of probability of an unfavorable outcome and its ability to make a reasonable estimate of the amount of loss.

The filing of a suit or formal assertion of a claim or assessment, or the disclosure of any such suit or assertion, does not necessarily indicate that accrual of a loss is appropriate.

The outcome of these matters may have a material adverse effect on the results of operations, financial position and net assets of the Company.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**c)** **Trade accounts and other receivables from unrelated parties and expected credit losses**

Trade accounts and other receivables from unrelated parties are a substantial asset of the Company and the expected credit losses are based upon a significant estimate made by management (see note 8).The Company sells healthcare products directly or through distributors in more than 140 countries and operates dialysis clinics in more than 30 countries. Most payors are government institutions or government-sponsored programs with significant variations between the countries and even between payors within one country in local payment and collection practices.

Receivables resulting from revenue recognized for healthcare services provided are recorded at amounts estimated to be collectable under government reimbursement programs and reimbursement arrangements with third party payors. U.S. Medicare and Medicaid government programs are billed at pre-determined net realizable rates per treatment that are established by statute or regulation. Revenues for non-governmental payors with which the Company has contracts or letters of agreement in place are recognized at the prevailing contract rates. The remaining non-governmental payors are billed at the Company's standard rates for services and, for U.S. revenue within the Company's Care Delivery segment, a contractual adjustment is recorded to recognize revenues based on historic reimbursement. The contractual adjustment and the expected credit losses are reviewed quarterly for their adequacy. No material changes in estimates were recorded for the contractual allowance in the periods presented. The collectability of receivables is reviewed locally on a regular basis, generally monthly. For further information, see note 1 k).

In the Company's U.S. operations within its Care Delivery segment, the collection process is usually initiated shortly after service is provided or upon the expiration of the time provided by contract. For Medicare and Medicaid, once the services are approved for payment, the collection process begins upon the expiration of a period of time based upon experience with Medicare and Medicaid. In all cases where co-payment is required the collection process usually begins within 30 days after service has been provided. In those cases where claims are approved for amounts less than anticipated or if claims are denied, the collection process usually begins upon notice of approval of the lesser amounts or upon denial of the claim. The collection process can be confined to internal efforts, including the accounting and sales staffs and, where appropriate, local management staff. If appropriate, external collection agencies may be engaged.

Public health institutions in a number of countries outside the U.S. require a significant amount of time until payment is made because a substantial number of payors are government entities whose payments are often determined by local laws and regulations and budget constraints. Depending on local facts and circumstances, the period of time to collect can be quite lengthy. In those instances where there are commercial payors, the same type of collection process is initiated as in the U.S.

Due to the number of subsidiaries and different countries that the Company operates in, the Company's policy of determining when an individual expected credit loss is required considers the appropriate individual local facts and circumstances that apply to an account. While payment and collection practices vary significantly between countries and even agencies within one country, government payors usually represent low to moderate credit risks. It is the Company's policy to determine when receivables should be classified as bad debt on a local basis taking into account local payment practices and local collection experience. An individual expected credit loss is calculated locally if specific circumstances indicate that amounts will not be collectible.

Receivables where the expected credit losses are not assessed individually are grouped based on geographical regions and the impairment is assessed based on macroeconomic indicators such as credit default swaps. For more information regarding the impairment on trade accounts and other receivables from unrelated parties, refer to note 1 i).

When all efforts to collect a receivable, including the use of outside sources where required and allowed, have been exhausted, and after appropriate management review, a receivable deemed to be uncollectible is considered a bad debt and written off.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Write offs are taken on a claim-by-claim basis. Due to the fact that a large portion of its reimbursement is provided by public healthcare organizations and private insurers, the Company expects that most of its accounts receivables will be collectible, albeit potentially more slowly outside the U.S. A significant change in the Company's collection experience, deterioration in the aging of receivables, and collection difficulties could require that the Company increases its estimate of the expected credit losses. Any such additional bad debt charges could materially and adversely affect the Company's future operating results.

If, in addition to the Company's existing expected credit losses, 1% of the gross amount of the Company's trade accounts and other receivables from unrelated parties as of December 31, 2025 were uncollectible through either a change in the Company's estimated contractual adjustment or revised estimate of the collectability, the Company's operating income for 2025 would have been reduced by approximately 1.8%.

The following table shows the portion of major debtors or debtor groups of trade accounts and other receivables from unrelated parties as of December 31, 2025 and 2024. Other than U.S. Medicare and Medicaid, no single debtor accounted for more than 5% of total trade accounts and other receivables from unrelated parties in either of these years.

---

| | | |
|:---|:---|:---|
| **Composition of trade accounts and other receivables from unrelated parties in %** | **Composition of trade accounts and other receivables from unrelated parties in %** | **Composition of trade accounts and other receivables from unrelated parties in %** |
|  | **December 31,**  | **December 31,**  |
|  | **2025** | **2024** |
| U.S. Government healthcare programs | 33 | 34 |
| U.S. commercial payors | 17 | 18 |
| U.S. hospitals | 5 | 4 |
| Self-pay of U.S. patients | 3 | 2 |
| Other U.S. payors | 1 | 1 |
| Product customers and healthcare payors outside U.S. | 41 | 41 |
| **Total** | **100** | **100** |

---

**d)** **Self-insurance programs**

Under the Company's insurance programs for professional, product and general liability, auto liability, worker's compensation, and medical malpractice claims, the Company's largest subsidiary, which is located in the U.S., is partially self-insured for professional liability claims. For all other coverages, the Company assumes responsibility for incurred claims up to predetermined amounts above which third party insurance applies. Reported liabilities for the year represent estimated future payments of the anticipated expense for claims incurred (both reported and incurred but not reported) based on historical experience and existing claim activity. This experience includes both the rate of claims incidence (number) and claim severity (cost) and is combined with individual claim expectations to estimate the reported amounts. For further information, see note 15 and note 18.

**e)** **Level 3 financial instruments**

Put option liabilities, variable payments outstanding for acquisitions, equity investments, derivatives embedded in vPPAs, receivables for royalty payments from one of the Company's equity investments, and certain receivables from the sale of investments are recognized at their fair value. Each put option contract contains specific clauses related to the terms of exercisability, which require significant judgment in order to determine appropriate liability recognition and classification. For further information related to the significant judgments and estimates related to these instruments and their fair values, see notes 1 h) and 26.

**f)** **Income taxes**

The Company is subject to ongoing and future tax audits in the U.S., Germany and other jurisdictions. Different interpretations of tax laws, particularly due to the Company's international activities, may lead to potential additional tax payments or tax refunds for prior years. To consider income tax liabilities or income tax receivables of uncertain tax assessments management's estimations are based on experiences with previous tax audits and local tax rules of the respective tax jurisdiction and the interpretation of such. Differences between actual results and management's estimates or future changes in these estimates may have an impact on future tax payments or tax refunds. Estimates are revised in the period in which there is sufficient evidence to revise the assumption. For further information to estimates related to the recoverability of deferred taxes, see notes 1 n) and 5 g). Further information on the status of current tax audits or objections from taxation authorities is provided in note 25.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**g)** **Business combinations and disposal groups classified as held for sale**

The Company measures the noncontrolling interest in an acquisition at fair value using the full goodwill method and classifies costs related to its business combinations within general and administrative expense. In determining whether an intangible asset related to a business combination is identifiable and should be separated from goodwill, significant judgment is required. Additionally, estimation of the acquisition-date fair values of identifiable assets acquired and liabilities assumed also involves significant judgment. The applicable measurements and inputs used in this estimation (including revenue growth rates, gross profit margin adjusted for synergy assumptions associated with manufacturing savings, and the discount rate) are based upon information available at the acquisition date using expectations and assumptions that management deems reasonable. Such judgments, estimates, and assumptions could materially affect the Company's business, results of operations, and financial condition, primarily due to:

● Fair values assigned to assets subject to depreciation and amortization directly impact the depreciation and amortization recorded in the Company's consolidated statements of income in periods subsequent to a related acquisition;

● Any subsequent measurement resulting in a decrease in the estimated fair values of assets acquired may result in impairment; and

● Subsequent changes resulting in an increase or decrease to the estimated fair values of liabilities assumed may result in additional expense or income, respectively.

For further information on business combinations, see note 3.

A non-current asset or a disposal group is classified as held for sale if its carrying amount will be recovered principally through a sale transaction rather than through continuing use. The criteria for held for sale classification is only met if the asset or group is available for immediate sale in its present condition and the sale transaction is considered highly probable. A transaction is assumed to be highly probable if there is no significant risk of completion of the transaction. Non-current assets and disposal groups are recognized at the lower of their carrying amounts or fair value less costs to sell. Any impairment loss on the disposal group is allocated first to goodwill and then to the remaining non-current assets within the IFRS 5 measurement scope on a pro rata basis. The determination of the fair value less costs to sell requires the use of estimates and assumptions.

For further information on disposal groups classified as held for sale, see note 4.

**h)** **Leases and interest rate determination**

IFRS 16 requires the Company to make judgments that affect the valuation of lease liabilities as well as of right- of-use assets (see notes 24 and 26), including the determination of which contracts are within the scope of IFRS 16, identifying the contract lease term and determining the incremental borrowing rate.

The lease term is determined as the non-cancellable period of a lease, together with periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. During the "reasonably certain" assessments, the Company considers all relevant facts and circumstances that create an economic incentive for the Company to exercise, or not to exercise, an option, including any expected changes in facts and circumstances (e.g., contract-, object-, entity-, or market-specific factors) from the commencement date until the exercise date of the option. Other examples of considered terms are termination penalties or costs relating to the termination of the lease, such as negotiation costs, relocation costs, costs of identifying another lease asset suitable for the Company's needs, costs of integrating a new asset into the Company's operations, and termination penalties and similar costs, including costs associated with returning the underlying asset in a contractually specified condition or to a contractually specified location. Additionally, the Company's historical practice regarding the period over which it has typically used particular types of assets, and its economic reasons for doing so, is also relevant. Unrecognized extension options are shown as potential future cash outflows (see note 24).

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The Company uses the rate implicit in the lease if agreed with the lessor and/or available, while the incremental borrowing rate is used for all other leases. The incremental borrowing rate is defined as the rate that the lessee would have to pay on the commencement date of the lease for a similar loan (regarding its term, security, underlying asset, and economic environment). The incremental borrowing rate is determined when the Company initiates a lease contract or changes an existing lease. The interest rate is calculated based on following components: available interest rate sampling points, group risk margins, shadow rating (credit risk) margins, country risk margins, handling margins, and other risk margins.

The Company is subject to residual value guarantees in certain lease contracts, primarily real estate contracts, for which it is the lessee. Under the terms of these leases, the Company has the option to remarket the underlying leased properties to satisfy its residual value guarantee obligations at the end of the lease term. At the end of each reporting period, the expected residual values are compared to the estimated fair market value of the underlying leased assets utilizing third-party valuations. For additional information regarding residual value guarantees in certain lease contracts, see note 25.

&nbsp;&nbsp;&nbsp;&nbsp;**3.** **Acquisitions, business combinations, investments (including debt securities), purchases of intangible assets, divestitures, and sale of debt securities** 

The Company completed acquisitions, investments (including debt securities), and the purchase of intangible assets in the amount of €109,785, €104,621, and €137,626 in 2025, 2024, and 2023, respectively. In 2025, €109,493 was paid in cash and €292 were assumed obligations and non-cash consideration. In 2024, €104,567 was paid in cash and €54 were assumed obligations and non-cash consideration. In 2023, €137,565 was paid in cash and €61 were assumed obligations and non-cash consideration.

**Acquisitions**

The Company made acquisitions of €15,594, €231, and €3,203 in 2025, 2024, and 2023, respectively in order to expand the scope of its services and to increase its market shares in the respective countries. In 2025, €15,302 was paid in cash and €292 were assumed obligations and non-cash consideration. In 2024, €177 was paid in cash and €54 were assumed obligations and non–cash consideration. In 2023, €3,142 was paid in cash and €61 were assumed obligations or non-cash consideration.

In 2025, the Company's acquisition spending was driven by the purchase of dialysis clinics. In 2024, the Company's acquisition spending was driven by the purchase of certain assets from a medical technology business. In 2023, the Company's acquisition spending was driven primarily by the purchase of dialysis clinics and other healthcare service facilities in the normal course of its operations.

***Impacts on consolidated financial statements from acquisitions***

The assets and liabilities of all acquisitions were recorded at their estimated fair value at the date of the acquisition and are included in the Company's financial statements and operating results from the effective date of acquisition. The measurement period adjustments from the previous year's acquisitions did not have a significant impact on the consolidated financial statements in 2025.

The excess of the total acquisition costs over the fair value of the net assets acquired resulted in goodwill of €14,302 and €231 at December 31, 2025 and 2024, respectively.

The purchase price allocations for all collectively and individually non-material acquisitions for 2025 are not yet finalized. The Company is in the process of obtaining and evaluating the information necessary for the purchase price allocations, primarily related to property, plant, and equipment, intangible assets, accounts receivable, and other liabilities. In 2025, based on preliminary purchase price allocations, the Company recorded €14,302 of goodwill, which represents the share of both controlling and noncontrolling interests. Goodwill is mainly attributable to anticipated synergies and future cash flows expected to be generated for these acquisitions.

Business combinations during 2025 increased the Company's net income attributable to shareholders of FME AG (Net Income) by €1,370, excluding the costs of the acquisitions, and revenue increased by €6,475. Total assets increased €23,055 mainly due to business combinations.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**Investments (including debt securities) and purchases of intangible assets** 

Investments (including debt securities) and purchases of intangible assets were €94,191, €104,390, and €134,423 in 2025, 2024, and 2023, respectively. These amounts were primarily driven by investments in debt securities in 2025, 2024, and 2023. Of these amounts, €94,191, €104,390, and €134,423 were paid in cash in 2025, 2024, and 2023, respectively.

**Divestitures and sale of debt securities and equity investments**

Proceeds from divestitures, net of cash disposed, and sale of debt securities were €301,610, €910,911, and €326,696 in 2025, 2024, and 2023, respectively. For 2025, 2024, and 2023, these amounts are mainly related to the divestments as part of our review of our business portfolio, mainly due to exiting unsustainable markets and divesting non-core businesses, as well as the cessation of certain R&D programs to enable more focused capital allocation towards areas in our core business that are expected to have higher profitable growth (Legacy Portfolio Optimization) and also include divestments of debt securities and equity investments. In 2025, €285,637 was received in cash and €15,973 were non–cash components. In 2024, €704,883 was received in cash and €206,028 were non-cash components. In 2023, €261,796 was received in cash and €64,900 were non-cash components.

As a result of the loss of control relating to divestitures, the Company divested current assets of €138,892, €746,181, and €119,709 (including cash of €5,025, €13,622, and €33,151), non-current assets of €46,755, €326,525 and €402,702, current liabilities of €35,605, €352,869 and €53,015, and non-current liabilities of €30,021, €213,743, and €26,491 in 2025, 2024, and 2023, respectively.

**4.** **Disposal groups classified as held for sale**

In February 2025, the Company's management entered into an agreement to sell select assets of the Company's wholly owned Spectra Laboratories, which was included in its Care Delivery segment. In December 2025, the closing conditions necessary to complete the sale were met and control of the assets were transferred to the buyer. The sale of the select assets qualifies as a divestiture of a business. The divestiture did not result in an impairment loss based upon the measurement of assets held for sale and the disposal group is recorded at its carrying amount. See note 5 e) for further details on impairment losses based upon the measurement of assets held for sale as well as other impairment of assets related to the proposed divestitures during 2025, 2024, and 2023.

As of December 31, 2025 and 2024, the following assets and liabilities were classified as held for sale. As a result of the completion of transactions during 2025, the amounts presented in the current year represent assets of disposal groups classified as held for sale that are immaterial both individually and in the aggregate:

---

| | | |
|:---|:---|:---|
| **Assets and liabilities of disposal groups classified as held for sale** |  |  |
| *in € K* |  |  |
|  | **2025** | **2024** |
| Cash and cash equivalents |  | 5141 |
| Trade accounts and other receivables from unrelated parties |  | 27085 |
| Property, plant and equipment |  | 16346 |
| Right-of-use assets |  | 5915 |
| Goodwill <sup>(1)</sup> |  | 92557 |
| Other | 3595 | 13969 |
| **Assets held for sale** | **3595** | **161013** |
| Accounts payable to unrelated parties |  | 1628 |
| Lease liabilities |  | 6097 |
| Provisions and other liabilities |  | 19786 |
| **Liability directly associated with assets held for sale** | **—** | **27511** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Goodwill was allocated to the disposal groups on a relative fair value basis.

As of December 31, 2025, 2024, and 2023, the accumulated foreign currency translation losses recognized in other comprehensive income related to the disposal groups amounted to €0, €44,693, and €4,230, respectively.

For information regarding disposal groups previously held for sale and subsequently divested, including the gains and losses recorded as a result of these divestitures, see notes 3 and 5 e).

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**5.** **Notes to the consolidated statements of income**

**a)** **Revenue**

The Company recognized the following revenue in the consolidated statements of income for the years ended December 31, 2025, 2024, and 2023:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Revenue** |  |  |  |  |
| *in € K* |  |  |  |  |
|  | **Revenue from** | **Revenue from** | **Revenue from** |  |
|  | **contracts with** | **insurance** | **lease** |  |
|  | **customers** | **contracts** | **contracts** | **Total** |
|  | **For the year ended December 31, 2025** | **For the year ended December 31, 2025** | **For the year ended December 31, 2025** | **For the year ended December 31, 2025** |
| Healthcare services | 13097267 |  |  | 13097267 |
| Healthcare products | 4325723 |  | 87902 | 4413625 |
| Insurance contracts |  | 2116710 |  | 2116710 |
| **Total** | **17422990** | **2116710** | **87902** | **19627602** |
|  | **For the year ended December 31, 2024** | **For the year ended December 31, 2024** | **For the year ended December 31, 2024** | **For the year ended December 31, 2024** |
| Healthcare services | 13471363 |  |  | 13471363 |
| Healthcare products | 4186195 |  | 64327 | 4250522 |
| Insurance contracts |  | 1614024 |  | 1614024 |
| **Total** | **17657558** | **1614024** | **64327** | **19335909** |
|  | **For the year ended December 31, 2023** | **For the year ended December 31, 2023** | **For the year ended December 31, 2023** | **For the year ended December 31, 2023** |
| Healthcare services | 14166796 |  |  | 14166796 |
| Healthcare products | 3979122 |  | 80559 | 4059681 |
| Insurance contracts |  | 1227140 |  | 1227140 |
| **Total** | **18145918** | **1227140** | **80559** | **19453617** |

---

The following table contains a disaggregation of revenue by categories for the years ended December 31, 2025, 2024, and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Disaggregation of revenue by categories** |  |  |  |
| *in € K* |  |  |  |
|  | **For the year ended December 31,**  | **For the year ended December 31,**  | **For the year ended December 31,**  |
|  | **2025** | **2024** | **2023** |
| **Care Delivery** | **13736272** | **14003461** | **14748611** |
| &nbsp;&nbsp;Thereof: U.S. | 11506548 | 11526296 | 11836065 |
| &nbsp;&nbsp;Thereof: International | 2229724 | 2477165 | 2912546 |
| **Value-Based Care** | **2247373** | **1752456** | **1277116** |
| **Care Enablement** | **5476187** | **5556534** | **5345428** |
| **Inter-segment eliminations** | **(1832230)** | **(1976542)** | **(1917538)** |
| **Total** | **19627602** | **19335909** | **19453617** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) For further information on the revenue attributable to the Company's operating segments, see note 29.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The Company recognized the following amounts as receivables and contract liabilities relating to contracts with customers for the years ended December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| **Trade accounts receivables from unrelated parties and contract liabilities** | **Trade accounts receivables from unrelated parties and contract liabilities** | **Trade accounts receivables from unrelated parties and contract liabilities** |
| *in € K* | *in € K* | *in € K* |
|  | **2025** | **2024** |
| Trade accounts receivables from unrelated parties | 2,988,956 | 3,238,090 |
| Contract liabilities | 113,154 | 66,735 |

---

Impairment loss in the amount of €29,252, €18,694, and €111,193 for the years ended December 31, 2025, 2024, and 2023, respectively, related to receivables arising from contracts with customers.

The change in contract liabilities during the period results from the ordinary course of business.

Contract liabilities primarily relate to advance payments from customers and to sales of dialysis machines where revenue is recognized upon installation and provision of the necessary technical instructions.

Contract liabilities are shown in the consolidated balance sheet in line items "Current provisions and other current liabilities" and "Non-current provisions and other non-current liabilities."

At December 31, 2025, revenue recognized that was included in contract liabilities at the beginning of the period was €46,252 (2024: €31,713).

At December 31, 2025, performance obligations of €771,302 (2024: €697,620) are unsatisfied (or partially unsatisfied).

The expected recognition of the transaction price allocated to unsatisfied performance obligations as revenue for the next five years and in the aggregate for the five years thereafter is as follows:

---

| | | |
|:---|:---|:---|
| **Unsatisfied performance obligations** | **Unsatisfied performance obligations** | **Unsatisfied performance obligations** |
| *in € K* |  |  |
|  | **2025** | **2024** |
| 1 year | 288738 | 234739 |
| 1 - 3 years | 301932 | 308734 |
| 3 - 5 years | 110105 | 122351 |
| 5 - 10 years | 70527 | 31796 |
| **Total** | **771302** | **697620** |

---

**b)** **Selling, general and administrative expense**

Selling, general and administrative expense recorded in the consolidated statements of income comprises both distribution costs as well as general and administrative expense. Distribution costs are generated in the selling, marketing, and warehousing functions of the Company which are not attributable to production or R&D. General and administrative expense is generated in the administrative function of the Company's business and is not attributable to selling, production or R&D.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The following table discloses the distribution costs as well as general and administrative expense recorded by the Company for the years ended December 31, 2025, 2024, and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Selling, general and administrative expense** | **Selling, general and administrative expense** | **Selling, general and administrative expense** | **Selling, general and administrative expense** |
| *in € K* |  |  |  |
|  | **2025** | **2024** | **2023** |
| Distribution costs<sup>(1)</sup> | 618137 | 660433 | 706401 |
| General and administrative expense<sup>(1)</sup> | 2414591 | 2482386 | 2489935 |
| **Selling, general and administrative expense**  | **3032728** | **3142819** | **3196336** |

---

(1)The Company reclassified €116,099 and €101,560 from "Distribution costs" to "General and administrative expense" for the years ended December 31, 2024 and 2023 as a result of a change in accounting policy made to improve the presentation of core administrative functions that support the Company's operational infrastructure, particularly in relation to patient service-related costs within the revenue cycle management process, including insurance verification, pre-authorizations, coding, claims submission, cash posting, and denial management.

**c)** **Cost of materials**

The cost of materials for the year ended December 31, 2025, 2024, and 2023 consisted of the following:

---

| | | | |
|:---|:---|:---|:---|
| **Cost of materials** | **Cost of materials** | **Cost of materials** | **Cost of materials** |
| *in € K* | *in € K* | *in € K* | *in € K* |
|  | **2025** | **2024** | **2023** |
| Cost of raw materials, supplies and purchased components | 4107887 | 4023978 | 4170690 |
| Cost of purchased services | 409553 | 354417 | 316945 |
| **Cost of materials** | **4517440** | **4378395** | **4487635** |

---

**d)** **Personnel expenses**

Personnel expenses included within costs of revenue, selling, general and administrative expenses, and research and development expenses consisted of the following:

---

| | | | |
|:---|:---|:---|:---|
| **Personnel expenses** | **Personnel expenses** | **Personnel expenses** | **Personnel expenses** |
| *in € K* | *in € K* | *in € K* | *in € K* |
|  | **2025** | **2024** | **2023** |
| Wages and salaries | 6242754 | 6425067 | 6437582 |
| Social security contributions and cost of retirement benefits and social assistance | 1408300 | 1363751 | 1330628 |
| &nbsp;&nbsp;thereof retirement benefits | 185119 | 199265 | 194307 |
| **Personnel expenses** | **7651054** | **7788818** | **7768210** |

---

The Company employed the following personnel on a total headcount basis, on average, for the following years:

---

| | | | |
|:---|:---|:---|:---|
| **Employees by function** | **Employees by function** | **Employees by function** | **Employees by function** |
|  | **2025** | **2024** | **2023** |
| Production and services | 95025 | 96938 | 105894 |
| Administration<sup>(1)</sup> | 7920 | 8339 | 9118 |
| Sales and marketing<sup>(1)</sup> | 6627 | 7212 | 6808 |
| Research and development | 1452 | 1351 | 1300 |
| **Total employees** | **111024** | **113840** | **123120** |

---

(1)The Company reclassified personnel on a total headcount basis, on average, in the amount of 1,071 and 1,185 from "Sales and marketing" to "Administration" for the years ended December 31, 2024 and 2023 as a result of a change in accounting policy made to improve the presentation of core administrative functions that support the Company's operational infrastructure, particularly in relation to patient service - related costs within the revenue cycle management process, including insurance verification, pre-authorizations, coding, claims submission, cash posting, and denial management.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**e)** **Other operating income and expense**

The following table contains reconciliations of the amounts included in other operating income and expense for the years ended December 31, 2025, 2024, and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Other operating income** |  |  |  |
| *in € K* | **For the year ended December 31,**  | **For the year ended December 31,**  | **For the year ended December 31,**  |
|  | **2025** | **2024** | **2023** |
| Foreign exchange gains | 359962 | 352041 | 280323 |
| Gains on right-of-use assets, from the sale of fixed assets, clinics and investments | 9136 | 29579 | 33921 |
| Revaluation of certain investments <sup>(1)</sup> | 7254 | 51572 | 14671 |
| Income from strategic transactions and programs | 17795 | 116607 | 60843 |
| Income attributable to a consent agreement on foregone profits from the sale of certain pharmaceuticals to non-associated companies | 43050 | 71994 | 46919 |
| Other | 90902 | 138325 | 78570 |
| **Other operating income** | **528099** | **760118** | **515247** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Other operating expense** |  |  |  |
| *in € K* | **For the year ended December 31,**  | **For the year ended December 31,**  | **For the year ended December 31,**  |
|  | **2025** | **2024** | **2023** |
| Foreign exchange losses | 403756 | 375098 | 315821 |
| Losses on right-of-use assets, from the sale of fixed assets, clinics and investments | 8143 | 14923 | 29082 |
| Revaluation of certain investments <sup>(1)</sup> | 84292 | 7544 |  |
| Expenses from strategic transactions and programs | 122162 | 434088 | 320765 |
| Other | 102304 | 101285 | 98625 |
| **Other operating expense** | **720657** | **932938** | **764293** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Primarily driven by the remeasurement of the Company's investment in Humacyte, Inc. for the years ended December 31, 2025, 2024, and 2023.

Included within the "income from strategic transactions and programs" line item in other operating income are the gains from divestitures of certain businesses in connection with strategic programs such as Legacy Portfolio Optimization. The amount presented for the year ended December 31, 2025 primarily relates to the recovery of receivables associated with the divestiture of the Company's service business in Ecuador, gains from the sale of the Company's service businesses in Kazakhstan and Malaysia, and the gain from the sale of select assets of the Company's wholly owned Spectra Laboratories. The amount presented for the year ended December 31, 2024 primarily relates to the revaluation of certain assets held for sale in the amount of €14,896 and gains from the divestiture of certain businesses in the amount of €89,248. The gains from the divestiture of certain businesses relate primarily to the divestiture of Cura Day Hospitals Group in Australia and the divestiture of certain clinics, both as part of Legacy Portfolio Optimization. The amount presented for the year ended December 31, 2023 relates to a gain on the divestiture of National Cardiovascular Partners (NCP).

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Included within the "expenses from strategic transactions and programs" line item in other operating expense are the divestitures (including proposed divestitures as of each reporting date and associated impairment losses) of certain businesses in connection with strategic programs such as Legacy Portfolio Optimization and the FME25+ Program. For further information on the proposed divestitures and associated impairment losses, see note 4. Consistent with the Company's policy to present impairment losses within other operating expense, such costs related to costs of revenue, selling, general and administrative expense, or R&D expense are included within other operating expense. "Expenses from strategic transactions and programs" primarily consist of:

● strategic divestiture program expenses identified during the Legacy Portfolio Optimization program. In 2025, 2024, and 2023, the amounts primarily include the proposed divestitures identified in note 4, the cessation of a dialysis cycler development program, impairment losses resulting from the measurement of asset held for sale (NCP as well as the Company's service businesses in Brazil, Colombia, Curacao, Ecuador, Guatemala, Kazakhstan, Malaysia, Peru, and Türkiye), the divestitures of the Company's service businesses in Argentina, Brazil, Chile, Colombia, Curacao, Ecuador, Guatemala, Sub-Saharan Africa, Peru, Türkiye, and the Cura Day Hospitals Group in Australia (in connection with Legacy Portfolio Optimization) and the write-down of non-current assets and a provision for onerous contracts related to the proposed divestitures. For the year ended December 31, 2025, the Company recorded a net loss related to reclassification adjustments of foreign currency translation in the amount of €61,520 , of which €60,415 related to the Legacy Portfolio Optimization program. For the year ended December 31, 2024, the Company recorded a net loss related to reclassification adjustments of foreign currency translation in the amount of €115,570 , of which €120,885 related to the Legacy Portfolio Optimization program. For the year ended December 31, 2023, the Company recorded a net loss related to reclassification adjustments of foreign currency translation in the amount of €17,125 , of which €19,422 related to the Legacy Portfolio Optimization program. Reclassification adjustments of foreign currency translation that do not relate to strategic programs are included in the "Other" line item in the table above;

● certain impairment losses in connection with the FME25+ Program; and

● certain costs associated with the Conversion, primarily related to the requisite relabeling of its products, transaction costs (such as costs for external advisors and conducting an extraordinary general meeting) and costs related to the establishment of dedicated administrative functions required to manage certain services which have historically been administered at the Fresenius SE group level and paid by the Company through corporate charges (Legal Form Conversion Costs).

Expenses from strategic transactions and programs comprised the following for the years ended December 31, 2025, 2024, and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Expenses from strategic transactions and programs** |  |  |  |
| *in € K* |  |  |  |
|  | **For the year ended December 31,**  | **For the year ended December 31,**  | **For the year ended December 31,**  |
|  | **2025** | **2024** | **2023** |
| **Derecognition of capitalized development costs and termination costs**<sup>(1)</sup> | **—** | **—** | **58818** |
| &nbsp;&nbsp;Legacy Portfolio Optimization |  |  | 58818 |
| **Impairment of intangible and tangible assets**<sup>(2)</sup> | **14961** | **112095** | **48768** |
| &nbsp;&nbsp;Legacy Portfolio Optimization | 13797 | 105845 | 34894 |
| &nbsp;&nbsp;FME25+ Program | 1164 | 6250 | 13874 |
| **Impairment resulting from the measurement of assets held for sale** | **8793** | **118375** | **74616** |
| &nbsp;&nbsp;Legacy Portfolio Optimization | 8793 | 118375 | 62724 |
| &nbsp;&nbsp;FME25+ Program |  |  | 11892 |
| **Loss from the sale of business** | **47241** | **132202** | **93859** |
| &nbsp;&nbsp;Legacy Portfolio Optimization | 47241 | 132202 | 93859 |
| **Other**<sup>(3)</sup> | **51167** | **71416** | **44704** |
| &nbsp;&nbsp;Legacy Portfolio Optimization | 47660 | 61536 | 14744 |
| &nbsp;&nbsp;Legal Form Conversion Costs | 3507 | 9330 | 29960 |
| &nbsp;&nbsp;FME25+ Program |  | 550 |  |
| **Expenses from strategic transactions and programs** | **122162** | **434088** | **320765** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Primarily R&D expense.

&nbsp;&nbsp;&nbsp;&nbsp;(2) For the years ended December 31, 2025 and 2024, the amounts relate primarily to costs of revenue and selling, general and administrative expense, while the amounts for the year ended December 31, 2023 relates primarily to R&D expense.

&nbsp;&nbsp;&nbsp;&nbsp;(3) For the years ended December 31, 2025, 2024, and 2023, the amounts relate primarily to selling, general and administrative expense.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

For more information on the disposal groups classified as held for sale, see note 4.

**f)** **Net interest**

Net interest in the amount of €314,798 (2024: €335,469 and 2023: €336,423) included interest expense of €384,409 (2024: €407,044 and 2023: €424,640) and interest income of €69,611 (2024: €71,575 and 2023: €88,217). Interest expense resulted mainly from the Company's financial liabilities including outstanding bonds and loans (see note 16 and note 17), lease liabilities and lease liabilities from related parties (see note 6 b) and note 24), foreign currency swaps and, in 2024, interest expense on taxes related to a settlement. In 2025, interest income primarily resulted from bank deposits, investments and debt securities, foreign currency swaps, finance lease receivables, and trade accounts receivable from unrelated parties. In 2024, interest income primarily resulted from bank deposits, investments and debt securities, finance lease receivables, and foreign currency swaps. In 2023, interest income primarily resulted from investments, debt securities and royalty receivables, interest on lease receivables, and interest on bank deposits.

**g)** **Income taxes**

Income before income taxes is attributable to the following geographic locations:

---

| | | | |
|:---|:---|:---|:---|
| **Income before income taxes** | **Income before income taxes** | **Income before income taxes** | **Income before income taxes** |
| *in € K* | *in € K* | *in € K* | *in € K* |
|  | **2025** | **2024** | **2023** |
| Germany | 179681 | (30436) | (91082) |
| United States | 863117 | 688903 | 725848 |
| Other | 469440 | 398459 | 398249 |
| **Total** | **1512238** | **1056926** | **1033015** |

---

Income tax expense (benefit) for the years ended December 31, 2025, 2024, and 2023 consisted of the following:

---

| | | | |
|:---|:---|:---|:---|
| **Income tax expense (benefit)** | **Income tax expense (benefit)** | **Income tax expense (benefit)** | **Income tax expense (benefit)** |
| *in € K* | *in € K* | *in € K* | *in € K* |
|  | **2025** | **2024** | **2023** |
| **Current** |  |  |  |
| &nbsp;&nbsp;Germany | 45967 | 69971 | 20947 |
| &nbsp;&nbsp;United States | 168024 | 179423 | 290787 |
| &nbsp;&nbsp;Other | 134192 | 139333 | 110972 |
|  | **348183** | **388727** | **422706** |
| **Deferred** |  |  |  |
| &nbsp;&nbsp;Germany | 11033 | (37765) | 34018 |
| &nbsp;&nbsp;United States | (13922) | (48565) | (150225) |
| &nbsp;&nbsp;Other | (24323) | 13659 | (5942) |
|  | **(27212)** | **(72671)** | **(122149)** |
| **Total** | **320971** | **316056** | **300557** |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The expected corporate income tax expense is computed by applying the German corporation tax rate (including the solidarity surcharge) and the trade tax rate on income before income taxes. The German combined statutory tax rates were 30.28%, 30.34%, and 30.32% for the fiscal years ended December 31, 2025, 2024, and 2023, respectively. A reconciliation between the expected and actual income tax expense is shown below. In 2025, the decrease in non - deductible expenses as compared to 2024 results from lower non - deductible expenses related to Legacy Portfolio Optimization while the change from tax expense for prior years recorded in 2024 to tax income for prior years recorded in 2025 is mainly related to the derecognition of certain deferred tax liabilities initially established in connection with the 2022 Interwell Health transaction (Interwell Health Deferred Tax Reversal) (see note 26). In Germany, the legislature implemented a gradual reduction of the corporate tax rate from 15% to 10% from 2028 until 2032 leading to increased effects in tax rate changes. The increase in withholding taxes in 2025 as compared to 2024 mainly relates to non - deductible and non - creditable foreign taxes in the U.S.

---

| | | | |
|:---|:---|:---|:---|
| **Reconciliation of income taxes** | **Reconciliation of income taxes** | **Reconciliation of income taxes** | **Reconciliation of income taxes** |
| *in € K* | *in € K* | *in € K* | *in € K* |
|  | **2025** | **2024** | **2023** |
| Expected corporate income tax expense | 457906 | 320671 | 313158 |
| Tax free income | (41691) | (40859) | (39550) |
| Income from equity method investees | (53085) | (33142) | (25570) |
| Tax rate differentials | (62739) | (45636) | (47586) |
| Non-deductible expenses | 47103 | 97141 | 114182 |
| Tax expense (income) for prior years | (32129) | 10087 | (16867) |
| Noncontrolling partnership interests | (54363) | (46779) | (58345) |
| Tax rate changes | (7463) | (166) | 442 |
| Change in realizability of deferred tax assets and tax credits | 30529 | 32415 | 44287 |
| Withholding taxes | 21820 | 8371 | 15124 |
| Other | 15083 | 13953 | 1282 |
| **Income tax expense** | **320971** | **316056** | **300557** |
| Effective tax rate | 21.2% | 29.9% | 29.1% |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The tax effects of the temporary differences and net operating losses that give rise to deferred tax assets and liabilities at December 31, 2025 and 2024, are presented below:

---

| | | |
|:---|:---|:---|
| **Deferred income tax assets and liabilities** | **Deferred income tax assets and liabilities** | **Deferred income tax assets and liabilities** |
| *in € K* | *in € K* | *in € K* |
|  | **2025** | **2024** |
| **Deferred tax assets** |  |  |
| Trade accounts receivable | 49679 | 46585 |
| Inventories | 72048 | 93831 |
| Intangible assets | 1395 | 1193 |
| Property, plant and equipment and other non-current assets | 74131 | 95587 |
| Lease liabilities | 643689 | 779241 |
| Provisions and other liabilities | 283654 | 286048 |
| Pension liabilities | 97252 | 123368 |
| Net operating loss carryforwards, tax credit carryforwards and interest carryforwards | 97891 | 119453 |
| Derivatives | 2535 | 8704 |
| Other | 7824 | 7168 |
| **Total deferred tax assets** | **1330098** | **1561178** |
| **Deferred tax liabilities** |  |  |
| Trade accounts receivable | 35502 | 3650 |
| Inventories | 4041 | 3464 |
| Intangible assets | 812160 | 936036 |
| Property, plant and equipment and other non-current assets | 175443 | 183762 |
| Right-of-use assets | 548195 | 676860 |
| Provisions and other liabilities | 5665 | 39826 |
| Pension liabilities | 1978 | 1 |
| Derivatives | 4073 | 6530 |
| Other | 196017 | 190430 |
| **Total deferred tax liabilities** | **1783074** | **2040559** |
| **Net deferred tax liabilities** | **(452976)** | **(479381)** |

---

In the consolidated balance sheets, the accumulated amounts of deferred tax assets and liabilities are shown as follows:

---

| | | |
|:---|:---|:---|
| **Net deferred income tax assets and liabilities** | **Net deferred income tax assets and liabilities** | **Net deferred income tax assets and liabilities** |
| *in € K* | *in € K* | *in € K* |
|  | **2025** | **2024** |
| Deferred tax assets | 236547 | 229509 |
| Deferred tax liabilities | 689523 | 708890 |
| **Net deferred tax liabilities** | **(452976)** | **(479381)** |

---

The change in the balance of deferred tax assets and deferred tax liabilities does not equal the deferred tax expense/(benefit) due to deferred taxes that are booked directly to equity, the effects of exchange rate changes on tax assets and liabilities denominated in currencies other than euro, and the acquisition and disposal of entities as part of ordinary activities.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The net operating losses included in the table below reflect U.S. federal tax, German corporate income tax, and other tax loss carryforwards in the various countries in which the Company operates, and expire as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Net operating loss carryforwards** | **Net operating loss carryforwards** | **Net operating loss carryforwards** | **Net operating loss carryforwards** |
| *in € K* |  |  |  |
| **For the year ended December 31, 2025** | **For the year ended December 31, 2025** | **For the year ended December 31, 2024** | **For the year ended December 31, 2024** |
| 2026 | 31501 | 2025 | 13993 |
| 2027 | 48245 | 2026 | 32500 |
| 2028 | 31521 | 2027 | 49674 |
| 2029 | 84242 | 2028 | 34646 |
| 2030 | 26498 | 2029 | 89237 |
| 2031 | 1960 | 2030 | 23492 |
| 2032 | 6738 | 2031 | 12357 |
| 2033 | 2796 | 2032 | 5175 |
| 2034 | 801 | 2033 | 2127 |
| 2035 and thereafter | 235354 | 2034 and thereafter | 202457 |
| Without expiration date | 442371 | Without expiration date | 491773 |
| **Total** | **912027** | **Total** | **957431** |

---

Included in the balance of net operating loss carryforwards at December 31, 2025 are €689,694 (2024: €731,303) not expected to be absorbed. Deferred tax assets regarding this portion are not recognized. The utilization of deferred tax assets arising from entities which suffered a loss is dependent on future taxable profits in excess of the profits arising from the reversal of existing taxable differences. Additionally, at December 31, 2025 and 2024, the Company had an unrecognized net deferred tax asset arising from unutilized notional interest deduction of $479,008 and $323,999, respectively (€407,667 and €311,867, respectively).

In assessing the realizability of deferred tax assets, management considers to which extent it is probable that the deferred tax asset will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences and tax loss carryforwards become deductible. Management considers the expected reversal of deferred tax liabilities and projected future taxable income in making this assessment and believes it is probable the Company will realize the benefits of these deferred tax assets at December 31, 2025.

The Company provides for income taxes and foreign withholding taxes on the cumulative earnings of foreign subsidiaries and foreign subsidiaries in which the Company has ownership of less than 100% that will not be reinvested. At December 31, 2025, the Company provided for €10,523 (2024: €8,643) of deferred tax liabilities associated with earnings that are likely to be distributed in the following year(s). Provision has not been made for additional taxes on €8,967,622 (2024: €9,558,889) undistributed earnings of foreign subsidiaries as these earnings are considered indefinitely reinvested. The earnings could become subject to additional tax if remitted or deemed remitted as dividends; however, calculation of such additional tax is not practicable. These taxes would predominantly comprise foreign withholding tax on dividends of foreign subsidiaries, and German income tax; however, those dividends and capital gains would generally be 95% tax free for German tax purposes.

At December 31, 2025, the Company recognized income tax expenses related to Pillar Two income taxes in the amount of €7,630 (2024: €5,702). The main jurisdictions in which exposures to this tax exist include Malta and Türkiye.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**6.**Related party transactions

Based on its current share ownership as of December 31, 2025, Fresenius SE, under the Company's Articles of Association, has the right to appoint one of the six shareholder representatives to the Company's Supervisory Board. The Else Kröner-Fresenius-Stiftung is the sole shareholder of Fresenius Management SE, the general partner of Fresenius SE, and has sole power to elect the supervisory board of Fresenius Management SE. In March 2025, Fresenius SE sold 10,600,000 of the Company's shares, and in addition issued bonds to investors that are exchangeable for shares of the Company to be delivered by Fresenius SE. In announcing these transactions, Fresenius SE stated that it intends to retain no less than 25% plus one share of the Company's shares. After giving effect to its sale of 10,600,000 shares, Fresenius SE remains the Company's largest shareholder and owns 27.8% of the Company's issued shares at December 31, 2025.

The Company has entered into certain arrangements for services and products with Fresenius SE or its subsidiaries and with certain of the Company's equity method investees as described in item a) below. The arrangements for leases with Fresenius SE or its subsidiaries are described in item b) below. The Company's terms related to the receivables or payables for these services, products and leases are generally consistent with the normal terms of the Company's ordinary course of business transactions with unrelated parties and the Company believes that these arrangements reflect fair market terms. The Company utilizes various methods to verify the commercial reasonableness of its related party arrangements. Financing arrangements with certain equity-method investees as described in item c) below have agreed-upon terms which are determined at the time such financing transactions occur and reflect market rates at the time of the transaction. The relationship between the Company and its key management personnel who are considered to be related parties is described in item d) below.

**a)**Service agreements and products

Prior to the Conversion, the Company was party to service agreements with Fresenius SE and certain of its affiliates (collectively, Fresenius SE Companies) to receive services, including, but not limited to: administrative services, management information services, employee benefit administration, insurance, information technology services, tax services and treasury management services. These related party agreements generally had a duration of 1 to 5 years and were renegotiated on an as needed basis when the respective agreement expired.

Post-Conversion, the Company is party to service agreements with Fresenius SE Companies to receive services, including, but not limited to: administrative and facility management services, employee benefit administration, information technology and certain treasury services. These related party agreements have generally been entered into for periods, or in some cases transitional periods, from several months up to four years (in some cases subject to change requests or with extension options).

The Company provides administrative services to one of its equity method investees. The Company also sells products to Fresenius SE Companies and purchases products from Fresenius SE Companies and equity method investees. The Company has also entered into a limited amount of shared procurement contracts with Fresenius SE Companies for the purchase of products from third parties.

In December 2010, the Company and Galenica Ltd. (now known as CSL Vifor) formed the renal pharmaceutical company Vifor Fresenius Medical Care Renal Pharma Ltd., an equity method investee of which the Company owns 45%. The Company has entered into exclusive supply agreements to purchase certain pharmaceuticals from, as well as into certain exclusive distribution agreements with, Vifor Fresenius Medical Care Renal Pharma Ltd. Under the terms of certain unconditional purchase agreements, the Company is obligated to purchase approximately €226,723 of pharmaceuticals, of which €226,723 is committed at December 31, 2025 for 2026 (€522,091 and €265,666, respectively, at December 31, 2024 for 2025). The terms of these agreements run up to, latest, December 31, 2028. For further information regarding the Company's interest in associates, including this equity method investment, see note 13.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Below is a summary, including the Company's receivables from and payables to the indicated parties, resulting from the above-described transactions with related parties.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Service agreements and products with related parties** | **Service agreements and products with related parties** | **Service agreements and products with related parties** | **Service agreements and products with related parties** | **Service agreements and products with related parties** | **Service agreements and products with related parties** | **Service agreements and products with related parties** | **Service agreements and products with related parties** | **Service agreements and products with related parties** | **Service agreements and products with related parties** | **Service agreements and products with related parties** |
| *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* |
|  | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** |
|  | **Sales of** | **Purchases of** | **Sales of** | **Purchases of** | **Sales of** | **Purchases of** |  |  |  |  |
|  | **goods and** | **goods and** | **goods and** | **goods and** | **goods and** | **goods and** | **Accounts** | **Accounts** | **Accounts** | **Accounts** |
|  | **services** | **services** | **services** | **services** | **services** | **services** | **receivable** | **payable** | **receivable** | **payable** |
| **Service agreements** <sup>(1)</sup> |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Fresenius SE | 75 | 9366 | 241 | 24106 | 136 | 40478 | 173 | 1488 | 83 | 196 |
| &nbsp;&nbsp;Fresenius SE affiliates | 4106 | 46773 | 1535 | 75465 | 3324 | 87984 | 396 | 649 | 1555 | 3170 |
| &nbsp;&nbsp;Equity method investees | 5550 | 43 | 6192 | 18 | 8573 | 154 | 4734 |  | 19408 |  |
| **Total** | **9731** | **56182** | **7968** | **99589** | **12033** | **128616** | **5303** | **2137** | **21046** | **3366** |
| **Products** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Fresenius SE affiliates | 68428 | 43706 | 70875 | 22785 | 72500 | 25148 | 27380 | 9624 | 19890 | 7818 |
| &nbsp;&nbsp;Equity method investees |  | 550641 |  | 381383 |  | 437288 |  | 73228 |  | 43544 |
| **Total** | **68428** | **594347** | **70875** | **404168** | **72500** | **462436** | **27380** | **82852** | **19890** | **51362** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) In addition to the above shown accounts payable, accrued expenses for service agreements with related parties amounted to €1,333 and €11,581 at December 31, 2025 and 2024, respectively.

**b)** **Lease agreements**

In addition to the above-mentioned product and service agreements, the Company is a party to real estate lease agreements with Fresenius SE Companies, which mainly include leases for the Company's corporate headquarters in Bad Homburg, Germany, and, until December 31, 2025, included the Company's production sites in Schweinfurt and St. Wendel, Germany. The corporate headquarter leases have maturities up to the end of 2029.

Effective December 31, 2025, pursuant to an agreement signed on October 17, 2025, Fresenius Medical Care Deutschland GmbH purchased the Company's production sites in Schweinfurt and St. Wendel, Germany, which were previously leased from Fresenius SE Companies, for a total transaction cost of €181,373 (including a purchase price paid to Fresenius SE Companies in the amount of €171,642). The Company applied the component approach in accordance with IAS 16, recognizing significant parts of the acquired assets as separate component assets and assigned each component its own useful life and associated depreciation methodology for the transaction.

Below is a summary resulting from the above described lease agreements with related parties.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Lease agreements with related parties** | **Lease agreements with related parties** | **Lease agreements with related parties** | **Lease agreements with related parties** | **Lease agreements with related parties** | **Lease agreements with related parties** | **Lease agreements with related parties** | **Lease agreements with related parties** | **Lease agreements with related parties** | **Lease agreements with related parties** |
| *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* |
|  | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2023** | **2023** | **2023** |
|  |  | **Interest** | **Lease** |  | **Interest** | **Lease** |  | **Interest** | **Lease** |
|  | **Depreciation** | **expense** | **expense** <sup>(1)</sup> | **Depreciation** | **expense** | **expense** <sup>(1)</sup> | **Depreciation** | **expense** | **expense** <sup>(1)</sup> |
| Fresenius SE | 6757 | 230 | 233 | 6591 | 306 | 398 | 7738 | 1148 | 291 |
| Fresenius SE affiliates | 16496 | 1284 |  | 18347 | 1907 |  | 17817 | 1438 |  |
| **Total** | **23253** | **1514** | **233** | **24938** | **2213** | **398** | **25555** | **2586** | **291** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Short-term leases and expenses relating to variable lease payments as well as low value leases are exempted from balance sheet recognition.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Lease agreements with related parties** | **Lease agreements with related parties** | **Lease agreements with related parties** | **Lease agreements with related parties** | **Lease agreements with related parties** |
| *in € K* | *in € K* | *in € K* | *in € K* | *in € K* |
|  | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** |
|  | **Right-of-use** | **Lease** | **Right-of-use** | **Lease** |
|  | **asset** | **liability** | **asset** | **liability** |
| Fresenius SE | 17522 | 18102 | 22997 | 24953 |
| Fresenius SE affiliates |  |  | 87044 | 87910 |
| **Total** | **17522** | **18102** | **110041** | **112863** |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**c)** **Financing**

As of December 31, 2025 and December 31, 2024, the Company had outstanding accounts payable related to a cash pooling program with certain equity-method investees in the amount of €12,962 and €25,316, respectively. The interest rates for these cash management arrangements were set on a daily basis and were based on the then-prevailing overnight reference rate, with a floor of zero, for the respective currencies.

**d)**Key management personnel

Due to the Company's previous legal form of a German partnership limited by shares until the effectiveness of the Conversion, Fresenius Medical Care Management AG (Management AG), the Company's former general partner (General Partner), held a key management position within the Company. In addition, as key management personnel, members of the management board and supervisory board of Management AG, as well as their close relatives, were considered related parties. Upon effectiveness of the Conversion, the General Partner exited the Company and is no longer entitled to reimbursement of the remuneration of its board members. The members of the Supervisory Board and the Management Board, as key management personnel, as well as their close relatives, are considered related parties of the Company. Also upon effectiveness of the Conversion, the existing service agreements between the General Partner and the members of the management board of Management AG were transferred to FME AG at unchanged conditions. The Company's unfunded pension plan in Germany also comprises the benefit obligations of former board members of Management AG as well as of active board members which were appointed to the Management Board before January 1, 2019 in the amount of €55,434 and €60,381 as of December 31, 2025 and 2024, respectively. The plan which was funded by insurance contracts comprised the benefit obligations of active board members which were appointed to the Management Board after January 1, 2019 in the amount of €4,137 as of December 31, 2024. This plan was settled in 2025 through an early payment of the entitlements resulting in no remaining benefit obligations as of December 31, 2025. The Company has also entered into service agreements with new members of the Management Board who joined subsequent to the Conversion. The long-term incentive plans of Management AG applying to the former members of the management board of Management AG established before the Conversion were adopted by the Supervisory Board as compensation plans of the Company. Certain members of the Supervisory Board are employed by the Company and receive salary and benefits under their employment arrangements. Such arrangements reflect the nature and requirements of their functions and are consistent with the Company's general remuneration framework. For further information regarding the Conversion, see note 1.

Prior to the Conversion, the Company's Articles of Association provided that the General Partner shall be reimbursed for any and all expenses in connection with the management of the Company's business, including remuneration of the members of the General Partner's supervisory board and the members of the management board of Management AG. The aggregate amount reimbursed to the General Partner was €31,361 for its management services during 2023 and included an annual fee of €110 as compensation for assuming liability as general partner. The Company's Articles of Association set the annual fee at 4% of the amount of the General Partner's share capital (€3,000 as of the date of the Conversion).

For information regarding compensation of the Management Board and the Supervisory Board of the Company see note 31.

**7.**Cash and cash equivalents

As of December 31, 2025 and 2024, cash and cash equivalents are as follows:

---

| | | |
|:---|:---|:---|
| **Cash and cash equivalents** | **Cash and cash equivalents** | **Cash and cash equivalents** |
| *in € K* | *in € K* | *in € K* |
|  | **2025** | **2024** |
| Cash  | 929,692 | 837,328 |
| Securities and time deposits | 669,421 | 342,859 |
| **Cash and cash equivalents** | **1,599,113** | **1,180,187** |

---

The cash and cash equivalents disclosed in the table above, and respectively in the consolidated statement of cash flows, include at December 31, 2025 an amount of €16,595 (2024: €29,240), primarily related to collateral requirements towards an insurance company in the U.S. that are not available for use, but are accessible upon demand.

For further information on the Company's multi-currency notional pooling cash management system, see note 16.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**8.**Trade accounts and other receivables from unrelated parties

As of December 31, 2025 and December 31, 2024, trade accounts and other receivables from unrelated parties are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Trade accounts and other receivables from unrelated parties** | **Trade accounts and other receivables from unrelated parties** | **Trade accounts and other receivables from unrelated parties** | **Trade accounts and other receivables from unrelated parties** | **Trade accounts and other receivables from unrelated parties** |
| *in € K* | *in € K* | *in € K* | *in € K* | *in € K* |
|  | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** |
|  |  | **thereof credit-** |  | **thereof credit-** |
|  |  | **impaired** <sup>(1)</sup> |  | **impaired** <sup>(1)</sup> |
| Trade accounts and other receivables, gross | 3349982 | 403806 | 3573550 | 371862 |
| &nbsp;&nbsp;thereof finance lease receivables | 64385 |  | 68460 |  |
| less expected credit losses | (207684) | (158233) | (206439) | (139170) |
| **Trade accounts and other receivables** | **3142298** | **245573** | **3367111** | **232692** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Trade accounts receivable balances are credit-impaired when one or more events have occurred that have a detrimental impact on the estimated future cash flows of the receivable balance (e.g. overdue by more than one year, etc.).

Other receivables in the amount of €124,294 at December 31, 2025 (December 31, 2024: €108,931) include receivables from finance leases, operating leases and insurance contracts. For further information, see note 1 k).

All trade accounts and other receivables from unrelated parties are due within one year.

Trade accounts receivables and finance lease receivables with a term of more than one year in the amount of €102,235 at December 31, 2025 (December 31, 2024: €111,864) are included in the balance sheet item "Other non-current financial assets." The majority of finance lease receivables are due within 5 years.

The following table shows the development of expected credit losses in the fiscal years 2025, 2024, and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Development of expected credit losses for doubtful accounts from unrelated parties** | **Development of expected credit losses for doubtful accounts from unrelated parties** | **Development of expected credit losses for doubtful accounts from unrelated parties** | **Development of expected credit losses for doubtful accounts from unrelated parties** |
| *in K €* | *in K €* | *in K €* | *in K €* |
|  | **2025** | **2024** | **2023** |
| **Expected credit losses as of January 1** | **206439** | **261854** | **168681** |
| Change in valuation allowances as recorded in the consolidated statements of income | 28966 | 18968 | 112242 |
| Write-offs and recoveries of amounts previously written-off | (19685) | (37622) | (11617) |
| Changes in consolidation group | (106) | (23030) | (872) |
| Reclassifications <sup>(1)</sup> |  | (13264) | (924) |
| Foreign currency translation | (7930) | (467) | (5656) |
| **Expected credit losses as of December 31** | **207684** | **206439** | **261854** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes expected credit losses related to trade accounts and other receivables from unrelated parties which have been reclassified as assets held for sale.

The following tables show the aging analysis of trade accounts and other receivables from unrelated parties and expected credit losses as of December 31, 2025 and as of December 31, 2024:

#### Aging analysis of trade accounts and other receivables from unrelated parties 2025
*in € K*

---

| | | | |
|:---|:---|:---|:---|
|  | <br>**not overdue** | **more than**<br>**12 months**<br>**overdue** | <br>**Total** |
| Trade accounts and other receivables | 2215955 | 218403 | 3349982 |
| less expected credit losses | (36890) | (148908) | (207684) |
| **Trade accounts and other receivables, net** | **2179065** | **69495** | **3142298** |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

#### Aging analysis of trade accounts and other receivables from unrelated parties 2024
*in € K*

---

| | | | |
|:---|:---|:---|:---|
|  | <br>**not overdue** | **more than**<br>**12 months**<br>**overdue** | <br>**Total** |
| Trade accounts and other receivables | 2147823 | 240496 | 3573550 |
| less expected credit losses | (34555) | (132661) | (206439) |
| **Trade accounts and other receivables, net** | **2113268** | **107835** | **3367111** |

---

The following table provides a reconciliation of the Company's portfolios of insurance and reinsurance contracts, showing the change in insurance and reinsurance contract receivables (liabilities) as of December 31, 2025 and 2024.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Reinsurance contract receivables and liabilities** |  |  |  |  |  |  |
| *in € K* | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
|  |  | **Risk**  |  |  | **Risk**  |  |
|  | **Present**  | **adjustment**  |  | **Present**  | **adjustment**  |  |
|  | **value of**  | **for non-** |  | **value of**  | **for non-** |  |
|  | **future** | **financial**  |  | **future** | **financial**  |  |
|  | **cash flows** | **risk** | **Total** | **cash flows** | **risk** | **Total** |
| **Reinsurance contract receivables (liabilities) as at January 1,** | (9287) | (701) | (9988) | 53137 | (931) | 52206 |
| Incurred claims and other directly attributable expenses | (211997) | 208 | (211789) | (245035) | 278 | (244757) |
| Changes that relate to past service – changes in the fulfillment cash-flows relating to LIC<sup>(1)</sup> | 19354 |  | 19354 | (58654) |  | (58654) |
| Claims and other directly attributable expenses paid | (618473) |  | (618473) | (562067) |  | (562067) |
| Premium revenue | 827891 |  | 827891 | 802597 |  | 802597 |
| Foreign currency translation and other changes | 433 | 74 | 507 | 735 | (48) | 687 |
| **Reinsurance contract receivables (liabilities) as at December 31,**  | **7921** | **(419)** | **7502** | **(9287)** | **(701)** | **(9988)** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Changes that relate to past service include premium revenue, or a reduction in premium revenue, for past performance years of €32,974 and €(14,916) as of December 31, 2025 and 2024, respectively.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Insurance contract receivables and liabilities** |  |  |  |  |  |  |
| *in € K* | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
|  |  | **Risk**  |  |  | **Risk**  |  |
|  | **Present**  | **adjustment**  |  | **Present**  | **adjustment**  |  |
|  | **value of** | **for non-** |  | **value of** | **for non-** |  |
|  | **future**  | **financial**  |  | **future**  | **financial**  |  |
|  | **cash flows** | **risk** | **Total** | **cash flows** | **risk** | **Total** |
| **Insurance contract receivables (liabilities) as at January 1,** | (7751) | (588) | (8339) | 27389 | (553) | 26836 |
| Incurred claims and other directly attributable expenses | (367292) | (58) | (367350) | (242885) |  | (242885) |
| Changes that relate to past service – changes in the fulfillment cash-flows relating to LIC<sup>(1)</sup> | 8475 |  | 8475 | (16108) |  | (16108) |
| Claims and other directly attributable expenses paid | (845988) |  | (845988) | (604843) |  | (604843) |
| Premium revenue | 1225709 |  | 1225709 | 828437 |  | 828437 |
| Foreign currency translation and other changes | 95 | 70 | 165 | 259 | (35) | 224 |
| **Insurance contract receivables (liabilities) as at December 31,**  | **13248** | **(576)** | **12672** | **(7751)** | **(588)** | **(8339)** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Changes that relate to past service include premium revenue, or a reduction in premium revenue, for past performance years of €30,137 and €(2,095) as of December 31, 2025 and 2024, respectively.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**9.**Inventories

At December 31, 2025 and December 31, 2024, inventories consisted of the following:

#### Inventories
*in € K*

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| Finished goods | 1,251,141 | 1,182,034 |
| Healthcare supplies | 413,453 | 417,475 |
| Raw materials and purchased components | 329,299 | 344,311 |
| Work in process | 146,878 | 124,102 |
| **Inventories** | **2,140,771** | **2,067,922** |

---

Under the terms of certain unconditional purchase agreements, the Company is obligated to purchase approximately €396,702 of materials, of which €246,754 is committed at December 31, 2025 for 2026 (€278,139 and €191,982, respectively, at December 31, 2024 for 2025). The terms of these agreements run 1 to 5 years. Further unconditional purchase agreements exist with an equity method investee of the Company. For further information on these agreements, see note 6.

Write-downs of inventories amounted to €135,005 and €116,358 for the years ended December 31, 2025 and 2024, respectively.

**10.** **Other current financial and non-financial assets**

#### At December 31, 2025 and 2024, other current financial assets consisted of the following:

---

| | | |
|:---|:---|:---|
| **Other current financial assets** |  |  |
| *in € K* |  |  |
|  | **2025** | **2024** |
| Debt securities | 127536 | 149361 |
| Notes receivable | 65417 | 48049 |
| Receivables for supplier rebates | 94785 | 27696 |
| Derivatives | 23684 | 24088 |
| Third party receivables from the sale of investments | 9417 | 23560 |
| Deposit / guarantee / security | 13477 | 13732 |
| Loans to customers or suppliers | 953 | 986 |
| Other | 111235 | 146268 |
| **Total** | **446504** | **433740** |

---

#### The item "Other" in the table above includes receivables related primarily to a consent agreement on certain pharmaceuticals as of December 31, 2025.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

#### At December 31, 2025 and 2024, other current assets consisted of the following:

#### Other current assets
*in € K*

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| Income tax receivable | 126197 | 248668 |
| Other tax receivable | 164192 | 142573 |
| Payments on account | 138225 | 127116 |
| Prepaid insurance | 5440 | 27068 |
| Interest receivables related to income tax | 21397 | 21289 |
| Prepaid rent | 4398 | 14556 |
| Other | 73587 | 90565 |
| **Total** | **533436** | **671835** |

---

The item "Other" in the table above includes various prepaid expenses relating to, amongst others, utility costs and freight expense.

**11.** **Property, plant and equipment**

At December 31, 2025 and 2024, the acquisition or manufacturing costs and the accumulated depreciation and impairment of property, plant and equipment consisted of the following:

#### Acquisition or manufacturing costs
*in € K*

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**January 1,**<br>**2025** | **Foreign**<br>**currency**<br>**translation** | **Changes in**<br>**consolidation**<br>**group** | <br>**Additions** | <br>**Reclassifications** <sup>(1)</sup> | <br>**Disposals** | <br>**December 31,** <br>**2025** |
| Land | 63134 | (3858) |  | 10178 | 2549 | (480) | 71523 |
| Buildings and improvements | 4580202 | (431944) | (5549) | 197168 | 173216 | (107161) | 4405932 |
| Machinery and equipment | 5525448 | (406550) | 2161 | 271610 | 19024 | (316502) | 5095191 |
| Rental & loaned equipment | 891699 | (30467) | (13310) | 99178 | 65126 | (62528) | 949698 |
| Construction in progress | 385659 | (20832) |  | 246507 | (257694) | (3006) | 350634 |
| **Property, plant and equipment** | **11446142** | **(893651)** | **(16698)** | **824641** | **2221** | **(489677)** | **10872978** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes amounts reclassified as assets held for sale.

*in € K*

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**January 1,**<br>**2024** | **Foreign**<br>**currency**<br>**translation** | **Changes in**<br>**consolidation**<br>**group** | <br>**Additions** | <br>**Reclassifications** <sup>(1)</sup> | <br>**Disposals** | <br>**December 31,** <br>**2024** |
| Land | 65649 | (773) | (452) | 453 | (835) | (908) | 63134 |
| Buildings and improvements | 4306223 | 199727 | (10821) | 35332 | 173622 | (123881) | 4580202 |
| Machinery and equipment | 5354640 | 174082 | (24624) | 272238 | (38940) | (211948) | 5525448 |
| Rental & loaned equipment | 873055 | 7820 | (4742) | 87501 | 10862 | (82797) | 891699 |
| Construction in progress | 384052 | 1247 | (236) | 250854 | (241893) | (8365) | 385659 |
| **Property, plant and equipment** | **10983619** | **382103** | **(40875)** | **646378** | **(97184)** | **(427899)** | **11446142** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes amounts reclassified as assets held for sale.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

#### Accumulated depreciation and impairment
*in € K*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**January 1,**<br>**2025** | **Foreign**<br>**currency**<br>**translation** | **Changes in**<br>**consolidation**<br>**group** | <br>**Additions** | <br>**Impairment** | <br>**Reclassifications** <sup>(1)</sup> | <br>**Disposals** | <br>**December 31,** <br>**2025** |
| Land | 457 | (49) |  |  | 50 | (3) |  | 455 |
| Buildings and improvements | 3199847 | (317718) | (5325) | 242021 | 3545 | 942 | (104047) | 3019265 |
| Machinery and equipment | 4011144 | (286739) | (3667) | 343864 | 5578 | (11718) | (291384) | 3767078 |
| Rental & loaned equipment | 588568 | (26046) | (7388) | 88685 | 574 | 12680 | (57186) | 599887 |
| Construction in progress |  |  |  |  |  |  |  |  |
| **Property, plant and equipment** | **7800016** | **(630552)** | **(16380)** | **674570** | **9747** | **1901** | **(452617)** | **7386685** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes amounts reclassified as assets held for sale.

*in € K*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**January 1,**<br>**2024** | **Foreign**<br>**currency**<br>**translation** | **Changes in**<br>**consolidation**<br>**group** | <br>**Additions** | <br>**Impairment** | <br>**Reclassifications** <sup>(1)</sup> | <br>**Disposals** | <br>**December 31,** <br>**2024** |
| Land | 512 | (19) |  |  | 340 | (340) | (36) | 457 |
| Buildings and improvements | 2904572 | 148407 | (4661) | 260168 | 32010 | (24597) | (116052) | 3199847 |
| Machinery and equipment | 3721399 | 118873 | (7746) | 389972 | 34363 | (39948) | (205769) | 4011144 |
| Rental & loaned equipment | 574305 | 10900 | (4176) | 72685 | 10928 | 2895 | (78969) | 588568 |
| Construction in progress | 51 |  |  |  |  | (51) |  |  |
| **Property, plant and equipment** | **7200839** | **278161** | **(16583)** | **722825** | **77641** | **(62041)** | **(400826)** | **7800016** |

---

(1)Includes amounts reclassified as assets held for sale.

#### Book value
*in € K*

---

| | | |
|:---|:---|:---|
|  | **December 31,** <br>**2025** | **December 31,** <br>**2024** |
| Land | 71068 | 62677 |
| Buildings and improvements | 1386667 | 1380355 |
| Machinery and equipment | 1328113 | 1514304 |
| Rental & loaned equipment | 349811 | 303131 |
| Construction in progress | 350634 | 385659 |
| **Property, plant and equipment** | **3486293** | **3646126** |

---

Depreciation expense for property, plant and equipment amounted to €674,570, €722,825, and €759,732 for the years ended December 31, 2025, 2024, and 2023, respectively. These expenses are allocated within costs of revenue, selling, general and administrative and R&D expenses depending upon the area in which the asset is used.

Under the terms of certain unconditional purchase agreements, the Company is obligated to purchase approximately €22,003 of property, plant and equipment, of which €19,636 is committed at December 31, 2025 for 2026 (€15,472 and €12,182, respectively, at December 31, 2024 for 2025). The terms of these agreements run 1 to 3 years.

Included in rental & loaned equipment are peritoneal dialysis cycler machines which the Company leases to customers with ESRD on a month-to-month basis and hemodialysis machines which the Company leases to physicians under operating leases.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**12.** **Intangible assets and goodwill**

At December 31, 2025 and 2024, the acquisition or manufacturing costs and the accumulated amortization and impairment of intangible assets and goodwill consisted of the following:

#### Acquisition or manufacturing costs
*in € K*

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**January 1,**<br>**2025** | **Foreign** <br>**currency**<br>**translation** | **Changes in**<br>**consolidation**<br>**group** | <br>**Additions** | <br>**Reclassifications**<sup>(1)</sup> | <br>**Disposals** | <br>**December 31,** <br>**2025** |
| **Amortizable intangible assets** |  |  |  |  |  |  |  |
| Non-compete agreements | 33745 | (10842) | 719 |  |  | (3972) | 19650 |
| Technology | 701385 | (73616) |  |  | 432 | (173) | 628028 |
| Licenses and distribution agreements  | 75635 | (3958) |  |  | (3737) | (20358) | 47582 |
| Customer relationships | 74575 | (7639) |  |  |  | (18295) | 48641 |
| Intangible assets under construction | 417861 | (14486) |  | 133111 | (298043) | (2023) | 236420 |
| Internally developed intangibles | 425227 | (24221) | (633) | 8710 | 294761 | (37235) | 666609 |
| Other | 244947 | (9354) | 1525 | 5196 | 2388 | (48367) | 196335 |
|  | **1973375** | **(144116)** | **1611** | **147017** | **(4199)** | **(130423)** | **1843265** |
| **Non-amortizable intangible assets** |  |  |  |  |  |  |  |
| Trade names | 252825 | (29244) |  |  |  |  | 223581 |
| Management contracts | 2594 | (205) |  |  |  | (770) | 1619 |
| Emission certificates | 37354 |  |  |  |  | (6480) | 30874 |
|  | **292773** | **(29449)** | **—** | **—** | **—** | **(7250)** | **256074** |
| **Intangible assets** | **2266148** | **(173565)** | **1611** | **147017** | **(4199)** | **(137673)** | **2099339** |
| **Goodwill** | **15671740** | **(1642863)** | **14283** | **—** | **(94060)** | **—** | **13949100** |

---

(1) Includes amounts reclassified as assets held for sale.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

*in € K*

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**January 1,**<br>**2024** | **Foreign**<br>**currency**<br>**translation** | **Changes in**<br>**consolidation**<br>**group** | <br>**Additions** | <br>**Reclassifications**<sup>(1)</sup> | <br>**Disposals** <sup>(2)</sup> | <br>**December 31,** <br>**2024** |
| **Amortizable intangible assets** |  |  |  |  |  |  |  |
| Non-compete agreements | 328688 | 7074 | (1905) | 394 | (4301) | (296205) | 33745 |
| Technology | 664620 | 37955 |  |  | (73) | (1117) | 701385 |
| Licenses and distribution agreements  | 162687 | 2741 | (4) | 610 | (295) | (90104) | 75635 |
| Customer relationships | 71484 | 3280 |  |  |  | (189) | 74575 |
| Intangible assets under construction | 350991 | 8341 |  | 82252 | (22731) | (992) | 417861 |
| Internally developed intangibles | 527282 | 10284 | (277) | 17984 | 20578 | (150624) | 425227 |
| Other | 411803 | 3590 | (5122) | 5226 | (27006) | (143544) | 244947 |
|  | **2517555** | **73265** | **(7308)** | **106466** | **(33828)** | **(682775)** | **1973375** |
| **Non-amortizable intangible assets** |  |  |  |  |  |  |  |
| Trade names | 225664 | 14788 |  |  | 13673 | (1300) | 252825 |
| Management contracts | 2534 | 47 | 13 |  |  |  | 2594 |
| Emission certificates | 39874 |  |  |  |  | (2520) | 37354 |
|  | **268072** | **14835** | **13** | **—** | **13673** | **(3820)** | **292773** |
| **Intangible assets** | **2785627** | **88100** | **(7295)** | **106466** | **(20155)** | **(686595)** | **2266148** |
| **Goodwill** | **15247800** | **812893** | **(81891)** | **—** | **(307062)** | **—** | **15671740** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes amounts reclassified as assets held for sale.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Included within the amounts presented for non-compete agreements, licenses and distribution agreements, internally developed intangibles, and other intangible assets are €280,839 , €90,044 , €102,244 and €119,358 , respectively, for disposals of fully-amortized intangibles from prior periods.

#### Accumulated amortization and impairment
*in € K*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**January 1,**<br>**2025** | **Foreign**<br>**currency**<br>**translation** | **Changes in**<br>**consolidation**<br>**group** | <br>**Additions** | <br>**Impairment**<br>**loss** | <br>**Reclassifications**<sup>(1)</sup> | <br>**Disposals** | <br>**December 31,**<br>**2025** |
| **Amortizable intangible assets** |  |  |  |  |  |  |  |  |
| Non-compete agreements | 24589 | (10092) |  | 3379 | 536 |  | (3973) | 14439 |
| Technology | 373236 | (37767) |  | 48992 |  |  | (173) | 384288 |
| Licenses and distribution agreements  | 67677 | (3550) |  | 2726 |  |  | (20358) | 46495 |
| Customer relationships | 32327 | (3073) |  | 4504 | 2118 | 5 | (18296) | 17585 |
| Intangible assets under construction |  |  |  |  |  |  |  |  |
| Internally developed intangibles | 243809 | (10279) | (509) | 63237 | 1 | (95) | (36421) | 259743 |
| Other | 152439 | (2613) | (116) | 18385 | 980 | 81 | (47946) | 121210 |
|  | **894077** | **(67374)** | **(625)** | **141223** | **3635** | **(9)** | **(127167)** | **843760** |
| **Non-amortizable intangible assets** |  |  |  |  |  |  |  |  |
| Trade names | 439 | (10) |  |  |  |  |  | 429 |
| Management contracts | 1552 | (121) |  |  |  |  | (770) | 661 |
|  | **1991** | **(131)** | **—** | **—** | **—** | **—** | **(770)** | **1090** |
| **Intangible assets** | **896068** | **(67505)** | **(625)** | **141223** | **3635** | **(9)** | **(127937)** | **844850** |
| **Goodwill** | **501088** | **(43142)** | **—** | **—** | **8171** | **(88411)** | **—** | **377706** |

---

(1) Includes amounts reclassified as assets held for sale.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

*in € K*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**January 1,**<br>**2024** | **Foreign**<br>**currency**<br>**translation** | **Changes in**<br>**consolidation**<br>**group** | <br>**Additions** | <br>**Impairment**<br>**loss** | <br>**Reclassifications**<sup>(1)</sup> | <br>**Disposals** <sup>(2)</sup> | <br>**December**<br>**31, 2024** |
| **Amortizable intangible assets** |  |  |  |  |  |  |  |  |
| Non-compete agreements | 315649 | 6546 | (1900) | 4689 | 55 | (4275) | (296175) | 24589 |
| Technology | 305567 | 17469 |  | 51300 |  | 17 | (1117) | 373236 |
| Licenses and distribution agreements  | 152706 | 2493 | (2) | 2772 |  | (200) | (90092) | 67677 |
| Customer relationships | 26713 | 1139 |  | 4652 |  |  | (177) | 32327 |
| Intangible assets under construction | 339 | 7 |  |  |  |  | (346) |  |
| Internally developed intangibles | 334404 | 5783 | (151) | 52695 | 1291 | (1292) | (148921) | 243809 |
| Other | 284645 | 441 | (4545) | 21076 | 8320 | (14008) | (143490) | 152439 |
|  | **1420023** | **33878** | **(6598)** | **137184** | **9666** | **(19758)** | **(680318)** | **894077** |
| **Non-amortizable intangible assets** |  |  |  |  |  |  |  |  |
| Trade names | 1769 | (30) |  |  |  |  | (1300) | 439 |
| Management contracts | 1508 | 44 |  |  |  |  |  | 1552 |
|  | **3277** | **14** | **—** | **—** | **—** | **—** | **(1300)** | **1991** |
| **Intangible assets** | **1423300** | **33892** | **(6598)** | **137184** | **9666** | **(19758)** | **(681618)** | **896068** |
| **Goodwill** | **597792** | **4723** | **(32633)** | **—** | **62189** | **(130983)** | **—** | **501088** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes amounts reclassified as assets held for sale.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Included within the amounts presented for non-compete agreements, licenses and distribution agreements, internally developed intangibles and other intangible assets are €280,839 , €90,044 , €102,244 and €119,358 , respectively, for disposals of fully-amortized intangibles from prior periods.

#### Book value
*in € K*

---

| | | |
|:---|:---|:---|
|  | **December 31, 2025** | **December 31, 2024** |
| **Amortizable intangible assets** |  |  |
| Non-compete agreements | 5211 | 9156 |
| Technology | 243740 | 328149 |
| Licenses and distribution agreements  | 1087 | 7958 |
| Customer relationships | 31056 | 42248 |
| Intangible assets under construction | 236420 | 417861 |
| Internally developed intangibles | 406866 | 181418 |
| Other | 75125 | 92508 |
|  | **999505** | **1079298** |
| **Non-amortizable intangible assets** |  |  |
| Trade names | 223152 | 252386 |
| Management contracts | 958 | 1042 |
| Emission certificates | 30874 | 37354 |
|  | **254984** | **290782** |
| **Intangible assets** | **1254489** | **1370080** |
| **Goodwill** | **13571394** | **15170652** |

---

The amortization of intangible assets amounted to €141,223, €137,184, and €152,333 for the years ended December 31, 2025, 2024, and 2023, respectively. These expenses are allocated within costs of revenue, selling, general and administrative, and R&D expenses depending upon the area in which the asset is used.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The Company capitalized development costs of €134,644 in 2025 (€91,066 in 2024), which is included in the line items Internally developed intangibles and Intangible assets under construction in the schedule above and is primarily comprised of healthcare product and IT software development.

**Goodwill and intangible assets with indefinite useful lives**

The decrease in the carrying amount of goodwill during 2025 is mainly a result of the impact of foreign currency translations.

The carrying amount of goodwill and intangibles with indefinite useful lives is allocated to the groups of CGUs at December 31, 2025 and 2024:

#### Allocation of the carrying amount to the groups of CGUs
*in € K*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Care Delivery** | **Care Delivery** | **Care Enablement** | **Care Enablement** | **Value-Based Care** | **Value-Based Care** |
|  | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| Goodwill | 11212997 | 13014925 | 1989734 | 2155727 | 368663 | n.a. |
| Management contracts with indefinite useful life | 958 | 1043 |  |  |  | n.a. |
| Trade names with indefinite useful life | 171492 | 208204 | 39064 | 44181 | 12596 | n.a. |
| Emission certificates |  |  | 30874 | 37354 |  | n.a. |

---

The Company did not record any impairment losses related to goodwill in 2025 and 2024 after comparing the value in use to the respective carrying amount for the Care Delivery, Care Enablement, and Value-Based Care groups of CGUs. See note 29 for a further discussion on our operating segments.

**13.** **Interests in associates**

The following table shows the Company's interests in associates of the Company which management considered to be material to the Company as of December 31, 2025 and 2024:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Interests in associates** |  |  |  |  |  |
| *in € K, except where otherwise specified* |  |  |  |  |  |
|  | **Country of**  | **Ownership**  | **Method of**  |  |  |
| **Name of the entity** | **incorporation** | **interest in %** | **measurement** | **Carrying value** | **Carrying value** |
|  |  |  |  | **2025** | **2024** |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | Switzerland | 45 | Equity method | 632026 | 580973 |
| Other associates |  |  |  | 31626 | 39858 |
| **Equity method investees** |  |  |  | 663652 | 620831 |

---

In December 2010, the Company and CSL Vifor formed a new renal pharmaceutical company, Vifor Fresenius Medical Care Renal Pharma Ltd., recognized as an equity method investee of which the Company owns 45%. Vifor Fresenius Medical Care Renal Pharma Ltd. develops and distributes products focused on addressing distinct complications and areas of chronic kidney disease, renal anemia management, mineral and bone management, kidney function preservation and improvement, conditions associated with kidney impairment and its treatment, and cardio-renal management.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The following table contains the summarized financial information for Vifor Fresenius Medical Care Renal Pharma Ltd as of and for the year ended December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| **Summarized financial information** |  |  |
| *In € K* |  |  |
| **Summarized balance sheets** | **2025** | **2024** |
| Current assets | 824062 | 914502 |
| Non-current assets | 439909 | 518589 |
| Current liabilities | 277103 | 480640 |
| Non-current liabilities | 32534 | 34116 |
| **Net assets** | 954334 | 918335 |

---

---

| | | |
|:---|:---|:---|
| **Reconciliation to carrying amounts (net assets)** | **2025** | **2024** |
| Opening balance net assets January 1, | 918335 | 893505 |
| Profit for the period | 456306 | 290766 |
| Other comprehensive income | (3428) | (116914) |
| Dividends paid | (304832) | (205301) |
| Foreign currency translation | (112047) | 56279 |
| **Closing balance net assets December 31,**  | 954334 | 918335 |
| Company's share in net assets | 429450 | 413251 |
| Other reconciling items<sup>(1)</sup> | 257528 | 219166 |
| Eliminations | (54952) | (51444) |
| **Carrying amount** | 632026 | 580973 |

---

---

| | | |
|:---|:---|:---|
| <br>**Summarized statement of comprehensive income** | **For the year ended**<br>**December 31, 2025** | **For the year ended**<br>**December 31, 2024** |
| Revenue | 950888 | 741183 |
| Profit from continuing operations | 456306 | 290766 |
| **Profit for the period** | 456306 | 290766 |
| Other comprehensive income | (3428) | (116914) |
| **Total comprehensive income** | 452878 | 173852 |
| Dividends received | 137174 | 92386 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes Goodwill as well as impacts from foreign currency translation.

**14.** **Other non-current financial assets**

At December 31, 2025 and 2024, other non-current financial assets consisted of the following:

---

| | | |
|:---|:---|:---|
| **Other non-current financial assets** |  |  |
| *in € K* |  |  |
|  | **2025** | **2024** |
| Debt securities  | 302683 | 316071 |
| Equity investments | 89508 | 187600 |
| Other financial assets | 267640 | 292185 |
| **Total** | **659831** | **795856** |

---

Other financial assets in the table above includes receivables from licensing agreements, finance leases, and deposits and guarantees.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**15.** **Current provisions and other current financial and non-financial liabilities**

**Current provisions**

The following table shows a reconciliation of the current provisions for 2025:

#### Development of current provisions
*in € K*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**January 1,**<br>**2025** | **Foreign**<br>**currency**<br>**translation** | **Changes in**<br>**consolidation**<br>**group** | <br>**Utilized** | <br>**Reversed** | <br>**Additions** | <br>**Reclassifications** | <br>**December 31, 2025** |
| Personnel expenses | 244382 | (19118) |  | (143751) | (10845) | 134132 | 26486 | 231286 |
| Self-insurance programs | 106520 | (13086) |  | (55328) | (42117) | 104777 | 12166 | 112932 |
| Risk of lawsuit | 16334 | (1377) |  | (4695) | (2289) | 17551 | (2427) | 23097 |
| Other current provisions | 81132 | (3884) |  | (16402) | (9598) | 12834 | (27) | 64055 |
| **Current provisions** | **448368** | **(37465)** | **—** | **(220176)** | **(64849)** | **269294** | **36198** | **431370** |

---

***Self-insurance programs***

See note 2 d).

***Personnel expenses***

Personnel expenses mainly refer to provisions for the Company's global performance-based compensation plan for managerial staff, the current portion of the provisions for accrued severance payments, provisions for cash-settled share-based plans and jubilee payments. As of December 31, 2025, provisions for the Company's global performance-based compensation plan for managerial staff amounted to €101,965 (December 31, 2024: €142,446), provisions for accrued severance payments amounted to €53,366 (December 31, 2024: €45,077) and provisions for cash-settled share-based plans amounted to €32,194 (December 31, 2024: €25,309). For further information regarding share-based plans, see note 23.

***Risk of lawsuit***

Legal matters that the Company currently deems to be material or noteworthy are described in note 25.

***Other current provisions***

The item "Other current provisions" in the table above includes provisions for repayment obligations related to governmental expenditure ceilings in certain countries, and warranties.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

***Other current financial liabilities***

As of December 31, 2025 and 2024 other current financial liabilities consisted of the following:

---

| | | |
|:---|:---|:---|
| **Other current financial liabilities** |  |  |
| *in € K* |  |  |
|  | **2025** | **2024** |
| Put option liabilities | 638009 | 807207 |
| Unapplied cash and receivable credit balances | 392047 | 464182 |
| Invoices outstanding | 263330 | 251980 |
| Derivatives | 10834 | 41859 |
| Customer rebates, bonuses, commissions | 130639 | 34416 |
| Legal matters, advisory and audit fees | 17910 | 27540 |
| Variable payments outstanding for acquisitions | 238 | 1127 |
| Other | 148510 | 159062 |
| **Other current financial liabilities** | **1601517** | **1787373** |

---

For information regarding the settlement of put options held by non-physician investors originally granted as part of the 2022 merger of Cricket Health, Interwell Health LLC and Fresenius Health Partners, Inc., see note 26.

***Other current liabilities***

As of December 31, 2025 and 2024 other current liabilities consisted of the following:

#### Other current liabilities
*in € K*

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| Personnel liabilities | 683813 | 726278 |
| VAT and other (non-income) tax liabilities | 139244 | 139981 |
| Contract liabilities | 97951 | 66735 |
| Deferred Income | 16414 | 15430 |
| Other liabilities | 102321 | 103142 |
| **Other current liabilities** | **1039743** | **1051566** |

---

***Personnel liabilities***

The personnel liabilities mainly refer to liabilities for wages and salaries, bonuses and vacation payments.

***Contract liabilities***

Contract liabilities also relate to advance payments from customers and to sales of dialysis machines where revenue is recognized upon installation and provision of the necessary technical instructions.

***Other liabilities***

The item "Other liabilities" in the table above includes interest payables related to income taxes and liabilities for the current portion of pension liabilities.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**16.**Short-term debt

At December 31, 2025 and December 31, 2024, short-term debt consisted of the following:

#### Short-term debt
*in € K*

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| Borrowings under lines of credit | 16,852 | 1,941 |
| Other | 163 | 158 |
| **Short-term debt** | **17,015** | **2,099** |

---

**Commercial paper program**

The Company maintains a commercial paper program under which short-term notes of up to €1,500,000 can be issued. As of December 31, 2025 and 2024, the Company did not utilize the commercial paper program.

**Borrowings under lines of credit and further availabilities**

Borrowings under lines of credit in the amount of €16,852 and €1,941 at December 31, 2025 and 2024, respectively, represented amounts borrowed by the Company and its subsidiaries under lines of credit with commercial banks. The average interest rates on these borrowings at December 31, 2025 and 2024 were 6.51% and 8.57%, respectively.

Excluding amounts available under the Syndicated Credit Facility (see note 17 below), at December 31, 2025 and 2024, the Company had €1,306,931 and €1,508,486 available under other commercial bank agreements, excluding agreements on a subsidiary level, which are readily available for liability management purposes. In some instances, lines of credit are secured by assets of the Company's subsidiary that is party to the agreement or may require the Company's, or its subsidiaries', guarantee.

The Company and certain consolidated entities operate a multi-currency notional cash pooling management system. In this cash pooling management system, amounts in euro and other currencies are offset without being transferred to a specific cash pool account. The system is used for an efficient utilization of funds within the Company. The Company met the conditions to offset balances within this cash pool for reporting purposes. At December 31, 2025 and 2024, cash and borrowings under lines of credit in the amount of €262,385 and €251,353, respectively, were offset under this cash pooling management system. Before this offset, cash and cash equivalents as of December 31, 2025 was €1,861,498 (December 31, 2024: €1,431,540) and short-term debt from unrelated parties was €279,400 (December 31, 2024: €253,452).

**17.**Long-term debt

As of December 31, 2025 and 2024, long-term debt consisted of the following:

#### Long-term debt
*in € K*

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| Schuldschein loans | 227296 | 228399 |
| Bonds | 6967743 | 6492120 |
| Other  | 92842 | 115589 |
| Long-term debt | 7287881 | 6836108 |
| Less current portion | (1596029) | (575283) |
| **Long-term debt, less current portion** | **5691852** | **6260825** |

---

The Company's long-term debt as of December 31, 2025, all of which ranks equally in rights of payment, are described as follows:

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**Schuldschein loans**

On February 14, 2022, the Company issued €25,000 and €200,000 tranches of Schuldschein loans with maturities of 5 and 7 years, respectively, at variable interest rates. The proceeds were used for general corporate purposes including refinancing of existing liabilities.

**Bonds**

At December 31, 2025 and 2024, the Company's bonds consisted of the following:

#### Bonds
*in K*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | | **Book value in €** | **Book value in €** |
| <br>**Issuer/Transaction** | **Face**<br>**amount** | <br>**Maturity** | <br>**Coupon** | **2025** | **2024** |
| Fresenius Medical Care AG, 2018 | 500000 | July 11, 2025 | 1.500% |  | 503204 |
| Fresenius Medical Care AG, 2020 | 399975 | May 29, 2026 | 1.000% | 402073 | 501787 |
| Fresenius Medical Care AG, 2019 | 400025 | November 30, 2026 | 0.625% | 399648 | 598438 |
| Fresenius Medical Care US Finance III, Inc. 2021 | $850000 | December 1, 2026 | 1.875% | 723260 | 816438 |
| Fresenius Medical Care AG, 2022 | 750000 | September 20, 2027 | 3.875% | 756094 | 754936 |
| Fresenius Medical Care AG, 2025 | 600000 | December 8, 2028 | 3.125% | 597521 |  |
| Fresenius Medical Care US Finance III, Inc. 2019 | $500000 | June 15, 2029 | 3.750% | 422965 | 477290 |
| Fresenius Medical Care AG, 2019 | 500000 | November 29, 2029 | 1.250% | 499293 | 498971 |
| Fresenius Medical Care AG, 2020 | 750000 | May 29, 2030 | 1.500% | 754473 | 753979 |
| Fresenius Medical Care AG, 2025 | 500000 | November 24, 2030 | 3.250% | 498176 |  |
| Fresenius Medical Care US Finance III, Inc. 2020 | $1000000 | February 16, 2031 | 2.375% | 854570 | 965623 |
| Fresenius Medical Care US Finance III, Inc. 2021 | $650000 | December 1, 2031 | 3.000% | 550209 | 621454 |
| Fresenius Medical Care AG, 2025 | 500000 | April 8, 2032 | 3.750% | 509461 |  |
|  |  |  |  | **6967743** | **6492120** |

---

All bonds issued by Fresenius Medical Care US Finance III, Inc. are guaranteed by the Company. All U.S. dollar bonds outstanding may be redeemed at the option of the respective issuers at any time at 100% of principal plus accrued interest and a premium calculated pursuant to the terms of the applicable indenture. The holders of the Company's bonds have the right to request that the issuers repurchase the bonds at 101% of principal plus accrued interest upon the occurrence of a change of control of the Company followed by a decline in the ratings of the respective bonds.

The Company has agreed to a number of covenants to provide protection to the bond holders which, under certain circumstances, limit the ability of the Company and its subsidiaries to, among other things, incur debt, incur liens, engage in sale-leaseback transactions and merge or consolidate with other companies or sell assets. At December 31, 2025, the Company was in compliance with all of its covenants under the bonds.

Since 2018, bonds can be issued with different maturities under the Company's €10,000,000 Debt Issuance Program (Debt Issuance Program). On April 1, 2025, the Company issued bonds with an aggregate principal amount of €1,100,000 in the following two tranches:

● €600,000 aggregate principal amount of 3.125% bonds maturing December 8, 2028; and

● €500,000 aggregate principal amount of 3.750% bonds maturing April 8, 2032.

Additionally, on November 17, 2025, the Company issued bonds in an aggregate principal amount of €500,000 with a maturity of 5 years and a coupon rate of 3.250%.

The proceeds for the bonds issued in April and November 2025 were used for general corporate purposes, including the refinancing of existing financial liabilities.

On April 10, 2025, in connection with an offer to purchase its outstanding 1.000% bonds due May 29, 2026 and 0.625% bonds due November 30, 2026, the Company settled an aggregate principal amount of €300,000 of bonds.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

On July 11, 2025, FME AG redeemed €500,000 aggregate principal amount of bonds at maturity.

**Credit Facilities**

*Syndicated Credit Facility*

The Company entered into a €2,000,000 sustainability-linked syndicated revolving credit facility (Syndicated Credit Facility) in July 2021, which serves as a back-up line for general corporate purposes and was undrawn as of December 31, 2025 and 2024. On June 2, 2023, the Syndicated Credit Facility was extended an additional year until July 1, 2028, with a maximum available borrowing amount of €1,959,184 in the last year.

**Other**

At December 31, 2025 and 2024, in conjunction with certain acquisitions and investments, the Company had fixed payments outstanding for acquisitions totaling approximately €16 and €1,725, respectively, of which €16 and €98, respectively, were classified as the current portion of long-term debt.

**18.** **Non-current provisions and other non-current financial and non-financial liabilities**

Of the total amount of non-current provisions and other non-current financial and non-financial liabilities amounting to €503,080 at December 31, 2025 (2024: €912,848), €310,020 (2024: €657,027) are due in between more than one and three years, €103,599 (2024: €137,435) are due in between three to five years, and €89,460 (2024: €118,386) are due after five years.

The following table shows the development of non-current provisions in the fiscal year:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Development of non-current provisions** | **Development of non-current provisions** | **Development of non-current provisions** | **Development of non-current provisions** | **Development of non-current provisions** | **Development of non-current provisions** | **Development of non-current provisions** | **Development of non-current provisions** | **Development of non-current provisions** |
| *in € K* |  |  |  |  |  |  |  |  |
|  |  | **Foreign** | **Changes in** |  |  |  |  |  |
|  | **January 1,** | **currency** | **consolidation** |  |  |  |  | **December 31,**  |
|  | **2025** | **translation** | **group** | **Utilized** | **Reversed** | **Additions** | **Reclassifications** | **2025** |
| Self-insurance programs | 116848 | (13159) |  |  |  | 92 | (12166) | 91615 |
| Personnel expenses | 53068 | (3502) |  | (5227) | (663) | 30675 | (24059) | 50292 |
| Asset retirement obligations | 12966 | (876) |  | (180) | (26) | 685 | 26 | 12595 |
| Interest payable related to income taxes | 4930 | (314) |  |  |  | 5972 |  | 10588 |
| Other non-current provisions | 8704 | (416) |  | (1395) | (3270) | 4638 |  | 8261 |
| **Non-current provisions** | **196516** | **(18267)** | **—** | **(6802)** | **(3959)** | **42062** | **(36199)** | **173351** |

---

For further information regarding self-insurance programs, see note 2 d).

Personnel expenses mainly refer to provisions for severance payments and provisions for cash-settled share-based plans. As of December 31, 2025, provisions for cash-settled share-based plans amounted to €37,489 (2024: €40,035) and provisions for severance payments amounted to €6,656 (2024: €7,976). For further information regarding share-based plans, see note 23.

The item "Other non-current provisions" in the table above includes provisions for litigation and warranties. The decrease during the period that arises from the passage of time and the effect of any change in the discount rate are not material.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

***Other non-current financial liabilities***

As of December 31, 2025 and 2024 other non-current financial liabilities consisted of the following:

---

| | | |
|:---|:---|:---|
| **Other non-current financial liabilities** |  |  |
| *in € K* |  |  |
|  | **2025** | **2024** |
| Put option liabilities | 155035 | 491910 |
| Variable payments outstanding for acquisitions | 3023 | 6806 |
| Other | 24108 | 39969 |
| **Other non-current financial liabilities** | **182166** | **538685** |

---

For information regarding the settlement of put options held by non - physician investors originally granted as part of the 2022 merger of Cricket Health, Interwell Health LLC and Fresenius Health Partners, Inc., see note 26.

***Other non-current liabilities***

As of December 31, 2025 and 2024 other non-current liabilities consisted of the following:

---

| | | |
|:---|:---|:---|
| **Other non-current liabilities** |  |  |
| *in € K* |  |  |
|  | **2025** | **2024** |
| Labor Expense non-current | 104578 | 121731 |
| Deferred Income | 9760 | 34018 |
| Other | 33225 | 21898 |
| **Other non-current liabilities** | **147563** | **177647** |

---

**19.** **Employee benefit plans**

***General***

The Company recognizes pension costs and related pension liabilities for current and future benefits to qualified current and former employees of the Company. The Company's pension plans are structured in accordance with the differing legal, economic, and fiscal circumstances in each country. The Company currently has two types of plans, defined benefit and defined contribution plans. In general, plan benefits in defined benefit plans are based on all or a portion of the employees' years of services and final salary. Plan benefits in defined contribution plans are determined by the amount of contribution by the employee and the employer, both of which may be limited by legislation, and the returns earned on the investment of those contributions.

Upon retirement under defined benefit plans, the Company is required to pay defined benefits to former employees when the defined benefits become due. Defined benefit plans may be funded or unfunded. The Company has five major defined benefit plans, one funded plan in the U.S. and one in France, one unfunded plan in Germany and two in France. The Company signed a resolution to spin-off the liabilities and assets of the Fresenius Medical Care North America Retirement Plan for all active participants employed in Puerto Rico into a new plan, the Fresenius Medical Care Puerto Rico Retirement Plan, effective December 31, 2025. Under this new plan, the Company will remain obligated to fund the plan after the spin-off. Due to the Conversion, the unfunded plan in Germany also comprises the benefit obligations of former board members of Management AG as well as of active board members which were appointed to the Management Board before January 1, 2019 in the amount of €55,434 and €60,381 as of December 31, 2025 and 2024. The plan which was funded by insurance contracts comprised the benefit obligations of active board members which were appointed to the Management Board after January 1, 2019 in the amount of €4,137 as of December 31, 2024. This plan was settled in 2025 through an early payment of the entitlements resulting in no remaining benefit obligations as of December 31, 2025.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Actuarial assumptions generally determine benefit obligations under defined benefit plans. The actuarial calculations require the use of estimates. The main factors used in the actuarial calculations affecting the level of the benefit obligations are: assumptions on life expectancy, the discount rate, and future salary and benefit levels. Under the Company's funded plans, assets are set aside to meet future payment obligations. An estimated return on the plan assets is recognized as income in the respective period. Actuarial gains and losses are generated when there are variations in the actuarial assumptions and by differences between the actual and the estimated projected benefit obligations and the return on plan assets for that year. The Company's pension liability is impacted by these actuarial gains or losses.

Under defined contribution plans, the Company pays defined contributions to an independent third party as directed by the employee during the employee's service life, which satisfies all obligations of the Company to the employee. The employee retains all rights to the contributions made by the employee and to the vested portion of the Company–paid contributions upon leaving the Company. The Company has a defined contribution plan in the U.S.

***Defined benefit pension plans***

During the first quarter of 2002 FMCH, the Company's U.S. subsidiary, curtailed its defined benefit and supplemental executive retirement plans. Under the curtailment amendment for substantially all employees eligible to participate in the plan, benefits have been frozen as of the curtailment date and no additional defined benefits for future services will be earned. The Company has retained all employee benefit obligations as of the curtailment date. Each year FMCH contributes at least the minimum amount required by the Employee Retirement Income Security Act of 1974, as amended. In 2025, FMCH did not have a minimum funding requirement. The Company voluntarily provided €54,955 to the defined benefit plan. Expected funding for 2026 is €6,106.

On December 4, 2025, an annuity purchase transaction, commonly known as a "buy-in", was executed for the main defined benefit pension plan in the U.S. covering the majority of the pension obligations. Through this transaction, the main defined benefit plan in the U.S. is largely insured against investment, longevity, interest rate, and inflation risks. Future pension obligations will be funded by the insurer's annuity payments and the annuity policies are held as an asset of the pension plan. After the buy-in transaction, the Company retains the legal responsibility to pay all covered pension benefit payments. As such, the plan liabilities remain on the Company's consolidated balance sheets alongside the corresponding pension assets.

The Company paid contributions to the plan in Germany which was funded by insurance contracts as defined in the pension plan of €792 in 2025. Due to the settlement of this plan in 2025, no further funding is expected for 2026.

The benefit obligation for all defined benefit plans at December 31, 2025 and 2024, including funded and unfunded obligations, are presented in the following table:

---

| | | |
|:---|:---|:---|
| **Benefit obligation for defined benefit plans** |  |  |
| *in € K* |  |  |
|  | **2025** | **2024** |
| **Partially funded obligations** |  |  |
| &nbsp;&nbsp;U.S. plan | 304184 | 338757 |
| &nbsp;&nbsp;French plan | 5639 | 5780 |
| **Funded obligations by insurance contracts** |  |  |
| &nbsp;&nbsp;German plan |  | 4137 |
| **Unfunded obligations** |  |  |
| &nbsp;&nbsp;German plan | 498282 | 557185 |
| &nbsp;&nbsp;French plans | 10232 | 11212 |
| **Total benefit obligations** | **818337** | **917071** |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Controlling and managing the administration of the plan in the U.S. was delegated by the Company to an administrative committee. This committee has the authority and discretion to manage the assets of the fund and to approve and adopt certain plan amendments. The board of directors of National Medical Care, Inc., a subsidiary of the Company, reserves the right to approve or adopt all major plan amendments, such as termination, modification or termination of the future benefit accruals, and plan mergers with other pension plans.

Related to defined benefit plans, the Company is exposed to certain risks. Besides general actuarial risks, such as longevity and interest rate risks, the Company is exposed to market risk as well as to investment risk.

The following table shows the changes in benefit obligations, the changes in plan assets, the net funded position, and the net liability of the pension plans. Benefits paid as shown in the changes in benefit obligations represent payments made from both the funded and unfunded plans while the benefits paid as shown in the changes in plan assets include only benefit payments from the Company's funded benefit plans.

---

| | | | |
|:---|:---|:---|:---|
| **Net pension liability** | **Net pension liability** | **Net pension liability** | **Net pension liability** |
| *in € K* | *in € K* | *in € K* | *in € K* |
|  |  | **2025** | **2024** |
| **Change in benefit obligation:** |  |  |  |
| Benefit obligation at beginning of year |  | 917071 | 890025 |
| Foreign currency translation (gains) losses |  | (39423) | 20472 |
| Current service cost |  | 23755 | 28748 |
| Past service cost |  | (1678) | (481) |
| Interest cost |  | 37980 | 37304 |
| (Gains) losses from settlement |  | 216 |  |
| Transfer of plan participants |  | (1063) | 18 |
| Actuarial (gains) losses arising from changes in financial assumptions |  | (75217) | (19944) |
| Actuarial (gains) losses arising from changes in demographic assumptions |  | 5 | 17 |
| Actuarial (gains) losses arising from experience adjustments |  | (1572) | (185) |
| &nbsp;&nbsp;Remeasurements |  | *(76784)* | *(20112)* |
| Benefits paid |  | (36899) | (38903) |
| Settlements paid |  | (4838) |  |
| **Benefit obligation at end of year** |  | **818337** | **917071** |
| **Change in plan assets:** |  |  |  |
| Fair value of plan assets at beginning of year |  | 259832 | 255772 |
| Foreign currency translation gains (losses) |  | (31103) | 15547 |
| Interest income from plan assets |  | 13135 | 13169 |
| Actuarial gains (losses) arising from experience adjustments |  | (4322) | (4122) |
| &nbsp;&nbsp;Actual return on plan assets |  | *8813* | *9047* |
| Employer contributions |  | 55746 | 7968 |
| Benefits paid |  | (25059) | (28502) |
| Settlements paid |  | (4622) |  |
| Fair value of plan assets at end of year |  | **263607** | **259832** |
| **Net funded position at end of year** |  | **554730** | **657239** |
| Benefit plans offered by other subsidiaries |  | 35954 | 35399 |
| **Net pension liability at end of year** |  | **590684** | **692638** |

---

For the years 2025 and 2024, there were no effects from the asset ceiling.

At December 31, 2025, the weighted average duration of the defined benefit obligation was 14 years (2024: 15 years).

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Pension assets and liabilities related to benefit plans offered by the Company and its subsidiaries as of December 31, 2025 and 2024 are presented in the following table:

---

| | | |
|:---|:---|:---|
| **Pension plan assets and liabilities** |  |  |
| *in € K* |  |  |
|  | **2025** | **2024** |
| **Pension plan liabilities** |  |  |
| &nbsp;&nbsp;U.S. plan | 40650 | 83148 |
| &nbsp;&nbsp;German plan | 498282 | 557185 |
| &nbsp;&nbsp;French plans | 15798 | 16906 |
| **Total** | **554730** | **657239** |
| &nbsp;&nbsp;Thereof current<sup>(1)</sup> | 15096 | 12876 |
| &nbsp;&nbsp;Thereof non-current<sup>(2)</sup> | 539634 | 644363 |
| **Benefit plans offered by other subsidiaries** |  |  |
| &nbsp;&nbsp;Pension assets <sup>(3)</sup> | (1143) | (531) |
| &nbsp;&nbsp;Current pension liabilities<sup>(1)</sup> | 1924 | 1620 |
| &nbsp;&nbsp;Non-current pension liabilities<sup>(2)</sup> | 35173 | 34310 |
| **Total other pension liabilities, net** | **35954** | **35399** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Recorded in the line item "Current provisions and other current liabilities" in the consolidated balance sheets.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Recorded in non-current liabilities as "Pension liabilities" in the consolidated balance sheets.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Recorded as "Other non-current assets" in the consolidated balance sheets.

Non-current pension liabilities were €574,807 and €678,673 at December 31, 2025 and 2024, respectively. The decrease was mainly attributable to an actuarial gain arising from changes in financial assumptions, which is recognized in the line item "actuarial gain (loss) on defined benefit pension plans" within the consolidated statements of comprehensive income. For the German benefit plan, which accounts for a substantial part of the pension liability, an interest rate of 4.50% was applied as of December 31, 2025 (December 31, 2024: 3.70%).

Approximately 62% of the beneficiaries are located in the U.S. and 9% in France, with the majority of the remaining 29% located in Germany.

The discount rates for all plans are based upon yields of portfolios of highly rated debt instruments with maturities that mirror each plan's benefit obligation. The Company's discount rates at December 31, 2025 and 2024 are the weighted average of these plans based upon their benefit obligations.

The following weighted-average assumptions were utilized in determining benefit obligations at December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| **Weighted average assumptions**  | **Weighted average assumptions**  | **Weighted average assumptions**  |
| *in %* | *in %* | *in %* |
|  | **2025** | **2024** |
| Discount rate | 4.85 | 4.39 |
| Rate of compensation increase | 3.18 | 3.18 |
| Rate of pension increase | 2.00 | 2.00 |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

***Sensitivity analysis***

Increases and decreases in principal actuarial assumptions by 0.5 percentage points would affect the pension liability at December 31, 2025 as follows:

---

| | | |
|:---|:---|:---|
| **Sensitivity analysis** | **Sensitivity analysis** | **Sensitivity analysis** |
| *in € K* | *in € K* | *in € K* |
|  | **0.5% increase** | **0.5% decrease** |
| Discount rate | (54284) | 61260 |
| Rate of compensation increase | 7985 | (7825) |
| Rate of pension increase | 31332 | (28619) |

---

An increase of the mortality rate of 10% would reduce the pension liability by €18,686, while a decrease of 10% would increase the pension liability by €20,864 as of December 31, 2025.

The sensitivity analysis was calculated based on the average duration of the pension obligations determined at December 31, 2025. The calculations were performed isolated for each significant actuarial parameter, in order to show the effect on the fair value of the pension liability separately.

The sensitivity analysis for compensation increases and for pension increases excludes the U.S. pension plan because it is frozen and therefore is not affected by changes from these two actuarial assumptions.

The defined benefit pension plans' net periodic benefit costs are comprised of the following components for the years ended December 31, 2025, 2024 and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Components of net periodic benefit cost** | **Components of net periodic benefit cost** | **Components of net periodic benefit cost** | **Components of net periodic benefit cost** |
| *in € K* | *in € K* | *in € K* | *in € K* |
|  | **2025** | **2024** | **2023** |
| Service cost | 23755 | 28748 | 32399 |
| Net interest cost | 24845 | 24135 | 23721 |
| Prior service cost | (1678) | (481) | (538) |
| (Gains) losses from settlements | 216 |  |  |
| **Net periodic benefit costs** | **47138** | **52402** | **55582** |

---

Service cost and net interest cost are allocated as personnel expense within costs of revenues, selling, general and administrative expense, or R&D expense depending upon the area in which the beneficiary is employed. The gain from settlement is included in selling, general and administrative expense.

The following weighted-average assumptions were used in determining net periodic benefit cost for the years ended December 31, 2025, 2024, and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Weighted average assumptions**  | **Weighted average assumptions**  | **Weighted average assumptions**  | **Weighted average assumptions**  |
| *in %* | *in %* | *in %* | *in %* |
|  | **2025** | **2024** | **2023** |
| Discount rate | 4.39 | 4.22 | 4.86 |
| Rate of compensation increase | 3.18 | 3.18 | 3.22 |
| Rate of pension increase | 2.00 | 2.00 | 2.00 |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Expected benefit payments are as follows:

---

| | | |
|:---|:---|:---|
| **Defined benefit pension plans: cash outflows** | **Defined benefit pension plans: cash outflows** | **Defined benefit pension plans: cash outflows** |
| *in € K* | *in € K* | *in € K* |
|  | **2025** | **2024** |
| 1 year | 37456 | 37074 |
| 1 - 3 years | 79346 | 82307 |
| 3 - 5 years | 85408 | 90462 |
| 5 - 10 years | 234397 | 249343 |
| **Total** | **436607** | **459186** |

---

***Plan Assets***

The following table presents the fair values of the Company´s pension plan assets at December 31, 2025 and 2024:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Fair values of plan assets** | **Fair values of plan assets** | **Fair values of plan assets** | **Fair values of plan assets** | **Fair values of plan assets** | **Fair values of plan assets** | **Fair values of plan assets** | **Fair values of plan assets** | **Fair values of plan assets** |
| *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* |
|  |  | **Quoted prices** |  |  |  | **Quoted prices** |  |  |
|  |  | **in active** |  |  |  | **in active** |  |  |
|  |  | **markets for** | **Significant** | **Significant** |  | **markets for** | **Significant** | **Significant** |
|  |  | **identical** | **observable** | **unobservable** |  | **identical** | **observable** | **unobservable** |
| **Asset category** | **Total** | **assets** | **inputs** | **inputs** | **Total** | **assets** | **inputs** | **inputs** |
|  |  | **(Level 1)** | **(Level 2)** | **(Level 3)** |  | **(Level 1)** | **(Level 2)** | **(Level 3)** |
|  |  | **2025** | **2025** | **2025** |  | **2024** | **2024** | **2024** |
| **Equity investments** |  |  |  |  |  |  |  |  |
| Index funds<sup>(1)</sup> |  |  |  |  | 73272 | 9570 | 63702 |  |
| **Fixed income investments** |  |  |  |  |  |  |  |  |
| Government securities<sup>(2)</sup> |  |  |  |  | 190 | 19 | 171 |  |
| Corporate bonds<sup>(3)</sup> |  |  |  |  | 171860 |  | 171860 |  |
| Other bonds<sup>(4)</sup> |  |  |  |  | 6668 |  | 331 | 6337 |
| U.S. treasury money market funds<sup>(5)</sup> | 60741 | 60741 |  |  | 3619 | 3619 |  |  |
| **Other types of investments** |  |  |  |  |  |  |  |  |
| Cash, money market and mutual funds<sup>(6)</sup> | 73 | 73 |  |  | 4223 | 86 | 4137 |  |
| Annuity buy-in contract<sup>(7)</sup> | 202793 |  |  | 202793 |  |  |  |  |
| **Total** | **263607** | **60814** | **—** | **202793** | **259832** | **13294** | **240201** | **6337** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) This category comprises low-cost equity index funds not actively managed that track the S&P 500, S&P 400, Russell 2000, MSCI Emerging Markets Index, and the MSCI EAFE Index.

&nbsp;&nbsp;&nbsp;&nbsp;(2) This category comprises fixed income investments by the U.S. government and government sponsored entities.

&nbsp;&nbsp;&nbsp;&nbsp;(3) This category primarily represents investment grade bonds of U.S. issuers from diverse industries.

&nbsp;&nbsp;&nbsp;&nbsp;(4) This category comprises private placement bonds as well as collateralized mortgage obligations.

&nbsp;&nbsp;&nbsp;&nbsp;(5) This category represents funds that invest in U.S. treasury obligations directly or in U.S. treasury backed obligations.

&nbsp;&nbsp;&nbsp;&nbsp;(6) This category represents cash, money market funds, and mutual funds comprised of high grade corporate bonds.

&nbsp;&nbsp;&nbsp;&nbsp;(7) This category comprises an annuity buy-in insurance contract.

The methods and inputs used to measure the fair value of plan assets at the balance sheet date are as follows:

● Common stocks are valued at their market prices.

● Index funds are valued based on market quotes.

● Government bonds are valued based on both market prices and market quotes.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

● Corporate bonds and other bonds are valued based on market quotes.

● Cash is stated at nominal value which equals the fair value.

● U.S. Treasury money market funds as well as other money market and mutual funds are valued at their market price.

● The fair value of the annuity buy-in contract is deemed equivalent to the total accumulated benefit obligation as the future plan obligation payments will be covered by the annuity contract.

***Plan investment policy and strategy in the U.S.***

The Company periodically reviews the assumptions for long-term expected return on pension plan assets. As part of the assumptions review, a range of reasonable expected investment returns for the pension plan as a whole was determined based on an analysis of expected future returns for each asset class weighted by the allocation of the assets. The range of returns developed relies both on forecasts, which include the actuarial firm's expected long-term rates of return for each significant asset class or economic indicator, and on broad-market historical benchmarks for expected return, correlation, and volatility for each asset class.

Historically, the Company´s overall investment strategy is to achieve a mix of approximately 99% of investments for long-term growth and income and 1% in cash or cash equivalents. Investment income and cash or cash equivalents are used for near-term benefit payments. Investments are governed by the plan investment policy and include well diversified index funds or funds targeting index performance. The total portfolio will be measured against a custom index that reflects the asset class benchmarks and the target asset allocation. The plan investment policy does not allow investments in securities of the Company or other related party securities.

As of December 31, 2025, the plan assets were held in cash and cash equivalents in the amount of €60,741 and an annuity buy-in policy in the amount of €202,793 was recorded. Historically, the plan assets have been spread across fixed income and equity investments, however at year end these assets were liquidated into cash and cash equivalents to affect the above discussed buy-in transaction and the Puerto Rico retirement plan spin-off. Once the final allocation of assets to the Puerto Rico retirement plan is determined, the investment asset allocation for that specific pool of assets will be determined and implemented.

***Defined contribution plans***

Most FMCH employees are eligible to join a 401(k) savings plan. Employees can deposit up to 75% of their pay up to a maximum of $23.5 (€20.8) if under 50 years old ($31.0 (€27.4) if 50 or over) under this savings plan. The Company will match 50% of the employee deposit up to a maximum Company contribution of 3% of the employee's pay. The Company's total expense under this defined contribution plan for the years ended December 31, 2025, 2024, and 2023, was €72,473, €76,552, and €71,750 respectively.

Additionally, the Company contributed for the years ended December 31, 2025, 2024, and 2023 €33,330, €31,072, and €29,787 to state pension plans.

**20.** **Shareholders' equity** 

***Capital stock***

At December 31, 2025, the Company's share capital consists of 293,413,449 bearer ordinary shares without par value (*Stückaktien*) and a nominal value of €1.00 each. The Company's share capital has been fully paid in.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Pursuant to Sections 33 and 34 of the German Securities Trading Act (WpHG) any party subject to the notification requirement shall notify the Company when certain mandatory reportable thresholds for voting rights, also by taking into account attribution provisions, are reached, exceeded or fallen below. Section 38 WpHG also stipulates a notification requirement when certain thresholds are reached, exceeded or have fallen below through directly or indirectly held instruments and Section 39 WpHG also stipulates a notification requirement when certain thresholds are reached, exceeded or have fallen below through the addition of voting rights according to Section 33 WpHG and instruments according to Section 38 WpHG. Notifications received by the Company subject to the notification requirements were published in accordance with the applicable legal provisions, as well as posted in the Investors section of the Company's website.

At December 31, 2025, Fresenius SE held 27.8% of the Company's issued shares and voting rights.

On March 7, 2025, Else Kröner-Fresenius-Stiftung, Bad Homburg v.d.Höhe, Germany, with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 28.55% of the voting rights of the Company were held as of March 4, 2025.

On January 21, 2026, BlackRock, Inc., Wilmington, Delaware, U.S., with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 4.74% of the voting rights of the Company and pursuant to Section 38 of the WpHG that instruments relating to 0.34% of the voting rights of the Company were held as of January 16, 2026.

On August 22, 2025, Artisan Partners Asset Management Inc., Wilmington, Delaware, U.S., with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 2.99% of the voting rights of the Company were held as of August 19, 2025.

On July 9, 2025, Dodge & Cox International, San Francisco, California, U.S., disclosed pursuant to Section 33 of the WpHG that 4.98% of the voting rights of the Company were held as of July 3, 2025. According to an amended Schedule 13G filed with the SEC on February 13, 2024, Dodge & Cox, an investment adviser registered under the U.S. Investment Advisers Act of 1940, is the beneficial owner of 7.4% of the Company's shares. The Schedule 13G states that Dodge & Cox has sole voting power and sole dispositive power over such shares, and that clients of Dodge & Cox, including investment companies registered under the U.S. Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, such shares.

On April 16, 2025, Harris Associates L.P., Wilmington, Delaware, U.S., with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 2.98% of the voting rights of the Company were held as of April 14, 2025.

On February 28, 2025, Dodge & Cox International Stock Fund, San Francisco, California, U.S., disclosed pursuant to Section 33 of the WpHG that 5.00% of the voting rights of the Company were held as of February 24, 2025.

On January 7, 2025, Harris Associates Investment Trust, Boston, Massachusetts, U.S., disclosed pursuant to Section 33 of the WpHG that 3.00% of the voting rights of the Company were held as of January 3, 2025.

On October 28, 2022, Richard Pzena, with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 5.20% of the voting rights of the Company were held as of October 24, 2022.

The general meeting of the Company may approve Authorized Capital (*genehmigtes Kapital*). The resolution creating Authorized Capital requires the affirmative vote of a majority of three quarters of the capital represented at the vote and may authorize the Management Board to issue new shares up to a stated amount for a period of up to five years. The nominal value of any proposed increase of the Authorized Capital may not exceed half of the issued capital stock at the time of the authorization.

In addition, the general meeting of the Company may create Conditional Capital (*bedingtes Kapital*) for the purpose of issuing (i) new shares to holders of convertible bonds or other securities which grant a right to shares, (ii) new shares as the consideration in a merger with another company, or (iii) new shares offered to management or employees. In each case, the authorizing resolution requires the affirmative vote of a majority of three quarters of the capital represented at the vote. The nominal value for any Conditional Capital may not exceed 60% of the Company's issued capital at the time of the resolution. The nominal value for any Conditional Capital created for the purpose of issuing new shares to holders of convertible bonds or other securities which grant a right to shares may not exceed 50% of the Company's issued capital at the time of the resolution. The nominal value for any Conditional Capital created for the purpose of issuing shares to management and employees may not exceed 20% of the Company's issued capital at the time of the resolution.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

***Authorized capital***

By resolution of the Company's AGM on May 22, 2025, the Management Board is authorized until May 21, 2030, to increase the share capital of the Company with the approval of the Supervisory Board by up to €60,000 for cash and/or contributions in kind by issuing new bearer shares with no-par value on one or more occasions (Authorized Capital 2025). The number of shares must be increased in the same proportion as the share capital. The new shares shall participate in the profits from the start of the fiscal year in which they are issued. In deviation therefrom and to the extent legally permissible, the Management Board may stipulate with the approval of the Supervisory Board that the new shares will participate in profits as of the beginning of a fiscal year that has already ended and for which no resolution on the allocation of distributable profit has been passed by the general meeting at the time of their issue. In general, the shareholders have a subscription right. The new shares can also be obtained by a credit institution, a securities institution or a company operating in accordance with sec. 53 (1) sentence 1 of the German Banking Act (*Kreditwesengesetz* – KWG) or sec. 53b (1) sentence 1 or (7) KWG (financial institution) or a consortium of such credit institutions, securities institutions and/or financial institutions retained by the Management Board with the obligation to offer the shares to the Company's shareholders for subscription.

However, the Management Board is authorized with the approval of the Supervisory Board to exclude the shareholders' subscription rights in particular in the following cases:

● to eliminate fractional amounts from the subscription right;

● to grant subscription rights, as a compensation for dilutive effects, to the holders or creditors of option or conversion rights to shares of the Company or those liable under the corresponding option or conversion obligations arising from bonds issued or guaranteed by the Company or its group companies to the extent to which they would be entitled after exercising these option or conversion rights or fulfillment of these option or conversion obligations;

● in the case of one or more capital increases for contributions in kind for the purpose of acquiring companies, parts of companies, interests in companies or other assets; or

● in the case of one or more capital increases for cash if the issue price for the shares does not significantly fall below the stock exchange price of the shares already listed and the proportionate amount of the share capital of the Company attributable to the shares issued with exclusion of subscription rights exceeds 10 % of the share capital neither at the time of this authorization coming into effect nor at the time of the exercise of this authorization. This limit shall include the proportionate amount of share capital attributable to new shares or treasury shares previously acquired by the Company which are issued or sold during the period of validity of this authorization with exclusion of subscription rights in direct, analogous or corresponding application of sec. 186 (3) sentence 4 AktG as well as the proportionate amount of the share capital attributable to shares issued or to be issued to satisfy option or conversion rights or to fulfil option or conversion obligations from bonds, if the bonds are issued during the period of validity of this authorization with exclusion of subscription rights in analogous application of sec. 186 (3) sentence 4 AktG.

The Management Board may only exercise the aforementioned authorization to exclude subscription rights to the extent that the proportional amount of the total shares issued subject to an exclusion of subscription rights exceeds 10% of the share capital neither at the time of this authorization coming into effect nor at the time of the exercise of this authorization. In case that during the period of validity of the Authorized Capital 2025 until its utilization, other authorizations on the issuance or on the sale of shares of the Company or the issuance of rights which authorize or bind to the subscription of shares of the Company are exercised and the subscription rights are excluded, such subscription rights will be taken into account with regard to the aforementioned limit.

The Management Board is further authorized to determine with the approval of the Supervisory Board the further details for the implementation of capital increases from the Authorized Capital 2025. The Supervisory Board is authorized to amend the wording of the corresponding provisions of the Articles of Association after a total or partial implementation of the increase of the share capital from the Authorized Capital 2025 in accordance with the volume of such capital increase and, if the Authorized Capital 2025 has not been used or not fully used by May 21, 2030, after the expiry of the authorization.

No Authorized Capital 2025 has been issued at December 31, 2025.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

***Conditional capital***

By resolution of the Company's AGM on May 22, 2025, the share capital of the Company is conditionally increased by up to €29,341 through issuing up to 29,341,344 bearer shares with no-par value (Conditional Capital 2025). The conditional capital increase will only be implemented to the extent that the holders of convertible bonds issued for cash or of warrants from option bonds issued for cash by the Company or a group company until May 21, 2030, on the basis of the authorization granted to the Management Board by the AGM of May 22, 2025, exercise their option or conversion rights or fulfill a possible conversion obligation and as long as no other forms of settlement are used. The new shares shall participate in the profits from the start of the fiscal year in which they are issued. In deviation therefrom and to the extent legally permissible, the Management Board may stipulate with the approval of the Supervisory Board that the new shares will participate in profits as of the beginning of a fiscal year that has already ended and for which no resolution on the allocation of distributable profit has been passed by the General Meeting at the time of their issue.

The Management Board is authorized to determine the further details regarding the implementation of the conditional capital increase. The Supervisory Board is authorized to amend the version of Article 4 (4) of the Articles of Association in accordance with the utilization of the Conditional Capital 2025 from time to time. The same applies if the authorization to issue option or convertible bonds is not exercised by the end of the authorization period and if the Conditional Capital 2025 is not utilized by the expiry of all option and conversion periods.

The authorization to issue convertible bonds or options bonds has not been used at December 31, 2025. No shares have been issued from the Conditional Capital 2025 at December 31, 2025.

***Treasury stock***

By resolution of the Company's AGM on May 20, 2021, amended by the Company's EGM on July 14, 2023 in its wording with respect to the Company's change of legal form, the Management Board is authorized until May 19, 2026 to purchase treasury shares up to a maximum amount of 10% of the registered share capital existing at the time of this resolution (€29,289). The shares acquired, together with other treasury shares held by the Company or attributable to the Company pursuant to sections 71a et seqq. AktG, must at no time exceed 10% of the registered share capital. Purchases may be made through the stock exchange, by way of a public tender offer, or a public invitation to shareholders to submit an offer for sale. This authorization may not be used for the purpose of trading in treasury shares. The Management Board is authorized to use treasury shares purchased on the basis of this authorization or any other earlier authorization for any legally permissible purpose, in particular (i) to redeem shares without requiring any further resolution by the general meeting, (ii) to sell treasury shares to third parties against contributions in kind, (iii) to award treasury shares, in lieu of the utilization of conditional capital of the Company, to employees of the Company and companies affiliated with the Company, including members of the management of affiliated companies, and use them to service options or obligations to purchase shares of the Company and (iv) to use treasury shares to service bonds carrying warrant and/or conversion rights or conversion obligations issued by the Company or companies affiliated with the Company pursuant to section 17 AktG.

On the basis of this authorization, the Company launched its €1,000,000 share buyback program (excluding ancillary transaction costs) in two tranches to be completed within two years by August 10, 2027. Under the first tranche, shares were to be acquired up to a maximum of €600,000 including any true-ups over a period ending latest April 30, 2026. The first tranche was initiated on August 11, 2025 and completed ahead of schedule on December 29, 2025 with a €1,165 liability remaining related to the final true - up of share repurchases. For further discussion regarding the Company's announcement in January 2026 of its second tranche, see note 30. As of December 31, 2025, the Company holds 14,124,564 treasury shares. These shares will be used predominantly to reduce the registered share capital of the Company by cancellation of the acquired shares and, to a significantly lesser extent, may be used for allocations under incentive-based compensation plans.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The following tabular disclosure provides the number of shares acquired in the context of the share buyback program:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Treasury Stock** | | | | |
| <br>**Period** | <br>**Total number of**<br>**shares purchased** | <br>**Average price per**<br>**share** | <br>**Total number of**<br>**shares purchased**<br>**and retired**<br>**as part of publicly**<br>**announced plans or**<br>**programs** | <br>**Maximum value of**<br>**shares that may yet**<br>**be purchased under**<br>**the plans or**<br>**programs** |
|  |  | in € |  | in € K |
| August 2025 | 2084733 | 42.68 | 2084733 | 511021 |
| September 2025 | 1479790 | 42.45 | 1479790 | 448210 |
| October 2025 | 788260 | 46.38 | 788260 | 411651 |
| November 2025 | 4164232 | 41.10 | 4164232 | 240485 |
| December 2025 | 5607549 | 40.26 | 5607549 |  |
| **Total repurchased Treasury Stock** | **14124564** | **41.44** | **14124564** | **—** |

---

**Additional paid-in capital** 

Additional paid-in capital is comprised of the premium paid on the issue of shares and stock options, the tax effects from stock options, the compensation expense from stock options and other equity-settled share-based compensation components, which is recognized according to IFRS 2, as well as changes in ownership interest in a subsidiary that do not result in a loss of control. Additional paid in capital decreased primarily as a result of transactions with noncontrolling interests in the United States.

**Retained earnings**

Retained earnings is comprised mainly of earnings generated by group entities in prior years, to the extent that they have not been distributed, as well as changes of put option liabilities.

**Dividends**

Under German law, the amount of dividends available for distribution to shareholders is based upon the unconsolidated balance sheet profit (*Bilanzgewinn*) of the Company as reported in its balance sheet determined in accordance with the German Commercial Code (*Handelsgesetzbuch*).

Cash dividends of €422,515 for 2024 in the amount of €1.44 per share entitled to a dividend were paid on May 27, 2025.

Cash dividends of €349,162 for 2023 in the amount of €1.19 per share entitled to a dividend were paid on May 22, 2024.

Cash dividends of €328,623 for 2022 in the amount of €1.12 per share entitled to a dividend were paid on May 22, 2023.

At the Company's AGM scheduled to be held on May 21, 2026, the Company's Management Board and Supervisory Board intend to propose to the shareholders a dividend of €1.49 per share entitled to a dividend for 2025, payable in 2026. The total expected dividend payment is approximately €416,140 based on shares outstanding as of December 31, 2025. This amount considers the 14,124,564 treasury shares held by the Company as of December 31, 2025, which are not entitled to dividends.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**Noncontrolling interests** 

Noncontrolling interests represent the proportion of the net assets of consolidated subsidiaries owned by minority shareholders. The Company has purchase obligations under put options held by the holders of noncontrolling interests in certain of its subsidiaries. These obligations result from contractual put options and are exercisable by the owners of the noncontrolling interests. In addition to noncontrolling interests, the related potential obligations under these put options are reclassified from equity of the Company, with no impact to the income statement, and recognized as a put option liability at the present value of the exercise price of the options in other current or non-current liabilities. Accumulated other comprehensive income allocated to noncontrolling interests mainly relates to currency effects from the translation of foreign operations.

For information regarding the settlement of put options held by non-physician investors originally granted as part of the 2022 merger of Cricket Health, Interwell Health LLC and Fresenius Health Partners, Inc., and its impact on additional paid-in capital, retained earnings and noncontrolling interests, see note 26.

**21.**Capital management

The principle objectives of the Company's capital management strategy are to optimize the weighted average cost of capital and to achieve a balanced mix of total equity and debt. The dialysis industry, in which the Company has a strong market position in global, growing, and largely non-cyclical markets, is characterized by recurring cash flows. Due to the Company's payors' mostly high credit quality, it is able to generate high, stable, predictable, and sustainable cash flows. These generated cash flows allow a reasonable proportion of debt. As of December 31, 2025 and December 31, 2024, total equity and debt were as follows:

---

| | | |
|:---|:---|:---|
| **Total equity, debt and total assets** | **Total equity, debt and total assets** | **Total equity, debt and total assets** |
| *in € K* |  |  |
|  | **2025** | **2024** |
| &nbsp;&nbsp;Total equity including noncontrolling interests | 14282809 | 15768513 |
| &nbsp;&nbsp;Debt and lease liabilities (including amounts directly associated with assets held for sale) | 10795605 | 10988807 |
| &nbsp;&nbsp;Total assets  | 31002333 | 33566579 |
| &nbsp;&nbsp;Debt and lease liabilities in % of total assets | 34.8 | 32.7 |
| &nbsp;&nbsp;Total equity in % of total assets (equity ratio) | 46.1 | 47.0 |

---

The Company is not subject to any capital requirements provided for in its Articles of Association.

The Company conducts a share buyback program. These shares will be used predominantly to reduce the registered share capital of the Company by cancellation of the acquired shares and, to a significantly lesser extent, may be used for allocations under incentive-based compensation plans (see note 20).

The Company's financing strategy aims at ensuring financial flexibility, managing financial risks, and optimizing financing costs. Financial flexibility is ensured through maintaining sufficient liquidity. Refinancing risks are limited due to the Company's balanced maturity profile, which is characterized by a wide range of maturities of up to 2032. When deciding upon the use of available financing instruments, market capacity, investor diversification, financing conditions, and the existing maturity profile are taken into account (see note 17).

The Company's financing structure and business model are reflected in its credit ratings. The Company is rated investment grade by S&P Global, Moody's and Fitch. The Company's current corporate credit ratings and outlooks from the credit rating agencies are provided in the table below:

---

| | | | |
|:---|:---|:---|:---|
| **Rating** <sup>(1)</sup> | **Rating** <sup>(1)</sup> | **Rating** <sup>(1)</sup> | **Rating** <sup>(1)</sup> |
|  | **S&P Global** | **Moody's** | **Fitch**  |
| Corporate credit rating  | BBB- | Baa3 | BBB- |
| Outlook  | stable | stable | stable |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) A rating is not a recommendation to buy, sell or hold securities of the Company, and may be subject to suspension, change or withdrawal at any time by the assigning rating agency.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**22.** **Earnings per share**

The following table contains reconciliations of the numerators and denominators of the basic and diluted earnings per share computations for 2025, 2024, and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Reconciliation of basic and diluted earnings per share** | **Reconciliation of basic and diluted earnings per share** | **Reconciliation of basic and diluted earnings per share** | **Reconciliation of basic and diluted earnings per share** |
| *in € K, except share and per share data* |  |  |  |
|  | **2025** | **2024** | **2023** |
| **Numerator:** |  |  |  |
| Net income attributable to shareholders of FME AG | 978367 | 537913 | 498997 |
| **Denominators:** |  |  |  |
| Weighted average number of shares outstanding | 291190575 | 293413449 | 293413449 |
| Potentially dilutive shares (see note 23) |  |  |  |
| Basic earnings per share | 3.36 | 1.83 | 1.70 |
| Diluted earnings per share | 3.36 | 1.83 | 1.70 |

---

**23.**Share-based plans

***General information on the Company's long-term incentive plans (performance shares)***

The Company accounts for its share-based plans in accordance with IFRS 2 and has, as of December 31, 2025, various share-based compensation plans, which may either be equity- or cash-settled. These plans enable the members of the Management Board and managerial staff members to adequately participate in the long-term, sustained success of the Company. The following table provides an overview of the Company's plans which are, or were, each variable compensation programs with long-term incentive effects which allocate or allocated performance shares, which are non-equity virtual compensation instruments subject to the fulfillment of a service condition and to the attainment of pre-defined performance targets (Performance Shares):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**Fresenius Medical**<br>**Care Long-Term**<br>**Incentive Plan**<br>**2025+ (LTIP 2025+)** | **Fresenius Medical**<br>**Care Management**<br>**Board Long-Term**<br>**Incentive Plan**<br>**2024+ (MB LTIP 2024+)** | <br>**Fresenius Medical**<br>**Care Long-Term**<br>**Incentive Plan**<br>**2024+ (LTIP 2024+)** | <br>**Fresenius Medical**<br>**Care Long Term**<br>**Incentive Plan**<br>**2022+ (LTIP 2022+)** | **Fresenius Medical**<br>**Care Management**<br>**Board Long Term**<br>**Incentive Plan**<br>**2020 (MB LTIP 2020)** | <br>**Fresenius Medical**<br>**Care Long Term**<br>**Incentive Plan**<br>**2019 (LTIP 2019)** | **Fresenius Medical**<br>**Care Management**<br>**Board Long Term**<br>**Incentive Plan**<br>**2019 (MB LTIP 2019)** |
| **Eligible persons** | Managerial staff members | Members of the Management Board <sup>(1)</sup> | Managerial staff members | Managerial staff members | Members of the Management Board <sup>(1)</sup> | Managerial staff members | Members of the Management Board <sup>(1)</sup> |
| **Years in which an allocation occurred** | 2025 | 2024, 2025 | 2024 | 2022, 2023 | 2020–2023 | 2019–2021 | 2019 |
| **Months in which an allocation occurred** | July, December | March (2024, 2025), June (2024) | July, December | July, December | November (2020), March (2021–2023), October (2022, 2023) | July, December | July, December |
| **Type of settlement** | Equity or cash (determined prior to the respective allocation date) | Equity or cash (determined prior to the respective allocation date) | In cash | In cash | In cash | In cash | In cash |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Also includes former members of the management board of the General Partner.

Under the LTIP 2025+ and under the MB LTIP 2024+, the Management Board (for the LTIP 2025+) or the Supervisory Board (for the MB LTIP 2024+), prior to an allocation, may determine whether the Performance Shares of an allocation are settled in shares of the Company or in cash. The other plans are always settled in cash. For all allocations that are settled in cash, the cash amount depends on the Company's share price development throughout the respective vesting period. The final cash payments under the MB LTIP 2019 took place in 2023 and the final cash payments under the LTIP 2019 took place in 2024.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

For members of the Management Board, the respective allocation value is determined by the Supervisory Board. For managerial staff members, the determination of the allocation value will be made by the Management Board, taking into account the individual responsibilities of each plan participant. In order to determine the number of Performance Shares that each plan participant receives, the allocation value is divided by the value per Performance Share at the time of the allocation, which in turn is determined based on the Company's average share price over a period of thirty calendar days prior to the respective allocation date and assuming a 100% target achievement for the performance target total shareholder return (TSR) compared to competitors (Relative TSR) which is described below.

During 2025, the Company allocated 230,873 Performance Shares under the MB LTIP 2024+ at a weighted average grant date fair value of €37.09 each and a total grant date fair value of €8,562, reflecting all market conditions such as the projected target achievement for the Relative TSR target at the measurement date. The Supervisory Board decided to settle the Performance Shares allocated in 2025 in shares of the Company. As such, the Company accounts for these allocations as an equity-settled share-based payment transaction. The total fair value will be amortized over the vesting period.

During 2025, the Company allocated 1,391,945 Performance Shares under the LTIP 2025+. Depending on the country of their employment relationship, some of these participants received an allocation that will be settled in shares of the Company and some plan participants received an allocation that will be settled in cash. As such, the Company accounts for allocations to the first group of participants (1,259,234 Performance Shares with a weighted average grant date fair value of €40.87 each and a total fair value of €51,464) as an equity-settled share-based payment transaction and for allocations to the second group of participants (132,711 Performance Shares with a weighted average fair value at December 31, 2025, of €35.59 each and a total fair value of €4,723) as a cash-settled share-based payment transaction. The total fair value will be amortized over the vesting period and reflects all market conditions such as the projected target achievement for the Relative TSR target at the grant date or the respective measurement date; for participants who received an allocation that will be settled in cash, the amount will be revalued for changes in fair value.

For allocations made in fiscal year 2025, the Company utilizes a Monte Carlo model to determine the grant date fair values. For the Relative TSR target, the share prices of all shares within the European and U.S. peer groups are simulated, considering historical volatilities and correlations between the different shares as well as risk-free interest rates derived from interest curves for sovereign bonds, depending on the currency for which the respective shares are listed. Additional input factors include the Company's closing share price as of the grant date, expected dividends and the 400% overall cap which is described further below. Material input factors are included in the following table:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Material input factors to the determination of the weighted average grant date fair value for allocations during 2025** | **Material input factors to the determination of the weighted average grant date fair value for allocations during 2025** | **Material input factors to the determination of the weighted average grant date fair value for allocations during 2025** | **Material input factors to the determination of the weighted average grant date fair value for allocations during 2025** | **Material input factors to the determination of the weighted average grant date fair value for allocations during 2025** | **Material input factors to the determination of the weighted average grant date fair value for allocations during 2025** | **Material input factors to the determination of the weighted average grant date fair value for allocations during 2025** |
|  | **LTIP 2025+** | **LTIP 2025+** | **LTIP 2025+** | **LTIP 2025+** | **MB LTIP 2024+** | **MB LTIP 2024+** |
| Allocation date | **July 28, 2025** | **July 28, 2025** | **December 1, 2025** | **December 1, 2025** | **March 1, 2025** | **March 1, 2025** |
| Share price at grant date | € | 44.75 | € | 40.71 | € | 45.00 |
| Expected volatility of the Company's share price |  | 32.75% |  | 31.99% |  | 31.78% |
| Vesting period | Three years | Three years | Three years | Three years |  | Four years |
| Expected dividends for the Company's shares | Based on proposed dividends, publicly available estimations by financial institutions and projections | Based on proposed dividends, publicly available estimations by financial institutions and projections | Based on proposed dividends, publicly available estimations by financial institutions and projections | Based on proposed dividends, publicly available estimations by financial institutions and projections | Based on proposed dividends, publicly available estimations by financial institutions and projections | Based on proposed dividends, publicly available estimations by financial institutions and projections |
| Risk-free interest rate for the Company's share price |  | 1.97% |  | 2.10% |  | 2.24% |

---

For all allocations made in fiscal year 2025, the number of allocated Performance Shares may change over the performance period, which commenced on January 1, 2025 and will end on December 31, 2027, depending on the degree of achievement of the performance targets.

During 2024, the Company allocated 304,043 Performance Shares under the MB LTIP 2024+ at a weighted average fair value at December 31, 2024, of €45.52 each and a total fair value of €13,840, which will be revalued if the fair value changes. The total fair value will be amortized over the vesting period.

During 2024, the Company allocated 1,908,038 Performance Shares under the LTIP 2024+ at a weighted average fair value at December 31, 2024, of €46.56 each and a total fair value of €88,838, which will be revalued if the fair value changes. The total fair value will be amortized over the vesting period.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

During 2023, the Company allocated 283,624 Performance Shares under the MB LTIP 2020 at a weighted average fair value at December 31, 2023, of €35.84 each and a total fair value of €10,165, which will be revalued if the fair value changes. The total fair value will be amortized over the vesting period.

During 2023, the Company allocated 1,460,049 Performance Shares under the LTIP 2022+ at a weighted average fair value at December 31, 2023, of €34.64 each and a total fair value of €50,576, which will be revalued if the fair value changes. The total fair value will be amortized over the vesting period.

***The Company's long-term incentive plans during 2025 (Performance Shares)***

The Supervisory Board has approved and adopted the MB LTIP 2024+ effective January 1, 2024, for members of the Management Board. For managerial staff members, the Management Board has approved and adopted the LTIP 2025+ effective January 1, 2025.

For allocations made in fiscal year 2025, the performance targets are as follows: (i) return on invested capital (ROIC), (ii) Relative TSR and (iii) reduction in market-based CO<sub>2</sub> equivalents emissions (CO<sub>2</sub>e Reduction). For all three performance targets, target achievement corridors which will be used for the calculation of the respective target achievements were defined. These corridors were defined by the Supervisory Board for the MB LTIP 2024+ and by the Management Board for the LTIP 2025+. The corridors are identical for both plans.

For allocations made in fiscal year 2025, the ROIC target is measured on the basis of the average of the three annual ROIC figures during the performance period. The ROIC metric is not audited, however, this metric is derived from the Company's consolidated financial statements prepared in accordance with IFRS Accounting Standards, adjusted to apply the respective plan conditions. The ROIC performance target is weighted with 40% within the calculation of the degree of overall target achievement.

For allocations made in fiscal year 2025, the performance target Relative TSR is measured on the basis of the TSR compared to European and U.S. peer groups. For each of the peer groups, the target achievement is determined using the percentile ranking method. For this purpose, the TSR values of the peer companies within the respective comparison groups over the performance period are ranked and the relative positioning of the Company within the respective comparison group is determined on the basis of the percentile achieved. The target achievement within the respective peer group is weighted equally when determining the target achievement for the performance target Relative TSR, which is weighted with 40% within the calculation of the degree of overall target achievement.

For allocations made in fiscal year 2025, the achievement of the sustainability performance target CO<sub>2</sub>e Reduction is based on the Company's sustainability statement,and is measured by the reduction of market-based emissions in CO<sub>2</sub> equivalents in comparison to the base year 2020. This reduction is expressed in percent. The CO<sub>2</sub>e Reduction performance target has a weight of 20% within the calculation of the degree of overall target achievement. The applicable target achievement of the CO<sub>2</sub>e Reduction performance target is calculated based on the average annual achievement in CO<sub>2</sub>e Reductions. For this purpose, each annual target achievement is weighted equally (1/3 each).

Neither the individual target achievements nor the overall target achievements will exceed 200%. The number of Performance Shares allocated at the beginning of the performance period to the plan participants is multiplied with the degree of overall target achievement to determine the final number of Performance Shares.

Under the MB LTIP 2024+, the final number of Performance Shares generally vests four years after the respective allocation date. Several payout conditions, such as the continuation of the service relationship (with exceptions, e.g., in the event of occupational disability or retirement), apply. The performance shares proceeds, for which allocations made in 2025 will be settled in shares of the Company, are capped at 400% of the respective allocation value and can be reduced to meet the respective maximum compensation of the participant.

For allocations made in fiscal year 2025 under the LTIP 2025+, the final number of Performance Shares generally vests three years after the respective allocation date. Several payout conditions, such as the continuation of the employment or service relationship (with exceptions, e.g., in the event of occupational disability or retirement), apply. The performance shares proceeds, which will either be settled in shares of the Company or paid out as cash compensation (cash amount depends on the average share price of the Company during a period of 30 days prior to the end of the vesting period), are capped at 400% of the respective allocation value.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

***The Company's long-term incentive plans during 2019–2024 (Performance Shares)***

For allocations made in 2024 under the MB LTIP 2024+ and under the LTIP 2024+, the performance targets and their weightings are aligned with those for allocations made in fiscal year 2025 under the MB LTIP 2024+ and under the LTIP 2025+. The performance period commenced on January 1, 2024 and will end on December 31, 2026. For all three performance targets, target achievement corridors which will be used for the calculation of the respective target achievements were defined. These corridors were defined by the Supervisory Board for the MB LTIP 2024+ and by the Management Board for the LTIP 2024+. The corridors are identical for both plans.

For allocations made until 2023, the performance targets are as follows: (i) revenue growth at constant currency (Revenue Growth), (ii) net income growth at constant currency (Net Income Growth) and (iii) ROIC.

Revenue Growth, Net Income Growth, and ROIC are not audited, however, these metrics are derived from the Company's consolidated financial statements prepared in accordance with IFRS Accounting Standards, adjusted to apply the respective plan conditions.

For Performance Shares allocated in years 2022 and 2023 under the LTIP 2022+ and under the MB LTIP 2020, the target achievements of the performance targets Revenue Growth and Net Income Growth are calculated based on a Compound Annual Growth Rate (CAGR) over the 3-year performance period. For ROIC, annual target values apply. For all three performance targets, target achievement corridors which are used for the calculation of the respective target achievements were defined.

For Performance Shares allocated in years 2022 and 2023 under the LTIP 2022+ and under the MB LTIP 2020, the degree of target achievement for all three performance targets is weighted with 1/3 for the purpose of determining the overall target achievement at the end of the performance period. The relevant target achievement for Revenue Growth and Net Income Growth is determined based on the CAGR over the entire performance period. The relevant target achievement for the ROIC target is determined based on the average annual target achievement for the ROIC during the performance period (i.e., 1/3 weighting per performance year). The overall target achievement cannot exceed 200%.

For Performance Shares allocated in years 2020 and 2021 under the MB LTIP 2020 and under the LTIP 2019, for each individual year of the three-year performance period an annual target achievement level of 100% was reached for the Revenue Growth performance target if Revenue Growth was 6%; Revenue Growth of 1% led to a target achievement level of 0% and the maximum target achievement level of 200% was reached in case of Revenue Growth of at least 11%. If Revenue Growth ranged between these values, the degree of target achievement was linearly interpolated between these values.

For Performance Shares allocated in years 2020 and 2021 under the MB LTIP 2020 and under the LTIP 2019, for each individual year of the three-year performance period an annual target achievement level of 100% for the Net Income Growth performance target was reached if Net Income Growth was 5%. In case of Net Income Growth of 0%, the target achievement level was 0%; the maximum target achievement of 200% was reached in the case of Net Income Growth of at least 10%. If Net Income Growth ranged between these values, the degree of target achievement was linearly interpolated between these values.

For Performance Shares allocated in years 2020 and 2021 under the MB LTIP 2020 and under the LTIP 2019, for each individual year of the three-year performance period an annual target achievement level of 100% for the ROIC performance target was reached if ROIC was 6.0%. In case of a ROIC of 5.5%, the target achievement level was 0%; the maximum target achievement of 200% was reached in the case of a ROIC of at least 6.5%. Between these values, the degree of target achievement was determined by means of linear interpolation.

For Performance Shares allocated during 2019 under the LTIP 2019 and under the MB LTIP 2019, for each individual year of the three-year performance period an annual target achievement level of 100% was reached for the Revenue Growth performance target if Revenue Growth was 7%; Revenue Growth of 0% led to a target achievement level of 0% and the maximum target achievement level of 200% was reached in case of Revenue Growth of at least 16%. If Revenue Growth ranged between these values, the degree of target achievement was linearly interpolated between these values.

For Performance Shares allocated during 2019 under the LTIP 2019 and under the MB LTIP 2019, for each individual year of the three-year performance period an annual target achievement level of 100% for the Net Income Growth performance target was reached if Net Income Growth was 7%. In case of Net Income Growth of 0%, the target achievement level was also 0%; the maximum target achievement of 200% was reached in the case of Net Income Growth of at least 14%. Between these values, the degree of target achievement was determined by means of linear interpolation.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

For Performance Shares allocated during 2019 under the LTIP 2019 and under the MB LTIP 2019, an annual target achievement level of 100% for ROIC was reached if the target ROIC as defined for the applicable year was reached. The target ROIC was 7.9% for 2019, 8.1% for 2020 and 8.1% for 2021. A target achievement level of 0% was reached if the ROIC fell below the target ROIC for the applicable year by 0.2 percentage points or more, whereas the maximum target achievement level of 200% was reached if the target ROIC for the respective year was exceeded by 0.2 percentage points or more. The degree of target achievement was determined by means of linear interpolation if the ROIC ranged between these values. In case the annual ROIC target achievement level in the third year of a performance period was equal to or higher than the ROIC target achievement level in each of the two previous years of such performance period, the ROIC target achievement level of the third year was deemed to be achieved for all years of the applicable performance period.

For Performance Shares allocated during the period from 2019 to 2021 under the MB LTIP 2020, under the LTIP 2019, and under the MB LTIP 2019, the target achievement level for each of the three performance targets was weighted annually at one-third to determine the yearly target achievement for each year of the three-year performance period. The level of overall target achievement over the three-year performance period was then determined on the basis of the mean of these three average yearly target achievements. The overall target achievement could be in a range of 0% to 200%.

The number of Performance Shares allocated to the plan participants at the beginning of the performance period is multiplied by the level of overall target achievement in order to determine the final number of Performance Shares.

Under the MB LTIP 2024+, the final number of Performance Shares generally vests four years after the respective allocation date. Several payout conditions, such as the continuation of the service relationship (with exceptions, e.g., in the event of occupational disability or retirement), apply. The performance shares proceeds, which for allocations made in 2024 will be paid out as cash compensation (cash amount depends on the average share price of the Company during a period of 30 days prior to the end of the vesting period), are capped at 400% of the respective allocation value and can be reduced to meet the respective maximum compensation of the participant.

Under the LTIP 2024+, the final number of Performance Shares generally vests three years after the respective allocation date. Several payout conditions, such as the continuation of the service relationship (with exceptions, e.g., in the event of occupational disability or retirement), apply. The number of vested Performance Shares is then multiplied with the average share price of the Company during a period of 30 days prior to the lapse of the vesting period. The resulting amount is capped in total at an amount equaling 400% of the respective allocation value and will be paid out as cash compensation.

Under the LTIP 2022+, the final number of Performance Shares generally vests three years after the respective allocation date. Several payout conditions, such as the continuation of the service relationship (with exceptions, e.g., in the event of occupational disability or retirement), apply. The number of vested Performance Shares is then multiplied with the average share price of the Company during a period of 30 days prior to the lapse of the vesting period. The resulting amount is capped in total at an amount equaling 400% of the respective allocation value and will be paid out as cash compensation.

Under the MB LTIP 2020, the final number of Performance Shares generally vests three years after the respective allocation date. Several payout conditions, such as the continuation of the service relationship (with exceptions, e.g., in the event of occupational disability or retirement), apply. The number of such vested Performance Shares is then multiplied by the average share price of the Company over a period of thirty calendar days prior to the lapse of the vesting period. The respective resulting amount, which is capped in total at an amount equaling 400% of the respective allocation value and which can be reduced to meet the respective maximum compensation of the participant, less taxes and contributions is generally transferred to a settlement institution which uses it for the purchase of shares of the Company on the stock exchange on behalf of the participants. Shares acquired in this way are subject to a holding period of at least one year. After the lapse of this holding period, the participant can decide to further hold or sell these shares.

Under the LTIP 2019, the final number of Performance Shares generally vested three years after the respective allocation date. Several payout conditions, such as the continuation of the service relationship (with exceptions, e.g., in the event of occupational disability or retirement), applied. The number of such vested Performance Shares was then multiplied by the average share price of the Company over a period of thirty calendar days prior to the lapse of the vesting period. The respective resulting amount was capped in total at an amount equaling 400% of the respective allocation value and was paid out as cash compensation.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Under the MB LTIP 2019, the final number of Performance Shares generally vested four years after the respective allocation date. Several payout conditions, such as the continuation of the service relationship (with exceptions, e.g., in the event of occupational disability or retirement), applied. The number of such vested Performance Shares was then multiplied by the average share price of the Company over a period of thirty calendar days prior to the lapse of the vesting period. The resulting amount was paid out as cash compensation.

***Additional information on share-based plans***

At December 31, 2025 and 2024, the members of the Management Board and plan participants other than the members of the Management Board held the following Performance Shares that will be settled in cash:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Outstanding Performance Shares that will be settled in cash** | **Outstanding Performance Shares that will be settled in cash** | **Outstanding Performance Shares that will be settled in cash** |  |  |  |  |
|  | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
|  | **Members of the** |  |  | **Members of the** |  |  |
|  | **Management** | **Other plan** |  | **Management** | **Other plan** |  |
|  | **Board** | **participants** | **Total** | **Board** | **participants** | **Total** |
| LTIP 2025+ |  | 132711 | 132711 |  |  |  |
| MB LTIP 2024+ | 220955 | 37546 | 258501 | 266497 | 37546 | 304043 |
| LTIP 2024+ |  | 1768618 | 1768618 |  | 1906842 | 1906842 |
| LTIP 2022+ |  | 1205535 | 1205535 |  | 2691190 | 2691190 |
| MB LTIP 2020 | 114395 | 126377 | 240772 | 236574 | 267539 | 504113 |

---

The table below provides reconciliations for outstanding Performance Shares that will be settled in shares of the Company at December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| **Reconciliation of Performance Shares that will be settled in shares of the Company** | **Reconciliation of Performance Shares that will be settled in shares of the Company** | **Reconciliation of Performance Shares that will be settled in shares of the Company** |
|  | **LTIP 2025+** | **MB LTIP 2024+** |
| &nbsp;&nbsp;**Balance at December 31, 2024** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 1259234 | 230873 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercised |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited |  | (36643) |
| &nbsp;&nbsp;**Balance at December 31, 2025** | **1259234**<br><sup>(1)</sup> | **194230**<br><sup>(2)</sup> |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Performance Shares will be automatically exercised after the lapse of the vesting period, and the weighted average remaining contractual life amounts to 2.60 years.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The Performance Shares will be automatically exercised after the lapse of the vesting period, and the weighted average remaining contractual life amounts to 3.17 years.

The compensation expense related to share-based payment transactions is determined based upon the fair value of the Performance Shares which will be recognized over the vesting period; for participants who receive an allocation that will be settled in cash, the amount is revalued for changes in fair value. The compensation expense that the Company recognized for Performance Shares for the fiscal years ended December 31, 2025, 2024 and 2023, respectively, is presented in the table below.

---

| | | | |
|:---|:---|:---|:---|
| **Compensation expense for share-based compensation plans** |  |  |  |
| *in € K* |  |  |  |
|  | **2025** | **2024** | **2023** |
| **Equity-settled allocations** |  |  |  |
| LTIP 2025+ | 6293 |  |  |
| MB LTIP 2024+ | 2078 |  |  |
| **Cash-settled allocations** |  |  |  |
| LTIP 2025+ | 536 |  |  |
| MB LTIP 2024+ | 2173 | 3468 |  |
| LTIP 2024+ | 20452 | 12078 |  |
| LTIP 2022+ | 12784 | 24013 | 17181 |
| MB LTIP 2020 | 808 | (1675) | 5417 |
| LTIP 2019 |  | 574 | 9138 |
| MB LTIP 2019 |  |  | 779 |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**24.**Leases

The Company leases land, buildings and improvements, machinery and equipment, as well as IT- and office equipment under various lease agreements.

**Leasing in the consolidated statements of income** 

The following table shows the effects from lease agreements on the consolidated statements of income for the year ended December 31, 2025, 2024, and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Leasing in the consolidated statements of income**  | **Leasing in the consolidated statements of income**  | **Leasing in the consolidated statements of income**  | **Leasing in the consolidated statements of income**  |
| *in € K* |  |  |  |
|  | **2025** | **2024** | **2023** |
| Depreciation on right-of-use assets | 647620 | 675526 | 700671 |
| Impairments on right-of-use assets | 15443 | 57226 | 25486 |
| Expenses relating to short-term leases | 65209 | 53057 | 59327 |
| Expenses relating to leases of low-value assets | 14249 | 20104 | 22188 |
| Expenses relating to variable lease payments | 2833 | 6343 | 10465 |
| Income from subleasing right-of-use assets | 4094 | 3957 | 3655 |
| Interest expense on lease liabilities | 143211 | 148420 | 148789 |

---

For information regarding leases with related parties, see note 6 b).

**Leases in the consolidated balance sheets** 

At December 31, 2025 and 2024, the acquisition costs and the accumulated depreciation of right-of-use assets consisted of the following:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Acquisition costs** | **Acquisition costs** | **Acquisition costs** | **Acquisition costs** | **Acquisition costs** | **Acquisition costs** | **Acquisition costs** | **Acquisition costs** |
| *in € K* |  |  |  |  |  |  |  |
|  |  | **Foreign** | **Changes in** |  |  |  |  |
|  | **January 1,** | **currency** | **consolidation** |  |  |  | **December 31,**  |
|  | **2025** | **translation** | **group** | **Additions** | **Reclassifications** | **Disposals** | **2025** |
| Right-of-use assets: Land | 41202 | (1281) |  | 3443 | (17) | (2934) | 40413 |
| Right-of-use assets: Buildings and improvements | 7108897 | (704079) | (5868) | 470089 | 920 | (282677) | 6587282 |
| Right-of-use assets: Machinery and equipment | 193265 | (17232) |  | 33361 | (1208) | (30435) | 177751 |
| **Right-of-use assets** | **7343364** | **(722592)** | **(5868)** | **506893** | **(305)** | **(316046)** | **6805446** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Acquisition costs** | **Acquisition costs** | **Acquisition costs** | **Acquisition costs** | **Acquisition costs** | **Acquisition costs** | **Acquisition costs** | **Acquisition costs** |
| *in € K* |  |  |  |  |  |  |  |
|  |  | **Foreign** | **Changes in** |  |  |  |  |
|  | **January 1,** | **currency** | **consolidation** |  |  |  | **December 31,**  |
|  | **2024** | **translation** | **group** | **Additions** | **Reclassifications** | **Disposals** <sup>(1)</sup> | **2024** |
| Right-of-use assets: Land | 41202 | 427 | (82) | 4282 | (1329) | (3298) | 41202 |
| Right-of-use assets: Buildings and improvements | 6557178 | 323334 | (46109) | 556872 | (57944) | (224434) | 7108897 |
| Right-of-use assets: Machinery and equipment | 324167 | 9751 |  | 60731 | 63 | (201447) | 193265 |
| **Right-of-use assets** | **6922547** | **333512** | **(46191)** | **621885** | **(59210)** | **(429179)** | **7343364** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Included within the amounts presented for "Right-of-use assets: Building and improvements" and "Right-of-use assets: Machinery and equipment" are €34,878 and €129,377 , respectively, for disposals of fully depreciated or impaired right-of-use assets from prior periods.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** |
| *in € K* |  |  |  |  |  |  |  |  |
|  |  | **Foreign** | **Changes in** |  |  |  |  |  |
|  | **January 1,** | **currency** | **consolidation** |  | **Impairment** |  |  | **December 31,**  |
|  | **2025** | **translation** | **group** | **Additions** | **loss** | **Reclassifications** | **Disposals** | **2025** |
| Right-of-use assets: Land | 19108 | (764) |  | 3766 | 2 | (17) | (1674) | 20421 |
| Right-of-use assets: Buildings and improvements | 3590355 | (372103) | (3979) | 614884 | 15483 | 913 | (183404) | 3662149 |
| Right-of-use assets: Machinery and equipment | 121445 | (11019) |  | 28970 | (42) | (1146) | (28834) | 109374 |
| **Right-of-use assets** | **3730908** | **(383886)** | **(3979)** | **647620** | **15443** | **(250)** | **(213912)** | **3791944** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** |
| *in € K* |  |  |  |  |  |  |  |  |
|  |  | **Foreign** | **Changes in** |  |  |  |  |  |
|  | **January 1,** | **currency** | **consolidation** |  | **Impairment** |  |  | **December 31,**  |
|  | **2024** | **translation** | **group** | **Additions** | **loss** | **Reclassifications** | **Disposals** <sup>(1)</sup> | **2024** |
| Right-of-use assets: Land | 17743 | 179 | (25) | 3923 | 12 | (930) | (1794) | 19108 |
| Right-of-use assets: Buildings and improvements | 2997179 | 159501 | (23175) | 642415 | 56894 | (42315) | (200144) | 3590355 |
| Right-of-use assets: Machinery and equipment | 236384 | 6689 |  | 29188 | 320 | (145) | (150991) | 121445 |
| **Right-of-use assets** | **3251306** | **166369** | **(23200)** | **675526** | **57226** | **(43390)** | **(352929)** | **3730908** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Included within the amounts presented for "Right-of-use assets: Building and improvements" and "Right-of-use assets: Machinery and equipment" are €34,878 and €129,377 , respectively, for disposals of fully depreciated or impaired right-of-use assets from prior periods.

---

| | | |
|:---|:---|:---|
| **Book value**  | **Book value**  | **Book value**  |
| *in € K* |  |  |
|  | **December 31,**  | **December 31,**  |
|  | **2025** | **2024** |
| Right-of-use assets: Land | 19992 | 22094 |
| Right-of-use assets: Buildings and improvements | 2925133 | 3518542 |
| Right-of-use assets: Machinery and equipment | 68377 | 71820 |
| **Right-of-use assets** | **3013502** | **3612456** |

---

Depreciation expense is allocated within costs of revenue, selling, general and administrative, and R&D expenses, depending upon the area in which the asset is used.

Impairment losses are allocated within costs of revenue, selling, general and administrative, and R&D expenses, depending upon the area in which the asset is used, or are included within other operating expense in certain instances when the corresponding assets have been identified as strategic transactions and/or programs.

For a maturity analysis of lease liabilities see note 26.

**Leasing in the consolidated statements of cash flows**

Total cash outflows from leases were €872,517 for the year ended December 31, 2025 (December 31, 2024 and 2023: €901,938 and €965,486, respectively). Of this amount, €649,038 for the year ended December 31, 2025 (December 31, 2024 and 2023: €676,513 and €727,369, respectively), was presented within the repayment of lease liabilities from unrelated and related party line items within Net cash provided by (used in) financing activities in the consolidated statements of cash flows. Cash outflows of €223,479 for the year ended December 31, 2025 (December 31, 2024 and 2023: €225,425 and €238,117, respectively) were reported within the Net income and Paid interest line items within Net cash provided by (used in) operating activities in the consolidated statements of cash flows.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Leases that the Company entered into as a lessee that have not yet begun as of December 31, 2025 will result in future cash outflows of €32,245 (December 31, 2024 and 2023: €52,309 and €109,012, respectively).

Potential future cash outflows resulting from extension options of €6,736,406 were not reflected in the measurement of the lease liabilities as of December 31, 2025, as the exercise of the respective options is not reasonably certain (December 31, 2024 and 2023: €7,513,645 and €7,213,730, respectively). The major part of these potential future cash outflows relates to extension options in real estate lease agreements, primarily for dialysis clinics in the Care Delivery segment. Individual lease agreements include multiple extension options. The Company uses extension options to obtain a high degree of flexibility in performing its business. These extension options held are exercisable solely by the Company.

Potential future cash outflows resulting from termination options of €3 were not reflected in the measurement of the lease liabilities as of December 31, 2025, as the exercise of the respective options is not reasonably certain (December 31, 2024 and 2023: €4 and €2,956, respectively).

For additional information regarding residual value guarantees in certain lease contracts, see note 25.

**25.**Commitments and contingencies

***Legal and regulatory matters***

The Company is routinely involved in claims, lawsuits, regulatory and tax audits, investigations and other legal matters arising, for the most part, in the ordinary course of its business of providing healthcare services and products. Legal matters that the Company currently deems to be material or noteworthy are described below. The Company records its litigation reserves for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of loss can be reasonably estimated. For the other matters described below, the Company believes that the loss is not probable and/or the loss or range of possible losses cannot be reasonably estimated at this time. The outcome of litigation and other legal matters is always difficult to predict accurately and outcomes that are not consistent with the Company's view of the merits can occur. The Company believes that it has valid defenses to the legal matters pending against it and is defending itself vigorously. Nevertheless, it is possible that the resolution of one or more of the legal matters currently pending or threatened could have a material adverse effect on its business, results of operations and financial condition.

Since 2012, the Company has made significant investments in its compliance and financial controls and in its compliance, legal and financial organizations and is continuing to further implement its compliance program in connection with its prior resolution with the DOJ and SEC related to conduct that might violate the U.S. Foreign Corrupt Practices Act (FCPA). The Company continues to address post-FCPA review matters on various levels. The Company also continues to be fully committed to compliance with the FCPA and other applicable anti-bribery laws.

In 2015, the Company self-reported certain legacy conduct in West Africa with a potential nexus to Germany to the German prosecutor in the state of Hesse and continues to cooperate with government authorities in Germany in their review of allegations previously communicated to the Company regarding conduct in countries outside the U.S. that might violate anti-bribery laws. In September 2023, the Hessian prosecutor opened independent disgorgement proceedings against a German subsidiary of the Company relating to the aforementioned conduct.

In 2014, two New York physicians filed under seal a qui tam complaint in the U.S. District Court for the Eastern District of New York (Brooklyn), alleging violations of the False Claims Act relating to FMCH's vascular access line of business. On October 6, 2015, the U.S. Attorney for the Eastern District of New York (Brooklyn) issued subpoenas to FMCH indicating that its investigation is likely to be related to the two relators' complaint. FMCH cooperated in the Brooklyn investigation, which was understood to be separate and distinct from settlements entered in 2015 in Connecticut, Florida and Rhode Island of allegations against American Access Care LLC (AAC) following FMCH's 2011 acquisition of AAC.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

On July 12, 2022, after the court denied the USAO's motions to renew the sealing of the relators' complaint, the USAO filed a complaint-in-intervention. *United States ex rel. Pepe and Sherman v. Fresenius Vascular Care, Inc. et al, 1:14-cv-3505*. On October 3, 2023, the states of New York, New Jersey, and Georgia filed a consolidated complaint-in-intervention. The U.S.'s, the three states', and relators' complaints each allege that the defendants billed and received government payment for surgery that was not medically necessary. On October 31, 2024, the court granted FMCH's motion to dismiss the relators' complaint. FMCH is defending the allegations asserted in the litigation now proceeding with the remaining governmental complainants.

On January 3, 2023, FMCH received a subpoena from the Attorney General for the District of Columbia related to the activities of the American Kidney Foundation (AKF) that is grounded in anti-trust concerns, including market allocation within the District of Columbia. FMCH's relationship with AKF was the subject of a previously reported and resolved investigation by agencies of the U.S.and litigation against UnitedHealthcare Inc. FMCH is cooperating in the District of Columbia investigation.

On February 20, 2023, the Company received a statement of claim via the London Court of International Arbitration from its former distributor in Iraq. The Company terminated the distribution agreement in 2018. The former distributor sought, inter alia, compensation for alleged wrongful termination and "quality issues," as well as damages for lost profits. The Company denied the allegations and filed a counterclaim for malperformance under the distribution agreement. On October 28, 2025, the arbitral tribunal issued its decision by which it dismissed the distributor's claims in their entirety, granted the Company's counterclaims fully, and awarded all the Company's cost claims.

On April 5, 2024, FMCH received two civil investigative demands (CIDs) from the U.S. Federal Trade Commission (FTC) indicating it was investigating whether FMCH, among others in the industry, has engaged in unfair or exclusionary conduct in violation of Section 5 of the FTC Act in the acquisition of medical director services or provision of dialysis services. The CIDs indicate they cover the period from January 1, 2016 to the present and generally request information related to FMCH's dialysis services, including information related to restrictive covenants such as non-competes with physicians. The Company is cooperating with the investigation. On May 2, 2025, the Company received a Florida Antitrust Act CID from the Attorney General of Florida commencing an investigation into possible anticompetitive conduct in connection with the acquisition of medical director services or provisions of dialysis services, which appears similar to the FTC investigation as well as looking at the Company's business related to hospitals. On December 1, 2025, the Company received a CID from the Attorney General for the State of Washington commencing an investigation into possible anticompetitive conduct in connection with the acquisition of medical director services or provision of dialysis services, which appears similar to the FTC investigation.

On March 24, 2025, FMCH received a CID from the U.S. DOJ concerning an investigation as to whether FMCH's subsidiary, Azura Vascular Care (Azura), billed for certain intravascular ultrasound procedures that were not medically necessary and were upcoded. FMCH is cooperating with the government in the investigation.

On May 9, 2025, a purported class action was filed against the Company alleging violations of the U.S. antitrust laws including allegations of price fixing and territory allocation. *United Food and Commercial Workers Local 1776 and Participating Employers Health and Welfare Fund, et al. v. Fresenius Medical Care AG and Fresenius Medical Care Holdings, Inc., U.S.D.C. Colorado, C.A. No. 1:25-cv-01478*. The Company is defending itself in this matter.

On December 18, 2025, the Antimonopoly Committee of Ukraine (AMCU) completed an investigation and ruled that one of the Company's Ukrainian subsidiaries, which represented less than 0.1% of the Company's total revenue for the year ended December 31, 2025, was allegedly engaged in anti - competitive conduct in connection with certain public tenders. AMCU imposed a fine of around €543 on the subsidiary and banned it from participation in public tenders for three years. The Company's Ukrainian subsidiary is currently considering filing an appeal.

From time to time, the Company is a party to or may be threatened with other litigation or arbitration, claims or assessments arising in the ordinary course of its business. Management regularly analyzes current information including, as applicable, the Company's defenses and insurance coverage and, as necessary, provides accruals for probable liabilities for the eventual disposition of these matters.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The Company, like other healthcare providers, insurance plans and suppliers, conducts its operations under intense government regulation and scrutiny. The Company must comply with regulations which relate to or govern the safety and efficacy of medical products and supplies, the marketing and distribution of such products, the operation of manufacturing facilities, laboratories, dialysis clinics and other healthcare facilities, and environmental and occupational health and safety. With respect to its development, manufacture, marketing and distribution of medical products, if such compliance is not maintained, the Company could be subject to significant adverse regulatory actions by the U.S. Food and Drug Administration (FDA) and comparable regulatory authorities outside the U.S. These regulatory actions could include warning letters or other enforcement notices from the FDA, and/or comparable foreign regulatory authority which may require the Company to expend significant time and resources in order to implement appropriate corrective actions. If the Company does not address matters raised in warning letters or other enforcement notices to the satisfaction of the FDA and/or comparable regulatory authorities outside the U.S., these regulatory authorities could take additional actions, including product recalls, injunctions against the distribution of products or operation of manufacturing plants, civil penalties, seizures of the Company's products and/or criminal prosecution. FMCH completed remediation efforts with respect to a pending FDA warning letter issued in 2011 and is awaiting confirmation whether the letter is now closed. FMCH responded to a second warning letter issued in December 2023 and is engaged with the FDA about continuing remediation efforts under that letter. The Company must also comply with the laws of the U.S., including the federal Anti-Kickback Statute, the federal False Claims Act, the federal Stark Law, the federal Civil Monetary Penalties Law and the federal Foreign Corrupt Practices Act as well as other federal and state fraud and abuse laws. In Germany, where corporations are not subject to criminal law, management boards of companies must ensure business activities comply with the anti-corruption provisions of the criminal code (*Strafgesetzbuch*), sections 331 et seq.; breaches by individuals exercising commercial activity are subject to prosecution which can result in corporate fines and/or orders for the disgorgement of profit. Applicable laws or regulations may be amended, or enforcement agencies or courts may make interpretations that differ from the Company's interpretations or the manner in which it conducts its business. In the U.S., enforcement is a high priority for the federal government and some states. In addition, the provisions of the False Claims Act authorizing payment of a portion of any recovery to the party bringing the suit encourage private plaintiffs to commence whistleblower actions. By virtue of this regulatory environment, the Company's business activities and practices are subject to extensive review by regulatory authorities and private parties, and continuing audits, subpoenas, other inquiries, claims and litigation relating to the Company's compliance with applicable laws and regulations. The Company may not always be aware that an inquiry or action has begun, particularly in the case of whistleblower actions, which are initially filed under court seal.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The Company operates many facilities and handles the personal data of its patients and beneficiaries throughout the U.S. and other parts of the world and engages with other business associates to help it carry out its healthcare activities. While the Company is committed to training its employees and business associates on applicable laws and procedures, investigating concerns and incidents in a timely manner and taking remedial and corrective action (including disciplinary action) as necessary, in such a widespread, global system it may be difficult to maintain the desired level of oversight and control over the thousands of individuals employed by the Company, its many affiliated companies and its service providers or business associates. The Company recognizes that the laws, regulations and interpretative guidance on data privacy are evolving along with potential litigation and enforcement risks, and it continues to review its processes to adapt to those changes. On occasion, the Company or its business associates may experience a breach under the Health Insurance Portability and Accountability Act Privacy Rule and Security Rules, the EU's General Data Protection Regulation or other similar laws (Data Protection Laws), which may involve certain impermissible use, access, or disclosure of unsecured personal data pertaining to patients, employees, beneficiaries or others. On those occasions, the Company is committed to compliance with applicable notification and/or reporting requirements and to take appropriate remedial and corrective action, including notification requirements under SEC rules that require public companies to report the occurrence of material cybersecurity incidents. Any such report could trigger litigation arising out of the incident. Cybersecurity incidents involving unauthorized or impermissible access to the Company's data can also involve encryption or other efforts to deny access to such data and necessitate significant expenditures by the Company to recover or regain access to the data. On September 29, 2023, Cardiovascular Consultants, Ltd. (CCL), a former subsidiary of the Company located in the U.S., became aware that some of its computer systems in the U.S. were affected by a security incident. The Company publicly disclosed information regarding this security breach in a Form 6-K furnished to the SEC, noting that the Company does not expect the incident to have a material impact on its financial condition or results of operations. Subsequently, Fresenius Vascular Care, Inc. d/b/a Azura Vascular Care, a wholly owned subsidiary of the Company located in the U.S., became aware that some of its files had been affected by the same security incident. There are two putative class action lawsuits pending in connection with this incident: one in Arizona state court against CCL (with which four voluntarily dismissed federal purported class actions have been combined) and one in Pennsylvania federal court against Azura (with which two purported class actions filed against Azura were later consolidated). The plaintiffs originally alleged that CCL and Azura breached various duties relating to the safeguarding of confidential patient information and seek injunctive relief requiring that CCL and Azura implement various data protection processes and pay unspecified monetary damages. The court in the CCL lawsuit dismissed nearly all counts against CCL; one negligence claim against CCL survived. The parties in the Azura lawsuit agreed to settle the lawsuit on a class-wide basis, which has been finally approved by the court. The parties in the CCL lawsuit reached an agreement in principal to settle the lawsuit, though the agreement will need to be approved by the court. None of the actions has received class certification. Under the Company's 2023 agreement for the sale of CCL, the Company retains responsibility for defending against the CCL case. In addition, the Company continues to cooperate with requests for information from the U.S. Department of Health & Human Services' Office for Civil Rights related to this matter.

The Company relies upon its management structure, regulatory and legal resources, and the effective operation of its compliance program to direct, manage and monitor the activities of its employees. On occasion, the Company may identify instances where employees or other agents deliberately, recklessly or inadvertently contravene the Company's policies or violate applicable law and, in such instances, the Company will take appropriate corrective and/or disciplinary action. The actions of such persons may subject the Company and its subsidiaries to liability under the Anti-Kickback Statute, the Stark Law, the False Claims Act, Data Protection Laws, the Health Information Technology for Economic and Clinical Health Act and the FCPA, among other laws and comparable state laws or laws of other countries.

Physicians, hospitals and other participants in the healthcare industry are also subject to a large number of lawsuits alleging professional negligence, malpractice, product liability, worker's compensation or related claims, many of which involve large claims and significant defense costs. The Company has been and is currently subject to these suits due to the nature of its business and expects that those types of lawsuits may continue. Although the Company maintains insurance at a level which it believes to be prudent, it cannot assure that the coverage limits will be adequate or that insurance will cover all asserted claims. A successful claim against the Company or any of its subsidiaries in excess of insurance coverage could have a material adverse effect upon it and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business.

The Company has also had claims asserted against it and has had lawsuits filed against it relating to alleged patent infringements or businesses that it has acquired or divested. These claims and suits relate both to operation of the businesses and to acquisition and divestiture transactions. The Company has, when appropriate, asserted its own claims, and claims for indemnification. A successful claim against the Company or any of its subsidiaries could have a material adverse effect upon its business, financial condition, and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The Company is subject to ongoing and future tax audits in the U.S., Germany and other jurisdictions in the ordinary course of business. Tax authorities routinely pursue adjustments to the Company's tax returns and disallowances of claimed tax deductions. When appropriate, the Company defends these adjustments and disallowances and asserts its own claims. A successful tax related claim against the Company or any of its subsidiaries could have a material adverse effect upon its business, financial condition, and results of operations.

The German tax authorities re-qualified dividends received in connection with intercompany mandatorily redeemable preferred shares into fully taxable interest payments for the years 2006 until 2013, which could lead to additional tax payments in the mid-double-digit million range. Additionally, German tax authorities objected to the Company's tax returns and took the position that income of one of the Company's finance entities for 2017 and future periods should be subject to German Controlled Foreign Corporation taxation resulting in potential additional income tax payments in the low end of triple-digit millions. In both cases, the Company will take any appropriate legal action to defend its position.

The Company is subject to residual value guarantees in certain lease contracts, primarily real estate contracts, for which it is the lessee in the amount of €1,080,041 and €1,067,726 as of December 31, 2025 and 2024, respectively. As of December 31, 2025 and 2024, the estimated fair market value of the underlying leased assets exceeded the related residual value guarantees and, therefore, the Company did not have any risk exposure relating to these guarantees.

Other than those individual contingent liabilities mentioned above, the current estimated amount of the Company's other known individual contingent liabilities is immaterial. For further information regarding the Company's purchase commitments, see note 9 and note 11.

**26.**Financial instruments

The following tables show the carrying amounts and fair values of the Company's financial instruments at December 31, 2025 and December 31, 2024:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** |  |
| *in € K* |  |  |  |  |  |  |  |  |
| **December 31, 2025** | **Carrying amount** | **Carrying amount** | **Carrying amount** | **Carrying amount** | **Carrying amount** | **Fair value** | **Fair value** | **Fair value** |
|  | **Amortized** |  |  | **Not** |  |  |  |  |
|  | **cost** | **FVPL** | **FVOCI** | **classified** | **Total** | **Level 1** | **Level 2** | **Level 3** |
| Cash and cash equivalents | 1341121 | 257992 |  |  | 1599113 | 257992 |  |  |
| Trade accounts and other receivables from unrelated parties | 3018004 |  |  | 89499 | 3107503 |  |  |  |
| Accounts receivable from related parties | 32683 |  |  |  | 32683 |  |  |  |
| &nbsp;&nbsp;Derivatives - cash flow hedging instruments |  |  |  | 13856 | 13856 |  | 13856 |  |
| &nbsp;&nbsp;Derivatives - not designated as hedging instruments |  | 11546 |  |  | 11546 |  | 11546 |  |
| &nbsp;&nbsp;Derivatives embedded in vPPAs |  | 7730 |  |  | 7730 |  |  | 7730 |
| &nbsp;&nbsp;Equity investments |  | 31011 | 58497 |  | 89508 | 15239 | 60498 | 13771 |
| &nbsp;&nbsp;Debt securities |  | 73924 | 356295 |  | 430219 | 430219 |  |  |
| &nbsp;&nbsp;Other financial assets<sup>(1)</sup> | 365081 | 99154 |  | 89241 | 553476 |  |  | 99154 |
| Other current and non-current assets | 365081 | 223365 | 414792 | 103097 | 1106335 |  |  |  |
| **Financial assets** | **4756889** | **481357** | **414792** | **192596** | **5845634** |  |  |  |
| Accounts payable to unrelated parties | 722974 |  |  |  | 722974 |  |  |  |
| Accounts payable to related parties | 97951 |  |  |  | 97951 |  |  |  |
| Short-term debt | 17015 |  |  |  | 17015 |  |  |  |
| Long-term debt | 7287881 |  |  |  | 7287881 | 6716223 | 318336 |  |
| Lease liabilities |  |  |  | 3490709 | 3490709 |  |  |  |
| &nbsp;&nbsp;Derivatives - cash flow hedging instruments |  |  |  | 2647 | 2647 |  | 2647 |  |
| &nbsp;&nbsp;Derivatives - not designated as hedging instruments |  | 9147 |  |  | 9147 |  | 9147 |  |
| &nbsp;&nbsp;Derivatives embedded in vPPAs |  | 9463 |  |  | 9463 |  |  | 9463 |
| &nbsp;&nbsp;Variable payments outstanding for acquisitions |  | 3262 |  |  | 3262 |  |  | 3262 |
| &nbsp;&nbsp;Put option liabilities |  |  |  | 793043 | 793043 |  |  | 793043 |
| &nbsp;&nbsp;Other financial liabilities<sup>(2)</sup> | 966121 |  |  |  | 966121 |  |  |  |
| Other current and non-current liabilities | 966121 | 21872 |  | 795690 | 1783683 |  |  |  |
| **Financial liabilities** | **9091942** | **21872** | **—** | **4286399** | **13400213** | **—** | **—** | **—** |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** | **Carrying amount and fair value of financial instruments** |  |
| *in € K* |  |  |  |  |  |  |  |  |
| **December 31, 2024** | **Carrying amount** | **Carrying amount** | **Carrying amount** | **Carrying amount** | **Carrying amount** | **Fair value** | **Fair value** | **Fair value** |
|  | **Amortized**  |  |  |  |  |  |  |  |
|  | **cost** | **FVPL** | **FVOCI** | **Not classified** | **Total** | **Level 1** | **Level 2** | **Level 3** |
| Cash and cash equivalents | 939197 | 240990 |  |  | 1180187 | 240990 |  |  |
| Trade accounts and other receivables from unrelated parties | 3258181 |  |  | 87479 | 3345660 |  |  |  |
| Accounts receivable from related parties | 40936 |  |  |  | 40936 |  |  |  |
| &nbsp;&nbsp;Derivatives - cash flow hedging instruments |  |  |  | 4362 | 4362 |  | 4362 |  |
| &nbsp;&nbsp;Derivatives - not designated as hedging instruments |  | 21453 |  |  | 21453 |  | 21453 |  |
| &nbsp;&nbsp;Equity investments |  | 120813 | 66787 |  | 187600 | 90483 | 67963 | 29154 |
| &nbsp;&nbsp;Debt securities |  | 95574 | 369858 |  | 465432 | 465432 |  |  |
| &nbsp;&nbsp;Other financial assets<sup>(1)</sup> | 307163 | 142264 |  | 101322 | 550749 |  |  | 142264 |
| Other current and non-current assets | 307163 | 380104 | 436645 | 105684 | 1229596 |  |  |  |
| **Financial assets** | **4545477** | **621094** | **436645** | **193163** | **5796379** | **—** | **—** | **—** |
| Accounts payable to unrelated parties | 864500 |  |  |  | 864500 |  |  |  |
| Accounts payable to related parties | 80044 |  |  |  | 80044 |  |  |  |
| Short-term debt | 2099 |  |  |  | 2099 |  |  |  |
| Long-term debt | 6836108 |  |  |  | 6836108 | 6015977 | 340921 |  |
| Lease liabilities |  |  |  | 4140701 | 4140701 |  |  |  |
| &nbsp;&nbsp;Derivatives - cash flow hedging instruments |  |  |  | 15388 | 15388 |  | 15388 |  |
| &nbsp;&nbsp;Derivatives - not designated as hedging instruments |  | 26615 |  |  | 26615 |  | 26615 |  |
| &nbsp;&nbsp;Derivatives embedded in vPPAs |  | 25394 |  |  | 25394 |  |  | 25394 |
| &nbsp;&nbsp;Variable payments outstanding for acquisitions |  | 7933 |  |  | 7933 |  |  | 7933 |
| &nbsp;&nbsp;Put option liabilities |  |  |  | 1299117 | 1299117 |  |  | 1299117 |
| &nbsp;&nbsp;Other financial liabilities<sup>(2)</sup> | 951611 |  |  |  | 951611 |  |  |  |
| Other current and non-current liabilities | 951611 | 59942 |  | 1314505 | 2326058 |  |  |  |
| **Financial liabilities** | **8734362** | **59942** | **—** | **5455206** | **14249510** | **—** | **—** | **—** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) As of December 31, 2025 other financial assets primarily include receivables related to a royalty stream that the Company is entitled to base on sales made by Humacyte, Inc. in the U.S., vendor and supplier rebates, lease receivables, notes receivable, receivables related to consent agreement on certain pharmaceuticals as well as deposits, guarantees, and securities. As of December 31, 2024, other financial assets primarily include receivables for royalty payments from one of the Company's equity investments, lease receivables, notes receivable, deposits, guarantees, securities, receivables related to consent agreement on certain pharmaceuticals, vendor and supplier rebates as well as receivables from sale of investments.

&nbsp;&nbsp;&nbsp;&nbsp;(2) As of December 31, 2025 and 2024 other financial liabilities primarily include receivable credit balances and goods and services received.

Derivative and non-derivative financial instruments are categorized in the following three-tier fair value hierarchy that reflects the significance of the inputs in making the measurements. Level 1 inputs are quoted prices for similar instruments in active markets. Level 2 is defined as using valuation models (i.e. mark-to-model) with input factors that are inputs other than quoted prices in active markets that are directly or indirectly observable. Level 3 is defined as using valuation models (i.e. mark-to-model) with input factors that are unobservable inputs for which little or no market data exists, therefore requiring the Company to develop its own assumptions. Fair value information is not provided for financial instruments for circumstances in which the carrying amount is a reasonable estimate of fair value due to the relatively short period of maturity of these instruments. This includes cash and cash equivalents measured at amortized costs, trade accounts and other receivables from unrelated parties, accounts receivable from related parties, other financial assets, accounts payable to unrelated parties, accounts payable to related parties, short-term debt, and other financial liabilities. Transfers between levels of the fair value hierarchy have not occurred as of December 31, 2025 or December 31, 2024. The Company accounts for transfers at the end of the reporting period.

#### Non-derivative financial instruments
The significant methods and assumptions used for the classification and measurement of non-derivative financial instruments are as follows:

The Company assessed its business models and the cash flow characteristics of its financial assets. The vast majority of the non-derivative financial assets are held in order to collect contractual cash flows. The contractual terms of the financial assets allow the conclusion that the cash flows represent payment of principal and interest only. Trade accounts and other receivables from unrelated parties, accounts receivable from related parties, and other financial assets are consequently measured at amortized cost.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Cash and cash equivalents are comprised of cash funds and other short-term investments. Cash funds are measured at amortized cost. Short-term investments are highly liquid and readily convertible to known amounts of cash. Short-term investments are measured at FVPL. The risk of changes in fair value is insignificant.

Equity investments are not held for trading. At initial recognition, the Company elected, on an instrument-by-instrument basis, to represent subsequent changes in the fair value of individual strategic investments in OCI. All equity investments for which changes in fair value are recorded in OCI relate to purchases of publicly traded shares or percentage ownership of companies in the health sciences or adjacent fields and are made up of individually non-significant investments. At December 31, 2025, the Company held 10 non-listed equity investments (December 31, 2024: 11) and no listed equity investments (December 31, 2024: 0). During 2025, gains of €21,125 (December 31, 2024: €0) were transferred from OCI to retained earnings due to the disposal of an investment. Dividends of €44 were recognized during 2025 (2024: €65) from these equity investments. If equity instruments are quoted in an active market, the fair value is based on price quotations at the period-end-date. As necessary, the Company engages external valuation firms to assist in determining the fair value of Level 3 equity investments. The external valuation uses a discounted cash flow model, which includes significant unobservable inputs such as investment specific forecasted financial statements and weighted average cost of capital, that reflects current market assessments as well as a terminal growth rate. The Company's listed and non-listed equity investments measured at FVOCI had the following fair values at December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| **Equity investments measured at FVOCI** |  |  |
| *in € K* |  |  |
|  | **2025** | **2024** |
| Listed equity investments |  |  |
| Non-listed equity investments | 58497 | 66787 |
| **Equity investments FVOCI** | **58497** | **66787** |

---

The majority of the debt securities are held within a business model whose objective is achieving both contractual cash flows and selling the securities. The standard coupon bonds give rise on specified dates to cash flows that are solely payments of principal and interest on the outstanding principal amount. Subsequently, these financial assets have been classified as FVOCI. The smaller part of debt securities does not give rise to cash flows that are solely payments of principal and interest. Consequently, these securities are measured at FVPL. In general, most of the debt securities are quoted in an active market.

Long-term debt is initially recognized at its fair value and subsequently measured at amortized cost. The fair values of major long-term debt are calculated on the basis of market information. Liabilities for which market quotes are available are measured using these quotes. The fair values of the other long-term debt are calculated at the present value of the respective future cash flows. To determine these present values, the prevailing interest rates and credit spreads for the Company as of the balance sheet date are used.

Variable payments outstanding for acquisitions are recognized at their fair value. The estimation of the individual fair values is based on the key inputs of the arrangement that determine the future contingent payment as well as the Company's expectation of these factors. The Company assesses the likelihood and timing of achieving the relevant objectives. The underlying assumptions are reviewed regularly.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Put option liabilities are recognized at the present value of the exercise price of the option. The exercise price of the option is generally based on fair value and, in certain limited instances, might contain a fixed floor price. The methodology the Company uses to estimate the fair values assumes the greater of net book value or a multiple of earnings, based on historical earnings, development stage of the underlying business, and other factors. From time to time, the Company engages an external valuation firm to assist in the valuation of certain put options. The external valuation assists the Company in estimating the fair values using a combination of discounted cash flows and a multiple of earnings and/or revenue. Under those limited circumstances in which the put option might contain a fixed floor price, the external valuation firm may assist the Company with the valuation by performing a Monte Carlo Simulation analysis to simulate the exercise price. The put option liabilities are discounted at a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the liability. The estimated fair values of these put options can also fluctuate, and the discounted cash flows as well as the implicit multiple of earnings and/or revenue at which these obligations may ultimately be settled could vary significantly from the Company's current estimates depending upon market conditions. For the purpose of analyzing the impact of changes in unobservable inputs on the fair value measurement of put option liabilities, the Company assumes an increase on earnings (or enterprise value, where applicable) of 10% compared to the actual estimation as of the balance sheet date. The corresponding increase in fair value of €61,570 is then compared to the total liabilities and the shareholder's equity of the Company. This analysis shows that an increase of 10% in the relevant earnings (or enterprise value, where applicable) would have an effect of less than 1% on the total liabilities and less than 1% on the shareholder's equity of the Company.

During the second quarter of 2025, the Company entered into an agreement with shareholders of Interwell Health (the Company's value and risk-based care subsidiary) to accelerate the settlement of put options held by non-physician investors originally granted as part of the 2022 merger of Cricket Health, Interwell Health LLC and Fresenius Health Partners, Inc. The settlement in the amount of $363,272 (€311,614) for this transaction occurred during September 2025 and represented a transaction with noncontrolling interests without loss of control. In connection with the settlement, the Company incurred cash outflows of €311,614 for the year ended December 31, 2025 which are included within the line item "Distributions to noncontrolling interests" within "Financing activities" in the consolidated statements of cash flows. The related decrease in noncontrolling interests of €76,201 and additional paid in capital of €235,413 as of December 31, 2025 are included within the line item "Transactions with noncontrolling interests without loss of control" in the consolidated statements of shareholders' equity. Additionally, the decrease in put option liabilities in the amount of €312,941 and a corresponding increase in retained earnings are reflected in the consolidated balance sheets within line item "Other current financial liabilities" and the line item "Put option liabilities" in the consolidated statements of shareholders' equity, respectively. A deferred tax liability initially established in 2022 (as a result of a remeasurement gain recognized for the transaction) was reversed with the corresponding tax income of $38,792 (€34,679) recognized in the line item "Income tax expense" in the consolidated statements of income. As a result of the transaction, the Company's ownership of Interwell Health increased from 75% to approximately 92% as of December 31, 2025.

At December 31, 2025, 2024, and 2023 the Company's potential obligations under these put option liabilities, which are recorded in other current financial liabilities and other non-current financial liabilities, were €793,043, €1,299,117, and €1,372,008, respectively. At December 31, 2025, 2024, and 2023, put option liabilities with an aggregate purchase obligation of €438,740, €527,592, and €563,692, respectively, were exercisable. In the last three fiscal years ending December 31, 2025, 47 such put options, excluding the settlement of Interwell Health put options noted above, have been exercised for a total consideration of €81,325.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The following table provides a reconciliation of Level 3 financial instruments, excluding vPPAs as disclosed below, at December 31, 2025, 2024 and 2023:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation from beginning to ending balance of level 3 financial instruments** |  |  |  |  |
| *in € K* |  |  |  |  |
|  | **2025** | **2025** | **2025** | **2025** |
|  |  | **Variable** |  |  |
|  |  | **payments** |  | **Other financial** |
|  | **Equity** | **outstanding for** | **Put option** | **assets measured at** |
|  | **investments** | **acquisitions** | **liabilities** | **FVPL** <sup>(1)</sup> |
| Beginning balance at January 1, | 29154 | 7933 | 1299117 | 142264 |
| Increase | 2002 | 1507 | 32307 | 7808 |
| Decrease |  | (4581) | (341992) | (22855) |
| Reclassifications |  |  |  |  |
| Gain / loss recognized in profit or loss<sup>(2)</sup> | (14487) | (928) |  | (13460) |
| Gain / loss recognized in equity |  |  | (54964) |  |
| Foreign currency translation and other changes | (2898) | (669) | (141425) | (14603) |
| Ending balance at December 31, | 13771 | 3262 | 793043 | 99154 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Reconciliation from beginning to ending balance of level 3 financial instruments** | **Reconciliation from beginning to ending balance of level 3 financial instruments** | **Reconciliation from beginning to ending balance of level 3 financial instruments** | **Reconciliation from beginning to ending balance of level 3 financial instruments** | **Reconciliation from beginning to ending balance of level 3 financial instruments** | **Reconciliation from beginning to ending balance of level 3 financial instruments** | **Reconciliation from beginning to ending balance of level 3 financial instruments** | **Reconciliation from beginning to ending balance of level 3 financial instruments** |
| *in € K* |  |  |  |  |  |  |  |
|  | **2024** | **2024** | **2024** | **2024** | **2023** | **2023** | **2023** |
|  |  | **Variable** |  | **Other** |  | **Variable** |  |
|  |  | **payments** |  | **financial assets**  |  | **payments** |  |
|  | **Equity** | **outstanding for** | **Put option** | **measured** | **Equity** | **outstanding for** | **Put option** |
|  | **investments** | **acquisitions** | **liabilities** | **at FVPL** <sup>(1)</sup> | **investments** | **acquisitions** | **liabilities** |
| Beginning balance at January 1,  | 32002 | 35751 | 1372008 |  | 42793 | 37846 | 1468517 |
| Increase | 3085 | 86 | 8127 | 41225 | 4833 | 5232 | 31050 |
| Decrease |  | (23472) | (71990) | (2292) |  | (3603) | (42490) |
| Reclassifications |  |  |  | 90457 |  |  |  |
| Gain / loss recognized in profit or loss<sup>(2)</sup> | (7773) | (4796) |  | 4987 | (14340) | (3366) |  |
| Gain / loss recognized in equity |  |  | (91987) |  |  |  | (28034) |
| Foreign currency translation and other changes | 1840 | 364 | 82959 | 7887 | (1284) | (358) | (57035) |
| Ending balance at December 31,  | 29154 | 7933 | 1299117 | 142264 | 32002 | 35751 | 1372008 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) As of December 31, 2025 and 2024, other financial assets measured at FVPL consist mainly of receivables related to a royalty stream that the Company is entitled to base on sales made by Humacyte, Inc. in the U.S. and, in 2024, receivables from the sale of investments.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Includes realized and unrealized gains / losses.

**Derivative financial instruments**

**Derivative financial risks**

The Company is exposed to effects related to foreign exchange fluctuations in connection with its international business activities that are denominated in various currencies. In order to finance its business operations, the Company issues bonds and enters mainly into long-term credit agreements with banks. Due to these financing activities, the Company is exposed to changes to the prevailing interest rates.

In order to manage the risk of currency exchange rate and interest rate fluctuations, the Company enters into various hedging transactions by means of derivative instruments with highly rated financial institutions (generally investment grade) as authorized by the Company's Management. On a quarterly basis, the Company performs an assessment of its counterparty credit risk. The Company currently considers this risk to be low (as the counterparties are generally investment grade). The Company's policy, which has been consistently followed, is that financial derivatives be used only for the purpose of hedging foreign currency and interest rate exposure.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

In certain instances, the Company enters into derivative contracts that do not qualify for hedge accounting but are utilized for economic purposes (economic hedges). The Company does not use financial instruments for trading purposes. The Company established guidelines for risk assessment procedures and controls for the use of financial instruments. They include a clear segregation of duties with regard to execution on one side and administration, accounting, and controlling on the other.

To reduce the credit risk arising from derivatives, the Company entered into master netting agreements with banks. Through such agreements, positive and negative fair values of the derivative contracts could be offset against one another if a partner becomes insolvent. This offsetting is valid for transactions where the aggregate amount of obligations owed to and receivable from are not equal. If insolvency occurs, the party which owes the larger amount is obliged to pay the other party the difference between the amounts owed in the form of one net payment.

These master netting agreements do not provide a basis for offsetting the fair values of derivative financial instruments in the statement of financial position as the offsetting criteria under IFRS Accounting Standards are not satisfied.

At December 31, 2025 and December 31, 2024, the Company had €23,539 and €25,806 of derivative financial assets subject to netting arrangements and €12,013 and €41,897 of derivative financial liabilities subject to netting arrangements. Offsetting these derivative financial instruments would have resulted in net assets of €14,908 and €10,305 as well as net liabilities of €3,381 and €26,396 at December 31, 2025 and December 31, 2024, respectively.

The Company calculates benchmarks for individual exposures in order to quantify interest and foreign exchange risks. The benchmarks are derived from achievable and reasonable market rates. Depending on the individual benchmarks, hedging strategies are agreed on and implemented.

In April 2024, the Company signed several vPPAs with wind and solar energy project developers in Germany and in the U.S. with terms of up to 15 years. The German vPPA contracts have been signed with two developers and produced 106 gigawatt hours (GWh) in 2025 which is equivalent to 61% of the electricity consumption used by the Company in the European Union during this year. The U.S. vPPA contract has been concluded with one developer and produced 423 GWh in 2025 which corresponds to 50% of the electricity consumption used by the Company in the U.S. during this year. All of the wind and solar parks are operational as of December 31, 2025. The Company does not have control or any other rights in relation to the usage of the energy-producing facilities. All contracts are designed as non-deliverable for the electricity produced and provide for the delivery of energy attribute certificates, commonly known in the U.S. and Germany as renewable energy certificates and guarantees of origin, respectively. All contracts are analyzed as physical host contracts to purchase the certificates and separable embedded electricity swaps to pay a fixed price for the electricity produced and to receive a variable spot energy price in the respective countries. The host contracts fulfill the "own-use" criteria in accordance with IFRS 9, Financial Instruments (IFRS 9). The derivatives embedded in the vPPAs are recognized separately at fair value through profit or loss. Embedded derivatives with positive fair values are recorded in other non-current financial assets within the consolidated balance sheets. Embedded derivatives with negative fair value are recorded in other non-current financial liabilities within the consolidated balance sheets. The fair value allocated to level 3 is derived from the present value of the expected cash flows from the derivatives. The main valuation parameters include significant unobservable inputs such as electricity future price curves and expected electricity production volumes. A change in the key valuation parameters as of December 31, 2025 and 2024 would have affected the fair value of the derivatives embedded in vPPAs as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Sensitivities of derivatives embedded in vPPAs to changes in unobservable inputs** | **Sensitivities of derivatives embedded in vPPAs to changes in unobservable inputs** | **Sensitivities of derivatives embedded in vPPAs to changes in unobservable inputs** | **Sensitivities of derivatives embedded in vPPAs to changes in unobservable inputs** | **Sensitivities of derivatives embedded in vPPAs to changes in unobservable inputs** | **Sensitivities of derivatives embedded in vPPAs to changes in unobservable inputs** |
| *in € K* | *in € K* | *in € K* | *in € K* | *in € K* | *in € K* |
| **2025** |  |  |  |  |  |
| **Change in expected electricity prices** | **Change in expected electricity prices** | **Change in expected production volumes** | **Change in expected production volumes** | **Change in expected interest rates** | **Change in expected interest rates** |
| 10% increase | 10% decrease | 10% increase | 10% decrease | 1% increase | 1% decrease |
| 24356 | (24305) | 155 | (155) | (183) | 196 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **2024** |  |  |  |  |  |
| **Change in expected electricity prices** | **Change in expected electricity prices** | **Change in expected production volumes** | **Change in expected production volumes** | **Change in expected interest rates** | **Change in expected interest rates** |
| 10% increase | 10% decrease | 10% increase | 10% decrease | 1% increase | 1% decrease |
| 26774 | (26761) | (2540) | 2540 | 2247 | (2507) |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Changes in the fair value of the derivatives in the vPPAs are recognized in other operating income or other operating expense, as applicable, in the consolidated statements of income. Due to the volatile nature of such instruments which may be considered to be speculative, it is difficult to accurately predict what impact the volatility of unobservable inputs, such as changes in expected energy prices or production volumes, may have on the valuation of such instruments in the future. The estimated fair values of these derivative instruments may fluctuate significantly from quarter to quarter and the price at which these derivatives may ultimately be settled could vary significantly from the Company's current estimates, depending upon market conditions.

The following table provides a reconciliation of derivatives embedded in the vPPAs at December 31, 2025:

---

| | | |
|:---|:---|:---|
| **Reconciliation of derivatives embedded in vPPAs** |  |  |
| *in € K* | **2025** | **2024** |
|  | **Derivatives embedded in** | **Derivatives embedded in** |
|  | **the vPPAs - (Liabilities)/Assets** | **the vPPAs - (Liabilities)/Assets** |
| Beginning balance at January 1, | (25394) |  |
| Settlements | 10867 | 460 |
| Gain (loss) recognized in profit or loss <sup>(1)</sup> | 11308 | (24959) |
| Foreign currency translation and other changes | 1486 | (895) |
| **Ending balance at December 31,**  | (1733) | (25394) |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes realized and unrealized gains / losses.

***Market risk***

***Foreign exchange risk management***

The Company conducts business on a global basis in various currencies, though a majority of its operations are in Germany and the United States. For financial reporting purposes, the Company reports in euro pursuant to Section 315e and Section 244 HGB. Therefore, changes in the rate of exchange between the euro and the local currencies in which the financial statements of the Company's international operations are maintained affect its results of operations and financial position as reported in its consolidated financial statements.

At December 31, 2025, if the euro had strengthened 10% against the U.S. dollar with all other variables held constant, net income attributable to shareholders of FME AG for the year would have been €88,942 lower, and other comprehensive income would have been €1,298,437 lower. Conversely, if the euro had weakened 10% against the U.S. dollar with all other variables held constant, net income attributable to shareholders of FME AG would have been €108,707 higher, and other comprehensive income would have been €1,586,979 higher.

Additionally, individual subsidiaries are exposed to transactional risks mainly resulting from intercompany purchases between production sites and other subsidiaries with different functional currencies. This exposes the subsidiaries to fluctuations in the rate of exchange between the invoicing currencies and the currency in which their local operations are conducted. For the purpose of hedging existing and foreseeable foreign exchange transaction exposures, the Company enters into foreign exchange hedge contracts, such as foreign exchange forward contracts and foreign exchange option contracts.

The notional amounts of foreign exchange contracts in place that are designated and qualify as cash flow hedges totaled €789,230 and €475,890 at December 31, 2025 and December 31, 2024, respectively. At December 31, 2025, the Company had foreign exchange derivatives with maturities of up to 34 months. Earnings of the Company were not materially affected by hedge ineffectiveness in the reporting period since the critical terms of the foreign exchange derivatives matched the critical terms of the underlying exposures.

The Company also enters into derivative contracts for forecasted product purchases and sales and for intercompany loans in foreign currencies which do not qualify for hedge accounting but are utilized for economic hedges, as defined above. The notional amounts of economic hedges totaled €2,381,239 and €2,421,508 at December 31, 2025 and December 31, 2024, respectively.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The Company uses a Cash-Flow-at-Risk (CFaR) model in order to estimate and quantify transaction risks from foreign currencies. The basis for the analysis of the currency risks are the foreign currency cash flows that are reasonably expected to arise within the following twelve months, less any hedges. Under the CFaR approach, the potential currency fluctuations of these net exposures are shown as probability distributions based on historical volatilities and correlations using the values of the last 50 exchange rates with an interval of 21 trading days. The calculation is made assuming a confidence level of 95% and a holding period of up to one year. The aggregation of currency risks has risk-mitigating effects due to correlations between the transactions concerned, i.e. the overall portfolio's risk exposure is generally less than the total of the underlying individual risks. Based on a net exposure of €704,670, the Company's CFaR amounts to €52,106 at December 31, 2025, this means with a probability of 95% a potential loss in relation to the forecasted foreign exchange cash flows of the next twelve months will be not higher than €52,106.

The following table shows the average hedging rate and the profile of the timing of the nominal amount of the foreign exchange forward contracts as well as of the foreign exchange option contracts for the currencies with highest hedging volume for contracts that are designated and qualify as cash flow hedges at December 31, 2025. For foreign exchange option contracts, the Company uses the strike price as the hedging rate.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Significant currency pairs** | **Significant currency pairs** | **Significant currency pairs** | **Significant currency pairs** | **Significant currency pairs** | **Significant currency pairs** |
| *in € K* |  |  |  |  |  |
|  | **Timing profile of the nominal amount** | **Timing profile of the nominal amount** | **Timing profile of the nominal amount** | **Timing profile of the nominal amount** |  |
|  | **Less than 1** |  |  |  | **Average** |
|  | **year** | **1 - 3 years** | **3 - 5 years** | **Over 5 years** | **hedging rate** |
| EUR/USD | 245536 | 44743 |  |  | 1.1774 |
| EUR/CNY | 163366 | 28367 |  |  | 8.2921 |
| EUR/GBP | 38388 | 4835 |  |  | 0.8754 |

---

***Interest rate risk management***

The Company's interest rate risks mainly arise from money market and capital market transactions of the group for financing its business activities.

For purposes of analyzing the impact of changes in the relevant reference interest rates on the Company's results of operations, the Company calculates the portion of financial debt which bears variable interest rate and which has not been hedged by means of interest rate swaps or options against rising interest rates. For this particular part of its liabilities, the Company assumes an increase in the Reference Rates of 0.5% compared to the actual rates as of the balance sheet date. The corresponding additional annual interest expense is then compared to the Company's net income. This analysis shows that an increase of 0.5% in the relevant Reference Rates would have an effect of less than 1% on the consolidated net income and less than 0.1% on the shareholder's equity of the Company.

The Company entered into interest rate hedges (pre-hedges) in anticipation of future long-term debt issuance. These pre-hedges are used to hedge interest rate exposures with regard to interest rates which are relevant for the future long-term debt issuance and which could rise until the respective debt is actually issued. These pre-hedges were settled at the issuance date of the corresponding long-term debt with the settlement amount recorded in AOCI amortized to interest expense over the life of the debt. At December 31, 2025 and December 31, 2024, the Company had €3,233 and €4,714, respectively, related to settlements of pre-hedges deferred in AOCI, net of tax.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

***Derivative financial instruments valuation***

The following table shows the carrying amounts of the Company's derivatives at December 31, 2025 and December 31, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Derivative financial instruments valuation** | **Derivative financial instruments valuation** | **Derivative financial instruments valuation** | **Derivative financial instruments valuation** | **Derivative financial instruments valuation** |
| *in € K* |  |  |  |  |
|  | **2025** | **2025** | **2024** | **2024** |
|  | **Assets** | **Liabilities** | **Assets** | **Liabilities** |
| Current |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange contracts | 12138 | (2643) | 4362 | (15388) |
| Non-current |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange contracts | 1718 | (4) |  |  |
| **Derivatives in cash flow hedging relationships** | 13856 | (2647) | 4362 | (15388) |
| Current |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange contracts | 11546 | (8191) | 19726 | (26471) |
| Non-current |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange contracts |  | (956) | 1727 | (144) |
| &nbsp;&nbsp;Derivatives embedded in vPPAs | 7730 | (9463) |  | (25394) |
| **Derivatives not designated as hedging instruments** | 19276 | (18610) | 21453 | (52009) |

---

The significant methods and assumptions used in estimating the fair values of derivative financial instruments are as follows:

To determine the fair value of foreign exchange forward contracts, the contracted forward rate is compared to the current forward rate for the remaining term of the contract as of the balance sheet date. The result is then discounted on the basis of the market interest rates prevailing at the balance sheet date for the applicable currency. To determine the fair value of foreign exchange option contracts, the Black-Scholes model is used. This model provides the option value based on parameters such as forward rate as of the balance sheet date, contracted strike price, time to expiry, implied volatility, and both the domestic and foreign interest rates. The total option value is split into its intrinsic value and time value components. Intrinsic value is determined by comparing the contracted strike price to the forward rate for the remaining term of the contract as of the balance sheet date. The time value is then calculated as the difference between the total option value and the intrinsic value.

The Company's own credit risk is incorporated in the fair value estimation of derivatives that are liabilities. Counterparty credit risk adjustments are factored into the valuation of derivatives that are assets. The Company monitors and analyses the credit risk from derivative financial instruments on a regular basis. For the valuation of derivative financial instruments, the credit risk is considered in the fair value of every individual instrument. The default probability is based upon the credit default swap spreads of each counterparty appropriate for the duration. The calculation of the credit risk considered in the valuation is performed by multiplying the default probability appropriate for the duration with the expected discounted cash flows of the derivative financial instrument.

**The effect of financial instruments on the consolidated statements of income**

The effects of financial instruments recorded in the consolidated statements of income consist of interest income of €68,022 (2024: €68,998), interest expense of €375,216 (2024: €393,322), as well as expected credit losses of €28,966 (2024: €18,968).

In the fiscal year 2025, net losses from foreign currency transactions amount to €43,794 (2024: net losses €23,057).

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The following table shows the effect of derivatives in cash flow hedging relationship on the consolidated financial statement:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **The effect of derivatives in cash flow hedging relationships on the consolidated financial statements** | **The effect of derivatives in cash flow hedging relationships on the consolidated financial statements** | **The effect of derivatives in cash flow hedging relationships on the consolidated financial statements** | **The effect of derivatives in cash flow hedging relationships on the consolidated financial statements** | **The effect of derivatives in cash flow hedging relationships on the consolidated financial statements** | **The effect of derivatives in cash flow hedging relationships on the consolidated financial statements** |
| *in € K* |  |  |  |  |  |
|  | **Fair value gain** | **Fair value gain** |  |  |  |
|  | **(loss) recognized in** | **(loss) recognized in** |  | **Amount** | **Amount** |
|  | **AOCI on hedging** | **AOCI on hedging** | **Location of** | **reclassified** | **reclassified** |
|  | **instrument (hedge** | **instrument (cost of** | **reclassified** | **from hedge** | **from cost of** |
|  | **reserve)** | **hedging)** | **amounts from AOCI** | **reserve** | **hedging** |
| **For the year ended December 31, 2025** |  |  |  |  |  |
| Interest rate contracts | 1061 |  | Interest income/expense | 1146 |  |
| Foreign exchange contracts | 26885 | (3841) | thereof: |  |  |
|  |  |  | Revenue | (9265) | 2516 |
|  |  |  | Other operating income/expense | 2606 | 184 |
| **Total** | **27946** | **(3841)** |  | **(5513)** | **2700** |
| **For the year ended December 31, 2024** |  |  |  |  |  |
| Interest rate contracts |  |  | Interest income/expense | 1318 |  |
| Foreign exchange contracts | (7159) | (895) | thereof: |  |  |
|  |  |  | Revenue | (1840) | 2641 |
|  |  |  | Costs of revenue | (5136) | 300 |
| **Total** | **(7159)** | **(895)** |  | **(5658)** | **2941** |

---

The following table shows the effect of derivatives not designated as hedging instruments on the consolidated financial statements:

---

| | | | |
|:---|:---|:---|:---|
| **The effect of derivatives not designated as hedging instruments on the consolidated financial statements** | **The effect of derivatives not designated as hedging instruments on the consolidated financial statements** | **The effect of derivatives not designated as hedging instruments on the consolidated financial statements** | **The effect of derivatives not designated as hedging instruments on the consolidated financial statements** |
| *in € K* |  |  |  |
|  |  | **Amount of (gain) loss recognized in** | **Amount of (gain) loss recognized in** |
|  |  | **income on derivatives** | **income on derivatives** |
|  | **Location of (gain) loss recognized in** | **for the year ended, December 31** | **for the year ended, December 31** |
|  | **income on derivatives** | **2025** | **2024** |
| Foreign exchange contracts | Other operating income/expense | (159082) | 49806 |
| Foreign exchange contracts | Interest income/expense | 30152 | 9984 |
| Derivatives embedded in vPPAs | Other operating income/expense | (11308) | 24959 |
| **Derivatives not designated as hedging instruments** |  | **(140238)** | **84749** |

---

**Credit risk**

The Company is exposed to potential losses in the event of non-performance by counterparties. With respect to derivative financial instruments it is not expected that any counterparty will fail to meet its obligations as the counterparties are highly rated financial institutions (generally investment grade). The maximum credit exposure of derivatives is represented by the fair value of those contracts with a positive fair value at the balance sheet date. The maximum credit exposure of all derivatives amounted to €33,132 at December 31, 2025 (2024: €25,815). The maximum credit risk resulting from the use of non-derivative financial instruments is defined as the total amount of all financial assets. In order to control this credit risk, the Company's management carries out an aging analysis of trade accounts and other receivables from unrelated parties. For details on the aging analysis and on expected credit losses, see note 8.

**Liquidity risk**

The liquidity risk is defined as the risk that a company is potentially unable to meet its financial obligations. The Management of the Company manages the liquidity of the group by means of effective working capital and cash management as well as an anticipatory evaluation of refinancing alternatives. The Company's management believes that existing credit facilities, net cash provided by operating activities, and additional short-term debt are sufficient to meet the Company's foreseeable demand for liquidity (see note 16).

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The following table shows the future undiscounted contractual cash flows (including interest) resulting from recognized financial liabilities and derivative financial instruments recorded in the consolidated balance sheets:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Payments agreed by contracts** | **Payments agreed by contracts** | **Payments agreed by contracts** | **Payments agreed by contracts** | **Payments agreed by contracts** |
| *in € K* |  |  |  |  |
|  | **Payments due by period of** | **Payments due by period of** | **Payments due by period of** | **Payments due by period of** |
|  | **Less than 1 year** | **1 - 3 years** | **3 - 5 years** | **Over 5 years** |
| **2025** |  |  |  |  |
| **Non-Derivatives** |  |  |  |  |
| Accounts payable to unrelated parties | 722974 | 206 |  |  |
| Accounts payable to related parties | 97951 |  |  |  |
| Other financial liabilities | 952436 | 267 | 429 | 12784 |
| Short-term debt | 17015 |  |  |  |
| Bonds | 1696547 | 1627094 | 2355856 | 1968541 |
| Other long-term debt | 33606 | 68562 | 235990 | 1602 |
| Lease liabilities <sup>(1)</sup> | 710456 | 1305953 | 905037 | 1102559 |
| Variable payments outstanding for acquisitions | 238 | 157 |  | 2905 |
| Put option liabilities | 638009 | 85062 | 58808 | 27280 |
|  | 4869232 | 3087301 | 3556120 | 3115671 |
| **Derivatives** |  |  |  |  |
| **Derivative financial instruments - in cash flow hedging relationships** |  |  |  |  |
| (Inflow) | (202641) | (7910) |  |  |
| Outflow | 205879 | 7728 |  |  |
|  | 3238 | (182) |  |  |
| **Derivative financial instruments - not designated as hedging instrument** |  |  |  |  |
| (Inflow) | (799873) | (27542) | (7444) | (38283) |
| Outflow | 810124 | 35790 | 9226 | 24683 |
|  | 10251 | 8248 | 1782 | (13600) |
| **Total**  | 4882721 | 3095367 | 3557902 | 3102071 |
| **2024** |  |  |  |  |
| **Non-Derivatives** |  |  |  |  |
| Accounts payable to unrelated parties | 904278 | 378 |  |  |
| Accounts payable to related parties | 80044 |  |  |  |
| Other financial liabilities | 937181 | 365 | 363 | 13324 |
| Short-term debt | 2099 |  |  |  |
| Bonds | 638721 | 2906524 | 1128390 | 2460076 |
| Other long-term debt | 46220 | 81585 | 242992 | 3564 |
| Lease liabilities <sup>(1)</sup> | 783791 | 1476278 | 1067295 | 1408652 |
| Variable payments outstanding for acquisitions | 1127 | 4986 | 157 | 1739 |
| Put option liabilities | 807207 | 402667 | 90460 | 24902 |
|  | 4200668 | 4872783 | 2529657 | 3912257 |
| **Derivatives** |  |  |  |  |
| **Derivative financial instruments - in cash flow hedging relationships** |  |  |  |  |
| (Inflow) | (371514) |  |  |  |
| Outflow | 388522 |  |  |  |
|  | 17008 |  |  |  |
| **Derivative financial instruments - not designated as hedging instrument** |  |  |  |  |
| (Inflow) | (1774151) | (16598) | (4747) | (18954) |
| Outflow | 1818926 | 19182 | 11401 | 52269 |
|  | 44775 | 2584 | 6654 | 33315 |
| **Total**  | 4262451 | 4875367 | 2536311 | 3945572 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes amounts from related parties.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**27.** **Other comprehensive income (loss)**

The changes in the components of other comprehensive income (loss) for the years ended December 31, 2025, 2024, and 2023 are as follows:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Other comprehensive income (loss)** | **Other comprehensive income (loss)** | **Other comprehensive income (loss)** | **Other comprehensive income (loss)** | **Other comprehensive income (loss)** | **Other comprehensive income (loss)** | **Other comprehensive income (loss)** | **Other comprehensive income (loss)** | **Other comprehensive income (loss)** | **Other comprehensive income (loss)** |
| *in € K* |  |  |  |  |  |  |  |  |  |
|  | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2023** | **2023** | **2023** |
|  | **Pretax** | **Tax effect** | **Net** | **Pretax** | **Tax effect** | **Net** | **Pretax** | **Tax effect** | **Net** |
| **Components that will not be reclassified to profit or loss:** |  |  |  |  |  |  |  |  |  |
| FVOCI equity investments | 6537 | 215 | 6752 | (15586) | (98) | (15684) | 18046 | (209) | 17837 |
| Actuarial gain (loss) on defined benefit pension plans | 72462 | (23173) | 49289 | 15990 | (2843) | 13147 | (58455) | 16405 | (42050) |
| **Components that may be reclassified subsequently to profit or loss:** |  |  |  |  |  |  |  |  |  |
| Foreign currency translation adjustment, net of reclassification adjustments resulting from deconsolidation | (1544634) |  | (1544634) | 727473 |  | 727473 | (607873) |  | (607873) |
| FVOCI debt securities | 7639 | (1265) | 6374 | (857) | 271 | (586) | 7299 | (1321) | 5978 |
| Other comprehensive income (loss) relating to cash flow hedges: |  |  |  |  |  |  |  |  |  |
| Changes in fair value of cash flow hedging reserve during the period | 27946 | (8425) | 19521 | (7159) | 783 | (6376) | 2787 | (1031) | 1756 |
| Cost of hedging | (3842) | 1161 | (2681) | (895) | 39 | (856) | (3547) | 1132 | (2415) |
| Reclassification adjustments | (2812) | 1784 | (1028) | (2718) | 1502 | (1216) | (4718) | 1474 | (3244) |
| Total other comprehensive income (loss) relating to cash flow hedges | 21292 | (5480) | 15812 | (10772) | 2324 | (8448) | (5478) | 1575 | (3903) |
| Other comprehensive income (loss) | (1436704) | (29703) | (1466407) | 716248 | (346) | 715902 | (646461) | 16450 | (630011) |

---

**28.**Supplementary cash flow information

The following additional information is provided with respect to net cash provided by (used in) investing activities for the years ended December 31, 2025, 2024 and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Details for net cash provided by (used in) investing activities** | **Details for net cash provided by (used in) investing activities** | **Details for net cash provided by (used in) investing activities** | **Details for net cash provided by (used in) investing activities** |
| *in € K* |  |  |  |
|  | **2025** | **2024** | **2023** |
| **Details for acquisitions** |  |  |  |
| Assets acquired | (23055) | (231) | (3770) |
| Liabilities assumed | 2747 |  |  |
| Noncontrolling interests | 3494 |  | 567 |
| Non-cash consideration | 292 | 54 | 61 |
| Cash paid | (16522) | (177) | (3142) |
| Less cash acquired | 1220 |  |  |
| **Net cash paid for acquisitions** | **(15302)** | **(177)** | **(3142)** |
| **Cash paid for investments** | **(2002)** | **(14345)** | **(5694)** |
| **Cash paid for intangible assets** | **(4668)** | **(8544)** | **(26366)** |
| **Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets** | **(21972)** | **(23066)** | **(35202)** |
| **Details for divestitures** |  |  |  |
| Cash received from sale of subsidiaries or other businesses, less cash disposed | 202140 | 629749 | 172201 |
| **Proceeds from divestitures** | **202140** | **629749** | **172201** |

---

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

The following table shows a reconciliation of debt to net cash provided by (used in) financing activities for 2025:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** |
| *in € K* |  |  |  |  |  |  |  |
|  |  |  | **Non-cash changes** | **Non-cash changes** | **Non-cash changes** | **Non-cash changes** |  |
|  |  |  |  |  | **Amortization** |  |  |
|  |  |  | **Acquisitions** | **Foreign** | **of debt** |  |  |
|  | **January 1,** | **Cash** | **(net of**  | **currency** | **issuance costs** |  | **December 31,**  |
|  | **2025** | **Flow** | **divestitures)** | **translation** | **and discounts** | **Other** | **2025** |
| Short-term debt from unrelated parties | 2099 | 15652 |  | (722) |  | (14) | 17015 |
| Long-term debt | 6836108 | 782968 | 227 | (346181) | 10113 | 4646 | 7287881 |
| Lease liabilities from unrelated parties | 4027838 | (623323) | (2010) | (395778) |  | 465880<br> <sup>(1)</sup> | 3472607 |
| Lease liabilities from related parties | 112863 | (25715) |  | 24 |  | (69070)<br> <sup>(1)</sup> | 18102 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes newly concluded leases, lease modifications and reassessments of leases with third parties and related parties. Furthermore, interest expense in the amount of €143,211 , net of interest paid (included in Net cash provided by (used in) operating activities), are included.

The following table shows a reconciliation of debt to net cash provided by (used in) financing activities for 2024:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** | **Reconciliation of debt to net cash provided by (used in) financing activities** |
| *in € K* |  |  |  |  |  |  |  |
|  |  |  | **Non-cash changes** | **Non-cash changes** | **Non-cash changes** | **Non-cash changes** |  |
|  |  |  |  |  | **Amortization** |  |  |
|  |  |  | **Acquisitions** | **Foreign** | **of debt** |  |  |
|  | **January 1,** | **Cash** | **(net of**  | **currency** | **issuance costs** |  | **December 31,**  |
|  | **2024** | **Flow** | **divestitures)** | **translation** | **and discounts** | **Other** | **2024** |
| Short-term debt from unrelated parties | 456904 | (455687) | 2105 | 83 |  | (1306) | 2099 |
| Long-term debt (excluding Accounts Receivable Facility)<sup>(1)</sup> | 7424705 | (772949) | (2593) | 183142 | 9029 | (5226) | 6836108 |
| Accounts Receivable Facility<sup>(1)</sup> | 22857 | (23096) |  | 477 |  | (238) |  |
| Lease liabilities from unrelated parties | 4012371 | (651686) | (53764) | 193046 |  | 527871<br> <sup>(2)</sup> | 4027838 |
| Lease liabilities from related parties | 133575 | (24827) |  | (20) |  | 4135<br> <sup>(2)</sup> | 112863 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Company maintained an accounts receivable securitization program (Accounts Receivable Facility) with a maximum capacity of $900,000 (€768,049 at the date of execution) and an ending term date of August 11, 2024. On May 31, 2024, the Company voluntarily terminated the Accounts Receivable Facility.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Includes newly concluded leases, lease modifications and reassessments of leases with third parties and related parties. Furthermore, interest expense in the amount of €148,420 , net of interest paid (included in Net cash provided by (used in) operating activities), are included.

Interest payments are included in operating activities in the consolidated statements of cash flows in the amount of €350,789 and €367,503 as of December 31, 2025 and 2024.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

**29.**Segment and corporate information

The operating segments are determined based upon how the Company manages its businesses and allocates resources with responsibilities by products and services and is aligned to the financial information that is presented on a quarterly basis to the chief operating decision maker. The Care Enablement segment is primarily engaged in the distribution of healthcare products and equipment, including R&D, manufacturing, supply chain, and commercial operations, as well as supporting functions such as regulatory and quality management. The Care Delivery segment is primarily engaged in providing healthcare services for the treatment of CKD, ESRD, and other extracorporeal therapies. Care Delivery also includes the pharmaceutical products business and the income from equity method investees related to the sale of certain renal pharmaceuticals from Vifor Fresenius Medical Care Renal Pharma Ltd., which are used in the Company's clinics to provide healthcare services to its patients. As of June 1, 2025, a new reportable segment, "Value-Based Care," was created to align with recent changes to internal management reporting. The Value-Based Care operating segment is primarily focused on value-based kidney care, including contracting and performance management, clinical care models supported by a national network of nephrologists, and tech-enabled platforms that leverage proprietary informatics and patient engagement tools. Value and risk-based care arrangements with private payors or government programs may include shared savings or losses from reductions or increases in the overall medical spend of a population under management which are accounted for in accordance with IFRS 15, Revenue from Contracts with Customers. Premiums and medical costs included in full risk arrangements, however, are accounted for in accordance with IFRS 17, Insurance Contracts. Premium revenue and claim costs are presented separately as insurance revenue and insurance costs of revenue, respectively, on the consolidated statements of income and constitute the majority of revenue and costs of revenue for the segment. Prior to June 1, 2025, discrete financial information was not provided to the chief operating decision maker on the basis of the new structure and the necessary systems and reporting changes to effect the new structure were not in place.

The Company's Global Medical Office, which seeks to optimize medical treatments and clinical processes within the Company and supports both Care Delivery and Care Enablement, is centrally managed and its profit and loss are allocated to those specific segments. Similarly, costs related primarily to headquarters overhead charges, including accounting and finance as well as certain human resources, legal, and IT costs, are allocated as these costs are attributable to the segments, and used in the allocation of resources to Care Delivery and Care Enablement. These costs are allocated at budgeted amounts, with the difference between budgeted and actual figures recorded at the corporate level. The Value-Based Care segment maintains its own separate finance, accounting, human resources, legal, medical office, and other administrative functions and is therefore excluded from the allocation process. Additionally, certain costs, which relate mainly to shareholder activities, management activities, global internal audit, and the remeasurement of certain investments and virtual power purchase agreements, are not allocated to a segment but are accounted for as corporate expenses. These activities do not fulfill the definition of a segment according to IFRS 8, Operating Segments, and are reported separately as Corporate (Corporate). Interest income, interest expense, and tax expense are neither included within the measure of segment profit or loss reviewed by the chief operating decision maker nor otherwise regularly provided to the chief operating decision maker by segment and are therefore not included in the presented segment information.

Management evaluates each segment using measures that reflect all of the segment's controllable revenues and expenses. With respect to the performance of business operations, management believes that the most appropriate measures are revenue and operating income. Services provided by the Care Delivery segment in the U.S. for patients managed under the Value-Based Care segment are provided at fair market value. The Company also transfers products from the Care Enablement segment to the Care Delivery segment at fair market value. The associated internal revenues and expenses and any remaining internally generated profit or loss for the products transferred and services provided are recorded within the operating segments initially, are eliminated upon consolidation and are included within "Inter-segment eliminations." Capital expenditures for production are based on the expected demand of the segments and consolidated profitability considerations.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

Information pertaining to the Company's segment and Corporate activities for the years ended December 31, 2025, 2024 and 2023 is set forth below. The prior year figures have been restated to align to the new operating and reportable segment structure:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Segment and corporate information** | **Segment and corporate information** | **Segment and corporate information** | **Segment and corporate information** | **Segment and corporate information** | **Segment and corporate information** | **Segment and corporate information** | **Segment and corporate information** |
| *in € K* |  |  |  |  |  |  |  |
|  | **Care** |  | **Care** | **Total** | **Inter-segment** |  |  |
|  | **Delivery** | **Value-Based Care** | **Enablement** | **Segment** | **eliminations** | **Corporate** | **Total** |
| **2025** |  |  |  |  |  |  |  |
| Revenue from healthcare services<sup>(1)</sup> | 12966604 | 130663 |  | 13097267 |  |  | 13097267 |
| Revenue from healthcare products<sup>(1)</sup> | 271717 |  | 4054006 | 4325723 |  |  | 4325723 |
| Revenue from contracts with customers<sup>(1)</sup> | 13238321 | 130663 | 4054006 | 17422990 |  |  | 17422990 |
| Revenue from insurance contracts<sup>(1)</sup> |  | 2116710 |  | 2116710 |  |  | 2116710 |
| Revenue from lease contracts<sup>(1)</sup> |  |  | 87902 | 87902 |  |  | 87902 |
| Revenue from external customers | 13238321 | 2247373 | 4141908 | 19627602 |  |  | 19627602 |
| Inter-segment revenue | 497951 |  | 1334279 | 1832230 | (1832230) |  |  |
| Revenue | 13736272 | 2247373 | 5476187 | 21459832 | (1832230) |  | 19627602 |
| Costs of revenue | (10517158) | (2132390) | (3780225) | (16429773) | 1835995 | (4895) | (14598673) |
| Research and development |  |  | (158181) | (158181) |  | 206 | (157975) |
| Operating income (loss) | 1614099 | 1225 | 325893 | 1941217 | 4924 | (119105) | 1827036 |
| Interest |  |  |  |  |  |  | (314798) |
| Income before income taxes |  |  |  |  |  |  | 1512238 |
| Depreciation and amortization | (976400) | (4939) | (457103) | (1438442) | 41991 | (66962) | (1463413) |
| Impairment loss | (31583) | (2118) | (3288) | (36989) |  | (7) | (36996) |
| Income (loss) from equity method investees | 181368 |  |  | 181368 |  |  | 181368 |
| Total assets<sup>(1)</sup> | 39239152 | 640213 | 13555088 | 53434453 | (33430072) | 10997952 | 31002333 |
| thereof investment in equity method investees<sup>(1)</sup> | 663652 |  |  | 663652 |  |  | 663652 |
| Additions of property, plant and equipment, intangible assets and right-of-use assets<sup>(1)</sup> | 726505 | 364 | 736725 | 1463594 | (29475) | 44432 | 1478551 |
| **2024** |  |  |  |  |  |  |  |
| Revenue from healthcare services<sup>(1)</sup> | 13332931 | 138432 |  | 13471363 |  |  | 13471363 |
| Revenue from healthcare products<sup>(1)</sup> | 189733 |  | 3996462 | 4186195 |  |  | 4186195 |
| Revenue from contracts with customers<sup>(1)</sup> | 13522664 | 138432 | 3996462 | 17657558 |  |  | 17657558 |
| Revenue from insurance contracts<sup>(1)</sup> |  | 1614024 |  | 1614024 |  |  | 1614024 |
| Revenue from lease contracts<sup>(1)</sup> |  |  | 64327 | 64327 |  |  | 64327 |
| Revenue from external customers | 13522664 | 1752456 | 4060789 | 19335909 |  |  | 19335909 |
| Inter-segment revenue | 480797 |  | 1495745 | 1976542 | (1976542) |  |  |
| Revenue | 14003461 | 1752456 | 5556534 | 21312451 | (1976542) |  | 19335909 |
| Costs of revenue | (10922292) | (1678638) | (3915405) | (16516335) | 1952344 | (15266) | (14579257) |
| Research and development | (41) |  | (183449) | (183490) |  | (3) | (183493) |
| Operating income (loss) | 1217971 | (28152) | 267098 | 1456917 | (16571) | (47951) | 1392395 |
| Interest |  |  |  |  |  |  | (335469) |
| Income before income taxes |  |  |  |  |  |  | 1056926 |
| Depreciation and amortization | (1040805) | (4375) | (462507) | (1507687) | 44073 | (71922) | (1535536) |
| Impairment loss | (185156) |  | (21555) | (206711) |  | (10) | (206721) |
| Income (loss) from equity method investees | 134875 |  |  | 134875 |  |  | 134875 |
| Total assets<sup>(1)</sup> | 42719297 | 679712 | 14685989 | 58084998 | (35330991) | 10812572 | 33566579 |
| thereof investment in equity method investees<sup>(1)</sup> | 620831 |  |  | 620831 |  |  | 620831 |
| Additions of property, plant and equipment, intangible assets and right-of-use assets<sup>(1)</sup> | 882599 | 480 | 506501 | 1389580 | (56301) | 41450 | 1374729 |
| **2023** |  |  |  |  |  |  |  |
| Revenue from healthcare services<sup>(1)</sup> | 14116820 | 49976 |  | 14166796 |  |  | 14166796 |
| Revenue from healthcare products<sup>(1)</sup> | 184021 |  | 3795101 | 3979122 |  |  | 3979122 |
| Revenue from contracts with customers<sup>(1)</sup> | 14300841 | 49976 | 3795101 | 18145918 |  |  | 18145918 |
| Revenue from insurance contracts<sup>(1)</sup> |  | 1227140 |  | 1227140 |  |  | 1227140 |
| Revenue from lease contracts<sup>(1)</sup> |  |  | 80559 | 80559 |  |  | 80559 |
| Revenue from external customers | 14300841 | 1277116 | 3875660 | 19453617 |  |  | 19453617 |
| Inter-segment revenue | 447770 |  | 1469768 | 1917538 | (1917538) |  |  |
| Revenue | 14748611 | 1277116 | 5345428 | 21371155 | (1917538) |  | 19453617 |
| Costs of revenue | (11348785) | (1250330) | (3834084) | (16433199) | 1904833 | (246) | (14528612) |
| Research and development | (42) |  | (231656) | (231698) |  | (272) | (231970) |
| Operating income (loss) | 1611544 | (95732) | (66521) | 1449291 | (12705) | (67148) | 1369438 |
| Interest |  |  |  |  |  |  | (336423) |
| Income before income taxes |  |  |  |  |  |  | 1033015 |
| Depreciation and amortization | (1120107) | (5518) | (457497) | (1583122) | 41079 | (70694) | (1612737) |
| Impairment loss | (89963) |  | (49154) | (139117) |  | (117) | (139234) |
| Income (loss) from equity method investees | 115354 |  | 6431 | 121785 |  |  | 121785 |
| Total assets<sup>(1)</sup> | 41058324 | 655345 | 13392422 | 55106091 | (31135993) | 9959710 | 33929808 |
| thereof investment in equity method investees<sup>(1)</sup> | 642928 |  |  | 642928 |  |  | 642928 |
| Additions of property, plant and equipment, intangible assets and right-of-use assets<sup>(1)</sup> | 775274 | 860 | 528769 | 1304903 | (31118) | 42953 | 1316738 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) These line items are included to comply with requirements under IFRS 8 and IFRS 15 or are provided on a voluntary basis, but not included in the information regularly reviewed by the chief operating decision maker.

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

For the geographic presentation, revenues are attributed to specific countries based on the end user's location for products and the country in which the service is provided. Information with respect to the Company's geographic operations is set forth in the table below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Geographic presentation**  |  |  |  |  |  |  |
| *in € K* |  |  |  |  |  |  |
|  | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
|  | **Revenue from** |  | **Revenue from** |  | **Revenue from** |  |
|  | **external customers** | **Non-current assets** | **external customers** | **Non-current assets** | **external customers** | **Non-current assets** |
| Germany | 494574 | 2040299 | 478962 | 1866455 | 484238 | 2053635 |
| Rest of the world | 19133028 | 20167305 | 18856947 | 22754054 | 18969379 | 22188768 |
| &nbsp;&nbsp;thereof U.S. | 14180803 | 17105345 | 13667244 | 19681537 | 13506250 | 18932918 |
| Total | 19627602 | 22207604 | 19335909 | 24620509 | 19453617 | 24242403 |

---

**30.**Subsequent events

On January 9, 2026, the Company announced that it would accelerate its share buyback program and start the repurchase of the second tranche. The program has a total volume of €1,000,000. The first tranche of the Company's share buyback program was completed ahead of schedule on December 29, 2025, under which 14,124,564 shares were repurchased for €586,450 (including true-ups). Under the second tranche, the Company plans to repurchase a total amount of around €413,550 from January 12 to May 8, 2026. The share buyback program is expected to be completed significantly earlier than originally planned, in less than a year. The purchase of the shares is based on the authorization granted by the General Meeting on May 20, 2021. Additionally, on February 20, 2026, the U.S. Supreme Court ruled that the tariffs imposed under International Emergency Economic Powers Act of 1977 (IEEPA) enacted by the Trump Administration in the U.S. exceed the power provided by the IEEPA, although uncertainty regarding global trade policies remains as the administration indicated it could enact tariffs under other mechanisms. The previously imposed tariffs did not have a material impact on the Company as of and for the year ended December 31, 2025.

No other significant activities have taken place subsequent to the balance sheet date December 31, 2025 that have a material impact on the key figures and earnings presented.

In connection with the retirement of Mr. Franklin W. Maddux, MD as Global Chief Medical Officer and a member of the Management Board and the retirement of Dr. Katarzyna Mazur - Hofsäß as the member of the Management Board responsible for Care Enablement, Mr. Charles Hugh - Jones, MD, FRCP and Mr. Joseph E. (Joe) Turk, respectively, were appointed to the Management Board, effective January 1, 2026. Currently, there are no other significant changes in the Company's structure, management, legal form or personnel.

**31.** **Compensation of the Management Board and the Supervisory Board**

**Compensation of the Management Board**

The total compensation of the members of the Management Board for the fiscal year 2025 amounted to €27,848 (2024: €21,109) and consisted of non-performance-based compensation (including, for example, base salaries, fringe benefits and cash pension allowances) in the total amount of €13,609 (2024: €8,915), short-term performance-based compensation in the total amount of €5,677 (2024: €7,094) and components with long-term incentive effects (multi-year variable compensation) with a total grant date fair value of €8,562 (2024: €5,100). The components with long-term incentive effects consist of 230,873 Performance Shares allocated under the MB LTIP 2024+ which will be settled in shares of the Company (2024: 266,497 Performance shares which will be settled in cash). The fringe benefits for 2024 included a cash payment of €416 which was provided as payment for forfeited compensation from a previous employment relationship and of which 50% of the net amount was invested in shares of the Company in line with a contractual agreement.

Under IFRS Accounting Standards, pension expense (service costs) for the members of the Management Board in 2025 amounted to €621 (2024: €1,737), expense from long-term incentive share-based compensation plans amounted to €4,784 (2024: €1,757) and expense for termination benefits amounted to €15 (2024: €—); no expense for other long-term benefits was incurred (2024: €144). Total compensation expense, in accordance with IFRS Accounting Standards, for the members of the Management Board amounted to €24,706 (2024: €19,647).

[**Table of Contents**](#TOC)

**FRESENIUS MEDICAL CARE AG**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in K, except share and per share data)**

As of December 31, 2025, outstanding balances with respect to the members of the Management Board amounted to €17,624 (December 31, 2024: €18,283) and consisted mainly of pension commitments, provisions for performance-based compensation components as well as entitlements under long-term incentive plans. Short-term performance-based compensation is linked to the achievement of three financial targets (based on Revenue, Operating income and Net income) and one non-financial target (Sustainability), which for 2025 consists of the two equally weighted sub-targets patient satisfaction and employee satisfaction. The individual contractual defined benefit pension commitments provide for pension and survivor benefits as of the time of conclusively ending active work or in case of full or partial reduction in earning capacity, and the amount of such benefits is calculated by reference to the amount of the Management Board member's most recent base salary. For information on the terms and conditions of the long-term incentive plans see note 23.

The total compensation of former members of the Management Board and the management board of Fresenius Medical Care Management AG amounted to €2,553 (2024: €2,525). As of December 31, 2025, pension obligations, according to IAS 19, towards this group of persons exist in an amount of €57,086 (December 31, 2024: €58,609).

**Compensation of the supervisory board**

In 2025, the total compensation of the members of the Supervisory Board amounted to €3,245 (2024: €3,002).

**32.** **Principal accountant fees and services**

In 2025, 2024, and 2023, fees for the auditor, PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft (PwC), and its affiliates were expensed as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Fees** | **Fees** | **Fees** | **Fees** | **Fees** | **Fees** | **Fees** |
| *in € K* |  |  |  |  |  |  |
|  | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
|  | **Consolidated** | **thereof** | **Consolidated** | **thereof** | **Consolidated** | **thereof** |
|  | **group** | **Germany** | **group** | **Germany** | **group** | **Germany** |
| Audit fees  | 13330 | 3241 | 16126 | 4694 | 14250 | 3215 |
| Audit-related fees  | 1403 | 704 | 1549 | 960 | 1897 | 937 |
| Tax fees | 23 |  |  |  |  |  |
| Other fees | 16 |  |  |  |  |  |

---

Audit fees are the aggregate fees billed by the Company's auditors for the audit of the Company's consolidated financial statements and the statutory financial statements of FME AG and of its subsidiaries, reviews of interim financial statements and attestation services that are provided in connection with statutory and regulatory filings or engagements. Fees related to the audit of internal control over financial reporting are included in audit fees.

Audit-related fees are fees charged by the Company's auditors for assurance and related services that are reasonably related to the performance of the audit or review of the Company's financial statements and are not reported under audit fees. This category mainly comprises fees billed by PwC for comfort letters, audit of the compensation report of the management board, audit of the sustainability reporting with limited assurance, agreed-upon procedure engagements, project related audits of IT migrations, and other attestation services subject to regulatory requirements.

Tax fees are fees for professional services rendered by the Company's auditors for tax advisory services required by law in the U.S. and transfer pricing tax compliance services in Ukraine. Other fees include amounts related to licenses for access to accounting literature resources.

[**Table of Contents**](#TOC)

**Item 19.** **Exhibits**

Pursuant to the provisions of the Instructions for the filings of Exhibits to Annual Reports on Form 20-F, Fresenius Medical Care AG (the Registrant) is filing the following exhibits:

1.1 [Convenience translation of the Articles of Association (Satzung) of the Registrant (incorporated by reference to Exhibit 3. 1 to Registrant's Report on Form 6-K for the month of August 2025, furnished August 5, 2025).](https://www.sec.gov/Archives/edgar/data/1333141/000110465925074015/fms-20250331xex3d1.htm)

2.1 [Description of Securities (filed herewith).](fms-20251231xex2d1.htm)

2.2 [Amended and Restated Deposit Agreement dated as of November 30, 2023 between The Bank of New York Mellon and the Registrant relating to ordinary share ADSs (incorporated by reference to Exhibit 2.2 to the Registrant's Annual Report on form 20-F for the year ended December 31, 2023, filed February 20, 2024).](https://www.sec.gov/Archives/edgar/data/1333141/000110465924025293/fms-20231231xex2d2.htm)

2.3 [Form of American Depositary Receipt for American Depositary Shares representing ordinary shares (included as Exhibit A to the Amended and Restated Deposit Agreement dated as of November 30, 2023. See Exhibit 2.2).](https://www.sec.gov/Archives/edgar/data/1333141/000110465924025293/fms-20231231xex2d2.htm)

2.4 [Indenture (including the Guarantee set forth therein) dated as of June 20, 2019 by and among Fresenius Medical Care US Finance III, Inc., the Company and Fresenius Medical Care Holdings, Inc., as Guarantors <sup>(1)</sup> , and U.S. Bank National Association, as Trustee, related to the 3.750% Notes due 2029 of Fresenius Medical Care US Finance III, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant's report on Form 6-K for the month of July 2019, furnished July 30, 2019).](https://www.sec.gov/Archives/edgar/data/1333141/000104746919004442/a2239341zex-10_1.htm)

2.5 [Indenture (including the Guarantee set forth therein) dated as of September 16, 2020 by and among Fresenius Medical Care US Finance III, Inc., the Company and Fresenius Medical Care Holdings, Inc., as Guarantors <sup>(1)</sup> , and U.S. Bank National Association, as Trustee, related to the 2.375% Notes due 2031 of Fresenius Medical Care US Finance III, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant's report on Form 6-K for the month of October 2020, furnished October 29, 2020).](https://www.sec.gov/Archives/edgar/data/1333141/000104746920005337/a2242489zex-10_3.htm)

2.6 [Indenture (including the Guarantee set forth therein) dated as of May, 18, 2021 by and among Fresenius Medical Care US Finance III, Inc. as issuer, the Company and Fresenius Medical Care Holdings, Inc., as Guarantors <sup>(1)</sup> , and U.S. Bank National Association, as Trustee, related to the 1.875% Notes due 2026 of Fresenius Medical Care US Finance III, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant's Report on Form 6-K for the month of July 2021, furnished July 30, 2021).](https://www.sec.gov/Archives/edgar/data/1333141/000110465921098033/fms-20210630xex10d1.htm)

2.7 [Indenture (including the Guarantee set forth therein) dated as of May 18, 2021 by and among Fresenius Medical Care US Finance III, Inc. as issuer, the Company and Fresenius Medical Care Holdings, Inc., as Guarantors <sup>(1)</sup> , and U.S. Bank National Association, as Trustee, related to the 3.000% Notes due 2031 of Fresenius Medical Care US Finance III, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant's Report on Form 6-K for the month of July 2021, furnished July 30, 2021).](https://www.sec.gov/Archives/edgar/data/1333141/000110465921098033/fms-20210630xex10d2.htm)

2.8 [Final Terms dated November 27, 2019 for EUR 600,000,000 0.625% Fixed Rate Euro-Denominated Bonds due 2026 (incorporated by reference to Exhibit 2.21 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2019, filed February 20, 2020). <sup>(1)</sup>](https://www.sec.gov/Archives/edgar/data/1333141/000104746920000960/a2240706zex-2_21.htm)

2.9 [Final Terms dated November 27, 2019 for EUR 500,000,000 1.250% Fixed Rate Euro-Denominated Bonds due 2029 (incorporated by reference to Exhibit 2.22 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2019, filed February 20, 2020). <sup>(1)</sup>](https://www.sec.gov/Archives/edgar/data/1333141/000104746920000960/a2240706zex-2_22.htm)

2.10 [Final Terms dated May 27, 2020 for EUR 750,000,000 1.500% Fixed Rate Euro-Denominated Bonds due 2030 (incorporated by reference to Exhibit 10.1 to the Registrant's Report on Form 6-K for the month of July 2020, furnished July 30, 2020). <sup>(1)</sup>](https://www.sec.gov/Archives/edgar/data/1333141/000104746920004330/a2241947zex-10_1.htm)

2.11 [Final Terms dated May 27, 2020 for EUR 500,000,000 1.000% Fixed Rate Euro-Denominated Bonds due 2026 (incorporated by reference to Exhibit 10.2 to the Registrant's Report on Form 6-K for the month of July 2020, furnished July 30, 2020). <sup>(1)</sup>](https://www.sec.gov/Archives/edgar/data/1333141/000104746920004330/a2241947zex-10_2.htm)

2.12 [Final Terms dated September 15, 2022 for EUR 750,000,000 3.875% Fixed Rate Euro-Denominated Bonds due 2027 (incorporated by reference to Exhibit 10.3 to the Registrant's Report on Form 6-K for the month of October 2022, furnished October 31, 2022). <sup>(1)</sup>](https://www.sec.gov/Archives/edgar/data/1333141/000110465922112897/fms-20220930xex10d3.htm)

2.13 [Final Terms dated April 4, 2025 for EUR 600,000,000 3.125% Fixed Rate Euro-Denominated Bonds due 2028 (incorporated by reference to Exhibit 10.1 to the Registrant's Report on Form 6-K for the month of May 2025, furnished May 6, 2022).](https://www.sec.gov/Archives/edgar/data/1333141/000110465925045038/fms-20250331xex10d1.htm)

2.14 [Final Terms dated April 4, 2025 for EUR 500,000,000 3.750% Fixed Rate Euro-Denominated Bonds due 2032 (incorporated by reference to Exhibit 10.2 to the Registrant's Report on Form 6-K for the month of May 2025, furnished May 6, 2022).](https://www.sec.gov/Archives/edgar/data/1333141/000110465925045038/fms-20250331xex10d2.htm)

2.15 [Final Terms dated November 24, 2025 for EUR 500,000,000 3.250% Fixed Rate Euro-Denominated Bonds due 2030 (filed herewith).](fms-20251231xex2d15.htm)

2.16 [Sustainability-Linked Revolving Credit Facility Agreement dated July 1, 2021 between the Company and Fresenius Medical Care Holdings, Inc. as borrowers and guarantors, and the financial institutions party thereto in their respective capacities as Coordinators, Bookrunners, Arrangers, Original Lenders (including their respective Original Lending Affiliates), Sustainability Agent, Agent and Swingline Agent (incorporated by reference to Exhibit 10.3 to the Registrant's Report on Form 6-K for the month of July 2021, furnished July 30, 2021).](https://www.sec.gov/Archives/edgar/data/1333141/000110465921098033/fms-20210630xex10d3.htm)

[**Table of Contents**](#TOC)

2.17 [Amendment dated June 8, 2022 to the Sustainability-Linked Revolving Credit Facility Agreement dated July 1, 2021 between the Company and Fresenius Medical Care Holdings, Inc. as borrowers and guarantors, and the financial institutions party thereto in their respective capacities as Coordinators, Bookrunners, Arrangers, Original Lenders (including their respective Original Lending Affiliates), Sustainability Agent, Agent and Swingline Agent (incorporated by reference to Exhibit 10.1 to the Registrant's Report on Form 6-K for the month of August 2022, furnished August 2, 2022).](https://www.sec.gov/Archives/edgar/data/1333141/000110465922085015/fms-20220630xex10d1.htm)

2.18 [Amendment and Restatement Agreement dated November 26, 2024 amending the Sustainability-Linked Revolving Credit Facility Agreement dated July 1, 2021, as previously amended, between the Company and Fresenius Medical Care Holdings, Inc. as borrowers and guarantors, and the financial institutions party thereto in their respective capacities as Coordinators, Bookrunners, Arrangers, Original Lenders (including their respective Original Lending Affiliates), Sustainability Agent, Agent and Swingline Agent (incorporated by reference to Exhibit 2.16 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2024, filed February 25, 2025).](https://www.sec.gov/Archives/edgar/data/1333141/000110465925016784/fms-20241231xex2d16.htm)

4.1 [Lease Agreement for Office Facilities dated March 9, 2017, effective as of January 1, 2017, as amended, by and between Fresenius SE & Co. KGaA and Fresenius Medical Care AG and Fresenius Medical Care Deutschland GmbH (incorporated by reference to Exhibit 4.3 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2024, filed February 25, 2025). <sup>(2)</sup>](https://www.sec.gov/Archives/edgar/data/1333141/000110465925016784/fms-20241231xex4d3.htm)

4.2 [Lease Agreement for Office Facilities - EK 3, Bad Homburg dated June 1, 2020, effective as of December 31, 2019, as amended. by and between Fresenius SE & Co. KGaA and Fresenius Medical Care Deutschland GmbH (incorporated by reference to Exhibit 4.4 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2024, filed February 25, 2025). <sup>(2)</sup>](https://www.sec.gov/Archives/edgar/data/1333141/000110465925016784/fms-20241231xex4d4.htm)

4.3 Trademark License Agreement dated September 27, 1996 by and between Fresenius AG and Fresenius Medical Care Deutschland GmbH. (Incorporated by reference to Exhibit 10.8 to Fresenius Medical Care AG's Registration Statement on Form F-1, Registration No. 333-05922, filed November 16, 1996).

4.4 [Long form of Amendment dated December 22, 2025 to the Trademark License Agreement dated September 27, 1996 by and between Fresenius SE & Co. KGaA and Fresenius Medical Care Deutschland GmbH (filed herewith). <sup>(2)</sup>](fms-20251231xex4d4.htm)

4.5 [English convenience translation of the Fresenius Medical Care Management Board Long-Term Incentive Plan 2020 (incorporated by reference to Exhibit 4.13 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2020, filed February 22, 2021).](https://www.sec.gov/Archives/edgar/data/1333141/000104746921000424/a2242850zex-4_13.htm)

4.6 [English convenience translation of the Appendix to the Fresenius Medical Care Management Board Long-Term Incentive Plan 2020 Target Values and Determination of Target Achievement for the Grants of Performance Shares in Fiscal Years 2022 and 2023 (incorporated by reference to Exhibit 4.11 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2022 filed February 22, 2023).](https://www.sec.gov/Archives/edgar/data/1333141/000110465923024168/fms-20221231xex4d11.htm)

4.7 [English convenience translation of the Appendix to the Fresenius Medical Care Management Board Long-Term Incentive Plan 2020 Target Values and Determination of Target Achievement for the Grants of Performance Shares in Fiscal Year 2023 (incorporated by reference to Exhibit 4.12 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2022 filed February 22, 2023).](https://www.sec.gov/Archives/edgar/data/1333141/000110465923024168/fms-20221231xex4d12.htm)

4.8 [English convenience translation of the Fresenius Medical Care & Co. KGaA Long-Term Incentive Plan 2022+ (incorporated by reference to Exhibit 4.13 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2022 filed February 22, 2023).](https://www.sec.gov/Archives/edgar/data/1333141/000110465923024168/fms-20221231xex4d13.htm)

4.9 [Amendment to the Fresenius Medical Care AG & Co. KGaA Long Term Incentive Plan 2022+ (incorporated by reference to Exhibit 4.12 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2023, filed February 20, 2024).](https://www.sec.gov/Archives/edgar/data/1333141/000110465924025293/fms-20231231xex4d12.htm)

4.10 [Fresenius Medical Care AG Management Board Bonus Plan 2024+ (incorporated by reference to Exhibit 10.1 to Registrant's Report on Form 6-K for the month of May 2024, furnished May 7, 2024).](https://www.sec.gov/Archives/edgar/data/1333141/000110465924057786/fms-20240331xex10d1.htm)

4.11 [Fresenius Medical Care AG Management Board Long-Term Incentive Plan 2024+ as amended on May 15, 2024 (incorporated by reference to Exhibit 10.3 to Registrant's Report on Form 6-K for the month of July 2024, furnished July 30, 2024).](https://www.sec.gov/Archives/edgar/data/1333141/000110465924083777/fms-20240630xex10d3.htm)

4.12 [Fresenius Medical Care AG Long-Term Incentive Plan 2024+ (incorporated by reference to Exhibit 10.4 to Registrant's Report on Form 6-K for the month of November 2024, furnished November 5, 2024).](https://www.sec.gov/Archives/edgar/data/1333141/000110465924114165/fms-20240930xex10d4.htm)

4.13 [Fresenius Medical Care AG Long-Term Incentive Plan 2025+ (incorporated by reference to Exhibit 10.3 to Registrant's Report on Form 6-K for the month of August 2025, furnished August 5, 2025).](https://www.sec.gov/Archives/edgar/data/1333141/000110465925074015/fms-20250331xex10d3.htm)

4.14 [Non-Prosecution Agreement with the U.S. Department of Justice dated February 25, 2019 (incorporated by reference to Exhibit 4.15 to the Registrant's Report on Form 6-K for the month of May 2019, furnished May 2, 2019).](https://www.sec.gov/Archives/edgar/data/1333141/000104746919002820/a2238651zex-4_15.htm)

4.15 [Corrected Order Instituting Cease-And-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, And Imposing a Cease-And-Desist Order from the U.S. Securities and Exchange Commission (incorporated by reference to Exhibit 4.16 to the Registrant's Report on Form 6-K for the month of May 2019, furnished May 2, 2019).](https://www.sec.gov/Archives/edgar/data/1333141/000104746919002820/a2238651zex-4_16.htm)

4.16 [Framework Agreement in Relation to the Separation of Fresenius Medical Care Management AG entered into July 14, 2023 between Fresenius Medical Care Management AG, Fresenius Medical Care AG & Co. KGaA, Fresenius Medical Care Deutschland GmbH, Fresenius Medical Care Holdings, Inc. and Fresenius SE & Co. KGaA (incorporated by reference to Exhibit 4.17 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2023, filed February 20, 2024). <sup>(2)</sup>](https://www.sec.gov/Archives/edgar/data/1333141/000110465924025293/fms-20231231xex4d17.htm)

[**Table of Contents**](#TOC)

---

| | |
|:---|:---|
| 4.17 | [Group Separation Agreement relating to the deconsolidation of Fresenius Medical Care AG & Co. KGaA from Fresenius SE & Co. KGaA dated November 30, 2023 between Fresenius SE & Co. KGaA and Fresenius Medical Care AG & Co. KGaA (incorporated by reference to Exhibit 4.18 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2023, filed February 20, 2024). <sup>(2)</sup>](https://www.sec.gov/Archives/edgar/data/1333141/000110465924025293/fms-20231231xex4d18.htm) |
| 4.18 | [Master Agreement for Transitional Services relating to the deconsolidation of Fresenius Medical Care AG & Co. KGaA dated November 30, 2023 between Fresenius SE & Co. KGaA and Fresenius Medical Care AG & Co. KGaA (incorporated by reference to Exhibit 4.19 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2023, filed February 20, 2024). <sup>(2)</sup>](https://www.sec.gov/Archives/edgar/data/1333141/000110465924025293/fms-20231231xex4d19.htm) |
| 4.19 | [Insurance Brokerage Agreement dated November 2023, between Fresenius Medical Care AG & Co. KGaA and Fresenius Versicherungsvermittlungs GmbH (incorporated by reference to Exhibit 4.20 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2023, filed February 20, 2024).](https://www.sec.gov/Archives/edgar/data/1333141/000110465924025293/fms-20231231xex4d20.htm) |
| 8.1 | [List of Significant Subsidiaries. Our significant subsidiaries are identified in "Item 4.C. Information on the Company — Organizational structure."](#Item4C) |
| 11.1 | Code of Business Conduct. A copy of the Registrant's revised Code of Ethics and Business Conduct is available on the Registrant's website at: www.freseniusmedicalcare.com/en/about-us/compliance/our-code-of-ethics-and-business-conduct/  |
| 11.2 | Global Code of Conduct for Business Partners. A copy of the Registrant's Global Code of Conduct for Business Partners is available on the Registrant's website at: https://freseniusmedicalcare.com/en/sustainability/supply-chain/ |
| 11.3 | [Global Insider Policy (filed herewith).](fms-20251231xex11d3.htm) |
| 12.1 | [Certification of Chief Executive Officer and Chair of the Management Board of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).](fms-20251231xex12d1.htm) |
| 12.2 | [Certification of Chief Financial Officer and member of the Management Board of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).](fms-20251231xex12d2.htm) |
| 13.1 | [Certification of Chief Executive Officer and Chair of the Management Board of the Company Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). (This Exhibit is furnished herewith, but not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that we explicitly incorporate it by reference.)](fms-20251231xex13d1.htm) |
| 13.2 | [Certification of Chief Financial Officer and member of the Management Board of the Company Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). (This Exhibit is furnished herewith, but not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that we explicitly incorporate it by reference.)](fms-20251231xex13d2.htm) |
| 97 | [Fresenius Medical Care AG Incentive-Based Compensation Recovery Policy (incorporated by reference to Exhibit 97 to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2023 filed February 20, 2024).](https://www.sec.gov/Archives/edgar/data/1333141/000110465924025293/fms-20231231xex97.htm) |
| 101 | The following financial statements as of and for the twelve-month period ended December 31, 2025 from the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2025, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Income, (ii) Consolidated Statements of Comprehensive Income, (iii) Consolidated Balance Sheets, (iv) Consolidated Statements of Cash Flows, (v) Consolidated Statements of Shareholders' Equity and (vi) notes to the consolidated financial statements (filed herewith). |
| 104 | Cover page interactive data file (formatted as Inline XBRL and included in Exhibit 101). |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to the Amendment and Restatement Agreement (Exhibit 2.18), FMCH ceased to be a borrower and a guarantor under the Sustainability-Linked Revolving Credit Facility Agreement (Exhibit 2.16). The termination of FMCH's guarantee under this agreement terminated FMCH's guarantee under each of the indentures listed as Exhibits 2.4, 2.5, 2.6, and 2.7 relating to the USD denominated notes issued by Fresenius Medical Care US Finance III, Inc. under such indentures and under the final terms of each issue of Euro-Denominated Bonds listed as Exhibits 2.8, 2.9, 2.10, 2.11 and 2.12 issued by Fresenius Medical Care AG.

&nbsp;&nbsp;&nbsp;&nbsp;(2) In accordance with the Instructions as to Exhibits to Form 20-F, certain schedules and annexes to this exhibit have been omitted.

## Exhibit 2.1

**Exhibit 2.1**

**Description of Securities**

The following description of the share capital of Fresenius Medical Care AG (the Company or FME AG) constitutes Exhibit 2.1, the "Description of Securities" required to be filed as an Exhibit to the Company's Annual Report on Form 20-F. In accordance with paragraph 2(d) of the Instructions as to Exhibits in Form 20-F, it contains the information required by Items 9.A.3, 9.A.5, 9.A.6, and 9.A.7, Items 10.B.3, 10.B.4, 10.B.6, 10.B.7, 10.B.8, 10.B.9, and 10.B.10, and Items 12.D.1 and 12.D.2 of Form 20-F. (Items 12.A, 12.B, and 12.C referred to in said instructions are not applicable to the Company). In this Exhibit, "we", "us," and "our" refer either to the Company or the Company and its subsidiaries on a consolidated basis, as the context requires. Capitalized terms used in this Exhibit without definition have the meanings assigned to them in the Company's Annual Report on Form 20-F.

**Information pertaining to Item 9. The offer and listing details.**

**A. Offer and listing details.**

**General Information regarding our share capital**

Our share capital consists of bearer shares (*Inhaberaktien*) without par value (*Stückaktien*) and a nominal value of €1.00 each. Our shares are deposited as share certificates in global form (*Sammelurkunden*) with Clearstream Banking AG, Frankfurt am Main, Germany. Shareholders are not entitled to share certificates with respect to their individual shareholdings. Our subscribed capital consists solely of ordinary shares. All shares of FME AG are freely transferable, subject to any restrictions imposed by applicable securities laws. Our share capital has been fully paid in, and holders of our shares are not liable for capital calls.

**General provisions on increasing the capital of stock corporations and partnerships limited by shares**

The general meeting of a stock corporation may approve Authorized Capital (*genehmigtes Kapital*). The resolution creating Authorized Capital requires the affirmative vote of a majority of three quarters of the capital represented at the vote and may authorize the management board to issue, with the approval of the supervisory board, new shares up to a stated amount for a period of up to five years. The nominal value of any proposed increase of the Authorized Capital may not exceed half of the issued capital stock at the time of the authorization.

In addition, the general meeting of a stock corporation may create Conditional Capital (*bedingtes Kapital*) for the purpose of issuing (i) new shares to holders of convertible bonds or other securities which grant a right to shares, (ii) new shares as the consideration in a merger with another company, or (iii) new shares offered to management or employees. In each case, the authorizing resolution requires the affirmative vote of a majority of three quarters of the capital represented at the vote.The nominal value for any Conditional Capital may not exceed 60% of the Company's issued capital at the time of the resolution. The nominal value for any Conditional Capital created for the purpose of issuing new shares to holders of convertible bonds or other securities which grant a right to shares may not exceed 50% of the Company's issued capital at the time of the resolution. The nominal value for any Conditional Capital created for the purpose of issuing shares to management and employees may not exceed 20% of the Company's issued capital at the time of the resolution.

**The Company's Authorized Capital**

By resolution of the Company's Annual General Meeting of shareholders (AGM) on May 22, 2025, the Management Board is authorized, with the approval of the Supervisory Board, to increase, on one or more occasions, the Company's share capital until May 21, 2030 up to a total of €60,000,000 through issue of new bearer ordinary shares for cash or contributions in kind (Authorized Capital 2025). The number of shares must be increased in the same proportion as the share capital. To facilitate the processing, the new shares can also be issued to credit institutions, security institutions, or financial institutions, or a consortium of such institutions retained by the Management Board with the obligation to offer the shares to the Company's shareholders for subscription in accordance with their subscription right (indirect subscription right).

In principle, the shareholders have subscription (pre-emptive) rights in connection with the issuance of shares from the Authorized Capital 2025. However, the Management Board is authorized with the approval of the Supervisory Board to exclude the shareholders' subscription rights in the interests of the Company, in particular in the following cases:

● The Management Board shall be able to exclude subscription rights of shareholders in order to eliminate fractional amounts from the subscription rights.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

● The Management Board shall be able to exclude subscription rights of the shareholders in order to grain subscription rights, as a compensation for dilutive effects, to the holders of option or conversion rights to shares of the Company or those liable under the corresponding option or conversion obligations arising from bonds issued or guaranteed by the Company or a Group Company (as defined below) to the extent to which they would be entitled after exercising these options or conversion rights or fulfillment of these option or conversion rights.

● The Management Board shall be able to exclude subscription rights of shareholders in the case of capital increases for contributions in kind. In such cases, the Management Board has a statutory obligation to issue the new shares in the event of a capital increase in kind at an issue price that is in an appropriate relative proportion to the value of the contribution in kind.

● The Management Board shall be able to exclude subscription rights of the shareholders in case of capital increases for cash pursuant to sec. 203 (2) sentence 2, 186 (3) sentence 4 AktG if the issue price for the shares does not significantly fall below the stock exchange price of the shares of the Company already listed at the time of the determination of the issue price, and the proportionate amount of the share capital of the Company attributable to the shares issued exceeds 10% of the share capital existing neither at the time of this authorization coming into effect nor at the time of the exercise of this authorization.

The Management Board may only exercise the authorization to exclude subscription rights granted in regard to the Authorized Capital 2025 in the shareholders' interest to the extent that the proportional amount of the total shares issued subject to an exclusion of subscription rights exceeds 10% of the share capital neither at the time of this authorization coming into effect nor at the time of the exercise of this authorization. In case that during the period of validity of the Authorized Capital 2025 until its utilization, other authorizations on the issuance or on the sale of shares of the Company or the issuance of rights which authorize or bind to the subscription of shares of the Company are exercised and the subscription rights are excluded, such subscription rights will be taken into account with regard to the aforementioned limit of 10% of the share capital.

**Convertible Bonds, Warrants and Options; The Company's Conditional Capital**

By resolution of the Company's AGM on May 22, 2025, the Management Board is authorized, with the approval of the Supervisory Board, to issue on one or more occasions, and also concurrently denominated in various tranches, bearer option bonds and/or convertible bonds or any combination of such instruments (Bonds) in the total nominal value of up to €2,000,000,000.00 and to grant the bearers of Bonds option or conversion rights for a total of up to 29,341,344 bearer shares with no-par value of the Company with a proportional amount of the share capital of up to €29,341,344.00 as set forth in detail under the relevant terms and conditions of the Bonds (Bond Conditions). The respective Bond Conditions may also provide for mandatory conversion at the end of the term or at other times, including the requirement to exercise the option or conversion rights. The Bonds are to be issued for cash or non-cash consideration.

In order to grant shares to the holders of Bonds which are issued for cash consideration on the basis of the authorization outlined above, by resolution of the Company's AGM on May 22, 2025, the share capital of the Company is conditionally increased by up to €29,341,344.00 through issuing up to 29,341,344 bearer shares with no-par value (Conditional Capital 2025). The conditional capital increase will only be implemented to the extent that the holders of convertible bonds issued for cash or of warrants from option bonds issued for cash by the Company or a domestic or foreign company in which the Company holds the majority of shares (Group Company) until May 21, 2030, on the basis of the authorization granted to the Management Board by the Annual General Meeting of May 22, 2025, exercise their option or conversion rights or fulfill a possible conversion obligation and as long as no other forms of settlement are used. The new shares shall participate in the profits from the start of the fiscal year in which they are issued. In deviation therefrom and to the extent legally permissible, the Management Board may stipulate with the approval of the Supervisory Board that the new shares will participate in profits as of the beginning of a fiscal year that has already ended and for which no resolution on the allocation of distributable profit has been passed by the General Meeting at the time of their issue.

The Management Board is authorized to determine the further details regarding the implementation of the conditional capital increase.

Shareholders in general shall be granted a right to subscribe for the Bonds. The subscription rights may also be granted in such a way that the Bonds are underwritten by a credit or securities institution or a company (financial institution) operating in accordance with sec. 53 (1) sentence 1 or sec. 53b (1) sentence 1 or (7) KWG or a consortium consisting of such credit, securities, or financial institutions with the obligation to offer the Bonds to the shareholders for subscription. To the extent that the Bonds are issued by a Group Company, the Company in general must ensure that

------

shareholders are granted their statutory subscription rights. The Management Board, however, is authorized, with the approval of the Supervisory Board, to exclude the shareholders' subscription rights in the following cases:

● to eliminate fractional amounts from subscription rights;

● to grant holders or creditors of option or conversion rights to shares of the Company or debtors of option or conversion obligations under Bonds issued or guaranteed by the Company or any of its Group Companies subscription rights as compensation against effects of dilution to the extent to which they would be entitled to such rights upon exercising such option or conversion rights or fulfilling such option or conversion obligations;

● if the Bonds are issued against contributions in kind for the purpose of acquiring companies, parts of companies, interests in companies, or other assets; or

● insofar as the issue price of a bond is not significantly lower than the theoretical market value calculated according to recognized actuarial methods. The sum of these shares issued subject to an exclusion of subscription rights must not exceed 10% of the respective share capital, neither at the time of resolution on such authorization nor at the time of its utilization. If, during the term of this authorization and until its utilization, other authorizations for the issuance or the disposal of shares of the Company, or the issuance of rights that authorize or bind to the purchase of shares of the Company are used and thereby subscription rights are excluded in direct, analogous, or corresponding application of sec. 186 (3) sentence 4 AktG, the same shall be taken into account with regard to the aforementioned 10% limit.

The Management Board may only exercise the aforementioned authorization to exclude subscription rights to the extent that the proportional amount of all shares issued subject to an exclusion of subscription rights does not exceed 10% of the share capital, neither at the time of resolution on such authorization nor at the time of its utilization. If, during the term of this authorization to issue option bonds and/or convertible bonds or combinations of such instruments until the utilization thereof, other authorizations for the issuance or sale of shares of the Company, or the issuance of rights that authorize or bind to the purchase of shares in the Company are used and subscription rights are excluded, this will be taken into account with regard to the 10% limit.

**Information pertaining to Item 10. Additional Information**

**B. Articles of Association**

FME AG is a stock corporation AG or *Aktiengesellschaft*) organized under the laws of Germany. FME AG is registered with the commercial register of the local court (*Amtsgericht*) of Hof (Saale), Germany, under HRB 6841. Our registered office (Sitz) is Hof (Saale), Germany. Our registered business address is Else-Kröner-Strasse 1, 61352 Bad Homburg, Germany, telephone +49-6172-609-0.

The following summary of the material provisions of our Articles of Association (*Satzung*) is qualified in its entirety by reference to the complete text of our Articles of Association. An English convenience translation of our Articles of Association has been filed with the Securities and Exchange Commission, www.sec.gov, and can also be found on our website under www.freseniusmedicalcare.com.

**Corporate purposes**

Under Article 2 of our Articles of Association, our business purposes are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●the development, production and distribution of, as well as the trading in, products, systems and procedures in the areas of medical care and healthcare, including dialysis and associated forms of treatment, as well as the provision of any services in such areas;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●the projecting, planning, establishment, acquisition and operation of healthcare businesses, including dialysis centers, also in separate enterprises or through third parties as well as the participation in such dialysis centers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●the development, production and distribution of other pharmaceutical products and the provision of services in this field;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●the provision of advice in the medical and pharmaceutical areas as well as scientific information and documentation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●the provision of laboratory services for dialysis and non-dialysis patients and homecare medical services.

We conduct our business directly and through subsidiaries within and outside Germany.

------

**Our share capital**

Certain general information on the Company's capital stock, authorized capital and conditional capital is set forth above within "The offer and listing details — General Information regarding our share capital."

***Voting rights***

Each share entitles the holder thereof to one vote on all matters submitted to a vote at annual general meetings of shareholders of FME AG. Resolutions are passed at annual and extraordinary general meetings of our shareholders by a majority of the votes cast, unless a higher vote is required by law or our Articles of Association. Resolutions on the dismissal of Supervisory Board members elected by the General Meeting shall be adopted by a simple majority of the votes cast. Unless expressly otherwise resolved by the general meeting, the terms of office of the members of the Supervisory Board elected by the shareholders will expire at the end of the general meeting of shareholders of FME AG in which the shareholders discharge the Supervisory Board for the fourth fiscal year following the year in which they were elected, but not counting the fiscal year in which such member's term begins (for information regarding the election and terms of office of the members of the Supervisory Board elected as representatives of the Company's employees, see Item 6. Directors, senior management and employees). Our articles of association provide that Fresenius SE shall have the right to appoint two of the six shareholder representatives to our Supervisory Board if it holds 30% or more of the Company's share capital and the right to appoint one of the six shareholder representatives to the Supervisory Board if it holds at least 15% (but less than 30%) of the Company's share capital, and to dismiss those appointed shareholder representatives. Fresenius SE appointed two members of our Supervisory Board at our Extraordinary General Meeting held July 14, 2023, when Fresenius SE held more than 30% of our share capital, both of whom may continue to serve as board members for the remainder of their respective terms. Certain matters requiring a resolution at the general meeting require a qualified majority of 75% of the share capital represented at the time of the vote, such as capital increases (including the creation of authorized and conditional capital) and decreases, the issuance of convertible bonds, corporate measures, such as mergers or spin-offs, the conclusion of intercompany agreements (*Unternehmensverträge*) such as domination and/or profit and loss transfer agreements (*Beherrschungs- und/oder Gewinnabführungsverträge*), amendments to the Articles of Association, dissolution of the Company, a change in the legal form of the stock corporation and other fundamental changes. Fresenius SE & Co. KGaA (Fresenius SE), as the holder of approximately 27.8% of our share capital, therefore has a de facto veto right over such resolutions adopted by shareholders.

***Dividend rights***

Under German law, dividends may only be paid based on our balance sheet profits (*Bilanzgewinn*) as determined by our unconsolidated annual financial statements. Our unconsolidated annual financial statements are adopted by approval of our Supervisory Board unless the Management Board and Supervisory Board decide to leave the adoption of the unconsolidated annual financial statements to the Annual General Meeting. Unlike our consolidated annual financial statements, which are prepared on the basis of International Financial Reporting Standards (IFRS Accounting Standards) as issued by the International Accounting Standards Board (IASB), the unconsolidated annual financial statements referred to above are prepared on the basis of the accounting principles of the German Commercial Code (*Handelsgesetzbuch* or HGB). Since our shares that are entitled to dividend payments are held in a clearing system, the dividends will be distributed in accordance with the rules of the individual clearing system. We will publish notice of the dividends to be paid and the appointment of the paying agent or agents for this purpose in the German Federal Gazette (*Bundesanzeiger*).

In the case of holders of American Depositary Receipts (ADRs), the depositary will receive all cash dividends and distributions on all deposited securities and will, as promptly as practicable, distribute the dividends and distributions to the holders of ADRs entitled to the dividend, after deducting its fees and expenses and any taxes or governmental charges. See "Description of Securities Other than Equity Securities — American Depositary Shares — Description of American depositary receipts," below.

***Liquidation rights***

We may be dissolved by a resolution of our general meeting of shareholders passed with a majority of at least three quarters of our share capital represented at such general meeting, in accordance with the AktG. In such a case, any liquidation proceeds remaining after paying all of our liabilities will be distributed among our shareholders in proportion to the total number of shares held by each shareholder.

***Pre-emption rights***

Under the AktG, each shareholder in a stock corporation has a preferential right to subscribe for any issue by that company of shares, debt instruments convertible into shares, e.g. convertible bonds or option bonds, and participating debt instruments, e.g. profit participation rights or participating certificates, in proportion to the number of shares held by that shareholder in the existing share capital of that company. Generally, such pre-emption rights are freely

------

assignable. These rights may also be traded on German stock exchanges within a specified period of time prior to the expiration of the subscription period for the offer. Our general meeting of shareholders may exclude pre-emption rights by passing a resolution with a majority of at least three quarters of our share capital represented at such general meeting of shareholders. In addition, an exclusion of pre-emption rights requires a report by the Management Board justifying the exclusion by explaining why the interest of FME AG in excluding the pre-emption rights outweighs our shareholders' interests in receiving such rights. However, such justification is in principle not required for any issue of new shares if we increase our share capital against contributions in cash, the amount of the capital increase does not exceed 10% of our existing share capital, and the issue price of the new shares is not significantly lower than the price for the shares quoted on a stock exchange. Following a change in the German law, future authorizations may set the aforementioned limit at 20% of the existing share capital. For information regarding the Management Board's authorization to exclude preferential subscription rights in connection with the issuance of ordinary shares from the Company's Authorized Capital and in connection with the issuance of convertible Bonds, see "Offer and listing details — the Company's Authorized Capital," and "— Convertible Bonds, Warrants and Options; The Company's Conditional Capital," above.

***Exclusion ("Squeeze-out") of minority shareholders***

Under the provisions of Sections 327a et seq. of the AktG concerning squeeze-outs, a shareholder who owns at least 95% of the issued share capital (a principal shareholder) may request that the general meeting of shareholders of a stock corporation resolve to transfer the shares of the minority shareholders to the principal shareholder. Under Section 62 of the German Transformation Act (*Umwandlungsgesetz, or UmwG)* concerning group mergers, in case a shareholder is a German stock corporation that owns at least 90% of the issued share capital, such shareholder may request the company to be merged with such shareholder. The adequate amount of cash compensation to be paid to the minority shareholders in return must take into account the issuer's financial condition at the time the resolution is passed. The full value of the issuer, which is usually calculated using the capitalization of earnings method (*Ertragswertmethode*), is decisive for determining the compensation amount.

In addition to the provisions for squeeze-outs of minority shareholders, Sections 319 et seqq. of the AktG provide for the integration of stock corporations. In contrast to the squeeze-out of minority shareholders, integration is only possible when the future principal company is a stock corporation with a statutory seat in Germany.

***Annual general meeting***

Our Annual General Meeting (AGM) must be held within the first eight months of each fiscal year at the location of FME AG's registered office, or in a German city where a stock exchange is situated, or at the location of a registered office of a domestic affiliated company. To attend the AGM and exercise voting rights, shareholders must register for the AGM and provide evidence of ownership of shares. The relevant evidence date is the close of business of the 22nd day prior to the AGM. The invitation for our AGM that we publish includes information regarding how to comply with these requirements.

***Amendments to the Articles of Association***

An amendment to our Articles of Association requires a voting majority of at least three quarters of the share capital represented at the general meeting of shareholders. The Supervisory Board of FME AG has been granted the authority to make amendments to the Articles of Association that relate solely to the wording (*Fassungsänderungen*).

***Restrictions on share ownership***

For information regarding restrictions on share ownership imposed by German law, see Item 10.D "Exchange controls" in the Company's Form 20-F.

***Potential limits on a change of control***

Fresenius SE owns in excess of 25% of our shares. Fresenius SE's significant ownership interest, combined with its right to appoint two of the six shareholder representatives to our Supervisory Board if it holds 30% or more of the Company's share capital and to appoint one of such representatives if it holds at least 15% (but less than 30%) of the Company's share capital could serve to discourage third parties from attempting to acquire control of the Company, since such third parties could not obtain absolute control without the cooperation, or at least the acquiescence, of Fresenius SE. As indicated above (see "—Voting rights," above), certain matters requiring a resolution at the general meeting (including mergers and spin-offs) require the vote of a qualified majority of 75% of the share capital represented at the time of the vote. Thus, if and to the extent that a potential change of control transaction would require shareholder resolutions to approve a matter or matters requiring the vote of such a qualified majority, Fresenius SE would be able to prevent the passing of any such resolutions so long as Fresenius SE continues to own more than 25% of our shares.

------

In addition to the provisions of our Articles of Association, under German law a party that acquires 30% or more of our voting shares must undertake a public purchase offer for the remainder of our shares. The obligation to undertake such an offer and the related costs could serve as an additional factor discouraging a change of control of the Company.

***Disclosure of share ownership***

Our Articles of Association do not contain any provisions requiring disclosure of share ownership above a threshold ownership amount or percentage. Information regarding disclosure requirements under the EU Market Abuse Regulation, the German Securities Trading Act (*Wertpapierhandelsgesetz*), and the U.S. Securities Exchange Act of 1934, as amended, may be found in Item 7A, "Major shareholders and related party transactions — Major shareholders — Security ownership of certain beneficial owners of Fresenius Medical Care" in the Company's Form 20-F.

**Information pertaining to Item 12. Description of Securities Other than Equity Securities.**

**D. American Depositary Shares**

**Description of American depositary receipts**

***General***

The Bank of New York Mellon, a New York banking corporation, is the depositary for ADSs representing our shares. Each ADS represents an ownership interest in one-half of a share. The deposited shares are deposited with a custodian, as agent of the depositary, under the deposit agreement among ourselves, the depositary and all of the holders and owners of ADSs from time to time (who become bound by the deposit agreement by their acceptance of American Depositary Receipts, or ADRs, evidencing their ADSs). Each ADS also represents any securities, cash or other property deposited with the depositary but not distributed by it directly to ADS holders. The ADSs may be evidenced by certificates or may also be uncertificated. If ADSs are issued in uncertificated form, owners holding ADSs in book-entry form will receive periodic statements from the depositary showing their ownership of ADSs. In the case of beneficial holders of ADSs, owners will receive these periodic statements through their brokers or financial institutions.

The depositary's office is located at 240 Greenwich Street, New York, NY 10286, U.S.A.

An investor may hold ADSs either directly or indirectly through a broker or other financial institution. Investors who hold ADSs directly, by having ADSs registered in their names on the books of the depositary, are ADS owners. This description assumes an investor holds ADSs directly. Investors who hold ADSs through their brokers or financial institution nominees must rely on the procedures of their brokers or financial institutions to assert the rights of an ADS owner described in this section. Investors should consult with their brokers or financial institutions to find out what those procedures are.

As an ADS owner, we will not treat you as one of our shareholders and you will not have shareholder rights. German law governs shareholder rights. The depositary will be the holder of the shares underlying your ADSs. As a registered owner of ADSs, you will have ADS owner rights. The deposit agreement sets out ADS owner rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.

The following is a summary of the material terms of the deposit agreement. Because it is a summary, it does not contain all the information that may be important to investors, and is qualified in its entirety by the complete text of the deposit agreement, as amended and restated in December 2023. For more complete information, investors should read the entire deposit agreement and the form of ADR which contains the terms of the ADSs. The deposit agreement is available in electronic form on the website maintained by the SEC, www.sec.gov.

***Share dividends and other distributions***

We may make different types of distributions with respect to our shares. The depositary has agreed to pay to investors the cash dividends or other distributions it or the custodian receives on the shares or other deposited securities, after deducting its fees and expenses. Investors will receive these distributions in proportion to the number of underlying shares their ADSs represent.

Except as stated below, to the extent the depositary is legally permitted it will deliver distributions to ADS owners in proportion to their interests in the following manner:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●*Cash*. The depositary, or one of its agents or the custodian shall convert cash distributions from foreign currency to U.S. dollars if conversion is permissible and can be done on a reasonable basis. The depositary will endeavor to distribute cash in a practicable manner, and may deduct any taxes or other governmental charges required to be withheld, any expenses of converting foreign currency and transferring funds to the

------

United States, and certain other fees and expenses. In addition, before making a distribution the depositary will deduct any taxes withheld. If exchange rates fluctuate during a time when the depositary cannot convert a foreign currency, investors may lose some or all of the value of the distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●*Shares*. If we make a distribution in shares, the depositary may deliver additional ADSs to represent the distributed shares, unless the number of shares represented by our ADSs is adjusted in connection with the distribution. Only whole ADSs will be issued. Any shares which would result in fractional ADSs will be sold and the net proceeds will be distributed to the ADS owners otherwise entitled to receive fractional ADSs. If the Company declares a distribution in which holders of shares or other deposited securities have a right to elect whether to receive cash, shares or other securities or a combination of those things, or a right to elect to have a distribution sold on their behalf, the depositary may, after consultation with the Company, make that right of election available for exercise by owners of ADSs in any manner the depositary considers to be lawful and practical. As a condition of making a distribution election right available to the owners, the depositary may require satisfactory assurances from the Company that doing so does not require registration of any securities under the U.S. Securities Act of 1933 (the Securities Act) that has not been effected.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●*Rights to receive additional shares*. If rights are granted to the depositary in respect of deposited shares to purchase additional shares or other securities, the Company and the depositary shall endeavor to consult as to the actions, if any, the depositary should take in connection with that grant of rights. The depositary may, to the extent deemed by it to be lawful and practical (i) if requested in writing by the Company, grant to all or certain owners rights to instruct the depositary to purchase the securities to which the rights relate and deliver those securities or ADSs representing those securities to owners, (ii) if requested in writing by the Company, deliver the rights to or to the order of certain owners, or (iii) sell the rights to the extent practicable and distribute the net proceeds of that sale to owners entitled to those proceeds. To the extent rights are not exercised, delivered or disposed of under (i), (ii) or (iii) above, the depositary shall permit the rights to lapse unexercised.

If the depositary will act under (i) or (ii) above in connection with a distribution of rights, we and the depositary will enter into a separate agreement setting forth the conditions and procedures applicable to the particular offering. The depositary will not act under (i) above unless the offer and sale of the securities to which the rights relate are registered under the Securities Act or the depositary has received an opinion of United States counsel that is satisfactory to it to the effect that those securities may be sold and delivered to the applicable owners without such registration. We have no obligation to file a registration statement under the Securities Act in order to make any rights or other distributed securities available to ADS owners. If the depositary will act under (iii) above, the depositary will use reasonable efforts to sell the rights in proportion to the number of ADSs held by the applicable owners and pay the net proceeds to the owners otherwise entitled to the rights that were sold.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●*Other Distributions*. If we make a distribution of securities or property on deposited securities other than those described above (but not in exchange for or in conversion of or in lieu of deposited securities), the depositary may either:

● distribute the securities or property in any manner it deems fair and equitable (which may be a distribution of depositary shares representing the securities received); or

● sell the securities or property and distribute any net proceeds in the same way it distributes cash.

The depositary may withhold any distribution of securities referred to in the immediately preceding paragraph if it has not received satisfactory assurances from the Company that the distribution does not require registration under the Securities Act.

Any U.S. dollars will be distributed by checks drawn on a bank in the United States for whole dollars and cents (fractional cents will be rounded to the nearest whole cent). Registered owners will receive the checks directly, while the distributions for beneficial owners will be first sent to their brokers or other nominees, who will then distribute the cash to the rightful owners.

The depositary may choose any practical method of distribution for any specific ADS owner, including the distribution of foreign currency, securities or property, or it may retain the items, without paying interest on or investing them, on behalf of the ADS owner as deposited securities.

The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS owners.

The depositary may convert currency itself or through any of its affiliates or, the custodian or the Company may convert currency and pay dollars to the depositary. Where the depositary converts currency itself, or through any of its affiliates, the depositary acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other

------

person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS owners. The methodology used to determine exchange rates used in currency conversions made by the depositary is available upon request from the depositary. Where the custodian converts currency, the custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate will be determined will be the most favorable to owners, and the depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate. In certain instances, the depositary may receive dividends or other distributions from the Company in dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by or on behalf of the Company or an affiliate of the Company and, in such cases, the depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor the Company makes any representation that the rate obtained or determined by or on behalf of the Company is the most favorable rate and neither it nor the Company will be liable for any direct or indirect losses associated with the rate. There can be no assurance that the depositary, the custodian or the Company will be able to convert any currency at a specified exchange rate or that the depositary will be able to sell any property, rights, shares or other securities at a specified price, or that any of these transactions can be completed within a specified time period.

***Tender and Exchange Offers, Redemption, Replacement or Cancellation of Deposited Securities***

The depositary shall not tender any deposited securities in response to any voluntary cash tender offer, exchange offer, or similar offer made to holders of deposited securities, except when instructed in writing to do so by an owner surrendering ADSs representing such deposited securities and subject to any conditions or procedures the depositary may require.

If the depositary is notified that deposited securities have been redeemed for cash or otherwise purchased for cash in a transaction that is mandatory and binding on the depositary as a holder of those deposited securities and the redeemed or purchased securities are the only class of deposited securities (a Redemption), the depositary shall (i) if required, surrender deposited securities that have been redeemed to the issuer of those securities or its agent on the redemption date, (ii) disseminate a notice to owners (A) notifying them of that Redemption, (B) calling for surrender of a corresponding number of ADSs and (C) notifying them that the called ADSs have been converted into a right only to receive the money received by the depositary upon that Redemption and those net proceeds shall be the deposited securities to which owners shall be entitled, upon surrender of those ADSs, and (iii) distribute the money received upon that Redemption to the owners entitled to it upon surrender by them of called ADSs. In the case of a partial Redemption of deposited securities, the outstanding ADSs to be converted and surrendered in exchange for the Redemption net proceeds shall be allocated among the owners pro-rata to their respective holdings of ADSs.

Upon any change in nominal value or any subdivision, combination or any other reclassification of the deposited securities or any recapitalization, reorganization, sale of assets substantially as an entirety, merger or consolidation affecting the issuer of the deposited securities or to which it is a party that is mandatory and binding on the depositary as a holder of deposited securities and as a result securities or other property have been or will be delivered in exchange, conversion, replacement or in lieu of, deposited securities (a Replacement), the depositary shall, if required, surrender the old deposited securities affected by that Replacement of shares and hold, as new deposited securities under the deposit agreement, the new securities or other property delivered to it in that Replacement. In connection with a Replacement, the depositary shall be entitled to request and receive an opinion of counsel to the Company to the effect that under the Securities Act it may lawfully retain the new deposited securities under the deposit agreement and that, upon deposit, the depositary could freely distribute such securities to owners and holders of ADSs in the United States. In the absence of such an opinion, the depositary may elect to sell those new deposited securities and proceed as if those new deposited securities had undergone a Redemption, as described above.

***Deposits, Withdrawals and Cancellations***

The depositary will deliver ADSs if an investor or his broker deposits shares or evidence of rights to receive shares with the custodian, or upon receiving notice of such a deposit from the custodian. Shares deposited with the custodian must be accompanied by certain documents, including instruments showing that such shares have been properly transferred or endorsed by the person on whose behalf the deposit is being made.

------

The custodian will hold all deposited shares for the account of the depositary. ADS holders thus have no direct ownership interest in the shares and only have the rights that are contained in the deposit agreement. For German tax purposes, ADS holders will generally be treated as the economic owners of the deposited shares represented by the ADSs (and, therefore, as a shareholder of the Company), and for U.S. federal income tax purposes, ADSs owners will generally be treated as the owners of such shares. For additional information, see Item 10.E., "Additional Information — Taxation — U.S. and German tax consequences of holding ADSs" in the Company's Form 20-F. The custodian will also hold any additional securities, property and cash received on or in substitution for the deposited shares. The deposited shares and any additional items are referred to as "deposited securities."

Upon each deposit of shares, receipt of related delivery documentation and compliance with the other provisions of the deposit agreement, including the payment of the fees and charges of the depositary and any taxes or other fees or charges owing, the depositary will deliver ADSs representing the deposited shares as instructed. The foregoing notwithstanding, the depositary may refuse to accept deposits of shares for delivery of ADSs or to register transfers of ADSs in particular instances, or may suspend deposits of shares or registration of transfer generally, whenever it or the Company considers it necessary or advisable to do so. The depositary shall not knowingly accept for deposit under the deposit agreement any shares that, at the time of deposit, are restricted securities, as defined the deposit agreement.

All ADSs issued will, unless specifically requested to the contrary, be delivered through the book-entry settlement system of The Depository Trust Company, also referred to as DTC, or be uncertificated and held through the book-entry direct registration system (DRS) of DTC, and a registered owner will receive periodic statements from the depositary which will show the number of ADSs registered in the owner's name. An ADS owner can request that the ADSs not be held through the depositary's DRS and that an ADR in certificated form be issued to evidence those ADSs. ADRs will be delivered at the depositary's principal New York office or any other location that it may designate as its transfer office.

DRS is the system administered by DTC that facilitates interchange between registered holding of uncertificated securities and holding of security entitlements in those securities through DTC and a DTC participant. Profile Modification System (Profile) is a required feature of DRS which allows a participant in DTC, claiming to act on behalf of a registered owner of ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS registered owner to register that transfer.

In connection with DRS/Profile, the parties to the deposit agreement acknowledge that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS registered owner in requesting a registration of transfer and delivery described in the paragraph above has the actual authority to act on behalf of that owner (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary's reliance on and compliance with instructions received by the depositary through the DRS/Profile System and in accordance with the deposit agreement, shall not constitute negligence or bad faith on the part of the depositary. The deposit agreement provides expressly that the limitations on the respective obligations and liability of the depositary and the Company, and the indemnification provisions of the deposit agreement, apply to the matters arising from the use of the DRS, and that the depositary shall not be liable for the acts or omissions of any securities depository, clearing agency or settlement system in connection with or arising out of book-entry settlement of ADSs or deposited securities or otherwise.

When an investor surrenders ADSs at the depositary's office, the depositary will, upon payment of certain applicable fees, governmental charges and taxes, and upon receipt of proper instructions, deliver the whole number of shares represented by the surrendered ADSs (to the extent that delivery can be lawfully made) to or as instructed by the owner. It is expected that the delivery of shares shall be made to an account the owner directs within Clearstream Banking AG, the central German clearing firm. However, the depositary will not deliver any money or other property as to which a record date for distribution to owners has passed (since money or other property of that kind will be delivered or paid on the scheduled payment date to the owner as of that record date), and the depositary shall not be required to accept surrender of ADSs for the purpose of withdrawal to the extent it would require delivery of a fraction of a deposited security.

The depositary may restrict the withdrawal of deposited securities only in connection with:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●temporary delays caused by the closing of the depositary's ADS register or any register of holders of our shares maintained by us or on our behalf, or the deposit of shares in connection with voting at a general meeting of shareholders', or the payment of dividends,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●the payment of fees, taxes and similar charges,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●compliance with any U.S. or foreign laws or governmental regulations relating to the ADSs, or

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●such other reason, if any, that, at the time, is permitted under paragraph I(A)(1) of the General Instructions to Form F-6 under the Securities Act or any successor to that provision.

This right of withdrawal may not be limited by any other provision of the deposit agreement.

***Voting rights***

You may instruct the depositary to vote the number of shares your ADSs represent. The depositary will notify you of general meetings of shareholders and arrange to deliver our voting materials to you if we ask it to do so. Those materials will describe the matters to be voted on and explain how you may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary.

The depositary will try, as far as practical, subject to German law and the provisions of our constitutive documents, to vote the number of shares or other deposited securities represented by your ADSs as you instruct. The depositary will only vote or attempt to vote as you instruct or as described below.

We will include in voting materials distributed to ADS owners the date by which their voting instructions must be received by the depositary. However, we cannot ensure that you will receive voting materials or otherwise learn of an upcoming general meeting of shareholders in time to ensure that you can timely instruct the depositary to vote the shares represented by your ADSs. In addition, in the absence of bad faith on its part, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to vote, and you may have no recourse if your shares are not voted as you requested.

Under the deposit agreement, our Management Board or our Supervisory Board (or, in case of "conflicting proposals" within the meaning of Section 135 of the German Stock Corporation Law (*AktG*), the Supervisory Board) proposing a matter for a shareholder vote also constitutes a recommendation that shareholders vote in favor of the matter or matters. If (i) we timely ask the depositary to solicit your voting instructions, (ii) the depositary does not receive voting instructions from you by the specified date, and (iii) we confirm to the depositary in writing that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●we do not know of any substantial shareholder opposition to the particular matter; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●the particular matter would not have an adverse impact on our shareholders;

we will be deemed to have instructed the depositary to give a proxy, and the depositary will consider you to have authorized and directed it to give a proxy to a person designated by the Company, with instructions to vote the number of deposited securities represented by your ADSs in favor of the proposal or proposals of the Management Board or our Supervisory Board, as the case may be (or, in case of "conflicting proposals" within the meaning of Section 135 *AktG*, the proposal or proposals of the Supervisory Board).

***Fees and expenses***

For information regarding fees and expenses payable by owners of ADSs and amounts payable by the depositary to us, see Item 12.D, "Description of securities other than equity securities — American Depositary Shares — Fees and expenses" in the Company's Form 20-F.

***Payment of taxes***

ADS owners must pay any tax or other governmental charge payable by the custodian or the depositary on any ADS or ADR, deposited security or distribution. If an ADS owner owes any tax or other governmental charge, the depositary may (i) deduct the amount thereof from any cash distributions, or (ii) sell deposited securities and deduct the amount owing from the net proceeds of such sale. In either case the ADS owner remains liable for any shortfall. Additionally, if any tax or governmental charge is unpaid, the depositary may also refuse to effect any registration, registration of transfer, split-up or combination of deposited securities or withdrawal of deposited securities (except under limited circumstances mandated by securities regulations). If any tax or governmental charge is required to be withheld on any non-cash distribution, the depositary may sell the distributed property or securities to pay such taxes and distribute any remaining net proceeds to the ADS owners entitled thereto.

------

***Limitations on obligations and liability***

The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith. In particular, the depositary shall not be a fiduciary or have any fiduciary duty to owners or holders of ADSs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●are not liable if we are or it is prevented or delayed by law, regulation or other act of government or circumstances beyond our or its control (whether natural or caused by a person or persons) from performing our or its obligations under the deposit agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●are not liable if we exercise or it exercises discretion permitted under the deposit agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;

● shall not be liable for any action or non-action in reliance upon the advice of or information from legal counsel, accountants, any person presenting shares for deposit, any owner or any other person we or it believe in good faith to be competent to give such advice or information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person.

In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.

***Requirements for depositary actions***

Before the depositary will deliver or register a transfer of an ADS, make a distribution on an ADS, or permit withdrawal of shares, the depositary may require:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.

The depositary may refuse to deliver ADSs or register transfers of ADSs generally when the transfer books of the depositary are closed or at any time if the depositary or we think it advisable to do so.

***Shareholder communications; inspection of register of owners of ADSs***

The depositary, as a holder of deposited securities, will make available for your inspection at its office all reports and communications that it receives from us that we make generally available to holders of deposited securities. If we request the depositary to do so, the depositary will send you copies of those communications or otherwise make them available to owners in a manner that we specify as substantially equivalent to the manner in which those communications are made available to our shareholders and compliant with any stock exchange requirements applicable to the ADSs. You have a right to inspect the register of owners of ADSs, but not for the purpose of contacting those owners about a matter unrelated to our business or the ADSs.

***Amendment of the deposit agreement***

We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes or other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS owners, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS owners of the amendment. At the time the amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.

***Termination of the deposit agreement***

We may initiate termination of the deposit agreement by notice to the depositary. The depositary may initiate termination of the deposit agreement if (i) at any time 60 days shall have expired after the depositary delivered a written resignation notice to us and a successor depositary has not been appointed and accepted its appointment, or (ii) a "Termination Option Event" (as defined below) has occurred. If termination of the deposit agreement is initiated, including upon occurrence of a Termination Option Event, the depositary shall disseminate a notice of termination to the owners of all

------

ADSs then outstanding setting a date for termination (the Termination Date), which shall be at least 90 days after the date of that notice, and the deposit agreement shall terminate on that Termination Date.

Each of the following transactions constitutes a "Termination Option Event":

● *Certain distributions*. A cash distribution, or any other distribution other than a distribution of our shares or of rights to purchase our shares or other securities, that would represent a return of all or substantially all the value of the deposited securities underlying the ADSs, in connection with which the depositary either (i) requires payment of or deducts a fee for the surrender of ADSs, or (ii) sells all the deposited securities, (other than the subject distribution) adds the sale proceeds to the distribution and requires surrender of the ADSs a condition to making the distribution;

● *Redemptions*. A redemption of all or substantially all of the deposited securities;

● *Certain Replacements*. A Replacement followed by a sale of the new deposited securities issued in the Replacement;

● *Certain Losses*. If the deposited securities are cancelled or have become apparently worthless and the depositary calls for surrender of the ADSs or cancels the ADSs upon notice to the owner;

● *Bankruptcy*. Certain bankruptcy events relating to the Company;

● *Delisting*. The delisting of our shares from a stock exchange outside the U.S. or from a U.S. stock exchange without a replacement listing on a non-U.S. stock exchange or U.S. stock exchange, as applicable or availability of over-the-counter trading in the U.S.; or

● *F-6 Registration Ineligibility*. The ADSs becoming ineligible for registration on Form F-6 under the Securities Act.

The depositary's notice of termination of the deposit agreement shall not affect the right of an Owner, prior to the Termination Date, to surrender ADSs for the purpose of withdrawal of deposited securities. At any time after the Termination Date, the depositary may sell the remaining deposited securities then held under the deposit agreement and may thereafter hold uninvested the net proceeds of any such sale, together with any other cash then held by it under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the owners of ADSs that remain outstanding, and those owners will be general creditors of the depositary with respect to those net proceeds and that other cash. After making that sale, the depositary shall be discharged from all obligations under the deposit agreement, except its obligations (i) to account for the net proceeds and other cash (after deducting, in each case, the fee of the depositary for the surrender of ADSs, any expenses for the account of the owner of such ADSs in accordance with the terms and conditions of the deposit agreement and any applicable taxes or governmental charges), (ii) to indemnify us as provided in the deposit agreement, and (iii) to act as provided in the following paragraph.

After the Termination Date, the depositary shall continue to receive dividends and other distributions pertaining to deposited securities (that have not been sold), may sell rights and other property as provided in the deposit agreement and shall deliver deposited securities (or sale proceeds) upon surrender of ADSs (after payment or upon deduction, in each case, of the fees, expenses and applicable taxes or governmental charges, as described in the preceding paragraph). After the Termination Date, the depositary shall not accept deposits of shares or deliver ADSs. After the Termination Date, (i) the depositary may refuse to accept surrenders of ADSs for the purpose of withdrawal of deposited securities (that have not been sold) or reverse previously accepted surrenders of that kind that have not settled if in its judgment the requested withdrawal would interfere with its efforts to sell the deposited securities, (ii) the depositary will not be required to deliver cash proceeds of the sale of deposited securities until all deposited securities have been sold and (iii) the depositary may discontinue the registration of transfers of ADSs and suspend the distribution of dividends and other distributions on deposited securities to the owners and need not give any further notices or perform any further acts, except as provided in the Deposit Agreement relating to its termination.

------

## Exhibit 2.15

**Exhibit 2.15**

**MIFID II PRODUCT GOVERNANCE / RETAIL INVESTORS, PROFESSIONAL INVESTORS AND ECPS TARGET MARKET** – Solely for the purposes of each manufacturer's product approval process, the target market assessment in respect of the Notes has led to the conclusion that: (i) the target market for the Notes is eligible counterparties, professional clients and retail clients, each as defined in Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments, as amended (***MiFID II***); and (ii) all channels for distribution to eligible counterparties and professional clients are appropriate; and (iii) the following channels for distribution of the Notes to retail clients are appropriate - investment advice, portfolio management and non-advised sales. Any person subsequently offering, selling or recommending the Notes (each a ***Distributor***) should take into consideration the manufacturers' target market assessment; however, a Distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Notes (by either adopting or refining the manufacturers' target market assessment) and determining appropriate distribution channels, subject to the Distributor's suitability and appropriateness obligations under MiFID II, as applicable. The targeted investors are expected to have (1) at least informed knowledge and/or experience with financial products, (2) the ability to bear losses resulting from interest rate changes and no capital loss bearing capacity if held to maturity, (3) a medium risk profile (4) a general capital formation/ asset optimization as investment objective and (5) a medium-term investment horizon. The Issuer is not a manufacturer or Distributor for the purposes of the MiFID Product Governance Rules**.**

***MiFID II PRODUKTÜBERWACHUNGSPFLICHTEN / ZIELMARKT KLEINANLEGER, PROFESSIONELLE INVESTOREN UND GEEIGNETE GEGENPARTEIEN*** *– Die Zielmarktbestimmung im Hinblick auf die Schuldverschreibungen hat – ausschließlich für den Zweck des Produktgenehmigungsverfahrens jedes Konzepteurs – zu dem Ergebnis geführt, dass (i) der Zielmarkt für die Schuldverschreibungen geeignete Gegenparteien, professionelle Kunden und Kleinanleger, jeweils im Sinne der Richtlinie 2014/65/EU des Europäischen Parlaments und des Rates vom 15. Mai 2014 über Märkte für Finanzinstrumente in der jeweils gültigen Fassung (****MiFID II****), umfasst; und (ii) alle Kanäle für den Vertrieb der Schuldverschreibungen an professionelle Investoren und geeignete Gegenparteien angemessen sind und (iii) die folgenden Kanäle für den Vertrieb der Schuldverschreibungen an Kleinanleger angemessen sind – Anlageberatung, Portfolio-Management und Verkäufe ohne Beratung. Jede Person, die in der Folge die Schuldverschreibungen anbietet, verkauft oder empfiehlt (jeweils ein* ***Vertriebsunternehmen****) soll die Beurteilung des Zielmarkts der Konzepteure berücksichtigen; ein Vertriebsunternehmen, welches MiFID II unterliegt, ist indes dafür verantwortlich, seine eigene Zielmarktbestimmung im Hinblick auf die Schuldverschreibungen durchzuführen (entweder durch die Übernahme oder durch die Präzisierung der Zielmarktbestimmung der Konzepteure) und angemessene Vertriebskanäle nach Maßgabe der Pflichten des Vertriebsunternehmens unter MiFID II im Hinblick auf die Geeignetheit bzw. Angemessenheit, zu bestimmen. Von den angesprochenen Anlegern wird erwartet, dass sie (1) zumindest über fundierte Kenntnisse und/oder Erfahrungen mit Finanzprodukten verfügen, (2) in der Lage sind, zinsbedingte Verluste zu tragen und keine Kapitalverluste hinnehmen müssen, wenn sie bis zur Fälligkeit gehalten werden, (3) ein mittleres Risikoprofil haben, (4) ein allgemeines Kapitalbildungs-/Vermögensoptimierungsziel verfolgen und (5) einen mittelfristigen Anlagehorizont haben. Die Emittentin ist kein Konzepteur oder ein Vertriebsunternehmen für Zwecke der MiFID Bestimmungen zu Produktüberwachungspflichten.*

**UNITED KINGDOM (UK) MiFIR PRODUCT GOVERNANCE / RETAIL INVESTORS, PROFESSIONAL INVESTORS AND ECPS ONLY TARGET MARKET** – Solely for the purposes of the manufacturer's product approval process, the target market assessment in respect of the Notes has led to the conclusion that: (i) the target market for the Notes is retail clients, as defined in point (8) of article 2 of Regulation (EU) No 2017/565 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 (***EUWA***), and eligible counterparties, as defined in the UK Financial Conduct Authority (***FCA***) Handbook Conduct of Business Sourcebook (***COBS***), and professional clients, as defined in Regulation (EU) No 600/2014 as it forms part of UK law by virtue of the EUWA (***UK MiFIR***); and (ii) all channels for distribution to eligible counterparties and professional clients are appropriate; and (iii) the following channels for distribution of the Notes to retail clients are appropriate - investment advice, portfolio management and non-advised sales. Any person subsequently offering, selling or recommending the Notes (each a ***UK Distributor***) should take into consideration the manufacturer's target market assessment; however, a UK Distributor subject to the FCA Handbook Product Intervention and Product Governance Sourcebook (the ***UK MiFIR Product Governance Rules***) is responsible for undertaking its own target market assessment in respect of the Notes (by either adopting or refining the manufacturer's target market assessment) and determining appropriate distribution channels, subject to the UK Distributor's suitability and appropriateness obligations under COBS, as applicable. The targeted investors are expected to have (1) at least informed knowledge and/or experience with financial products, (2) the ability to bear losses resulting from interest rate changes and no capital loss bearing capacity if held to maturity, (3) a medium risk profile (4) a general capital formation/ asset optimization as investment objective and (5) a medium-term investment horizon. The Issuer is not a manufacturer or UK Distributor for the purposes of the UK MiFIR Product Governance Rules.

------

***VEREINIGTES KÖNIGREICH (VK) MiFIR PRODUKTÜBERWACHUNGSPFLICHTEN / ZIELMARKT KLEINANLEGER, PROFESSIONELLE INVESTOREN UND GEEIGNETE GEGENPARTEIEN*** *– Die Zielmarktbestimmung im Hinblick auf die Schuldverschreibungen hat – ausschließlich für den Zweck des Produktgenehmigungsverfahrens des Konzepteurs – zu dem Ergebnis geführt, dass (i) der Zielmarkt für die Schuldverschreibungen Kleinanleger, im Sinne von Artikel 2 Nr. 8 der Verordnung (EU) Nr. 2017/565, welche durch das EU Austrittsabkommen 2018 (****EUWA****) Teil des Rechts des VK ist und geeignete Gegenparteien im Sinne des Handbuchs der Finanzaufsicht des VK (Financial Conduct Authority -* ***FCA****) "Conduct of Business Sourcebook" (****COBS****), und professionelle Kunden, jeweils im Sinne der Verordnung (EU) Nr. 600/2014, welche durch das EUWA Teil des Rechts des VK ist (****VK MiFIR****), umfasst; und (ii) alle Kanäle für den Vertrieb der Schuldverschreibungen an geeignete Gegenparteien und professionelle Kunden angemessen sind und (iii) die folgenden Kanäle für den Vertrieb der Schuldverschreibungen an Kleinanleger angemessen sind – Anlageberatung, Portfolio-Management und Verkäufe ohne Beratung. Jede Person, die in der Folge die Schuldverschreibungen anbietet, verkauft oder empfiehlt (jeweils ein* ***VK Vertriebsunternehmen****) soll die Beurteilung des Zielmarkts des Konzepteurs berücksichtigen; ein VK Vertriebsunternehmen, welches dem FCA Handbook Product Intervention and Product Governance Sourcebook (die* ***VK MiFIR Product Governance Rules****) unterliegt, ist indes dafür verantwortlich, seine eigene Zielmarktbestimmung im Hinblick auf die Schuldverschreibungen durchzuführen (entweder durch die Übernahme oder durch die Präzisierung der Zielmarktbestimmung des Konzepteurs) und angemessene Vertriebskanäle nach Maßgabe der Pflichten des VK Vertriebsunternehmens unter COBS im Hinblick Geeignetheit bzw. Angemessenheit, zu bestimmen. Von den angesprochenen Anlegern wird erwartet, dass sie (1) zumindest über fundierte Kenntnisse und/oder Erfahrungen mit Finanzprodukten verfügen, (2) in der Lage sind, zinsbedingte Verluste zu tragen und keine Kapitalverluste hinnehmen müssen, wenn sie bis zur Fälligkeit gehalten werden, (3) ein mittleres Risikoprofil haben, (4) ein allgemeines Kapitalbildungs-/Vermögensoptimierungsziel verfolgen und (5) einen mittelfristigen Anlagehorizont haben. Die Emittentin ist kein Konzepteur oder ein VK Vertriebsunternehmen für Zwecke der VK MiFIR Bestimmungen zu Produktüberwachungspflichten.*

**Singapore** – In connection with Section 309B of the Securities and Futures Act 2001 of Singapore (the ***SFA***) and the Securities and Futures (Capital Markets Products) Regulations 2018 of Singapore (the CMP Regulations 2018), the Issuer has determined, and hereby notifies all relevant persons (as defined in Section 309A(1) of the SFA), that the Notes are prescribed capital markets products (as defined in the CMP Regulations 2018) and are Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendation on Investment Products).

***Singapur*** *– In Verbindung mit Section 309B des Securities and Futures Act 2001 von Singapur (der* ***SFA****) und den Securities and Futures (Capital Markets Products) Regulations 2018 von Singapur (die* ***CMP Regulations 2018****), hat die Emittentin festgestellt und benachrichtigt hiermit alle relevanten Personen (wie in Section 309A(1) des SFA definiert), dass es sich bei den Schuldverschreibungen um prescribed capital markets products (wie in den CMP Regulations 2018 definiert) und um Excluded Investment Products (wie in der MAS-Mitteilung SFA 04-N12: Notice on the Sale of Investment Products und der MAS Notice FAA-N16: Notice on Recommendation on Investment Products definiert) handelt.*

*In case of Notes listed on the official list and admitted to trading on the regulated market of the Luxembourg Stock Exchange (Bourse de Luxembourg) or publicly offered in the Grand Duchy of Luxembourg (****Luxembourg****), the Final Terms of Notes will be displayed on the website of the Luxembourg Stock Exchange (www.luxse.com). In the case of Notes listed on any other stock exchange or publicly offered in one or more member states of the EEA other than Luxembourg, the Final Terms will be displayed on the website of Fresenius Medical Care (www.freseniusmedicalcare.com).*

------

**November 20, 2025**

***20. November 2025***

**FINAL TERMS**

***ENDGÜLTIGE BEDINGUNGEN***

Fresenius Medical Care AG

EUR 500,000,000 3.250 per cent. Notes due November 24, 2030

*EUR 500.000.000 3,250 % Schuldverschreibungen fällig am 24. November 2030*

Series:10, Tranche 1

*Serien:10, Tranche* 1

issued pursuant to the<br>*begeben aufgrund des*

**EUR 10,000,000,000**

**Debt Issuance Program**

Dated March 26, 2025<br>*vom 26. März 2025*

of<br>*der*

**Fresenius Medical Care AG**

Issue Price: 99.619 per cent.

*Ausgabepreis:* 99,619 *%*

Issue Date: November 24, 2025

*Begebungstag*: *24. November 2025*

------

**Important Notice**

These are the Final Terms of an issue of Notes under the EUR 10,000,000,000 Debt Issuance Program of Fresenius Medical Care AG (the ***Program***). These Final Terms have been prepared for the purpose of Article 8(5) in conjunction with Article 25(4) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, as amended, and must be read in conjunction with the base prospectus dated March 26, 2025 as supplemented by a supplement dated November 7, 2025 (the ***Prospectus***). Full information on Fresenius Medical Care AG and the offer of the Notes is only available on the basis of the combination of the Prospectus and these Final Terms. The Prospectus and any supplement thereto are available for viewing in electronic form on the website of the Luxembourg Stock Exchange (*www.luxse.com*).

A summary of the individual issue of the Notes is annexed to these Final Terms.

***Wichtiger Hinweis***

*Diese Endgültigen Bedingungen enthalten Angaben zur Emission von Schuldverschreibungen unter dem EUR 10.000.000.000 Debt Issuance Programm der Fresenius Medical Care AG (das* ***Programm****). Diese Endgültigen Bedingungen wurden für die Zwecke des Artikels 8 Absatz 5 i.V.m. Artikel 25 Absatz 4 der Verordnung (EU) 2017/1129 des Europäischen Parlaments und des Rates vom 14. Juni 2017, in der jeweils geltenden Fassung, abgefasst und sind in Verbindung mit dem Basisprospekt vom 26. März 2025 ergänzt durch den Nachtrag vom 7. November 2025 (der* ***Prospekt****) zu lesen. Vollständige Informationen über Fresenius Medical Care AG und das Angebot der Schuldverschreibungen sind nur verfügbar, wenn die Endgültigen Bedingungen und der Prospekt zusammengenommen werden. Der Prospekt sowie jeder Nachtrag können in elektronischer Form auf der Internetseite der Luxemburger Börse (www.luxse.com) eingesehen werden.*

*Eine Zusammenfassung der einzelnen Emission der Schuldverschreibungen ist diesen Endgültigen Bedingungen beigefügt.*

------

**Part I.: TERMS AND CONDITIONS**

***Teil I: EMISSIONSBEDINGUNGEN***

The Terms and Conditions applicable to the Notes (the ***Conditions***) and the English language translation thereof, are as set out below.

*Die für die Schuldverschreibungen geltenden Emissionsbedingungen (die* ***Bedingungen****) sowie die englischsprachige Übersetzung sind wie nachfolgend aufgeführt.*

------

---

| | |
|:---|:---|
| **Terms and Conditions** | **Emissionsbedingungen** |
| **§ 1**<br>**(CURRENCY, DENOMINATION, FORM)** | **§ 1**<br>**(WÄHRUNG, STÜCKELUNG, FORM)** |
| (1)<br>Currency; Denomination.<br>| (1)<br>Währung; Stückelung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This series of notes (the ***Notes***) of Fresenius Medical Care AG (also referred to as the ***Issuer***) is being issued in euro (***EUR***) (the ***Specified Currency***) in the aggregate principal amount (subject to § 1(4)) of EUR 500,000,000 (in words: euro five hundred million) in the denomination of EUR 1,000 (the ***Specified Denomination***). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diese Serie von Schuldverschreibungen (die ***Schuldverschreibungen***) der Fresenius Medical Care AG (auch als die ***Emittentin*** bezeichnet) wird in Euro (***EUR***)(die ***Festgelegte Währung***) im Gesamtnennbetrag (vorbehaltlich § 1(4)) von EUR 500.000.000 (in Worten: Euro fünfhundert Millionen) in einer Stückelung von EUR 1.000 (die ***Festgelegte Stückelung***) begeben. |
| (2)<br>Form.<br>| (2)<br>Form.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes are being issued in bearer form.  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Schuldverschreibungen lauten auf den Inhaber. |
| (3)<br>Temporary Global Note – Exchange.<br>(a)<br>The Notes are initially represented by a temporary global note (the ***Temporary Global Note***) without coupons. The interests in the Temporary Global Note will be exchangeable for interests in Notes in Specified Denominations represented by a permanent global note (the ***Permanent Global Note*** and together with the Temporary Global Note, the ***Global Notes***) without coupons. The details of such exchange shall be entered in the records of the ICSDs (as defined below). The Global Notes shall each bear the handwritten or facsimile signatures of two duly authorized representatives of the Issuer, shall each be provided with a handwritten or facsimile control signature by or on behalf of the Fiscal Agent and shall each bear the handwritten or facsimile signature by or on behalf of the common<br>| (3)<br>Vorläufige Globalurkunde – Austausch.<br>(a)<br>Die Schuldverschreibungen sind anfänglich durch eine vorläufige Globalurkunde (die ***Vorläufige Globalurkunde***) ohne Zinsscheine verbrieft. Die Anteile an der Vorläufigen Globalurkunde werden gegen Anteile an Schuldverschreibungen in den Festgelegten Stückelungen, die durch eine Dauerglobalurkunde (die ***Dauerglobalurkunde*** und zusammen mit der Vorläufigen Globalurkunde, die ***Globalurkunden***) ohne Zinsscheine verbrieft sind, ausgetauscht. Die Einzelheiten eines solchen Austausches werden in die Aufzeichnungen der ICSDs (wie nachstehend definiert) aufgenommen. Die Globalurkunden tragen jeweils die eigenhändigen oder faksimilierten Unterschriften von zwei ordnungsgemäß bevollmächtigten Vertretern der<br>|

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;safekeeper. Definitive Notes and interest coupons will not be issued. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emittentin, sind jeweils von der Emissionsstelle oder in deren Namen mit einer eigenhändigen oder faksimilierten Kontrollunterschrift versehen und tragen jeweils die eigenhändige oder faksimilierte Unterschrift von oder im Namen des gemeinsamen Wertpapierverwahrers (*common safekeeper*). Einzelurkunden und Zinsscheine werden nicht ausgegeben. |
| <br>(b)<br>Interests in the Temporary Global Note shall be exchanged for interests in the Permanent Global Note on or after a date (the ***Exchange Date***) not earlier than 40 days after the date of issue of the Notes. Such exchange shall only be made upon and to the extent of delivery of certifications to the effect that the beneficial owner or owners of the Notes is not a U.S. person (other than certain financial institutions or certain persons holding Notes through such financial institutions). Payment of interest on Notes represented by a Temporary Global Note will be made only after delivery of such certifications. A separate certification shall be required in respect of each such payment of interest. Any such certification received on or after the 40th day after the date of issue of the Notes will be treated as a request to exchange the Temporary Global Note pursuant to subparagraph (b) of this § 1(3). Any Notes delivered in exchange for the Temporary Global Note shall be delivered only outside of the United States (as defined in § 1(6)).<br>| <br>(b)<br>Anteile an der Vorläufigen Globalurkunde werden an oder nach einem Tag der Ausgabe der Vorläufigen Globalurkunde (der ***Austauschtag***) gegen Anteile an der Dauerglobalurkunde ausgetauscht, der nicht weniger als 40 Tage nach dem Tag der Begebung der Schuldverschreibungen liegt. Ein solcher Austausch darf nur nach Vorlage und im Umfang von Bescheinigungen erfolgen, wonach der oder die wirtschaftlichen Eigentümer der Schuldverschreibungen keine U.S.-Personen sind (ausgenommen bestimmte Finanzinstitute oder bestimmte Personen, die Schuldverschreibungen über solche Finanzinstitute halten). Solange die Schuldverschreibungen durch eine Vorläufige Globalurkunde verbrieft sind, werden Zinszahlungen erst nach Vorlage dieser Bescheinigungen vorgenommen. Eine gesonderte Bescheinigung ist für jede solche Zinszahlung erforderlich. Jede Bescheinigung, die am oder nach dem 40. Tag nach dem Tag der Begebung der Schuldverschreibungen eingeht, wird als ein Ersuchen behandelt werden, diese Vorläufige Globalurkunde gemäß Absatz (b) dieses § 1(3) auszutauschen. Schuldverschreibungen, die im Austausch für die Vorläufige <br>|

---

------

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Globalurkunde geliefert werden, dürfen nur außerhalb der Vereinigten Staaten (wie in § 1(6) definiert) geliefert werden. |
| (4)<br>Clearing System.<br>| (4)<br>Clearingsystem.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Global Note will be kept in custody by or on behalf of the Clearing System until all obligations of the Issuer under the Notes have been satisfied. ***Clearing System*** means each of the following: Clearstream Banking S.A. Luxembourg (***CBL***) and Euroclear Bank SA/NV Brussels as operator of the Euroclear System (***Euroclear***) and any successor in such capacity. ***International Central Securities Depositary*** or ***ICSD*** means each of CBL and Euroclear (together, the ***ICSDs***). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Globalurkunde wird solange von einem oder im Namen eines Clearingsystems verwahrt, bis sämtliche Verbindlichkeiten der Emittentin aus den Schuldverschreibungen erfüllt sind. ***Clearingsystem*** bedeutet jeweils folgendes: Clearstream Banking S.A., Luxemburg (***CBL***) und Euroclear Bank SA/NV Brüssel, als Betreiberin des Euroclear Systems (***Euroclear***) sowie jeder Funktionsnachfolger. ***International Central Securities Depositary*** oder ***ICSD*** bezeichnet jeweils CBL und Euroclear (zusammen die ***ICSDs***). |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes are issued in new global note (***NGN***) form and are kept in custody by a common safekeeper on behalf of both ICSDs. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Schuldverschreibungen werden in Form einer New Global Note (***NGN***) ausgegeben und von einem gemeinsamen Wertpapierverwahrer (*common safekeeper*) im Namen beider ICSDs verwahrt. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The principal amount of Notes represented by the Global Note shall be the aggregate amount from time to time entered in the records of both ICSDs. The records of the ICSDs (which expression means the records that each ICSD holds for its customers which reflect the amount of such customer's interest in the Notes) shall be conclusive evidence of the principal amount of Notes represented by the Global Note and, for these purposes, a statement issued by an ICSD stating the principal amount of Notes so represented at any time shall be conclusive evidence of the records of the relevant ICSD at that time. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Der Nennbetrag der durch die Globalurkunde verbrieften Schuldverschreibungen entspricht dem jeweils in den Registern beider ICSDs eingetragenen Gesamtbetrag. Die Register der ICSDs (unter denen man die Register versteht, die jeder ICSD für seine Kunden über den Betrag ihres Anteils an den Schuldverschreibungen führt) sind schlüssiger Nachweis über den Nennbetrag der durch die Globalurkunde verbrieften Schuldverschreibungen und eine zu diesen Zwecken von einem ICSD jeweils ausgestellte Bestätigung mit dem Nennbetrag der so verbrieften Schuldverschreibungen ist zu jedem Zeitpunkt ein schlüssiger Nachweis über den Inhalt des Registers des jeweiligen ICSD. |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On any redemption or payment of interest being made in respect of, or purchase and cancellation of, any of the Notes represented by the Global Note the Issuer shall procure that details of any redemption, payment or purchase and cancellation (as the case may be) in respect of the Global Note shall be entered ***pro rata*** in the records of the ICSDs and, upon any such entry being made, the principal amount of the Notes recorded in the records of the ICSDs and represented by the Global Note shall be reduced by the aggregate principal amount of the Notes so redeemed or purchased and cancelled. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bei Rückzahlung oder Zinszahlung bezüglich der durch die Globalurkunde verbrieften Schuldverschreibungen bzw. bei Kauf und Entwertung der durch die Globalurkunde verbrieften Schuldverschreibungen stellt die Emittentin sicher, dass die Einzelheiten über jede Rückzahlung und Zahlung bzw. Kauf und Löschung bezüglich der Globalurkunden ***pro rata*** in die Unterlagen der ICSDs eingetragen werden, und nach dieser Eintragung vom Nennbetrag der in die Register der ICSDs aufgenommenen und durch die Globalurkunde verbrieften Schuldschreibungen der Gesamtnennbetrag der zurückgezahlten bzw. gekauften und entwerteten Schuldverschreibungen abgezogen wird. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On an exchange of a portion only of the Notes represented by a Temporary Global Note, the Issuer shall procure that details of such exchange shall be entered *pro rata* in the records of the ICSDs. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bei Austausch nur eines Teils von Schuldverschreibungen, die durch eine Vorläufige Globalurkunde verbrieft sind, wird die Emittentin sicherstellen, dass die Einzelheiten dieses Austauschs *pro rata* in die Register der ICSDs aufgenommen werden. |
| (5)<br>Holder of Notes.<br>| (5)<br>Gläubiger von Schuldverschreibungen.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Holder*** means any holder of a proportionate co-ownership or other beneficial interest or right in the Notes. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Gläubiger*** bedeutet jeder Inhaber eines Miteigentumsanteils oder anderen vergleichbaren Rechts an den Schuldverschreibungen. |
| (6)<br>United States.<br>| (6)<br>Vereinigte Staaten.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of these Terms and Conditions, ***United States*** means the United States of America (including the States thereof and the District of Columbia) and its territories and possessions (including Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, Wake Island and Northern Mariana Islands). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Für die Zwecke dieser Emissionsbedingungen bezeichnet ***Vereinigte Staaten*** die Vereinigten Staaten von Amerika (einschließlich deren Bundesstaaten und des District of Columbia) sowie deren Territorien und Besitztümer (einschließlich Puerto Rico, der U.S. Virgin Islands, Guam, American Samoa, Wake Island und Northern Mariana Islands). |

---

------

---

| | |
|:---|:---|
| **§ 2**<br>**(STATUS, NEGATIVE PLEDGE)** | **§ 2**<br>**(STATUS, NEGATIVVERPFLICHTUNG)** |
| (1)<br>Status.<br>| (1)<br>Status.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The obligations under the Notes constitute unsecured and unsubordinated obligations of the Issuer ranking *pari passu* among themselves and *pari passu* with all other present or future unsecured and unsubordinated obligations of the Issuer, unless such obligations are accorded priority under mandatory provisions of statutory law. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Schuldverschreibungen begründen nicht besicherte und nicht nachrangige Verbindlichkeiten der Emittentin, die untereinander und mit allen anderen gegenwärtigen und künftigen nicht besicherten und nicht nachrangigen Verbindlichkeiten der Emittentin gleichrangig sind, soweit diesen Verbindlichkeiten nicht durch zwingende gesetzliche Bestimmungen ein Vorrang eingeräumt wird. |
| (2)<br>Negative Pledge.<br>| (2)<br>Negativverpflichtung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;So long as any of the Notes remain outstanding, but only up to the time all amounts of principal and interest have been placed at the disposal of the Fiscal Agent, the Issuer undertakes (i) not to grant or permit to subsist any mortgage, land charge, lien or any other security right in rem (*dingliches Sicherungsrecht*) (the ***Security Interest***) over any or all of its present or future assets, as security for any present or future Capital Market Indebtedness and (ii) to procure, to the extent legally possible, that none of its Subsidiaries will grant or permit to subsist any Security Interest over any or all of its present or future assets, as security for any present or future Capital Market Indebtedness, without at the same time having the Holders share equally and ratably in such Security Interest. This undertaking shall not apply with respect to any Security Interest which (i) is provided over any of the Issuer's claims or claims of any of its Subsidiaries against any affiliated companies within the meaning of sections 15 et seqq. of the German Stock Corporation Act (*Aktiengesetz*) or any third party, which claims exist now or arise at any time in the future, as a result of the passing on of the proceeds from the sale by the issuer of any securities, provided that any such | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Emittentin verpflichtet sich, solange Schuldverschreibungen ausstehen, jedoch nur bis zu dem Zeitpunkt, an dem alle Beträge an Kapital und Zinsen der Emissionsstelle zur Verfügung gestellt worden sind, (i) keine Grundpfandrechte, Pfandrechte oder sonstigen dinglichen Sicherungsrechte (ein ***Sicherungsrecht***) an gegenwärtigen oder zukünftigen Teilen ihres Vermögens oder ihres Vermögens insgesamt zur Sicherung der gegenwärtigen oder zukünftigen Kapitalmarktverbindlichkeiten zu bestellen oder fortbestehen zu lassen, und (ii) soweit rechtlich möglich, zu veranlassen, dass keine ihrer Tochtergesellschaften Sicherungsrechte an gegenwärtigen oder zukünftigen Teilen ihres Vermögens oder ihres Vermögens insgesamt zur Sicherung der gegenwärtigen oder zukünftigen Kapitalmarktverbindlichkeiten bestellt oder fortbestehen lässt, ohne jeweils die Gläubiger zur gleichen Zeit auf gleiche Weise und anteilig an diesen Sicherungsrechten teilhaben zu lassen. Diese Verpflichtung gilt nicht in Bezug auf Sicherungsrechte, die (i) an gegenwärtigen oder zukünftigen Ansprüchen der Emittentin oder Ansprüchen einer ihrer Tochtergesellschaften gegen |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;security serves to secure obligations under such securities issued by the Issuer or by any of its Subsidiaries, (ii) is existing on assets at the time of the acquisition thereof by the Issuer or by any of its Subsidiaries or is existing over assets of a newly acquired company which becomes a member of the Fresenius Medical Care Group, (iii) is existing on the issue date of the Notes, (iv) secures a Capital Market Indebtedness existing at the time of acquisition that becomes an obligation of the Issuer or of any company within the Fresenius Medical Care Group as a consequence of such acquisition, provided that such Capital Market Indebtedness was not created in contemplation of such acquisition (v) is mandatory pursuant to applicable laws or required as a prerequisite for obtaining any governmental approvals, (vi) is provided in connection with any issuance of asset backed securities by the Issuer or by any of its Subsidiaries, (vii) is provided in respect of any issuance of asset backed securities made by a special purpose vehicle where the Issuer or any of its Subsidiaries is the originator of the underlying assets, (viii) is provided in connection with the renewal, extension or replacement of any security pursuant to foregoing (i) through (vii) and, (ix) secures Capital Market Indebtedness the principal amount of which (when aggregated with the principal amount of any other Capital Market Indebtedness which has the benefit of a security other than any permitted under the subparagraphs (i) to (viii) above) does not exceed EUR 100,000,000 (or its equivalent in other currencies at any time).  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;verbundene Unternehmen im Sinne der §§ 15 ff. Aktiengesetz oder gegen Dritte aufgrund einer Übertragung von Erlösen aus dem Verkauf von Wertpapieren bestehen, soweit diese Sicherheiten zur Sicherung von Verpflichtungen aus diesen durch die Emittentin oder durch eine ihrer Tochtergesellschaften ausgegebenen Wertpapieren dienen, (ii) zur Sicherung von Vermögensgegenständen bestellt sind, die bereits zum Zeitpunkt ihres Erwerbs durch die Emittentin oder durch eine ihrer Tochtergesellschaften bestanden, oder am Vermögen einer neu erworbenen Gesellschaft bestehen, die Mitglied des Fresenius Medical Care-Konzerns wird, (iii) zum Ausgabetag der Schuldverschreibungen bestehen, (iv) eine im Zeitpunkt einer Akquisition bestehende Kapitalmarktverbindlichkeit besichern, die infolge der Akquisition eine Verpflichtung der Emittentin oder einer Gesellschaft des Fresenius Medical Care-Konzerns wird, sofern diese Kapitalmarktverbindlichkeit nicht im Hinblick auf diese Akquisition begründet wurde, (v) aufgrund anwendbaren Rechts gesetzlich vorgeschriebene Sicherheiten sind oder solche, deren Bestehen eine Voraussetzung zur Erteilung einer behördlichen Genehmigung sind, (vi) im Zusammenhang mit durch die Emittentin oder durch eine ihrer Tochtergesellschaften begebenen Asset Backed Securities (ABS) stehen, (vii) im Zusammenhang mit durch Zweckgesellschaften begebenen Asset Backed Securities (ABS) stehen, bei denen die Emittentin oder eine ihrer Tochtergesellschaften der Originator der zugrundeliegenden Vermögensgegenstände ist, (viii) der Erneuerung, Verlängerung oder dem Austausch irgendeiner Sicherheit gemäß vorstehend (i) bis (vii) dienen und (ix) Kapitalmarktverbindlichkeiten besichern, deren Kapitalbetrag (bei Aufaddierung auf den Kapitalbetrag sonstiger Kapitalmarktverbindlichkeiten, für die andere Sicherheiten als die nach (i) bis (viii) zulässigen bestehen) |

---

------

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EUR 100.000.000 (oder deren jeweiligen Gegenwert in anderen Währungen) nicht überschreitet. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of these Terms and Conditions, ***Capital Market Indebtedness*** means any obligation for the payment of borrowed money which is evidenced by a certificate of indebtedness (*Schuldscheindarlehen*) or which is represented by any bond or debt security with an original maturity of more than one year which is, or is intended to be, or is capable of being listed or traded on a stock exchange or other recognized securities market.  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Im Sinne dieser Emissionsbedingungen bezeichnet ***Kapitalmarktverbindlichkeit*** jede Verbindlichkeit zur Rückzahlung aufgenommener Geldbeträge, die durch Schuldscheindarlehen dokumentiert ist oder durch Schuldverschreibungen oder sonstige Wertpapiere mit einer ursprünglichen Laufzeit von mehr als einem Jahr, die an einer Börse oder an einem anderen anerkannten Wertpapiermarkt zugelassen oder gehandelt werden oder zugelassen oder gehandelt werden können, verbrieft, verkörpert oder dokumentiert ist. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Fresenius Medical Care Group*** means the Issuer and its Subsidiaries on a consolidated basis. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Fresenius Medical Care-Konzern*** bezeichnet die Emittentin und ihre Tochtergesellschaften auf konsolidierter Basis. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Subsidiary*** means, with respect to any Person, any corporation, limited liability company, association, partnership or other business entity whose results of operations are consolidated in accordance with IFRS Accounting Standards with those of: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Tochtergesellschaft*** bezeichnet in Bezug auf einen Rechtsträger, eine Kapitalgesellschaft, eine Gesellschaft mit Haftungsbeschränkung, eine Vereinigung, eine Personengesellschaft oder ein sonstiges Unternehmen, deren bzw. dessen Ergebnisse gemäß den IFRS Accounting Standards mit den Ergebnissen folgender Personen konsolidiert werden: |
| <br>(a)<br>such Person;<br>| <br>(a)<br>dieses Rechtsträgers;<br>|
| <br>(b)<br>such Person and one or more Subsidiaries of such Person; or<br>| <br>(b)<br>dieses Rechtsträgers und einer oder mehreren Tochtergesellschaften dieses Rechtsträgers; oder<br>|
| <br>(c)<br>one or more Subsidiaries of such Person. <br>| <br>(c)<br>einer oder mehrerer Tochtergesellschaften dieses Rechtsträgers.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***IFRS Accounting Standards*** refers to IFRS Accounting Standards of the International Accounting Standards Board (IASB), as adopted by the European Union. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***IFRS Accounting Standards*** bezeichnet die IFRS Accounting Standards des International Accounting Standards Board (IASB), wie sie von  |

---

------

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;der Europäischen Union anerkannt werden. |
| **§ 3**<br>**(INTEREST)** | **§ 3**<br>**(ZINSEN)** |
| (1)<br>Rate of Interest and Interest Payment Dates.<br>| (1)<br>Zinssatz und Zinszahlungstage.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes shall bear interest on their Specified Denomination at the rate of 3.250 % *per annum* from (and including) November 24, 2025 to (but excluding) the Maturity Date (as defined in § 5(1)). Interest shall be payable in arrear on November 24 in each year (each such date, an ***Interest Payment Date***). The first payment of interest shall be made on November 24, 2026. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Schuldverschreibungen werden bezogen auf ihre Festgelegte Stückelung verzinst, und zwar vom 24. November 2025 (einschließlich) bis zum Fälligkeitstag (wie in § 5(1) definiert) (ausschließlich) mit jährlich 3,250 %. Die Zinsen sind nachträglich am 24. November eines jeden Jahres zahlbar (jeweils ein ***Zinszahlungstag***). Die erste Zinszahlung erfolgt am 24. November 2026. |
| (2)<br>Accrual of Interest.<br>| (2)<br>Auflaufende Zinsen.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes shall cease to bear interest from the expiry of the day preceding the day on which they are due for redemption. If the Issuer for any reason fails to redeem the Notes when due, interest shall continue to accrue at the default rate of interest established by statutory law<sup>1</sup> on the outstanding aggregate principal amount of the Notes from (and including) the due date to (but excluding) the day on which such redemption payment is made to the Holders. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Der Zinslauf der Schuldverschreibungen endet mit Ablauf des Tages, der dem Tag vorangeht, an dem sie zur Rückzahlung fällig werden. Falls die Emittentin die Schuldverschreibungen bei Fälligkeit aus irgendeinem Grund nicht zurückzahlt, wird der ausstehende Gesamtnennbetrag der Schuldverschreibungen von dem Tag der Fälligkeit (einschließlich) bis zum Tag der vollständigen Rückzahlung an die Gläubiger (ausschließlich) mit dem gesetzlich bestimmten Verzugszins<sup>2</sup> verzinst. |
| (3)<br>Calculation of Interest for Periods other than a full year.<br>| (3)<br>Berechnung der Zinsen für Zeiträume, die nicht einem vollen Jahr entsprechen.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If interest is to be calculated for a period other than a full year, it shall be calculated on the basis of the Day Count Fraction (as defined below). The number of Interest Payment Dates per | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sofern Zinsen für einen Zeitraum, der nicht einem vollen Jahr entspricht, zu berechnen sind, erfolgt die Berechnung auf der Grundlage des Zinstagequotienten (wie nachfolgend |

---

------

<sup>1</sup> The default rate of interest established by statutory law is five percentage points above the basis rate of interest published by *Deutsche Bundesbank* from time to time, §§ 288(1), 247(1) of the German Civil Code.

<sup>2</sup> Der gesetzliche Verzugszinssatz beträgt für das Jahr fünf Prozentpunkte über dem von der Deutsche Bundesbank von Zeit zu Zeit veröffentlichten Basiszinssatz, §§ 288 Abs. 1, 247 Abs. 1 BGB.

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;calendar year (each a ***Determination Date***) is one. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;definiert). Die Anzahl der Zinszahlungstage im Kalenderjahr (jeweils ein ***Feststellungstermin***) beträgt Eins. |
| (4)<br>Day Count Fraction.<br>| (4)<br>Zinstagequotient.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Day Count Fraction*** means with regard to the calculation of the amount of interest on the Notes for any period of time (the ***Calculation Period***): | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Zinstagequotient*** bezeichnet im Hinblick auf die Berechnung von Zinsbeträgen auf die Schuldverschreibungen für einen beliebigen Zeitraum (der ***Zinsberechnungszeitraum***): |
| <br>(a)<br>if the Calculation Period is equal to or shorter than the Determination Period during which the Calculation Period ends, the number of days in such Calculation Period divided by the product of (1) the number of days in such Determination Period and (2) the number of Determination Dates (as specified in § 3(3)) that would occur in one calendar year; or<br>| <br>(a)<br>wenn der Zinsberechnungszeitraum kürzer ist als die Feststellungsperiode, in die das Ende des Zinsberechnungszeitraumes fällt oder ihr entspricht, die Anzahl der Tage in dem betreffenden Zinsberechnungszeitraum geteilt durch das Produkt (1) der Anzahl der Tage in der Feststellungsperiode und (2) der Anzahl der Feststellungstermine (wie in § 3(3) angegeben) in einem Kalenderjahr; oder<br>|
| <br>(b)<br>if the Calculation Period is longer than the Determination Period during which the Calculation Period ends, the sum of: (A) the number of days in such Calculation Period falling in the Determination Period in which the Calculation Period begins divided by the product of (1) the number of days in such Determination Period and (2) the number of Determination Dates (as specified in § 3(3)) that would occur in one calendar year and (B) the number of days in such Calculation Period falling in the next Determination Period divided by the product of (1) the number of days in such Determination Period and (2) the number of Determination Dates (as specified in § 3(3)) that would occur in one calendar year.<br>| <br>(b)<br>wenn der Zinsberechnungszeitraum länger ist als die Feststellungsperiode, in die das Ende des Zinsberechnungszeitraumes fällt, die Summe aus (A) der Anzahl der Tage in dem Zinsberechnungszeitraum, die in die Feststellungsperiode fallen, in welcher der Zinsberechnungszeitraum beginnt, geteilt durch das Produkt aus (1) der Anzahl der Tage in dieser Feststellungsperiode und (2) der Anzahl der Feststellungstermine (wie in § 3(3) angegeben) in einem Kalenderjahr und (B) der Anzahl der Tage in dem Zinsberechnungszeitraum, die in die nächste Feststellungsperiode fallen, geteilt durch das Produkt aus (1) der Anzahl der Tage in dieser Feststellungsperiode und (2) der Anzahl der <br>|

---

------

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Feststellungstermine (wie in § 3(3) angegeben) in einem Kalenderjahr. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Determination Period*** means the period from (and including) a Determination Date to, (but excluding) the next Determination Date. For the purpose of determining the relevant Determination Period, November 24 shall each be deemed to be a Determination Date. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Feststellungsperiode*** ist die Periode ab einem Feststellungstermin (einschließlich desselben) bis zum nächsten Feststellungstermin (ausschließlich desselben). Zum Zwecke der Bestimmung der maßgeblichen Feststellungsperiode ist der 24. November jeweils ein Feststellungstermin. |
| **§ 4**<br>**(PAYMENTS)** | **§ 4**<br>**(ZAHLUNGEN)** |
| (1)<br>Payment of Principal and Payment of Interest.<br>| (1)<br>Zahlungen auf Kapital und Zahlung von Zinsen.<br>|
| <br>(a)<br>Payment of principal in respect of the Notes shall be made, subject to subparagraph (2) below, to the Clearing System or to its order for credit to the accounts of the relevant account holders of the Clearing System.<br>| <br>(a)<br>Zahlungen von Kapital auf die Schuldverschreibungen erfolgen nach Maßgabe des nachstehenden Absatzes (2) an das Clearingsystem oder dessen Order zur Gutschrift auf den Konten der jeweiligen Kontoinhaber des Clearingsystems.<br>|
| <br>(b)<br>Payment of Interest on the Notes shall be made, subject to subparagraph (2) below, to the Clearing System or to its order for credit to the accounts of the relevant account holders of the Clearing System.<br>| <br>(b)<br>Die Zahlung von Zinsen auf die Schuldverschreibungen erfolgt nach Maßgabe des nachstehenden Absatzes (2) an das Clearingsystem oder dessen Order zur Gutschrift auf den Konten der jeweiligen Kontoinhaber des Clearingsystems.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of interest on Notes represented by the Temporary Global Note shall be made, subject to subparagraph (2) below, to the Clearing System or to its order for credit to the accounts of the relevant account holders of the Clearing System, upon due certification as provided in § 1(3)(b). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Zahlung von Zinsen auf Schuldverschreibungen, die durch die Vorläufige Globalurkunde verbrieft sind, erfolgt nach Maßgabe des nachstehenden Absatzes (2) an das Clearingsystem oder dessen Order zur Gutschrift auf den Konten der jeweiligen Kontoinhaber des Clearingsystems, und zwar nach ordnungsgemäßer Bescheinigung gemäß § 1(3)(b). |
| (2)<br>Manner of Payment.<br>| (2)<br>Zahlungsweise.<br>|

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to applicable fiscal and other laws and regulations, payments of amounts due in respect of the Notes shall be made in the Specified Currency. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vorbehaltlich geltender steuerlicher und sonstiger gesetzlicher Regelungen und Vorschriften erfolgen zu leistende Zahlungen auf die Schuldverschreibungen in der Festgelegten Währung. |
| (3)<br>Discharge.<br>| (3)<br>Erfüllung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Issuer shall be discharged by payment to, or to the order of, the Clearing System. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Emittentin wird durch Leistung der Zahlung an das Clearingsystem oder dessen Order von ihrer Zahlungspflicht befreit. |
| (4)<br>Payment Business Day.<br>| (4)<br>Zahltag.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the date for payment of any amount in respect of any Note is not a Payment Business Day, then the Holder shall not be entitled to payment until the next such day in the relevant place and shall not be entitled to further interest or other payment in respect of such delay. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fällt der Fälligkeitstag einer Zahlung in Bezug auf eine Schuldverschreibung auf einen Tag, der kein Zahltag ist, dann hat der Gläubiger keinen Anspruch auf Zahlung vor dem nächsten Zahltag am jeweiligen Geschäftsort. Der Gläubiger ist nicht berechtigt, weitere Zinsen oder sonstige Zahlungen aufgrund dieser Verspätung zu verlangen. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For these purposes, ***Payment Business Day*** means any day (other than a Saturday or a Sunday) on which the Clearing System is operational as well as all relevant parts of T2 are operational to forward the relevant payment. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Für diese Zwecke bezeichnet ***Zahltag*** einen Tag (außer einem Samstag oder Sonntag), an dem das Clearingsystem betriebsbereit ist, sowie alle betroffenen Bereiche des T2 betriebsbereit sind, um die betreffenden Zahlungen weiterzuleiten. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**T2** means the real time gross settlement system operated by the Eurosystem, or any successor system. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**T2** bezeichnet das Echtzeit-Bruttoabwicklungssystem betrieben durch das Eurosystem, oder ein Nachfolgesystem. |
| (5)<br>References to Principal and Interest.<br>| (5)<br>Bezugnahmen auf Kapital und Zinsen.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References in these Terms and Conditions to principal in respect of the Notes shall be deemed to include, as applicable: the Call Redemption Amount of the Notes; and any premium and any other amounts which may be payable under or in respect of the Notes. References in these Terms and Conditions to interest in respect of the Notes shall be deemed to include, as | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bezugnahmen in diesen Emissionsbedingungen auf Kapital der Schuldverschreibungen schließen, soweit anwendbar, die folgenden Beträge ein: den Wahl-Rückzahlungsbetrag (Call) der Schuldverschreibungen; sowie jeden Aufschlag sowie sonstige auf oder in Bezug auf die Schuldverschreibungen zahlbaren Beträge. Bezugnahmen in diesen Emissionsbedingungen auf  |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;applicable, any Additional Amounts which may be payable under § 7. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Zinsen auf die Schuldverschreibungen sollen, soweit anwendbar, sämtliche gemäß § 7 zahlbaren Zusätzlichen Beträge einschließen. |
| (6)<br>Deposit of Principal and Interest.<br>| (6)<br>Hinterlegung von Kapital und Zinsen.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Issuer may deposit with the local court (***Amtsgericht***) in Frankfurt/Main principal or interest not claimed by Holders within twelve months after the Maturity Date, even though such Holders may not be in default of acceptance of payment. If and to the extent that the deposit is effected and the right of withdrawal is waived, the respective claims of such Holders against the Issuer shall cease. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Emittentin ist berechtigt, beim Amtsgericht Frankfurt am Main Zins- oder Kapitalbeträge zu hinterlegen, die von den Gläubigern nicht innerhalb von zwölf Monaten nach dem Fälligkeitstag beansprucht worden sind, auch wenn die Gläubiger sich nicht in Annahmeverzug befinden. Soweit eine solche Hinterlegung erfolgt, und auf das Recht der Rücknahme verzichtet wird, erlöschen die diesbezüglichen Ansprüche der Gläubiger gegen die Emittentin. |
| **§ 5**<br>**(REDEMPTION)** | **§ 5**<br>**(RÜCKZAHLUNG)** |
| (1)<br>Final Redemption.<br>| (1)<br>Rückzahlung bei Endfälligkeit.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless previously redeemed in whole or in part or purchased and cancelled, the Notes shall be redeemed at their principal amount on November 24, 2030 (the ***Maturity Date***). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soweit nicht zuvor bereits ganz oder teilweise zurückgezahlt oder angekauft und entwertet, werden die Schuldverschreibungen zu ihrem Nennbetrag am 24. November 2030 (der ***Fälligkeitstag***) zurückgezahlt. |
| (2)<br>Early Redemption at the option of the Issuer for Reasons of Taxation.<br>| (2)<br>Vorzeitige Rückzahlung nach Wahl der Emittentin aus steuerlichen Gründen.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If as a result of any change in, or amendment to, the laws, treaties, regulations or official position of any Relevant Taxing Jurisdiction (as defined in § 7 herein) or any political subdivision or taxing authority thereto or therein affecting taxation or the obligation to pay duties of any kind, or any change in, or amendment to, an official interpretation or application of such laws or regulations (including the enactment of any legislation and the publication of any judicial decision or regulatory determination), which amendment or change is effective on or after the date on which the series of Notes was issued, the Issuer is required  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Schuldverschreibungen können insgesamt, jedoch nicht teilweise, nach Wahl der Emittentin mit einer Kündigungsfrist von nicht mehr als 60 und nicht weniger als 30 Tagen durch Erklärung gegenüber der Emissionsstelle und Benachrichtigung gemäß § 12 gegenüber den Gläubigern vorzeitig gekündigt und zu ihrem Nennbetrag zuzüglich etwaiger bis zum für die Rückzahlung festgesetzten Tag (ausschließlich) aufgelaufener Zinsen zurückgezahlt werden, falls die Emittentin als Folge einer Änderung oder Ergänzung der Steuer- oder Abgabengesetze, - abkommen, - vorschriften und offiziellen |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to pay Additional Amounts (as defined in § 7 herein) on the next succeeding Interest Payment Date (as defined in § 3(1)), and this obligation cannot be avoided by the use of reasonable measures available to the Issuer, the Notes may be redeemed, in whole but not in part, at the option of the Issuer, upon not more than 60 days' nor less than 30 days' prior notice of redemption given to the Fiscal Agent and, in accordance with § 12, to the Holders, at their principal amount, together with interest (if any) accrued to the date fixed for redemption (excluding). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Verlautbarungen einer Relevanten Steuerjurisdiktion (wie in § 7 dieser Bedingungen definiert) oder deren politischen Untergliederungen oder Steuerbehörden oder als Folge einer Änderung oder Ergänzung der Anwendung oder der offiziellen Auslegung dieser Gesetze und Vorschriften (einschließlich des Erlasses von Gesetzen sowie Bekanntmachung gerichtlicher oder aufsichtsrechtlicher Entscheidungen) (vorausgesetzt, diese Änderung oder Ergänzung wird am oder nach dem Tag, an dem die Serie von Schuldverschreibungen begeben wird, wirksam) am nächstfolgenden Zinszahlungstag (wie in § 3(1) definiert) zur Zahlung von Zusätzlichen Beträgen (wie in § 7 dieser Bedingungen definiert) verpflichtet sein wird und diese Verpflichtung nicht durch das Ergreifen zumutbarer, der Emittentin zur Verfügung stehender Maßnahmen vermieden werden kann. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;However, no such notice of redemption may be given (i) earlier than 90 days prior to the earliest date on which the Issuer would be obligated to pay such Additional Amounts were a payment in respect of the Notes then due, or (ii) if at the time such notice is given, such obligation to pay such Additional Amounts does not remain in effect. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eine solche Kündigung darf allerdings nicht (i) früher als 90 Tage vor dem frühestmöglichen Termin erfolgen, an dem die Emittentin verpflichtet wäre, solche Zusätzlichen Beträge zu zahlen, falls eine Zahlung auf die Schuldverschreibungen dann fällig sein würde, oder (ii) erfolgen, wenn zu dem Zeitpunkt, zu dem die Kündigung erklärt wird, die Verpflichtung zur Zahlung von Zusätzlichen Beträgen nicht mehr wirksam ist. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any such notice shall be given in accordance with § 12. It shall be irrevocable, must specify the date fixed for redemption and must set forth a statement in summary form of the facts constituting the basis for the right of the Issuer so to redeem. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eine solche Kündigung ist gemäß § 12 bekanntzumachen. Sie ist unwiderruflich, muss den für die Rückzahlung festgelegten Termin nennen und eine zusammenfassende Erklärung enthalten, welche die das Rückzahlungsrecht der Emittentin begründenden Umständen darlegt. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before the publication of any notice of redemption pursuant to this subparagraph, the Issuer shall deliver to the Fiscal Agent a certificate signed by a member of the Issuer's management body stating that the Issuer is entitled to effect such redemption and setting forth | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vor Bekanntgabe einer Mitteilung über eine Rückzahlung gemäß diesen Bestimmungen hat die Emittentin der Emissionsstelle eine von einem Mitglied des Geschäftsführungsorgans der Emittentin unterzeichnete Bescheinigung zukommen zu lassen, |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a statement of facts showing that the conditions precedent to the right of the Issuer so to redeem have occurred, and an opinion of independent legal counsel or tax advisers of recognized standing to the effect that the Issuer has or will become obliged to pay such Additional Amounts as a result of such change or amendment. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;der zufolge die Emittentin berechtigt ist, eine entsprechende Rückzahlung zu leisten, und in der nachvollziehbar dargelegt ist, dass die Bedingungen für das Recht der Emittentin zur Rückzahlung gemäß diesen Bestimmungen erfüllt sind; zusätzlich hat die Emittentin ein von unabhängigen und anerkannten Rechts- oder Steuerberatern erstelltes Gutachten vorzulegen, demzufolge die Emittentin in Folge einer entsprechenden Änderung oder Ergänzung zur Zahlung Zusätzlicher Beträge verpflichtet ist oder sein wird. |
| (3)<br>Early Redemption at the Option of the Issuer for Reasons of Minimal Outstanding Principal Amount.<br>| (3)<br>Vorzeitige Rückzahlung nach Wahl der Emittentin bei geringfügigem ausstehendem Nennbetrag.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If 80% or more in principal amount of the Notes then outstanding have been redeemed or purchased by the Issuer or any Subsidiary of the Issuer, the Issuer may, on not less than 30 or more than 60 days' notice to the Holders redeem, at its option, the remaining Notes as a whole at their principal amount, together with interest (if any) accrued to the date fixed for redemption (excluding). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wenn 80% oder mehr des Nennbetrags der dann ausstehenden Schuldverschreibungen durch die Emittentin oder eine Tochtergesellschaft der Emittentin zurückgezahlt oder zurückerworben wurde, ist die Emittentin berechtigt, nach ihrer Wahl alle ausstehenden Schuldverschreibungen mit einer Frist von mindestens 30 und höchstens 60 Tagen gegenüber den Gläubigern zu kündigen und zum Nennbetrag zuzüglich etwaiger bis zum Rückzahlungstag (ausschließlich) aufgelaufener Zinsen zurückzuzahlen. |
| (4)<br>Early Redemption at the Option of the Holders upon a Change of Control.<br>| (4)<br>Vorzeitige Rückzahlung nach Wahl der Gläubiger bei Vorliegen eines Kontrollwechsels.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Holder of the Notes, upon the occurrence of a Change of Control Triggering Event, will have the right (unless, prior to the giving of the Put Event Notice referred to below, the Issuer gives notice to redeem the Notes in accordance with § 5(2), i.e. for taxation reasons) to require that the Issuer repurchases such Holder's Notes on the Optional Redemption Date at a purchase price in cash equal to 101% of the principal amount together with interest (if any) accrued to the Optional Redemption Date (excluding). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Falls ein Kontrollwechselereignis stattfindet, hat jeder Gläubiger das Recht (soweit die Emittentin nicht bereits vor Abgabe der Vorzeitigen Rückkaufsgrunderklärung (wie nachstehend definiert) die Rückzahlung gemäß § 5(2), d.h. aus steuerlichen Gründen, erklärt hat) von der Emittentin am Stichtag den Rückkauf seiner Schuldverschreibungen zu einem Kaufpreis von 101% des Nennbetrags zuzüglich etwaiger bis zum Stichtag (ausschließlich) aufgelaufener Zinsen zu verlangen. |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In this context the following provisions apply: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In diesem Zusammenhang finden die folgenden Vorschriften Anwendung: |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Change of Control Triggering Event*** means the occurrence of a Change of Control together with a Ratings Decline. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ein ***Kontrollwechselereignis*** liegt vor, wenn ein Kontrollwechsel zusammen mit einer Ratingherabstufung eintreten. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Rating Agency*** means (1) S&P Global Ratings Europe Limited and its subsidiaries or successors (***S&P***), (2) Moody's Deutschland GmbH and its subsidiaries or successors (***Moody's***), and (3) Fitch Ratings Ireland Limited and its subsidiaries or successors (***Fitch***), or (4) if S&P, Moody's or Fitch, or all three do not make a rating of the Issuer publicly available, a European-wide reputable securities rating agency or agencies, as the case may be, selected by the Issuer, which shall be substituted for S&P, Moody's or Fitch or all three, as the case may be. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Ratingagentur*** bezeichnet (1) S&P Global Ratings Europe Limited sowie deren Tochter- oder Nachfolgergesellschaften (***S&P***), (2) Moody's Deutschland GmbH sowie deren Tochter- oder Nachfolgergesellschaften (***Moody's***), (3) Fitch Ratings Ireland Limited sowie deren Tochter- oder Nachfolgergesellschaften (***Fitch***), oder (4) falls S&P, Moody's oder Fitch oder alle drei kein Rating für die Emittentin öffentlich zur Verfügung stellen, eine Ratingagentur oder Ratingagenturen mit europaweitem Ansehen, die von der Emittentin ausgewählt wird und S&P, Moody's oder Fitch oder alle diese Agenturen ersetzt. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Ratings Decline*** means that if (a), at the time of the occurrence of a Change of Control, the Issuer (i) has been rated Investment Grade by at least two Rating Agencies and such rating is, within 120 days from such time, either downgraded to a non-investment grade rating or withdrawn by at least two Rating Agencies and is not within such 120-day period subsequently (in the case of a downgrade) upgraded to Investment Grade by two of the three Rating Agencies, or (in the case of withdrawal) replaced by an Investment Grade rating from any other Rating Agency or Rating Agencies; or (ii) rated below Investment Grade and such rating from any Rating Agency is, within 120 days from such time, downgraded by one or more gradations (including gradations within Rating Categories as well as between Rating Categories) and is not within such 120-day period subsequently upgraded to its earlier credit rating or better by such Rating Agency, provided that if at the time of the occurrence of a Change of Control the Issuer carries an Investment Grade rating of only one Rating Agency, it shall be sufficient if the | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eine ***Ratingherabstufung*** liegt vor, falls (a) die Emittentin bei Eintritt des Kontrollwechsels (i) von mindestens zwei Ratingagenturen mit Investment Grade bewertet ist und diese Ratings von mindestens zwei Ratingagenturen innerhalb von 120 Tagen nach dem Kontrollwechsel zu einem Non-Investment-Grade-Rating herabgestuft oder das Rating zurückgezogen wurde und nicht innerhalb dieser 120-Tagesperiode anschließend (im Falle einer Herabstufung) durch mindestens zwei Ratingagenturen wieder auf ein Investment Grade Rating heraufgestuft oder (im Falle eines Zurückziehens) durch das Investment Grade Rating einer anderen Ratingagentur oder Ratingagenturen ersetzt wurde; oder (ii) unterhalb von Investment Grade bewertet ist und dieses Rating von einer Ratingagentur innerhalb von 120 Tagen nach dem Kontrollwechsel um eine oder mehrere Stufen (einschließlich Untergliederungen innerhalb von sowie zwischen Ratingkategorien) herabgestuft und nicht innerhalb dieser 120-Tagesperiode anschließend wieder auf das ursprüngliche oder ein besseres |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requirements under sub-paragraph (i) are met with respect to such Rating Agency; and (b) in making any of the decisions referred to above, the relevant Rating Agency announces publicly or confirms in writing to the Issuer that its decision resulted, in whole or in part, from the occurrence of the Change of Control. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rating durch diese Ratingagentur heraufgestuft wurde, wobei, falls die Emittentin zum Eintritt des Kontrollwechsels über ein Investment-Grade-Rating von nur einer Ratingagentur verfügt, es bereits ausreichend ist, wenn die Voraussetzungen in Unterabsatz (i) im Hinblick auf diese Ratingagentur erfüllt sind; und (b) im Zusammenhang mit einer der oben genannten Entscheidungen die betreffende Ratingagentur öffentlich bekannt macht oder gegenüber der Emittentin schriftlich bestätigt, dass ihre Entscheidung ganz oder teilweise auf den Kontrollwechsel zurückzuführen ist. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provided however that no Ratings Decline will occur if at the end of the 120-day period the Issuer has been rated by at least two Rating Agencies, it has solicited, Investment Grade. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eine Ratingherabstufung liegt jedoch nicht vor, falls die Emittentin, aufgrund einer Beauftragung durch die Emittentin, am Ende der 120-Tagesperiode von mindestens zwei Ratingagenturen mit Investment Grade bewertet wird. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Rating Category*** means: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Ratingkategorie*** bezeichnet: |
| <br>(a)<br>with respect to S&P or Fitch, any of the following categories: BB, B, CCC, CC, C and D (or equivalent successor categories);<br>| <br>(a)<br>in Bezug auf S&P oder Fitch eine der folgenden Kategorien: BB, B, CCC, CC, C und D (bzw. entsprechende Nachfolgekategorien);<br>|
| <br>(b)<br>with respect to Moody's, any of the following categories: Ba, B, Caa, Ca, C and D (or equivalent successor categories); and<br>| <br>(b)<br>in Bezug auf Moody's eine der folgenden Kategorien: Ba, B, Caa, Ca, C und D (bzw. entsprechende Nachfolgekategorien); und<br>|
| <br>(c)<br>the equivalent of any such category of S&P, Moody's or Fitch used by another rating agency in determining whether the rating of the Issuer has decreased by one or more gradations, gradations within rating categories ("+" and "-" for S&P, "1", "2" and "3" for Moody's, "+" and "-" for Fitch; or the equivalent gradations for another rating agency) shall be taken into account (e.g., with respect to S&P, a decline in a rating from <br>| <br>(c)<br>diesen Kategorien von S&P oder Moody's oder Fitch entsprechende Ratingkategorien einer anderen Ratingagentur. Bei der Bestimmung, ob das Rating der Emittentin um eine oder mehrere Stufen herabgestuft wurde, werden die jeweiligen Ratingkategorien weiter untergliedernde Zusätze ("+" und "-" bei S&P, "1", "2" und "3" bei Moody's, "+" und "-" bei Fitch bzw. entsprechende Zusätze anderer Ratingagenturen)<br>|

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"BB+" to "BB", as well as from "BB-" to "B+", will constitute a decrease of one gradation). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;berücksichtigt (z. B. entspricht bei S&P eine Ratingänderung von "BB+" auf "BB" oder von "BB-" auf "B+" jeweils einer Herabstufung um eine Stufe). |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Investment Grade*** means a rating of (i) "BBB-" or higher by S&P and Fitch, and (ii) "Baa3" or higher by Moody's, or the equivalent of such ratings by S&P, Moody's or Fitch and the equivalent in respect of rating categories of any Rating Agencies substituted for S&P, Moody's or Fitch. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Investment Grade*** bezeichnet ein Rating von (i) "BBB-" oder höher im Fall von S&P und Fitch und (ii) "Baa3" oder höher im Fall von Moody's, oder das entsprechende Äquivalent dieser Ratings im Fall von S&P, Moody's oder Fitch sowie das entsprechende Äquivalent in den Ratingkategorien einer anderen Ratingagentur, durch die S&P, Moody's oder Fitch ersetzt wurde. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A ***Change of Control*** means the occurrence of one or more of the following events: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ein ***Kontrollwechsel*** bezeichnet den Eintritt eines oder mehrerer der folgenden Ereignisse: |
| <br>(a)<br>any event the result of which is that (A) any person or group (***Relevant Person(s***)) acting in concert (as defined in section 30(2) of the German Securities Acquisition and Takeover Act (*Wertpapiererwerbs- und Übernahmegesetz*)) or any person or group acting on behalf of any such Relevant Person(s), other than a Permitted Holder, is or becomes the direct or indirect legal or beneficial ownership or any legal or beneficial entitlement (as defined in section 34 of the German Securities Trading Act (*Wertpapierhandelsgesetz*)) of, in the aggregate, more than 50% of the voting shares of the Issuer; or<br>| <br>(a)<br>ein Ereignis, in dessen Folge (A) eine Person oder mehrere Personen (***Relevante Personen***), die abgestimmt handeln (wie in § 30 Abs. 2 Wertpapiererwerbs- und Übernahmegesetz definiert), oder einer oder mehrere Dritte, die im Auftrag einer solchen Relevanten Person(en) handeln, mit Ausnahme eines Zulässigen Inhabers, unmittelbar oder mittelbar rechtliches oder wirtschaftliches Eigentum in jedweder Form bzw. die unmittelbare oder mittelbare rechtliche oder wirtschaftliche Verfügungsbefugnis in jedweder Form (wie in § 34 Wertpapierhandelsgesetz beschrieben) an insgesamt mehr als 50% der stimmberechtigten Aktien der Emittentin erlangen; oder<br>|
| <br>(b)<br>any sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of the Issuer (held directly or indirectly) to any Relevant Person other than a Permitted Holder, or any person or group <br>| <br>(b)<br>ein Verkauf, ein Leasing, ein Tausch oder eine sonstige Übertragung (im Rahmen einer einzigen Transaktion oder einer Reihe miteinander zusammenhängender Transaktionen) aller oder aller wesentlichen Vermögenswerte (direkt oder indirekt gehalten) der <br>|

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acting on behalf of any such Relevant Person(s). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emittentin an eine oder mehrere Relevante Personen, mit Ausnahme eines Zulässigen Inhabers, oder einen oder mehrere Dritte, die im Auftrag solcher Relevanten Personen handeln. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Person*** means any individual, corporation, partnership, joint venture, association, joint-stock company, trust, unincorporated organization, government or any agency, instrumentality or political subdivision thereof, or any other entity. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Person*** bezeichnet eine natürliche Person, eine Körperschaft, eine Personengesellschaft, ein Joint Venture, eine Vereinigung, eine Aktiengesellschaft, einen Trust, eine Einrichtung ohne eigene Rechtspersönlichkeit, eine staatliche Stelle oder Behörde, eine Gebietskörperschaft oder einen sonstigen Rechtsträger. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Permitted Holder*** means Fresenius SE & Co. KGaA and any of its Affiliates, as long as and to the extent Fresenius SE & Co. KGaA or the relevant Affiliate(s) is or are not acting in concert with, or on behalf of, a Relevant Person(s).  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Zulässiger Inhaber*** bezeichnet die Fresenius SE & Co. KGaA und alle mit ihr verbundenen Personen, sofern und soweit die Fresenius SE & Co. KGaA oder eine oder mehrere mit ihr verbundene Person(en) nicht gemeinsam mit oder im Auftrag einer oder mehrerer Relevanten Person(en) handeln. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Affiliate*** of any specified Person means: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Verbundene Person*** einer bestimmten Person bezeichnet: |
| <br>(a)<br>any other Person, directly or indirectly, controlling or controlled by such specified Person, or<br>| <br>(a)<br>jede andere Person, die diese Person direkt oder indirekt kontrolliert bzw. direkt oder indirekt von ihr kontrolliert wird, oder<br>|
| <br>(b)<br>under direct or indirect common control with such specified Person.<br>| <br>(b)<br>mit dieser bestimmten Person unter direkter oder indirekter gemeinsamer Kontrolle steht.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of this definition, "control" when used with respect to any Person means the power to direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise (section 15 of the German Stock Corporation Act (*Aktiengesetz*)); and the terms "controlling" and "controlled" have meanings correlative to the foregoing. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Für den Zweck dieser Definition bezeichnet "Kontrolle" bei Verwendung in Bezug auf eine Person die Befugnis, deren Geschäftsführung und Unternehmenspolitik direkt oder indirekt zu bestimmen (§ 15 Aktiengesetz), sei es durch den Besitz von stimmberechtigten Kapitalanteilen, eine vertragliche Festlegung oder anderweitig, und die Bedeutung der Begriffe "kontrolliert" und "kontrollieren" ist entsprechend zu verstehen. |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within 30 days upon the Issuer becoming aware that a Change of Control Triggering Event has occurred, the Issuer shall give notice (a ***Put Event Notice***) to the Holders in accordance with § 12 stating: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Innerhalb von 30 Tagen, nachdem die Emittentin von einem Kontrollwechselereignis Kenntnis erlangt hat, wird die Emittentin dies den Gläubigern gemäß § 12 bekannt machen (***Vorzeitige Rückkaufsgrunderklärung***) und dabei folgendes mitteilen: |
| <br>(a)<br>that a Change of Control Triggering Event has occurred;<br>| <br>(a)<br>dass ein Kontrollwechselereignis eingetreten ist;<br>|
| <br>(b)<br>the circumstances and relevant facts regarding such Change of Control Triggering Event;<br>| <br>(b)<br>die Umstände und relevanten Informationen bezüglich des Kontrollwechselereignisses;<br>|
| <br>(c)<br>the repurchase date (which shall be no earlier than 30 days nor later than 60 days from the date such Put Event Notice is given) (the ***Optional Redemption Date***);<br>| <br>(c)<br>den Tag des Rückkaufs (der nicht früher als 30 und nicht später als 60 Tage nach dem Tag, an dem die Vorzeitige Rückkaufsgrunderklärung erfolgt, liegen darf) (der ***Stichtag***);<br>|
| <br>(d)<br>that each Note will be subject to repurchase only in integral multiples of the Specified Denomination; and<br>| <br>(d)<br>dass die Schuldverschreibungen nur in ganzen Vielfachen der Festgelegten Stückelung zurückgekauft werden; und<br>|
| <br>(e)<br>the instructions determined by the Issuer that a Holder must follow in order to have its Notes purchased pursuant to this § 5(4).<br>| <br>(e)<br>die Anweisungen, die ein Gläubiger befolgen muss, damit die Schuldverschreibungen gemäß diesem § 5(4) zurückgekauft werden.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to exercise such option, the Holder must submit during normal business hours at the specified office of the Fiscal Agent a duly completed option exercise notice in the form available from the specified office of the Fiscal Agent within the period of 20 days after a Put Event Notice is given. No option so exercised may be revoked or withdrawn without the prior consent of the Issuer. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Um ein solches Recht auszuüben, muss ein Gläubiger während der allgemeinen Geschäftszeiten bei der angegebenen Geschäftsstelle der Emissionsstelle eine vollständig ausgefüllte Ausübungserklärung in der durch die Emissionsstelle bereitgestellten Form innerhalb eines Zeitraums von 20 Tagen nach Bekanntmachung der Vorzeitigen Rückzahlungserklärung übermitteln. Kein in dieser Form ausgeübtes Recht kann ohne vorherige Zustimmung der Emittentin widerrufen oder zurückgezogen werden. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Issuer will comply with the requirements of any applicable securities laws or regulations in connection with an early redemption of Notes at the option of the Holders upon a Change of Control pursuant to this §  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Emittentin wird die Anforderungen der anwendbaren Wertpapiergesetze oder - vorschriften im Zusammenhang mit einer vorzeitigen Rückzahlung von Schuldverschreibungen nach Wahl der Inhaber bei einem Kontrollwechsel  |

---

------

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5(4). To the extent that the provisions of any securities laws or regulations or applicable stock exchange listing rules conflict with the provisions of this § 5(4), the Issuer will comply with the applicable securities laws, regulations and listing rules and will not be deemed to have breached its obligations under this § 5(4) by virtue thereof. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5(4). To the extent that the provisions of any securities laws or regulations or applicable stock exchange listing rules conflict with the provisions of this § 5(4), the Issuer will comply with the applicable securities laws, regulations and listing rules and will not be deemed to have breached its obligations under this § 5(4) by virtue thereof. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;gemäß diesem § 5(4) erfüllen. Soweit die Bestimmungen eines Wertpapiergesetzes oder - verordnung oder eines anwendbaren Börsenzulassungsregelwerks im Widerspruch zu den Bestimmungen dieses § 5(4) stehen, wird die Emittentin die anwendbaren Wertpapiergesetze, - verordnungen und - regelwerke einhalten und dies wird nicht als Verletzung ihrer Pflichten aus diesem § 5(4) angesehen werden. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;gemäß diesem § 5(4) erfüllen. Soweit die Bestimmungen eines Wertpapiergesetzes oder - verordnung oder eines anwendbaren Börsenzulassungsregelwerks im Widerspruch zu den Bestimmungen dieses § 5(4) stehen, wird die Emittentin die anwendbaren Wertpapiergesetze, - verordnungen und - regelwerke einhalten und dies wird nicht als Verletzung ihrer Pflichten aus diesem § 5(4) angesehen werden. |
| (5)<br>Early Redemption at the Option of the Issuer. | (5)<br>Early Redemption at the Option of the Issuer. | (5)<br>Vorzeitige Rückzahlung nach Wahl der Emittentin. | (5)<br>Vorzeitige Rückzahlung nach Wahl der Emittentin. |
| <br>(a)<br>The Issuer may, upon notice given in accordance with subparagraph (b), redeem all or some only of the Notes within the Call Redemption Period(s) at the Call Redemption Amount(s) set forth below together with accrued interest, if any, to (but excluding) the relevant redemption date. | <br>(a)<br>The Issuer may, upon notice given in accordance with subparagraph (b), redeem all or some only of the Notes within the Call Redemption Period(s) at the Call Redemption Amount(s) set forth below together with accrued interest, if any, to (but excluding) the relevant redemption date. | <br>(a)<br>Die Emittentin kann, nachdem sie gemäß Absatz (b) gekündigt hat, die Schuldverschreibungen insgesamt oder teilweise innerhalb des/der Wahl- Rückzahlungszeitraums/-räume (*Call*) zum/zu den Wahl- Rückzahlungsbetrag/-beträgen (*Call*), wie nachfolgend angegeben, nebst etwaigen bis zum maßgeblichen Rückzahlungstag (ausschließlich) aufgelaufenen Zinsen zurückzahlen. | <br>(a)<br>Die Emittentin kann, nachdem sie gemäß Absatz (b) gekündigt hat, die Schuldverschreibungen insgesamt oder teilweise innerhalb des/der Wahl- Rückzahlungszeitraums/-räume (*Call*) zum/zu den Wahl- Rückzahlungsbetrag/-beträgen (*Call*), wie nachfolgend angegeben, nebst etwaigen bis zum maßgeblichen Rückzahlungstag (ausschließlich) aufgelaufenen Zinsen zurückzahlen. |
| Call Redemption<br>Period(s) | Call Redemption<br>Amount(s) | Wahl-<br>Rückzahlungszeitraum/-räume <br>(Call) | Wahl-<br>Rückzahlungsbetrag/-beträge <br>(Call) |
| August 24, 2030<br>(including) to<br>November 23, 2030<br>(including) | 100 per cent. of the<br>principal amount | 24. August 2030<br>(einschließlich) bis<br>23. November 2030<br>(einschließlich) | 100% des<br>Nennbetrags |
| <br>(b)<br>Notice of redemption shall be given by the Issuer to the Holders of the Notes in accordance with § 12. Such notice shall specify:  | <br>(b)<br>Notice of redemption shall be given by the Issuer to the Holders of the Notes in accordance with § 12. Such notice shall specify:  | <br>(b)<br>Die Kündigung ist den Gläubigern der Schuldverschreibungen durch die Emittentin gemäß § 12 bekanntzugeben. Sie muss die folgenden Angaben enthalten: | <br>(b)<br>Die Kündigung ist den Gläubigern der Schuldverschreibungen durch die Emittentin gemäß § 12 bekanntzugeben. Sie muss die folgenden Angaben enthalten: |
| <br>(i)<br>the series of Notes subject to redemption; | <br>(i)<br>the series of Notes subject to redemption; | <br>(i)<br>die zurückzuzahlende Serie von Schuldverschreibungen;  | <br>(i)<br>die zurückzuzahlende Serie von Schuldverschreibungen;  |
| <br>(ii)<br>whether such series is to be redeemed in whole or in part only and, if in part only, the aggregate  | <br>(ii)<br>whether such series is to be redeemed in whole or in part only and, if in part only, the aggregate  | <br>(ii)<br>eine Erklärung, ob diese Serie ganz oder teilweise zurückgezahlt wird und im letzteren Fall den  | <br>(ii)<br>eine Erklärung, ob diese Serie ganz oder teilweise zurückgezahlt wird und im letzteren Fall den  |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;principal amount of the Notes which are to be redeemed; | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gesamtnennbetrag der zurückzuzahlenden Schuldverschreibungen; |
| <br>(iii)<br>the relevant redemption date, which shall be not less than 20 nor more than 40 days after the date on which notice is given by the Issuer to the Holders; and<br>| <br>(iii)<br>den maßgeblichen Rückzahlungstag, der nicht weniger als 20 und nicht mehr als 40 Tage nach dem Tag der Kündigung durch die Emittentin gegenüber den Gläubigern liegen darf; und<br>|
| <br>(iv)<br>the Call Redemption Amount at which such Notes are to be redeemed.<br>| <br>(iv)<br>den Wahl-Rückzahlungsbetrag (Call), zu dem die Schuldverschreibungen zurückgezahlt werden.<br>|
| <br>(c)<br>In the case of a partial redemption of Notes, Notes to be redeemed shall be selected in accordance with the rules of the relevant Clearing System. For technical procedure of the ICSDs, in the case of a partial redemption the outstanding redemption amount will be reflected in the records of the ICSDs as either a reduction in nominal amount or as a pool factor, at the discretion of the ICSDs.<br>| <br>(c)<br>Wenn die Schuldverschreibungen nur teilweise zurückgezahlt werden, werden die zurückzuzahlenden Schuldverschreibungen in Übereinstimmung mit den Regeln des betreffenden Clearingsystems ausgewählt. Für das technische Verfahren der ICSDs wird im Fall einer teilweisen Rückzahlung der entstehende Rückzahlungsbetrag entweder als reduzierter Nennbetrag oder als Poolfaktor nach Ermessen der ICSDs in das Register der ICSDs aufgenommen.<br>|
| **§ 6**<br>**(THE FISCAL AGENT AND THE PAYING AGENT)** | **§ 6**<br>**(DIE EMISSIONSSTELLE UND DIE ZAHLSTELLE)** |
| (1)<br>Appointment; Specified Office.<br>| (1)<br>Bestellung; bezeichnete Geschäftsstelle.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The initial fiscal agent (the ***Fiscal Agent***) and the initial paying agent (the ***Paying Agent***) and its initial specified office shall be: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die anfänglich bestellte Emissionsstelle (die ***Emissionsstelle***) und die anfänglich bestellte Zahlstelle (die ***Zahlstelle***) und ihre bezeichnete Geschäftsstelle lautet wie folgt: |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deutsche Bank<br>Aktiengesellschaft<br>Trust & Security Services<br>Operations Frankfurt<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deutsche Bank <br>Aktiengesellschaft<br>Trust & Security Services<br>Operations Frankfurt<br>|

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taunusanlage 12<br>60325 Frankfurt am Main<br>Federal Republic of Germany | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taunusanlage 12<br>60325 Frankfurt am Main<br>Deutschland |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Fiscal Agent and the Paying Agent reserve the right at any time to change their respective specified offices to some other specified office in the same country. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Emissionsstelle und die Zahlstelle behalten sich das Recht vor, jederzeit ihre jeweiligen bezeichneten Geschäftsstellen durch eine andere bezeichnete Geschäftsstelle in demselben Land zu ersetzen. |
| (2)<br>Variation or Termination of Appointment.<br>| (2)<br>Änderung der Bestellung oder Abberufung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Issuer reserves the right at any time to vary or terminate the appointment of the Fiscal Agent or any Paying Agent and to appoint another Fiscal Agent or additional or other Paying Agents. The Issuer shall at all times maintain (i) a Fiscal Agent, (ii) so long as the Notes are listed on the Luxembourg Stock Exchange, a Paying Agent (which may be the Fiscal Agent) with a specified office in Luxembourg and/or in such other place as may be required by the rules of such stock exchange and (iii) a Paying Agent in an EU Member State, if possible, that will not be obliged to withhold or deduct tax in connection with any payment made in relation to the Notes unless the Paying Agent would be so obliged in each other EU Member State if it were located there. Any variation, termination, appointment or change shall only take effect (other than in the case of insolvency, when it shall be of immediate effect) after not less than 30 nor more than 45 days' prior notice thereof shall have been given to the Holders in accordance with § 12. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Emittentin behält sich das Recht vor, jederzeit die Bestellung der Emissionsstelle oder einer Zahlstelle zu ändern oder zu beenden und eine andere Emissionsstelle oder zusätzliche oder andere Zahlstellen zu bestellen. Die Emittentin wird zu jedem Zeitpunkt (i) eine Emissionsstelle unterhalten, (ii) solange die Schuldverschreibungen an der Luxemburger Börse notiert sind, eine Zahlstelle (die die Emissionsstelle sein kann) mit bezeichneter Geschäftsstelle in Luxemburg und/oder an solchen anderen Orten unterhalten, die die Regeln dieser Börse verlangen und (iii) eine Zahlstelle in einem Mitgliedsstaat der Europäischen Union, sofern dies möglich ist, unterhalten, die nicht zum Einbehalt oder Abzug von Quellensteuern oder sonstigen Abzügen verpflichtet ist, es sei denn, dass eine solche Einbehalts- oder Abzugspflicht auch in allen anderen Mitgliedsstaaten der Europäischen Union bestünde. Eine Änderung, Abberufung, Bestellung oder ein sonstiger Wechsel wird nur wirksam (außer im Insolvenzfall, in dem eine solche Änderung sofort wirksam wird), sofern die Gläubiger hierüber gemäß § 12 vorab unter Einhaltung einer Frist von mindestens 30 und nicht mehr als 45 Tagen informiert wurden. |
| (3)<br>Agent of the Issuer.<br>| (3)<br>Erfüllungsgehilfe(n) der Emittentin.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Fiscal Agent and the Paying Agent act solely as the agents of the Issuer and do not assume any obligations  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Emissionsstelle und die Zahlstelle handeln ausschließlich als Erfüllungsgehilfen der Emittentin und  |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;towards or relationship of agency or trust for any Holder. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;übernehmen keinerlei Verpflichtungen gegenüber den Gläubigern und es wird kein Auftrags- oder Treuhandverhältnis zwischen ihnen und den Gläubigern begründet. |
| **§ 7**<br>**(TAXATION)** | **§ 7**<br>**(STEUERN)** |
| All payments of principal and interest made by the Issuer in respect of the Notes to the Holders shall be made free and clear of, and without withholding or deduction for, any present or future taxes or duties of whatever nature imposed or levied by way of deduction or withholding by or on behalf of (1) the Federal Republic of Germany or any authority therein or thereof having power to tax, (2) any jurisdiction from or through which payment on the Notes is made, or any political subdivision or governmental authority thereof or therein having the power to tax and/or (3) any other jurisdiction in which the payor is organized or otherwise considered to be resident or doing business for tax purposes, or any political subdivision or governmental authority thereof or therein having the power to tax (each a ***Relevant Taxing Jurisdiction***), unless such deduction or withholding is required by law. In that event the Issuer shall pay such additional amounts (the ***Additional Amounts***) as shall result in receipt by the Holders of such amounts as would have been received by them had no such withholding or deduction been required, except that no Additional Amounts shall be payable with respect to: | Alle in Bezug auf die Schuldverschreibungen von der Emittentin an die Gläubiger zahlbaren Kapital- oder Zinsbeträge werden ohne Einbehalt oder Abzug an der Quelle für oder wegen gegenwärtiger oder zukünftiger Steuern oder Abgaben gleich welcher Art gezahlt, die von oder im Namen (1) der Bundesrepublik Deutschland oder einer dort zur Steuererhebung ermächtigten Behörde, (2) einer Rechtsordnung, aus der bzw. über die eine Zahlung auf die Schuldverschreibungen geleistet wird, oder einer dort zur Steuererhebung ermächtigten Gebietskörperschaft oder Behörde, und/oder (3) einer anderen Rechtsordnung, in der die zahlende Partei errichtet ist oder anderweitig als gebietsansässig gilt oder im steuerlichen Sinn geschäftlich tätig ist, oder einer dort zur Steuererhebung ermächtigten Gebietskörperschaft oder Behörde (jeweils eine ***Relevante Steuerjurisdiktion***) im Wege des Abzugs oder Einbehalts auferlegt oder erhoben werden, es sei denn, ein solcher Abzug oder Einbehalt ist gesetzlich vorgeschrieben. In diesem Fall wird die Emittentin diejenigen zusätzlichen Beträge (***Zusätzliche Beträge***) zahlen, die erforderlich sind, damit die den Gläubigern zufließenden Nettobeträge nach diesem Einbehalt oder Abzug jeweils den Beträgen an Kapital und Zinsen entsprechen, die ohne einen solchen Einbehalt oder Abzug von den Gläubigern erhalten worden wären; jedoch sind solche Zusätzlichen Beträge nicht zu zahlen in Bezug auf: |
| <br>(a)<br>taxes or duties which are payable by any Person acting as custodian bank or collecting agent on behalf of a Holder, or otherwise in any manner which does not constitute a deduction or withholding by the Issuer from payments of principal or interest made by it; or<br>| <br>(a)<br>Steuern oder Abgaben, die von einer als Depotbank oder Inkassobeauftragter eines Gläubigers handelnden Person oder auf eine sonstige Weise zu entrichten sind, die keinen Abzug oder Einbehalt von Zahlungen von Kapital oder Zinsen durch die Emittentin darstellen; oder<br>|

---

------

---

| | |
|:---|:---|
| <br>(b)<br>payments that would not have been so imposed but for the existence of any present or former connection between such Holder (or between a fiduciary, settlor, beneficiary, member or shareholder of, or a person having a controlling power over, such Holder) and any Relevant Taxing Jurisdiction including, without limitation, such Holder (or such fiduciary, settlor, beneficiary, member, shareholder or person having such a controlling power) being or having been a citizen or resident or treated as a resident of, being or having been engaged in a trade or business in, or having or having had a permanent establishment in, a Relevant Taxing Jurisdiction other than any connections arising solely from a Holder acquiring, holding or disposing of, receiving any payment under or with respect to or enforcing a Note; or<br>| <br>(b)<br>Zahlungen, die nicht erhoben worden wären, wenn nicht (i) eine gegenwärtige oder ehemalige Beziehung zwischen dem betreffenden Gläubiger (oder einem Treuhänder, Treugeber, Begünstigten, Mitglied oder Gesellschafter dieses Gläubigers oder einer Person, die beherrschenden Einfluss auf diesen Gläubiger hat) und einer Relevanten Steuerjurisdiktion bestehen würde, unter anderem in der Form, dass der betreffende Gläubiger (bzw. Treuhänder, Treugeber, Begünstigte, Mitglied, Gesellschafter oder die Person, die beherrschenden Einfluss hat) Staatsbürger einer Relevanten Steuerjurisdiktion ist oder war oder dort ansässig ist oder war oder als dort ansässig gilt oder galt oder dort ein Gewerbe oder eine Geschäftstätigkeit betreibt oder betrieben hat oder dort eine Betriebsstätte unterhält oder unterhalten hat, mit Ausnahme von Beziehungen, die allein dadurch entstehen, dass ein Gläubiger eine Schuldverschreibung erwirbt, hält oder veräußert bzw. eine Zahlung darunter oder in Bezug auf diese erhält oder Ansprüche darauf geltend macht; oder<br>|
| <br>(c)<br>payments to, or to a third party on behalf of, a Holder where no such withholding or deduction would have been required to be made if the Notes were credited at the time of payment to a securities deposit account with a bank, financial services institution, securities trading business or securities trading bank, in each case outside the Relevant Taxing Jurisdiction; or<br>| <br>(c)<br>Zahlungen an den Gläubiger oder an einen Dritten für den Gläubiger, falls kein Einbehalt oder Abzug hätte erfolgen müssen, wenn die Schuldverschreibung zum Zeitpunkt der fraglichen Zahlung einem Depotkonto bei einer bzw. einem nicht in der Relevanten Steuerjurisdiktion ansässigen Bank, Finanzdienstleistungsinstitut, Wertpapierhandelsunternehmen oder Wertpapierhandelsbank gutgeschrieben gewesen wäre; oder<br>|

---

------

---

| | |
|:---|:---|
| <br>(d)<br>payments where such withholding or deduction is imposed pursuant to (i) any European Union Directive or Regulation concerning the taxation of savings, or (ii) any international treaty or understanding relating to such taxation and to which the Relevant Taxing Jurisdiction or the European Union is a party/are parties, or (iii) any provision of law implementing, or complying with, or introduced to conform with, such Directive, Regulation, treaty or understanding, or (iv) the Luxembourg law of 23 December 2005; or<br>| <br>(d)<br>falls der Einbehalt oder Abzug gemäß (i) einer Richtlinie oder Verordnung der Europäischen Union zur Zinsbesteuerung oder (ii) einem internationalen Abkommen oder Übereinkommen zu einer solchen Besteuerung, bei dem die Relevante Steuerjurisdiktion oder die Europäische Union Parteien sind, oder (iii) einem diese Richtlinie oder Verordnung oder dieses Abkommen oder Übereinkommen umsetzenden oder sie befolgenden oder zu ihrer Befolgung erlassenen Gesetz, oder (iv) dem Luxemburger Gesetz vom 23. Dezember 2005 erhoben wird; oder<br>|
| <br>(e)<br>payments to the extent such withholding or deduction is payable by or on behalf of a Holder who could lawfully mitigate (but has not so mitigated) such withholding or deduction by complying or procuring that any third party complies with any statutory requirements or by making or procuring that a third party makes a declaration of non-residence or other similar claim for exemption to any tax authority in the place where the payment is effected (including, in the case of a payment by a Paying Agent situated in the United States, by providing prior to the receipt of any such payment, a complete, correct and executed IRS Form W-8 or W-9 or successor form, as applicable, with all appropriate attachments); or<br>| <br>(e)<br>soweit der Einbehalt oder Abzug von dem Gläubiger oder von einem Dritten für den Gläubiger zahlbar ist, der einen solchen Einbehalt oder Abzug dadurch rechtmäßigerweise hätte vermindern können (aber nicht vermindert hat), dass er gesetzliche Vorschriften beachtet, oder dafür sorgt, dass Dritte dieses tun, oder dadurch dass er eine Nichtansässigkeitserklärung oder einen ähnlichen Antrag auf Quellensteuerbefreiung gegenüber der am Zahlungsort zuständigen Steuerbehörde; abgibt oder dafür sorgt, dass dies durch einen Dritten erfolgt (einschließlich, im Falle einer Zahlung durch eine Zahlstelle mit Sitz in den Vereinigten Staaten, durch Bereitstellung eines vollständigen, korrekten und ausgefüllten IRS-Formulars W-8 oder W-9 oder eines Nachfolgeformulars, falls zutreffend, mit allen entsprechenden Anlagen); oder<br>|
| <br>(f)<br>payments to the extent such withholding or deduction is payable by or on behalf of a Holder who would have been <br>| <br>(f)<br>soweit der Einbehalt oder Abzug von dem Gläubiger oder von einem Dritten für den Gläubiger vorzunehmen ist, der einen <br>|

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;able to mitigate such withholding or deduction by effecting a payment via another Paying Agent in a Member State of the European Union, not obliged to withhold or deduct tax; or | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;solchen Einbehalt oder Abzug durch die Bewirkung einer Zahlung über eine andere Zahlstelle in einem Mitgliedsstaat der Europäischen Union, welche nicht zu einem solchen Einbehalt oder Abzug verpflichtet ist, hätte vermindern können; oder |
| <br>(g)<br>payments to the extent such withholding or deduction is for or on account of the presentation by the Holder of any Note for payment on a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later; or<br>| <br>(g)<br>soweit der Einbehalt oder Abzug für einen Gläubiger oder dessen Rechnung vorzunehmen ist, der Schuldverschreibungen mehr als 30 Tage nach dem Tag, an dem eine Zahlung unter den Schuldverschreibungen fällig und zahlbar wurde bzw., soweit dies später eintritt, nach dem Tag, an dem die Zahlung ordnungsgemäß vorgenommen wurde, vorgelegt hat; oder<br>|
| <br>(h)<br>payments to the extent such withholding or deduction is required pursuant to sections 1471 through 1474 of the U.S. Internal Revenue Code of 1986, as amended (the ***Internal Revenue Code***), or any amended or successor version thereof, any current or future regulations or official interpretations thereof, any agreement entered into pursuant to section 1471(b) of the Internal Revenue Code, or any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement entered into in connection with the implementation of such sections of the Internal Revenue Code; or <br>| <br>(h)<br>soweit der Einbehalt oder Abzug gemäß §§ 1471 bis 1474 des U.S. Internal Revenue Code von 1986 in seiner jeweils gültigen Fassung (der ***Internal Revenue Code***), oder einer geänderten oder nachfolgenden Fassung davon, jeder gegenwärtigen oder zukünftigen Verordnung oder offiziellen Auslegung davon, jeder Vereinbarung, die gemäß § 1471(b) des Internal Revenue Codes eingegangen wurde oder jeder steuerlichen oder regulatorischen Gesetzgebung, sowie steuerlichen und regulatorischen Gesetzen oder Vorgehensweisen, die nach einem völkerrechtlichen Vertrag, der zur Umsetzung der Bestimmungen des Internal Revenue Codes geschlossen wurde, vorzunehmen ist; oder<br>|
| <br>(i)<br>any tax imposed on interest by the United States or any political subdivision or governmental authority thereof or therein by reason of any Holder holding or owning, actually or constructively, 10% or more of the total combined voting power <br>| <br>(i)<br>jede Steuer, die von den Vereinigten Staaten oder einer ihrer politischen Unterabteilungen oder Regierungsbehörden auf Zinsen erhoben wird, weil ein Inhaber tatsächlich oder konstruktiv 10 % oder mehr der gesamten kombinierten Stimmrechte aller <br>|

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of all classes of stock of the Issuer entitled to vote; or | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aktiengattungen der Emittentin hält oder besitzt; oder |
| <br>(j)<br>any tax imposed on interest by the United States or any political subdivision or governmental authority thereof or therein by reason of any Holder being a controlled foreign corporation that is a related person within the meaning of section 864(d)(4) of the Internal Revenue Code with respect to the Issuer; or<br>| <br>(j)<br>jede Steuer, die von den Vereinigten Staaten oder einer politischen Unterabteilung oder Regierungsbehörde der Vereinigten Staaten oder darin erhoben wird, weil ein Inhaber eine kontrollierte ausländische Körperschaft ist, die eine verwandte Person im Sinne von § 864(d)(4) des Internal Revenue Code in Bezug auf die Emittentin ist; oder<br>|
| <br>(k)<br>any tax imposed on interest by the United States or any political subdivision or governmental authority thereof or therein by reason of any Holder being a bank extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business; or<br>| <br>(k)<br>jede Steuer, die von den Vereinigten Staaten oder einer politischen Unterabteilung oder Regierungsbehörde der Vereinigten Staaten oder darin erhoben wird, weil ein Inhaber eine Bank ist, die einen Kredit gemäß einem Kreditvertrag gewährt, der im normalen Geschäftsverkehr abgeschlossen wurde; oder<br>|
| <br>(l)<br>any combination of items (a)- (k);<br>| <br>(l)<br>jegliche Kombination der Absätze (a)-(k).<br>|
| &nbsp;&nbsp;nor shall any Additional Amounts be paid with respect to any payment on a Note to a Holder who is a fiduciary or partnership or who is other than the sole beneficial owner of such payment to the extent such payment would be required by the laws of the Relevant Taxing Jurisdiction(s) to be included in the income, for tax purposes, of a beneficiary or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner who would not have been entitled to such Additional Amounts had such beneficiary, settlor, member or beneficial owner been the Holder of the Note. | &nbsp;&nbsp;Zudem werden keine Zusätzlichen Beträge im Hinblick auf Zahlungen auf die Schuldverschreibungen an einen Gläubiger gezahlt, welcher die Zahlung als Treuhänder oder Personengesellschaft oder als sonstiger nicht alleiniger wirtschaftlicher Eigentümer erhält, soweit nach den Gesetzen der Relevanten Steuerjurisdiktion(en) eine solche Zahlung für Steuerzwecke dem Einkommen des Begünstigten bzw. Gründers eines Treuhandvermögens oder dem Gesellschafter der Personengesellschaft zugerechnet würde, der jeweils selbst nicht zum Erhalt von Zusätzlichen Beträgen berechtigt gewesen wäre, wenn der Begünstigte, Gründer eines Treuhandvermögens, Gesellschafter oder wirtschaftliche Eigentümer unmittelbarer Gläubiger der Schuldverschreibungen wäre. |
| &nbsp;&nbsp;For the avoidance of doubt: No Additional Amounts will be paid with respect to German capital gains tax (*Kapitalertragsteuer*), including withholding tax (*Abgeltungsteuer*), to be deducted or withheld pursuant to the  | &nbsp;&nbsp;Zur Klarstellung: Keine Zusätzlichen Beträge werden gezahlt in Bezug auf die deutsche Kapitalertragsteuer (inklusive der sog. Abgeltungsteuer), die nach dem deutschen Einkommensteuergesetz abgezogen oder  |

---

------

---

| | |
|:---|:---|
| German Income Tax Act, even if the deduction or withholding has to be made by the Issuer or its representative, and the German Solidarity Surcharge (*Solidaritätszuschlag*) or any other tax which may substitute the German capital gains tax (*Kapitalertragsteuer*) or *solidarity surcharge* (*Solidaritätszuschlag*), as the case may be. | einbehalten wird, auch wenn der Abzug oder Einbehalt durch die Emittentin oder ihren Vertreter vorzunehmen ist, und den deutschen Solidaritätszuschlag oder jede andere Steuer, welche die deutsche Kapitalertragsteuer bzw. den Solidaritätszuschlag ersetzen sollte. |
| **§ 8**<br>**(PRESENTATION PERIOD)** | **§ 8**<br>**(VORLEGUNGSFRIST)** |
| The presentation period provided in section 801(1), sentence 1 of the German Civil Code (*Bürgerliches Gesetzbuch*) is reduced to ten years for the Notes. | Die in § 801 Abs. 1 Satz 1 BGB bestimmte Vorlegungsfrist wird für die Schuldverschreibungen auf zehn Jahre verkürzt. |
| **§ 9**<br>**(EVENTS OF DEFAULT)** | **§ 9**<br>**(KÜNDIGUNG)** |
| (1)<br>Events of default.<br>| (1)<br>Kündigungsgründe.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Holder shall be entitled to declare due and payable by notice to the Fiscal Agent its entire claims arising from the Notes and demand immediate redemption thereof at the principal amount together with accrued interest (if any) to (but excluding) the date of repayment, in the event that: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jeder Gläubiger ist berechtigt, seine sämtlichen Forderungen aus den Schuldverschreibungen durch Kündigung gegenüber der Emissionsstelle fällig zu stellen und die unverzügliche Rückzahlung zum Nennbetrag, zuzüglich etwaiger bis zum Tag der Rückzahlung (ausschließlich) aufgelaufener Zinsen zu verlangen, falls: |
| <br>(a)<br>the Issuer fails to pay principal or interest under the Notes within 30 days from the relevant due date, or<br>| <br>(a)<br>die Emittentin auf die Schuldverschreibungen Kapital oder Zinsen nicht innerhalb von 30 Tagen nach dem betreffenden Fälligkeitstag zahlt; oder<br>|
| <br>(b)<br>the Issuer fails to duly perform any other material obligation arising from the Notes and such failure continues unremedied for more than 60 days after the Fiscal Agent has received a request thereof in the manner set forth in § 9(3) from a Holder to perform such obligation; or<br>| <br>(b)<br>die Emittentin die ordnungsgemäße Erfüllung irgendeiner anderen wesentlichen Verpflichtung aus den Schuldverschreibungen unterlässt und die Unterlassung jeweils länger als 60 Tage fortdauert, nachdem die Emissionsstelle eine Aufforderung in der in § 9(3) vorgesehenen Art und Weise von dem Gläubiger erhalten hat, die Verpflichtung zu erfüllen; oder<br>|

---

------

---

| | |
|:---|:---|
| <br>(c)<br>any Capital Market Indebtedness of the Issuer or any of its Material Subsidiaries becomes prematurely repayable as a result of a default in respect of the terms thereof, or the Issuer or any of its Material Subsidiaries fails to fulfill any payment obligation in excess of EUR 75,000,000 or the equivalent thereof under any Capital Market Indebtedness or under any guarantees or suretyships given for any Capital Market Indebtedness of others within 30 days from its due date or, in the case of such guarantee or suretyship, within 30 days of such guarantee or suretyship being invoked, unless the Issuer or the relevant Material Subsidiary contests in good faith that such payment obligation exists or is due or that such guarantee or suretyship has been validly invoked or if a security granted therefor is enforced on behalf of or by the creditor(s) entitled thereto; or<br>| <br>(c)<br>eine Kapitalmarktverbindlichkeit der Emittentin oder einer ihrer Wesentlichen Tochtergesellschaften vorzeitig zahlbar wird aufgrund einer Pflichtverletzung aus dem dieser Kapitalmarktverbindlichkeit zugrunde liegenden Vertrag oder die Emittentin oder eine ihrer Wesentlichen Tochtergesellschaften eine Zahlungsverpflichtung in Höhe oder im Gegenwert von mehr als EUR 75.000.000 aus einer Kapitalmarktverbindlichkeit oder aufgrund einer Bürgschaft oder Garantie, die für Kapitalmarktverbindlichkeiten Dritter gegeben wurde, nicht innerhalb von 30 Tagen nach ihrer Fälligkeit bzw. im Fall einer Bürgschaft oder Garantie nicht innerhalb von 30 Tagen nach Inanspruchnahme aus dieser Bürgschaft oder Garantie erfüllt, es sei denn, die Emittentin oder die betreffende Wesentliche Tochtergesellschaft bestreitet in gutem Glauben, dass diese Zahlungsverpflichtung besteht oder fällig ist bzw. diese Bürgschaft oder Garantie berechtigterweise geltend gemacht wird, oder falls eine für solche Verbindlichkeiten bestellte Sicherheit für die oder von den daraus berechtigten Gläubiger(n) in Anspruch genommen wird; oder<br>|
| <br>(d)<br>the Issuer or any of its Material Subsidiaries announces its inability to meet its financial obligations or ceases its payments generally; or<br>| <br>(d)<br>die Emittentin oder eine ihrer Wesentlichen Tochtergesellschaften gibt ihre Zahlungsunfähigkeit bekannt oder stellt ihre Zahlungen ein; oder <br>|
| <br>(e)<br>a court opens insolvency proceedings against the Issuer and such proceedings are instituted and have not been discharged or stayed within 90 days, or the Issuer applies for or institutes such proceedings; or<br>| <br>(e)<br>ein Gericht ein Insolvenzverfahren gegen die Emittentin eröffnet, und ein solches Verfahren eingeleitet und nicht innerhalb von 90 Tagen aufgehoben oder ausgesetzt worden ist, oder die Emittentin die Eröffnung eines solchen <br>|

---

------

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Verfahrens beantragt oder einleitet; oder |
| <br>(f)<br>the Issuer enters into liquidation unless this is done in connection with a merger or other form of combination with another company and such company assumes all obligations contracted by the Issuer in connection with the Notes.<br>| <br>(f)<br>die Emittentin in Liquidation tritt, es sei denn, dies geschieht im Zusammenhang mit einer Verschmelzung oder einer anderen Form des Zusammenschlusses mit einer anderen Gesellschaft und die andere oder neue Gesellschaft übernimmt alle Verpflichtungen, die die Emittentin im Zusammenhang mit den Schuldverschreibungen eingegangen ist.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Material Subsidiary*** means any Subsidiary of the Issuer which: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Wesentliche Tochtergesellschaft*** bezeichnet eine Tochtergesellschaft der Emittentin: |
| <br>(a)<br>has unconsolidated EBITDA representing 5% or more of the EBITDA of the Issuer and its subsidiaries on a consolidated basis; or<br>| <br>(a)<br>deren unkonsolidiertes EBITDA 5% oder mehr des EBITDA der Emittentin und ihrer Tochtergesellschaften auf einer konsolidierten Basis darstellt, oder<br>|
| <br>(b)<br>has unconsolidated gross assets representing 5% or more of the gross assets of the Issuer and its subsidiaries on a consolidated basis, <br>| <br>(b)<br>deren unkonsolidiertes Bruttovermögen 5% oder mehr des Bruttovermögens der Emittentin und ihrer Tochtergesellschaften auf einer konsolidierten Basis darstellt, <br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in each case as determined by reference to the latest audited consolidated financial statements prepared in accordance with IFRS Accounting Standards. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in allen Fällen bestimmt nach dem letzten geprüften Konzernabschluss, der in Übereinstimmung mit IFRS Accounting Standards erstellt wurden. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***EBITDA*** means operating income plus depreciation and amortization and is derived from the operating income determined in accordance with IFRS Accounting Standards. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***EBITDA*** entspricht dem Operativen Ergebnis zuzüglich Abschreibungen und wird von dem nach IFRS Accounting Standards ermittelten Operativen Ergebnis abgeleitet. |
| (2)<br>No Termination.<br>| (2)<br>Keine Kündigung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The right to declare Notes due shall terminate if the situation giving rise to it has been cured before the right is exercised. No event or circumstance other than an event specified in § 9(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Das Kündigungsrecht erlischt, falls der Kündigungsgrund vor Ausübung des Rechts geheilt wurde. Vorbehaltlich anwendbaren zwingenden Rechts berechtigen andere Ereignisse oder  |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall entitle Holders to declare their Notes due and payable prior to their stated maturity save as expressly provided for in these Terms and Conditions and subject to applicable mandatory law. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Umstände als die in § 9(1) genannten den Gläubiger nicht dazu, seine Schuldverschreibungen vorzeitig zur Rückzahlung fällig zu stellen, es sei denn, dies ist ausdrücklich in diesen Emissionsbedingungen bestimmt. |
| (3)<br>Notice.<br>| (3)<br>Kündigungserklärung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any default notice in accordance with § 9(1) shall be made at least in text form (section 126b of the German Civil Code, *Bürgerliches Gesetzbuch*) to the specified office of the Fiscal Agent together with evidence by means of a certificate of the Holder's Custodian (as defined in § 14(3)) that such Holder, at the time of such notice, is a holder of the relevant Notes. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eine Kündigungserklärung gemäß § 9(1) hat in der Weise zu erfolgen, dass der Gläubiger bei der angegebenen Geschäftsstelle der Emissionsstelle eine entsprechende Erklärung zumindest in Textform (§ 126 Bürgerliches Gesetzbuch) übergibt und dabei durch eine Bescheinigung seiner Depotbank (wie in § 14(3) definiert) nachweist, dass er die betreffenden Schuldverschreibungen zum Zeitpunkt der Erklärung hält. |
| (4)<br>Quorum.<br>| (4)<br>Quorum. <br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the events specified in subparagraph (1)(b) and/or (1)(c) of this § 9, any notice declaring Notes due shall, unless at the time such notice is received any of the events specified in subparagraph (1)(a) and (1)(d) through (1)(f) of this § 9 entitling Holders to declare their Notes due has occurred, become effective only when the Fiscal Agent has received such default notices from the Holders representing at least 25% of the aggregate principal amount of Notes then outstanding. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In den Fällen gemäß Absatz (1)(b) und/oder (1)(c) dieses § 9 wird eine Kündigungserklärung, sofern nicht bei deren Eingang zugleich einer der in Absatz (1)(a) und (1)(d) bis (1)(f) dieses § 9 bezeichneten Kündigungsgründe vorliegt, erst wirksam, wenn bei der Emissionsstelle Kündigungserklärungen von Gläubigern im Nennbetrag von mindestens 25% des Gesamtnennbetrages der zu diesem Zeitpunkt noch insgesamt ausstehenden Schuldverschreibungen eingegangen sind. |
| **§ 10**<br>**(SUBSTITUTION)** | **§ 10**<br>**(ERSETZUNG)** |
| (1)<br>Substitution.<br>| (1)<br>Ersetzung<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Issuer (reference to which shall always include any previous Substitute Debtor (as defined below)) may, at any time, if no payment of principal of or interest on any of the Notes is in default, without the consent of the Holders, substitute for the Issuer any Affiliate (as defined below) of the Issuer as the  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Emittentin (wobei eine Bezugnahme auf die Emittentin auch alle früheren Nachfolgeschuldner (wie nachfolgend definiert) umfasst) ist jederzeit berechtigt, wenn kein Zahlungsverzug hinsichtlich Kapital oder Zinsen auf die Schuldverschreibungen vorliegt, ohne  |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;principal debtor in respect of all obligations arising from or in connection with the Notes (any such company, the ***Substitute Debtor***), provided that: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;weitere Zustimmung der Gläubiger ein mit der Emittentin verbundenes Unternehmen (wie nachfolgend definiert) an ihrer Stelle als Hauptschuldnerin (ein solches Unternehmen ist die ***Nachfolgeschuldnerin***) für alle Verpflichtungen aus und im Zusammenhang mit den Schuldverschreibungen einzusetzen, vorausgesetzt, dass: |
| <br>(a)<br>the Substitute Debtor assumes all obligations of the Issuer in respect of the Notes and is in a position to fulfill all payment obligations arising from or in connection with the Notes in the Specified Currency without, subject to subparagraph (e) below, the necessity of any taxes or duties levied by the country or jurisdiction in which the Substitute Debtor is domiciled (other than taxes which would also be levied in the absence of such substitution) to be withheld or deducted at source and to transfer all amounts which are required therefore to the Paying Agent without any restrictions, and that in particular all necessary authorizations to this effect by any competent authority have been obtained, and, to the extent service of process must be effected to the Substitute Debtor outside of Germany, a service of process agent in Germany is appointed;<br>| <br>(a)<br>die Nachfolgeschuldnerin alle Verpflichtungen der Emittentin im Zusammenhang mit den Schuldverschreibungen rechtswirksam übernimmt und sie sämtliche sich aus oder im Zusammenhang mit den Schuldverschreibungen ergebenden Zahlungsverpflichtungen in der Festgelegten Währung ohne die Notwendigkeit (vorbehaltlich Absatz (e)) einer Einbehaltung an der Quelle oder des Abzugs irgendwelcher Steuern oder Abgaben in dem Land oder Hoheitsgebiet, in dem die Nachfolgeschuldnerin ihren Sitz hat (mit Ausnahme von Steuern, die auch angefallen wären, wäre die Ersetzung nicht erfolgt), erfüllen sowie die hierzu erforderlichen Beträge ohne Beschränkungen an die Zahlstelle transferieren kann und sie insbesondere jede hierfür notwendige Genehmigung der Behörden ihres Landes erhalten hat, und, sofern eine Zustellung an die Nachfolgeschuldnerin außerhalb von Deutschland erfolgen müsste, ein Zustellungsbevollmächtigter in Deutschland bestellt wird;<br>|
| <br>(b)<br>the Issuer (provided that it is the issuer of the Notes at the time of such substitution) irrevocably and unconditionally guarantees (the ***Substitution Guarantee***) in favor of each Holder the payment of all sums payable by the Substitute Debtor in respect of <br>| <br>(b)<br>die Emittentin (vorausgesetzt, dass diese zum Zeitpunkt der Ersetzung Emittentin der Schuldverschreibungen ist) unwiderruflich und unbedingt gegenüber den Gläubigern die Zahlung aller von der Nachfolgeschuldnerin auf die <br>|

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Notes on market standard terms; | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schuldverschreibungen zahlbaren Beträge zu marktüblichen Bedingungen garantiert (die ***Ersetzungsgarantie***); |
| <br>(c)<br>the Substitute Debtor and the Issuer have obtained all necessary internal approvals and consents for such substitution and for the giving by the Issuer of the Substitution Guarantee in respect of the obligations of the Substitute Debtor, that all such approvals are in full force and effect and that the obligations assumed by the Substitute Debtor under the Notes and the Substitution Guarantee given by the Issuer are each valid and binding in accordance with their respective terms and enforceable by each Holder;<br>| <br>(c)<br>die Nachfolgeschuldnerin und die Emittentin alle für die Ersetzung und die Emittentin alle für die Abgabe der Ersetzungsgarantie notwendigen internen Ermächtigungen erhalten haben, diese Ermächtigungen weiterhin in vollem Umfang gültig und wirksam sind und die Verpflichtungen der Nachfolgeschuldnerin aus den Schuldverschreibungen und die von der Emittentin gestellte Ersetzungsgarantie gemäß ihren Bestimmungen wirksam, rechtsverbindlich und durch jeden Gläubiger durchsetzbar sind;<br>|
| <br>(d)<br>§ 9 shall be deemed to be amended so that it shall also be an Event of Default under such provision if the Substitution Guarantee shall cease to be valid or binding on or enforceable against the Issuer;<br>| <br>(d)<br>§ 9 dergestalt als ergänzt gilt, dass ein zusätzlicher Kündigungsgrund unter dieser Bestimmung der Wegfall der Wirksamkeit, Rechtsverbindlichkeit oder Durchsetzbarkeit der Ersetzungsgarantie gegen die Emittentin ist;<br>|
| <br>(e)<br>the Substitute Debtor undertakes to reimburse any Holder for such taxes, fees or duties which may be imposed upon such Holder in connection with any payments on the Notes (including taxes or duties being deducted or withheld at source), upon conversion or otherwise, as a consequence of the assumption of the Issuer's obligations by the Substitute Debtor, provided that such undertaking shall be limited to amounts that would not have been imposed upon the Holder had such substitution not occurred; and<br>| <br>(e)<br>die Nachfolgeschuldnerin sich verpflichtet, jedem Gläubiger alle Steuern, Gebühren oder Abgaben zu erstatten, die ihm im Zusammenhang mit Zahlungen auf die Schuldverschreibungen (einschließlich Steuern und Abgaben, die an der Quelle abgeführt oder einbehalten wurden), durch den Schuldnerwechsel oder in anderer Weise infolge der Schuldübernahme durch die Nachfolgeschuldnerin auferlegt werden, vorausgesetzt, dass sich die Verpflichtung auf Beträge beschränkt, die der Gläubiger ohne die Ersetzung der <br>|

---

------

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emittentin nicht hätte tragen müssen; und |
| <br>(f)<br>there shall have been delivered to the Fiscal Agent one opinion for each jurisdiction affected of lawyers of recognized standing to the effect that subparagraphs (a) through (e) above have been satisfied.<br>| <br>(f)<br>der Emissionsstelle jeweils ein Rechtsgutachten bezüglich der betroffenen Rechtsordnungen von anerkannten Rechtsanwälten vorgelegt wurden, die bestätigen, dass die Bestimmungen in den vorstehenden Unterabsätzen (a)bis (e) erfüllt wurden.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this § 10, ***Affiliate*** shall mean any affiliated company (*verbundenes Unternehmen*) within the meaning of sections 15 et seqq. of the German Stock Corporation Act (*Aktiengesetz*) held by the Issuer. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Für Zwecke dieses § 10 bedeutet ***verbundenes Unternehmen*** jedes von der Emittentin gehaltene verbundene Unternehmen im Sinne der §§ 15 ff. Aktiengesetz. |
| (2)<br>Discharge from Obligations. References.<br>| (2)<br>Schuldbefreiung. Bezugnahmen.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon a substitution in accordance with this § 10, the Substitute Debtor shall be deemed to be named in the Notes as the principal debtor in place of the Issuer as issuer and the Notes shall thereupon be deemed to be amended to give effect to the substitution including that the relevant jurisdiction in relation to the Issuer in § 7 shall be the Substitute Debtor's country of domicile for tax purposes. Furthermore, in the event of such substitution, in § 7 and § 5(2) an alternative reference to the Federal Republic of Germany shall be deemed to have been included in addition to the reference according to the preceding sentence to the country of domicile or residence for taxation purposes of the Substitute Debtor. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nach einer Ersetzung gemäß dieses § 10 gilt die Nachfolgeschuldnerin als in den Schuldverschreibungen an Stelle der Emittentin als Hauptschuldnerin bestimmt und die Schuldverschreibungen gelten als dementsprechend ergänzt, um der Ersetzung zur Durchsetzung zu verhelfen, und als die relevante Steuerjurisdiktion in Bezug auf § 7 gilt die Jurisdiktion, in der die Nachfolgeschuldnerin steuerlich ansässig ist. Des Weiteren gilt im Fall einer Ersetzung in § 7 und § 5(2) eine alternative Bezugnahme auf die Bundesrepublik Deutschland als aufgenommen (zusätzlich zu der Bezugnahme nach Maßgabe des vorstehenden Satzes auf das Land, in dem die Nachfolgeschuldnerin ihren Sitz oder Steuersitz hat). |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any such substitution, together with the notice referred to in subparagraph (3) below, shall, in the case of the substitution of any other company as principal debtor, operate to release the Issuer as issuer from all of its obligations as principal debtor in respect of the Notes. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jede Ersetzung zusammen mit der Mitteilung gemäß Absatz (3) dieser Bestimmung befreit, im Fall der Einsetzung einer anderen Gesellschaft als Hauptschuldnerin, die Emittentin von allen Verbindlichkeiten, die sie als Hauptschuldnerin unter den Schuldverschreibungen hatte. |

---

------

---

| | |
|:---|:---|
| (3)<br>Notification to Holders.<br>| (3)<br>Benachrichtigung der Gläubiger.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not later than 15 Payment Business Days after effecting the substitution, the Substitute Debtor shall give notice thereof to the Holders and, if any Notes are listed on any stock exchange, to such stock exchange in accordance with § 12 and to any other person or authority as required by applicable laws or regulations. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Spätestens 15 Zahltage nach Durchführung der Ersetzung wird die Nachfolgeschuldnerin dies den Gläubigern und, sollten die Schuldverschreibungen an einer Börse notiert sein, dieser Börse gemäß § 12 mitteilen und jede andere Person oder Stelle, gemäß den anwendbaren Gesetzen und Regelungen informieren. |
| **§ 11**<br>**(FURTHER ISSUES, PURCHASES AND CANCELLATION)** | **§ 11**<br>**(BEGEBUNG WEITERER SCHULDVERSCHREIBUNGEN, ANKAUF UND ENTWERTUNG)** |
| (1)<br>Further Issues.<br>| (1)<br>Begebung weiterer Schuldverschreibungen.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Issuer may from time to time, without the consent of the Holders, issue further Notes having the same terms and conditions as the Notes of this series in all respects (or in all respects except for the issue date, interest commencement date and/or the issue price) so as to form a single series with the Notes of this series. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Emittentin kann ohne Zustimmung der Gläubiger weitere Schuldverschreibungen begeben, die in jeder Hinsicht (gegebenenfalls mit Ausnahme des Tags der Begebung, des Zinslaufbeginns und/oder des Ausgabepreises) die gleichen Bedingungen wie die Schuldverschreibungen dieser Serie haben und die zusammen mit den Schuldverschreibungen dieser Serie eine einheitliche Gesamtemission bilden. |
| (2)<br>Purchases.<br>| (2)<br>Ankauf.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Issuer may at any time purchase Notes in the open market or otherwise and at any price. Notes purchased by the Issuer may, at the option of the Issuer, be held, resold or surrendered to the Fiscal Agent for cancellation. If purchases are made by tender, tenders for such Notes must be made available to all Holders of such Notes alike. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Emittentin ist berechtigt, jederzeit Schuldverschreibungen im Markt oder anderweitig zu jedem beliebigen Preis zu kaufen. Die von der Emittentin erworbenen Schuldverschreibungen können nach Wahl der Emittentin von ihr gehalten, weiterverkauft oder bei der Emissionsstelle zwecks Entwertung eingereicht werden. Sofern diese Käufe durch öffentliches Angebot erfolgen, muss dieses Angebot allen Gläubigern gemacht werden. |
| (3)<br>Cancellation.<br>| (3)<br>Entwertung.<br>|

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Notes redeemed in full shall be cancelled forthwith and may not be reissued or resold. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sämtliche vollständig zurückgezahlten Schuldverschreibungen sind unverzüglich zu entwerten und können nicht wiederbegeben oder wiederverkauft werden. |
| **§ 12**<br>**(NOTICES)** | **§ 12**<br>**(MITTEILUNGEN)** |
| (1)<br>Publication.<br>| (1)<br>Bekanntmachung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As long as the Notes are listed on the official list of the Luxembourg Stock Exchange and admitted to trading on the regulated market of the Luxembourg Stock Exchange (and as long as the rules and regulations of the Luxembourg Stock Exchange so require), all notices concerning the Notes will be made by means of electronic publication on the internet website of the Luxembourg Stock Exchange (*www.luxse.com*). Any notice will be deemed to have been validly given on the third day following the date of such publication (or, if published more than once, on the third day following the date of the first such publication). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Solange Schuldverschreibungen im amtlichen Kursblatt (official list) der Luxemburger Börse notiert und zum Handel am regulierten Markt der Luxemburger Börse zugelassen sind (und die Vorschriften der Luxemburger Börse dies verlangen), sind alle die Schuldverschreibungen betreffenden Mitteilungen auf der Internetseite der Luxemburger Börse (*www.luxse.com*) zu veröffentlichen. Jede derartige Mitteilung gilt mit dem dritten Tag nach dem Tag der Veröffentlichung (oder bei mehreren Veröffentlichungen mit dem dritten Tag nach dem Tag der ersten solchen Veröffentlichung) als wirksam erfolgt. |
| (2)<br>Notification to Clearing System.<br>| (2)<br>Mitteilungen an das Clearingsystem.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;So long as any Notes are listed on the official list of the Luxembourg Stock Exchange and admitted to trading on the regulated market of the Luxembourg Stock Exchange, subparagraph (1) shall apply. If the Rules of the Luxembourg Stock Exchange otherwise so permit, the Issuer may deliver the relevant notice to the Clearing System for communication by the Clearing System to the Holders, in lieu of publication as set forth in subparagraph (1) above; any such notice shall be deemed to have been given on the seventh day after the day on which the said notice was given to the Clearing System. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Solange Schuldverschreibungen im amtlichen Kursblatt (official list) der Luxemburger Börse notiert und zum Handel am regulierten Markt der Luxemburger Börse zugelassen sind, sind alle die Schuldverschreibungen betreffenden Mitteilungen gemäß Absatz (1) bekanntzumachen. Soweit die Regeln der Luxemburger Börse dies zulassen, kann die Emittentin eine Veröffentlichung nach Absatz (1) durch eine Mitteilung an das Clearing System zur Weiterleitung an die Gläubiger ersetzen; jede derartige Mitteilung gilt am siebten Tag nach dem Tag der Mitteilung an das Clearing System als den Gläubigern mitgeteilt. |

---

------

---

| | |
|:---|:---|
| **§ 13**<br>**AMENDMENTS TO THE TERMS AND CONDITIONS BY RESOLUTION OF THE HOLDERS, HOLDERS' REPRESENTATIVE** | **§ 13**<br>**ÄNDERUNG DER EMISSIONSBEDINGUNGEN DURCH BESCHLUSS DER GLÄUBIGER; GEMEINSAMER VERTRETER** |
| (1)<br>Majority resolutions pursuant to the German Act on Issues of Debt Securities.<br>| (1)<br>Mehrheitsbeschlüsse nach dem Schuldverschreibungsgesetz.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Holders may with consent of the Issuer (if required) by a majority resolution pursuant to sections 5 et seqq. of the German Act on Issues of Debt Securities (*Gesetz über Schuldverschreibungen aus Gesamtemissionen*) (the ***SchVG***), as amended from time to time, agree to amendments of the Terms and Conditions or resolve any other matters provided for by the SchVG. In particular, the Holders may consent to amendments which materially change the substance of the Terms and Conditions, including such measures as provided for under section 5(3) of the SchVG by resolutions passed by such majority of the votes of the Holders as stated under § 13(2) below. A duly passed majority resolution shall be binding upon all Holders. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Gläubiger können mit Zustimmung der Emittentin (soweit erforderlich) aufgrund Mehrheitsbeschlusses nach Maßgabe der §§ 5 ff. des Gesetzes über Schuldverschreibungen aus Gesamtemissionen (das ***SchVG***) in seiner jeweils gültigen Fassung die Emissionsbedingungen ändern oder sonstige Maßnahmen gemäß dem SchVG beschließen. Die Gläubiger können insbesondere einer Änderung wesentlicher Inhalte der Emissionsbedingungen, einschließlich der in § 5 Abs. 3 SchVG vorgesehenen Maßnahmen durch Beschlüsse mit den in dem nachstehenden § 13(2) genannten Mehrheiten zustimmen. Ein ordnungsgemäß gefasster Mehrheitsbeschluss ist für alle Gläubiger verbindlich. |
| (2)<br>Majority.<br>| (2)<br>Mehrheit.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as provided by the following sentence and provided that the quorum requirements are being met, the Holders may pass resolutions by simple majority of the voting rights participating in the vote. Resolutions which materially change the substance of the Terms and Conditions, in particular in the cases of section 5(3) numbers 1 through 9 SchVG, or relating to material other matters may only be passed by a majority of at least 75% of the voting rights participating in the vote (a ***Qualified Majority***). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vorbehaltlich des nachstehenden Satzes und der Erreichung der erforderlichen Beschlussfähigkeit, beschließen die Gläubiger mit der einfachen Mehrheit der an der Abstimmung teilnehmenden Stimmrechte. Beschlüsse, durch welche der wesentliche Inhalt der Emissionsbedingungen, insbesondere in den Fällen des § 5 Abs. 3 Nummern 1 bis 9 SchVG, geändert wird, bedürfen zu ihrer Wirksamkeit einer Mehrheit von mindestens 75% der an der Abstimmung teilnehmenden Stimmrechte (eine ***Qualifizierte Mehrheit***). |
| (3)<br>Passing of resolutions.<br>| (3)<br>Beschlussfassung.<br>|

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Holders can pass resolutions in a meeting (*Gläubigerversammlung*) in accordance with sections 5 et seqq. of the SchVG or by means of a vote without a meeting (*Abstimmung ohne Versammlung*) in accordance with section 18 and sections 5 et seqq. of the SchVG. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Gläubiger können Beschlüsse in einer Gläubigerversammlung gemäß §§ 5 ff. SchVG oder im Wege einer Abstimmung ohne Versammlung gemäß § 18 und §§ 5 ff. SchVG fassen. |
| (4)<br>Meeting.<br>| (4)<br>Gläubigerversammlung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attendance at the meeting and exercise of voting rights is subject to the Holders' registration. The registration must be received at the address stated in the convening notice no later than the third day preceding the meeting. As part of the registration, Holders must demonstrate their eligibility to participate in the vote in accordance with section 10(3) of the SchVG. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Teilnahme an der Gläubigerversammlung und die Ausübung der Stimmrechte ist von einer vorherigen Anmeldung der Gläubiger abhängig. Die Anmeldung muss unter der in der Bekanntmachung der Einberufung mitgeteilten Adresse spätestens am dritten Tag vor der Gläubigerversammlung zugehen. Mit der Anmeldung müssen die Gläubiger ihre Berechtigung zur Teilnahme an der Abstimmung gemäß § 10 Abs. 3 SchVG nachweisen. |
| (5)<br>Vote without a meeting.<br>| (5)<br>Abstimmung ohne Versammlung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Together with casting their votes Holders must demonstrate their eligibility to participate in the vote in accordance with section 10(3) of the SchVG. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Zusammen mit der Stimmabgabe müssen die Gläubiger ihre Berechtigung zur Teilnahme an der Abstimmung gemäß § 10 Abs. 3 SchVG nachweisen. |
| (6)<br>Second meeting.<br>| (6)<br>Zweite Versammlung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If it is ascertained that no quorum exists for the meeting pursuant to § 13(4) or the vote without a meeting pursuant to § 13(5), in case of a meeting the chair (*Vorsitzender*) may convene a second meeting in accordance with section 15(3) sentence 2 of the SchVG or in case of a vote without a meeting the scrutineer (*Abstimmungsleiter*) may convene a second meeting within the meaning of section 15 paragraph 3 sentence 3 of the SchVG. Attendance at the second meeting and exercise of voting rights is subject to the Holders' registration. The provisions set out in § 13(4) sentence 3 shall apply mutatis  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wird für die Gläubigerversammlung gemäß § 13(4) oder die Abstimmung ohne Versammlung gemäß § 13(5) die mangelnde Beschlussfähigkeit festgestellt, kann – im Fall der Gläubigerversammlung – der Vorsitzende eine zweite Versammlung im Sinne von § 15 Abs. 3 Satz 2 SchVG und – im Fall der Abstimmung ohne Versammlung – der Abstimmungsleiter eine zweite Versammlung im Sinne von § 15 Abs. 3 Satz 3 SchVG einberufen. Die Teilnahme an der zweiten Versammlung und die Ausübung der Stimmrechte sind von einer vorherigen Anmeldung der Gläubiger abhängig. Für die Anmeldung der Gläubiger zu  |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;mutandis to the Holders' registration for a second meeting. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;einer zweiten Versammlung gilt § 13(4) Satz 3 entsprechend. |
| (7)<br>Holders' Representative.<br>| (7)<br>Gemeinsamer Vertreter.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Holders may by majority resolution provide for the appointment or dismissal of a joint representative (the ***Holders' Representative***), the duties and responsibilities and the powers of such Holders' Representative, the transfer of the rights of the Holders to the Holders' Representative and a limitation of liability of the Holders' Representative. § 13(2) to (6) also apply to the resolution regarding the appointment of a Holders' Representative. Appointment of a Holders' Representative may only be passed by a Qualified Majority if such Holders' Representative is to be authorized to consent, in accordance with § 13(2) hereof, to a material change in the substance of the Terms and Conditions or other material matters. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Gläubiger können durch Mehrheitsbeschluss einen gemeinsamen Vertreter (der ***Gemeinsame Vertreter***) bestellen oder abberufen und die Pflichten, Aufgaben und Befugnisse des Gemeinsamen Vertreters, die Übertragung der Rechte der Gläubiger auf den Gemeinsamen Vertreter und eine Beschränkung der Haftung des Gemeinsamen Vertreters festlegen. Die § 13(2) bis (6) gelten auch für die Beschlussfassung über die Bestellung eines Gemeinsamen Vertreters. Die Bestellung eines Gemeinsamen Vertreters bedarf einer Qualifizierten Mehrheit, wenn der Gemeinsame Vertreter befugt ist, Änderungen des wesentlichen Inhalts der Emissionsbedingungen oder sonstigen wesentlichen Maßnahmen gemäß § 13(2) zuzustimmen. |
| (8)<br>Publication.<br>| (8)<br>Veröffentlichung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any notices concerning this § 13 shall be made exclusively pursuant to the provisions of the SchVG. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alle Bekanntmachungen diesen § 13 betreffend erfolgen ausschließlich gemäß den Bestimmungen des SchVG. |
| **§ 14**<br>**(APPLICABLE LAW, PLACE OF JURISDICTION AND ENFORCEMENT)** | **§ 14**<br>**(ANWENDBARES RECHT, GERICHTSSTAND UND GERICHTLICHE GELTENDMACHUNG)** |
| (1)<br>Applicable Law.<br>| (1)<br>Anwendbares Recht.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes, as to form and content, and all rights and obligations of the Holders and the Issuer, shall be governed in every respect by German law. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form und Inhalt der Schuldverschreibungen sowie die Rechte und Pflichten der Gläubiger und der Emittentin bestimmen sich in jeder Hinsicht nach deutschem Recht. |
| (2)<br>Place of Jurisdiction.<br>| (2)<br>Gerichtsstand.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to any mandatory jurisdiction for specific proceedings under the SchVG, the District Court (*Landgericht*) in Frankfurt am Main shall have non- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vorbehaltlich eines zwingenden Gerichtsstandes für besondere Rechtsstreitigkeiten im Zusammenhang mit dem SchVG, ist das Landgericht  |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;exclusive jurisdiction for any action or other legal proceedings (***Proceedings***) arising out of or in connection with the Notes. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Frankfurt am Main nicht ausschließlich zuständig für sämtliche im Zusammenhang mit den Schuldverschreibungen entstehenden Klagen oder sonstige Verfahren (***Rechtsstreitigkeiten***). |
| (3)<br>Enforcement.<br>| (3)<br>Gerichtliche Geltendmachung.<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any Holder of Notes may in any proceedings against the Issuer or to which such Holder and the Issuer are parties, protect and enforce in his own name his rights arising under such Notes on the basis of (i) a statement issued by the Custodian with whom such Holder maintains a securities account in respect of the Notes (a) stating the full name and address of the Holder, (b) specifying the aggregate principal amount of Notes credited to such securities account on the date of such statement and (c) confirming that the Custodian has given written notice to the Clearing System containing the information pursuant to (a) and (b) which has been confirmed by the Clearing System; (ii) a copy of the Note in global form certified as being a true copy by a duly authorized officer of the Clearing System or a depositary of the Clearing System, without the need for production in such proceedings of the actual records or the global note representing the Notes or (iii) any other means of proof permitted in legal proceedings in the country of enforcement. For purposes of the foregoing, ***Custodian*** means any bank or other financial institution of recognized standing authorized to engage in securities custody business with which the Holder maintains a securities account in respect of the Notes and which maintains an account with the Clearing System, and includes the Clearing System. Each Holder may, without prejudice to the foregoing, protect and enforce his rights under these Notes also in any other way which is admitted in the country of the Proceedings. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jeder Gläubiger von Schuldverschreibungen ist berechtigt, in jedem Rechtsstreit gegen die Emittentin oder in jedem Rechtsstreit, in dem der Gläubiger und die Emittentin Partei sind, seine Rechte aus diesen Schuldverschreibungen im eigenen Namen auf der folgenden Grundlage zu schützen oder geltend zu machen: (i) er bringt eine Bescheinigung der Depotbank bei, bei der er für die Schuldverschreibungen ein Wertpapierdepot unterhält, welche (a) den vollständigen Namen und die vollständige Adresse des Gläubigers enthält, (b) den Gesamtnennbetrag der Schuldverschreibungen bezeichnet, die unter dem Datum der Bestätigung auf dem Wertpapierdepot verbucht sind und (c) bestätigt, dass die Depotbank gegenüber dem Clearingsystem eine schriftliche Erklärung abgegeben hat, die die vorstehend unter (a) und (b) bezeichneten Informationen enthält und einen Bestätigungsvermerk des Clearingsystems trägt; (ii) er legt eine Kopie der die betreffenden Schuldverschreibungen verbriefenden Globalurkunde vor, deren Übereinstimmung mit dem Original eine vertretungsberechtigte Person des Clearingsystems oder des Verwahrers des Clearingsystems bestätigt hat, ohne dass eine Vorlage der Originalbelege oder der die Schuldverschreibungen verbriefenden Globalurkunde in einem solchen Verfahren erforderlich wäre oder (iii) auf jede andere Weise, die im Lande der Geltendmachung prozessual zulässig ist. Für die Zwecke des Vorstehenden bezeichnet ***Depotbank*** jede Bank oder ein sonstiges anerkanntes Finanzinstitut, das berechtigt ist, das Wertpapierverwahrungsgeschäft zu  |

---

------

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;betreiben und bei der/dem der Gläubiger ein Wertpapierdepot für die Schuldverschreibungen unterhält und ein Konto beim Clearingsystem unterhält, einschließlich des Clearingsystems. Jeder Gläubiger kann unbeschadet des Vorstehenden seine Rechte aus diesen Schuldverschreibungen auch auf jede andere Weise schützen und durchsetzen, die im Land des Verfahrens zulässig ist. |
| **§ 15**<br>**(LANGUAGE)** | **§ 15**<br>**(SPRACHE)** |
| These Terms and Conditions are written in the German language and provided with an English language translation. The German text shall be controlling and binding. The English language translation is provided for convenience only. | Diese Emissionsbedingungen sind in deutscher Sprache abgefasst. Eine Übersetzung in die englische Sprache ist beigefügt. Der deutsche Text ist bindend und maßgeblich. Die Übersetzung in die englische Sprache ist unverbindlich. |

---

------

**Part II.: ADDITIONAL INFORMATION**

***Teil II ZUSÄTZLICHE INFORMATIONEN***

---

| | |
|:---|:---|
| **A. Essential information**<br>***Grundlegende Angaben*** |  |
| **Interests of Natural and Legal Persons involved in the Issue/Offer**<br>***Interessen von Seiten natürlicher und juristischer Personen, die an der Emission/dem Angebot beteiligt sind*** | So far as the Issuer is aware, no person involved in the offer of the Notes has an interest material to the offer, except that certain Dealers and their affiliates may be customers of, and borrowers from, the creditors of the Issuer and its affiliates. In addition, certain of the Dealers and their affiliates have engaged, and may in future engage, in investment banking and/or commercial banking transactions with, and may perform services for, the Issuer or its affiliates in the ordinary course of business.<br>*Nach Kenntnis der Emittentin bestehen bei den an der Emission beteiligten Personen keine Interessen, die für das Angebot bedeutsam sind, außer, dass bestimmte Platzeure und mit ihnen verbundene Unternehmen Kunden von, Kreditnehmer der oder Kreditgeber der Emittentin und mit ihr verbundener Unternehmen sein können. Außerdem sind bestimmte Platzeure an Investment Banking Transaktionen und/oder Commercial Banking Transaktionen mit der Emittentin oder mit ihr verbundenen Unternehmen beteiligt oder könnten sich in Zukunft daran beteiligen.* |
| **Reasons for the offer to the public or for the admission to trading and use of proceeds**<br>***Gründe für das öffentliche Angebot oder die Zulassung zum Handel und Verwendung der Erlöse*** | General corporate purposes,<br> including the refinancing of existing<br>financial liabilities.<br>*Allgemeine Geschäftszwecke, einschließlich der Refinanzierung bestehender Finanzverbindlichkeiten.* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated net proceeds<br>*Geschätzter Nettobetrag der Erträge*  | EUR 496,470,000<br>*EUR 496.470.000* |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated total expenses (excluding commissions of the managers) of the issue *Geschätzte Gesamtkosten (ausschließlich Provisionen der Manager) der Emission* | EUR 65,000****<br> *EUR 65.000* |
| **Eurosystem eligibility**<br>***EZB-Fähigkeit*** |  |
| **☒**<br>Intended to be held in a manner which would allow Eurosystem eligibility<br>| Yes |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Soll in EZB-fähiger Weise gehalten werden* | *Ja* |
|  | Yes. Note that the designation "Yes" in the case of a NGN simply means that the Notes are intended upon issue to be deposited with one of the ICSDs as common safekeeper, and does not necessarily mean that the Notes will be recognized as eligible collateral for Eurosystem monetary policy and intraday credit operations by the Eurosystem either upon issue or at any or all times during their life. Such recognition will depend upon the ECB being satisfied that Eurosystem eligibility criteria have been met.  |
|  | *Ja. Es ist zu beachten, dass die Bestimmung "Ja" im Fall einer NGN lediglich bedeutet, dass die Schuldverschreibungen nach Begebung bei einer der ICSDs als gemeinsamer Verwahrer hinterlegt werden sollen, und es bedeutet nicht notwendigerweise, dass die Schuldverschreibungen als geeignete Sicherheit im Sinne der Währungspolitik des Eurosystems und der taggleichen Überziehungen (intraday credit operations) des Eurosystem entweder nach Begebung oder zu einem Zeitpunkt während ihrer Existenz anerkannt werden. Eine solche Anerkennung wird vom Urteil der EZB abhängen, dass die Eurosystemfähigkeitskriterien erfüllt werden.*  |
| **B. Information concerning the securities to be offered/admitted to trading**<br>***Informationen über die anzubietenden bzw. zum Handel zuzulassenden Wertpapiere*** |  |
| **Securities Identification Numbers**<br>**W*ertpapier-Kenn-Nummern*** |  |
| Common Code<br>*Common Code* | 323349908 |
| International Securities Identification Number (ISIN)<br>*Internationale Wertpapierkennnummer (ISIN)* | XS3233499089 |
| German Securities Code (WKN)<br>*Deutsche Wertpapierkennnummer (WKN)* | A460DH |

---

------

---

| | |
|:---|:---|
| Financial Instrument Short Name (FISN)<br>*Emittenten- und Instrumenten-Kurzname (FISN)* | FRESENIUS MEDIC/3.25 MTN 20301124 |
| Classification of Financial Instruments Code (CFI)<br>*Klassifikationscode von Finanzinstrumenten (CFI)* | DTFUFB |
| **Historic Interest Rates and future performance as well as volatility** | Not applicable<br>|
| ***Zinssätze der Vergangenheit und künftige Entwicklungen sowie ihre Volatilität*** | *Nicht anwendbar* |
| **Yield to final maturity**<br>***Rendite bei Endfälligkeit*** | 3.334 per cent.<br>*3,334* *%*** |
| Representation of debt security holders including an identification of the organization representing the investors and provisions applying to such representation. Indication of the website where the public may have free access to the contracts in relation to these forms of representation  | Not applicable |
| *Vertretung der Schuldtitelinhaber unter Angabe der die Anleger vertretenden Organisation und der für diese Vertretung geltenden Bestimmungen. Angabe der Website, auf der die Anleger die Verträge, die diese Repräsentationsformen regeln, kostenlos einsehen können* | *Nicht anwendbar* |
| **Resolutions, authorizations and approvals by virtue of which the Notes will be created** | The issue of the Notes has been authorized by resolutions of the management board of the Issuer dated May 12, 2025 and October 23, 2024 and by resolutions of the supervisory board of the Issuer dated June 10, 2025 and December 4, 2024. |
| ***Beschlüsse, Ermächtigungen und Genehmigungen, welche die Grundlage für die Schaffung der Schuldverschreibungen bilden*** | *Die Begebung der Schuldverschreibungen wurde ordnungsgemäß genehmigt durch Vorstandsbeschlüsse der Emittentin vom* 12. Mai 2025 und *23. Oktober 2024 sowie Aufsichtsratsbeschlüsse der Emittentin vom 10. Juni* 2025 und *4. Dezember 2024.* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.**<br>**Terms and conditions of the offer of the Notes to the public**<br>***Bedingungen und Konditionen des öffentlichen Angebots von Schuldverschreibungen*** |  |
| **C.1**<br>**Conditions, offer statistics, expected timetable and action required to apply for the offer *Angebotsstatistiken, erwarteter Zeitplan und erforderliche Maßnahmen für die Antragstellung*** | Not applicable**<br>|
| **C.1**<br>**Conditions, offer statistics, expected timetable and action required to apply for the offer *Angebotsstatistiken, erwarteter Zeitplan und erforderliche Maßnahmen für die Antragstellung*** | *Nicht anwendbar* |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.2**<br>**Plan of distribution and allotment**<br>***Plan für die Aufteilung der Wertpapiere und deren Zuteilung***  | Not applicable<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.2**<br>**Plan of distribution and allotment**<br>***Plan für die Aufteilung der Wertpapiere und deren Zuteilung***  | *Nicht anwendbar* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.3**<br>**Pricing**<br>***Kursfeststellung*** |  |
| Issue Price<br>*Ausgabepreis* | 99.619 per cent.<br>*99,619 %* |
| Expected price at which the Notes will be offered | Not applicable |
| *Preis zu dem die Schuldverschreibungen voraussichtlich <br>angeboten werden* | *Nicht anwendbar* |
| Amount of expenses and taxes charged to the subscriber / <br>purchaser | Not applicable<br>|
| *Kosten/Steuern, die dem Zeichner/Käufer in Rechnung gestellt* | *Nicht anwendbar* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.4**<br>**Placing and underwriting**<br>***Platzierung und Emission*** |  |
| Name and address of the coordinator(s) of the global offer and of single parts of the offer and, to the extent known to the Issuer or the offeror, of the placers in the various countries where the offer takes place | Not applicable<br>|
| *Name und Anschrift des Koordinators/der Koordinatoren des globalen Angebots oder einzelner Teile des Angebots und – sofern der Emittentin oder dem Bieter bekannt – Angaben zu den Platzierern in den einzelnen Ländern des Angebots* | *Nicht anwendbar* |
| **Method of distribution**<br>***Vertriebsmethode*** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☐ Non-syndicated<br>*Nicht syndiziert*<br>☒ Syndicated<br>*Syndiziert* |  |
| **Subscription Agreement**<br>***Übernahmevertrag*** |  |
| Date of Subscription Agreement<br>*Datum des Subscription Agreements* | November 20, 2025<br>*20. November 2025* |
| Material Features of the Subscription Agreement:<br>*Hauptmerkmale des Übernahmevertrages:* | Under the Subscription Agreement, the Issuer agrees to issue the Notes and each Dealer agrees to purchase the Notes; the Issuer and each Dealer agree *inter alia* on the aggregate principal amount of the issue, the principal amount of the Dealers' commitments, the Issue Price, the Issue Date and the<br>commissions*.* |

---

------

---

| | |
|:---|:---|
|  | *Unter dem Übernahmevertrag vereinbart die Emittentin, die Schuldverschreibungen zu begeben und jeder Platzeur stimmt zu, die Schuldverschreibungen zu erwerben. Die Emittentin und jeder Platzeur vereinbaren im Übernahmevertrag unter anderem den Gesamtnennbetrag der Emission, die gemäß der Übernahmeverpflichtung auf die Platzeure entfallenden Nennbeträge, den Ausgabepreis, den Valutierungstag und die<br>Provisionen.* |
| **Management Details including form of commitment**<br>***Einzelheiten bezüglich des Bankenkonsortiums einschließlich der Art der Übernahme***  |  |
| Specify Management Group or Dealer (names and addresses)<br>*Bankenkonsortium oder Platzeur angeben (Namen und Anschriften)* | <u>Active Bookrunners</u><br>*Aktive Bookrunner*<br>**BofA Securities Europe SA**<br> 51 rue La Boétie<br>75008 Paris<br>France/Frankreich<br>**Commerzbank<br>Aktiengesellschaft**<br>Kaiserstraße 16 (Kaiserplatz)<br>60311 Frankfurt am Main<br>Federal Republic of Germany/Bundesrepublik Deutschland<br>**Mizuho Bank Europe N.V.**<br> Atrium Amsterdam 3rd Floor<br>Strawinskylaan 3053<br>1077 ZX Amsterdam<br>The Netherlands/Niederlande<br>**Société Générale**<br>Immeuble Basalte<br>17 Cours Valmy<br>CS 50318<br>92972 Paris La Défense Cedex<br>France<br><u>Passive Bookrunners</u><br>*Passive Bookrunner*<br>|

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Crédit Agricole Corporate and Investment Bank**<br>12, Place des Etats-Unis<br>CS 70052<br>92547 Montrouge CEDEX<br>France/Frankreich<br>**UniCredit Bank GmbH**<br>Arabellastrasse 12<br>81925 Munich/München<br>Federal Republic of Germany/Bundesrepublik Deutschland |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ | Firm commitment<br>*Feste Zusage* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☐ | no firm commitment / best efforts<br>arrangements<br>*Keine feste Zusage / zu den<br>bestmöglichen Bedingungen* |  |
| **Commissions<br>*Provisionen*** | **Commissions<br>*Provisionen*** |  |
| Management/Underwriting Commission (specify)<br>*Management- und Übernahmeprovision (angeben)* | Management/Underwriting Commission (specify)<br>*Management- und Übernahmeprovision (angeben)* | 0.325 per cent.<br>*0,325* *%*** |
| Selling Concession (specify)<br>*Verkaufsprovision (angeben)* | Selling Concession (specify)<br>*Verkaufsprovision (angeben)* | Not applicable<br>*Nicht anwendbar* |
| Listing Commission (specify)<br>*Börsenzulassungsprovision (angeben)* | Listing Commission (specify)<br>*Börsenzulassungsprovision (angeben)* | Not applicable<br>*Nicht anwendbar* |
| **Prohibition of Sales to EEA Retail Investors**<br>***Verbot des Verkaufs an Kleinanleger im Europäischen<br>Wirtschaftsraum***  | **Prohibition of Sales to EEA Retail Investors**<br>***Verbot des Verkaufs an Kleinanleger im Europäischen<br>Wirtschaftsraum***  | Not applicable<br>*Nicht anwendbar* |
| **Prohibition of Sales to UK Retail Investors**<br>***Verbot des Verkaufs an Kleinanleger im Vereinigten<br>Königreich*** | **Prohibition of Sales to UK Retail Investors**<br>***Verbot des Verkaufs an Kleinanleger im Vereinigten<br>Königreich*** | Not applicable<br>*Nicht anwendbar* |
| **Stabilising Dealer/Manager**<br>***Kursstabilisierender Dealer/Manager*** | **Stabilising Dealer/Manager**<br>***Kursstabilisierender Dealer/Manager*** | Commerzbank Aktiengesellschaft******<br> *Commerzbank Aktiengesellschaft* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.5** **Public Offer Jurisdictions**<br>***Jurisdiktionen für öffentliches Angebot*** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.5** **Public Offer Jurisdictions**<br>***Jurisdiktionen für öffentliches Angebot*** |  |
| Public Offer Jurisdiction(s)<br>*Jurisdiktionen, in denen ein öffentliches Angebot stattfindet* | Public Offer Jurisdiction(s)<br>*Jurisdiktionen, in denen ein öffentliches Angebot stattfindet* | Luxembourg and Germany <br>*Luxemburg und Deutschland* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**D.**<br>**Listing(s) and admission to trading**<br>***Börsenzulassung(en) und Notierungsaufnahme*** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**D.**<br>**Listing(s) and admission to trading**<br>***Börsenzulassung(en) und Notierungsaufnahme*** | Yes<br>*Ja* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ | Regulated Market of the Luxembourg Stock<br>Exchange  |  |

---

------

---

| | | |
|:---|:---|:---|
|  | *Regulierter Markt der Luxemburger Wertpapierbörse* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☐ | Other<br>*Sonstige* |  |
| **Date of admission**<br>***Termin der Zulassung*** | **Date of admission**<br>***Termin der Zulassung*** | November 24, 2025<br>*24. November 2025* |
| Estimate of the total expenses related to admission to trading *<br>Geschätzte Gesamtkosten für die Zulassung zum Handel* | Estimate of the total expenses related to admission to trading *<br>Geschätzte Gesamtkosten für die Zulassung zum Handel* | Not applicable<br>*Nicht anwendbar* |
| All regulated markets or third-country markets, SME Growth Market or MTFs on which, to the knowledge of the Issuer, notes of the same class of the notes to be offered to the public or admitted to trading are already admitted to trading<br>*Angabe sämtlicher regulierter Märkte oder Märkte in Drittstaaten, KMU-Wachstumsmärkte oder MTFs, auf denen nach Kenntnis der Emittentin Schuldverschreibungen der gleichen Wertpapierkategorie, die öffentlich angeboten oder zum Handel zugelassen werden sollen, bereits zum Handel zugelassen sind* | All regulated markets or third-country markets, SME Growth Market or MTFs on which, to the knowledge of the Issuer, notes of the same class of the notes to be offered to the public or admitted to trading are already admitted to trading<br>*Angabe sämtlicher regulierter Märkte oder Märkte in Drittstaaten, KMU-Wachstumsmärkte oder MTFs, auf denen nach Kenntnis der Emittentin Schuldverschreibungen der gleichen Wertpapierkategorie, die öffentlich angeboten oder zum Handel zugelassen werden sollen, bereits zum Handel zugelassen sind* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☐ | Regulated Market of the Luxembourg Stock Exchange<br>*Regulierter Markt der Luxemburger Wertpapierbörse* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☐ | Other<br>*Andere* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ | not applicable<br>*nicht anwendbar* |  |
| Name and address of the entities which have a firm commitment to act as intermediaries in secondary trading, providing liquidity through bid and offer rates and description of the main terms of their commitment | Name and address of the entities which have a firm commitment to act as intermediaries in secondary trading, providing liquidity through bid and offer rates and description of the main terms of their commitment | Not applicable |
| *Name und Anschrift der Institute, die aufgrund einer festen Zusage als Intermediäre im Sekundärhandel tätig sind und Liquidität mittels Geld- und Briefkursen erwirtschaften, und Beschreibung der Hauptbedingungen der Zusagevereinbarung* | *Name und Anschrift der Institute, die aufgrund einer festen Zusage als Intermediäre im Sekundärhandel tätig sind und Liquidität mittels Geld- und Briefkursen erwirtschaften, und Beschreibung der Hauptbedingungen der Zusagevereinbarung* | *Nicht anwendbar* |
| **E.** **Additional Information <br>*Zusätzliche Informationen*** | **E.** **Additional Information <br>*Zusätzliche Informationen*** |  |
| **Rating of the Notes**<br>***Rating der Schuldverschreibungen*** | **Rating of the Notes**<br>***Rating der Schuldverschreibungen*** | The Issuer expects, that upon issuance, the Notes will be assigned a rating of BBB-<sup>3</sup> by Fitch Ratings Ireland Limited, |

---

------

---

| | |
|:---|:---|
| <sup>3.</sup> | According to the rating definitions published on its website, Fitch defines obligations rated 'BBB' as follows: " 'BBB' ratings indicate that expectations of default risk are currently low. The capacity for payment of financial commitments is considered adequate, but adverse business or economic conditions are more likely to impair this capacity." The modifiers "+" or "–" may be appended to a rating to denote relative status within major rating categories. |

---

------

---

| |
|:---|
| BBB-<sup>4</sup> by S&P Global Ratings Europe Limited and Baa3<sup>5</sup> by Moody's Deutschland GmbH.<br>*Die Emittentin erwartet, dass die Schuldverschreibungen nach ihrer Begebung ein Rating von BBB-*<sup>6</sup> *durch Fitch Ratings Ireland Limited, von BBB-*<sup>7</sup> *durch S&P Global Ratings Europe Limited und von Baa3*<sup>8</sup> *durch Moody's Deutschland GmbH erhalten werden.* |
| Fitch Ratings Ireland Limited is established in the European Union and is registered pursuant to Regulation (EC) No 1060/2009 of the European Parliament and of the Council of 16 September 2009 on credit rating agencies, as amended (the ***CRA Regulation***). S&P Global Ratings Europe Limited is established in Ireland and is registered pursuant to the CRA Regulation. Moody's Deutschland GmbH is established in Germany and is registered pursuant to the CRA Regulation. The European Securities and Markets Authority (***ESMA***) publishes on its website (*https://www.esma.europa.eu/credit-rating-agencies/cra-authorisation*<u>)</u> a list of credit rating agencies registered in accordance with the CRA Regulation. That list is updated within five working days following the adoption of a |

---

------

---

| | |
|:---|:---|
| <sup>4.</sup> | According to the rating definitions published by S&P on its homepage, 'BBB' means: "Adequate capacity to meet financial commitments, but more subject to adverse economic conditions." Ratings from 'AA' to 'CCC' may be modified by the addition of a plus (+) or minus (-) sign to show relative standing within the rating categories. |

---

---

| | |
|:---|:---|
| <sup>5.</sup> | According to the rating definitions published on its website, Moody's defines obligations rated 'Baa' as follows: "Obligations rated Baa are subject to moderate credit risk. They are considered medium-grade and as such may possess speculative characteristics." Moody's appends numerical modifiers 1, 2, and 3 to each generic rating classification from Aa through Caa. The modifier 3 indicates a ranking in the lower end of that generic rating category. |

---

---

| | |
|:---|:---|
| <sup>6.</sup> | *Gemäß der auf ihrer Website veröffentlichten Ratingdefinitionen werden Verbindlichkeiten mit einem Rating von 'BBB' von Fitch wie folgt definiert: "BBB Ratings weisen darauf hin, dass die Erwartungen hinsichtlich eines Ausfallrisikos momentan gering sind. Die Fähigkeit, finanzielle Verbindlichkeiten zu bezahlen, wird als adäquat angesehen, jedoch können nachteilige Geschäfts- oder Wirtschaftsbedingungen leichter zu einer Beeinträchtigung dieser Fähigkeit führen." Den Ratings kann ein Plus- oder ein Minuszeichen hinzugefügt werden, um den jeweiligen Rang innerhalb größerer Ratingkategorien anzuzeigen.* |

---

---

| | |
|:---|:---|
| <sup>7.</sup> | *Gemäß der von S&P auf ihrer Website veröffentlichten Ratingdefinitionen ist 'BBB' wie folgt definiert: "Adäquate Kapazität zur Erfüllung der finanziellen Verpflichtungen, aber anfälliger für nachteilige wirtschaftliche Bedingungen." Den Ratings von 'AA' bis 'CCC' kann ein Pluszeichen (+) oder Minuszeichen (-) hinzugefügt werden, um den jeweiligen Rang innerhalb der größeren Ratingkategorie anzuzeigen.* |

---

---

| | |
|:---|:---|
| <sup>8.</sup> | *Gemäß der auf ihrer Website veröffentlichten Ratingdefinitionen werden Verbindlichkeiten mit einem Rating von 'Baa' von Moody's wie folgt definiert: "Baa-geratete Verbindlichkeiten bergen ein moderates Kreditrisiko. Sie gelten als von mittlerer Qualität und weisen als solche mitunter spekulative Elemente auf." Moody's verwendet in den Ratingkategorien Aa bis Caa zusätzlich numerische Unterteilungen. Der Zusatz "3" bedeutet eine Einstufung in das untere Drittel der jeweiligen Ratingkategorie.* |

---

------

---

| |
|:---|
| decision under Article 16, 17 or 20 CRA Regulation. The European Commission shall publish that updated list in the Official Journal of the European Union within 30 days following such update. |
| *Fitch Ratings Ireland Limited hat ihren Sitz in der Europäischen Union und ist gemäß Verordnung (EG) Nr. 1060/2009 des Europäischen Parlaments und des Rates vom 16. September 2009 über Ratingagenturen (in der geänderten Fassung) (die* ***Ratingverordnung****) registriert. S&P Global Ratings Europe Limited hat ihren Sitz in Irland und ist gemäß der Ratingverordnung registriert. Moody's Deutschland GmbH hat ihren Sitz in Deutschland und ist gemäß der Ratingverordnung registriert. Die Europäische Wertpapier und Marktaufsichtsbehörde (****ESMA****) veröffentlicht auf ihrer Webseite (https://www.esma.europa.eu/credit-rating-agencies/cra-authorisation) ein Verzeichnis der nach der Ratingverordnung registrierten Ratingagenturen. Dieses Verzeichnis wird innerhalb von fünf Werktagen nach Annahme eines Beschlusses gemäß Artikel 16, 17 oder 20 der Ratingverordnung aktualisiert. Die Europäische Kommission veröffentlicht das aktualisierte Verzeichnis im Amtsblatt der Europäischen Union innerhalb von 30 Tagen nach der Aktualisierung.* |

---

&nbsp;&nbsp;&nbsp;&nbsp;**F.** **Information to be provided regarding the consent by the Issuer or person responsible for drawing up the Prospectus and the Final Terms** 

***Zur Verfügung zu stellende Informationen über die Zustimmung der Emittentin oder der für die Erstellung des Prospekts und der Endgültigen Bedingungen zuständigen Person***

The consent to the use of the Prospectus and these Final Terms for the subsequent resale or final placement of Notes by all financial intermediaries is given by the Issuer in relation to Luxembourg and Germany.

The subsequent resale or final placement of Notes by financial intermediaries can be made during the offer period. The offer period commences on November 20, 2025 and ends on November 24, 2025.

*Die Zustimmung zu der Verwendung des Prospekts und dieser Endgültigen Bedingungen zu der späteren Weiterveräußerung und der endgültigen Platzierung der Schuldverschreibungen durch alle Finanzintermediäre wird von der Emittentin in Bezug auf Luxemburg und Deutschland erteilt.* 

*Die spätere Weiterveräußerung und endgültige Platzierung der Wertpapiere durch Finanzintermediäre kann während der Angebotsfrist erfolgen. Die Angebotsfrist beginnt am 20. November 2025 und endet am 24. November 2025.*

**Third Party Information**

***Informationen von Seiten Dritter***

With respect to any information included herein and specified to be sourced from a third party (i) the Issuer confirms that any such information has been accurately reproduced and as far as the Issuer is aware and is able to ascertain from information available to it from such third party, no facts have been omitted which would render the reproduced information inaccurate or misleading

------

and (ii) the Issuer has not independently verified any such information and accepts no responsibility for the accuracy thereof.

*Hinsichtlich der hierin enthaltenen und als solche gekennzeichneten Informationen von Seiten Dritter gilt Folgendes: (i) Die Emittentin bestätigt, dass diese Informationen zutreffend wiedergegeben worden sind und - soweit es der Emittentin bekannt ist und sie aus den von diesen Dritten zur Verfügung gestellten Informationen ableiten konnte - wurden keine Fakten unterschlagen, die die wiedergegebenen Informationen unzutreffend oder irreführend gestalten würden; (ii) die Emittentin hat diese Informationen nicht selbständig überprüft und übernimmt keine Verantwortung für ihre Richtigkeit.*

------

**Fresenius Medical Care AG**

---

| | |
|:---|:---|
| /s/ Martin Fischer | /s/ Steffen Patzak |
| By: Martin Fischer | By: Steffen Patzak |
| Title: CFO | Title: SVP CFGT |

---

------

**Annex**

**Summary for the Individual Issue**

**Section A**

**INTRODUCTION CONTAINING WARNINGS**

This summary relates to the series EUR 500,000,000 3.250 per cent. Notes due November 24, 2030 with the ISIN XS3233499089 (the ***Notes***), issued by Fresenius Medical Care AG, Else-Kröner-Straße 1, 61352 Bad Homburg vor der Höhe, Germany (tel.: +49-6172-609-0; website: www.freseniusmedicalcare.com; LEI: 549300CP8NY40UP89Q40) (the ***Issuer*** and, together with its consolidated group companies, the ***Group***, also referred to as ***we***, ***us*** or ***our***) under the Issuer's EUR 10,000,000,000 Debt Issuance Program (the ***Program***).

The *Commission de Surveillance du Secteur Financier* (***CSSF***), 283, route d'Arlon L-1150 Luxembourg (tel.: +352 26 25 1 - 1; fax: +352 26 25 1 - 2601; e-mail: direction@cssf.lu) has approved the base prospectus for the Program (the ***Base Prospectus***) as the competent authority under Regulation (EU) 2017/1129 on March 26, 2025 and the first supplement to the Base Prospectus on November 7, 2025.

*This Summary has been prepared in accordance with Article 7 of Regulation (EU) 2017/1129 and should be read as an introduction to the Base Prospectus, as supplemented, and the applicable Final Terms. Any decision to invest in the Notes should be based on consideration of the Base Prospectus, as supplemented, as a whole, including any documents incorporated by reference therein, and the applicable Final Terms by the investor. An investor in the Notes could lose all or part of the invested capital. Where a claim relating to the information contained in the Base Prospectus, as supplemented, or the applicable Final Terms is brought before a court, the plaintiff investor might, under national law, have to bear the costs of translating the Base Prospectus, as supplemented, and the applicable Final Terms, before the legal proceedings are initiated. Civil liability attaches only to those persons who have tabled the Summary including any translation thereof, but only if the Summary is misleading, inaccurate or inconsistent, when read together with the Base Prospectus, as supplemented, and the applicable Final Terms, or where it does not provide, when read together with the Base Prospectus, as supplemented, and the applicable Final Terms, key information in order to aid investors when considering whether to invest in such Notes.*

**Section B**

**KEY INFORMATION ON THE ISSUER**

**B.1** **Who is the issuer of the securities?**

**B.1.1** **Domicile, legal form, LEI, law under which it operates and country of operation**

The Issuer is a German stock corporation (*Aktiengesellschaft*) with its registered seat (*Sitz*) at Hof (Saale), Germany, incorporated under and governed by the laws of Germany. The LEI of the Issuer is 549300CP8NY40UP89Q40.

**B.1.2** **Principal activities**

The Issuer's principal activity is to act as holding company for its subsidiaries. The Group provides dialysis and related services for individuals with renal diseases as well as other health care services. The Group also develops, manufactures and distributes a wide variety of health care products.

**B.1.3** **Major shareholders**

As of September 30, 2025, the Issuer's share capital consisted of 293,413,449 issued bearer shares 289,848,926 of which are outstanding. As of September 30, 2025, 3,564,523 shares are held as treasury shares. Fresenius SE & Co. KGaA (***Fresenius SE***) owned approximately 28.55% of the Issuer's shares on November 7, 2025. The Else Kröner-Fresenius-Stiftung is the sole shareholder of Fresenius Management SE, the general partner of Fresenius SE, and has sole power to elect the supervisory board of Fresenius Management SE. In addition, the Else Kröner-Fresenius-Stiftung owned approximately 27% of the share capital of Fresenius SE on September 30, 2025.

Pursuant to notifications received by the Issuer in accordance with the WpHG through November 7, 2025, the following shareholders directly or indirectly hold more than 3% of the Issuer's shares and (where applicable) financial instruments relating to the Issuer's shares:

------

---

| | |
|:---|:---|
| **Shareholder** | **Share of voting rights (in %)** |
| Else Kröner-Fresenius-Stiftung | 28.55 |
| Richard Pzena | 5.20 |
| Dodge & Cox, San Francisco, California, U.S. | 5.03 |
| Dodge & Cox International Stock Fund, San Francisco, California, U.S. | 4.98 |
| BlackRock, Inc., Wilmington, Delaware, U.S. | 4.995 |

---

**B.1.4** **Key managing directors**

The Issuer's management board (*Vorstand*) manages the Issuer and conducts its business. The current members of the management board are Helen Giza, Craig Cordola, Ed.D., Martin Fischer, Dr. Jörg Häring, Franklin W. Maddux, M.D., and Dr. Katarzyna Mazur-Hofsäß. On October 1, 2025, the Issuer announced the appointment of Joseph E. (Joe) Turk as a member of the management board, effective January 1, 2026, succeeding Dr. Katarzyna Mazur-Hofsäß.

**B.1.5** **Identity of the statutory auditors**

PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft, Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt am Main, Germany (***PwC***), a member of the German Chamber of Public Accountants (*Wirtschaftsprüferkammer*), Berlin, Germany, was appointed to serve as independent auditor of the Issuer for the fiscal years ended December 31, 2024 and 2023.

**B.2** **What is the key financial information regarding the Issuer?**

The following selected consolidated financial information has been taken or derived from the Issuer's consolidated financial statements prepared in accordance with International Financial Reporting Standards (***IFRS***<sup>®</sup>) Accounting Standards as adopted by the European Union as of and for each of the fiscal years ended December 31, 2024 and 2023 and the nine months ended September 30, 2025 and 2024. PwC audited the consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2023 and issued unqualified auditor's reports (*uneingeschränkte Bestätigungsvermerke*) thereon. The selected consolidated financial information as of and for the nine months ended September 30, 2025 and 2024 has been taken or derived from our unaudited consolidated interim financial statements as of and for the nine months ended September 30, 2025 prepared in accordance with IFRS applicable to interim financial reporting (IAS 34). Our unaudited consolidated interim financial statements were prepared on a basis substantially consistent with our audited consolidated financial statements.

This information should be read together with our consolidated financial statements incorporated by reference into the Base Prospectus, as supplemented.

**(a)** **Selected Consolidated Statements of Income Data**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the nine months ended** | **For the nine months ended** | **For the fiscal year ended** | **For the fiscal year ended** |
| **In € millions, except per** | **September 30,** | **September 30,** | **December 31,** | **December 31,** |
| **share amounts** | **2025** | **2024** | **2024** | **2023** |
|  | **(unaudited)** | **(unaudited)** | **(audited)** | **(audited)** |
| Revenue | 14558 | 14251 | 19336 | 19454 |
| Operating income | 1233 | 1133 | 1392 | 1369 |
| Net income attributable to shareholders of the Issuer | 651 | 471 | 538 | 499 |
| Basic earnings per share | 2.22 | 1.61 | 1.83 | 1.70 |
| Diluted earnings per share | 2.22 | 1.61 | 1.83 | 1.70 |

---

------

**(b)** **Selected Consolidated Balance Sheet Data**

---

| | | | |
|:---|:---|:---|:---|
|  | **As of September 30,** | **As of December 31,** | **As of December 31,** |
|  |  | **2024** | **2023** |
| **In € millions** | **2025** | **(audited, unless** | **(audited, unless** |
|  | **(unaudited)** | **stated otherwise)** | **stated otherwise)** |
| Total assets | 30887 | 33567 | 33930 |
| Total current liabilities | 5759 | 5660 | 6112 |
| Total liabilities | 16979 | 17798 | 19103 |
| Net debt<sup>(1)</sup> | 9218 | 9803 | 10760 |
| Total equity | 13908 | 15769 | 14827 |

---

<sup>(1)</sup> Unaudited. Net debt, a Non-IFRS<sup>®</sup> Measure, is defined as the sum of our debt and lease liabilities less our cash and cash equivalents, including cash and cash equivalents included within assets held for sale. Debt and lease liabilities includes the following balance sheet line items: short-term debt from unrelated parties, current portion of long-term debt, current portion of lease liabilities from unrelated parties, current portion of lease liabilities from related parties, long-term debt, less current portion, lease liabilities from unrelated parties, less current portion and lease liabilities from related parties, less current portion as well as debt and lease liabilities included within liabilities directly associated with assets held for sale, as presented in the consolidated balance sheets of the Issuer's consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2023 and the consolidated balance sheets of the Issuer's unaudited condensed consolidated interim financial statements as of and for the nine months ended September 30, 2025.

**(c)** **Selected Consolidated Statements of Cash Flow Data**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the nine months ended** | **For the nine months ended** | **For the fiscal year ended** | **For the fiscal year ended** |
|  | **September 30,** | **September 30,** | **December 31,** | **December 31,** |
| **In € millions** | **2025** | **2024** | **2024** | **2023** |
|  | **(unaudited)** | **(unaudited)** | **(audited)** | **(audited)** |
| Net cash provided by (used in) operating activities | 1679 | 1554 | 2386 | 2629 |
| Net cash provided by (used in) investing activities | (304) | 34 | (85) | (544) |
| Net cash provided by (used in) financing activities | (1195) | (1604) | (2569) | (1859) |
| Cash and cash equivalents at end of the period<sup>(1)</sup> | 1256 | 1387 | 1185 | 1427 |

---

<sup>(1)</sup> Includes cash and cash equivalents included within assets held for sale.

**B.3** **What are the key risks that are specific to the Issuer?**

The key risks relating to the Issuer and the Group are:

**(a)** **Risks relating to Legal and Regulatory Matters**

● We operate in a highly regulated industry such that the potential for legislative reform provides uncertainty and potential threats to our operating models and results.

● Changes in reimbursement, payor mix and/or governmental regulations for health care could materially decrease our revenues and operating profit.

------

**(b)** **Risks Relating to Internal Control and Compliance**

● We operate in many different jurisdictions and we could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar worldwide anti-corruption laws.

**(c)** **Risks Relating to Our Business Activities and Industry**

● If physicians and other referral sources cease referring patients to our health care service businesses and facilities or cease purchasing or prescribing our products, our revenues would decrease.

● As a company with operations spanning around 150 countries, we face specific risks from our global operations.

**(d)** **Risks Relating to Taxation and Accounting**

● There are significant risks associated with estimating the amount of health care service revenues that we recognize that could impact the timing of our recognition of revenues or have a significant impact on our operating results and financial condition.

● Diverging views of fiscal authorities or changes in tax legislation could require us to make additional tax payments.

**(e)** **Risks Relating to Our Financial Condition and Our Securities**

● Our indebtedness may prevent us from fulfilling our debt-service obligations or implementing certain elements of our business strategy.

● Although Fresenius SE no longer controls the Issuer through ownership of 100% of Fresenius Medical Care Management AG, its significant share of ownership, certain provisions of the Issuer's articles of association and certain provisions of our trademark license from Fresenius SE enable Fresenius SE to retain significant influence over the management of the Issuer.

**Section C**

**KEY INFORMATION ON THE SECURITIES**

**C.1** **What are the main features of the Securities?**

**C.1.1** **Type, class and ISIN**

The Notes are fixed rate notes. They are issued as Series number 10, Tranche number 1, ISIN XS3233499089.

**C.1.2** **Currency, denomination, par value, number of securities issued and duration**

The Notes are issued in euro (***EUR***). The specified denomination per Note is EUR 1,000. The number of Notes is 500,000. The term of the Notes is five years.

**C.1.3** **Rights attached to the Securities**

Each holder of a Note (each a ***Holder***) has the right towards the Issuer to claim payment of interest and nominal when such payments are due in accordance with the terms and conditions of the Notes (the ***Terms and Conditions***). Unless previously redeemed, or purchased and cancelled, each Note will be redeemed at its principal amount on the Maturity Date.

**Negative Pledge:** The Notes contain a limited negative pledge provision.

**Events of Default:** The Notes provide for events of default entitling Holders to demand immediate redemption of the Notes.

**Cross Default:** The Notes provide for cross default provisions.

**Change of Control:** Upon the occurrence of specific change of control events with a ratings decline, the Holders will have the right to require that the Issuer repurchases their Notes at 101% of the principal amount, plus accrued and unpaid interest (if any).

------

**Early Redemption:** The Notes may be called for redemption and redeemed prior to their stated maturity at the option of the Issuer for taxation reasons or within a certain call redemption period. The Notes may also be called for redemption and be redeemed prior to their stated maturity at the option of the Issuer for reason of minimal outstanding principal amount.

**Resolutions of Holders:** In accordance with the German Act on Debt Securities (*Gesetz über Schuldverschreibungen aus Gesamtemissionen,* ***SchVG***), the Notes contain provisions pursuant to which Holders may agree by resolution to amend the Terms and Conditions (with the consent of the Issuer) and to decide upon certain other matters regarding the Notes. Resolutions of Holders properly adopted, either in a meeting of Holders or by vote taken without a meeting in accordance with the Terms and Conditions, are binding upon all Holders. Resolutions providing for material amendments to the Terms and Conditions require a majority of not less than 75 % of the votes cast. Resolutions regarding other amendments are passed by a simple majority of the votes cast.

**Governing Law**: The Notes are governed by German law.

**C.1.4** **Rank of the Securities in the Issuer's capital structure upon insolvency**

The Notes constitute unsecured and unsubordinated obligations of the Issuer ranking *pari passu* among themselves and *pari passu* with all other present or future unsecured and unsubordinated obligations of the Issuer, unless such obligations are accorded priority under mandatory provisions of statutory law.

**C.1.5** **Restrictions on free transferability of the securities**

Not applicable. The Notes are freely transferable.

**C.1.6** **Payout policy (interest)**

The Notes bear interest on their specified denomination from (and including) November 24, 2025 to (but excluding) the Maturity Date at a fixed rate of 3.250 % *per annum*. Interest is payable in arrear on each Interest Payment Date.

***Interest Payment Date*** means November 24 each year with the first Interest Payment Date being November 24, 2026.

***Maturity Date*:** Unless previously redeemed in whole or in part or purchased and cancelled, the Notes shall be redeemed at their principal amount on November 24, 2030, together with interest from the most recent Interest Payment Date to (but excluding) the Maturity Date.

**Yield to final maturity:** The yield to final maturity equals 3.334 % *per annum*.

**C.2** **Where will the Securities be traded?**

Application has been made to list the Notes on the official list of the Luxembourg Stock Exchange and to admit the Notes to trading on the regulated market of the Luxembourg Stock Exchange.

**C.3** **Is there a guarantee attached to the securities?**

There is no guarantee attached to the securities.

**C.4** **What are the key risks that are specific to the Securities?**

**(a)** **Risks Relating to the Nature and Ranking of the Notes**

● The Notes are structurally subordinated to the claims of other creditors within the Group.

● The Notes will be effectively subordinated to secured debt of the Issuer to the extent such debt is secured by assets that are not also securing the Notes.

● The Issuer relies on distributions from its subsidiaries to meet its payment obligations.

● Notes may be denominated in a foreign currency.

**(b)** **Risks related to the Terms and Conditions of the Notes**

● We may not be able to make a change of control redemption upon demand.

● The Issuer may redeem the Notes early.

------

**Section D**

**KEY INFORMATION ON THE OFFER OF SECURITIES TO THE PUBLIC**

**AND THE ADMISSION TO TRADING ON A REGULATED MARKET**

**D.1** **Under which conditions and timetable can I invest in this security?**

Application has been made to list the Notes on the official list of the Luxembourg Stock Exchange and to admit the Notes to trading on the regulated market of the Luxembourg Stock Exchange.

There will be no public offer of the Notes by the Issuer. The consent to the use of the Base Prospectus, as supplemented and the Final Terms for the subsequent resale or final placement of Notes by all financial intermediaries is given by the Issuer in relation to Luxembourg and Germany. The subsequent resale or final placement of Notes by financial intermediaries can be made during the offer period which commences on November 20, 2025 and ends on November 24, 2025.

The estimated total expenses of the issue (excluding commissions of the managers) amount to EUR 65,000. The Issuer will not charge any costs, expenses or taxes directly to any investor in connection with the Notes. Investors must, however, inform themselves about any costs, expenses or taxes in connection with the Notes which are generally applicable in their respective country of residence, including any charges their own depository banks charge them for purchasing or holding securities.

**D.2** **Why has the Base Prospectus been produced?**

**D.2.1** **Reasons for the offer/Use and estimated net amount of proceeds**

The Issuer will use the net proceeds of the issuance for general corporate purposes, including refinancing of outstanding indebtedness.

The estimated net proceeds from the issue of the Notes amount to EUR 496,470,000.

**D.2.2** **Subscription agreement**

The issue of the Notes is subject to a subscription agreement dated November 20, 2025 on a firm commitment basis.

**D.2.3** **Material conflicts of interest**

So far as the Issuer is aware, no person involved in the offer of the Notes has an interest material to the offer, except that certain Dealers and their affiliates may be customers of, and borrowers from the creditors of the Issuer and its affiliates. In addition, certain of the Dealers and their affiliates have engaged, and may in future engage, in investment banking and/or commercial banking transactions with, and may perform services for, the Issuer or its affiliates in the ordinary course of business.

------

***German Translation of the Summary for the Individual Issue***

**Zusammenfassung für die Einzelemission**

**Section A**

**EINLEITUNG MIT WARNHINWEISEN**

Diese Zusammenfassung bezieht sich auf die Serie EUR 500.000.000 3,250 % Schuldverschreibungen fällig am 24. November 2030 mit der ISIN XS3233499089 (die ***Schuldverschreibungen***), ausgegeben durch die Fresenius Medical Care AG, Else-Kröner-Straße 1, 61352 Bad Homburg vor der Höhe, Deutschland (tel.: +49-6172-609-0; Website: www.freseniusmedicalcare.com; LEI: 549300CP8NY40UP89Q40) (die ***Emittentin*** und, zusammen mit ihren konsolidierten Konzerngesellschaften, die ***Gruppe***, auch als ***wir***, ***uns*** oder ***unser*** bezeichnet) aus dem EUR 10.000.000.000 Anleihemissionsprogramm der Emittentin (das ***Programm***).

Die *Commission de Surveillance du Secteur Financier* (***CSSF***), 283 Route d'Arlon, L-1150 Luxembourg (tel. +352 26 25 1 - 1; Fax: +352 26 25 1 – 2601; E-Mail direction@cssf.lu) hat den Basisprospekt für das Programm (der ***Basisprospekt***) als zuständige Behörde nach der Verordnung (EU) 2017/1129 am 26. März 2025 und den ersten Nachtrag zum Basisprospekt am 7. November 2025 gebilligt.

*Diese Zusammenfassung wurde in Übereinstimmung mit Artikel 7 der Verordnung (EU) 2017/1129 erstellt und sollte als Einleitung zu dem Basisprospekt, ergänzt durch den Nachtrag, sowie den jeweiligen Endgültigen Bedingungen verstanden werden. Der Anleger sollte sich bei jeder Entscheidung, in die Schuldverschreibungen zu investieren, auf den Basisprospekt, ergänzt durch den Nachtrag, als Ganzes, einschließlich aller durch Verweis darin aufgenommenen Dokumente, und die maßgeblichen Endgültigen Bedingungen stützen. Ein Anleger könnte gegebenenfalls das gesamte angelegte Kapital oder einen Teil davon verlieren. Für den Fall, dass vor einem Gericht Ansprüche aufgrund der in dem Basisprospekt, ergänzt durch den Nachtrag, oder den maßgeblichen Endgültigen Bedingungen enthaltenen Informationen geltend gemacht werden, könnte der als Kläger auftretende Anleger nach nationalem Recht die Kosten für die Übersetzung dieses Basisprospekts, ergänzt durch den Nachtrag, und der jeweiligen Endgültigen Bedingungen vor Prozessbeginn zu tragen haben. Zivilrechtlich haften nur diejenigen Personen, die die Zusammenfassung samt etwaiger Übersetzungen vorgelegt und übermittelt haben, und dies auch nur für den Fall, dass die Zusammenfassung, wenn sie zusammen mit dem Basisprospekt, ergänzt durch den Nachtrag, und den jeweiligen Endgültigen Bedingungen gelesen wird, irreführend, unrichtig oder widersprüchlich ist oder dass sie, wenn sie zusammen mit dem Basisprospekt, ergänzt durch den Nachtrag, und den jeweiligen Endgültigen Bedingungen gelesen wird, nicht die Basisinformationen vermittelt, die in Bezug auf Anlagen in die Schuldverschreibungen für die Anleger eine Entscheidungshilfe darstellen würden.*

**Section B**

**BASISINFORMATIONEN ÜBER DIE EMITTENTIN**

**B.1** **Wer ist die Emittentin der Wertpapiere?**

**B.1.1** **Sitz und Rechtsform der Emittentin, ihre LEI, für sie geltendes Recht und Land der Eintragung**

Die Emittentin ist eine nach deutschem Recht errichtete und deutschem Recht unterliegende Aktiengesellschaft (AG) mit satzungsmäßigem Sitz in Hof (Saale), Deutschland. Die LEI der Emittentin lautet 549300CP8NY40UP89Q40.

**B.1.2** **Haupttätigkeiten**

Die Haupttätigkeit der Emittentin besteht darin, als Holdinggesellschaft für ihre Tochtergesellschaften zu fungieren. Die Gruppe erbringt Dialysedienstleistungen und damit verbundene Dienstleistungen für Personen mit Nierenerkrankungen, sowie andere Gesundheitsdienstleistungen. Die Tätigkeiten der Gruppe umfassen zudem die Entwicklung, Herstellung und den Vertrieb einer Vielzahl von medizinischen Produkten.

**B.1.3** **Hauptanteilseigner**

Zum 30. September 2025 bestand das Grundkapital der Emittentin aus 293.413.449 ausgegebenen Inhaberaktien von denen 289.848.926 Aktien ausstehend sind. Zum 30. September 2025 werden

------

3.564.523 Aktien als eigene Aktien gehalten. Die Fresenius SE & Co. KGaA (***Fresenius SE***) hielt zum 7. November 2025 rund 28,55 % der Aktien der Emittentin. Die Else Kröner-Fresenius-Stiftung ist alleinige Aktionärin der Fresenius Management SE, der persönlich haftenden Gesellschafterin der Fresenius SE, und hat das alleinige Recht, den Aufsichtsrat der Fresenius Management SE zu wählen. Darüber hinaus hielt die Else Kröner-Fresenius Stiftung zum 30. September 2025 rund 27 % des Aktienkapitals der Fresenius SE.

Gemäß den Stimmrechtsmitteilungen, die die Emittentin gemäß dem Wertpapierhandelsgesetz bis zum 7. November 2025 erhalten hat, halten die folgenden Aktionäre unmittelbar oder mittelbar mehr als 3% der Aktien der Emittentin und (sofern zutreffend) Finanzinstrumente, die sich auf die Aktien der Emittentin beziehen:

---

| | |
|:---|:---|
| **Aktionär** | **Stimmrechtsanteil (in %)** |
| Else Kröner-Fresenius-Stiftung | 2855 |
| Richard Pzena | 520 |
| Dodge & Cox, San Francisco, Kalifornien, Vereinigte Staaten | 503 |
| Dodge & Cox International Stock Fund, San Francisco, Kalifornien, Vereinigte Staaten | 498 |
| BlackRock, Inc., Wilmington, Delaware, Vereinigte Staaten | 4995 |

---

**B.1.4** **Identität der Hauptgeschäftsführer**

Der Vorstand der Emittentin leitet die Emittentin und führt deren Geschäfte. Der Vorstand besteht derzeit aus Helen Giza, Craig Cordola, Ed.D., Martin Fischer, Dr. Jörg Häring, Franklin W. Maddux und Dr. Katarzyna Mazur-Hofsäß. Am 1. Oktober 2025 gab die Emittentin die Ernennung von Joseph E. (Joe) Turk zum Mitglied des Vorstands mit Wirkung zum 1. Januar 2026 bekannt, der damit die Nachfolge von Dr. Katarzyna Mazur-Hofsäß antritt.

**B.1.5** **Identität des Abschlussprüfers**

Die PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft, Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt am Main, Deutschland (***PwC***), ein Mitglied der Wirtschaftsprüferkammer, Berlin, Deutschland, wurde für die zum 31. Dezember 2024 und 2023 endenden Geschäftsjahre zur Abschlussprüferin der Emittentin bestellt.

**B.2** **Welches sind die wesentlichen Finanzinformationen über die Emittentin?**

Die folgenden ausgewählten konsolidierten Finanzinformationen für die zum 31. Dezember 2024 und 2023 endenden Geschäftsjahre und die zum 30. September 2025 und 2024 endenden Neun-Monatszeiträume, wurden aus unseren Konzernabschlüssen, die nach den International Financial Reporting Standards (***IFRS***<sup>®</sup>) Accounting Standards, wie sie von der Europäischen Union anerkannt werden, aufgestellt sind, entnommen oder daraus abgeleitet. PwC hat die Konzernabschlüsse für die zum 31. Dezember endenden Geschäftsjahre 2024 und 2023 geprüft und diese mit uneingeschränkten Bestätigungsvermerken versehen. Die ausgewählten konsolidierten Finanzinformationen zum und für die neun Monate bis zum 30. September 2025 und 2024 wurden unseren ungeprüften konsolidierten Zwischenabschlüssen zum und für die neun Monate bis zum 30. September 2025 entnommen oder daraus abgeleitet, die gemäß den für die Zwischenberichterstattung geltenden IFRS (IAS 34) erstellt wurden. Unsere ungeprüften konsolidierten Zwischenabschlüsse wurden im Wesentlichen auf der Grundlage unserer geprüften konsolidierten Abschlüsse erstellt.

Diese Informationen sollten zusammen mit unseren Konzernabschlüssen gelesen werden, die mittels Verweis in den Basisprospekt, *ergänzt durch den Nachtrag,* aufgenommen wurden.

**(a)** **Ausgewählte Zahlen aus der Konzern-Gewinn- und Verlustrechnung**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Für den neun-Monatszeitraum** | **Für den neun-Monatszeitraum** | **Für das Geschäftsjahr** | **Für das Geschäftsjahr** |
| **In Mio. €, mit Ausnahme** | **endend zum 30. September** | **endend zum 30. September** | **endend zum 31. Dezember** | **endend zum 31. Dezember** |
| **Beträge je Aktie** | **2025** | **2024** | **2024** | **2023** |
|  | **(ungeprüft)** | **(ungeprüft)** | **(geprüft)** | **(geprüft)** |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| Umsatzerlöse | 14.558 | 14.251 | 19.336 | 19.454 |
| Operatives Ergebnis | 1.233 | 1.133 | 1.392 | 1.369 |
| Konzernergebnis (Ergebnis, das auf die Anteilseigner der Emittentin entfällt) | 651 | 471 | 538 | 499 |
| Ergebnis je Aktie (unverwässert) | 222 | 161 | 183 | 170 |
| Ergebnis je Aktie (verwässert) | 222 | 161 | 183 | 170 |

---

**(b)** **Ausgewählte Zahlen aus der Konzern-Bilanz**

---

| | | | |
|:---|:---|:---|:---|
|  | **Zum 30. September** | **Zum 31. Dezember** | **Zum 31. Dezember** |
|  |  | **2024** | **2023** |
|  |  | **(geprüft, soweit** | **(geprüft, soweit** |
| **In Mio. €** | **2025** | **nicht anders** | **nicht anders** |
|  | **(ungeprüft)** | **angegeben)** | **angegeben)** |
| Summe Vermögenswerte | 30.887 | 33.567 | 33.930 |
| Summe kurzfristige Verbindlichkeiten | 5.759 | 5.660 | 6.112 |
| Summe Verbindlichkeiten | 16.979 | 17.798 | 19.103 |
| Nettofinanzverbindlichkeiten<sup>(1)</sup> | 9.218 | 9.803 | 10.760 |
| Summe Eigenkapital | 13.908 | 15.769 | 14.827 |

---

<sup>(1)</sup> Ungeprüft. Nettofinanzverbindlichkeiten, eine Non-IFRS<sup>®</sup>-Kennzahl, ist definiert als die Summe unserer Finanzverbindlichkeiten und Verbindlichkeiten aus Leasingverhältnissen abzüglich unserer flüssigen Mittel, einschließlich flüssiger Mittel, die in den zur Veräußerung gehaltenen Vermögenswerten enthalten sind. Finanzverbindlichkeiten und Verbindlichkeiten aus Leasingverhältnissen umfassen die folgenden Bilanzpositionen: Kurzfristige Finanzverbindlichkeiten gegenüber konzernfremden Dritten, kurzfristig fälliger Anteil der langfristigen Finanzverbindlichkeiten, kurzfristig fälliger Anteil der Verbindlichkeiten aus Leasingverhältnissen gegenüber konzernfremden Dritten, kurzfristig fälliger Anteil der Verbindlichkeiten aus Leasingverhältnissen gegenüber nahestehenden Unternehmen, langfristige Finanzverbindlichkeiten abzüglich des kurzfristig fälligen Anteils, Verbindlichkeiten aus Leasingverhältnissen gegenüber konzernfremden Dritten abzüglich des kurzfristig fälligen Anteils und Verbindlichkeiten aus Leasingverhältnissen gegenüber nahestehenden Unternehmen abzüglich des kurzfristigen Anteils sowie Finanzverbindlichkeiten und Verbindlichkeiten aus Leasingverhältnissen, die in den Verbindlichkeiten in direktem Zusammenhang mit zur Veräußerung gehaltenen Vermögenswerten enthalten sind, wie sie in der Konzernbilanz der Konzernabschlüsse der Emittentin für die zum 31. Dezember 2024 und 2023 endenden Geschäftsjahre und in den ungeprüften konsolidierten Zwischenabschlüssen für die zum 30. September 2025 endenden neun Monate dargestellt sind.

**(c)** **Ausgewählte Zahlen aus der Konzern-Kapitalflussrechnung**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Für den neun-Monatszeitraum** | **Für den neun-Monatszeitraum** | **Für das Geschäftsjahr** | **Für das Geschäftsjahr** |
|  | **endend zum 30. September** | **endend zum 30. September** | **endend zum 31. Dezember** | **endend zum 31. Dezember** |
| **In Mio. €** | **2025** | **2024** | **2024** | **2023** |
|  | **(ungeprüft)** | **(ungeprüft)** | **(geprüft)** | **(geprüft)** |
| **Cash Flow aus betrieblicher Geschäftstätigkeit** | 1.679 | 1.554 | 2.386 | 2.629 |

---

------

Cash Flow aus Investitionstätigkeit (304) 34 (85) (544) <br> Cash Flow aus Finanzierungstätigkeit (1.195) (1.604) (2.569) (1.859) <br> <u>Flüssige Mittel am Ende des Zeitraums<sup>(1)</sup></u> <u>1.256</u> <u>1.387</u> <u>1.185</u> <u>1.427</u>

<sup>(1)</sup> Beinhaltet Zahlungsmittel und Zahlungsmitteläquivalente, die in den zur Veräußerung gehaltenen Vermögenswerten enthalten sind.

**B.3** **Welches sind die zentralen Risiken, die für die Emittentin spezifisch sind?**

Die wichtigsten Risiken in Bezug auf die Emittentin und die Gruppe sind:

**(a)** **Risiken im Zusammenhang mit rechtlichen und regulatorischen Themen**

● Wir sind in einer stark regulierten Industrie tätig, sodass mögliche Reformen der Gesetzgebung einen Unsicherheitsfaktor und eine Gefahr für unser Geschäftsmodell und unsere Betriebsergebnisse darstellen könnten.

● Änderungen im Vergütungssystem, der Zusammensetzung der Kostenträger und/oder der gesetzlichen Vorschriften des Gesundheitswesens könnten zu einem erheblichen Rückgang unserer Umsatzerlöse und unseres operativen Gewinns führen.

**(b)** **Risiken in Bezug auf interne Kontrolle und Unternehmensführung**

● Wir sind in vielen verschiedenen Rechtsordnungen tätig und wir könnten durch eine Verletzung des U.S. Foreign Corrupt Practices Act und weltweit vergleichbarer anderer Anti-Korruptions-Gesetze beeinträchtigt werden.

**(c)** **Risiken in Bezug auf unsere Geschäftstätigkeiten und unsere Branche**

● Sollten Ärzte und andere Dienstleister keine Patienten mehr an unsere Gesundheitsdienstleistungseinrichtungen oder Kliniken überweisen oder unsere Erzeugnisse nicht mehr erwerben oder verschreiben, würde dies einen Rückgang unserer Umsatzerlöse zur Folge haben.

● Als ein Unternehmen, das in rund 150 Ländern tätig ist, sind wir aufgrund unserer globalen Aktivitäten mit spezifischen Risiken konfrontiert.

**(d)** **Risiken in Bezug auf Steuern und Rechnungslegung**

● Es bestehen erhebliche Risiken im Zusammenhang mit der Schätzung der Höhe der von uns erfassten Umsatzerlöse aus Gesundheitsdienstleistungen, die sich auf den Zeitpunkt der Umsatzrealisierung auswirken oder einen wesentlichen Einfluss auf unsere Ertrags- und Finanzlage haben könnten.

● Abweichende Ansichten der Finanzbehörden oder Änderungen im Steuerrecht könnten zu zusätzlichen Steuerzahlungen führen.

**(e)** **Risiken in Bezug auf unsere Finanzlage und Unternehmensstruktur**

● Unsere Verschuldung könnte uns daran hindern, unseren Schuldendienstverpflichtungen nachzukommen oder bestimmte Elemente unserer Geschäftsstrategie umzusetzen.

● Obwohl die Fresenius SE die Emittentin nicht mehr durch den 100%-igen Anteilsbesitz an der Fresenius Medical Care Management AG kontrolliert,

------

ermöglichen ihr bedeutender Anteil an der Emittentin, bestimmte Bestimmungen der Satzung der Emittentin und bestimmte Bestimmungen unserer Markenlizenz von der Fresenius SE der Fresenius SE, einen wesentlichen Einfluss auf die Geschäftsführung der Emittentin zu behalten.

**Section C**

**BASISINFORMATIONEN ÜBER DIE WERTPAPIERE**

**C.1** **Welches sind die wichtigsten Merkmale der Wertpapiere?**

**C.1.1** **Art, Gattung und ISIN**

Die Schuldverschreibungen sind fest verzinsliche Schuldverschreibungen. Sie werden unter der Seriennummer 10, Tranchennummer 1, ISIN XS3233499089 ausgegeben.

**C.1.2** **Währung, Stückelung, Nennwert, Anzahl der begebenen Wertpapiere und Laufzeit**

Die Schuldverschreibungen sind in Euro (***EUR***) begeben. Die festgelegte Stückelung je Schuldverschreibung ist EUR 1.000. Die Anzahl der Schuldverschreibungen beträgt 500.000. Die Laufzeit der Schuldverschreibungen beträgt fünf Jahre.

**C.1.3** **Mit den Wertpapieren verbundene Rechte**

Jeder Inhaber von Schuldverschreibungen (jeweils ein ***Gläubiger***) hat aus ihnen das Recht, Zahlungen von Zinsen und Kapital von der Emittentin zu verlangen, wenn diese Zahlungen gemäß den Emissionsbedingungen der Schuldverschreibungen (die ***Emissionsbedingungen***) fällig sind. Soweit nicht zuvor bereits zurückgezahlt oder angekauft und entwertet, wird jede Schuldverschreibung am Fälligkeitstag zum Nennbetrag zurückgezahlt.

**Negativverpflichtung:** Die Schuldverschreibungen enthalten eine eingeschränkte Negativverpflichtung.

**Kündigungsgründe:** Die Schuldverschreibungen sehen Kündigungsgründe vor, die die Gläubiger berechtigen, die unverzügliche Rückzahlung der Schuldverschreibungen zu verlangen.

**Cross-Default:** Die Schuldverschreibungen enthalten eine Cross-Default-Bestimmung.

**Kontrollwechsel:** Bei Eintritt bestimmter Kontrollwechselereignisse, die mit einer Ratingherabstufung eintreten, sind die Gläubiger berechtigt, von der Emittentin den Rückkauf ihrer Schuldverschreibungen zu 101 % des Nennbetrags zuzüglich etwaiger aufgelaufener und noch nicht gezahlter Zinsen zu verlangen.

**Vorzeitige Rückzahlung:** Die Schuldverschreibungen können vor Ablauf ihrer festgelegten Laufzeit nach Wahl der Emittentin aus steuerlichen Gründen oder innerhalb eines bestimmten Wahl-Rückzahlungszeitraums gekündigt und vorzeitig zurückgezahlt werden. Die Schuldverschreibungen können ferner nach Wahl der Emittentin bei geringfügigem ausstehendem Nennbetrag gekündigt und vorzeitig zurückgezahlt werden.

**Beschlüsse der Gläubiger**: In Übereinstimmung mit dem Gesetz über Schuldverschreibungen aus Gesamtemissionen (***SchVG***) enthalten die Schuldverschreibungen Bestimmungen, nach denen die Gläubiger der Schuldverschreibungen (mit Zustimmung der Emittentin) eine Änderung der Emissionsbedingungen oder sonstige Maßnahmen im Hinblick auf die Schuldverschreibungen beschließen können. Ordnungsgemäß – entweder in einer Gläubigerversammlung oder im Wege einer Abstimmung ohne Versammlung gemäß den Emissionsbedingungen – gefasste Beschlüsse der Gläubiger sind für alle Gläubiger verbindlich. Beschlüsse, welche Änderungen wesentlicher Inhalte der Emissionsbedingungen vorsehen, bedürfen einer Mehrheit von mindestens 75 % der teilnehmenden Stimmrechte. Beschlüsse, welche andere Änderungen vorsehen, werden mit einfacher Mehrheit der teilnehmenden Stimmrechte gefasst.

**Anwendbares Recht**: Die Schuldverschreibungen unterliegen deutschem Recht.

**C.1.4** **Rang der Wertpapiere in der Kapitalstruktur der Emittentin im Fall einer Insolvenz**

Die Schuldverschreibungen begründen nicht besicherte und nicht nachrangige Verbindlichkeiten der Emittentin, die untereinander und mit allen anderen gegenwärtigen und künftigen nicht besicherten und

------

nicht nachrangigen Verbindlichkeiten der Emittentin gleichrangig sind, soweit diesen Verbindlichkeiten nicht durch zwingende Bestimmungen ein Vorrang eingeräumt wird.

**C.1.5** **Beschränkungen der freien Handelbarkeit der Wertpapiere**

Entfällt. Die Handelbarkeit der Schuldverschreibungen ist nicht beschränkt.

**C.1.6** **Angaben zur Ausschüttungspolitik (Verzinsung)**

Die Schuldverschreibungen werden bezogen auf ihre festgelegte Stückelung vom 24. November 2025 (einschließlich) bis zum Fälligkeitstag (ausschließlich) zu einem festen Zinssatz von jährlich 3,250 % verzinst. Die Zinsen sind nachträglich an jedem Zinszahlungstag zahlbar.

***Zinszahlungstag*** bezeichnet den 24. November eines jeden Jahres; der erste Zinszahlungstag ist der 24. November 2026.

**Fälligkeitstag:** Soweit nicht zuvor bereits ganz oder teilweise zurückgezahlt oder angekauft und entwertet, werden die Schuldverschreibungen am 24. November 2030 zu ihrem Nennbetrag zusammen mit den Zinsen ab dem letzten Zinszahlungstag bis zum (aber nicht einschließlich) Fälligkeitstag zurückgezahlt.

**Rendite bei Endfälligkeit:** Die Rendite bei Endfälligkeit entspricht 3,334 % *per annum*.

**C.2** **Wo werden die Wertpapiere gehandelt?**

Für die Schuldverschreibungen ist ein Antrag auf Notierung in der Official List der Börse Luxemburg und Zulassung zum Börsenhandel am regulierten Markt der Börse Luxemburg gestellt worden.

**C.3** **Wird für die Wertpapiere eine Garantie gestellt?**

Für die Wertpapiere wird keine Garantie gestellt.

**C.4** **Welches sind die zentralen Risiken, die für die Wertpapiere spezifisch sind?**

**(a)** **Risiken in Bezug auf die Beschaffenheit und den Rang der Schuldverschreibungen**

● Die Schuldverschreibungen sind strukturell nachrangig gegenüber den Forderungen anderer Gläubiger innerhalb der Gruppe.

● Die Schuldverschreibungen sind besicherten Verbindlichkeiten der Emittentin und insoweit nachrangig, als diese Verbindlichkeiten durch Vermögenswerte besichert sind, die nicht auch die Schuldverschreibungen besichern.

● Die Emittentin ist auf Ausschüttungen ihrer Tochtergesellschaften angewiesen, um ihren Zahlungsverpflichtungen nachzukommen.

● Die Schuldverschreibungen können auf eine Fremdwährung lauten.

**(b)** **Risiken im Hinblick auf die Anleihebedingungen der Schuldverschreibungen**

● Es kann sein, dass wir bei Eintritt eines Kontrollwechselereignis nicht in der Lage sind, die geforderte vorzeitige Rückzahlung zu leisten.

● Die Emittentin könnte die Schuldverschreibungen vorzeitig kündigen.

------

**Section D**

**BASISINFORMATIONEN ÜBER DAS ÖFFENTLICHE ANGEBOT VON WERTPAPIEREN UND/ODER DIE ZULASSUNG ZUM HANDEL AN EINEM GEREGELTEN MARKT**

**D.1** **Zu welchen Konditionen und nach welchem Zeitplan kann ich in dieses Wertpapier investieren?**

Für die Schuldverschreibungen ist ein Antrag auf Notierung in der *Official List* der Börse Luxemburg und Zulassung zum Börsenhandel am regulierten Markt der Börse Luxemburg gestellt worden.

Die Schuldverschreibungen werden durch die Emittentin nicht öffentlich angeboten. Die Zustimmung zu der Verwendung des Basisprospekts*, ergänzt durch den Nachtrag,* und der Endgültigen Bedingungen zu der späteren Weiterveräußerung und der endgültigen Platzierung der Schuldverschreibungen durch alle Finanzintermediäre wird von der Emittentin in Bezug auf Luxemburg und Deutschland erteilt. Die spätere Weiterveräußerung und endgültige Platzierung der Wertpapiere durch Finanzintermediäre kann während der Angebotsfrist erfolgen, die am 20. November 2025 beginnt und am 24. November 2025 endet.

Die geschätzten Gesamtkosten der Emission (ausschließlich Provisionen der Manager) betragen EUR 65.000. Die Emittentin wird den Anlegern im Zusammenhang mit den Schuldverschreibungen keine Kosten, Auslagen oder Steuern direkt in Rechnung stellen. Anleger müssen sich jedoch über Kosten, Auslagen oder Steuern im Zusammenhang mit den Schuldverschreibungen, die in ihrem jeweiligen Wohnsitzland allgemein anfallen, einschließlich etwaiger Gebühren, die ihnen ihre eigene Depotbank für den Kauf oder das Halten von Wertpapieren berechnet, selbst informieren.

**D.2** **Weshalb wurde dieser Basisprospekt erstellt?**

**D.2.1** **Zweckbestimmung der Erlöse und geschätzte Nettoerlöse**

Die Emittentin wird die Nettoerlöse der Emission für allgemeine Geschäftszwecke, einschließlich der Refinanzierung ausstehender Schulden, verwenden.

Die geschätzten Nettoerlöse der Emission der Schuldverschreibungen betragen EUR 496.470.000.

**D.2.2** **Übernahmevertrag**

Die Emission der Schuldverschreibungen ist Gegenstand eines Übernahmevertrages mit fester Übernahmeverpflichtung vom 20. November 2025.

**D.2.3** **Wesentliche Interessenkonflikte**

Nach Kenntnis der Emittentin bestehen bei den an der Emission beteiligten Personen keine Interessen, die für das Angebot bedeutsam sind, außer, dass bestimmte Platzeure und mit ihnen verbundene Unternehmen Kunden von, Kreditnehmer der oder Kreditgeber der Emittentin und mit ihr verbundener Unternehmen sein können. Außerdem sind bestimmte Platzeure an Investment Banking Transaktionen und/oder Commercial Banking Transaktionen mit der Emittentin oder mit ihr verbundenen Unternehmen beteiligt oder könnten sich in Zukunft daran beteiligen.

------

## Exhibit 4.4

**Exhibit 4.4**

EXECUTION VERSION

------

LONG FORM OF AMENDMENT

TO THE TRADEMARK LICENSE AGREEMENT

DATED 27 SEPTEMBER 1996 by

and between

Fresenius SE & Co. KGaA and

Fresenius Medical Care Deutschland GmbH

------

LONG FORM OF AMENDMENT TO THE TRADEMARK LICENSE AGREEMENT

DATED 27 SEPTEMBER 1996 by and between

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Fresenius SE & Co. KGaA, a German partnership limited by shares (Kommanditgesellschaft auf Aktien), organized under the laws of the Federal Republic of Germany, registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Bad Homburg vor der Höhe, Germany, under registration number HRB 11852 and having its registered office in Bad Homburg vor der Höhe, Germany

-"FSE"-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Fresenius Medical Care Deutschland GmbH, a German limited liability company (Gesellschaft mit beschränkter Haftung), organized under the laws of the Federal Republic of Germany, registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Bad Homburg vor der Höhe, Germany, under registration number HRB 5748 and having its registered office in Bad Homburg vor der Höhe, Germany

-"FME" –

– jointly, as "Parties" and each a "Party" –

PREAMBLE

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) FME Group deconsolidated from FSE Group by changing the legal form of Fresenius Medical Care AG ("FME AG"), of which FME is a 100% subsidiary, from a partnership limited by shares (Kommanditgesellschaft auf Aktien) to the legal form of a stock corporation (Aktiengesellschaft) under German law while preserving FME AG's legal identity (identitätswahrender Formwechsel) pursuant to sections 190 et seqq., 238 et seqq. of the German Transformation Act (Umwandlungsgesetz) (the "Conversion").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) As a result of the Conversion that became effective on 30 November 2023, (i) FME Group has become deconsolidated from FSE and no longer forms part of a de facto group (faktischer Konzern) with FSE and (ii) FSE no longer controls FME AG within the meaning of sections 17, 18 para. 1 German Stock Corporation Act (Aktiengesetz). With the Conversion Effective Date, FSE Group and FME Group became two independent groups.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) In connection with the Conversion, the FSE and FME AG entered, among others, into a certain group separation agreement dated 30 November 2023 (the "Group Separation Agreement").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D) FSE as licensor and FME as licensee are parties to a trademark license agreement dated 27 September 1996 concluded between FSE (with its legal form as stock corporation at that time under Fresenius AG) and FME with effective date of 30 September 1996 governing the use of certain trademarks, in particular the trademark/name "Fresenius", by FME and its Affiliates (the "Original Trademark License Agreement"), which was amended by an agreement concluded between FSE and FME effective as of 1 January 2016 relating to the definition of "Fresenius Mark" and "Renal Business" and the tradename approvals granted by FSE and FME (but referred to in the approvals as "Fresenius Medical Care AG"), relating to the tradename "Fresenius USA, Inc." (dated 1 October 1996) and the tradename "Fresenius Canada Dialysis, Inc." (dated 30 July 1997).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E) The Conversion does not affect the validity of the Original Trademark License Agreement as amended by the aforementioned agreements/ approvals, but it was amended by Schedule 3 of

------

the Group Separation Agreement. FSE and FME AG agreed to implement such changes in a long form agreement by way of this Agreement, which particularly includes the addition and amendment of certain clauses to reflect the new relationship of FSE Group and FME Group, inter alia, with respect to the establishment of a Branding Committee and the implementation of Branding Guidelines as well as the resolution of disputes which FSE and FME wish to exclusively settle in the future before the economic board ("Wirtschaftsrat") of the Else Kröner-Fresenius-Stiftung in accordance with the TLA Arbitration Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F) The negotiations of this Agreement also revealed a need to clarify in writing the scope of the license granted to FME and its Affiliates under the Original Trademark License Agreement, with respect to the use of the Fresenius Mark, the "F" Logo and the Mixed Use Marks, to align with the mutual business understanding. The Parties therefore wish to legalize the past as practiced between the Parties and their Affiliates since the conclusion of the Original Trademark License Agreement and, at the same time, specify the future use of the Licensed Marks and the "Fresenius" name as of the signing date of this Agreement (the "Effective Date"). The Parties therefore agreed to further amend the Original Trademark License Agreement as amended by, inter alia, Schedule 3 of the Group Separation Agreement by way of this Agreement (such amended and current version hereinafter referred to as the "Trademark License Agreement").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G) FME AG must procure that FME, as an Affiliate of FME AG, complies with the terms of the Trademark License Agreement and that FME will formalize the amendment of the Trademark License Agreement (section 2.5.2 Group Separation Agreement).

Now, therefore, the Parties agree as follows:

Section 1

Branding Committee

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 The Parties shall establish a committee ("Branding Committee") which shall, inter alia:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Draft, issue and administrate independent guidelines that specify the standards and details for the form of use of the Licensed Marks and the "Fresenius" name by FME and FSE as well as their Affiliates (as amended or modified from time to time, the current draft version, reflecting the permissible form of use as of the Effective Date, is attached hereto as Exhibit I "Branding Guidelines"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Monitor the use of the Licensed Marks and the "Fresenius" name by FSE, FME and their Affiliates. In particular, the Branding Committee shall monitor the compliance of FME and its Affiliates with the Trademark License Agreement and evaluate the status at least once every six (6) months.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 The Branding Committee shall consist of four (4) members in total whereas two (2) shall be appointed by each of FSE and FME and:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Members shall be well experienced in corporate communication and/or trademark law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) FSE shall appoint one of the FSE members to be the chair of the Branding Committee.

In line with Schedule 3 of the Group Separation Agreement, FSE and FME have appointed their respective Branding Committee members and provided to the other Party the names, positions and contact details of the Branding Committee members appointed. If the Parties

------

change any of their Branding Committee members which they may do at their discretion, such change, including the aforementioned details, shall be notified to the other Party within one (1) week following the change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 Each Party may request a meeting of the Branding Committee in accordance with Section 1.4. Other than so requested, and unless otherwise agreed:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Branding Committee shall meet at least once every three (3) months during the calendar year 2026; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) afterwards at least once every half calendar year.

In each regular Branding Committee meeting, the date for the next regular meeting shall be set.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 Except for the regular meetings of the Branding Committee that have been set in a previous Branding Committee meeting, the meetings of the Branding Committee shall be called with a notice period of fourteen (14) calendar days. The meetings may be called in text form or by electronic means of communication (e.g., by e-mail). In urgent cases, the period pursuant to sentence 1 may be adequately shortened and the meeting may also be called orally or by telephone. The reason for such shortening of the period shall be explained in the meeting at the latest. Unless a Party has requested a meeting, the chair of the Branding Committee shall call the meetings. The items on the agenda for all meetings must be stated in the invitation to the meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 Unless otherwise agreed, meetings shall take place in person at the registered office of FME or FSE. The chair conducts the meetings and determines the order of the items to be discussed and the voting procedure. In exceptional cases, individual members may participate in meetings held by personal attendance by means of video and audio transmission or telephone. In principle, resolutions are adopted in meetings. If members are prevented from attending a meeting, they may authorize another member in writing (including by electronic means of communication, e.g., by e-mail) to submit their votes. Such delivery of votes shall be deemed to be participation in the adoption of the resolution. In individual cases, resolutions may be passed outside of meetings by circular resolution in writing or by electronic means of communication (e.g., by e-mail) upon order of the chair. The chair shall arrange for such a resolution to be taken within a reasonable period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 The Branding Committee shall only constitute a quorum if all of its four (4) members take part in the adoption of the resolution. The Branding Committee also has a quorum, if a member that is prevented from attending a meeting, has submitted its votes pursuant to Section 1.5.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 The following applies for the decision-making process:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Each member of the Branding Committee has one vote.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) No Branding Committee member, including the chair of the Branding Committee, has a casting vote.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The approval of the Branding Guidelines and any material changes to the Branding Guidelines require the unanimous decision of all four (4) Branding Committee members. All other matters within the Branding Committee's responsibility can be decided with the majority of the votes of the Branding Committee members.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 Decisions of the Branding Committee made according to Sections 1.3, 1.4, 1.5, 1.6 and 1.7 shall be binding for both FSE and FME. In case the Branding Committee cannot reach a decision according to Section 1.7 on the drafting of and/or administrating the Branding Guidelines,

● or

● the monitoring of the use of the Licensed Marks and/or the "Fresenius" name by FME and its Affiliates,

each Party is entitled to request escalation of such matter in accordance with the following escalation process ("Escalation Process"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) In principle, the members of the Branding Committee shall seek to reach a decision in the first place.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) If no decision in accordance with Section 1.7 can be reached by the Branding Committee, the chief executive officers (Vorstandsvorsitzende/r) of FSE's general partner (persönlich haftende/r Gesellschafter/in) Fresenius Management SE and FME's sole shareholder FME AG shall seek in good faith to reach an agreement and issue an unanimous decision within a reasonable period of time not exceeding three (3) months.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) If no agreement can be reached between the chief executive officers (Vorstandsvorsitzende/r) of FSE's general partner (persönlich haftende/r Gesellschafter/in) Fresenius Management SE and FME AG according to Section 1.8 (ii), FSE has the final decision right. This does not apply if the matter relates to the Licensed Mark's and "Fresenius" name's form of use in the Renal Business for which FME shall have the final decision right. Each decision made by FSE or FME respectively according to this Section must be provided in writing to the other Party within one (1) week following its issuance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) If a decision by FME relating to the form of use of the Licensed Marks or the "Fresenius" name in the Renal Business is unacceptable for FSE (e.g., if FSE assesses that FME's decision harms or has a risk to harm the legitimate interest of FSE to protect the reputation of FSE and/or the FSE Group or the value inherent to the Licensed Marks or the "Fresenius" name), FSE may appeal to the economic board (Wirtschaftsrat) of Else Kröner-FreseniusStiftung in accordance with the TLA Arbitration Agreement ("Right of Appeal").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) If the Parties are in dispute about the scope of use of the Licensed Marks and/or the "Fresenius" name or whether a matter relates to the Renal Business and according to Section 1.8 (iii), both Parties have a Right of Appeal within four (4) weeks after the decision was issued according to Section 1.8 (ii).

Any decisions made according to this Escalation Process, including the decisions made pursuant to the TLA Arbitration Agreement, shall have the effect of a decision made by the Branding Committee and shall be binding for FSE and FME.

------

Section 2

Branding Guidelines

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 The Branding Guidelines shall provide general standards for the form of use and further development of the Licensed Marks and the "Fresenius" name, including but not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Further specifying and/or amending their allowed use (colour, style, etc.) set out in Section 3 b) of the Original Trademark License Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) In addition, the Parties agree to discuss, develop with the communication and/or trademark teams of FSE Group and FME Group (if applicable), agreed with the Branding Committee according to Section 1, and include in the Branding Guidelines:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Further standards to specify and/or amend the prohibited use set out in Section 3 a) of the Original Trademark License Agreement, to ensure that the Licensed Marks and the "Fresenius" name may neither directly nor indirectly be used in particular within harmful contexts (politically sensitive circumstances/ politically sensitive countries, discrimination of any form, etc.), for illegal products (drugs, weapons, etc.) or for all kind of fraudulent business models;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Further standards to specify and/or amend the quality requirements and standards set out in Section 4 of the Original Trademark License Agreement, it being understood that such quality requirements shall at no time fall below the quality requirements as existing at the Effective Date; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Concrete common key performance indicators, to allow the Parties to measure, monitor and improve the Licensed Marks' and the "Fresenius" name's performance, based on specified parameters to quantify their overall brand awareness and brand promise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) All consents granted by FSE for the use of the Licensed Marks and/or the "Fresenius" name as used by FME and its Affiliates prior to the Effective Date shall be reflected and not invalidated in the Branding Guidelines.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) For the avoidance of doubt, the Branding Guidelines shall contain more than internal corporate identity provisions of one Party (including its Affiliates). The parts of the Branding Guidelines relating to the use of the Licensed Marks and the "Fresenius" name can include the content of the "Fresenius Medical Care global design manual", provided that it does not form the main content of the Branding Guidelines. With the aforementioned inclusion of the "Fresenius Medical Care global design manual", its content, to the extent included, will be part of the Branding Guidelines. The Branding Committee can designate certain portions of the Branding Guidelines, in particular the sections on guidelines for the FSE or FME logo, that are based on the "Fresenius Medical Care global design manual" or corresponding guidelines of FSE and which may be unilaterally amended from time to time by the respective Party on whose guidelines such portions are based. In all other cases, amendments to such guidelines shall only become part of the Branding Guidelines if so adopted by the Branding Committee. The provisions of the Trademark License Agreement and the parts of the Branding Guidelines that require adoption by the Branding Committee for their amendment shall take

------

precedence over parts of the Branding Guidelines that can be amended by either Party unilaterally.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) They must allow the Branding Committee to fulfil its tasks pursuant to Section 1.1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) The Branding Committee shall determine which terms of the Branding Guidelines qualify as key terms, a violation of which justifies termination pursuant to Section 8.6(iv) of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 The Branding Committee shall issue the initial Branding Guidelines until 31 March 2026 unless unanimously agreed otherwise in the Branding Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 In order to provide legal certainty about the past use and the current status of the use of the Licensed Marks and the "Fresenius" name by FME and FSE including their Affiliates and/or any third-party granted with a license by FME or FSE including their Affiliates until the Effective Date, the Parties agree that, irrespective of the other Party's knowledge, no such use shall be a breach of the Trademark License Agreement. Any future use of the Licensed Marks and the "Fresenius" name after the Effective Date is solely governed by Section 4 of this Agreement.

Section 3

Form of use of Licensed Marks and "Fresenius" name

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 Subject to Section 3.6, FME and its Affiliates may use the Licensed Marks and/or the "Fresenius" name as further specified and set out in the Branding Guidelines.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 To the extent no consent has been granted by FSE (as referred to in Section 2.3), the general rule shall be that FME and its Affiliates may not use the "Fresenius" name on a stand-alone basis without any additions. FME and its Affiliates shall in particular not use the Fresenius Mark and/or the "Fresenius" name as a stand-alone legal company name (Firma). However, the stand-alone use as a company name is permissible in the following cases (hereinafter referred to as "Permissible Business Names"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Any use of and doing business with legal company names existing at the Effective Date can be continued by FME and its Affiliates (including for the avoidance of doubt any newly incorporated Affiliates), within the scope of their existing business operations (as existing at the Effective Date) either (a) with the addition "a Fresenius Medical Care company" (unless and to the extent doing so would not be permissible, in which case the aforementioned addition can be omitted), (b) if the legal company name comprised the Fresenius Mark or the "Fresenius" name and the use and doing business occurs with the addition of at least one of the terms "renal", "kidney", "nephro" or "dialysis" (incl. corresponding translations) like for example the company names "Fresenius Hemo <u>dialysis</u> Center", "Fresenius <u>Nephro</u> Care" and "Fresenius <u>Kidney</u> Care". The same applies for the use of the Fresenius Mark or the "Fresenius" name as a legal company name on (i) business cards, letterheads, and (iii) website imprints, provided that the FME Branding is used in the context of the respective document or website even if not in the immediate vicinity of the legal company name, with further details specified in the Branding Guidelines. The addition "a Fresenius Medical Care company" is not required on regulatory relevant documents such as for example certificates, product labels and product names. The obligations to use the Permissible Business Names as set forth in this Section 3.2 (i) do not

------

include the obligation to amend the respective legal entities' company registrations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) New Affiliates of FME may not use and/or do business with the Fresenius Mark or the "Fresenius" name in any other form than by using the legal company name "Fresenius Medical Care" or with the addition of at least one of the terms "renal", "kidney", "nephro" or "dialysis" (incl. corresponding translations). For the avoidance of doubt, the company name "Fresenius Kidney Care" is covered by this Section and may be used by new Affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 Irrespective of the provisions of Section 3.2 above, FME and its Affiliates may use product marks, service marks and/or business names existing at the Effective Date on a stand-alone basis in communication materials or on products if used in the direct context of FME Branding. For the avoidance of doubt, this Section 3.3 does not apply to the use of the Fresenius Mark and/or the "Fresenius" name by FME and its Affiliates as legal company name, which shall be only permitted according to Section 3.2.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 VFMCRP shall only be entitled to acquire or establish subsidiaries with a legal company name comprising "Fresenius Medical Care" provided that such legal company name also contains the designation "Vifor", preceding the "Fresenius Medical Care" designation. In accordance with Section 3.2 of this Agreement, legal company names of existing subsidiaries can remain unchanged.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 In case of any disagreement or dispute about the rights of and implementation by FME and its Affiliates related to the Permissible Business Names according to this Section 3, both Parties have the Right of Appeal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6 Any form of use deviating from (i) the Branding Guidelines or (ii) the forms of use expressly permitted under this Section 3 of this Agreement is subject to FSE's prior written consent ("Additional Consent"), which shall not be unreasonably withheld or delayed. Withholding Additional Consent is (without limitation) not unreasonable, if the use by FME or its Affiliates would impact the Licensed Marks' or the "Fresenius" name's reputation or value in FSE's good faith assessment (in particular, in case of an intended use in a politically sensitive context or in politically sensitive countries). For the avoidance of doubt, Additional Consent can only be requested for additional forms to use the Licensed Marks and the "Fresenius" name but not to extend or amend the scope of licenses granted under the Trademark License Agreement as such.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7 If reasons that allow withholding the Additional Consent according to Section 3.6 arise at a later stage, FSE may revoke such Additional Consent (in total or in part). FME and/or its Affiliates are then obliged to cease and desist from using the Licensed Marks and/or the "Fresenius" name insofar within a reasonable time period, but in any case, no later than eighteen (18) months following FSE's revocation of the Additional Consent. FME shall and shall procure that any of its Affiliates will use its best efforts to comply with the revocation and adapt the use for which FSE revoked its consent. If due to exceptional or unforeseeable circumstances, FME and/or its Affiliates cannot cease and desist from using the Licensed Marks and/or the "Fresenius" name within eighteen (18) months after FSE has revoked its Additional Consent, FME has a Right of Appeal to request extension of the eighteen (18) months-period, which Right of Appeal must be exercised without undue delay and no later than four (4) weeks prior to the lapse of the eighteen (18) months-period. FME shall confirm the cease and desist in writing to FSE without undue delay after the completion of the cease and desist.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8 FSE shall not, and FSE shall procure that its Affiliates shall not use or license third parties to use the designations "Fresenius Medical Care", "a Fresenius Medical Care company", or one of the terms "renal", "kidney", "nephro" or "dialysis" (incl. corresponding translations) as addition to the Fresenius Mark or the "Fresenius" name or any confusingly similar designations.

Section 4

Amended Licensed Business Scope

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 As of the Effective Date, the scope of the rights of the Parties to use the Licensed Marks and/or the "Fresenius" name in the Worldwide Territory for products and/or services shall be governed by this Section 4, i.e. FME and its Affiliates can use the Licensed Marks and the "Fresenius" name within the scope of the license, and FSE and its Affiliates can use the Licensed Marks and the "Fresenius" name except where exclusivity applies, in each case in the Worldwide Territory. Past use legalized pursuant to Sections 2.3 or 8.2 of this Agreement can be continued, provided that such legalization hereunder for the period after the Effective Date concerns only the form to use the Licensed Marks and/or the "Fresenius" name (as set out in Section 3.6) but not the scope of licenses granted under this Section 4, for which only the amended scope of the license pursuant to this Section 4 applies. For the use of the Licensed Marks and the name "Fresenius" as Permissible Business Names Section 3 applies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 For the sake of clarity and in order to ensure that the license granted to FME and its Affiliates is in line with the mutual business understanding of the Parties for the current and future use of the Licensed Marks and the "Fresenius" name by the Parties and their Affiliates, the Parties acknowledge and agree that Section 2 of the Original Trademark License Agreement shall be replaced entirely by this Section 4.2 as follows and Section 2 of the Original Trademark License Agreement shall no longer apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)Medical Devices and Non-Medical Devices

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Except as otherwise provided in this Agreement and subject to Third Party Rights, FSE hereby grants to FME, for the use by FME and its Affiliates, an exclusive, royalty-free license to use the Licensed Marks and/or the "Fresenius" name in the Worldwide Territory on or in connection with the Bringing to Market and the sale to third parties (including the sale via third-party intermediaries) of Medical Devices with an Intended Use in the field of renal care and of Ancillary Products with no Intended Use in the field of renal care but that are sold to third parties for use in the field of renal care.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Except as otherwise provided in this Agreement and subject to Third Party Rights, FSE hereby grants to FME, for the use by FME and its Affiliates, a non-exclusive, royalty-free license to use the Licensed Marks and the "Fresenius" name in the Worldwide Territory on or in connection with the Bringing to Market and sale to third parties (including the sale via third-party intermediaries) of Medical Devices with an Intended Use for Extra-Corporeal Blood Treatment outside of an Intended Use in the field of renal care and of Ancillary Products with no Intended Use in in the field of renal care but that are sold to third parties for use in Extra-Corporeal Blood Treatment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) The licenses granted to FME with regard to Ancillary Products according to Sec-tions 4.2(i)a) and b) shall apply correspondingly to Non-Medical Devices.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) For the avoidance of doubt, all rights to use the Licensed Marks and the "Frese-nius" name for Medical Devices with an Intended Use other than for renal care, for Extra-Corporeal Blood Treatment or Peritoneal Dialysis, as well as for Ancillary Products or for Non-Medical Devices to be sold to third parties for use outside renal care, Extra-Corporeal Blood Treatment or Peritoneal Dialysis remain exclusively with FSE for the use by FSE and its Affiliates. The exclusive license granted to FME according to Section 4.2(i)a) shall in particular not prevent FSE and its Affiliates from establishing, acquiring or commercializing outside the Renal Business Medical Devices with no Intended Use in the field of renal care and products and services that are not qualified as Medical Devices and which are sold or provided to third parties for use outside the field of renal care but which generally could also be used for the renal care related treatment of patients. As far as FME or FME's Affiliates have sold Ancillary Products to third parties for use outside the field of Extra-Corporeal Blood Treatment or Peritoneal Dialysis prior to the Effective Date, this use may be continued until 31 December 2028. As of 1 January 2029, FME and its Affiliates may use Ancillary Products solely within the scope of Sections 4.2(i)a) und b) of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)Renal Pharmaceuticals

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Except as otherwise provided in this Agreement and subject to Third Party Rights, FSE hereby grants to FME, for the use by FME and its Affiliates, a non-exclusive, royalty-free license to use the Licensed Marks and/or the "Fresenius" name in the Worldwide Territory on or in connection with the Bringing to Market and sale to third parties (including the sale via third-party intermediaries) of Renal Pharmaceuticals and Nutrition Supplements if any Renal Pharmaceuticals are qualified by regulatory authorities as Nutrition Supplements in some jurisdictions. As far as the Renal Pharmaceuticals are included in the Pharmaceutical categories in Exhibit G, the license granted under this Section 4.2(ii)a) is granted exclusively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) The Parties acknowledge and agree that the license granted to FME and its Affil-iates according to Section 4.2(ii)a) of this Agreement shall also cover the right to use the Licensed Marks and/or the "Fresenius" name in the Renal Business for the solution "0.9% Sodium Chloride Injection", a parenteral fluid and electrolyte replenisher although this product has no Medical Indication in the Renal Business and, therefore, is no Renal Pharmaceutical, such use being permissible provided that FME and its Affiliates source the solution "0.9% Sodium Chloride Injection" manufactured by FSE or its Affiliates from FSE or its Affiliates or if this solution is manufactured by FME or its Affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) The exclusivity of the license granted to FME according to Section 4.2(ii)a) of this Agreement with regard to Renal Pharmaceuticals falling into the product groups listed in Exhibit G shall not apply with regard to any products falling into the product group "Phosphate Management Products" listed in Exhibit G which are commercialized in any countries at the Effective Date by FSE or its Affiliates under agreements with VFMCRP. If FSE or its Affiliates and VFMCRP decide to renew such agreements and/or extend their scope to other products of this product group and/or to additional countries, the exclusivity will be further limited accordingly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) For the avoidance of doubt, all rights to use the Licensed Marks and the "Frese-nius" name for Pharmaceuticals and Nutrition Supplements with a Medical Indication other than in the Renal Business remain exclusively with FSE for the use by FSE and its Affiliates.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)Services

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Notwithstanding the licenses granted to FME for the use by FME and its Affiliates according to Sections 4.2(i) and (ii) of this Agreement, FSE hereby grants to FME, for the use by FME and its Affiliates, an exclusive, royalty-free license to use the Licensed Marks and/or the "Fresenius" name in the Worldwide Territory on or in connection with (x) serving of patients ("Patientenversorgung") related to renal care, (y) services related to dialysis design consultancy, (z) services specifically intended for and directed to renal care including but not limited to maintenance and repair, technical support, water treatment system set-up, water treatment documentation and quality control, IT related consultancy, cloud computing, data management, automation of workflow and documentation of patient records, supply chain and logistics, insurance services, clinical application training and support, medical and scientific education.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Notwithstanding the licenses granted to FME for the use by FME and its Affiliates according to Sections 4.2 (i) and (ii) of this Agreement, FSE hereby grants to FME, for the use by FME and its Affiliates, an non-exclusive, royalty-free license to use the Licensed Marks and/or the "Fresenius" name in the Worldwide Territory on or in connection with (x) serving of patients ("Patientenversorgung") related to Extra-Corporal Blood Treatment, (y) services related to Extra-Corporal Blood Treatment design consultancy, and (z) services specifically intended for and directed to Extra-Corporal Blood Treatment including but not limited to maintenance and repair, technical support, IT related consultancy, cloud computing, data management, automation of workflow and documentation of patient records, supply chain and logistics, clinical application training and support, medical and scientific education.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) FSE maintains the right to decide in its discretion to use the Licensed Marks and the "Fresenius" name by itself or its Affiliates to serve patients as part of FSE's home care business as well as for renal care patients.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Legal Company Name

Subject to Section 3 of this Agreement, the remainder of this Section 4 and Third Party Rights, FSE hereby grants to FME, for the use by FME and its Affiliates a royalty-free license to use the name "Fresenius Medical Care" for their legal company name, with exclusivity for the name "Fresenius Medical Care".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Restrictions

All rights in the Licensed Marks and the "Fresenius" name other than those specifically granted under the Trademark License Agreement are reserved to FSE.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) Ownership

The Parties acknowledge and agree that as between FSE and FME, the "Fresenius" name and the Licensed Marks, subject to the transfers and allocations in Section 5 of this Agreement, are the sole and exclusive property of FSE. FME acknowledges and agrees that neither it nor any of its Affiliates shall acquire any right, title or interest in or to the "Fresenius" name or the Licensed Marks as a result of the Trademark License Agreement (other than the licenses granted it hereunder), or the use of the "Fresenius" name or the Licensed Marks by FME or any of its Affiliates, or as a result of any other act or thing; that neither FME nor any of its Affiliates will attack FSE's title to or ownership of the "Fresenius" name or the Licensed

------

Marks; and that all use of the "Fresenius" name or the Licensed Marks by FME and its Affiliates and all goodwill generated thereby shall inure to the benefit of FSE.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) Sublicenses

FME shall not grant any sublicense to use the Licensed Marks or any other rights licensed under the Trademark License Agreement without the express prior written approval of FSE. No Affiliate of FME shall have the right to grant any sublicense or transfer its rights to use the Licensed Marks, the "Fresenius" name or any other rights licensed under the Trademark License Agreement. In the event of any Approved Sublicense, FME shall remain primarily obligated under all of the provisions of the Trademark License Agreement and shall cause each sublicensee to enter into a written sublicense agreement in form and substance satisfactory to FSE which shall include provisions, stated in such agreement to be for the express benefit of FSE, consistent with the provisions of the Trademark License Agreement. FME shall provide prompt written notice to FSE of the execution of each sublicense agreement. No Approved Sublicense shall contain any terms or conditions, and FME shall not take or authorize any actions in connection with any Approved Sublicense, inconsistent with the terms and conditions of the Trademark License Agreement. FME shall, upon reasonable request by FSE, provide FSE with reasonable evidence that each Approved Sublicense entered into complies with the requirements of this Section 4.2(vii). FSE hereby appoints FME its agent solely for the purpose of exercising quality control as provided in the Trademark License Agreement over any such sublicensee, and FSE retains the right to revoke such appointment at any time if FSE reasonably believes that FME is not adequately exercising such quality control, and to reinstate such appointment at any time. Notwithstanding any such appointment, FSE shall have the independent right to exercise quality control directly over all sublicensees; provided, however, that FSE shall not independently act unless it in good faith believes that FME is not adequately exercising such quality control. FSE shall have the right to require FME to terminate any agreement purported to be entered into with a sublicensee in violation of the terms of this Section 4.2(vii), and FSE shall have the right to pursue all other rights or remedies available to it in connection therewith. FME will take all steps reasonably necessary or desirable to enforce the terms of the Trademark License Agreement against its sublicensees. As between FSE and FME, FME shall be responsible for, and shall indemnify, defend and hold harmless FSE from, and shall pay all costs, fees and expenses (including reasonable attorney's fees and court costs) incurred by FME or FSE in connection with Approved Sublicenses granted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) New Registrations

For the avoidance of doubt, the Parties agree that section 6 b Original Trademark License Agreement means that at FME's request, FSE agrees to file and use reasonable efforts to prosecute, in FSE's name and at FME's expense, new applications for Licensed Marks, in any country, for those goods and services that are covered by the scope of the licenses granted under this Section 4. However, FSE shall not be required to take any action pursuant to this Section if, in the exercise of its reasonable good faith judgment, such action would adversely affect FSE's rights in the Licensed Marks.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) Compensation

------

The licenses granted under the Trademark License Agreement are royaltyfree and fully paid up.

Section 5

Allocation and Transfer of Shared Trademarks

For trademarks that are partially used and/or registered by both FSE and FME the following principles shall apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Parties hereby acknowledge and agree that FME shall transfer and assign to FSE, and that FSE shall accept such transfer and assignment, all trademarks comprising the element "Fresenius", the "F" Logo and/or similar elements/logos which FME owned at the Effective Date ("Transferred FSE Marks"). For sake of clarity: Transferred FSE Marks are Licensed Marks under the Trademark License Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Parties further acknowledge and agree that FSE shall transfer and assign to FME, and that FME shall accept such transfer and assignment, such trademarks which do not comprise the element "Fresenius" and which are exclusively used by FME or its Affiliates in a FME business segment and/or for a FME product, as listed in the attached Exhibit E.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The trademarks affected by this Section 5 shall be transferred and assigned according to separate trademark transfer and assignment agreements to be agreed by the Parties. The Parties shall conclude the trademark transfer and assignment agreements without undue delay, and in no case later than six (6) months after the Effective Date. After the agreements' conclusion and no later than three (3) months thereafter, the respective assignee will make (at its costs and expenses) the necessary filings to update the records of the relevant trademark registers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) With regard to the trademarks comprising the element "Fresenius" and used for a FME product only, the Parties acknowledge and agree, by way of derogation from Section 6 (a) Original Trademark License Agreement, that FSE shall only prosecute and maintain in force and effect registrations for these trademarks with respect to the Licensed Goods and Services in FSE's name at FME's request and cost.

Section 6

Mutual Support

In addition to the mutual support obligation stipulated in Section 6 of the Original Trademark License Agreement, and in particular in line with the mechanisms on responsibility and costbearing therein, the Parties agree to support each other in (i) legal disputes relating to the enforcement of the Licensed Marks and/or the Permissible Business Names, in each case as permitted pursuant to Section 6 of the Original Trademark License Agreement, with respect to providing evidence of genuine use by the respective Parties and their Affiliates to the extent required in such legal disputes and (ii) any prosecution issues concerning the Licensed Marks and/or the Permissible Business Names that can only be resolved with the cooperation of the other Party, e.g., if a trademark application within the scope of and in compliance with the Trademark License Agreement cannot be registered in the name of one Party in a particular jurisdiction, the other Party shall provide the required support to enable such registration, for example by making respective notifications to the respective trademark office or by registering such trademark in its own name and to license it out to the other Party, it being understood that the Party that requests the support is obliged to reimburse the costs of the supporting party arising in the context of such support.

------

Section 7

Update of Exhibits

The Parties agree to review and, as far as required, to update and/or create by mutual support the Exhibit B (Fresenius Mark), Exhibit C (Mixed Use Marks) and Exhibit D (Third Party Rights) attached to the Original Trademark License Agreement until 31 January 2026 unless unanimously agreed otherwise between the Parties. Exhibit A ("F" Logo) will not be updated as the Parties acknowledge and agree that these trademarks and logos will no longer be part of the Licensed Marks as of the Effective Date.

Section 8

Termination Right for Material Breach

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 The Original Trademark License Agreement entitles FSE to terminate the Trademark License Agreement in the event of a material breach as further set out in Section 12 of the Original Trademark License Agreement. The Parties wish to clarify and replace the termination right for material breach in Section 12 (a) Original Trademark License Agreement in accordance with this Section 8. For the avoidance of doubt, other provisions relating to termination and rights on termination contained in the Original Trademark License Agreement remain unchanged.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 As of the Effective Date, the Parties confirm that they are not aware of any material breach of the Trademark License Agreement related to the use of the Licensed Marks and the "Fresenius" name by FME and its Affiliates, as well as by the minority shareholdings conclusively listed in Exhibit F ("Minority Shareholdings") for which FME confirms that these entities exist and that FME or its Affiliates hold a minority share in. Only with regard to the Minority Shareholdings' respective business as conducted at the Effective Date, the Minority Shareholdings shall be entitled to be granted Approved Sublicenses as stipulated in Section 4.2(vii) of this Agreement. FME shall conclude the Approved Sublicenses without undue delay, and in no case later than six (6) months after the Effective Date. Each Approved Sublicense granted to the Minority Shareholdings automatically and immediately terminates, if at any time FME or its Affiliates hold less registered share capital or voting rights in the respective Minority Shareholding than held at the Effective Date. For the avoidance of doubt, all Minority Shareholdings granted with an Approved Sublicense are prohibited from further transferring or sublicensing their rights granted under the Trademark License Agreement, this Agreement or the Approved Sublicenses to any third party. The Parties acknowledge and agree that any past use and the current status of the use of the Licensed Marks and/or the "Fresenius" name by FME and/or its Affiliates as well as by the Minority Shareholdings until the Effective Date (but not thereafter) shall be considered not to be in breach of the Trademark License Agreement, provided that, in the case of the Minority Shareholdings, this shall apply only.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3 FSE may terminate the Trademark License Agreement and any rights of FME or its Affiliates thereunder for material breach, if they fail to cure such material breach within a cure period of sixty (60) calendar days after FSE's written notice, which shall be extended by FSE if the period of time reasonably required to cure such breach exceeds sixty (60) calendar days. The extension shall be granted for up to an additional sixty (60) calendar days, provided that FME submits a comprehensive remediation plan no later than twenty (20) calendar days from the receipt of the written notice,

------

which demonstrates that the cure period reasonably required exceeds sixty (60) calendar days. FME shall use its best efforts to keep the cure period to a minimum.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4 No cure period is required and FSE may terminate the Trademark License Agreement and any and all rights of FME or its Affiliates thereunder, if the material breach is not curable or if the breach is so material that an immediate termination is justified.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.5 After termination for material breach, FSE shall grant FME, for use by FME and its Affiliates, a limited license to use the Licensed Marks and/or the "Fresenius" name for a reasonable grace period as required to promptly identify a new name, conduct trademark clearance searches, and make all necessary filings to execute regulatory and/or certification requirements, such grace period shall be in any case no longer than eighteen (18) months following the receipt of FSE's termination notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) If FME considers the grace period to be unreasonably short, FME has the Right of Appeal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) If, in exceptional cases, FSE considers the grace period to be unreasonably long, FSE has the Right of Appeal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.6 In particular and without limitation, the following events caused by the use of the Licensed Marks and/or the "Fresenius" name shall qualify as a material breach according to this Section 8:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) FME and/or its Affiliates materially tarnish the Licensed Marks and/or the name "Fresenius" in an unflattering way, so that they objectively lose significant value;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) FME and/or its Affiliates materially harm the reputation and/or goodwill of FSE, in a way that its external perception or goodwill is damaged by public statements and/or actions, so that the reputation and/or goodwill of FSE objectively loses significant value;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) FME and/or its Affiliates use the Licensed Marks and/or the "Fresenius" name outside of the applicable licensed business scope;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) FME and/or its Affiliates use the Licensed Marks and/or the "Fresenius" name in violation of key terms of the Branding Guidelines, which the Branding Committee has determined to constitute key terms for the purposes of this provision; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) FME and/or its Affiliates use the Licensed Marks and/or the "Fresenius" name within its business operation in another way than as "Fresenius Medical Care" and/or as "Fresenius + a term related to dialysis business" and/or without the addition "a Fresenius Medical Care company" unless authorized under this Agreement, in violation of its obligation to do so under the Trademark License Agreement.

Section 9

Termination Right for Change of Control; Divestments

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 FSE shall have the right to terminate the Trademark License Agreement for good cause in case of a Change of Control in FME AG and/or FME only as set out in this Section 9.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 FSE shall have the right to terminate the Trademark License Agreement with immediate effect in case a Direct Competitor to FSE acquires Control in FME AG and/or FME. In such case:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Termination shall be immediately effective, but FSE shall not assert any rights against FME AG respectively FME or its Affiliates in relation to its continued use of the Licensed Marks and/or the "Fresenius" name as was allowed and within such scope under the Trademark License Agreement within eighteen (18) months after the termination ("Non-Assert Period"), provided that FME AG respectively FME uses and procures that any of its Affiliates uses its best efforts to discontinue all use of the Licensed Marks and/or the "Fresenius" name in the shortest time possible after the termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) If FME AG respectively FME considers the Non-Assert Period to be unreasonably short, FME AG respectively FME has the Right of Appeal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) If, in exceptional cases, FSE considers the Non-Assert Period to be unreasonably long, FSE has the Right of Appeal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3 In case any other third party acquires Control in FME AG and/or FME, FSE shall have a right to terminate the Trademark License Agreement if FSE acting reasonably expects the acquisition to result in a risk of negative impact on the "Fresenius" brand, unless such negative impact would be insignificant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Termination shall be immediately effective, but FSE shall not assert any rights against FME AG respectively FME or its Affiliates within the Non-Assert Period, provided that FME AG respectively FME uses and procures that any of its Affiliates uses its best efforts to discontinue all use of the Licensed Marks and/or the "Fresenius" name in the shortest time possible after the termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) If FME AG respectively FME assumes that the termination right is not triggered or the Non-Assert Period is unreasonable short, FME AG respectively FME has the Right of Appeal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) If, in exceptional cases, FSE considers the Non-Assert Period to be unreasonably long, FSE has the Right of Appeal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4 In case any Affiliate ceases to be an Affiliate of FME (e.g., in the course of divestments), Section 12 (d) Original Trademark License Agreement applies accordingly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) FSE shall not assert any rights against such former FME Affiliate for six (6) months after the Affiliate ceases to be an Affiliate of FME, provided such former Affiliate uses its best efforts to discontinue all use of the Licensed Marks and/or the "Fresenius" name in the shortest time possible after it ceases to be an Affiliate of FME. Further, the former Affiliate may sell-off stock branded with the Licensed Marks and/or the "Fresenius" name within six (6) months after the Affiliate ceases to be an Affiliate of FME.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) If FME assumes the non-assert period in Section 9.4 (i) towards its former Affiliate is unreasonably short, FME has the Right of Appeal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) If, in exceptional cases, FSE considers the non-assert period in Section 9.4 (i) to be unreasonably long, FSE has the Right of Appeal.

Section 10

Additional Consequence of Termination

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 Upon termination of the Trademark License Agreement, FSE shall not use any of the trademarks used exclusively by FME or its Affiliates (i.e., such trademarks which FSE and its Affiliates may not use under the Trademark License Agreement) under the Trademark License Agreement in the field of business of FME and FSE shall not license or transfer such trademarks enabling such use by third parties.

Section 11

Change of FME Legal Company Name

In the event that FME's sole shareholder FME AG forms the legally relevant resolution to change its articles of association (Satzung) to change its legal company name to a new name not containing the "Fresenius" name, FME shall inform FSE immediately and in no case later than two (2) business days after such resolution. With such resolution, the Trademark License Agreement and all rights granted to FME and its Affiliates thereunder shall terminate (ten) 10 years following the legally binding resolution of FME AG, with no further grace period.

Section 12

Reporting Obligation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.1 If FME or its Affiliates harm the reputation of FSE or its Affiliates or tarnish the Licensed Marks and/or the "Fresenius" name, FME shall inform FSE immediately once the respective Branding Committee member of FME Group's global communication department became aware of such an incident. The same shall apply where actions made by FME or its Affiliates in good faith determine that there is a risk of such harm. Information should also be immediately provided from FSE to FME in case the "Fresenius" name is tarnished by FSE or its Affiliates once the respective Branding Committee member of FSE's corporate communication department became aware of such an incident.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.2 FME shall be obliged to provide and procure from its Affiliates in writing all information requested by FSE to evaluate the potential harm within two (2) weeks. The same applies upon reasonable request of FSE without prior notification from FME.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.3 Subject to proportionality, FME may request material information from FSE in writing to evaluate the potential harm to the "Fresenius" name in case it is tarnished by FSE or its Affiliates. FSE shall provide such information within two (2) weeks following FME's request.

Section 13

Effective Date

This Agreement shall become effective upon the Effective Date.

Section 14

Miscellaneous

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.1 Conclusion and Amendment

The Parties acknowledge and agree that FSE and FME are currently and will remain parties to the Trademark License Agreement. The Trademark License Agreement shall remain in full force and effect and shall prevail over the Original Trademark

------

License Agreement in its previously agreed form. Sections in the Original Trademark License Agreement other than those amended by this Agreement remain in full force and unchanged.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.2 Costs

Any costs associated with the implementation of the undertakings entered into in this Agreement, as well as any additional costs arising from or in connection with the amendment, modification, or supplementation of this Agreement, shall be borne by the Party which has the obligation to fulfil the respective undertaking. If both Parties are obliged to fulfil an undertaking, each Party will bear the costs it incurred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.3 Definitions

Capitalized Terms used herein and not otherwise defined shall have the meaning ascribed to them in the Original Trademark License Agreement.

The following terms and expressions shall have the meanings set out below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) "Additional Consent" has the meaning given to that term in Section 3.6;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) "Affiliate" means with retroactive effect as from the effective date of the Original Trademark License Agreement an Affiliate as originally defined in the Original Trademark License Agreement, including, without limitation, FME AG, until FME AG ceases to be affiliated with FME under German corporate law (sections 15 et seq. of the German Stock Corporation Act (Aktiengesetz)) and including VFMCRP which are considered Affiliates of FME for the purposes of the Trademark License Agreement and this Agreement. In deviation from the rules applicable to Affiliates under the Original Trademark License Agreement, if at any time FME or its affiliates (according to sections 15 et seq. of the German Stock Corporation Act (Aktiengesetz)) hold less registered share capital or voting rights than 20% (directly or indirectly) in any VFMCRP entity, such VFMCRP entity will no longer be considered an Affiliate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) "Agreement" means this agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) "Ancillary Products" means Medical Devices used during or in connection with therapies in the field of Extra-Corporeal Blood Treatment or Peritoneal Dialysis, but are not exclusively related to such therapies and, therefore, have no Intended Use in that field reflected in their regulatory documents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) "Approved Sublicense" means any sublicense granted pursuant to the express prior written approval of FSE to a third party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) "Branding Committee" has the meaning given to that term in Section 1.1;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) "Branding Guidelines" has the meaning given to that term in Section 1.1(i);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) "Bringing to Market" means any act related to the commercialization of goods or services under the Licensed Marks or the "Fresenius" name, including but not limited to the production, manufacture, sale, marketing, promotion, advertising, provision and distribution of goods and services.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) "Change of Control" shall be deemed to have occurred at each time (whether or not approved by the management board or supervisory board of FME AG) that any entity, person or persons acting in concert in accordance with the German Takeover Act (Wertpapiererwerbs- und Übernahmegesetz), at any time, directly or indirectly, (a) with regard to FME AG, acquire(s) and come(s) to own (i) 30 per cent or more of its registered share capital or (ii) such number of the shares in its registered share capital carrying 30 per cent or more of the voting rights, respectively, (b) with regard to FME, becomes an affiliated entity (verbundenes Unternehmen) pursuant to sections 15 et seq. of the German Stock Corporation Act (Aktiengesetz) of FME as the majority owning (mit Mehrheit beteiligt) or controlling (herrschend) entity, and "Control" shall be defined accordingly; for the avoidance of doubt, Change of Control also results from a divestment through corporate reorganisations relating to FME AG and/or FME, such as split-ups of legal entities, hive-downs and comparable measures, provided however, with respect to FME only if the divested part of FME becomes bound to the Trademark License;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) "Conversion" has the meaning given to that term in Preamble (A);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) "Conversion Effective Date" means the date the Conversion was recorded in the commercial register (Handelsregister);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) "Direct Competitor" means any undertaking that is at the relevant time selling, distributing, and/or marketing the same products and/or services on the same geographic market;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) "Effective Date" has the meaning given to that term in Recital (F);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) "Escalation Process" has the meaning given to that term in Section 1.8;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xv) "Extra-Corporeal Blood Treatment" means a medical procedure, including but not limited to renal care related treatments such as dialysis, that involves removing a patient's blood cells, plasma proteins and other components of whole blood, treating it with technologies that modifies some or all components of whole blood, and/or adds or extracts desirable components, and/or separates and/or removes undesirable components, and then returns the modified blood to the body;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvi) "FME" has the meaning given to that term in the Parties' Section (2);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvii) "FME AG" has the meaning given to the term in Preamble (A)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xviii) "FME Group" means FME AG together with its subsidiaries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xix) "FME Branding" means the rules on FME's and its Affiliates' use of the "Fresenius" name, to avoid use on a stand-alone basis without any additions, considering the provisions on Permissible Business Names herein and as further elaborated in the Branding Guidelines;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xx) "FSE" has the meaning given to that term in the Parties' Section (1);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxi) "FSE Group" means FSE together with its subsidiaries;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxii) "Group Separation Agreement" has the meaning given to that term in Preamble (C);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxiii) "Intended Use" means the use for which a Medical Device is intended according to the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxiv) "Licensed Marks" means the Fresenius Mark, the "F" Logo, those elements of the FMC Marks that are owned by Licensor, and the Mixed Use Trademarks, collectively. As of the Effective Date, the "F" Logo shall no longer be part of the Licensed Marks.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxv) "Medical Devices" means products or equipment intended for a medical purpose according to the relevant definition of the relevant regulatory authorities in respective markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxvi) "Medical Indication" means a medical condition that a Pharmaceutical is intended to treat, reflected in the regulatory approval, including the treatment, prevention and diagnosis of a disease, as well a definition of a specific target population;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxvii) "Minority Shareholdings" has the meaning given to that term in Section 8.2;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxviii) "Non-Assert Period" has the meaning given to that term in 9.2(i);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxix) "Non-Medical Devices" means products and services that are not qualified as Medical Devices (including but not limited to products in the fields of water technology or digital products) and, therefore, have no Intended Use in the field of Extra-Corporeal Blood Treatment or Peritoneal Dialysis but are sold or provided to third parties for use in the field of Extra-Corporeal Blood Treatment or Peritoneal Dialysis as intended by the Parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxx) "Nutrition Supplements" means concentrated sources of nutrients (i.e. minerals and vitamins) or other substances with a nutritional or physiological effect that are marketed in "dose" form (e.g. pills, tablets, capsules, powder, liquids in measured doses);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxxi) "Original Trademark License Agreement" has the meaning given to that term in the Preamble (D);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxxii) "Party" has the meaning given to this term in the Parties' Section;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxxiii) "Peritoneal Dialysis" means using the patient's own peritoneal membrane acting as a natural filter to remove undesirable components and excess fluid from the body. During the procedure, a solution (called dialysate) is introduced into the abdominal cavity and after a while is removed/replaced from the abdomen;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxxiv) "Permissible Business Names" has the meaning given to that term in Section 3.2(ii);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxxv) "Pharmaceuticals" means a substance or combination of substances that is intended to treat, prevent a disease, to make a pharmaceutical diagnosis, or to restore, correct or modify physiological functions by exerting a pharmacological, immunological

------

or metabolic action according to the relevant definition of the relevant approval bodies in respective markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxxvi) "Renal Business" means the business of supplying renal care related goods and services, including laboratories, provided that the home care business of FSE (and its Affiliates) is not, and shall not be deemed to be, a Renal Business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxxvii) "Renal Pharmaceuticals" means Pharmaceuticals with a Medical Indication in renal treatment as reflected in the regulatory approval;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxxviii) "Right of Appeal" has the meaning given to that term in Section 1.8(iv);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxxix) "Subsidiary" means an Affiliate that is controlled by the specified Person;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xl) "TLA Arbitration Agreement" means the arbitration agreement applying to the Trademark License Agreement, which is to be agreed shortly between the Parties, and an agreed version of which is enclosed as Exhibit H;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xli) "Trademark License Agreement" has the meaning given to that term in the Preamble (F);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xlii) "VFMCRP" means Vifor Fresenius Medical Care Renal Pharma Ltd., as well as its affiliates (according to sections 15 et seq. of the German Stock Corporation Act (Aktiengesetz)).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.4 Dispute Resolution

All disputes arising out of or in connection with the Trademark License Agreement or its validity shall be exclusively settled in arbitration proceedings in accordance with the TLA Arbitration Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.5 Interpretation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Singular, Plural, Gender References to one gender include all genders and references to the singular include the plural and vice versa.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) References

● The Original Trademark License Agreement uses FSE and FME synonymously as "Licensor" (FSE) and "Licensee" (FME). References to "FSE" and "FME" in this Agreement shall be read in the context of the Original Trademark License Agreement as references to "Licensor" (FSE) respectively "Licensee" (FME).

● References to the Trademark License Agreement shall be understood as references to the Original Trademark License Agreement as amended by Schedule 3 of the Group Separation Agreement and by this Agreement.

● References to a person shall include any company, partnership or unincorporated association (whether or not having separate legal personality).

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

● References to a company shall include any company, corporation or any corporate body, wherever incorporated.

● References to this Agreement shall include any recitals, preambles, clauses of, and annexes to, this Agreement.

● References to a statute or statutory provision include that statute or provision as from time to time modified, re-enacted, or consolidated whether before or after the Effective Date; and any subordinate legislation made from time to time under that statute or statutory provision which is in force at the Effective Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Legal Terms

References to any German legal term shall, in respect of any jurisdiction other than Germany, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Non-limiting Effect of Words

The words "including", "include", "in particular" and words of similar effect shall not be deemed to limit the general effect of the words that precede them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.6 Invalidity

Should any provision of this Agreement be or become invalid, ineffective, or unenforceable as a whole or in part, the validity, effectiveness, and enforceability of the remaining provisions shall not be affected thereby. Any such invalid, ineffective or unenforceable provision shall be deemed replaced by such valid, effective, and enforceable provision as comes closest to the economic intent and the purpose of such invalid, ineffective or unenforceable provision as regards subject-matter, amount, time, place, and extent. The aforesaid shall apply mutatis mutandis to any unintended gap in this Agreement. It is the explicit intent of the Parties that the severability clause in this Section 14.6 (Invalidity) shall not be construed as a mere reversal of the burden of proof (Beweislastumkehr) but rather as a contractual exclusion of section 139 German Civil Code (Bürgerliches Gesetzbuch) in its entirety.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.7 Notices

Section 13 (a) of the Original Trademark License Agreement is amended as follows:

Any notice, request, demand, waiver or other communication required or permitted to be given or requirement to notify under the Trademark License Agreement shall be in text form and additionally signed (as specified below) by or on behalf of the Party giving it and shall be sent by hand, courier and/or e-mail, marked for the attention of the relevant Party and to the address and/or e-mail address set out below. The signing of any notice shall not be valid unless and until it has been signed by the Party giving it by any of the following methods:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) by the addition of the relevant signature(s) to the notice via an electronic signature application;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) by the insertion of a handwritten signature on an original copy of the notice; or

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) by the insertion of a handwritten signature on an original copy of this notice which is then converted into an electronic 'PDF' format.

The addresses and e-mail addresses of the Parties for the purpose of Section 14.7 are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) To FSE:

Fresenius SE & Co. KGaA

Attention: Dr. Jan Winzen and Dr. Ivo Lewalter

Address: Else-Kröner-Str.1, 61352 Bad Homburg, Germany

E-mail: jan.winzen@fresenius.com and

ivo.lewalter@fresenius.com

with a copy to:

Dr. Michael Leicht (michael.leicht@linklaters.com) and Dr. Bolko Ehlgen

(bolko.ehlgen@linklaters.com)

Linklaters LLP

Taunusanlage 8

60329 Frankfurt am Main Germany

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To FME:

Fresenius Medical Care Deutschland GmbH

Attention: Charles Krauss and Florian Geyer, LL.M. (Boston)

Address: Else-Kröner-Str. 1, 61352 Bad Homburg, Germany

E-mail: Charles.Krauss@freseniusmedicalcare.com and

Florian.Geyer@freseniusmedicalcare.com

with a copy to:

Dr. Christoph Rieken, LL.M. (Christoph.Rieken@noerr.com)

Noerr Partnerschaftsgesellschaft mbB

Brienner-Straße 28

80333 München Germany

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.8 Electronic Signatures

This Agreement may be signed electronically (e.g., by DocuSign), regardless of its trust level as simple, advanced (AES) or qualified (QES) electronic signature, and that such electronic signatures are valid and shall be deemed equal to the written form. The Parties each represent and warrant that they will not contest the admissibility of authentic copies of electronically signed documents in any legal proceedings relating to this Agreement.

[Signature page to follow on next page.]

------

Bad Homburg v. d. Höhe, 22 December 2025

---

| | |
|:---|:---|
| /s/ Dr. Michael Moser | /s/ Dr. Alexander Moscho |
| Name: Dr. Michael Moser | Name: Dr. Alexander Moscho |
| Function: Member of the Management Board | Function: Head of Corporate Development |
| Fresenius SE & Co. KGaA represented by | Fresenius SE & Co. KGaA represented by |
| Fresenius Management SE Bad Homburg v. d. | Fresenius Management SE |
| Höhe, 22 December 2025 |  |

---

Bad Homburg v. d. Höhe, 22 December 2025

---

| |
|:---|
| /s/ Martin Fischer |
| Name: Martin Fischer |
| Function: Managing Director |
| Fresenius Medical Care Deutschland GmbH Bad |
| Homburg v. d. Höhe, 22 December 2025 |
| /s/ Dr. Jörg Häring |
| Name: Dr. Jörg Häring |
| Function: Managing Director |
| Fresenius Medical Care Deutschland GmbH |

---

------

## Exhibit 11.3

---

| |
|:---|
| &nbsp;&nbsp;**Exhibit 11.3** |
| &nbsp;&nbsp;![Graphic](fms-20251231xex11d3001.jpg) |
| &nbsp;&nbsp;**Global Insider Policy** |

---

---

| | |
|:---|:---|
| **Type:** | 2 Policy |
| **Version No.:** | 2 |
| **Reference No.:** | 10203 |
| **Scope:** | FME Group (All Fresenius Medical Care AG wholly or majority-owned entities and organizational units) |
| **Out of Scope:** | n/a |
| **Target Group:** | n/a |
| **Publication Date:** | 17/February/2026 |
| **Effective Date:** | 4 weeks after publication |
| **Status:** | Published |
| **Owner's Department:** | Global Legal |
| **Approver's Position:** | FME Management Board |
| **Approver's Position:** | n/a |

---

This document is internal and is the sole property of Fresenius Medical Care. It is issued by the Document Owner and is electronically published in the Policy Management database. Printouts of this document are for reference only. The user is always responsible for referring to the Policy Management database for the latest and valid version.

FOR INTERNAL USE ONLY Page: 1 of 11

------

---

| |
|:---|
| &nbsp;&nbsp;![Graphic](fms-20251231xex11d3001.jpg) |
| &nbsp;&nbsp;**Global Insider Policy** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CONTENT** | **CONTENT** | **CONTENT** | **CONTENT** |  |
| **1** | **PURPOSE** | **PURPOSE** | **PURPOSE** | **3** |
| **2** | **DEFINITIONS** | **DEFINITIONS** | **DEFINITIONS** | **4** |
| **3** | **REQUIREMENTS / PROCESS** | **REQUIREMENTS / PROCESS** | **REQUIREMENTS / PROCESS** | **4** |
|  | 3.1 | Background | Background | 4 |
|  | 3.2 | Insider Dealing | Insider Dealing | 5 |
|  |  | 3.2.1 | Insider Status | 5 |
|  |  | 3.2.2 | Non-Exhaustive Examples of Inside Information | 5 |
|  |  | 3.2.3 | Insider Dealing Rules | 6 |
|  |  | 3.2.4 | Periods in which dealing in FME Financial Instruments is prohibited | 8 |
|  |  | 3.2.5 | Trading Plans | 9 |
|  | 3.3 | Special and Prohibited Transactions | Special and Prohibited Transactions | 9 |
|  | 3.4 | Personal Responsibility | Personal Responsibility | 10 |
|  | 3.5 | Amendments | Amendments | 10 |
|  | 3.6 | Support by the Company | Support by the Company | 11 |
| **4** | **RELATED INTERNAL CONTROLS** | **RELATED INTERNAL CONTROLS** | **RELATED INTERNAL CONTROLS** | **11** |
| **5** | **RELATED DOCUMENTS** | **RELATED DOCUMENTS** | **RELATED DOCUMENTS** | **11** |
| **6** | **ANNEXES** | **ANNEXES** | **ANNEXES** | **11** |

---

FOR INTERNAL USE ONLY Page: 2 of 11

------

---

| |
|:---|
| &nbsp;&nbsp;![Graphic](fms-20251231xex11d3001.jpg) |
| &nbsp;&nbsp;**Global Insider Policy** |

---

**1** **PURPOSE**

Fresenius Medical Care AG ("**FME**" or the "**Company**") and its affiliates (together "**FME Group**") have issued and may continue to issue financial instruments such as, for example, shares, bonds, stock options and other securities in various ways on various markets (any such financial instruments, irrespective of whether issued by a member of the FME Group or a third party, hereinafter collectively referred to as "**Financial Instruments**" and, when issued by FME or an affiliate of FME, "**FME Financial Instruments**"). Currently, FME Financial Instruments have been issued in the European Union and the United States. FME's ordinary shares are listed on the Frankfurt Stock Exchange, and American Depositary Shares ("**ADS**") evidencing FME ordinary shares are listed on the New York Stock Exchange ("**NYSE**"). Bonds issued by FME are listed on the Luxembourg Stock Exchange.

Anybody working at FME Group may from time to time have access to Inside Information (as defined below) relating to FME Financial Instruments or any other non-public information relating to a company or Financial Instruments. Any appearance in the market of impropriety on the part of the Company or its employees could impair investor confidence in the Company and severely damage the Company's reputation and business relationships.

It is FME's policy to strictly oppose the misuse of Inside Information in securities dealings and the unauthorized disclosure of any non-public information acquired in the workplace. To this end, FME has adopted this policy (hereinafter referred to as FME's "**Insider Policy**") in addition to the respective provisions set out in FME's corporate compliance program. The purpose of this Insider Policy is to prevent misuse of Inside Information and to avert negative consequences both for individuals and for FME. <u>This Insider Policy must strictly be observed by all board members, directors, officers and employees of FME Group at all times.</u>

This Insider Policy provides an overview of the applicable legal provisions and FME's internal rules against

&nbsp;&nbsp;&nbsp;&nbsp;1. dealing in FME Financial Instruments and related derivative Financial Instruments using Inside Information as well as

&nbsp;&nbsp;&nbsp;&nbsp;2. other misuse of Inside Information (hereinafter jointly referred to as "**Insider Dealing** "; the laws and internal rules prohibiting Insider Dealing hereinafter referred to as "**Insider Dealing Rules** ").

This Insider Policy also outlines the specific rules for dealing in FME Financial Instruments including, but not limited to, FME Financial Instruments acquired under incentive compensation plans implemented by FME (hereinafter referred to as "**Incentive Plans**"), as well as in Financial Instruments of other companies with respect to which a person may have access to material non-public information obtained in the course of employment with, or other services performed on behalf of, the FME Group.

FOR INTERNAL USE ONLY Page: 3 of 11

------

---

| |
|:---|
| &nbsp;&nbsp;![Graphic](fms-20251231xex11d3001.jpg) |
| &nbsp;&nbsp;**Global Insider Policy** |

---

**2** **DEFINITIONS**

The terms used throughout this document are defined as per the Common Definition Framework. Definitions specific to this document are outlined below.

---

| | |
|:---|:---|
| &nbsp;&nbsp;Term<br><BORDER_TOP> | &nbsp;&nbsp;Definition<br><BORDER_TOP> |
| &nbsp;&nbsp;**Inside Information** | &nbsp;&nbsp;"Inside Information" is any non-public information of a precise nature relating, directly or indirectly, to the FME Group or Financial Instruments issued by FME or another member of the FME Group and which is "material" in the meaning that it, if it were made public, would likely have a significant effect on the prices of those Financial Instruments or on the price of related derivative Financial Instruments. Such likeliness exists when a reasonable investor would probably consider such information important in making an investment decision, i.e., if the information could reasonably be expected to affect the investment judgment of such an investor in deciding to buy, hold or sell that company's shares or other Financial Instruments. In the U.S. such information is generally referred to as "material inside" or "material non-public" information.<br>Inside Information may consist of – but is not limited to – matters of fact, research findings, business relations, contemplated transactions, value judgments, assessments and sometimes even rumors. A non-exclusive list of examples that can typically qualify as Inside Information is set forth in 3.2.2 below.<br>Inside Information relating to FME or FME Group may at the same time be "material" (as defined above) with respect to Fresenius SE & Co. KGaA ("FSE"), the major shareholder of FME. If so, the restrictions and limitations of this Insider Policy, as set forth in "Insider Dealing Rules" below, shall also apply to any such material non-public information relating to FSE and to the Financial Instruments issued by FSE (or any affiliates of FSE).<br>Dealings in Financial Instruments of other companies may also be subject to the restrictions and limitations of this Insider Policy, as set forth in "Insider Dealing Rules" below.  |
| &nbsp;&nbsp;**Potential Inside<br>Information** | &nbsp;&nbsp;"Potential Inside Information" is information that may qualify as Inside Information (in the meaning of this term as defined above) only in the further course of events. For instance, the Company may not have sufficient detail to assess the significance of an event or development, it may not yet be clear at a given point in time whether an event or development is likely to materialize, or whether it would be likely to have a significant effect on the prices of the Financial Instruments. Every board member, director, officer and employee of FME Group is advised to treat Potential Inside Information as if it were Inside Information and to observe the restrictions and limitations of this Insider Policy, as set forth in "Insider Dealing Rules" below, also with respect to Potential Inside Information. |

---

**3** **REQUIREMENTS / PROCESS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.1** **Background** 

Dealing in Financial Instruments is subject to specific laws enacted to prevent the misuse of Inside Information. Such laws vary in different jurisdictions. In Germany, for example, dealing in Financial Instruments is subject to the provisions of the Regulation (EU) No 596/2014 on market abuse (hereinafter referred to as "**MAR**") as well as the German Securities Trading Act ("Wertpapierhandelsgesetz", "**WpHG**") and supervised by the German Federal Financial Supervisory Authority ("Bundesanstalt für Finanzdienstleistungsaufsicht", "**BaFin**"). In the U.S., dealing in Financial Instruments is subject to the Securities Exchange Act of 1934 (the "**Exchange Act**") and the rules of the U.S. Securities and Exchange Commission ("**SEC**") under that Act (in particular, Section 10(b) of the Exchange Act and SEC Rule 10b-5), and supervised by the SEC and, in case of criminal violations of the securities laws, the U.S. Department of Justice. <u>Such laws and the jurisdiction of said authorities are not based on citizenship or residency in the respective jurisdiction but in principle apply to anyone dealing in financial instruments in the relevant capital markets.</u>

FOR INTERNAL USE ONLY Page: 4 of 11

------

---

| |
|:---|
| &nbsp;&nbsp;![Graphic](fms-20251231xex11d3001.jpg) |
| &nbsp;&nbsp;**Global Insider Policy** |

---

<u>Any violation of Insider Dealing Rules may constitute a criminal offense under European, German, U.S. and/or other applicable law.</u> Under German law, for example, Insider Dealing is punishable for individuals by fines of up to EUR 5 million or, as the case may be, by up to <u>5 years imprisonment</u> and in the U.S. with prison terms of up to 20 years and fines of up to the greater of USD 5 million or three times the gain received or loss avoided by a transaction prohibited by applicable U.S. legal provisions on Insider Dealings. In addition to governmental fines, civil injunctive relief and other sanctions, private actions for damages against public companies and their insiders for violation of insider trading laws may be brought and can involve substantial costs, both mandatory and in terms of time, even if the claim is ultimately settled or dismissed.

Board members, directors, officers and employees of FME Group should also be aware that the SEC, the NYSE, the BaFin and the internal compliance departments of many banks and securities dealers routinely scrutinize abnormal patterns of trading activity occurring in advance of the release of important company-related news.

The infringement of Insider Dealing Rules may also constitute a breach of the respective employment or service agreement with the respective FME Group company and result in disciplinary actions including the <u>termination of such employment or service agreement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.2** **Insider Dealing** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.2.1** **Insider Status** 

Any board member, director, officer and employee of FME Group who has access to Inside Information relating to the FME Group is an insider for purposes of the Insider Dealing Rules ("**Insider**") and as such subject to the Insider Dealing Rules. As further described below, a person may also become subject to the Insider Dealing Rules by receiving material non-public information regarding the "Business Partners" (as defined in "Insider Dealing Rules", below) of a member of the FME Group.

It is to be noted that the legal provisions on insider dealing do not apply only to board members, directors, officers and employees. Rather, they apply to any person. Therefore, closely associated persons such as, for instance, family members who reside with an Insider (including a spouse, children, stepchildren, parents, siblings and in-laws), anyone else who lives in an Insider's household, and any family member who does not live in an Insider's household but whose transactions in Financial Instruments are directed by, or subject to the influence or control of, the Insider (collectively, "**Family Members**") are subject to the specific laws and regulations enacted to prevent the misuse of Inside Information. In addition, FME expects that FME Insiders will inform their Family Members of this Policy and advise them that Family Members are required to observe the restrictions and limitations set forth in "Insider Dealing Rules", below.

Also, external third parties, for example consultants, temporary workers and external service providers, who have access to Inside Information are insiders and subject to the specific laws enacted to prevent the misuse of Inside Information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.2.2** **Non-Exhaustive Examples of Inside Information** 

In some cases, it may be difficult to determine whether information is "material" in the meaning that it, if made public, would likely have a significant effect on the price of a Financial Instrument or related derivative Financial Instruments. However, there are various categories of information regarding an issuer of Financial Instruments that are particularly sensitive and, as a rule, should always be considered material, at least as a precautionary measure, because they <u>could</u> qualify as Inside Information. Please note that the following list is non-exhaustive:

Intended/planned major/strategic acquisitions, divestures or mergers, spin-offs, takeover bids, and purchases or sales of material assets;

&nbsp;&nbsp;&nbsp;&nbsp;■ Material product or environmental liability, or other significant exposure due to actual or threatened litigation;

&nbsp;&nbsp;&nbsp;&nbsp;■ Entry into, or amendments to or termination of important contracts with customers and suppliers;

&nbsp;&nbsp;&nbsp;&nbsp;■ Changes in dividend policy;

&nbsp;&nbsp;&nbsp;&nbsp;■ Significant financing transactions, such as issuance of new equity or debt securities, other debt financings (e.g., significant credit agreements), or other transactions affecting FME Financial Instruments, such as share splits;

&nbsp;&nbsp;&nbsp;&nbsp;■ Insolvency risks or financial liquidity problems;

FOR INTERNAL USE ONLY Page: 5 of 11

------

---

| |
|:---|
| &nbsp;&nbsp;![Graphic](fms-20251231xex11d3001.jpg) |
| &nbsp;&nbsp;**Global Insider Policy** |

---

&nbsp;&nbsp;&nbsp;&nbsp;■ Significant regulatory actions including product recalls;

&nbsp;&nbsp;&nbsp;&nbsp;■ Financial or earnings information, including significant increases/decreases in quarterly/annual revenues or significant increases/decreases in quarterly/annual results;

&nbsp;&nbsp;&nbsp;&nbsp;■ Significant changes in sources or availability of raw materials or other supplies;

&nbsp;&nbsp;&nbsp;&nbsp;■ Projections or forecasts which deviate significantly from past financial results or which deviate from market expectations;

&nbsp;&nbsp;&nbsp;&nbsp;■ Capital investment plans or changes in such plans;

&nbsp;&nbsp;&nbsp;&nbsp;■ Default by major customers or borrowers;

&nbsp;&nbsp;&nbsp;&nbsp;■ Significant write-offs, impairment charges or restructuring measures which have a material effect on future business operations;

&nbsp;&nbsp;&nbsp;&nbsp;■ Changes in the composition of the Management Board or Supervisory Board of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;■ Development of new products, other R&D developments and patent milestones; and

&nbsp;&nbsp;&nbsp;&nbsp;■ Any other information which might have a significant impact on the respective issuer of Financial Instruments.

Whether a certain information qualifies as Inside Information is to be determined subject to the assessment in each individual case. In case of doubt whether specific information qualifies as Inside Information, the Legal Department can be contacted: please see "Support by the Company", below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.2.3** **Insider Dealing Rules** 

Under the Insider Dealing Rules the following are prohibited and any non-compliance with the following constitutes an infringement of the Insider Dealing Rules (as well as this Insider Policy):

&nbsp;&nbsp;&nbsp;&nbsp;■ Using Inside Information while, directly or indirectly, engaging or attempting to engage in transactions in FME Financial Instruments or related derivative Financial Instruments, in particular buying or selling FME's shares (including short selling FME's shares and buying options to acquire or dispose of FME's shares) or accepting or exercising compensation instruments, including stock options granted to board members, directors, officers or employees of FME Group under Incentive Plans, for its own account or for the account of a third party;<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;■ Using Inside Information also arises by cancelling or amending an order concerning an FME Financial Instrument or related derivative Financial Instruments to which the Inside Information relates even where the original order was placed before having access to the Inside Information.

------

<sup>1</sup> Pursuant to current BaFin practice, instruments settled in cash that are neither tradable nor assignable and are used to calculate a performance-based compensation entitlement (for example, so-called phantom stocks, stock appreciation rights, restricted stock units, etc.) do not qualify as Financial Instruments and are not subject to certain notification requirements under the MAR. Therefore, the granting and acceptance of so-called performance shares under the Company's long-term incentive plans as well as the payout of such performance shares under such plans each do not qualify as transactions in the meaning of this paragraph.

FOR INTERNAL USE ONLY Page: 6 of 11

------

---

| |
|:---|
| &nbsp;&nbsp;![Graphic](fms-20251231xex11d3001.jpg) |
| &nbsp;&nbsp;**Global Insider Policy** |

---

&nbsp;&nbsp;&nbsp;&nbsp;■ Recommending to or inducing another person to engage in using Inside Information ()"**Tipping**") while, directly or indirectly, engaging or attempting to engage in transactions in FME Financial Instruments or related derivative Financial Instruments, in particular buying or selling FME's shares (including short selling FME's shares and buying options to acquire or dispose of FME's shares), e.g., encouraging a third party to exercise options or to buy or sell FME's shares using Inside Information;

&nbsp;&nbsp;&nbsp;&nbsp;■ Unlawfully disclosing Inside Information to any other person (including Family Members and colleagues within FME Group). Disclosure is unlawful unless made in the normal course of an employment, a profession or a duty and on a strict need-to-know basis. Please note that Inside Information can also be disclosed inadvertently/unintentionally, e.g., by discussing business matters in public places such as elevators, hallways, restaurants, airplanes, taxicabs or any other place where the information can be overheard, or by leaving files such as DVDs, memory sticks or other documentation in areas where unauthorized individuals could readily retrieve such information, or using a laptop computer or tablet on public transportation or in areas such as stations, airport lounges or gate areas without exercising caution to preclude others from viewing information on the screen. The need-to-know exemption for disclosure of Inside Information is strictly business-oriented and to be interpreted narrowly.

&nbsp;&nbsp;&nbsp;&nbsp;■ Using material non-public information relating to other companies, including the Company's joint venture partners, equity investee companies, intellectual property licensors and licensees, suppliers and customers of any FME Group company, as well as parties with which an FME Group company is conducting due diligence or negotiating significant transactions, such as mergers and acquisitions, takeover bids, asset sales, significant investments, or matters relating to intellectual property rights (collectively, "**Business Partners** "), to trade in the Financial Instruments of such Business Partners. Any non-public information regarding an FME Group company Business Partner obtained in the course of employment with, or other services performed on behalf of the FME Group (including but not limited to participation on the "deal team" for a matter involving a Business Partner) should be regarded as subject to the same restrictions as Inside Information. All board members, directors, officers and employees of the FME Group should treat Inside Information about the FME Group's Business Partners with the same care and confidentiality required with respect to information related directly to the FME Group, should use such information only for the purpose with respect to which it was received, and must refrain from misusing such information to the same extent as is applicable to confidential and proprietary information of the FME Group. Civil and criminal penalties, and termination of employment or service, may result from trading in Financial Instruments of a Business Partner on the basis of material non-public information regarding the Business Partners to the same extent as trading in FME Financial Instruments on the basis of Inside Information.<sup>2</sup>

Please note that these Insider Dealing Rules apply to any person using Inside Information or other material non-public information, irrespective of nationality, place of residence or, in principle, the place from which Insider Dealing is being carried out.

------

<sup>2</sup> This Policy discusses Insider Dealing in the Financial Instruments, including related derivative Financial Instruments, of companies other than FME only with respect to FSE and FME's Business Partners, as defined above. However, all persons subject to this Policy should bear in mind that any Insider Dealing in the securities of any company will likely violate applicable laws regulating securities dealings and lead to civil and criminal penalties, regardless of whether such Insider Dealing is subject to this Policy.

FOR INTERNAL USE ONLY Page: 7 of 11

------

---

| |
|:---|
| &nbsp;&nbsp;![Graphic](fms-20251231xex11d3001.jpg) |
| &nbsp;&nbsp;**Global Insider Policy** |

---

Without limiting the generality of the Insider Dealing Rules, <u>all board members, directors, officers and employees of FME Group must:</u>

&nbsp;&nbsp;&nbsp;&nbsp;1. not respond to requests for an opinion or comment on FME Financial Instruments unless in the course of exercising their designated tasks, duties and responsibilities; in such latter case, they may respond solely by providing factual information that is consistent with the Company's public disclosures, regardless of having access to or possessing Inside Information at that point in time; and

&nbsp;&nbsp;&nbsp;&nbsp;2. refer any inquiry, question or discussion relating to or in connection with FME Financial Instruments from the press, analysts, brokers, proxy advisors, investors and investment advisors to the responsible Investor Relations or Corporate Communications department, as the case may be;

unless a different response or handling is appropriate in the course of exercising their designated tasks, duties and responsibilities and in accordance with applicable laws and regulation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.2.4** **Periods in which dealing in FME Financial Instruments is prohibited** 

<u>All board members, directors, officers and employees of FME Group remain at all times subject to the prohibitions of the Insider Dealing Rules.</u>

Without limiting the generality of the foregoing, no such person, and FME expects that no Family Member of any such person, shall engage in any transaction (large or small) involving a purchase or sale or offer to purchase or sell any FME Financial instrument, including FME ordinary shares, FME ADSs or related derivative Financial Instruments, during any period:

&nbsp;&nbsp;&nbsp;&nbsp;1. commencing with the point in time that they have access to Inside Information concerning the FME Group, and

&nbsp;&nbsp;&nbsp;&nbsp;2. ending

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. in case of public disclosure of that information, after a reasonable period of time has been allowed for the securities markets to absorb such information. For the purpose of this Insider Policy, it is the Company's view that this period of time extends until the close of trading on the relevant market on the trading day following the day of public disclosure of the information<sup>3</sup>, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. at such time as such non-public information is no longer material, i.e., no longer qualifies as Inside Information.

In addition to the Insider Dealing Rules, and irrespective of the existence of Inside Information, dealing in FME Financial Instruments (including the acceptance and exercise of equity-based compensation instruments received under Incentive Plans and the purchase or sale of FME ordinary shares, FME ADSs or related derivative Financial Instruments)<sup>4</sup> is prohibited during specified time periods (hereinafter referred to as the "**Restricted Periods**"):

&nbsp;&nbsp;&nbsp;&nbsp;1. for all board members, directors, officers and employees of FME Group, during a so-called "**Closed Period** ":

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. commencing 45 calendar days before the publication of interim, and 60 calendar days before the publication of year-end, financial results of FME<sup>5</sup>, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. ending after a reasonable period of time has been allowed for the securities markets to absorb such financial results. For the purpose of this Insider Policy, it is the Company's view that this period of time extends until the close of trading on the trading day on the relevant market following the publication of such financial results); and

------

<sup>3</sup> Example: If the inside information pertaining to FME has been disclosed to the public (the day of such disclosure being "D"), then the Company's position is that trading in FME Financial Instruments will be permitted under this Insider Policy on D+2.

<sup>4</sup> For the reasons stated in footnote 1, this does, however, not apply to the performance shares under the Company's long-term incentive plans.

<sup>5</sup> The dates on which such financial results will be made public are stated on the financial calendar published on the Company's website. In addition, the Closed Periods for the relevant year will be made available, e.g., via PolicyTech and/or in the intranet.

FOR INTERNAL USE ONLY Page: 8 of 11

------

---

| |
|:---|
| &nbsp;&nbsp;![Graphic](fms-20251231xex11d3001.jpg) |
| &nbsp;&nbsp;**Global Insider Policy** |

---

&nbsp;&nbsp;&nbsp;&nbsp;2. as the case may be, as provided for in the context of and based on the terms of any Incentive Plan.

Upon application and subject to applicable laws, FME may in its discretion permit dealing in FME Financial Instruments within a Closed Period in justified exceptional cases.

FME may also, in justified exceptional cases, determine additional or other Restricted Periods, in particular in the context of and based on the terms of the respective Incentive Plan. The relevant individuals will be notified of such changes sufficiently in advance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.2.5** **Trading Plans** 

Subject to satisfaction of certain conditions, it may be permissible to establish a plan or arrangement pursuant to which an agent, such as a bank, broker, or other party, carries out dealings on a person's behalf in FME ordinary shares, including ADSs evidencing such ordinary shares, during Restricted Periods or at other times when such person has access to Inside Information. In the U.S., such plans are known as "Rule 10b5-1 Plans". Such plans or arrangements are referred to below as "Trading Plans."

The legal requirements for a Trading Plan are detailed and complex but, generally, such plans must be adopted when a person does not have access to Inside Information, nor may a person who has entered into such a plan exert any influence over dealings under the plan or provide Inside Information to the plan administrator. Any FME board member, director, senior officer, or other person in FME Group having regular access to Inside Information who proposes to engage in regular or periodic dealing in FME Financial Instruments is encouraged to adopt a Trading Plan. Persons contemplating entering into or adopting a Trading Plan should consult with their broker, bank, or counsel who is an expert in applicable securities law matters.

FME board members, directors and senior officers and other persons contemplating entering into or adopting such a Trading Plan are required to submit the proposed plan to the Legal department under the address provided below under "Support by the Company" to enable the Company to review the proposed plan or arrangement. The sole purpose of such review is to confirm that the proposed plan or arrangement does not conflict with this Insider Policy. Any such review will not constitute approval of the plan or arrangement by FME, a recommendation by FME to engage in securities dealings pursuant to the plan or arrangement, or a determination or confirmation by FME that the Trading Plan complies with the Exchange Act, the rules of the SEC thereunder, the MAR, or any other applicable laws or regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.3** **Special and Prohibited Transactions** 

FME has determined that there is a heightened legal risk and/or possible greater appearance of improper or inappropriate conduct if the persons subject to this Insider Policy engage in certain types of transactions. Therefore, it is the Company's policy that board members, directors, officers and employees subject to this Insider Policy should consider the Company's preferences regarding the transactions described below and, where applicable, refrain from engaging in such transactions.

&nbsp;&nbsp;&nbsp;&nbsp;■ <u>Short-term trading.</u> Dealings in the Company's ordinary shares and ADSs are not subject to the "short-swing" profit disgorgement provisions of the Exchange Act. Nevertheless, short-term trading of FME Financial Instruments may be distracting and unduly focus a person on the Company's short-term stock exchange performance instead of its long-term strategy and business objectives. For these reasons, the Company discourages the purchase and sale, or sale and purchase, of any FME Financial Instruments of the same class on a short-term basis.

FOR INTERNAL USE ONLY Page: 9 of 11

------

---

| |
|:---|
| &nbsp;&nbsp;![Graphic](fms-20251231xex11d3001.jpg) |
| &nbsp;&nbsp;**Global Insider Policy** |

---

&nbsp;&nbsp;&nbsp;&nbsp;■ <u>Short sales.</u> Short sales of FME shares (i.e., the sale of shares that the seller does not own) may suggest an expectation by the seller that the shares will decline in value. This could signal to the market that the seller lacks confidence in the Company's prospects, particularly if the seller is a board member or holds a senior position in the FME Group. In addition, short sales could reduce a seller's incentive to seek to improve the Company's performance. For these reasons, short sales of FME Financial Instruments are prohibited.

&nbsp;&nbsp;&nbsp;&nbsp;■ <u>Publicly traded options.</u> Publicly traded options have relatively short terms. Therefore, transactions in such options could create the appearance that a board member, director, officer or employee is trading on the basis of Inside Information. Moreover, even lawful transactions in publicly traded options can focus the trader on short-term performance in lieu of the Company's long-term strategy and objectives. Accordingly, transactions in FME put options, FME call options, or other FME derivative securities on a stock exchange are prohibited by this Insider Policy.

&nbsp;&nbsp;&nbsp;&nbsp;■ <u>Hedging.</u> Hedging or monetization transactions can be effected through a number of possible mechanisms, including through the use of Financial Instruments, such as prepaid variable forwards, equity swaps and collars. Such transactions could permit a board member, director, officer or employee to continue to own FME Financial Instruments obtained as compensation instruments or otherwise, but without the full economic risks and rewards of ownership. That could cause the objectives of the board member, director, officer or employee to differ from those of the Company's other shareholders. Therefore, persons subject to this Insider Policy may not enter into hedging or monetization transactions or similar arrangements with respect to FME Financial Instruments.

&nbsp;&nbsp;&nbsp;&nbsp;■ <u>Margin Accounts and Pledged Securities.</u> Securities held in a margin account as collateral for a margin loan, or pledged as collateral for a conventional loan, may be sold by the broker or lender to meet a margin call or in foreclosure by the lender if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of Inside Information (or is otherwise not permitted to deal in FME Financial Instruments), board members, directors, officers and other employees are prohibited from holding FME Financial Instruments in a margin account or otherwise pledging FME Financial Instruments as collateral for a loan.

&nbsp;&nbsp;&nbsp;&nbsp;■ <u>Standing and Limit Orders.</u> Standing and limit order (other than such orders under Trading Plans described in this Insider Policy) create heightened risks for violations of Insider Dealing Rules similar to the use of margin accounts. There is no control over the timing of transactions that result from standing instructions to a broker, so the broker could (even unknowingly) execute a transaction when a board member, director, officer or employee possesses Inside Information. Therefore, persons subject to this Insider Policy are discouraged from placing standing or limit orders on FME Financial Instruments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.4** **Personal Responsibility** 

<u>Each person subject to this Insider Policy is individually responsible for ensuring compliance with the Insider Dealing Rules and it is of utmost importance for every board member, director, officer and employee of FME Group to be aware of their own responsibility to act accordingly, in particular to make any investment decisions with the appropriate diligence, deliberating on the possible non-public or confidential character of information to which they have access.</u> While the general observance of the Restricted Periods might also help avoiding Insider Dealing, the mere observance of such Restricted Periods does not replace the individual's general duty to refrain from conducting any dealings in Financial Instruments on the basis of Inside Information and otherwise to comply with the applicable Insider Dealing Rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.5** **Amendments** 

This Insider Policy may be amended or modified at any time or from time to time to comply with applicable laws, the rules and regulations of any governmental body or entity (including, without limitation, the BaFin or the SEC) or the rules and regulations of any stock exchange on which any Financial Instruments of any company within the FME Group may be listed, or for any other reason deemed necessary or appropriate by the Company.

FOR INTERNAL USE ONLY Page: 10 of 11

------

---

| |
|:---|
| &nbsp;&nbsp;![Graphic](fms-20251231xex11d3001.jpg) |
| &nbsp;&nbsp;**Global Insider Policy** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.6** **Support by the Company** 

The Company endeavors to assist FME Group's board members, directors, officers and employees with complying with the Insider Dealing Rules and avoiding Insider Dealing or any other misuse of Inside Information.

In case of queries with regard to this Insider Policy or in case of doubt whether or not specific information qualifies as Inside Information, the Legal Department can be contacted at info.insiders@freseniusmedicalcare.com.

**4** **RELATED INTERNAL CONTROLS**

<u>Subject</u> <u>Title</u> <br> <u>None</u>

**5** **RELATED DOCUMENTS**

<u>Document</u> <u>Title</u> <br> <u>#12862</u> <u>Reporting of Potential Inside Information SOP </u>

**6** **ANNEXES**

---

| | |
|:---|:---|
| &nbsp;&nbsp;Document | &nbsp;&nbsp;Title |
| &nbsp;&nbsp;Annex Implementation | &nbsp;&nbsp;Local Implementation Instructions for Document Owners |
| &nbsp;&nbsp;Annex 1 | &nbsp;&nbsp;Global Insider Policy - Annex: Blackout Periods  |

---

FOR INTERNAL USE ONLY Page: 11 of 11

------

## Exhibit 12.1

**Exhibit 12.1**

**CERTIFICATION PURSUANT TO SECTION 302**

**OF THE SARBANES-OXLEY ACT OF 2002**

I, Helen Giza, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this annual report on Form 20-F of Fresenius Medical Care AG;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: February 24, 2026 |  |  |
|  | By: | /s/ Helen Giza |
|  | Helen Giza | Helen Giza |
|  | Chief Executive Officer and Chair of the Management Board | Chief Executive Officer and Chair of the Management Board |

---

------

## Exhibit 12.2

**Exhibit 12.2**

**CERTIFICATION PURSUANT TO SECTION 302**

**OF THE SARBANES-OXLEY ACT OF 2002**

I, Martin Fischer, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this annual report on Form 20-F of Fresenius Medical Care AG;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: February 24, 2026 |  |  |
|  | By: | /s/ Martin Fischer |
|  | Martin Fischer | Martin Fischer |
|  | Chief Financial Officer and member of the Management Board | Chief Financial Officer and member of the Management Board |

---

------

## Exhibit 13.1

**Exhibit 13.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report on Form 20-F of Fresenius Medical Care AG (the Company) for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Helen Giza, Chief Executive Officer and Chair of the Management Board, certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | |
|:---|:---|
| By: | /s/ Helen Giza |
| Helen Giza | Helen Giza |
| Chief Executive Officer and Chair of the Management Board | Chief Executive Officer and Chair of the Management Board |
| February 24, 2026 | February 24, 2026 |

---

------

## Exhibit 13.2

**Exhibit 13.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report on Form 20-F of Fresenius Medical Care AG (the Company) for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Martin Fischer, Chief Financial Officer and member of the Management Board, certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | |
|:---|:---|
| By: | /s/ Martin Fischer |
| Martin Fischer | Martin Fischer |
| Chief Financial Officer and member of the Management Board | Chief Financial Officer and member of the Management Board |
| February 24, 2026 | February 24, 2026 |

---

------